"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,JP,A,JP 2008195722 A,090-069-248-235-568,2008-08-28,2008,JP 2008044964 A,2008-02-26,US 4567597 P,1997-05-06,INTRACELLULAR PRODUCTION OF HEPATITIS C E1 AND E2 TRUNCATED POLYPEPTIDES,"<P>PROBLEM TO BE SOLVED: To provide the methods for obtaining C-terminated E1 and E2 polypeptides from cell lysates. <P>SOLUTION: The invention is directed to a method for isolating a hepatitis C virus (HCV) E1 polypeptide that lacks a portion of its C-terminus beginning at about amino acid 370 but not extending beyond about 300 amino acids, numbered with reference to the HCV1 E1 amino acid sequence. The method includes: (a) providing a population of host cells transformed with a polynucleotide comprising a coding sequence for the HCV E1 polypeptide, wherein the coding sequence is operably linked to control elements so that the coding sequence can be transcribed and translated in the host cell; (b) culturing the population of cells under conditions whereby the HCV E1 polypeptide is expressed intracellularly; (c) disrupting the host cells; and (d) isolating the HCV E1 polypeptide from the disrupted cells. <P>COPYRIGHT: (C)2008,JPO&INPIT",NOVARTIS VACCINES & DIAGNOSTIC,HOUGTON MICHAEL;;CHOO QUI-LIM;;ABRIGNANI SERGIO;;CHEN DAVID;;SELBY MARK;;GLAZER EDWARD,,https://lens.org/090-069-248-235-568,Patent Application,no,0,0,17,17,4,A61K39/00;;C07K14/005;;C12N2770/24222;;Y10S977/923;;A61P31/14;;A61P37/04;;C07K14/005;;A61K39/00;;C12N2770/24222;;Y10S977/923,C07K14/18;;G01N33/576;;A61K39/00;;A61K39/29;;A61P31/14;;A61P37/04;;C07K1/22;;C12N15/08;;C12N15/09;;C12N15/40;;C12P21/02;;G01N30/88,,0,0,,,,DISCONTINUED
2,JP,A,JP 2009232863 A,042-244-709-565-813,2009-10-15,2009,JP 2009166155 A,2009-07-14,US 4567597 P,1997-05-06,INTRACELLULAR PRODUCTION OF HEPATITIS C E1 AND E2 TRUNCATED POLYPEPTIDE,"<P>PROBLEM TO BE SOLVED: To provide methods for obtaining C-terminally truncated E1 and E2 polypeptides from cell lysates. <P>SOLUTION: Provided is a method for isolating a hepatitis C virus (HCV) E1 polypeptide that lacks a portion of its C-terminus beginning at about amino acid 370 but not extending beyond about amino acid 300, numbered with reference to the HCV1 E1 amino acid sequence. The method comprises: (a) a step for providing a population of host cells transformed with a polynucleotide comprising a coding sequence for the HCV E1 polypeptide, wherein the coding sequence is operably linked to control elements such that the coding sequence can be transcribed and translated in the host cells; (b) a step for culturing the population of cells under conditions whereby the HCV E1 polypeptide is expressed intracellularly; (c) a step for disrupting the host cells; and (d) a step for isolating the HCV E1 polypeptide from the disrupted cells. <P>COPYRIGHT: (C)2010,JPO&INPIT",NOVARTIS VACCINES & DIAGNOSTIC,HOUGTON MICHAEL;;CHOO QUI-LIM;;ABRIGNANI SERGIO;;CHEN DAVID;;SELBY MARK;;GLAZER EDWARD,,https://lens.org/042-244-709-565-813,Patent Application,no,1,0,17,17,4,A61K39/00;;C07K14/005;;C12N2770/24222;;Y10S977/923;;A61P31/14;;A61P37/04;;C07K14/005;;A61K39/00;;C12N2770/24222;;Y10S977/923,C12N7/04;;G01N33/576;;A61K39/00;;A61K39/29;;A61P31/14;;C07K1/22;;C07K14/18;;C12N15/08;;C12N15/09;;C12N15/40;;C12P21/02,,0,0,,,,DISCONTINUED
3,CL,A1,CL 2021000694 A1,063-733-040-473-990,2021-09-24,2021,CL 2021000694 A,2021-03-20,US 201862737894 P,2018-09-27,Herbicidas de piridazinona e intermedios de piridazinona usados para preparar un herbicida,"Se describen compuestos de la Fórmula I y N-óxidos o sales de estos, en donde R1 es alquilo C1-C4 o cicloalquilo C3–C6; R2 es H, Cl, Br o I; R3 es Cl o OR4; R4 es H o alquilo C1-C4; R5 es H, F, Cl o CH3; y R6 es H o Cl.Se describe, además, una composición que contiene un compuesto de la Fórmula I, y métodos para controlar la vegetación indeseada que comprenden poner en contacto la vegetación indeseada o su medio ambiente con una cantidad eficaz de un compuesto de la Fórmula I o una composición de este. Se describen, además, métodos para preparar un compuesto de la Fórmula I.",FMC CORP,SELBY THOMAS PAUL;;STEVENSON THOMAS MARTIN;;MCCANN STEPHEN FREDERICK;;MARSHALL ERIC ALLEN;;CHEN YUZHONG,,https://lens.org/063-733-040-473-990,Patent Application,no,0,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,A01N43/58;;C07D237/14;;C07D237/16,,0,0,,,,PENDING
4,EP,A1,EP 3856723 A1,121-035-046-592-96X,2021-08-04,2021,EP 19783912 A,2019-09-26,US 201862737894 P;;US 2019/0053053 W,2018-09-27,PYRIDAZINONE HERBICIDES AND PYRIDAZINONE INTERMEDIATES USED TO PREPARE A HERBICIDE,,FMC CORP,SELBY THOMAS PAUL;;STEVENSON THOMAS MARTIN;;MCCANN STEPHEN FREDERICK;;MARSHALL ERIC ALLEN;;CHEN YUZHONG,,https://lens.org/121-035-046-592-96X,Patent Application,yes,0,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D237/14;;A01N43/58;;C07D237/16,,0,0,,,,PENDING
5,LT,T,LT 2439273 T,163-946-122-478-351,2019-05-10,2019,LT 11178191 T,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK;;CHEN BING;;CARDARELLI JOSEPHINE;;KORMAN ALAN;;HUANG HAICHUN,,https://lens.org/163-946-122-478-351,Unknown,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,PENDING
6,UY,A,UY 38392 A,036-440-639-722-772,2020-04-30,2020,UY 38392 A,2019-09-27,US 201862737894 P,2018-09-27,HERBICIDAS DE PIRIDAZINONA E INTERMEDIOS DE PIRIDAZINONA USADOS PARA PREPARAR UN HERBICIDA,"Se describen compuestos de la Fórmula I y N-óxidos o sales de estos, en donde R1 a R6 se definen como en la descripción; siempre que (a) cuando R3 es OH y R5 es H, entonces R6 es Cl; y (b) cuando R2 es Br y R3 es OH, entonces R6 es H. También se describe una composición que contiene un compuesto de la Fórmula I, métodos para preparar los compuestos de la Fórmula I y métodos para controlar la vegetación no deseada que comprende poner en contacto la vegetación no deseada o su entorno con una cantidad eficaz de un compuesto de la Fórmula I o una composición de esta.",FMC CORP,THOMAS MARTIN STEVENSON;;STEPHEN FREDERICK MCCANN;;ERIC ALLEN MARSHALL;;CHEN YUZHONG;;THOMAS PAUL SELBY,,https://lens.org/036-440-639-722-772,Patent Application,no,0,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D227/093;;A01N43/58,,0,0,,,,PENDING
7,SG,A,SG 11202102638W A,070-548-547-744-111,2021-04-29,2021,SG 11202102638W A,2019-09-26,US 201862737894 P;;US 2019/0053053 W,2018-09-27,PYRIDAZINONE HERBICIDES AND PYRIDAZINONE INTERMEDIATES USED TO PREPARE A HERBICIDE,,FMC CORP,SELBY THOMAS PAUL;;STEVENSON THOMAS MARTIN;;MCCANN STEPHEN FREDERICK;;MARSHALL ERIC ALLEN;;CHEN YUZHONG,,https://lens.org/070-548-547-744-111,Unknown,no,0,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D237/14;;A01N43/58;;C07D237/16,,0,0,,,,PENDING
8,WO,A1,WO 2020/069057 A1,141-346-620-720-983,2020-04-02,2020,US 2019/0053053 W,2019-09-26,US 201862737894 P,2018-09-27,PYRIDAZINONE HERBICIDES AND PYRIDAZINONE INTERMEDIATES USED TO PREPARE A HERBICIDE,"Disclosed are compounds of Formula I and N-oxides or salts thereof, wherein R 1 is C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl; R 2 is H, Cl, Br or I; R 3 is Cl or OR 4 ; R 4 is H or C 1 -C 4 alkyl; R 5 is H, F, Cl or CH 3 ; and R 6 is H or Cl. Also disclosed is a composition containing a compound of Formula I, and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound of Formula I or a composition thereof. Also dislosed are methods for preparing a compound of Formula I.",FMC CORP,SELBY THOMAS PAUL;;STEVENSON THOMAS MARTIN;;MCCANN STEPHEN FREDERICK;;MARSHALL ERIC ALLEN;;CHEN YUZHONG,,https://lens.org/141-346-620-720-983,Patent Application,yes,18,5,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D237/14;;A01N43/58;;C07D237/16,,15,2,041-698-848-654-955;;056-357-183-925-763,18444623;;10.1021/ja800861p;;10.1016/s0261-2194(97)00118-x,"""Polymorphism in the Pharmaceutical Industry"", 2006, WILEY-VCH;;POLISH JOURNAL OF CHEMISTRY, vol. 64, 1990, pages 741 - 392;;J. AM. CHEM. SOC., vol. 130, 2008, pages 6848;;WATKINS ET AL.: ""Handbook of Insecticide Dust Diluents and Carriers"", 1950, DORLAND BOOKS;;SISELYWOOD: ""McCutcheon's Emulsifiers and Detergents"", 1964, MCCUTCHEON'S DIVISION, THE MANUFACTURING CONFECTIONER PUBLISHING CO.;;A. S. DAVIDSONB. MILWIDSKY: ""Synthetic Detergents"", 1987, JOHN WILEY AND SONS;;""Agglomeration"", CHEMICAL ENGINEERING, vol. 2, 4 December 1967 (1967-12-04), pages 147 - 48;;""Perry's Chemical Engineer's Handbook"", 1963, MCGRAW-HILL, pages: 8 - 57;;T. S. WOODS: ""Pesticide Chemistry and Bioscience, The Food Environment Challenge,"", article ""The Formulator's Toolbox - Product Forms for Modern Agriculture"";;""Proceedings of the 9th International Congress on Pesticide Chemistry"", 1999, THE ROYAL SOCIETY OF CHEMISTRY, pages: 120 - 133;;KLINGMAN: ""Weed Control as a Science"", 1961, JOHN WILEY AND SONS, INC., pages: 81 - 96;;HANCE ET AL.: ""Weed Control Handbook"", 1989, SCIENTIFIC PUBLICATIONS;;""Developments in formulation technology"", 2000, PJB PUBLICATIONS;;""The Pesticide Manual"", 2003, BRITISH CROP PROTECTION COUNCIL;;""The BioPesticide Manual"", 2001, BRITISH CROP PROTECTION COUNCIL",PENDING
9,ES,T3,ES 2720160 T3,050-403-874-887-061,2019-07-18,2019,ES 11178191 T,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas,"Un anticuerpo monoclonal, o una porcion de union a antigeno del mismo, que se une especificamente a la proteina Muerte programada 1 (PD-1) humana y comprende una region variable de cadena pesada que comprende aminoacidos que tienen la secuencia definida en la SEQ ID NO:4 y una region variable de cadena ligera que comprende aminoacidos que tienen la secuencia definida en la SEQ ID NO: 11; para su uso en un metodo para tratar un cancer en un sujeto junto con un anticuerpo monoclonal, o una porcion de union a antigeno del mismo, que se une especificamente a CTLA-4 humano.",ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK;;CHEN BING;;CARDARELLI JOSEPHINE;;KORMAN ALAN;;HUANG HAICHUN,,https://lens.org/050-403-874-887-061,Granted Patent,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
10,NO,A1,NO 20200470 A1,055-809-868-339-60X,2008-02-11,2008,NO 20200470 A,2020-04-17,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,HUMANE MONOKLONALE ANTISTOFFER MOT PROGRAMMERT DØD 1 (PD-1) OG FREMGANGSMÅTER FOR Å BEHANDLE CANCER VED ANVENDELSE AV ANTI-PD-1 ANTISTOFFER ALENE ELLER I KOMBINASJON MED ANDRE IMMUNTERAPEUTIKA,,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,SRINIVASAN MOHAN;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN;;SELBY MARK J;;CHEN BINGLIANG;;KORMAN ALAN,,https://lens.org/055-809-868-339-60X,Unknown,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/395,,0,0,,,,PENDING
11,PE,A1,PE 20211219 A1,087-923-278-897-804,2021-07-05,2021,PE 2021000399 A,2019-09-26,US 201862737894 P;;US 2019/0053053 W,2018-09-27,HERBICIDAS DE PIRIDAZINONA E INTERMEDIOS DE PIRIDAZINONA USADOS PARA PREPARAR UN HERBICIDA,"Referida a compuestos herbicidas derivados de piridazinona de Formula I y N-oxidos o sales de estos, en donde R1 es alquilo C1-C4 o cicloalquilo C3-C6; R2 es H, Cl, Br o I; R3 es Cl o OR4; R4 es H o alquilo C1-C4; R5 es H, F, Cl o CH3; y R6 es H o Cl. Son compuestos preferidos: 6-cloro-4-(2,7-dimetil-1-naftalenil)-5-hidroxi-2-metil-3(2H)-piridazinona; 6-cloro-4-(7-fluoro-2-metil-1-naftalenil)-5-hidroxi-2-metil-3(2H)- piridazinona; 6-cloro-4-(7-cloro-2-metil-1-naftalenil)-5-hidroxi-2-metil-3(2H)- piridazinona; y 6-cloro-4-(4-cloro-2-metil-1-naftalenil)-5-hidroxi-2-metil-3(2H)- piridazinona. Tambien esta referida a metodos de preparacion, composiciones y mezclas que comprenden al compuesto de formula I. Dichos compuestos son utiles para controlar la vegetacion indeseada.",FMC CORP,SELBY THOMAS PAUL;;STEVENSON THOMAS MARTIN;;MCCANN STEPHEN FREDERICK;;MARSHALL ERIC ALLEN;;CHEN YUZHONG,,https://lens.org/087-923-278-897-804,Patent Application,no,0,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D237/14;;A01N43/58;;C07D237/16,,0,0,,,,PENDING
12,AR,A1,AR 116556 A1,037-097-991-366-085,2021-05-19,2021,AR P190102770 A,2019-09-27,US 201862737894 P,2018-09-27,HERBICIDAS DE PIRIDAZINONA E INTERMEDIOS DE PIRIDAZINONA USADOS PARA PREPARAR UN HERBICIDA,"Se describen compuestos de la fórmula (1), y N-óxidos o sales de estos, en donde R¹ es alquilo C₁₋₄ o cicloalquilo C₃₋₆; R² es H, Cl, Br o I; R³ es CI o OR⁴; R⁴ es H o alquilo C₁₋₄; R⁵ es H, F, Cl o CH₃; y R⁶ es H o CI; siempre que (a) cuando R³ es OR⁴ y R⁴ y R⁵ son ambos H, entonces R⁶ es Cl; y (b) cuando R² es Br, R³ es OR⁴ y R⁴ es H, entonces R⁶ es H. Se describe, además, una composición que contiene un compuesto de la fórmula (1), y métodos para controlar la vegetación indeseada que comprenden poner en contacto la vegetación indeseada o su medio ambiente con una cantidad eficaz de un compuesto de la fórmula (1) o una composición de este. Se describen, además, métodos para preparar un compuesto de la fórmula (1).",FMC CORP,CHEN YUZHONG;;MARSHALL ERIC ALLEN;;MCANN STEPHEN FREDERICK;;STEVENSON THOMAS MARTIN;;SELBY THOMAS PAUL,,https://lens.org/037-097-991-366-085,Patent Application,no,0,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D237/14;;A01N43/58;;A01P13/00;;C07D237/16,,0,0,,,,PENDING
13,CO,A2,CO 2021003758 A2,070-815-942-655-219,2021-04-08,2021,CO 2021003758 A,2021-03-24,US 2019/0053053 W;;US 201862737894 P,2018-09-27,Herbicidas de piridazinona e intermedios de piridazinona usados para preparar un herbicida,"RESUMEN Se describen compuestos de la Fórmula I y N-óxidos o sales de estos, en donde R1 es alquilo C1-C4 o cicloalquilo C3–C6; R2 es H, Cl, Br o I; R3 es Cl o OR4; R4 es H o alquilo C1-C4; R5 es H, F, Cl o CH3; y R6 es H o Cl. Se describe, además, una composición que contiene un compuesto de la Fórmula I, y métodos para controlar la vegetación indeseada que comprenden poner en contacto la vegetación indeseada o su medio ambiente con una cantidad eficaz de un compuesto de la Fórmula I o una composición de este. Se describen, además, métodos para preparar un compuesto de la Fórmula I.",FMC CORP,STEVENSON THOMAS MARTIN;;SELBY THOMAS PAUL;;MCCANN STEPHEN FREDERICK;;MARSHALL ERIC ALLEN;;CHEN YUZHONG,,https://lens.org/070-815-942-655-219,Patent Application,no,0,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D237/14;;A01N43/58;;C07D237/16,,0,0,,,,PENDING
14,PH,A1,PH 12021550651 A1,051-141-597-500-429,2022-02-14,2022,PH 12021550651 A,2021-03-22,US 201862737894 P;;US 2019/0053053 W,2018-09-27,PYRIDAZINONE HERBICIDES AND PYRIDAZINONE INTERMEDIATES USED TO PREPARE A HERBICIDE,"Disclosed are compounds of Formula I and N-oxides or salts thereof, wherein R1 is C1-C4alkyl or C3-C6cycloalkyl; R2 is H, Cl, Br or I; R3 is Cl or OR4; R4 is H or C1-C4 alkyl; R5 is H, F, Cl or CH3; and R6 is H or Cl. Also disclosed is a composition containing a compound of Formula I, and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound of Formula I or a composition thereof. Also dislosed are methods for preparing a compound of Formula I.",FMC CORP,SELBY THOMAS PAUL;;STEVENSON THOMAS MARTIN;;MCCANN STEPHEN FREDERICK;;MARSHALL ERIC ALLEN;;CHEN YUZHONG,,https://lens.org/051-141-597-500-429,Patent Application,no,0,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,A01N43/58;;C07D237/14;;C07D237/16,,0,0,,,,PENDING
15,AU,A2,AU 2019/347855 A2,121-779-654-231-756,2022-09-22,2022,AU 2019/347855 A,2019-09-26,US 201862737894 P;;US 2019/0053053 W,2018-09-27,Pyridazinone herbicides and pyridazinone intermediates used to prepare a herbicide,"Disclosed are compounds of Formula I and N-oxides or salts thereof, wherein R",FMC CORP,SELBY THOMAS PAUL;;STEVENSON THOMAS MARTIN;;MCCANN STEPHEN FREDERICK;;MARSHALL ERIC ALLEN;;CHEN YUZHONG,,https://lens.org/121-779-654-231-756,Patent Application,no,0,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D237/14;;A01N43/58;;C07D237/16,,0,0,,,,PENDING
16,US,A1,US 2022/0041560 A1,121-638-212-884-638,2022-02-10,2022,US 201917280611 A,2019-09-26,US 201917280611 A;;US 201862737894 P;;US 2019/0053053 W,2018-09-27,PYRIDAZINONE HERBICIDES AND PYRIDAZINONE INTERMEDIATES USED TO PREPARE A HERBICIDE,"Disclosed are compounds of Formula I and N-oxides or salts thereof, wherein R 1 is C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl; R 2 is H, Cl, Br or I; R 3 is Cl or OR 4 ; R 4 is H or C 1 -C 4 alkyl; R 5 is H, F, Cl or CH 3 ; and R 6 is H or Cl. Also disclosed is a composition containing a compound of Formula I, and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound of Formula I or a composition thereof. Also disclosed are methods for preparing a compound of Formula I.",FMC CORP,SELBY THOMAS PAUL;;STEVENSON THOMAS MARTIN;;MCCANN STEPHEN FREDERICK;;MARSHALL ERIC ALLEN;;CHEN YUZHONG,FMC CORPORATION (2020-02-06),https://lens.org/121-638-212-884-638,Patent Application,yes,0,2,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D237/16;;A01N43/58,,0,0,,,,PENDING
17,HU,T2,HU E044719 T2,138-399-369-877-171,2019-11-28,2019,HU E11178191 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK;;CHEN BING;;CARDARELLI JOSEPHINE;;KORMAN ALAN;;HUANG HAICHUN,,https://lens.org/138-399-369-877-171,Amended Patent,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,PENDING
18,KR,A,KR 20210065979 A,071-218-344-429-60X,2021-06-04,2021,KR 20217011978 A,2019-09-26,US 201862737894 P;;US 2019/0053053 W,2018-09-27,피리다지논 제초제 및 제초제 제조에 사용되는 피리다지논 중간체,"화학식 I의 화합물 및 그의 N-옥시드 또는 염이 개시되고, 여기서 R1이 C1-C4 알킬 또는 C3-C6 시클로알킬이고; R2가 H, Cl, Br 또는 I이고; R3이 Cl 또는 OR4이고; R4가 H 또는 C1-C4 알킬이고; R5가 H, F, Cl 또는 CH3이고; R6이 H 또는 Cl이다. 또한 화학식 I의 화합물을 함유하는 조성물, 및 바람직하지 않은 식생 또는 그의 환경을 유효량의 화학식 I의 화합물 또는 그의 조성물과 접촉시키는 것을 포함하는, 바람직하지 않은 식생을 방제하는 방법이 개시된다. 또한 화학식 I의 화합물을 제조하는 방법이 개시된다. TIFFpct00125.tif4440",FMC CORP,SELBY THOMAS PAUL;;STEVENSON THOMAS MARTIN;;MCCANN STEPHEN FREDERICK;;MARSHALL ERIC ALLEN;;CHEN YUZHONG,,https://lens.org/071-218-344-429-60X,Patent Application,no,0,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D237/14;;A01N43/58;;C07D237/16,,0,0,,,,DISCONTINUED
19,MX,A,MX 2021003530 A,027-925-849-524-933,2021-05-27,2021,MX 2021003530 A,2019-09-26,US 201862737894 P;;US 2019/0053053 W,2018-09-27,PYRIDAZINONE HERBICIDES AND PYRIDAZINONE INTERMEDIATES USED TO PREPARE A HERBICIDE.,"Disclosed are compounds of Formula I and N-oxides or salts thereof, wherein R<sup>1 </sup>is C<sub>1</sub>-C<sub>4</sub>alkyl or C<sub>3</sub>-C<sub>6</sub>cycloalkyl; R<sup>2 </sup>is H, Cl, Br or I; R<sup>3 </sup>is Cl or OR<sup>4</sup>; R<sup>4 </sup>is H or C<sub>1</sub>-C<sub>4 </sub>alkyl; R<sup>5 </sup>is H, F, Cl or CH<sub>3</sub>; and R<sup>6 </sup>is H or Cl. Also disclosed is a composition containing a compound of Formula I, and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound of Formula I or a composition thereof. Also dislosed are methods for preparing a compound of Formula I.",FMC CORP,MCCANN STEPHEN FREDERICK;;STEVENSON THOMAS MARTIN;;SELBY THOMAS PAUL;;CHEN YUZHONG;;MARSHALL ERIC ALLEN,,https://lens.org/027-925-849-524-933,Patent Application,no,0,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D237/14;;A01N43/58;;C07D237/16,,0,0,,,,PENDING
20,NO,A1,NO 20170138 A1,042-388-433-518-890,2008-02-11,2008,NO 20170138 A,2017-01-30,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,Humane monoklonale antistoffer mot programmert død 1 (PD-1) og fremgangsmåter for å behandle cancer ved anvendelse av anti-PD-1 antistoffer aleneeller i kombinasjon med andre immunterapeutika,,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,SRINIVASAN MOHAN;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN;;SELBY MARK J;;CHEN BINGLIANG;;KORMAN ALAN,,https://lens.org/042-388-433-518-890,Unknown,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395;;C07K16/28,,0,0,,,,ACTIVE
21,AU,A1,AU 2019/347855 A1,054-910-406-437-141,2021-04-08,2021,AU 2019/347855 A,2019-09-26,US 201862737894 P;;US 2019/0053053 W,2018-09-27,Pyridazinone herbicides and pyridazinone intermediates used to prepare a herbicide,"Disclosed are compounds of Formula I and N-oxides or salts thereof, wherein R",FMC CORP,SELBY THOMAS PAUL;;STEVENSON THOMAS MARTIN;;MCCANN STEPHEN FREDERICK;;MARSHALL ERIC ALLEN;;CHEN YUZHONG,,https://lens.org/054-910-406-437-141,Patent Application,no,0,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D237/14;;A01N43/58;;C07D237/16,,0,0,,,,PENDING
22,NO,B1,NO 344818 B1,066-290-833-729-086,2020-05-04,2020,NO 20170138 A,2017-01-30,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,Monoklonalt antistoff eller en antigenbindende del derav,,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,SRINIVASAN MOHAN;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN;;SELBY MARK J;;CHEN BINGLIANG;;KORMAN ALAN,,https://lens.org/066-290-833-729-086,Granted Patent,no,1,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395;;A61P35/00;;C07K16/28,,1,1,013-122-792-588-081,10.4049/jimmunol.170.3.1257;;12538684,"BROWN J. et al., Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine Production, Journal of Immunolgy, 2003, Vol. 170 (3), side 1257-1266, Dated: 01.01.0001",ACTIVE
23,CA,A1,CA 3113063 A1,103-057-578-452-903,2020-04-02,2020,CA 3113063 A,2019-09-26,US 201862737894 P;;US 2019/0053053 W,2018-09-27,PYRIDAZINONE HERBICIDES AND PYRIDAZINONE INTERMEDIATES USED TO PREPARE A HERBICIDE,"Disclosed are compounds of Formula I and N-oxides or salts thereof, wherein R1 is C1-C4alkyl or C3-C6cycloalkyl; R2 is H, Cl, Br or I; R3 is Cl or OR4; R4 is H or C1-C4 alkyl; R5 is H, F, Cl or CH3; and R6 is H or Cl. Also disclosed is a composition containing a compound of Formula I, and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound of Formula I or a composition thereof. Also dislosed are methods for preparing a compound of Formula I.",FMC CORP,SELBY THOMAS PAUL;;STEVENSON THOMAS MARTIN;;MCCANN STEPHEN FREDERICK;;MARSHALL ERIC ALLEN;;CHEN YUZHONG,,https://lens.org/103-057-578-452-903,Patent Application,no,0,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D237/14;;A01N43/58;;C07D237/16,,0,0,,,,PENDING
24,BR,A2,BR 112021005787 A2,013-918-496-525-450,2021-06-29,2021,BR 112021005787 A,2019-09-26,US 2019/0053053 W;;US 201862737894 P,2018-09-27,"composto, processos para a preparação de um composto, composições herbicidas, mistura herbicida e método para controlar o crescimento de vegetação indesejada","composto, processos para a preparação de um composto, composições herbicidas, mistura herbicida e método para controlar o crescimento de vegetação indesejada. são divulgados compostos de fórmula i e n-óxidos ou sais do mesmo, em que r1 é c1-c4 alquila ou c3-c6 cicloalquila; r2 é h, cl, br ou i; r3 é cl ou or4; r4 é h ou c1-c4 alquila; r5 é h, f, cl ou ch3; e r6 é h ou cl; desde que (a) quando r3 é or4 e r4 e r5 são ambos h, então r6 é cl; e (b) quando r2 é br, r3 é or4 e r4 é h, então r6 é h. também é divulgada uma composição contendo um composto de fórmula i e métodos para controlar a vegetação indesejada compreendendo o contato da vegetação indesejada ou seu ambiente com uma quantidade eficaz de um composto de fórmula i ou uma composição do mesmo. também são apresentados métodos para a preparação de um composto de fórmula i.",FMC CORP,ERIC ALLEN MARSHALL;;STEPHEN FREDERICK MCCANN;;THOMAS MARTIN STEVENSON;;THOMAS PAUL SELBY;;YUZHONG CHEN,,https://lens.org/013-918-496-525-450,Patent Application,no,0,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D237/14;;A01N43/58;;C07D237/16,,0,0,,,,PENDING
25,CN,A,CN 113166075 A,106-478-129-193-904,2021-07-23,2021,CN 201980077703 A,2019-09-26,US 201862737894 P;;US 2019/0053053 W,2018-09-27,PYRIDAZINONE HERBICIDES AND PYRIDAZINONE INTERMEDIATES USED TO PREPARE A HERBICIDE,"Disclosed are compounds of Formula I and N-oxides or salts thereof, wherein R1 is C1-C4alkyl or C3-C6cycloalkyl; R2 is H, Cl, Br or I; R3 is Cl or OR4; R4 is H or C1-C4 alkyl; R5 is H, F, Cl or CH3; and R6 is H or Cl. Also disclosed is a composition containing a compound of Formula I, and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound of Formula I or a composition thereof. Also dislosed are methods for preparing a compound of Formula I.",FMC CORP,SELBY THOMAS PAUL;;STEVENSON THOMAS MARTIN;;MCCANN STEPHEN FREDERICK;;MARSHALL ERIC ALLEN;;CHEN YUZHONG,,https://lens.org/106-478-129-193-904,Patent Application,no,2,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D237/14;;A01N43/58;;C07D237/16,,2,1,023-040-676-946-068,10.3987/com-02-9599,"R\'KYEK, OMAR ET AL.: ""Study of the reactivity of 5-alkynyl-4-chloro- and 4-alkynyl-5-chloropyridazin-3(2H)-ones towards oxygen and sulfur nucleophiles"", 《HETEROCYCLES》;;A.A.KATRUSIAK ET AL.: ""Ispo and cine Substitution of Bromine in Pyridazinones"", 《POLISH J. CHEM.》",PENDING
26,TW,A,TW 202012376 A,124-110-684-787-514,2020-04-01,2020,TW 108134814 A,2019-09-26,US 201862737894 P,2018-09-27,Pyridazinone herbicides and pyridazinone intermediates used to prepare a herbicide,"Disclosed are compounds of Formula I and N-oxides or salts thereof, wherein R1 is C1-C4 alkyl or C3-C6 cycloalkyl; R2 is H, Cl, Br or I; R3 is Cl or OR4; R4 is H or C1-C4 alkyl; R5 is H, F, Cl or CH3; and R6 is H or Cl; provided (a) when R3 is OR4 and R4 and R5 are both H, then R6 is Cl; and (b) when R2 is Br, R3 is OR4 and R4 is H, then R6 is H. Also disclosed is a composition containing a compound of Formula I, and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound of Formula I or a composition thereof. Also dislosed are methods for preparing a compound of Formula I.",FMC CORP,SELBY THOMAS PAUL;;STEVENSON THOMAS MARTIN;;MCCANN STEPHEN FREDERICK;;MARSHALL ERIC ALLEN;;CHEN YUZHONG,,https://lens.org/124-110-684-787-514,Patent of Addition,no,0,0,21,21,0,C07D237/14;;A01N43/58;;C07D237/16;;C07D237/14;;C07D237/16;;A01N43/58;;C07D237/14;;C07D237/16;;A01N43/58;;A01N43/58;;C07D237/16,C07D237/14;;A01N43/58;;A01P13/00;;C07D237/16,,0,0,,,,PENDING
27,JP,A,JP 2006340714 A,155-009-337-918-928,2006-12-21,2006,JP 2006128058 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,HUMAN MONOCLONAL ANTIBODY TO PD-1 (PROGRAMMED DEATH 1) AND METHOD FOR TREATING CANCER USING THE SAME ANTI-PD-1 ANTIBODY ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPY,"<P>PROBLEM TO BE SOLVED: To provide isolated human monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-1 (programmed death 1) with high affinity. <P>SOLUTION: The isolated human monoclonal antibodies cross-competing for binding to the PD-1 with a reference antibody containing a human heavy chain and a light chain variable regions composed of a specific amino acid sequence or binding portions thereof are provided. Methods for detecting the PD-1 are provided and various diseases including caner and infective diseases can be treated by preparing immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. Furthermore, hyperproliferative diseases such as cancer can be treated by using a combination immunotherapy such as the combination of anti-CTLA-4 and anti-PD-1 antibodies. Adverse events related to treatment with each of the antibodies are altered. <P>COPYRIGHT: (C)2007,JPO&INPIT",ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M,,https://lens.org/155-009-337-918-928,Patent Application,no,0,123,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;A01K67/027;;A61K39/395;;A61P31/04;;A61P31/12;;A61P33/00;;A61P35/00;;C07K16/18;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,0,0,,,,ACTIVE
28,AU,A1,AU 2006/244885 A1,087-370-116-051-788,2006-11-16,2006,AU 2006/244885 A,2006-05-02,US 73843405 P;;US 67946605 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,,MEDAREX INC;;ONO PHARMACEUTICAL CO,CARDARELLI JOSEPHINE M;;CHEN BING;;SELBY MARK J;;KORMAN ALAN J;;WANG CHANGYU;;SRINIVASAN MOHAN,,https://lens.org/087-370-116-051-788,Patent Application,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
29,WO,A1,WO 2006/121168 A1,189-780-986-231-459,2006-11-16,2006,JP 2006309606 W,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1(PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX INC;;KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M,,https://lens.org/189-780-986-231-459,Patent Application,yes,6,1488,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,5,4,093-666-562-457-905;;032-820-729-763-323;;090-247-610-825-843;;060-693-602-478-53X,10.1016/s0165-2478(02)00088-3;;12095712;;8159246;;10.1038/368856a0;;9332365;;10.1016/s0378-1119(97)00260-6;;7851902;;10.1006/geno.1994.1562,"IWAI Y. ET AL.: ""Microanatomical localization of PD-1 in human tonsils"", IMMUNOLOGY LETTERS, vol. 83, no. 3, 2002, pages 215 - 220, XP003007112;;LONBERG N. ET AL.: ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications"", NATURE, vol. 368, no. 6474, 1994, pages 856 - 859, XP000941636;;FINGER L.R. ET AL.: ""The human PD-1 gene: co,plete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors"", GENE, vol. 197, no. 1-2, 1997, pages 177 - 187, XP004126417;;SHINOHARA T. ET AL.: ""Structure and Chromosomal Localization of the Human PD-1 Gene (PDCD1)"", GENOMICS, vol. 23, 1994, pages 704 - 706, XP000647607;;See also references of EP 1896582A4",PENDING
30,EP,A3,EP 2439273 A3,031-844-085-432-093,2012-10-03,2012,EP 11178191 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;EP 09013687 A;;EP 06746353 A;;JP 2006309606 W,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX INC,SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;KORMAN ALAN J,"MEDAREX, L.L.C. (2014-04-23);;E. R. SQUIBB & SONS, L.L.C. (2015-03-04);;ONO PHARMACEUTICAL CO., LTD. (2015-03-04);;MEDAREX, INC. (2013-05-29)",https://lens.org/031-844-085-432-093,Search Report,yes,2,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,3,3,013-122-792-588-081;;032-820-729-763-323;;086-751-695-402-863,10.4049/jimmunol.170.3.1257;;12538684;;8159246;;10.1038/368856a0;;15705911;;10.1158/0008-5472.1089.65.3,"BROWN JULIA A ET AL: ""Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production"", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 170, no. 3, 1 February 2003 (2003-02-01), pages 1257 - 1266, XP002973918, ISSN: 0022-1767;;LONBERG N ET AL: ""ANTIGEN-SPECIFIC HUMAN ANTIBODIES FROM MICE COMPRISING FOUR DISTINCT GENETIC MODIFICATIONS"", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 368, no. 6474, 28 April 1994 (1994-04-28), pages 856 - 859, XP000941636, ISSN: 0028-0836;;HIRANO FUMIYA ET AL: ""Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 65, no. 3, 1 February 2005 (2005-02-01), pages 1089 - 1096, XP002419626, ISSN: 0008-5472",INACTIVE
31,EP,A4,EP 1896582 A4,121-755-824-627-977,2009-04-08,2009,EP 06746353 A,2006-05-02,JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1(PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,,ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M,,https://lens.org/121-755-824-627-977,Search Report,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,3,2,013-122-792-588-081;;044-871-232-135-52X,10.4049/jimmunol.170.3.1257;;12538684;;17898045;;10.1093/intimm/dxm091,"BROWN JULIA A ET AL: ""Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production"", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 170, no. 3, 1 February 2003 (2003-02-01), pages 1257 - 1266, XP002973918, ISSN: 0022-1767;;WONG RAYMOND M ET AL: ""Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs."", INTERNATIONAL IMMUNOLOGY OCT 2007, vol. 19, no. 10, October 2007 (2007-10-01), pages 1223 - 1234, XP009105472, ISSN: 0953-8178;;See also references of WO 2006121168A1",DISCONTINUED
32,EP,A3,EP 2418278 A3,064-435-444-095-579,2012-07-04,2012,EP 11178187 A,2006-05-02,EP 09013687 A;;EP 06746353 A;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX INC,SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;KORMAN ALAN J,"MEDAREX, L.L.C. (2014-04-23);;E. R. SQUIBB & SONS, L.L.C. (2015-03-04);;ONO PHARMACEUTICAL CO., LTD. (2015-03-04);;MEDAREX, INC. (2013-05-29)",https://lens.org/064-435-444-095-579,Search Report,yes,3,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,4,4,013-122-792-588-081;;032-820-729-763-323;;086-751-695-402-863;;117-415-766-090-626,10.4049/jimmunol.170.3.1257;;12538684;;8159246;;10.1038/368856a0;;15705911;;10.1158/0008-5472.1089.65.3;;10.1084/jem.20022119;;12847138;;pmc2196082,"BROWN JULIA A ET AL: ""Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production"", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 170, no. 3, 1 February 2003 (2003-02-01), pages 1257 - 1266, XP002973918, ISSN: 0022-1767;;LONBERG N ET AL: ""ANTIGEN-SPECIFIC HUMAN ANTIBODIES FROM MICE COMPRISING FOUR DISTINCT GENETIC MODIFICATIONS"", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 368, no. 6474, 28 April 1994 (1994-04-28), pages 856 - 859, XP000941636, ISSN: 0028-0836;;HIRANO FUMIYA ET AL: ""Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 65, no. 3, 1 February 2005 (2005-02-01), pages 1089 - 1096, XP002419626, ISSN: 0008-5472;;A. D. SALAMA ET AL: ""Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis"", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 198, no. 1, 1 January 2003 (2003-01-01), pages 71 - 78, XP055014704, ISSN: 0022-1007, DOI: 10.1084/jem.20022119",DISCONTINUED
33,AU,A1,AU 2011/203119 A1,050-935-367-933-809,2011-07-21,2011,AU 2011/203119 A,2011-06-27,AU 2011/203119 A;;AU 2006/244885 A;;US 73843405 P;;US 67946605 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,"HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1(PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS 5 Abstract The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells 1a and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides is methods for using a combination immunotherapy, such as the combination of anti-CT LA 4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;BING CHEN;;MOHAN SRINIVASAN;;CARDARELLI JOSEPHINE M;;SELBY MARK J;;CHANGYU WANG,,https://lens.org/050-935-367-933-809,Patent Application,no,0,6,3,125,0,Y02A50/30,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
34,NO,L,NO 20075697 L,069-647-985-991-25X,2008-02-11,2008,NO 20075697 A,2007-11-07,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,Humane monoklonale antistoffer mot programmert dod 1 (PD-1) og fremgangsmater for a behandle cancer ved anvendelse av anti-PD-1 antistoffer alene eller i kombinasjon med andre immunterapeutika,"SAMMENDRAG Den foreliggende oppfinnelse vedrører isolerte monoklonale antistoffer, særlig humane monoklonale antistoffer, som spesifikt binder til PD-1 med høy affinitet. Nukleinsyremolekyler som koder for antistoffene ifølge oppfinnelsen, ekspresjonsvektorer, vertsceller og fremgangsmåter for å uttrykke antistoffene ifølge oppfinnelsen er også tilveiebrakt. Immunokonjugater, bispesifikke molekyler og farmasøytiske sammensetninger som omfatter antistoffene ifølge oppfinnelsen er også tilveiebrakt. Oppfinnelsen tilveiebringer også fremgangsmåter for å detektere PD-1, så vel som fremgangsmåter for å behandle forskjellige sykdommer som inkluderer cancer og infeksjonssykdommer, ved anvendelse av anti-PD-1 antistoffer. Den foreliggende oppfinnelse tilveiebringer videre fremgangsmåter for å anvende en kombinasjonsterapi, slik som kombinasjon av anti-CTLA-4 og anti-PD-1 antistoffer, for å behandle hyperproliferativ sykdom, slik som cancer. Oppfinnelsen tilveiebringer også fremgangsmåter for å endre negative hendelser relatert til behandling med slike antistoffer individuelt.",MEDAREX INC,CARDARELLI JOSEPHINE M;;WANG CHANGYU;;SRINIVASAN MOHAN;;KORMAN ALAN J;;SELBY MARK J;;CHEN BING,"ONO PHARMACEUTICAL CO LTD, US (2015-08-31)",https://lens.org/069-647-985-991-25X,Abstract,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/18;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
35,ZA,B,ZA 200709631 B,075-321-962-191-329,2008-11-26,2008,ZA 200709631 A,2007-11-08,US 67946605 P,2005-05-09,Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,,ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;CHANGYU WANG;;BING CHEN;;MOHAN SRINIVASAN;;SELBY MARK J;;CARDARELLI JOSEPHINE M,,https://lens.org/075-321-962-191-329,Granted Patent,no,0,0,1,125,0,Y02A50/30,C07K/;;C12N/;;C12P/;;C12Q/,,0,0,,,,ACTIVE
36,CA,A1,CA 2607147 A1,108-509-456-010-775,2006-11-16,2006,CA 2607147 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1(PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,,ONO PHARMACEUTICAL CO;;MEDAREX INC,CARDERELLI JOSEPHINE M;;KORMAN ALAN J;;SRINIVASAN MOHAN;;CHEN BING;;SELBY MARK J;;WANG CHANGYU,,https://lens.org/108-509-456-010-775,Patent Application,no,0,5,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
37,BR,B8,BR PI0610235 B8,009-665-067-130-71X,2021-05-25,2021,BR PI0610235 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,"anticorpos monoclonais geneticamente modificados e diferentes daqueles encontrados na natureza, ou porção de ligação ao antígeno dos mesmos, usos terapêuticos dos mesmos, composições, imunoconjugado, molécula biespecífica compreendendo os mesmos, molécula de ácido nucléico e vetor de expressão","anticorpos monoclonais humanos para morte programada 1(pd-1) e usos de anticorpos anti-pd-1 sozinhos ou em combinação com outros imunoterapêuticos para preparação de composições farmacêuticas para tratamento do câncer a presente invenção provê anticorpos monoclonais geneticamente modificados e diferentes daqueles encontrados na natureza, particularmente anticorpos monoclonais humanos que se ligam especificamente ao pd-1 com afinidade alta. são também providas moléculas de ácido nucléico codificando os anticorpos da invenção, vetores de expressão, células hospedeiras e métodos para expressão dos anticorpos da invenção. são também providos imunoconjugados, moléculas biespecíficas e composições farmacêuticas compreendendo os anticorpos da invenção. a invenção também provê métodos para detectar pd-1, bem como métodos para tratamento de várias doenças, incluindo câncer e doenças infecciosas, usando anticorpos anti-pd-1. a presente invenção também provê métodos para emprego de uma imunoterapia de combinação, tal como, a combinação de anticorpos anti-ctla-4 e anticorpos anti-pd-1, para tratamento de doença hiperproliferativa, tal como, câncer. a invenção também provê métodos para alterar eventos adversos relacionados ao tratamento individual com tais anticorpos. além disso, a invenção revela usos de anticorpos anti-pd-l sozinhos ou em combinação com outros imunoterapêuticos para preparação de composições farmacêuticas para tratamento de câncer.",SQUIBB & SONS LLC;;MEDAREX INC;;MEDAREX LLC;;ONO PHARMACEUTICAL CO,ALAN J KORMAN;;BING CHEN;;CHANGYU WANG;;JOSEPHINE M CARDARELLI;;MARK J SELBY;;MOHAN SRINIVASAN,"ONO PHARMACEUTICAL CO., LTD. (JP) , E. R. SQUIBB A (2015-11-24);;ONO PHARMACEUTICAL CO., LTD. (JP) , MEDAREX, L.L.C (2014-09-23)",https://lens.org/009-665-067-130-71X,Amended Patent,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395;;A61P35/00;;C07K16/30;;C12N15/13;;C12P21/08,,0,0,,,,ACTIVE
38,EP,A1,EP 1896582 A1,035-036-482-129-661,2008-03-12,2008,EP 06746353 A,2006-05-02,JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1(PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,,ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M,,https://lens.org/035-036-482-129-661,Patent Application,yes,0,13,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,DISCONTINUED
39,TW,B,TW I379898 B,114-857-816-852-246,2012-12-21,2012,TW 95116202 A,2006-05-08,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics,,MEDAREX INC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M,,https://lens.org/114-857-816-852-246,Granted Patent,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,,,0,0,,,,ACTIVE
40,KR,A,KR 20080011428 A,133-098-254-617-387,2008-02-04,2008,KR 20077028376 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M,,https://lens.org/133-098-254-617-387,Patent Application,no,0,13,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28,,0,0,,,,ACTIVE
41,BR,B1,BR PI0610235 B1,165-730-332-546-199,2020-05-05,2020,BR PI0610235 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,"anticorpos monoclonais geneticamente modificados e diferentes daqueles encontrados na natureza, ou porção de ligação ao antígeno dos mesmos, usos terapêuticos dos mesmos, composições, imunoconjugado, molécula biespecífica compreendendo os mesmos, molécula de ácido nucléico e vetor de expressão","a presente invenção provê anticorpos monoclonais geneticamente modificados e diferentes daqueles encontrados na natureza, particularmente anticorpos monoclonais humanos que se ligam especificamente ao pd-1 com afinidade alta. são também providas moléculas de ácido nucléico codificando os anticorpos da invenção, vetores de expressão, células hospedeiras e métodos para expressão dos anticorpos da invenção. são também providos imunoconjugados, moléculas biespecíficas e composições farmacêuticas compreendendo os anticorpos da invenção. a invenção também provê métodos para detectar pd-1, bem como métodos para tratamento de várias doenças, incluindo câncer e doenças infecciosas, usando anticorpos anti-pd-1. a presente invenção também provê métodos para emprego de uma imunoterapia de combinação, tal como, a combinação de anticorpos anti-ctla-4 e anticorpos anti-pd-1, para tratamento de doença hiperproliferativa, tal como, câncer. a invenção também provê métodos para alterar eventos adversos relacionados ao tratamento individual com tais anticorpos. além disso, a invenção revela usos de anticorpos anti-pd-l sozinhos ou em combinação com outros ímunoterapêuticos para preparação de composições farmacêuticas para tratamento de câncer.",SQUIBB & SONS LLC;;MEDAREX INC;;MEDAREX LLC;;ONO PHARMACEUTICAL CO,ALAN J KORMAN;;BING CHEN;;CHANGYU WANG;;JOSEPHINE M CARDARELLI;;MARK J SELBY;;MOHAN SRINIVASAN,"ONO PHARMACEUTICAL CO., LTD. (JP) , E. R. SQUIBB A (2015-11-24);;ONO PHARMACEUTICAL CO., LTD. (JP) , MEDAREX, L.L.C (2014-09-23)",https://lens.org/165-730-332-546-199,Granted Patent,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395;;A61P35/00;;C07K16/30;;C12N15/13;;C12P21/08,,0,0,,,,ACTIVE
42,JP,A,JP 2009155338 A,030-634-154-032-930,2009-07-16,2009,JP 2009086400 A,2009-03-31,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,CANCER THERAPEUTIC METHOD SINGLY USING HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH 1 (PD-1) AND ANTI-PD-1 ANTIBODY OR CONCURRENTLY USING WITH OTHER IMMUNOTHERAPY,"<P>PROBLEM TO BE SOLVED: To provide an isolated monoclonal antibody with high affinity which specifically binds with a Programmed Death 1 (PD-1), particularly a human monoclonal antibody. <P>SOLUTION: An isolated human monoclonal antibody cross competitively binds with a reference antibody including human heavy- and light-chain variable areas composed of specific amino acid sequences and PD-1 or its binding site. An immunocomplex containing an antibody, a double specific molecule and a pharmaceutical composition are prepared to make possible a PD-1 detection method and curable various diseases including cancer and infectious diseases. Furthermore, highly proliferative diseases such as cancer can also be treated by a concurrent immunotherapy such as a combination of anti-CTLA-4 and anti-PD-1 antibodies. Harmful phenomena related to each therapy of such antibodies are modified. <P>COPYRIGHT: (C)2009,JPO&INPIT",ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M,,https://lens.org/030-634-154-032-930,Patent Application,no,4,12,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395;;A61P35/00;;A61P43/00;;C07K16/28,,0,0,,,,ACTIVE
43,AU,B2,AU 2011/203119 B2,050-654-620-648-083,2012-03-08,2012,AU 2011/203119 A,2011-06-27,AU 2011/203119 A;;AU 2006/244885 A;;US 73843405 P;;US 67946605 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,"HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1(PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS 5 Abstract The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells 1a and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides is methods for using a combination immunotherapy, such as the combination of anti-CT LA 4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;CHEN BING;;SRINIVASAN MOHAN;;CARDARELLI JOSEPHINE M;;SELBY MARK J;;WANG CHANGYU,,https://lens.org/050-654-620-648-083,Granted Patent,no,0,0,3,125,0,Y02A50/30,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
44,NZ,A,NZ 563193 A,056-606-711-572-637,2010-05-28,2010,NZ 56319306 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,"Disclosed is an isolated human monoclonal antibody, or an antigen-binding portion thereof, wherein the antibody cross-competes for binding to PD-1 with a reference antibody. Methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies are also disclosed.",ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M,"ONO PHARMACEUTICAL CO., LTD., NZ (2015-01-22);;E. R. SQUIBB + SONS, L.L.C., US (2015-01-22);;MEDAREX, L.L.C., NZ (2014-02-13)",https://lens.org/056-606-711-572-637,Patent Application,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,PENDING
45,BR,A2,BR PI0610235 A2,115-655-622-276-392,2010-06-08,2010,BR PI0610235 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,anticorpos monoclonais humanos para morte programada 1 (pd-1) e usos de anticorpos anti-pd-1 sozinhos ou em combinação com outros imunoterapêuticos para preparação de composições farmacêuticas para tratamento do cáncer,"A presente invenção provê anticorpos monoclonais geneticamente modificados e diferentes daqueles encontrados na natureza, particularmente anticorpos monoclonais humanos que se ligam especificamente ao PD-1 com afinidade alta. São também providas moléculas de ácido nucléico codificando os anticorpos da invenção, vetores de expressão, células hospedeiras e métodos para expressão dos anticorpos da invenção. São também providos imunoconjugados, moléculas biespecíficas e composições farmacêuticas compreendendo os anticorpos da invenção. A invenção também provê métodos para detectar PD-1, bem como métodos para tratamento de várias doenças, incluindo câncer e doenças infecciosas, usando anticorpos anti-PD-1. A presente invenção também provê métodos para emprego de uma imunoterapia de combinação, tal como, a combinação de anticorpos anti-CTLA-4 e anticorpos anti-PD-1, para tratamento de doença hiperproliferativa, tal como, câncer. A invenção também provê métodos para alterar eventos adversos relacionados ao tratamento individual com tais anticorpos. Além disso, a invenção revela usos de anticorpos Anti-PD-l sozinhos ou em combinação com outros ímunoterapêuticos para preparação de composições farmacêuticas para tratamento de câncer.",ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M,"ONO PHARMACEUTICAL CO., LTD. (JP) , E. R. SQUIBB A (2015-11-24);;ONO PHARMACEUTICAL CO., LTD. (JP) , MEDAREX, L.L.C (2014-09-23)",https://lens.org/115-655-622-276-392,Patent Application,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
46,AU,B2,AU 2006/244885 B2,021-670-659-348-318,2011-03-31,2011,AU 2006/244885 A,2006-05-02,US 73843405 P;;US 67946605 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,,SQUIBB & SONS LLC;;ONO PHARMACEUTICAL CO,CARDARELLI JOSEPHINE M;;CHEN BING;;SELBY MARK J;;KORMAN ALAN J;;WANG CHANGYU;;SRINIVASAN MOHAN,,https://lens.org/021-670-659-348-318,Granted Patent,no,2,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
47,MX,A,MX 2007013978 A,160-500-000-825-911,2008-02-22,2008,MX 2007013978 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006009606 W,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1(PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS.,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO,CARDARELLI JOSEPHINE M;;SRINIVASAN MOHAN;;KORMAN ALAN J;;WANG CHANGYU;;SELBY MARK J;;CHEN BING,,https://lens.org/160-500-000-825-911,Patent Application,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
48,US,A1,US 2009/0217401 A1,007-609-627-607-59X,2009-08-27,2009,US 91321706 A,2006-05-02,US 91321706 A;;US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,Human Monoclonal Antibodies To Programmed Death 1(PD-1) And Methods For Treating Cancer Using Anti-PD-1 Antibodies Alone or in Combination with Other Immunotherapeutics,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;ONO PHARMACEUTICAL CO. LTD (2007-12-27);;MEDAREX INC (2012-04-12),https://lens.org/007-609-627-607-59X,Patent Application,yes,21,301,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A01K67/027;;A61K39/395;;A61P35/00;;C07H21/00;;C07K16/18;;C12N5/10;;C12N5/16;;C12N15/74,800/18;;530/388.15;;424/142.1;;536/23.53;;435/320.1;;435/325;;435/326;;530/402,0,0,,,,ACTIVE
49,CA,A1,CA 3201163 A1,000-826-653-421-496,2007-01-11,2007,CA 3201163 A,2006-06-30,US 69642605 P;;CA 3018525 A,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. lmmunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",SQUIBB & SONS LLC,KORMAN ALAN;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/000-826-653-421-496,Patent Application,no,0,0,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,,,0,0,,,,PENDING
50,ME,B,ME 02260 B,101-747-843-255-528,2016-02-29,2016,ME P64815 A,2006-06-30,US 69642605 P;;EP 06786260 A;;US 2006/0026046 W,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),,MEDAREX INC,HUANG HAICHUN;;KORMAN ALAN;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;CHEN HAIBIN,,https://lens.org/101-747-843-255-528,Granted Patent,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
51,CN,A,CN 103059138 A,134-595-790-357-930,2013-04-24,2013,CN 201210554886 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;CN 200680023860 A,2005-05-09,Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/134-595-790-357-930,Patent Application,no,1,28,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/395;;A61P35/00;;C12N5/10;;C12N15/13;;C12N15/63,,2,2,005-416-473-959-707;;006-568-097-103-41X,15611321;;10.1093/intimm/dxh194;;10.1073/pnas.192461099;;12218188;;pmc129438,"YOSHIKO ET AL: ""PD-1 blokade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells"", 《INTERNATIONAL IMMUNOLOGY》;;YOSHIKO ET AL: ""Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade"", 《PNAS》",ACTIVE
52,TW,A,TW 200716743 A,176-001-709-507-106,2007-05-01,2007,TW 95116202 A,2006-05-08,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention farther provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",MEDAREX INC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANG-YU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M,,https://lens.org/176-001-709-507-106,Patent of Addition,no,0,1,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;A01K67/027;;A61K39/395;;A61P31/04;;A61P31/12;;A61P33/00;;A61P35/00;;C07K16/18;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08,,0,0,,,,ACTIVE
53,US,B2,US 9492540 B2,003-112-804-647-922,2016-11-15,2016,US 201414270750 A,2014-05-06,US 201414270750 A;;US 201113210137 A;;US 91321706 A;;JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Methods for treating cancer using anti-PD-1 antibodies,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",SQUIBB & SONS LLC;;ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;ONO PHARMACEUTICAL CO. LTD (2007-12-27);;MEDAREX INC (2012-04-12),https://lens.org/003-112-804-647-922,Granted Patent,yes,89,113,120,125,82,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395;;A61K39/00;;A61K47/48;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/46,,99,34,099-845-492-851-481;;029-890-487-783-799;;074-976-826-866-732;;001-256-484-369-395;;034-879-699-905-632;;010-811-198-482-852;;103-897-301-868-65X;;197-193-057-828-756;;001-779-867-387-972;;013-584-945-188-940;;115-398-566-039-426;;135-447-350-940-622;;052-153-724-747-948;;147-888-721-956-877;;166-025-821-402-033;;057-460-007-966-306;;006-463-263-246-432;;013-770-850-974-489;;124-864-341-496-45X;;152-923-894-609-509;;085-413-318-249-981;;063-455-531-393-728;;060-728-367-476-688;;010-097-148-050-263;;031-431-800-409-592;;051-918-569-782-385;;079-083-105-219-723;;042-819-179-681-837;;015-898-381-155-805;;025-253-136-774-180;;014-903-975-216-318;;043-030-710-125-973;;051-224-574-304-090;;083-811-051-643-47X,10.1016/j.pharmthera.2014.11.017;;25476108;;11973140;;10.1016/s0952-7915(02)00341-2;;9277127;;11470598;;10.1016/s1367-5931(00)00216-7;;7481795;;10.1126/science.270.5238.932;;15785203;;10.1089/hyb.2005.24.1;;pmc4348009;;10.1056/nejmoa1411087;;25482239;;10.1016/s0075-7535(08)70702-2;;10.1006/jmbi.1999.3192;;10543973;;10.1182/blood-2002-06-1761;;12393541;;10.1177/107327481402100112;;24357746;;pmc40169;;8552677;;10.1073/pnas.93.1.7;;16285013;;10.1002/eji.200535232;;10.1093/protein/11.1.65;;9579662;;10.1016/s0958-1669(98)80091-8;;9503595;;10.1016/s1535-6108(04)00083-2;;15093539;;10.2210/pdb1s78/pdb;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;18410894;;10.1016/j.bbmt.2008.02.010;;pmc2423190;;10.1038/78963;;10966641;;18429302;;9592769;;10.1007/bf02752698;;14530338;;10.4049/jimmunol.171.8.4156;;18059626;;10.1080/02648725.2007.10648092;;10.1089/hyb.1996.15.343;;8913783;;10.1074/jbc.m402194200;;15128741;;10.1038/ni1398;;17013388;;pmc1895332;;10.1182/blood-2005-04-1531;;16020508;;pmc2956066;;20817874;;10.4049/jimmunol.1001536;;16116203;;10.4049/jimmunol.175.5.3133;;19448431;;pmc2737335;;10.4161/cc.8.11.8738;;10.1182/blood-2005-06-2298;;pmc1895337;;16037385;;10.1182/blood-2004-07-2561;;15486062;;10.1016/j.clim.2014.02.015;;24631965;;pmc4082337;;17404099;;10.1158/1078-0432.ccr-06-2746,"Berman, D., et al., ""The Development of Immunomodulatory Monoclonal Antibodies as a New Therapeutic Modality for Cancer: The Bristol-Myers Squibb Experience,"" Pharmacology and Therapeutics 148:132-153, Elsevier, Inc., England (Apr. 2015).;;Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Jun. 30, 2015, 49 pages.;;Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Jul. 7, 2015, 48 pages.;;Declaration of James L. Riley, Ph.D., Aug. 10, 2015, 6 pages, submitted with Response to Grounds of Appeal, in European Patent No. 1537878.;;Greenwald, R.J., et al., ""Negative Co-receptors on Lymphocytes,"" Current Opinion in Immunology 14(3):391-396, Elsevier Science Ltd., England (Jun. 2002).;;Minutes of the Oral Proceedings of Dec. 17, 2014, in European Patent No. EP 0921183, 3 pages.;;Notice of Pre-grant Opposition mailed Jul. 21, 2015, in IN Patent Application No. 5057/CHENP/2007, Indian Pharmaceuticals Alliance, filed May 2, 2006.;;Response to Grounds of Appeal, dated Aug. 12, 2015, in European Patent No. EP 1537878, 76 pages.;;""Summary of a list of clinical trials available from the website ClinicalTrials.gov of the US National Institutes of Health,"" dated Aug. 10, 2015, 18 pages, submitted with Response to Grounds of Appeal in European Patent No. EP 1537878.;;Brief Supporting Motion to Dismiss, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Aug. 21, 2015, 25 pages.;;Brief Supporting Motion to Dismiss, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Aug. 28, 2015, 24 pages.;;Declaration of Andrew C. Mayo, Aug. 21, 2015, 2 pages.;;Declaration of John G. Day, Aug. 28, 2015, 2 pages.;;Motion to Dismiss, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Aug. 21, 2015. 3 pages.;;Motion to Dismiss, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck &. Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Aug. 28, 2015, 3 pages.;;Nema, S., et al., ""Excipients and Their Use in Injectable Products,"" PDA J Pharm Sci Technol. 51(4):166-171, Pda (Parenteral Drug Association), United States (1997).;;Plaintiff's Objections and Responses Admission, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Jul. 1, 2015, 11 pages.;;Van Dijk, M.A. and Van De Winkel J.G., ""Human antibodies as next generation therapeutics,"" Curr Opin Chem Biol. 5(4)368-374, Elsevier Ltd., England (2001).;;Office action mailed Nov. 18, 2015, in U.S. Appl. No. 14/227,733, inventors Korman. A., et al., filed Mar. 27, 2014.;;Abbas, A.K., et al., Cellular and Molecular Immunobiology, 2nd ed., pp. 8, 47-50, W.B. Saunders Company, United States (1991).;;Alignment of Amino Acid Sequences for Extracellular Domain of Wild-Type (UniProt Q15116) Human PD-1, Wild-Type (MednaBio) PD-1 ECD, C62S Variant of Wild-Type Human PD-1 ECD, and A101L Variant of Wild-Type Human PD-1 ECD, 1 pages, submitted with Opposition to EP Pat. No. 2161336 on Apr. 30, 2014.;;Allison, J.P. and Krummel, M.F., ""The Yin and Yang of T Cell Costimulation,"" Science 270(5238):932-933, American Association for the Advancement of Science, United States (1995).;;Amended Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Nov. 21, 2014, 11 pages.;;Andre, E., et al., ""Precise Characterization of the Epitope Recognized by a Monoclonal Antibody Against Escherichia coli RNA Polymerase,"" Hybridoma 24(1):1-5, Mary Ann Liebert, Inc., United States (Feb. 2005).;;Ansell, S.M., et al., ""PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma,"" The New England Journal of Medicine 372(4):311-319, Massachusetts Medical Society, United States (Jan. 22, 2015).;;Answer to Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Oct. 31, 2014, 15 pages.;;Answer to Plaintiffs' Amended Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Dec. 8, 2014, 17 pages.;;Anti-Human CD279 (PD-1) Datasheet, 14-2799, J105, eBioscience, Sep. 6, 2013, 1 page.;;Anti-Human CD279 (PD-1) Datasheet, 14-9989, J116, eBioscience, Sep. 6, 2013, 1 page.;;Anti-Human CD279 (PD-1) Purchase Receipts, eBioscience, Oct. 8, 2013, 4 pages.;;Antonia, S.J., et al., ""Association of tumor PD-L1 Expression and Immune Biomarkers with Clinical Activity in Patients with Non-small Cell Lung Cancer (NSCLC) Treated with Nivolumab (Anti-PD-1; BMS-936558; ONO-4538),"" 15th World Conference on Lung Cancer, Sydney, Australia, 15th WCLC: Best of Posters 1-IASLC Selection, P2.11-035, Oct. 27-30, 2013, accessed at http://web.oncoletter.ch/kongressberichte-videos-slides-Onkologie/id-15th-world-conference-on-lung-cancer-conference/conference-highlights.html, accessed on Jan. 8, 2015, 6 pages.;;Appendix to Declaration of Vassiliki A. Boussiotis, Apr. 28, 2014, Data and Records for Example Experiments 21 and 22, 18 pages.;;Armand, P., et al., ""289 Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma-Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study,"" 56th ASH Annual Meeting and Exposition, Abstracts & Program, San Francisco, CA, Dec. 6-9, 2014.;;Berg, J.M., et al., ""The Immune System,"" in Biochemistry 5th ed., pp. 921-950, W.H. Freeman and Company, United States (2002).;;Biacore, ""Application Note 1: Characterization of monoclonal antibody epitope specificity using Biacore's SPR technology,"" Biacore AB, 8 pages (2002).;;Biacore, Sensor Surface Handbook, BR-1005-71, edition AB, pp. 1-98, GE Healthcare (Feb. 2005).;;Biacore, ""The SPR signal, "" ""Interpreting experimental data,"" and ""BIA application areas,"" in BIAtechnology Handbook, version AB, chapters 4-6, 34 pages, Biacore AB (1998).;;Campbell, A.M., ""Characterisation of monoclonal antibodies,"" in Laboratory Techniques in Biochemistry and Molecular Biology, Monoclonal Antibody Technology: The Production and Characterization of Rodent and Human Hybridomas, vol. 13, pp. 186-215, Elsevier, the Netherlands (1984).;;CD279/PD-1, D132-3/J110 Datasheet, MBL Medical & Biological Laboratories Co., Ltd., Sep. 6, 2013, 2 pages.;;Chen, Y., et al., ""Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,"" Journal of Molecular Biology 293(4):865-881, Academic Press, England (1999).;;Communication pursuant to Article 94(3) EPC mailed on Dec. 22, 2014, in European Application No. 11 178 187.8-1410, European Patent Office, Germany.;;Communication pursuant to Article 94(3) EPC mailed on Dec. 22, 2014, in European Application No. 11 178 191.0-1410, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, mailed Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178187, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, mailed Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178188, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, mailed Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178191, European Patent Office, Germany.;;Complaint, Bristol-Myers Squibb Co. and Ono Pharmaceutical Co., Ltd. v. Merck & Co., Inc., 1:14-cv-01131-GMS, filed Sep. 4, 2014, 9 pages.;;Co-pending U.S. Appl. No. 14/547,026, inventors Korman, A.J., et al., filed Nov. 18, 2014 (Not Published).;;Co-pending U.S. Appl. No. 14/638,985, inventors Honjo, T., et al., filed Mar. 4, 2015 (Not Published).;;Cragg, M.S., et al., ""Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts,"" Blood 101(3):1045-1052, American Society of Hematology, United States (2003).;;Creelan, B.C., ""Update on Immune Checkpoint Inhibitors in Lung Cancer,"" Journal of the Moffitt Cancer Center 21(1):80-89, H. Lee Moffitt Cancer Center and Research Institute, United States (2014).;;Cruse, J.M. and Lewis, R.E., ""Antigens and Immunogens,"" in Atlas of Immunology, 2nd ed., pp. 105-126, CRC Press, United States (Dec. 29, 2003).;;Curriculum Vitae of Brian T. Fife, Ph.D., 7 pages, submitted with Response to Oppositions against EP Pat. No. 2161336 on Feb. 16, 2015.;;Curriculum Vitae of Dr. Robert J. Bloch, Apr. 11, 2012, 34 pages, submitted with Opposition to EP Pat. No. 2161336.;;Curriculum Vitae of Vassiliki A. Boussiotis, Nov. 8, 2013, 24 pages, submitted with Opposition to EP Pat. No. 2161336.;;Davies, D.R. and Cohen, G.H., ""Interactions of protein antigens with antibodies,"" Proceedings of the National Academy of Sciences USA 93(1):7-12, National Academy of Sciences, United States (1996).;;Declaration of Dr. Haidong Dong, Mar. 31, 2014, 15 pages, submitted with Opposition to EP Pat. No. 1537878.;;Declaration of Professor Brian T. Fife, Feb. 12, 2015, 4 pages, submitted with Response to Oppositions against EP Pat. No. 2161336.;;Del Rio, M-L., et al., ""Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation,"" European Journal of Immunology 35(12):3545-3560, Wiley-VCH Verlag GmbH & Co. KGaA, Germany (Dec. 2005).;;Dougan, D.A., et al., ""Effects of substitutions in the binding surface of an antibody on antigen affinity,"" Protein Engineering 11(1):65-74, Oxford University Press, England (1998).;;Email from MednaBio to Robert Bloch re: E1951MG1-Sequence Information, Apr. 25, 2014, 1 page.;;ExPASy Bioinformatics Resource Portal calculation based on ECD of UniProt Sequence Q15116, accessed at http://web.expasy.org/cgi-bin/compute-pi/pi-tool, accessed on Apr. 28, 2014, 1 page.;;Extended European Search Report for EP Application No. 06746353.9, European Patent Office, Germany, mailed on Mar. 6, 2009.;;Extended European Search Report for EP Application No. 09013687.0, European Patent Office, Germany, mailed on Jan. 29, 2010.;;Extended European Search Report for EP Application No. 10172772.5, European Patent Office, Netherlands, mailed on Sep. 9, 2010.;;Extended European Search Report for EP Application No. 11178187.8, European Patent Office, Germany, mailed on Jun. 1, 2012.;;Extended European Search Report for EP Application No. 11178188.6, European Patent Office, Germany, mailed on Jun. 27, 2013.;;Extended European Search Report for EP Application No. 11178191.0, European Patent Office, Germany, mailed on Sep. 5, 2012.;;Fivash, M., et al., ""BIAcore for macromolecular interaction,"" Current Opinion in Biotechnology 9(1):97-101, Current Biology, England (1998).;;Franklin, M.C., et al., ""Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex,"" Cancer Cell 5(4):317-328, Cell Press, United States (Apr. 2004).;;Freeman, G.J., et al., ""Engagement of the PD-1 Immunoinhibitory by a Novel B7-Family Member Leads to Negative Regulation of Lymphocyte Activation,"" Blood 96(11):810a-811a, (Abstract No. 3502) (2000).;;Ge, X., et al., ""CD134-Allodepletion Allows Selective Elimination of Alioreactive Human T Cells without Loss of Virus-Specific and Leukemia-Specific Effectors,"" Biology of Blood and Marrow Transplantation 14(5):518-530, American Society for Blood and Marrow Transplantation, United States (2008).;;Greenspan, N.S., ""Epitopes, paratopes and other topes: do immunologists know what they are talking about?"" Bulletin de l'Institut Pasteur 90(4):267-279, Elsevier, France (1992).;;Harlow, E. and Lane, D., ""Using Antibodies: A Laboratory Manual,"" Cold Spring Harbor Laboratory Press, Cold Spring Harbor, United States various pages (1999).;;International Preliminary Report on Patentability for International Application No. PCT/JP2006/309606, The International Bureau of WIPO, Switzerland, issued on Nov. 13, 2007.;;International Search Report for International Application No. PCT/JP03/08420, Japanese Patent Office, Japan, mailed Oct. 21, 2003.;;International Search Report for International Application No. PCT/JP2006/309606, Japanese Patent Office, Japan, mailed on Aug. 15, 2006.;;Ishima, R. and Torchia, D.A., ""Protein Dynamics from NMR,"" Nature Structural Biology 7(9):740-743, Nature Publishing Company, United States (2000).;;J105/D133-3 Datasheet, MBL Medical & Biological Laboratories Co., Ltd., Mar. 20, 2013, 2 pages.;;J105/D133-3 Purchase Order, MBL Medical & Biological Laboratories Co., Ltd., Apr. 11, 2014, 1 page.;;J105/D133-3 Purchase Receipts, Invoice MINV52635, MBL International Corporation, Oct. 2, 2013, 2 pages.;;Jason-Moller, L., et al., ""Overview of Biacore Systems and Their Applications,"" Current Protocols in Protein Science S45:19.13.1-19.13.14, John Wiley & Sons, Inc., United States (2006).;;Johne, B., ""Protocol: Epitope Mapping by Surface Plasmon Resonance in the BIAcore,"" Molecular Biotechnology 9(1):65-71, Humana Press, United States (1998).;;Kanai, T., et al., ""Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation,"" The Journal of Immunology 171(8):4156-4163, American Association of Immunologists, Inc., United States (2003).;;Ladner, R.C., ""Mapping the Epitopes of Antibodies,"" Biotechnology and Genetic Engineering Reviews 24(1):1-30, Taylor & Francis, England (2007).;;Laricchia-Robbio, L., et al., ""Mapping of Monoclonal Antibody- and Receptor-Binding Domains on Human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF) Using a Surface Plasmon Resonance-Based Biosensor,"" Hybridoma 15(5):343-350, Mary Ann Liebert, Inc., United States (1996).;;Lesokhin, A.M., et al., ""291 Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed of Refractory Lymphoid Malignancies,"" 56th ASH Annual Meeting and Exposition, Abstracts & Program, San Francisco, CA, United States, Dec. 6-9, 2014.;;Lewis, D.E., et al., ""Tumor Necrosis Factor-alpha and CD80 Modulate CD28 Expression through a Similar Mechanism of T-cell Receptor-Independent Inhibition of Transcription,"" The Journal of Biological Chemistry 279(28):29130-29138, The American Society for Biochemistry and Molecular Biology, Inc., United States (Jul. 2004).;;Li, L., et al., ""A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance,"" Nature Immunology 7(11):1157-1165, Nature Publishing, United States (2006).;;Li, L., et al., ""CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties and T-cell anergy,"" Blood 106(9):3068-3073, American Society of Hematology, United States (Nov. 2005).;;Li, L., et al., ""IL-1beta-Mediated Signals Preferentially Drive Conversion of Regulatory T Cells but Not Conventional T Cells into IL-17-Producing Cells,"" The Journal of Immunology 185(7):4148-4153, American Association of Immunologists, Inc., United States (2010).;;Li, L., et al., ""Rap1-GTP is a Negative Regulator of Th Cell Function and Promotes the Generation of CD4+CD103+ Regulatory T Cells in Vivo,"" The Journal of Immunology 175(5):3133-3139, American Association of Immunologists, Inc., United States (Sep. 2005).;;Li, L., et al., ""The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD,"" Cell Cycle 8(11):1794-1802, Landes Bioscience, United States (2009).;;""List of Clinical Trials with Nivolumab from the website ClinicalTrials.gov of U.S. National Institutes of Health"" submitted with Response to Oppositions against EP Pat. No. 2161336, mailed on Feb. 16, 2015, 11 pages.;;Lute, K.D., et al., ""Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies,"" Blood 106(9):3127-3133, American Society of Hematology, United States (Nov. 2005).;;May, K.F., Jr., et al., ""Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies,"" Blood 105(3):1114-1120, American Society of Hematology, United States (Feb. 2005).;;Nellore, A., et al., ""The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors,"" Clinical Immunology 152(1-2):48-57 (May-Jun. 2014; Epub Mar. 12, 2014).;;Nomi, T., et al., ""Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer,"" Clinical Cancer Research 13(7):2151-2157, The Association, United States (2007).;;Office Action mailed Apr. 13, 2015, in U.S. Appl. No. 14/638,985, inventors Honjo, T., et al., filed Mar. 4, 2015.;;Office Action mailed Jan. 7, 2015, in U.S. Appl. No. 14/550,585, inventors Honjo, T., et al., filed Nov. 21, 2014.",ACTIVE
54,EP,A1,EP 2161336 A1,013-007-411-317-963,2010-03-10,2010,EP 09013687 A,2006-05-02,EP 06746353 A;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,"ONO PHARMACEUTICAL CO., LTD., US (2015-01-30);;MEDAREX, L.L.C. (2014-03-03);;MEDAREX, L.L.C., PRINCETON, US (2014-04-01);;E.R. SQUIBB & SONS, L.L.C., PRINCETON, NJ, US (2015-07-15);;ONO PHARMACEUTICAL CO., LTD., OSAKA-SHI, OSAKA, JP (2015-07-15);;MEDAREX, L.L.C., PRINCETON, NEW JERSEY, US (2014-06-05);;MEDAREX, L.L.C., US (2014-04-01);;E. R. SQUIBB & SONS, L.L.C. (2015-04-22);;E. R. SQUIBB & SONS, L.L.C. (N.D.GES.D. STAATE, US (2015-02-05);;ONO PHARMACEUTICAL CO., LTD., JP (2016-04-19);;ONO PHARMACEUTICAL CO., LTD. (2015-04-22);;E. R. SQUIBB & SONS, L.L.C., US (2016-04-19);;MEDAREX, INC. (2013-05-29);;ONO PHARMACEUTICAL CO., LTD.; US (2015-02-13)",https://lens.org/013-007-411-317-963,Patent Application,yes,114,68,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,162,128,013-122-792-588-081;;032-820-729-763-323;;076-092-237-434-500;;127-416-339-660-812;;117-522-189-960-276;;004-728-346-095-981;;043-645-889-898-36X;;020-766-613-912-972;;006-463-263-246-432;;052-597-675-128-75X;;081-074-583-383-824;;076-731-232-972-252;;066-015-167-169-542;;006-568-097-103-41X;;013-122-792-588-081;;062-940-851-081-865;;048-060-748-635-820;;117-415-766-090-626;;038-551-014-784-214;;074-046-354-648-540;;008-208-772-364-327;;020-598-246-146-62X;;074-297-827-128-411;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;026-164-216-541-151;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;042-204-626-457-327;;006-574-964-805-278;;030-323-674-660-051;;092-023-577-402-127;;022-179-293-052-569;;004-458-031-333-650;;024-929-137-199-30X;;003-752-183-823-430;;070-318-112-524-781;;032-624-544-479-82X;;002-264-966-090-625;;030-630-100-818-462;;106-753-778-592-300;;032-820-729-763-323;;083-549-078-331-651;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;033-754-369-798-314;;077-525-954-203-403;;028-969-172-280-017;;060-375-551-951-388;;020-753-772-581-741;;038-613-711-274-229;;047-951-914-695-080;;062-485-301-455-912;;032-820-729-763-323;;023-676-781-371-861;;026-744-100-669-883;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;030-769-003-988-749;;057-971-690-843-179;;145-254-035-276-41X;;026-646-521-253-318;;000-331-240-115-824;;065-438-177-962-139;;006-574-942-364-256;;101-640-792-825-42X;;070-316-527-354-375;;040-550-546-463-785;;046-168-111-025-234;;043-654-077-374-418;;084-388-182-984-099;;042-354-196-879-741;;005-112-559-456-657;;052-219-543-437-800;;007-364-858-655-289;;056-942-841-068-650;;107-302-749-967-437;;039-238-464-990-600;;036-564-551-324-053;;020-123-860-433-320;;011-516-147-270-264;;025-182-641-289-850;;076-731-232-972-252;;066-015-167-169-542;;006-568-097-103-41X;;013-122-792-588-081;;005-416-473-959-707;;020-986-423-793-233;;067-739-856-772-54X;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;007-709-585-201-038;;042-688-967-632-553;;056-422-417-058-69X;;005-022-447-377-963;;127-416-339-660-812;;098-407-145-404-736;;066-749-017-721-197;;001-467-559-709-949;;078-061-292-153-737;;055-646-175-554-792;;129-390-507-012-794;;008-213-515-306-640;;053-703-232-770-99X;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;029-697-384-910-375;;038-613-711-274-229;;062-418-979-939-961,10.4049/jimmunol.170.3.1257;;12538684;;8159246;;10.1038/368856a0;;10.4049/jimmunol.170.2.711;;12517932;;9930702;;10.1038/16717;;10.1002/j.1460-2075.1992.tb05481.x;;pmc556898;;1396582;;10.1093/intimm/8.5.765;;8671665;;10.1084/jem.181.6.1953;;7539033;;pmc2192041;;10.1016/s0167-5699(97)80025-4;;9190115;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;11224527;;10.1038/85330;;11857337;;10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9;;10.1007/s00262-004-0593-x;;15599732;;10.1158/1078-0432.ccr-04-0428;;15297412;;10.1073/pnas.192461099;;12218188;;pmc129438;;10.4049/jimmunol.170.3.1257;;12538684;;10.1016/s1074-7613(00)80089-8;;10485649;;10.1126/science.291.5502.319;;11209085;;10.1084/jem.20022119;;12847138;;pmc2196082;;14764622;;10.1093/hmg/ddh076;;pmc61133;;10.1073/pnas.231486598;;11698646;;4703766;;10.1093/jnci/50.4.1013;;pmc1866856;;10.1016/s0002-9440(10)65141-3;;10433938;;1330947;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;3382986;;10.1093/bioinformatics/4.1.11;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;3127726;;10.1038/332323a0;;10.1038/321522a0;;3713831;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;11096108;;10.1074/jbc.m009483200;;10.1002/bit.20151;;15352059;;11986321;;10.1074/jbc.m202069200;;10.1038/6179;;10052355;;1201277;;10.1021/bi00696a021;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1038/348552a0;;2247164;;1172191;;10.1038/256495a0;;8159246;;10.1038/368856a0;;10.1007/978-3-642-78432-3_3;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;8144892;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nbt727;;12172556;;8159246;;10.1038/368856a0;;10.1126/science.3929380;;3929380;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;12564977;;10.1016/s0169-409x(02)00179-5;;10.1007/s00262-002-0352-9;;12700948;;12676579;;10.1016/s1535-6108(03)00057-6;;10.1038/nrc903;;12360278;;12186272;;10.1016/s0169-409x(01)00206-x;;11744170;;10.1201/b14193-19;;7042536;;10.1111/j.1600-065x.1982.tb00392.x;;10.4049/jimmunol.155.10.4996;;7594506;;8954257;;1371789;;6239899;;10.1084/jem.160.6.1686;;pmc2187539;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;3833240;;10.1126/science.3925553;;3925553;;2958547;;10.4049/jimmunol.139.7.2367;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;3390170;;10.1016/s0006-291x(88)81333-0;;10.1128/aac.39.1.180;;pmc162506;;7695303;;7907597;;10.1016/s0021-9258(17)37081-3;;10.1016/0014-5793(94)00313-0;;8206150;;7820457;;10.1006/immu.1994.1029;;12721664;;10.1007/s00109-003-0430-2;;10.1007/s00262-004-0593-x;;15599732;;10.1158/1078-0432.ccr-04-0428;;15297412;;10.1073/pnas.192461099;;12218188;;pmc129438;;10.4049/jimmunol.170.3.1257;;12538684;;15611321;;10.1093/intimm/dxh194;;15470033;;10.4049/jimmunol.173.8.4919;;10.1016/s0960-7404(97)90012-8;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;9624003;;10.1038/30989;;10.1016/s0171-2985(00)80072-8;;10834311;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;9930702;;10.1038/16717;;10417377;;10.1126/science.285.5427.546;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;pmc15881;;10.1073/pnas.96.6.2982;;10077623;;10.1097/00002371-199601000-00009;;8859727;;10.1038/22124;;10408445;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;9850053;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1002/j.1460-2075.1993.tb05721.x;;pmc413278;;8458339;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1126/science.271.5256.1734;;8596936,"BROWN JULIA A ET AL: ""Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production"", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 170, no. 3, 1 February 2003 (2003-02-01), pages 1257 - 1266, XP002973918, ISSN: 0022-1767;;LONBERG N ET AL: ""ANTIGEN-SPECIFIC HUMAN ANTIBODIES FROM MICE COMPRISING FOUR DISTINCT GENETIC MODIFICATIONS"", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 368, no. 6474, 28 April 1994 (1994-04-28), pages 856 - 859, XP000941636, ISSN: 0028-0836;;OKAZAKI ET AL., CURR. OPIN. IMMUNOL, vol. 14, 2002, pages 391779 - 82;;BENNETT ET AL., J IMMUNOL, vol. 170, 2003, pages 711 - 8;;HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 263 - 266;;HANSEN ET AL., IMMUNOGENICS, vol. 10, 1980, pages 247 - 260;;ISHIDA ET AL., EMBO J, vol. 11, 1992, pages 3887 - 95;;AGATA ET AL., INT IMMUNOL, vol. 8, 1996, pages 765 - 72;;THOMAS, M.L., JEXP MED, vol. 181, 1995, pages 1953 - 6;;VIVIER, E; DAERON, M, IMMUNOL TODAY, vol. 18, 1997, pages 286 - 91;;FREEMAN ET AL., JEXP MED, vol. 192, 2000, pages 1027 - 34;;LATCHMAN ET AL., NAT IMMUNOL, vol. 2, 2001, pages 261 - 8;;CARTER ET AL., EUR J IMMUNOL, vol. 32, 2002, pages 634 - 43;;DONG ET AL., NAT. MED, vol. 8, 2002, pages 787 - 9;;DONG ET AL., J. MOI. MED., vol. 8, no. 1, 2003, pages 281 - 7;;BLANK ET AL., CANCER LMMUNOL. ININIUNOTHER., vol. 54, 2005, pages 307 - 314;;KONISHI ET AL., CANCER RES., vol. 10, 2004, pages 5094 - 100;;IWAI ET AL., PROC. NAT'L. ACAD SCI. USA, vol. 99, 2002, pages 12293 - 7;;BROWN ET AL., J. IRNMUNOL., vol. 170, 2003, pages 1257 - 66;;OKAZAKI ET AL., CURR OPIN IMMUNOL, vol. 14, 2002, pages 391779 - 82;;NISHIMURA ET AL., IMMUNITY, vol. 11, 1999, pages 141 - 51;;NISHIMURA ET AL., SCIENCE, vol. 291, 2001, pages 319 - 22;;SALAMA ET AL., JEXP MED, vol. 198, 2003, pages 71 - 78;;PROKUNINA; ALARCON-RIQUELME, HUM MOL GENET, vol. 13, 2004, pages R143;;NIELSEN ET AL., LUPUS, vol. 13, 2004, pages 510;;OKAZAKI ET AL., PNAS, vol. 98, 2001, pages 13866 - 71;;MURPHY; HRUSHESKY, J. NAT'L. CANCER RES., vol. 50, 1973, pages 1013 - 1025;;MURATA, AM, I PATHOL., vol. 155, 1999, pages 453 - 460;;BALZANO, INT. J. CANCER SUPPL., vol. 7, 1992, pages 28 - 32;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON, PROC. NATL. ACAD SCI. USA, vol. 85, 1988, pages 5879 - 5883;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, pages: 91 - 3242;;COMPUT. APPL. BIOSCI., vol. 4, 1988, pages 11 - 17;;NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 1 7, 1997, pages 3 3 89 - 3402;;RIECHMANN, L. ET AL., NATURE, vol. 332, 1998, pages 323 - 327;;JONES, P. ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;QUEEN, C. ET AL., PROC. NATL. ACAD SEE. U.S.A., vol. 86, 1989, pages 10029 - 10033;;KABAT, E. A ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, pages: 91 - 3242;;TOMLINSON, I. M. ET AL.: ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: doi:10.1016/0022-2836(92)90223-7;;COX, J. P. L ET AL.: ""A Directory of Human Germ-line VH Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;SHIELDS, R.L. ET AL., J. BIOL CHEM., vol. 276, 2001, pages 6591 - 6604;;YAMANE-OHNUKI ET AL., BIOTECHNOL BIOENG, vol. 87, 2004, pages 614 - 22;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;TARENTINO, A.L. ET AL., BIOCHEM., vol. 14, 1975, pages 5516 - 23;;""Current Protocols in Molecular Biology"", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;;KABAT, E. A.: ""Sequences of Proteins of Immunological Interest"", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, pages: 91 - 3242;;HUSTON ET AL., PROC. NATL. ACAD SCI. USA, vol. 85, 1988, pages 5879 - 5883;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;LONBERG, N., HANDBOOK OF EXPERIMENTAL PHARMACOLOGY, vol. 113, 1994, pages 49 - 101;;LONBERG, N.; HUSZAR, D., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F.; LONBERG, N., ANN. N.Y. ACAD SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J. ET AL., INTERNATIONALLMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD SCI. USA, vol. 90, 1993, pages 3720 - 3724;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J. ET AL., EMBO J., vol. 12, 1993, pages 821 - 830;;TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;TAYLOR, L. ET AL., INTERNATIONALLMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;TOMIZUKA ET AL., PROC. NATL. ACAD SCI. USA, vol. 97, 2000, pages 722 - 727;;KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894;;LONBERG, N. ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;MORRISON, S., SCIENCE, vol. 229, 1985, pages 1202;;GOEDDEL: ""Gene Expression Technology. Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;TAKEBE, Y. ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;BOSS, M. A.; WOOD, C. R, IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMAN; P. A. SHARP, MOL. BIOL, vol. 159, 1982, pages 601 - 621;;SAITO, G. ET AL., ADV DRUG DELIV. REV., vol. 55, 2003, pages 199 - 215;;TRAIL, P.A. ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 52, 2003, pages 328 - 337;;PAYNE, G., CANCER CELL, vol. 3, 2003, pages 207 - 212;;ALLEN, T.M., NAT. REV. CANCER, vol. 2, 2002, pages 750 - 763;;PASTAN, I.; KREITMAN, R. J., CUM. OPIN. INVESTIG. DRUGS, vol. 3, 2002, pages 1089 - 1091;;SENTER, P.D.; SPRINGER, C.J., ADV DRUG DELIV. REV., vol. 53, 2001, pages 247 - 264;;ARNON ET AL.: ""Monoclonal Antibodies And Cancer Therapy"", 1985, ALAN R. LISS, INC., article ""Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy"", pages: 243 - 56;;HELLSTROM ET AL.: ""Controlled Drug Delivery"", 1987, MARCEL DEKKER, INC., article ""Antibodies For Drug Delivery"", pages: 623 - 53;;THORPE ET AL.: ""Monoclonal Antibodies '84: Biological And Clinical Applications"", 1985, article ""Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review"", pages: 475 - 506;;""Monoclonal Antibodies For Cancer Detection And Therapy"", 1985, ACADEMIC PRESS, article ""Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy"", pages: 303 - 16;;THORPE ET AL.: ""The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates"", IMMUNOL. REV., vol. 62, 1982, pages 119 - 58, XP001179872, DOI: doi:10.1111/j.1600-065X.1982.tb00392.x;;GRAZIANO, RF. ET AL., J. IMMUNOL, vol. 155, no. 10, 1995, pages 4996 - 5002;;MORTON, H.C. ET AL., CRITICAL REVIEWS IN INIMUNOLOGY, vol. 16, 1996, pages 423 - 440;;MONTEIRO, RC. ET AL., J IMMUNOL, vol. 148, 1992, pages 1764;;KARPOVSKY ET AL., J. EXP. MED., vol. 160, 1984, pages 1686;;LIU, MA ET AL., PROC. NATL. ACAD SCI. USA, vol. 82, 1985, pages 8648;;PAULUS, BEHRING INS. MITT., vol. 78, 1985, pages 118 - 132;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83;;GLENNIE ET AL., J. IMMUNOL., vol. 139, 1987, pages 2367 - 2375;;WEINTRAUB, B.: ""Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques"", THE ENDOCRINE SOCIETY, March 1986 (1986-03-01);;BERGE, S.M. ET AL., J. PHARNZ. SCI., vol. 66, 1977, pages 1 - 19;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;RANADE, J. CLIN. PHARMACOL., vol. 29, 1989, pages 685;;UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 153, 1988, pages 1038;;P.G. BLOEMAN ET AL., FEBS LETT., vol. 357, 1995, pages 140;;M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 39, 1995, pages 180;;BRISCOE ET AL., ANZ. J. PHYSIOL., vol. 1233, 1995, pages 134;;SCHREIER ET AL., J. BIOL.. CHENI., vol. 269, 1994, pages 9090;;K. KEINANEN; M.L. LAUKKANEN, FEBS LEFT., vol. 346, 1994, pages 123;;J.J. KILLION; I.J. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273;;DONG ET AL., NATMED, vol. 8, 2002, pages 787 - 9;;DONG ET AL., J MOL MED, vol. 81, 2003, pages 281 - 7;;BLANK, CANCER IMMUNOL. IMMUNOTHER., vol. 54, 2005, pages 307 - 314;;KONISHI ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 5094 - 100;;IWAI ET AL., PNAS, vol. 99, 2002, pages 12293 - 7;;BROWN ET AL., J. IMMUNOL., vol. 170, 2003, pages 1257 - 66;;IWAI ET AL., INT. IMMUNOL., vol. 17, 2005, pages 133 - 144;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;ROSENBERG, S.: ""Development of Cancer Vaccines"", ASCO EDUCATIONAL BOOK SPRING, 2000, pages 60 - 62;;LOGOTHETIS, C., ASCO EDUCATIONAL BOOK SPRING, 2000, pages 300 - 302;;KHAYAT, D., ASCO EDUCATIONAL BOOK SPRING, 2000, pages 414 - 428;;FOON, K., ASCO EDUCATIONAL BOOK SPRING, 2000, pages 730 - 738;;RESTIFO, N.; SZNOL, M., CANCER VACCINES, CH., vol. 61, pages 3023 - 3043;;""Cancer: Principles and Practice of Oncology."", 1997;;DRANOFF ET AL., PROC. NATL. ACAD SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, SA, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM, N ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT, R; SRIVASTAVA, P, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA, Y. ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE, F. ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER, A. ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR, M. ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL, J. ET AL., J: EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARD, M.; O'GARRA, A., IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE, M. ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;RIDGE, J. ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;ITO, N. ET AL., IMMUNOBIOLOGY, vol. 201, no. 5, 2000, pages 527 - 40;;WEINBERG, A. ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO, I. ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF, A ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;GREENBERG, R; RIDDELL, S., SCIENCE, vol. 285, 1999, pages 546 - 51;;HOLLIGER, PROC. NATL. ACAD SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;OVERWIJK, W. ET AL., PROC. NATL. ACAD SCI. U.S.A., vol. 96, 1999, pages 2982 - 2987;;ROSENBERG, SA; WHITE, DE, J. IMMUNOTHER EMPHASIS TUMOR IMMUNOL, vol. 19, no. 1, 1996, pages 81 - 4;;SCHENK ET AL., NATURE, vol. 400, 1999, pages 173 - 177;;HARLOW; LANE: ""Antibodies, A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY PRESS;;HURWITZ ET AL., PROC. NATL. ACAD SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071;;CAMACHO ET AL., J. CLIN. ONCOLOGY, vol. 22, no. 145, 2004, pages 2505;;MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304;;RESTIFO; SZNOL: ""Cancer Vaccines"", pages: 3023 - 3043;;""Cancer: Principles and Practice of Oncology"", 1997;;DRANOFFET, PROC. NATL. ACAD SCI U S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT; SRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1 5 8 5 - 1 5 8 8;;TAMURA ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL, J., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050;;WEINBERG, A ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;HUTLOFF, A. ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;GREENBERG, R.; RIDDELL, S., SCIENCE, vol. 285, 1999, pages 546 - 51;;CHEN ET AL., EMBO J., vol. 12, 1993, pages 811 - 820;;FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;LONBERG, N ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;LEACH ET AL., SCIENCE, vol. 271, 1996, pages 1734 - 1736",ACTIVE
55,AU,C1,AU 2011/203119 C1,061-827-927-515-025,2018-06-14,2018,AU 2011/203119 A,2011-06-27,AU 2011/203119 A;;AU 2006/244885 A;;US 73843405 P;;US 67946605 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,"HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1(PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS 5 Abstract The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells 1a and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides is methods for using a combination immunotherapy, such as the combination of anti-CT LA 4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",SQUIBB & SONS LLC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;CHEN BING;;SRINIVASAN MOHAN;;CARDARELLI JOSEPHINE M;;SELBY MARK J;;WANG CHANGYU;;HUANG HAICHUN,,https://lens.org/061-827-927-515-025,Amended Patent,no,2,0,3,125,0,Y02A50/30,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
56,CA,A1,CA 3151350 A1,099-023-422-703-763,2006-11-16,2006,CA 3151350 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;CA 2970873 A,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",SQUIBB & SONS LLC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/099-023-422-703-763,Patent Application,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A01K67/027;;C07K16/30;;C07K16/46;;C12N5/16;;C12N15/13,,0,0,,,,PENDING
57,US,B2,US 9084776 B2,151-769-123-163-335,2015-07-21,2015,US 201414547026 A,2014-11-18,US 201414547026 A;;US 201414270750 A;;US 201113210137 A;;US 91321706 A;;JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Methods for treating cancer using anti-PD-1 antibodies,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD- 1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD- 1 , as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD- 1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA- 4 and anti-PD- 1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",MEDAREX LLC;;ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;MEDAREX INC (2014-12-02),https://lens.org/151-769-123-163-335,Granted Patent,yes,81,161,120,125,82,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395;;A61K39/00;;C07K16/28,,99,57,027-748-683-255-715;;004-728-346-095-981;;023-222-320-518-73X;;076-092-237-434-500;;049-336-842-920-389;;076-731-232-972-252;;067-760-343-772-225;;107-581-406-479-794;;051-040-695-254-214;;074-668-310-987-029;;013-122-792-588-081;;197-193-057-828-756;;113-346-509-283-257;;016-221-116-270-759;;145-209-675-614-912;;081-074-583-383-824;;020-140-165-898-622;;022-735-509-615-805;;022-179-293-052-569;;025-182-641-289-850;;122-644-406-202-233;;090-247-610-825-843;;006-463-263-246-432;;041-874-179-970-386;;020-986-423-793-233;;086-751-695-402-863;;127-672-559-644-411;;127-416-339-660-812;;117-522-189-960-276;;006-568-097-103-41X;;093-666-562-457-905;;005-416-473-959-707;;022-983-190-510-755;;045-008-500-970-273;;063-640-752-709-241;;119-897-745-760-544;;066-015-167-169-542;;060-728-367-476-688;;052-597-675-128-75X;;062-418-979-939-961;;031-431-800-409-592;;032-820-729-763-323;;014-903-975-216-318;;043-030-710-125-973;;051-224-574-304-090;;044-695-670-834-937;;048-060-748-635-820;;062-940-851-081-865;;014-507-730-965-260;;023-766-913-246-333;;074-046-354-648-540;;055-448-448-628-332;;062-761-744-997-508;;088-474-798-925-827;;038-551-014-784-214;;027-477-313-726-928;;117-415-766-090-626,10.1038/nbt1137;;16151408;;10.1093/intimm/8.5.765;;8671665;;10.1084/jem.20022125;;12847137;;pmc2196083;;10.4049/jimmunol.170.2.711;;12517932;;10.1158/1078-0432.ccr-07-4079;;18483370;;10.1007/s00262-004-0593-x;;15599732;;14871849;;10.1158/0008-5472.can-03-3259;;8871619;;10.4049/jimmunol.157.8.3250;;10.1200/jco.2008.26.15_suppl.3006;;pmc4834717;;20516446;;10.1200/jco.2009.26.7609;;10.4049/jimmunol.170.3.1257;;12538684;;10.1016/s0075-7535(08)70702-2;;11861596;;10.1146/annurev.immunol.20.091101.091806;;14552835;;10.1016/j.it.2003.08.005;;12947224;;10.1385/ir:28:1:49;;11857337;;10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9;;15122199;;10.1038/nri1349;;9801349;;10.1128/cdli.5.6.862-870.1998;;pmc96216;;10.1002/eji.1830240409;;8149953;;12721664;;10.1007/s00109-003-0430-2;;12091876;;10.1038/nm730;;9332365;;10.1016/s0378-1119(97)00260-6;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;10.1007/bf01561573;;15470033;;10.4049/jimmunol.173.8.4919;;15705911;;10.1158/0008-5472.1089.65.3;;10882809;;10.1016/s0163-7258(00)00052-8;;9930702;;10.1038/16717;;10.1002/j.1460-2075.1992.tb05481.x;;pmc556898;;1396582;;10.1073/pnas.192461099;;12218188;;pmc129438;;10.1016/s0165-2478(02)00088-3;;12095712;;15611321;;10.1093/intimm/dxh194;;10.1084/jem.20022235;;12847136;;pmc2196084;;20139271;;10.4049/jimmunol.0901652;;7581696;;10.1385/0-89603-275-2:171;;10.1161/01.atv.0000145015.23656.e4;;15374847;;10.1158/1078-0432.ccr-04-0428;;15297412;;18059626;;10.1080/02648725.2007.10648092;;11224527;;10.1038/85330;;10.1126/science.271.5256.1734;;8596936;;10.1074/jbc.m402194200;;15128741;;8159246;;10.1038/368856a0;;10.1182/blood-2005-06-2298;;pmc1895337;;16037385;;10.1182/blood-2004-07-2561;;15486062;;10.1016/j.clim.2014.02.015;;24631965;;pmc4082337;;15352422;;10.1191/0961203303lu1052oa;;10.1126/science.291.5502.319;;11209085;;10.1016/s1074-7613(00)80089-8;;10485649;;9796923;;10.1093/intimm/10.10.1563;;12413529;;10.1016/s0952-7915(02)00398-9;;pmc61133;;10.1073/pnas.231486598;;11698646;;10.4049/jimmunol.169.11.6546;;12444166;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;11329858;;10.1016/s0065-3233(01)56010-6;;14764622;;10.1093/hmg/ddh076;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1084/jem.20022119;;12847138;;pmc2196082,"Abbas, A.K., et al., Cellular and Molecular Immunobiology, 2nd ed., pp. 8, 47-50, W.B. Saunders Company, United States (1991).;;""About the Internet Archive: General Information"", Internet Archive, 2001, 10 pages, retrieved online from http://www.archive.org/about/about.php on Apr. 5, 2011.;;Adams, G.P. and Weiner, L.M., ""Monoclonal antibody therapy of cancer,"" Nature Biotechnology 23(9):1147-1157, Nature Publishing Group, United States (2005).;;Affidavit of Christopher Butler, Apr. 23, 2014, 8 pages.;;Affinity purified anti-mouse PD-1 (PD1): Archived website information for J43 and J116 antibodies; eBioscience and Waybackmachine/org 2002, accessed on Jun. 14, 2011, 4 pages, accessed from http://web.archive.org/web/20020301031217 and http://ebioscience/specs/antibody14/14-9985.;;Agata, Y., et al., ""Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes,"" International Immunology 8(5):765-772, Oxford University Press, England (1996).;;Ansari, M.J., et al., ""The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice,"" The Journal of Experimental Medicine 198(1):63-69, The Rockefeller University Press, United States (2003).;;Anti-Human CD279 (PD-1) Datasheet, 14-2799, J105, eBioscience, Sep. 6, 2013, 1 page.;;Anti-Human CD279 (PD-1) Datasheet, 14-9989, J116, eBioscience, Sep. 6, 2013, 1 page.;;Anti-Human CD279 (PD-1) Purchase Receipts, eBioscience, Oct. 8, 2013, 4 pages.;;Appendix to Declaration of Vassiliki A. Boussiotis, Apr. 28, 2014, Data and Records for Example Experiments 21 and 22, 18 pages.;;Bennett, F., et al., ""Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses,"" The Journal of Immunology 170(2):711-718, The American Association of Immunologists, United States (2003).;;Berger, R., et al., ""Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies,"" Clinical Cancer Research 14(10):3044-3051, American Association for Cancer Research, United States (2008).;;Blank, C., et al., ""Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy,"" Cancer Immunology Immunotherapy 54(4):307-314, Springer-Verlag, Germany (2005).;;Blank, C., et al., ""PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells,"" Cancer Research 64(3):1140-1145, American Association for Cancer Research, United States (2004).;;Blazar, B.R., et al., ""Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclenal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells,"" The Journal of Immunology 157(8):3250-3259, The American Association of Immunologists, United States (1996).;;Brahmer, J.R., et al., ""Safety and activity of MDX-1106 (ONO-4538) anti-PD-1 monoclonal antibody in patients with selected refractory or relapsed malignancies,"" Journal of Clinical Oncology 26:Abstract No. 3006, American Society of Clinical Oncology, United States (2008).;;Brahmer., J.R., et al., ""Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates,"" Journal of Clinical Oncology 28(19):3167-3175, American Society of Clinical Oncology, United States (2005).;;Brown, J.A., et al., ""Blockade of PD-1 ligands on dendritic cells enhances T cells activation and cytokine production,"" FASEB Journal 16(4):A710-517.4, Federation of American Societies for Experimental Biology, United States (2002).;;Brown, J.A., et al., ""Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production,"" The Journal of Immunology 170(3):1257-1266, The American Association of Immunologists, United States (2003).;;Brown, J.A., et al., ""Expression and functional consequences PD-1 ligands on natural APCS and tumors,"" The FASEB Journal 15(4):A345 (abstract No. 275.23), Federation of American Societies for Experimental Biology, United States (2001).;;Campbell, A.M., ""Characterisation of monoclonal antibodies,"" in Laboratory Techniques in Biochemistry and Molecular Biology, Monoclonal Antibody Technology: The Production and Characterization of Rodent and Human Hybridomas, vol. 13, pp. 186-215, Elsevier, the Netherlands (1984).;;Carreno, B,M, and Collins, M., ""The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses,"" Annual Review of Immunology 20:29-53, Annual Reviews, United States (2002).;;Carreno, B.M., ""BTLA: a new inhibitory receptor with a B7-like ligand,"" TRENDS in Immunology 24(10):524-527, Elsevier, England (2003).;;Carter, L.L. and Carreno, B.M., et al., ""Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation,"" Immunologic Research 28(1):49-59, Humana Press, United States (2003).;;Carter, L.L., et al., ""PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2,"" European Journal of Immunology 32(3):634-643, WILEY-VCH Verlag GmbH, Germany (2002).;;Chen, L., ""Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity,"" Nature Reviews Immunology 4(5):336-347, Nature Publishing Group, England (2004).;;Clark, M.R., ""Antibody engineering IgG effector mechanisms,"" Chemical Immunology 65:88-110 (1997), reprint from http://www.path.cam.ac.ukfmrc7 /publications/reprints/PP 1997CI65 88.pdf.;;Cloeckaert, A., et al., ""O-Polysaccharide epitopic heterogeneity at the surface of Brucella spp.studied by enzyme-linked immunosorbent assay and flow cytometry,"" Clinical and Diagnostic Laboratory Immunology 5(6):862-870, American Society for Microbiology, United States (1998).;;Communication from the Japanese Patent Office drafted Jul. 4, 2012, in Japanese application No. 2009-203514,;;Communication pursuant to Article 94(3) EPC mailed Apr. 23, 2014 for EP Application No. 06786260.7.;;Communication pursuant to Rule 114(2) EPC, mailed Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178187, observations submitted on Jul. 10, 2014, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, mailed Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178188, observations submitted on Jul. 10, 2014, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, mailed Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178191, observations submitted on Jul. 10, 2014, European Patent Office, Germany.;;Cox, J.P., et al., ""A directory of human germ-line Vx segments reveals a strong bias in their usage,"" European Journal of Immunology 24(4):827-836, Verlag Chemie GmbH, Germany (1994).;;Declaration of Dr. Andrea Van Elsas, including Annex A and B, Apr. 29, 2014, 17 pages.;;Declaration of Dr. Jennifer Mataraza, Apr. 28, 2014, 11 pages.;;Declaration of Dr. Robert J. Bloch, Apr. 29, 2014, 82 pages.;;Declaration of Vassiliki A. Boussiotis, Apr. 28, 2014, 15 pages.;;Dong, H. and Chen, L., ""B7-H1 pathway and its role in the evasion of tumor immunity,"" Journal of Molecular Medicine 81(5):281-287, Springer, Germany (2003).;;Dong, H., et al., ""Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion,"" Nature Medicine 8(8):793-800, Nature Publishing Company, United States (2002).;;eBioscience, Information Sheet, ""Anti-Human CD279 (PD-1) Functional Grade Purified: Murine anti PD-1 antibody J116,"" 2000, 2 pages.;;EP Application No. 03741154.3 Notice of Opposition dated Jul. 8, 2011, issued by the EPO in the name of Ono Pharmaceutical Co., Ltd. et al.;;EP Publication No. 1576014, Excerpt from Register of European Patents, retrieved online from https://register.epo.org/espacenet/application?number=EP03780521 accessed on May 27, 2011.;;European Office Action issued Aug. 18, 2011, in European Patent Application No. 10172772.5, Ono Pharmaceutical Co., Ltd.;;Exhibit 1 ""Human anti-PD-1 antibodies: binding to PD-1, cross-competition with 5C4 and affinity to PD-1,"" 6 pages, in Notice of Opposition mailed Apr. 29, 2014, in EP Patent No. EP 2161326, 4-Antibody AG filed May 2, 2006.;;Extended European Search Report for EP Application No. 10161767.8, European Patent Office, Netherlands, mailed on Oct. 5, 2010.;;Extended European Search Report for EP Application No. 10161767.8, European Patent Office, Netherlands, mailed on Jun. 7, 2010.;;Finger, L.R., et al., ""The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors,"" Gene 197(1-2):177-187, Elsevier, United States (1997).;;Freeman, G.J., et al., ""Engagement of PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation,"" The Journal of Experimental Medicine 192(7):1027-1034, The Rockefeller University Press, United States (2000).;;Hansen, J.A., et al., ""Monoclonal Antibodies Identifying a Novel T-Cell Antigen and Ia Antigens of Human Lymphocytes,"" Immunogenetics 10:247-260, Springer-Verlag (1980).;;He, Y-F., et al., ""Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine,"" The Journal of Immunology 173(8):4919-4928, The American Association of Immunologists, United States (2004).;;Hirano, F., et al., ""Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity,"" Cancer Research 65(3):1089-1096, American Association for Cancer Research, United States (2005).;;Honjo, T., et al., Deposit receipt for Accession No. FERM BP-8392 mentioned in EP-A1537878, Jun. 5, 2003, 1 page.;;Huang, Z., ""Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis,"" Pharmacology & Therapeutics 86(3):201-215, Pergamon Press, England (2000).;;Hutloff, A., et al.,""ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28,"" Nature 397(6716):263-266, Nature Publishing Group, England (1999).;;International Preliminary Report on Patentability for International Application No. PCT/JP2006/309606, The International Bureau of WIPO, Switzerland, issued on Nov. 13, 2007.;;International Search Report for International Application No. PCT/JP02/08420, Japanese Patent Office, Japan, mailed Nov. 5, 2002.;;International Search Report for International Application No. PCT/JP2006/309606, Japanese Patent Office, Japan, mailed on Aug. 15, 2006.;;Ishida, Y., et al., ""Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death,"" The EMBO Journal 11(11):3887-3895, Oxford University Press, England (1992).;;Iwai, Y., et al., ""Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade,"" Proceedings of the National Academy of Sciences 99(19):12293-12297, The National Academy of Sciences of the United States (2002).;;Iwai, Y., et al., ""Microanatomical localization of PD-1 in human tonsils,"" Immunology Letters 83(3):215-220, Elsevier, Netherlands (2002).;;Iwai, Y., et al., ""PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells,"" International Immunology 17(2):133-144, Oxford University Press, England (2005).;;Iwai, Y., et al., ""PD-1 inhibits antiviral immunity at the effector phase in the liver,"" The Journal of Experimental Medicine 198(1):39-50, The Rockefeller University Press, United States (2003).;;Janeway, C.A., et al. ""The Humoral Immune Response,"" in Immunobiology: The immune system in health and disease, Sixth Edition, Chapter 9, pp. 367-408, Garland Science, New York, United States (2005).;;Kasagi, S., et al., ""Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W Fl mice,"" The Journal Immunology 184(5):2337-2347, The American Association of Immunologists, United States (2010).;;Kaveri, S., ""Epitope and idiotope mapping using monoclonal antibodies,"" Medthods in Molecular Biology 51:171-181, Humana Press, United States (1995).;;Koga, N., et al., ""Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts,"" Arteriosclerosis, Thrombosis, and Vascular Biology 24(11):2057-2062, American Heart Association, Inc., United States (2004).;;Konishi, J., et al., ""B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression,"" Clinical Cancer Research 10(15):5094-5100, American Association for Cancer Research, United States (2004).;;Ladner, R.C., ""Mapping the epitopes of Antibodies,"" Biotechnology and Genetic Engineering Reviews 24(1):1-30, Taylor & Francis, England (2007).;;Latchman, Y., et al., ""PD-L2 is a second ligand for PD-1 and inhibits T cell activation,"" Nature Immunology 2(3):261-268, Nature Publishing Group, United States (2001).;;Leach, D.R., et al., ""Enhancement of antitumor immunity by CTLA-4 blockade,"" Science 271(5256):1734-1736, American Association for the Advancement of Science, United States (1996).;;Lewis, D.E., et al., ""Tumor Necrosis Factor-alpha and CD80 Modulate CD28 Expression through a Similar Mechanism of T-cell Receptor-Independent of Transcription,"" The Journal of Biological Chemistry 279(28):29130-29138, The American Society for Biochemistry and Molecular Biology, Inc., United States (2004).;;Lonberg, N., et al., ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications,"" Nature 368(6474):856-859, Nature Publishing Group, United States (1994).;;Lute, K.D., et al., ""Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies,"" Blood 106(9):3127-3133, American Society of Hematology, United States (2005).;;May, K.F., Jr., et al., ""Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity it a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies,"" Blood 105(3):1114-1120, American Society of Hematology, United States (2005).;;Nagler, A., et al., ""Phase I clinical trial of CT-011, a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced hematological malignancies,"" 34th Annual Meeting: ISEH-Abstracts/Experimental Hematology 33(7):97, Abstract No. 227, Elsevier, United States (2005).;;Nellore, A., et al., ""The cyclin dependent kinase inhibitor (R)- roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors,"" Clinical Immunology 152(1-2):48-57 (May-Jun. 2014; Epub Mar. 12, 2014).;;Nielsen, C., et al., ""A putative regulatory polymorphism in PD-1 is associated with nephropathy in a population-based cohort of systemic lupus erythematosus patients,"" Lupus 13(7):510-516, SAGE, England (2004).;;Nishimura, H., et al., ""Autoimmune dilated cardiomyopathy Science in PD-1 receptor-deficient mice,"" Science 291(5502):319-322, American Association for the Advancement of Science, United States (2001).;;Nishimura, H., et al., ""Development of lupus-like autoimmune diseases by disruption of the PD-1gene encoding an ITIM motif-carrying immunoreceptor,"" Immunity 11(2):141-151, Cell Press, United States (1999).;;Nishimura, H., et al., ""Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses,"" International Immunology 10(10):1563-1572, Oxford University Press, England (1998).;;Notice of Opposition mailed Apr. 25, 2014, in EP Patent No. EP 2161336, Novartis A.G., filed May 2, 2006.;;Notice of Opposition mailed Apr. 29, 2014, in EP 2151336, 4-Antibody AG filed May 2, 2006.;;Notice of Opposition mailed Apr. 30, 2014, in EP Patent No. EP 2161336, Janssen Biotech, Inc., filed May 2, 2006.;;Notice of Opposition mailed Apr. 30, 2014 in EP Patent No. EP 2161336, Merck & Co., filed May 2, 2006.;;Okazaki, T., et al., ""New regulatory co-receptors: inducible co-stimulator and PD-1,"" Current Opinion in Immunology 14(6):779-782, Elsevier, England (2002).;;Okazaki, T., et al., ""PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phophotyrosine,"" Proceeding of the National Academy of Sciences 98(24):13866-13871, National Academy of Sciences, United States (2001).;;Ozkaynak, E., et al., ""Programmed death-1 targeting can promote allograft survival,"" The Journal of Immunology 169(11):6546-6553, The American Association of Immunologists, United States (2002).;;Panka, D.J., et al., ""Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies,"" Proceedings of the National Academy of Sciences 85(9):3080-3084, National Academy of Sciences, United States (1988).;;Park, J.W. and Smolen, J., ""Monoclonal antibody therapy,"" Advances in Protein Chemistry 56:369-421, Academic Press, United States (2001).;;Patentee's response to Examination Report for EP Application No. 09013687.0, mailed Nov. 24, 2011.;;Product Specifications for AffiniPure Goat Anti-Human IgG, Fcgamma Fragment Specific (minimal cross-reaction to Bovine, Horse, and Mouse Serum Proteins), Code No. 109-005-098, Lot No. 11632, Jackson ImmunoResearch Laboratories, Inc, Sep. 12, 2013, 1 page.;;Prokunina, L. and Alarcon-Riquelme, M., ""The genetic basis of systemic lupus erythematosus -knowledge of today and thoughts for tomorrow,"" Human Molecular Genetics 13(1):R143-R148, Oxford University Press, England (2004).;;Response to request further processing of EP Application No. 11178191.0, mailed on Jan. 13, 2014, 13 pages.;;Response to the communication pursuant to Art. 96(2) for EP Application No. 03741154.3, mailed on Jun. 25, 2007, 7 pages.;;Rudikoff, S., et al., ""Single amino acid substitution altering antigen-binding specificity,"" Proceedings of the National Academy of Sciences 79(6):1979-1983, The National Academy of Sciences, United States (1982).;;Salama, A.D., et al., ""Critical role of the programmed death- I (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis,"" The Journal of Experimental Medicine 198(1):71-78, The Rockefeller University Press, United States (2003).;;Sequence alignments between PD-1 and each of CTLA-4, CD28 and ICOS, accessed at http://www.ebi.ac.uk/Tools/services/web/toolresult.ebi?jobId=clustalo-I20- 140410-15, accessed on Apr. 10, 2014.",ACTIVE
58,CY,T1,CY 1116843 T1,036-269-040-203-207,2017-03-15,2017,CY 151100952 T,2015-10-26,EP 06786260 A;;US 69642605 A,2005-07-01,ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΠΡΟΣ ΣΥΝΔΕΤΗ 1 ΠΡΟΓΡΑΜΜΑΤΙΣΜΕΝΟΥ ΘΑΝΑΤΟΥ (PD-L1),"Η παρούσα αποκάλυψη παρέχει απομονωθέντα μονοκλωνικά αντισώματα, ιδιαιτέρως ανθρώπινα μονοκλωνικά αντισώματα που ειδικώς συνδέονται προς PD-L1 με υψηλή συνάφεια. Επίσης παρέχονται μόρια νουκλεϊνικού οξέος που κωδικοποιούν τα αντισώματα αυτής της αποκάλυψης, φορείς έκφρασης, κύτταρα ξενιστές και μέθοδοι για έκφραση των αντισωμάτων της παρούσας περιγραφής. Επίσης παρέχονται ανοσοπροϊόντα σύζευξης, διπλά-ειδικά μόρια και φαρμακευτικές συνθέσεις που περιλαμβάνουν τα αντισώματα της εφεύρεσης. Η αποκάλυψη επίσης παρέχει μεθόδους για ανίχνευση PD-L1, καθώς επίσης μεθόδους για θεραπεία διαφόρων ασθενειών, που συμπεριλαμβάνουν καρκίνο και μολυσματώδεις ασθένειες, χρησιμοποιώντας αντι-PD-L1 αντισώματα.",SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/036-269-040-203-207,Granted Patent,no,0,0,1,1,0,,A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
59,HK,A1,HK 1117850 A1,055-977-416-640-293,2009-01-23,2009,HK 08111004 A,2008-10-02,US 2006/0026046 W;;US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1) 1(PD-L1),,SQUIBB & SONS LLC,ALAN J KORMAN;;MARK J SELBY;;CHANGYU WANG;;MOHAN SRINIVASAN;;DAVID B PASSMORE;;HAICHUN HUANG;;HAIBIN CHEN,,https://lens.org/055-977-416-640-293,Patent Application,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K/;;C07K/,,0,0,,,,PENDING
60,EP,B2,EP 2161336 B2,064-435-166-138-101,2017-03-29,2017,EP 09013687 A,2006-05-02,EP 06746353 A;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,"ONO PHARMACEUTICAL CO., LTD., US (2015-01-30);;MEDAREX, L.L.C. (2014-03-03);;MEDAREX, L.L.C., PRINCETON, US (2014-04-01);;E.R. SQUIBB & SONS, L.L.C., PRINCETON, NJ, US (2015-07-15);;ONO PHARMACEUTICAL CO., LTD., OSAKA-SHI, OSAKA, JP (2015-07-15);;MEDAREX, L.L.C., PRINCETON, NEW JERSEY, US (2014-06-05);;MEDAREX, L.L.C., US (2014-04-01);;E. R. SQUIBB & SONS, L.L.C. (2015-04-22);;E. R. SQUIBB & SONS, L.L.C. (N.D.GES.D. STAATE, US (2015-02-05);;ONO PHARMACEUTICAL CO., LTD., JP (2016-04-19);;ONO PHARMACEUTICAL CO., LTD. (2015-04-22);;E. R. SQUIBB & SONS, L.L.C., US (2016-04-19);;MEDAREX, INC. (2013-05-29);;ONO PHARMACEUTICAL CO., LTD.; US (2015-02-13)",https://lens.org/064-435-166-138-101,Granted Patent,yes,2,4,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,2,1,006-568-097-103-41X,10.1073/pnas.192461099;;12218188;;pmc129438,"IWAI Y. ET AL: ""Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade"", PNAS, vol. 99, no. 19, 2002, pages 12293 - 12297;;Second Declaration of Professor Brian Fife.",ACTIVE
61,DK,T3,DK 1907424 T3,063-163-349-402-320,2015-11-09,2015,DK 06786260 T,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,HUMANE MONOKLONALE ANTISTOFFER MOD PROGRAMMERET DØDSLIGAND 1 (PD-L1),,SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/063-163-349-402-320,Granted Patent,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
62,US,A1,US 2016/0362495 A1,123-043-934-094-486,2016-12-15,2016,US 201615188860 A,2016-06-21,US 201615188860 A;;US 201514807522 A;;US 201313746773 A;;US 201113091936 A;;US 91772708 A;;US 2006/0026046 W;;US 69642605 P,2005-07-01,Human Monoclonal Antibodies to Programmed Death Ligand 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically hind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;MEDAREX INC (2008-03-26),https://lens.org/123-043-934-094-486,Patent Application,yes,0,37,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/395;;C07K16/28;;A61K45/06,,0,0,,,,ACTIVE
63,JP,A,JP 2016006123 A,173-332-635-473-608,2016-01-14,2016,JP 2015193989 A,2015-09-30,US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"PROBLEM TO BE SOLVED: To provide isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity.SOLUTION: This method for preparing an anti-PD-L1 antibody includes the following steps of: (a) providing a heavy chain variable region antibody sequence comprising a specific CDR3 sequence, and/or a light chain variable region antibody sequence comprising a specific CDR3 sequence; (b) altering at least one amino acid residue within the heavy chain variable region antibody sequence and/or light chain variable region antibody sequence to create at least one altered antibody sequence; and (c) expressing the altered antibody sequence as a protein.",E R SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/173-332-635-473-608,Patent Application,no,3,0,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A01K67/027;;A61K38/00;;A61K39/395;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P43/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/09,,7,5,119-897-745-760-544;;067-760-343-772-225;;050-992-361-999-488;;022-046-054-886-073;;092-023-577-402-127,10.1161/01.atv.0000145015.23656.e4;;15374847;;14871849;;10.1158/0008-5472.can-03-3259;;12520872;;10.1080/02648725.2002.10648023;;pmc127659;;11796590;;10.1128/iai.70.2.612-619.2002;;1404388;;10.1016/0022-2836(92)90223-7,"""Arteriosclerosis, Thrombosis, and Vascular Biology"", 2004, VOL.24, PP.2057-2062, JPN6011069191, ISSN: 0003401869;;""Cancer Research"", 2004, VOL.64, PP.1140-1145, JPN6011069192, ISSN: 0003401870;;""Biotechnology & Genetic Engineering Reviews"", 2002, VOL.19, PP.73-82, JPN6011069194, ISSN: 0003401871;;""Infection and Immunity"", 2002, VOL.70, NO.2, PP.612-619, JPN6011069195, ISSN: 0003401872;;""Proceedings of the National Academy of Sciences of USA"", 2000, VOL.97, PP.722-727, JPN6011069197, ISSN: 0003401873;;""Journal of Molecular Biology"", 1992, VOL.227, PP.776-798, JPN6011069199, ISSN: 0003401874;;""European Journal of Immunology"", 1994, VOL.24, PP.827-836, JPN6011069200, ISSN: 0003401875",DISCONTINUED
64,CN,B,CN 101213297 B,087-214-871-984-333,2013-02-13,2013,CN 200680023860 A,2006-05-02,JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,,ONO PHARMACEUTICAL CO;;MEDAREX INC,WANG CHANGYU;;SELBY MARK J;;CARDARELLI JOSEPHINE M;;CHEN BINGLIANG;;KORMAN ALAN J;;SRINIVASAN MOHAN;;HUANG HAICHUN,,https://lens.org/087-214-871-984-333,Granted Patent,no,0,3,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
65,EP,B1,EP 1907424 B1,098-923-734-939-748,2015-07-29,2015,EP 06786260 A,2006-06-30,US 2006/0026046 W;;US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),,SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,"MEDAREX, L.L.C. (2013-08-14);;E. R. SQUIBB & SONS, L.L.C. (2015-03-04)",https://lens.org/098-923-734-939-748,Granted Patent,yes,0,3,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/00;;C07K16/28,,2,2,074-067-544-364-744;;013-122-792-588-081,10.1038/nature04444;;16382236;;10.4049/jimmunol.170.3.1257;;12538684,"BARBER DANIEL L ET AL: ""Restoring function in exhausted CD8 T cells during chronic viral infection"", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 439, no. 7077, 9 February 2006 (2006-02-09), pages 682 - 687, XP002419629, ISSN: 0028-0836, DOI: 10.1038/NATURE04444;;BROWN JULIA A ET AL: ""Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production"", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 170, no. 3, 1 February 2003 (2003-02-01), pages 1257 - 1266, XP002973918, ISSN: 0022-1767",ACTIVE
66,AU,A1,AU 2006/265108 A1,143-179-366-369-450,2007-01-11,2007,AU 2006/265108 A,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,Human monoclonal antibodies to programmed death ligand 1 (PD-L1),,MEDAREX INC,WANG CHANGYU;;PASSMORE DAVID B;;SRINIVASAN MOHAN;;KORMAN ALAN J;;CHEN HAIBIN;;SELBY MARK J;;HUANG HAICHUN,,https://lens.org/143-179-366-369-450,Patent Application,no,0,3,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28,,0,0,,,,ACTIVE
67,DK,T4,DK 2161336 T4,144-968-020-404-851,2017-04-24,2017,DK 09013687 T,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;EP 06746353 A,2005-05-09,Humane monoklonale antistoffer til programmeret død 1(PD-1) samt fremgangsmåder til behandling af kræft under brug af anti-PD-1 antistoffer alene eller kombineret med andre immunterapier,,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/144-968-020-404-851,Amended Patent,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
68,JP,A,JP 2021182929 A,153-636-685-343-34X,2021-12-02,2021,JP 2021127464 A,2021-08-03,JP 2020000605 A;;US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"To provide an isolated monoclonal antibody, particularly human monoclonal antibody, that specifically binds to PD-L1 with high affinity.SOLUTION: A method for preparing an anti-PD-L1 antibody comprises: (a) providing a heavy chain variable region antibody sequence including a specific CDR3 sequence, and/or a light chain variable region antibody sequence including a specific CDR3 sequence; (b) altering at least one amino acid residue within the heavy chain variable region antibody sequence and/or the light chain variable region antibody sequence to create at least one altered antibody sequence; and (c) expressing the altered antibody sequence as a protein.SELECTED DRAWING: Figure 47",E R SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/153-636-685-343-34X,Patent Application,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C12N15/13;;A61K39/395;;A61K47/68;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/04;;C07K16/30;;C07K16/46;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N5/12;;C12N15/62;;C12N15/63,,0,0,,,,PENDING
69,EA,B1,EA 019344 B1,173-165-781-376-405,2014-03-31,2014,EA 200800229 A,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1) AND USES THEREOF,"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",MEDAREX LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/173-165-781-376-405,Granted Patent,no,1,12,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A61K39/395;;A61P31/00;;A61P33/00;;A61P35/00,,4,4,119-897-745-760-544;;067-760-343-772-225;;092-023-577-402-127;;022-179-293-052-569,10.1161/01.atv.0000145015.23656.e4;;15374847;;14871849;;10.1158/0008-5472.can-03-3259;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953,"KOGA NORITAKA ET AL.: ""Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts"". ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, vol. 24, no. 11, November 2004 (2004-11), pages 2057-2062, XP002411528, ISSN: 1079-5642, the whole document;;BLANK CHRISTIAN ET AL.: ""PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells"". CANCER RESEARCH, vol. 64, no. 3, 1 February 2004 (2004-02-01), pages 1140-1145, XP002411529, ISSN: 0008-5472, the whole document;;TOMLINSON I.M. ET AL.: ""THE REPERTOIRE OF HUMAN GERMLINE VH SEQUENCES REVEALS ABOUT FIFTY GROUPS OF VH SEGMENTS WITH DIFFERENT HYPERVARIABLE LOOPS"". JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 227, 1992, pages 776-798, XP000990787, ISSN: 0022-2836, the whole document;;COX J.P.L. ET AL.: ""A directory of human germ-line Vkappa segments reveals a strong bias in their usage"". EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 24, 1994, pages 827-836, XP003004702, ISSN: 0014-2980, the whole document",ACTIVE
70,NO,B1,NO 341219 B1,052-473-570-244-100,2017-09-18,2017,NO 20075697 A,2007-11-07,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,"Isolert, humant monoklonal antistoff, immunokonjugat, sammensetning og bispesifikt molekyl",,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,CARDARELLI JOSEPHINE M;;WANG CHANGYU;;SRINIVASAN MOHAN;;HUANG HAICHUN;;KORMAN ALAN J;;SELBY MARK J;;CHEN BINGLIANG,"ONO PHARMACEUTICAL CO LTD, US (2015-08-31)",https://lens.org/052-473-570-244-100,Granted Patent,no,2,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/395,,1,0,,,"DR. BRIAN T. FIFE, Second Declaration (European Patent No. 2,161,336), 2016.05.03, Dated: 01.01.0001",ACTIVE
71,CA,A1,CA 3018525 A1,051-444-110-870-814,2007-01-11,2007,CA 3018525 A,2006-06-30,US 69642605 P;;CA 2612241 A,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/051-444-110-870-814,Patent Application,no,0,0,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A01K67/027;;C07K16/46;;C12N5/16;;C12N15/13;;C12P21/08,,0,0,,,,PENDING
72,DK,T3,DK 2439273 T3,071-261-328-412-692,2019-06-03,2019,DK 11178191 T,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;EP 09013687 A,2005-05-09,HUMANE MONOKLONALE ANTISTOFFER TIL PROGRAMMERET DØD-1(PD-1) OG FREMGANGSMÅDER TIL BEHANDLING AF CANCER VED ANVENDELSE AF ANTI-PD-1- ANTISTOFFER ALENE ELLER I KOMBINATION MED ANDRE IMMUNTERAPEUTIKA,,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,SRINIVASAN MOHAN;;WANG CHANGYU;;CHEN BING;;HUANG HAICHUN;;SELBY MARK J;;CARDARELLI JOSEPHINE M;;KORMAN ALAN J,,https://lens.org/071-261-328-412-692,Granted Patent,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
73,KR,A,KR 20130114226 A,095-257-265-120-463,2013-10-16,2013,KR 20137020114 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,,ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/095-257-265-120-463,Patent Application,no,0,0,120,125,84,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61P35/00;;C07K16/28,,0,0,,,,ACTIVE
74,ZA,B,ZA 200710919 B,098-333-030-779-547,2008-10-29,2008,ZA 200710919 A,2007-12-14,US 69642605 P,2005-07-01,Human monoclonal antibodies to programmed death ligand 1 (PD-L1),,MEDAREX INC,KORMAN ALAN J;;CHANGYU WANG;;PASSMORE DAVID B;;HAIBIN CHEN;;SELBY MARK J;;MOHAN SRINIVASAN;;HAICHUN HUANG,,https://lens.org/098-333-030-779-547,Granted Patent,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K/,,0,0,,,,ACTIVE
75,UA,C2,UA 99701 C2,097-468-549-533-254,2012-09-25,2012,UA A200801212 A,2006-06-30,US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",MEDAREX INC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/097-468-549-533-254,Limited Patent,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A61K39/395;;A61P35/00;;C12N5/20;;C12N15/13,,0,0,,,,EXPIRED
76,SI,T1,SI 2161336 T1,115-575-828-814-109,2013-11-29,2013,SI 200631652 T,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;EP 09013687 A,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,,ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/115-575-828-814-109,Granted Patent,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/00;;C07K16/00;;C12N5/00;;C12P21/00;;C12Q1/00,,0,0,,,,ACTIVE
77,SI,T1,SI 1907424 T1,127-422-111-320-484,2015-12-31,2015,SI 200631983 T,2006-06-30,US 69642605 P;;US 2006/0026046 W;;EP 06786260 A,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),,SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/127-422-111-320-484,Granted Patent,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/00;;C07K16/00,,0,0,,,,ACTIVE
78,NZ,A,NZ 564592 A,148-006-676-857-640,2011-11-25,2011,NZ 56459206 A,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,Human monoclonal antibodies to programmed death ligand 1 (PD-L1),"Disclosed is a human monoclonal antibody or antigen-binding portion thereof which specifically binds to PD-L1, wherein the antibody or antigen-binding portion thereof crosscompetes for binding to PD-L1 with a reference antibody or reference antigen-binding portion thereof comprising: a heavy chain variable region that comprises amino acids having the sequence set forth in SEQ ID NO: 2; and a light chain variable region that comprises amino acids having the sequence set forth in SEQ NO: 12. Also a human monoclonal antibody or antigen-binding portion thereof which specifically binds to PD-L1, wherein the antibody or antigen-binding portion thereof crosscompetes for binding to PD-Li with a reference antibody or reference antigen-binding portion thereof comprising a heavy chain variable region that comprises CDR1, CDR2, and CDR3 domains; and a light chain variable region that comprises CDR1, CDR2, and CDR3 domains, wherein: (a) the heavy chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 42; (b) the light chain variable region CDR3 comprises amino acids having the sequence set forth in SEQ ID NO: 72, and conservative modifications thereof. Further disclosed is the use of the said antibodies for the preparation of a medicament for modulating an immune response in a subject.",MEDAREX INC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,"E. R. SQUIBB + SONS, L.L.C., US (2015-01-22);;MEDAREX, L.L.C., NZ (2013-07-18)",https://lens.org/148-006-676-857-640,Patent Application,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A61K39/395;;A61P35/00,,0,0,,,,PENDING
79,ES,T3,ES 2546333 T3,145-120-293-593-107,2015-09-22,2015,ES 06786260 T,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,Anticuerpos monoclonales humanos para ligandos 1 (PD-L1) de muerte programada,"Un anticuerpo monoclonal humano aislado o una porción de enlace a antígeno del mismo que se enlazan específicamente a PD-L1, que comprende: (a) una región variable de cadena pesada CDR1 que comprende aminoácidos que tienen la secuencia definida en la SEC ID nº 22; (b) una región variable de cadena pesada CDR2 que comprende aminoácidos que tienen la secuencia definida en la SEC ID nº 32; (c) una región variable de cadena pesada CDR3 que comprende aminoácidos que tienen la secuencia definida en la SEC ID nº 42; (d) una región variable de cadena ligera CDR1 que comprende aminoácidos que tienen la secuencia definida en la SEC ID nº 52; (e) una región variable de cadena ligera CDR2 que comprende aminoácidos que tienen la secuencia definida en la SEC ID nº 62 y (f) una región variable de cadena ligera CDR3 que comprende aminoácidos que tienen la secuencia definida en la SEC ID nº 72.",SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/145-120-293-593-107,Granted Patent,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
80,US,A1,US 2020/0138945 A1,183-122-012-854-196,2020-05-07,2020,US 201916600272 A,2019-10-11,US 201916600272 A;;US 201615288545 A;;US 201414248462 A;;US 201113210137 A;;US 91321709 A;;JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Monoclonal Antibodies to Programmed Death 1 (PD-1),"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",SQUIBB & SONS LLC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;ONO PHARMACEUTICAL CO. LTD (2007-12-27);;MEDAREX INC (2014-12-02),https://lens.org/183-122-012-854-196,Patent Application,yes,15,17,120,125,82,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395;;A61K39/00;;A61K47/68;;A61K51/10;;A61P7/06;;C07K16/18;;C07K16/28;;C07K16/46,,1,1,021-013-379-669-176,10.3389/fimmu.2018.00395;;29568296;;pmc5852061,"D’Angelo et al. (2018) Many Routes to an Antibody Heavy-Chain CDR3: Necessary, Yet Insufficient, for Specific Binding. Frontiers in Immunology 9: 395 (p. 1-13).",DISCONTINUED
81,US,B2,US 9102725 B2,028-237-977-204-843,2015-08-11,2015,US 201313746773 A,2013-01-22,US 201313746773 A;;US 201113091936 A;;US 91772706 A;;US 2006/0026046 W;;US 69642605 P,2005-07-01,Human monoclonal antibodies to programmed death ligand 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",MEDAREX INC;;SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30),https://lens.org/028-237-977-204-843,Granted Patent,yes,42,95,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A61K39/00;;A61K39/395,,45,24,037-833-888-905-08X;;000-592-435-005-508;;027-727-853-855-594;;059-733-201-044-050;;012-269-427-021-802;;011-092-736-500-72X;;039-555-401-046-267;;074-067-544-364-744;;027-960-937-319-909;;067-760-343-772-225;;013-122-792-588-081;;022-179-293-052-569;;050-992-361-999-488;;063-455-531-393-728;;009-746-604-420-355;;119-897-745-760-544;;022-046-054-886-073;;062-761-744-997-508;;116-193-705-533-609;;027-477-313-726-928;;047-951-914-695-080;;092-023-577-402-127;;045-556-293-127-132;;088-581-950-418-154,22588271;;10.1038/mt.2012.98;;pmc3437589;;22023178;;10.2174/157488712799363262;;pmc3804573;;10.1371/journal.pone.0077780;;24204962;;pmc3958087;;10.1128/jvi.02034-13;;24352453;;24739950;;pmc3989168;;10.1371/journal.pone.0092934;;10.1021/ja00084a073;;10.1073/pnas.92.7.2529;;pmc42251;;7708679;;10.1038/nature04444;;16382236;;10.1006/jmbi.2000.3512;;10677285;;14871849;;10.1158/0008-5472.can-03-3259;;10.4049/jimmunol.170.3.1257;;12538684;;10.1002/eji.1830240409;;8149953;;12520872;;10.1080/02648725.2002.10648023;;14530338;;10.4049/jimmunol.171.8.4156;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;10.1161/01.atv.0000145015.23656.e4;;15374847;;pmc127659;;11796590;;10.1128/iai.70.2.612-619.2002;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;1404388;;10.1016/0022-2836(92)90223-7;;10.1016/s1074-7613(00)00006-6;;10933393;;10.4049/jimmunol.164.3.1432;;10640759,"Dai et al., Molecular Therapy, 2012; 20(9): 1800-1809.;;Sakthivel et al., Reviews on Recent clinical trials, 2012; 7:10-23.;;Seung et al., 2013; PLoS One 8(10):e77780. doi:10.1371/journal.pone.0077780.;;Porichis et al., Journal of Virology, 2014; 88(5): 2508-2518.;;Siewe et al., 2014; PLoS One 9(4):e92934. doi:10.1371/journal.pone.0092934.;;U.S. Appl. No. 11/917,727, Dec. 6, 2011 Certificate of Correction.;;U.S. Appl. No. 11/917,727, Nov. 1, 2011 Request for Certificate of Correction.;;U.S. Appl. No. 11/917,727, Apr. 4, 2011 Issue Fee payment.;;U.S. Appl. No. 11/917,727, Jan. 4, 2011 Notice of Allowance.;;U.S. Appl. No. 11/917,727, Dec. 21, 2010 Response to Final Office Action.;;U.S. Appl. No. 11/917,727, Oct. 22, 2010 Final Office Action.;;U.S. Appl. No. 11/917,727, Sep. 8, 2010 Response to Non-Final Office Action.;;U.S. Appl. No. 11/917,727, Jun. 8, 2010 Non-Final Office Action.;;U.S. Appl. No. 11/917,727, Mar. 15, 2010 Response to Restriction Requirement.;;U.S. Appl. No. 11/917,727, Dec. 14, 2009 Restriction Requirement.;;U.S. Appl. No. 13/091,936, Jul. 9, 2013 Certificate of Correction.;;U.S. Appl. No. 13/091,936, Jun. 13, 2013 Request for Certificate of Correction.;;U.S. Appl. No. 13/091,936, Jan. 22, 2013 Issue Fee payment.;;U.S. Appl. No. 13/091,936, Jan. 18, 2013 Response to Amendment under Rule 312.;;U.S. Appl. No. 13/091,936, Jan. 10, 2013 Amendment after Notice of Allowance.;;U.S. Appl. No. 13/091,936, Oct. 23, 2012 Notice of Allowance.;;U.S. Appl. No. 13/091,936, Aug. 20, 2012 Amendment and Request for Continued Examination (RCE).;;U.S. Appl. No. 13/091,936, May 2, 2012 Notice of Allowance.;;U.S. Appl. No. 13/091,936, Apr. 9, 2012 Response to Non-Final Office Action.;;U.S. Appl. No. 13/091,936, Jan. 31, 2012 Non-Final Office Action.;;Barbas, et al., ""Recognition of DNA by synthetic Antibodies"", J. Am. Chem., Soc., 116:2161-2162 (1994).;;Barbas, et al., ""Human Autoantibody Recognition of DNA"", PNAS, 92:2529-2533 (1995).;;Barber, et al., ""Restoring function in exhausted CD8 T cells during chronic viral infection"", Nature: International Weekly Journal of Science, Nature Publishing Group, 439(7077):682-687 (2006).;;Beiboer, et al., ""Guided slection of a Pan Carcinoma Specific antibody Reveals Similar Binding Characteristics Yet Structural Divergence Between the Original Murine Antibody and its Human Equivalent"", JMB, 296:833-849 (2000).;;Blank, et al., ""PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells"", Cancer Research, 64:1140-1145 (2004).;;Brown, et al., ""Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production"", Journal of Immunology, American Association of Immunologists, 170(3):1257-1266 (2003).;;Cox, et al., ""A Directory of Human Germ-line Vkappa Segments Reveals a Strong Bias in Their Usage"", Eur. J. Immunol., 24:827-836 (1994).;;Ishida, et al., ""TransChromo Mouse"", Biotechnology & Genetic Engineering Reviews, 19:73-82 (2002).;;Kanai, et al., ""Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation"", The Journal of Immunology, 171:4156-4163 (2003).;;Klimka, et al., ""Human Anti-CD30 Recombinant Antibodies by Guided Phage Antibody Selection Using Cell Panning"", British Journal of Cancer, 83(2):252-260 (2000).;;Koga, et al., ""Blockade of the Interaction Between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts"", Arterioscler. Thromb. Vasc. Biol., 24(11):2057-2062 (2004).;;Mukherjee, et al., ""Human Stx2-Specific Monoclonal Antibodies Prevent Systemic Complications of Escherichia coli O157:H7 Infection"", Infection and Immunity, 70(2): 612-619 (2002).;;Panka, et al., ""Variable Region Framework Differences Result in Decreased or Increased Affinity of Variant Anti-Digoxin Antibodies"", PNAS, 85:3080-3084 (1988).;;Rader, et al., ""A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries"", PNAS, 95:8910-8915 (1998).;;Rudikoff, et al., ""Single Amino acid Substitution altering Antigen-Binding Specificity"", PNAS, 79:1979-1983 (1982).;;Tomizuka, et al., ""Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing lg heavy and kappa loci and expression of fully human antibodies"", Proceedings of the National Academy of Sciences of USA, 97(2):723-727 (2000).;;Tomlinson, et al., ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops"", J. Mol. Biol., 227:776-798 (1992).;;Xu, et al., ""Diversity in the CDR3 Region of VH Is Sufficient for Most Antibody Specificities"", Immunity, 13:37-45 (2000).;;Tamura, et al., ""Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs only"", The Journal of Immunology, 164(3):1432-1441 (2000).;;Brah-mer, et al., ""Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer"", NEJM, (11 pages) (2012).",ACTIVE
82,EP,A2,EP 2418278 A2,026-571-170-392-725,2012-02-15,2012,EP 11178187 A,2006-05-02,EP 09013687 A;;EP 06746353 A;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX INC,SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;KORMAN ALAN J;;HUANG HAICHUN,"MEDAREX, L.L.C. (2014-04-23);;E. R. SQUIBB & SONS, L.L.C. (2015-03-04);;ONO PHARMACEUTICAL CO., LTD. (2015-03-04);;MEDAREX, INC. (2013-05-29)",https://lens.org/026-571-170-392-725,Patent Application,yes,115,21,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,158,122,076-092-237-434-500;;127-416-339-660-812;;117-522-189-960-276;;004-728-346-095-981;;043-645-889-898-36X;;020-766-613-912-972;;006-463-263-246-432;;052-597-675-128-75X;;081-074-583-383-824;;025-182-641-289-850;;076-731-232-972-252;;066-015-167-169-542;;006-568-097-103-41X;;062-940-851-081-865;;048-060-748-635-820;;117-415-766-090-626;;038-551-014-784-214;;074-046-354-648-540;;008-208-772-364-327;;020-598-246-146-62X;;074-297-827-128-411;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;026-164-216-541-151;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;042-204-626-457-327;;006-574-964-805-278;;030-323-674-660-051;;092-023-577-402-127;;022-179-293-052-569;;004-458-031-333-650;;024-929-137-199-30X;;003-752-183-823-430;;070-318-112-524-781;;032-624-544-479-82X;;030-630-100-818-462;;106-753-778-592-300;;032-820-729-763-323;;083-549-078-331-651;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;033-754-369-798-314;;077-525-954-203-403;;028-969-172-280-017;;060-375-551-951-388;;020-753-772-581-741;;038-613-711-274-229;;047-951-914-695-080;;062-485-301-455-912;;032-820-729-763-323;;023-676-781-371-861;;026-744-100-669-883;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;030-769-003-988-749;;057-971-690-843-179;;145-254-035-276-41X;;026-646-521-253-318;;000-331-240-115-824;;065-438-177-962-139;;006-574-942-364-256;;101-640-792-825-42X;;070-316-527-354-375;;040-550-546-463-785;;046-168-111-025-234;;043-654-077-374-418;;084-388-182-984-099;;042-354-196-879-741;;005-112-559-456-657;;052-219-543-437-800;;007-364-858-655-289;;056-942-841-068-650;;107-302-749-967-437;;039-238-464-990-600;;020-123-860-433-320;;011-516-147-270-264;;025-182-641-289-850;;076-731-232-972-252;;006-568-097-103-41X;;013-122-792-588-081;;005-416-473-959-707;;020-986-423-793-233;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;007-709-585-201-038;;042-688-967-632-553;;056-422-417-058-69X;;005-022-447-377-963;;127-416-339-660-812;;098-407-145-404-736;;066-749-017-721-197;;001-467-559-709-949;;078-061-292-153-737;;055-646-175-554-792;;129-390-507-012-794;;008-213-515-306-640;;053-703-232-770-99X;;020-986-423-793-233;;067-739-856-772-54X;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;005-022-447-377-963;;029-697-384-910-375;;038-613-711-274-229;;062-418-979-939-961,10.4049/jimmunol.170.2.711;;12517932;;9930702;;10.1038/16717;;10.1002/j.1460-2075.1992.tb05481.x;;pmc556898;;1396582;;10.1093/intimm/8.5.765;;8671665;;10.1084/jem.181.6.1953;;7539033;;pmc2192041;;10.1016/s0167-5699(97)80025-4;;9190115;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;11224527;;10.1038/85330;;11857337;;10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9;;12721664;;10.1007/s00109-003-0430-2;;10.1007/s00262-004-0593-x;;15599732;;10.1158/1078-0432.ccr-04-0428;;15297412;;10.1073/pnas.192461099;;12218188;;pmc129438;;10.1016/s1074-7613(00)80089-8;;10485649;;10.1126/science.291.5502.319;;11209085;;10.1084/jem.20022119;;12847138;;pmc2196082;;14764622;;10.1093/hmg/ddh076;;pmc61133;;10.1073/pnas.231486598;;11698646;;4703766;;10.1093/jnci/50.4.1013;;pmc1866856;;10.1016/s0002-9440(10)65141-3;;10433938;;1330947;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;3382986;;10.1093/bioinformatics/4.1.11;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;3127726;;10.1038/332323a0;;10.1038/321522a0;;3713831;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;11096108;;10.1074/jbc.m009483200;;10.1002/bit.20151;;15352059;;11986321;;10.1074/jbc.m202069200;;10.1038/6179;;10052355;;1201277;;10.1021/bi00696a021;;10.1038/348552a0;;2247164;;1172191;;10.1038/256495a0;;8159246;;10.1038/368856a0;;10.1007/978-3-642-78432-3_3;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;8144892;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nbt727;;12172556;;8159246;;10.1038/368856a0;;10.1126/science.3929380;;3929380;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;12564977;;10.1016/s0169-409x(02)00179-5;;10.1007/s00262-002-0352-9;;12700948;;12676579;;10.1016/s1535-6108(03)00057-6;;10.1038/nrc903;;12360278;;12186272;;10.1016/s0169-409x(01)00206-x;;11744170;;10.1201/b14193-19;;7042536;;10.1111/j.1600-065x.1982.tb00392.x;;10.4049/jimmunol.155.10.4996;;7594506;;8954257;;1371789;;6239899;;10.1084/jem.160.6.1686;;pmc2187539;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;3833240;;10.1126/science.3925553;;3925553;;2958547;;10.4049/jimmunol.139.7.2367;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;3390170;;10.1016/s0006-291x(88)81333-0;;10.1128/aac.39.1.180;;pmc162506;;7695303;;10.1016/0014-5793(94)00313-0;;8206150;;7820457;;10.1006/immu.1994.1029;;12721664;;10.1007/s00109-003-0430-2;;10.1007/s00262-004-0593-x;;15599732;;10.1073/pnas.192461099;;12218188;;pmc129438;;10.4049/jimmunol.170.3.1257;;12538684;;15611321;;10.1093/intimm/dxh194;;15470033;;10.4049/jimmunol.173.8.4919;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;9624003;;10.1038/30989;;10.1016/s0171-2985(00)80072-8;;10834311;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;9930702;;10.1038/16717;;10417377;;10.1126/science.285.5427.546;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;pmc15881;;10.1073/pnas.96.6.2982;;10077623;;10.1097/00002371-199601000-00009;;8859727;;10.1038/22124;;10408445;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;9850053;;15470033;;10.4049/jimmunol.173.8.4919;;10.1016/s0960-7404(97)90012-8;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;9176498;;10.1038/nm0697-682;;10.1002/j.1460-2075.1993.tb05721.x;;pmc413278;;8458339;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1126/science.271.5256.1734;;8596936,"OKAZAKI ET AL., CUIR. OPIN. IMMUNOL., vol. 14, 2002, pages 391779 - 82;;BENNETT ET AL., J IMMUNOL, vol. 170, 2003, pages 711 - 8;;HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 263 - 266;;HANSEN ET AL., 1MMUNOGENICS, vol. 10, 1980, pages 247 - 260;;ISHIDA ET AL., EMBO J, vol. 11, 1992, pages 3887 - 95;;AGATA, INT IMMUNOL, vol. 8, 1996, pages 765 - 72;;THOMAS, M.L., J EXP MED, vol. 181, 1995, pages 1953 - 6;;VIVIER, E, DAERON, M, IMMUNOL TODAY, vol. 18, 1997, pages 286 - 91;;FREEMAN ET AL., JEXP MED, vol. 192, 2000, pages 1027 - 34;;LATCHMAN ET AL., NAT IMMUNOL, vol. 2, 2001, pages 261 - 8;;CARTER ET AL., EUR J IMMUNOL, vol. 32, 2002, pages 634 - 43;;DONG ET AL., NAT. MED, vol. 8, 2002, pages 787 - 9;;DONG, BLANK ET AL., J. MOL. MED., vol. 81, 2003, pages 281 - 7;;CANCER IMMUNOL. IMMUNOTHER., vol. 54, 2005, pages 307 - 314;;KONISHI ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 5094 - 100;;IWAI ET AL., PROC. NAT'L. ACAD SCI. USA, vol. 99, 2002, pages 1.2293 - 7;;BROWN ET AL., J IMMUNOL., vol. 170, 2003;;OKAZAKI ET AL., CURR OPIN IMMUNOL, vol. 14, 2002, pages 391779 - 82;;NISHIMURA, NISHIMURA ET AL., IMMUNITY, vol. 11, 1999, pages 141 - 51;;SCIENCE, vol. 291, 2001, pages 319 - 22;;SALAMA ET AL., JEXP MED, vol. 198, 2003, pages 71 - 78;;PROKUNINA, ALARCON-RIQUELME, HUM MOL GENET, vol. 13, 2004, pages R143;;NIELSEN ET AL., LUPUS, vol. 13, 2004, pages 510;;OKAZAKI ET AL., PNAS, vol. 98, 2001, pages 13866 - 71;;MURPHY, HRUSHESKY, J. NAT'L. CANCER RES., vol. 50, 1973, pages 1013 - 1025;;MURATA, AM. J PATHOL., vol. 155, 1999, pages 453 - 460;;BALZANO, INT. J CANCER SUPPL., vol. 7, 1992, pages 28 - 32;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD SCI. USA, vol. 85, 1988, pages 5879 - 5883;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, NIH PUBLICATION NO. 91-3242;;E. MEYERS, W. MILLER, COMPUT. APPL. BIOSCI., vol. 4, 1988, pages 11 - 17;;NEEDLEMAN, WUNSCH, J MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL, J. MOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;RIECHMANN, L. ET AL., NATURE, vol. 332, 1998, pages 323 - 327;;JONES, P. ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;QUEEN, C., PROC. NATL. ACAD SEE. U.S.A., vol. 86, 1989, pages 10029 - 10033;;TOMLINSON, I. M.: ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops"", 1. MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: doi:10.1016/0022-2836(92)90223-7;;COX, J. P. L. ET AL.: ""A Directory of Human Germ-line VH Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;SHIELDS, R.L. ET AL., J BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;YAMANE-OHNUKI ET AL., BIOTECHNOL BIOENG, vol. 87, 2004, pages 614 - 22;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;TARENTINO, A.L. ET AL., BIOCHEM., vol. 14, 1975, pages 5516 - 23;;F. AUSUBEL: ""Current Protocols in Molecular Biology"", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;;KABAT, E. A.: ""Sequences of Proteins of Immunological Interest"", 1991, NIH PUBLICATION NO. 91-3242;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;KOHLER, MILSTEIN, NATURE, vol. 256, 1975, pages 495;;LONBERG ET AL., NATURE, vol. 368, no. 6474, pages 856 - 859;;LONBERG, N.: ""Handbook ofExperimental Pharmacology"", vol. 113, 1994, pages: 49 - 101;;LONBERG, N., HUSZAR, D., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F., LONBERG, N., ANN. N.Y. ACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 2, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD SCI. USA, vol. 90, 1993, pages 3720 - 3724;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J. ET AL., EMBO J., vol. 12, 1993, pages 821 - 830;;TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;TOMIZUKA ET AL., PROC. NATL. ACAD SCI. USA, vol. 97, 2000, pages 722 - 727;;KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894;;LONBERG, N. ET AL., NATURE, vol. 3 68, no. 6474, 1994, pages 856 - 859;;MORRISON, S., SCIENCE, vol. 229, 1985, pages 1202;;GOEDDEL: ""Gene Expression Technology. Methods in Enzymology"", 1990, ACADEMIC PRESS, pages: 185;;TALCEBE, Y., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;BOSS, M. A., WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB, CHASIN, PROC. NATL. ACAD SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMAN, P. A. SHARP, MOL. BIOL.., vol. 159, 1982, pages 601 - 621;;SAITO, G., ADV. DRUG DELIV. REV., vol. 55, 2003, pages 199 - 215;;TRAIL, P.A. ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 52, 2003, pages 328 - 337;;PAYNE, G., CANCER CELL, vol. 3, 2003, pages 207 - 212;;ALLEN, T.M., NAT. REV. CANCER, vol. 2, 2002, pages 750 - 763;;PASTAN, 1., KREITMAN, R. J., CURR. OPIN. INVESTIG. DRUGS, vol. 3, 2002, pages 1089 - 1091;;SENTER, P.D., SPRINGER, C.J., ADV. DRUG DELIV. REV, vol. 53, 2001, pages 247 - 264;;ARNON ET AL.: ""Monoclonal Antibodies And Cancer Therapy"", 1985, ALAN R. LISS, INC., article ""Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy"", pages: 243 - 56;;HELLSTROM ET AL.: ""Controlled Drug Delivery"", 1987, MARCEL DEKKER, INC., article ""Antibodies For Drug Delivery"", pages: 623 - 53;;THORPE ET AL.: ""Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review"", MONOCLONAL ANTIBODIES '84: BIOLOGICAL AND CLINICAL APPLICATIONS, 1985, pages 475 - 506;;""Monoclonal Antibodies For Cancer Detection And Therapy"", 1985, ACADEMIC PRESS, article ""Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy"", pages: 303 - 16;;THORPE ET AL.: ""The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates"", IMMUNOL. REV., vol. 62, 1982, pages 119 - 5,8;;GRAZIANO, R.F. ET AL., J. IMMUNOL, vol. 155, no. 10, 1995, pages 4996 - 5002;;MORTON, H.C. ET AL., CRITICAL REVIEWS IN IMMUNOLOGY, vol. 16, 1996, pages 423 - 440;;MONTEIRO, RC. ET AL., J IMMUNOL., vol. 148, 1992, pages 1764;;KARPOVSKY ET AL., J EXP. MED., vol. 160, 1984, pages 1686;;LIU, MA ET AL., PROC. NATL. ACAD SCI. USA, vol. 82, 1985, pages 8648;;PAULUS, BEHRING INS. MITT. NO. 78, 1985, pages 118 - 132;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83;;GLENNIE ET AL., J. 1MMUNOL, vol. 139, 1987, pages 2367 - 2375;;WEINTRAUB, B.: ""Seventh Training Course on Radioligand Assay Techniques"", March 1986, THE ENDOCRINE SOCIETY, article ""Principles ofRadioimmunoassays"";;BERGE, S.M. ET AL., J. PHCIRM. SCI., vol. 66, 1977, pages 1 - 19;;""Sustained and ControlledRelease Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;RANADE, J CLIN. PHARMACOL., vol. 29, 1989, pages 685;;UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 153, 1988, pages 1038;;P.G. BLOERNAN ET AL., FEBS LETT., vol. 357, 1995, pages 140;;M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 39, 1995, pages 180;;BRISCOE ET AL., AM. J. PHYSIOL., vol. 1233, 1995, pages 134;;SCHREIER ET AL., J. BIAL. CHEM., vol. 269, 1994, pages 9090;;K. KEINANEN, M.L. LAUKKANEN, FEBSLETT., vol. 346, 1994, pages 123;;J.J. KILLION, I.J. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273;;DONG ET AL., NATMED, vol. 8, 2002, pages 787 - 9;;DONG ET AL., JMOL MED, vol. 81, 2003, pages 281 - 7;;BLANK ET AL., CANCER IMMUNOL. IMMUNOFHER., vol. 54, 2005, pages 307 - 314;;IWAI ET AL., PNAS, vol. 99, 2002, pages 12293 - 7;;BROWN ET AL., J. IMMUNOL., vol. 170, 2003, pages 1257 - 66;;IWAI ET AL., INT. IMMUNOL., vol. 17, 2005, pages 133 - 144;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;ROSENBERG, S.: ""ASCO Educational Book Spring"", 2000, article ""Development of Cancer Vaccines"", pages: 60 - 62;;LOGOTHETIS, C.: ""ASCO Educational Book Spring"", 2000, pages: 300 - 302;;KHAYAT, D.: ""ASCO Educational Book Spring"", 2000, pages: 414 - 428;;FOON, K.: ""ASCO Educational Book Spring"", 2000, pages: 730 - 738;;RESTIFO, N., SZNOL, M.: ""Cancer: Principles and Practice of Oncology"", 1997, article ""Cancer Vaccines"", pages: 3023 - 3043;;DRANOFF ET AL., PROC. NAFL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, SA, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM, N ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT, R, SRIVASTAVA, P, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA, Y. ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE, F. ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER, A. ET AL., NATUREMEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR, M. ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL, J. ET AL., J EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARD, M., O'GARRA, A., IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE, M. ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;RIDGE, J. ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;ITO, N. ET AL., IMMUNOBIOLOGY, vol. 201, no. 5, 2000, pages 527 - 40;;WEINBERG, A. ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO, 1. ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF A. ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;GREENBERG, R., RIDDELL, S., SCIENCE, vol. 285, 1999, pages 546 - 51;;HOLLIGER, PROC. NAFL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;OVERWIJK, W. ET AL., PROC. NATL. ACAD SCI. U.S.A., vol. 96, 1999, pages 2982 - 2987;;ROSENBERG, SA, WHITE, DE, J. IMMUNOTHER EMPHASIS TUMOR IMMUNOL, vol. 19, no. 1, 1996, pages 81 - 4;;SCHENK ET AL., NATURE, vol. 400, 1999, pages 173 - 177;;HARLOW, LANE: ""Antibodies, A Laboratoly Manual"", 1988, COLD SPRING HARBOR LABORATORY PRESS;;HURWITZ ET AL., PROC. NATL. ACAD SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071;;CAMACHO ET AL., J CLIN. ONCOLOGY, vol. 22, 2004, pages 145;;MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304;;HE ET AL., J 1MMUNOL., vol. 173, 2004, pages 4919 - 28;;RESTIFO, SZNOL: ""Cancer Vaccines"", 1997, pages: 3023 - 3043;;""Cancer: Principles and Practice of Oncology"", 1997;;DRANOFF ET AL., PROC. NAFL. ACAD SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT, SRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;MELERO, I. ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF, A. ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;""PDR"", 2004, pages: 608 - 610;;CHEN ET AL., EMBO 1., vol. 12, 1993, pages 811 - 820;;FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;LONBERG, N. ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;HARLOW, LANE: ""Antibodies, A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY PRESS;;LEACH ET AL., SCIENCE, vol. 271, 1996, pages 1734 - 1736",DISCONTINUED
83,US,B2,US 9273135 B2,117-346-323-970-118,2016-03-01,2016,US 201514796956 A,2015-07-10,US 201514796956 A;;US 201313746773 A;;US 201113091936 A;;US 91772706 A;;US 2006/0026046 W;;US 69642605 P,2005-07-01,Human monoclonal antibodies to programmed death ligand 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-LI antibodies.",SQUIBB & SONS LLC;;SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;MEDAREX INC (2008-03-26),https://lens.org/117-346-323-970-118,Granted Patent,yes,46,89,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/395;;A61K39/00;;C07K16/28,,50,27,039-555-401-046-267;;011-092-736-500-72X;;074-067-544-364-744;;027-960-937-319-909;;067-760-343-772-225;;038-040-632-602-487;;013-122-792-588-081;;022-179-293-052-569;;037-833-888-905-08X;;050-992-361-999-488;;063-455-531-393-728;;009-746-604-420-355;;119-897-745-760-544;;022-046-054-886-073;;062-761-744-997-508;;059-733-201-044-050;;116-193-705-533-609;;027-477-313-726-928;;000-592-435-005-508;;027-727-853-855-594;;012-269-427-021-802;;088-581-950-418-154;;047-951-914-695-080;;092-023-577-402-127;;045-556-293-127-132;;058-883-699-331-571;;006-568-097-103-41X,10.1073/pnas.92.7.2529;;pmc42251;;7708679;;10.1021/ja00084a073;;10.1038/nature04444;;16382236;;10.1006/jmbi.2000.3512;;10677285;;14871849;;10.1158/0008-5472.can-03-3259;;10.1056/nejmoa1200694;;pmc3563263;;22658128;;10.4049/jimmunol.170.3.1257;;12538684;;10.1002/eji.1830240409;;8149953;;22588271;;10.1038/mt.2012.98;;pmc3437589;;12520872;;10.1080/02648725.2002.10648023;;14530338;;10.4049/jimmunol.171.8.4156;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;10.1161/01.atv.0000145015.23656.e4;;15374847;;pmc127659;;11796590;;10.1128/iai.70.2.612-619.2002;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;pmc3958087;;10.1128/jvi.02034-13;;24352453;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;22023178;;10.2174/157488712799363262;;pmc3804573;;10.1371/journal.pone.0077780;;24204962;;24739950;;pmc3989168;;10.1371/journal.pone.0092934;;10.4049/jimmunol.164.3.1432;;10640759;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;1404388;;10.1016/0022-2836(92)90223-7;;10.1016/s1074-7613(00)00006-6;;10933393;;10.1002/ijc.21775;;16482562;;10.1073/pnas.192461099;;12218188;;pmc129438,"Amendment after Notice of Allowance mailed Jan. 10, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Amendment and Request for Continued Examination (RCE) mailed Aug. 20, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Barbas, S.M., et al., ""Human Autoantibody Recognition of DNA,"" Proceedings of the National Academy of Sciences of the United States of America 92(7):2529-2533, National Academy of Sciences, United States (1995).;;Barbas, S.M., et al., ""Recognition of DNA by Synthetic Antibodies,"" Journal of the American Chemical Society 116(5):2161-2162, American Chemical Society, United States (1994).;;Barber, D.L., et al., ""Restoring Function in Exhausted CD8 T Cells during Chronic Viral Infection,"" Nature 439(7077):682-687, Nature Publishing Group, United States (2006).;;Beiboer, S.H., et al., ""Guided Selection of a Pan Carcinoma Specific Antibody Reveals Similar Binding Characteristics Yet Structural Divergence between the Original Murine Antibody and its Human Equivalent,"" Journal of Molecular Biology 296(3):833-849, Elsevier, England (2000).;;Blank, C., et al., ""PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells,"" Cancer Research 64(3):1140-1145, American Association for Cancer Research, United States (2004).;;Brahmer, J.R., et al., ""Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer,"" The New England Journal of Medicine 366(26):2455-2465, Massachusetts Medical Society, United States (2012).;;Brown, J.A., et al., ""Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production,"" The Journal of Immunology 170(3):1257-1266, The American Association of Immunologists, United States (2003).;;Certificate of Correction mailed Dec. 6, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Certificate of Correction mailed Jul. 9, 2013, in U.S. Appl. No. 13/091,936. Alan, J., et al., filed Apr. 21, 2011.;;Cox, J.P., et al., ""A Directory of Human Germ-line V kappa Segments Reveals a Strong Bias in their Usage,"" European Journal of Immunology 24(4):827-836, VCH Verlagsgesellschaft mbH, Germany (1994).;;Dai, B., et al., ""PD-1/PD-L1 Blockade can Enhance HIV-1 Gag-Specific T Cell Immunity Elicited by Dendritic Cell-Directed Lentiviral Vaccines,"" Molecular Therapy 20(9):1800-1809, The American Society of Gene & Cell Therapy, United States (2012).;;Final Office Action mailed Oct. 22, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;International Preliminary Report on Patentability for International Application No. PCT/US2006/026046, International Bureau of WIPO, Switzerland, mailed on Jan. 9, 2008,11 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2006/026046, European Patent Office, Netherlands, mailed on Apr. 3, 2007,17 pages.;;Ishida, I., et al., ""TransChromo Mouse,"" Biotechnology & Genetic Engineering Reviews 19:73-82, Taylor & Francis, England (2002).;;Issue Fee payment mailed Apr. 4, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Issue Fee payment mailed Jan. 22, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Kanai, T., et al., ""Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation,"" The Journal of Immunology 171(8):4156-4163, American Association of Immunologists, Inc., United States (2003).;;Klimka, A., et al., ""Human Anti-CD30 Recombinant Antibodies by Guided Phage Antibody Selection Using Cell Panning,"" British Journal of Cancer 83(2):252-260, Cancer Research Campaign, England (2000).;;Koga, N., et al., ""Blockade of the Interaction Between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts,"" Arteriosclerosis, Thrombosis and Vascular Biology 24(11):2057-2062, American Heart Association, Inc., United States (2004).;;Mukherjee, J., et al., ""Human ,Stx2-Specific Monoclonal Antibodies Prevent Systemic Complications of Escherichia coli O157:H7 Infection,"" Infection and Immunity 70(2):612-619, American Society for Microbiology, United States (2002).;;Non-Final Office Action mailed Jan. 31, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Non-Final Office Action mailed Jun. 8, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al, filed Jun. 9, 2008.;;Notice of Allowance mailed Jan. 4, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Notice of Allowance mailed May 2, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Notice of Allowance mailed Oct. 23. 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Panka, D.J., et al., ""Variable Region Framework Differences Result in Decreased or Increased Affinity of Variant Anti-digoxin Antibodies,"" Proceedings of the National Academy of Sciences 85(9):3080-3084, National Academy of Sciences, United States (1988).;;Porichis, F., et al., ""Differential impact PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions,"" Journal of Virology 88(5):2508-2518, American Society for Microbiology, United States (Mar. 2014).;;Rader, C., et al., ""A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries,"" Proceedings of the National Academy of Sciences of the United States of America 95(15):8910-8915, National Academy of Sciences, United States (1998).;;Request for Certificate of Correction mailed Jun. 13, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Request for Certificate of Correction mailed Nov. 1, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Response to Amendment under Rule 312 mailed Jan. 18, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Response to Final Office Action mailed Dec. 21, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Response to Non-Final Office Action mailed Apr. 9, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Response to Non-Final Office Action mailed Sep. 8, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Response to Restriction Requirement mailed Mar. 15, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Restriction Requirement mailed Dec. 14, 2009, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Rudikoff, S., et al., ""Single Amino Acid Substitution Altering Antigen-Binding Specificity,"" Proceedings of the National Academy of Sciences 79(6):1979-1983, The National Academy of Sciences, United States (1982).;;Sakthivel, P., et al., ""Therapeutic Intervention in Cancer and Chronic Viral Infections: Antibody Mediated Manipulation of PD-1/PD-LI Interaction,"" Reviews on Recent Clinical Trials 7(1):10-23, Bentham Science Pub., United Arab Emirates (2012).;;Seung, E., et al., ""PD-1 Blockade in Chronically HIV-1-Infected Humanized Mice Suppresses Viral Loads,"" PloS One 8(10):e77780, Public Library of Science, United States (Oct. 2013).;;Siewe, B., et al., ""Regulatory B Cells Inhibit Cytotoxic T Lymphocyte (CTL) Activity and Elimination of Infected CD4 T Cells after in Vitro Reactivation of HIV Latent Reservoirs,"" PloS One 9(4):e92934, Public Library of Science, United States (Apr. 2014).;;Tamura, M. et al., ""Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs only,"" Journal of Immunology 164(3):1432-1441, American Association of Immunologists, United States (2000).;;Tomizuka, K., et al., ""Double Trans-Chromosomic Mice: Maintenance of Two Individual Human Chromosome Fragments Containing Ig Heavy and kappa loci and Expression of Fully Human Antibodies,"" Proceedings of the National Academy of Sciences of the United States of America 97(2):722-727, National Academy of Sciences, United States (2000).;;Tomlinson, I.M., et al., ""The Repertoire of Human Germline VH Sequences Reveals About Fifty Groups of VH segments with Different Hypervariable Loops,"" Journal of Molecular Biology 227(3):776-798, Academic Press Limited, England (1992).;;Xu, J.L. and Davis, M.M., ""Diversity in the CDR3 Region of VH is Sufficient for Most Antibody Specificities,"" Immunity 13(l):37-45, Cell Press, United States (2000).;;Blank, C., et al.,, ""Blockade of PD-L I (B7-H1) augments human tumor-specific T cell responses in vitro,"" International Journal of Cancer 119(2):317-327, International Union Against Cancer, United States (2006).;;Iwai, Y., et al., ""Involvement of PD-L I on tumor cells in the escape from host immune system and tumor immunotherapy by PD-Ll blockade,"" Proceeding's of the National Academy of Sciences of the United States of America 99(19):12293-12297, National Academy of Sciences, United States (2002).;;Extended European Search Report and Search Opinion for EP Application No. 15172571.0, European Patent Office, Germany, mailed on Dec. 17, 2015.",ACTIVE
84,CA,C,CA 2970873 C,134-077-987-289-273,2022-05-17,2022,CA 2970873 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;CA 2607147 A,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti- CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",SQUIBB & SONS LLC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/134-077-987-289-273,Granted Patent,no,0,0,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A01K67/027;;A61K39/395;;A61K47/68;;C07K16/46;;C12N5/16;;C12N15/13,,0,0,,,,PENDING
85,JP,A,JP 2017052784 A,131-152-555-616-216,2017-03-16,2017,JP 2016220640 A,2016-11-11,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,HUMAN MONOCLONAL ANTIBODY AGAINST PROGRAMMED DEATH 1 (PD-1) AND METHOD FOR TREATING CANCER USING ANTI-PD-1 ANTIBODY ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPY,"PROBLEM TO BE SOLVED: To provide an isolated monoclonal antibody specifically binding to Programmed Death 1 (PD-1) with high affinity, particularly a human monoclonal antibody.SOLUTION: The present invention provides an isolated monoclonal antibody or a binding portion thereof, which performs a cross-competition for binding to a reference antibody comprising a human heavy chain and light chain variable regions consisting of specific amino acid sequences and PD-1. According to the present invention, by preparing an immunocomplex, a bispecific molecule, and a pharmaceutical composition, which are comprising the antibody, it is possible to provide a PD-1 detection method and treat various disorders including cancer and infectious diseases. According to the present invention, it is also possible to treat hyperproliferative disorders, such as cancer, using a combination immunotherapy, such as a combination of anti-CTLA-4 and anti-PD-1 antibodies. Adverse treatment-related adverse events by each of such antibodies are altered.SELECTED DRAWING: None",ONO PHARMACEUTICAL CO;;ER SQUIBB & SONS LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/131-152-555-616-216,Patent Application,no,7,0,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395;;A61P35/00,,2,0,,,"庄雅之他, 日本癌学会学術総会記事, 2005 AUG, VOL.64, P.56, W-102, JPN6014051260, ISSN: 0003911743;;庄雅之他, 日本癌治療学会誌, 2005 SEP, VOL.40, NO.2, P.590, PS22-5, JPN6014051261, ISSN: 0003911744",PENDING
86,US,A1,US 2017/0158767 A1,124-482-803-026-863,2017-06-08,2017,US 201715413244 A,2017-01-23,US 201715413244 A;;US 201615188860 A;;US 201514807522 A;;US 201313746773 A;;US 201113091936 A;;US 91772708 A;;US 2006/0026046 W;;US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/124-482-803-026-863,Patent Application,yes,8,31,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/395;;C07K16/28,,14,12,083-230-750-341-053;;004-509-656-230-835;;086-751-695-402-863;;004-098-011-038-578;;031-217-961-878-413;;010-809-130-428-953;;096-836-496-369-605;;060-550-110-687-29X;;107-025-092-815-187;;119-913-141-042-40X;;082-582-463-785-201;;105-890-842-208-495,10.1038/nm.4224;;27820605;;pmc5301914;;10.1128/9781555817411.ch6;;10.1128/microbiolspec.aid-0028-2014;;26104550;;15705911;;10.1158/0008-5472.1089.65.3;;15776005;;10.1038/nrc1586;;10.1016/j.cell.2015.05.007;;26004070;;pmc4683157;;10.1080/19420862.2016.1276683;;28055305;;pmc5384726;;10.1016/j.molimm.2004.05.004;;15302161;;10.1016/j.ymeth.2017.01.003;;28088364;;10.4161/19420862.2015.989047;;pmc4622072;;25530082;;10.1111/imm.12838;;pmc5721244;;28898398;;pmc4966639;;10.1080/19420862.2015.1118596;;26652308;;27065089;;10.1016/j.coi.2016.03.008;;pmc5203765,"Khan et al. Sci. Rep. (2017) 7, 45163; doi: 10.1038/srep45163 (12 pages).;;Lee et al. Nature Medicine (2016) 22: 1456–1464.;;Van Regenmortel MHV. Front. Immunol. (2018) Vol. 8, Article 2009 (11 pages).;;Sheehan et al. Microbiol. Spectr. (2015) 3(1): AID-0028-2014; 17 pages.;;Hirano et al. (Cancer Res 2005; 65(3): 1089-1096).;;Zou W. Nature Reviews Cancer (2005) 5: 263–274.;;Zhu et al. Cell (2015) 161: 1280–1292.;;Konitzer et al. mAbs (2017) 9: 536-549.;;Damschroder et al. Molecular Immunology (2004) 41: 985–1000.;;Conroy et al. Methods (2017) 116: 12–22.;;Ferrara et al. mAbs (2015) 7: 32-41.;;Parola et al. Immunology (2018) 153: 31-41.;;Abdiche et al. mAbs (2016) 8: 264–277.;;Boyd et al. Current Opinion in Immunology 2016, 40: 103–109.",DISCONTINUED
87,CA,C,CA 2607147 C,007-656-605-726-266,2018-07-17,2018,CA 2607147 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/007-656-605-726-266,Granted Patent,no,0,0,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12P21/08,,0,0,,,,ACTIVE
88,US,A1,US 2011/0209230 A1,037-638-815-677-334,2011-08-25,2011,US 201113091936 A,2011-04-21,US 201113091936 A;;US 91772706 A;;US 2006/0026046 W;;US 69642605 P,2005-07-01,Human Monoclonal Antibodies To Programmed Death Ligand 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30),https://lens.org/037-638-815-677-334,Patent Application,yes,27,62,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07H21/04;;A01K67/027;;C12N5/10;;C12N15/63;;C12P21/08,800/18;;536/23.53;;435/320.1;;435/325;;435/69.6,4,4,027-960-937-319-909;;009-746-604-420-355;;116-193-705-533-609;;045-556-293-127-132,10.1006/jmbi.2000.3512;;10677285;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;10.1016/s1074-7613(00)00006-6;;10933393,"Beiboer et al., J. Mol. Biol. (2000), 296: 833-849.;;Klimka et al., British Journal of Cancer (2000), 83: 252-260.;;Rader et al., Proc. Natl. Acad. Sci. USA (1998), 95: 8910-8915.;;Xu et al., Immunity (2000), 13: 37-45.",ACTIVE
89,US,A1,US 2014/0348743 A1,045-929-397-292-545,2014-11-27,2014,US 201414248462 A,2014-04-09,US 201414248462 A;;US 201113210137 A;;US 91321706 A;;JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1),"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;ONO PHARMACEUTICAL CO. LTD (2007-12-27);;MEDAREX INC (2012-04-12),https://lens.org/045-929-397-292-545,Patent Application,yes,0,86,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K47/48;;A61K51/10;;C07K16/46,424/1.49;;530/388.15;;530/387.3;;530/388.22;;424/142.1;;424/178.1;;424/183.1,0,0,,,,ACTIVE
90,US,A1,US 2014/0328833 A1,036-574-417-409-717,2014-11-06,2014,US 201414270750 A,2014-05-06,US 201414270750 A;;US 201113210137 A;;US 91321706 A;;JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",MEDAREX LLC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;ONO PHARMACEUTICAL CO. LTD (2007-12-27);;MEDAREX INC (2012-04-12),https://lens.org/036-574-417-409-717,Patent Application,yes,0,81,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/18,424/133.1;;424/155.1;;424/142.1,0,0,,,,ACTIVE
91,US,A1,US 2014/0294852 A1,098-607-483-494-398,2014-10-02,2014,US 201414244405 A,2014-04-03,US 201414244405 A;;US 201113210137 A;;US 91321706 A;;JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1),"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;ONO PHARMACEUTICAL CO. LTD (2007-12-27);;MEDAREX INC (2012-04-12),https://lens.org/098-607-483-494-398,Patent Application,yes,0,79,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K47/48;;C07K16/46,424/143.1;;530/387.1;;530/387.3;;530/388.15;;530/388.22;;530/391.1;;530/391.3;;530/391.7,0,0,,,,ACTIVE
92,CA,C,CA 2612241 C,108-324-947-213-269,2018-11-06,2018,CA 2612241 A,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-Ll antibodies.",MEDAREX INC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/108-324-947-213-269,Granted Patent,no,0,0,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C12N15/13;;A01K67/027;;A61K39/395;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;C07K14/705;;C07K16/28;;C07K16/46,,0,0,,,,ACTIVE
93,US,A1,US 2016/0075782 A1,100-863-236-935-072,2016-03-17,2016,US 201514807522 A,2015-07-23,US 201514807522 A;;US 201313746773 A;;US 201113091936 A;;US 91772708 A;;US 2006/0026046 W;;US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;MEDAREX INC (2008-03-26),https://lens.org/100-863-236-935-072,Patent Application,yes,99,49,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28,,74,42,058-883-699-331-571;;006-568-097-103-41X;;039-555-401-046-267;;011-092-736-500-72X;;074-067-544-364-744;;027-960-937-319-909;;067-760-343-772-225;;038-040-632-602-487;;013-122-792-588-081;;022-179-293-052-569;;037-833-888-905-08X;;050-992-361-999-488;;063-455-531-393-728;;009-746-604-420-355;;119-897-745-760-544;;022-046-054-886-073;;062-761-744-997-508;;059-733-201-044-050;;116-193-705-533-609;;027-477-313-726-928;;000-592-435-005-508;;027-727-853-855-594;;012-269-427-021-802;;088-581-950-418-154;;047-951-914-695-080;;092-023-577-402-127;;045-556-293-127-132;;076-731-232-972-252;;113-346-509-283-257;;081-074-583-383-824;;122-644-406-202-233;;025-182-641-289-850;;079-214-893-487-418;;006-463-263-246-432;;006-463-263-246-432;;020-986-423-793-233;;086-751-695-402-863;;066-015-167-169-542;;083-811-051-643-47X;;057-629-746-536-175;;078-115-905-519-238;;033-225-590-843-088,10.1002/ijc.21775;;16482562;;10.1073/pnas.192461099;;12218188;;pmc129438;;10.1073/pnas.92.7.2529;;pmc42251;;7708679;;10.1021/ja00084a073;;10.1038/nature04444;;16382236;;10.1006/jmbi.2000.3512;;10677285;;14871849;;10.1158/0008-5472.can-03-3259;;10.1056/nejmoa1200694;;pmc3563263;;22658128;;10.4049/jimmunol.170.3.1257;;12538684;;10.1002/eji.1830240409;;8149953;;22588271;;10.1038/mt.2012.98;;pmc3437589;;12520872;;10.1080/02648725.2002.10648023;;14530338;;10.4049/jimmunol.171.8.4156;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;10.1161/01.atv.0000145015.23656.e4;;15374847;;pmc127659;;11796590;;10.1128/iai.70.2.612-619.2002;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;pmc3958087;;10.1128/jvi.02034-13;;24352453;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;22023178;;10.2174/157488712799363262;;pmc3804573;;10.1371/journal.pone.0077780;;24204962;;24739950;;pmc3989168;;10.1371/journal.pone.0092934;;10.4049/jimmunol.164.3.1432;;10640759;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;1404388;;10.1016/0022-2836(92)90223-7;;10.1016/s1074-7613(00)00006-6;;10933393;;10.1007/s00262-004-0593-x;;15599732;;11861596;;10.1146/annurev.immunol.20.091101.091806;;11857337;;10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9;;12091876;;10.1038/nm730;;12721664;;10.1007/s00109-003-0430-2;;10581077;;10.1038/70932;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;15470033;;10.4049/jimmunol.173.8.4919;;15705911;;10.1158/0008-5472.1089.65.3;;10.1158/1078-0432.ccr-04-0428;;15297412;;17404099;;10.1158/1078-0432.ccr-06-2746;;10.1182/blood.v97.6.1809;;11238124;;12421930;;10.4049/jimmunol.169.10.5538;;18500231;;10.1038/nri2326,"U.S. Appl. No. 15/188,860, filed Jun. 2016, Korman, A.;;Blank, C., at al., ""Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro,"" International Journal of Cancer 119(2):317-327, International Union Against Cancer, United States (2006).;;Iwai, Y., et al., ""Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade,"" Proceedings of the National Academy of Sciences of the United States of America 99(19):12293-12297, National Academy of Sciences, United States (2002).;;Extended European Search Report and Search Opinion for EP Application No. 15172571.0, European Patent Office, Germany, mailed on Dec. 17, 2015.;;Amendment after Notice of Allowance mailed Jan. 10, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Amendment and Request for Continued Examination (RCE) mailed Aug. 20, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Barbas, S.M., et al., ""Human Autoantibody Recognition of DNA,"" Proceedings of the National Academy of Sciences of the United States of America 92(7):2529-2533, National Academy of Sciences, United States (1995).;;Barbas, S.M., et al., ""Recognition of DNA by Synthetic Antibodies,"" Journal of the American Chemical Society 116(5):2161-2162, American Chemical Society, United States (1994).;;Barber, D.L., et al., ""Restoring Function in Exhausted CD8 T Cells during Chronic Viral Infection,"" Nature 439(7077):682-687, Nature Publishing Group, United States (2006).;;Beiboer, S.H., et al., ""Guided Selection of a Pan Carcinoma Specific Antibody Reveals Similar Binding Characteristics Yet Structural Divergence between the Original Murine Antibody and its Human Equivalent,"" Journal of Molecular Biology 296(3):833-849, Elsevier, England (2000).;;Blank, C., et al., ""PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells,"" Cancer Research 64(3):1140-1145, American Association for Cancer Research, United States (2004).;;Brahmer, J.R., et al., ""Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer,"" The New England Journal of Medicine 366(26):2455-2465, Massachusetts Medical Society, United States (2012).;;Brown, J.A., et al., ""Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production,"" The Journal of Immunology 170(3):1257-1266, The American Association of Immunologists, United States (2003).;;Certificate of Correction mailed Dec. 6, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Certificate of Correction mailed Jul. 9, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Cox, J.P., et al., ""A Directory of Human Germ-Line V kappa Segments Reveals a Strong Bias in their Usage,"" European Journal of Immunology 24(4):827-836, Verlag Chemie GmbH, Germany (1994).;;Dai, B., et al., ""PD-1/PD-L1 Blockade can Enhance HIV-1 Gag-Specific T Cell Immunity Elicited by Dendritic Cell-Directed Lentiviral Vaccines,"" Molecular Therapy 20(9):1800-1809, Academic Press, United States (2012).;;Final Office Action mailed Oct. 22, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;International Preliminary Report on Patenetability for International Application No. PCT/US2006/026046, International Bureau of WIPO, Switzerland, mailed on Jan. 9, 2008,11 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2006/026046, European Patent Office, Netherlands, mailed on Apr. 3, 2007,17 pages.;;Ishida, I., et al., ""TransChromo Mouse,"" Biotechnology & Genetic Engineering Reviews 19:73-82, Taylor & Francis, England (2002).;;Issue Fee payment mailed Apr. 4, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Issue Fee payment mailed Jan. 22, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Kanai, T., et al., ""Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation,"" The Journal of Immunology 171(8):4156-4163, American Association of Immunologists, Inc., United States (2003).;;Klimka, A., et al., ""Human Anti-CD30 Recombinant Antibodies by Guided Phage Antibody Selection Using Cell Panning,"" British Journal of Cancer 83(2):252-260, Cancer Research Campaign, England (2000).;;Koga, N., et al., ""Blockade of the Interaction Between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts,"" Arteriosclerosis, Thrombosis and Vascualr Biology 24(11):2057-2062, American Heart Association, Inc., United States (2004).;;Mukherjee, J., et al., ""Human Stx2-Specific Monoclonal Antibodies Prevent Systemic Complications of Escherichia coli O157:H7 Infection,"" Infection and Immunity 70(2):612-619, American Society for Microbiology, United States (2002).;;Non-Final Office Action mailed Jan. 31, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Non-Final Office Action mailed Jun. 8, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Notice of Allowance mailed Jan. 4, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Notice of Allowance mailed May 2, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Notice of Allowance mailed Oct. 23, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Panka, D.J., et al., ""Variable Region Framework Differences Result in Decreased or Increased Affinity of Variant Anti-digoxin Antibodies,"" Proceedings of the National Academy of Sciences 85(9):3080-3084, National Academy of Sciences, United. States (1988).;;Porichis, F., et al., ""Differential impact PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions,"" Journal of Virology 88(5):2508-2518, American Society for Microbiology, United States (2014).;;Rader, C., et al., ""A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries,"" Proceedings of the National Academy of Sciences of the United States of America 95(15):8910-8915, National Academy of Sciences, United Ststes (1998).;;Request for Certificate of Correction mailed Jun. 13, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Request for Certificate of Correction mailed Nov. 1, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Response to Amendment under Rule 312 mailed Jan. 18, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Response to Final Office Action mailed Dec. 21, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Response to Non-Final Office Action mailed Apr. 9, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Response to Non-Final Office Action mailed Sep. 8, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Response to Restriction Requirement mailed Mar. 15, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Restriction Requirement mailed Dec. 14, 2009, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Rudikoff, S., et al., ""Single Amino Acid Substitution Altering Antigen-Binding Specificity,"" Proceedings of the National Academy of Sciences 79(6):1979-1983, The National Academy of Sciences, United States (1982).;;Sakthivel, P., et al., ""Therapeutic Intervention in Cancer and Chronic Viral Infections: Antibody Mediated Manipulation of PD-1/PD-L1 Interation,"" Reviews on Recent Clinical Trials 7(1):10-23, Bentham Science Pub., United Arab Emirates (2012).;;Seung, E., et al., ""PD-1 Blockade in Chronically HIV-1-Infected Humanized Mice Suppresses Viral Loads,"" PloS One 8(10):e77780, Public Library of Science, United States(Oct. 2013).;;Siewe, B., et al., ""Regulatory B Cells Inhibit Cytotoxic T Lymphocyte (CTL) Activity and Elimination of Infected CD4 T Cells after In Vitro Reactivation of HIV Latent Reservoirs,"" PloS One 9(4):e92934, Public Library of Science, United States (Apr. 2014).;;Tamura, M., et al., ""Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Delevlopment of a Minimally Immunogenic Antibody Variant by Retention of SDRs only,"" Journal of Immunology 164(3):1432-1441, American Association of Immunologist, United States (2000).;;Tomizuka, K., et al., ""Double Trans-Chromosomic Mice: Maintenance of Two Individual Human Chromosome Fragments Containing Ig Heavy and Kappa loci and Expression of Fully Human Antibodies,"" Proceedings of the National Academy of Sciences of the United States of America 97(2):722-727, National Academy of Sciences, United States (2000).;;Tomlinson, I.M., et al., ""The Repertoire of Human Germline VH Sequences Reveals About Fifty Groups of VH segments with Different Hypervariable Loops,"" Journal of Molecular Biology 227(3):776-798, Elsevier, Netherlands (1992).;;Xu, J.L. and Davis, M.M., ""Diversity in the CDR3 Region of V(H) is Sufficient for Most Antibody Specificities,"" Immunity 13(1):37-45, Cell Press, United States (2000).;;Antonia, S.J., et al., ""Association of tumor PD-L1 Expression and Immune Biomarkers with Clinical Activity in Patients with Non-small Cell Lung Cancer (NSCLC) Treated with Nivolumab (Anti-PD-1; BMS-936558; ONO-4538),"" 15th World Conference on Lung Cancer, Sydney, Australia, 15th WCLC: Best of Posters 1-IASLC Selection, P2.11-035, Oct. 27-30, 2013, accessed at http://web.oncoletter.ch/kongressberichte-videos-slides-Onkologie/id-15th-world-conference-on-lung-cancer-conference/conference-highlights.html, accessed on Jan. 8, 2015, 6 pages.;;Blank, C., et al., ""Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy,"" Cancer Immunology, Immunotherapy 54:307-314, Springer Science+ Business Media, Germany (2005).;;Brown, J.A., et al., ""Expression and functional consequences of PD-1 ligands on natural APCS and tumors,"" The FASEB Journal 15(4):A345 (abstract No. 275.23), Federation of American Societies for Experimental Biology, United States (2001).;;Brown, J.A., et al., ""Blockade of PD-1 ligands on dendritic cells enhances T cells activation and cytokine production,"" FASEB Journal 16(4):710-517.4, Federation of American Societies for Experimental Biology, United States (2002).;;Carreno, B.M., et al., ""The B7 family of ligands and its receptors: New pathways for co-stimulation and inhibition of immune responses,"" Annu Rev. Immunol, 20:29-53, Annual reviews, United States (2002).;;Carter, L., et al., ""PD-1: PD-L inhibitory pathway affects both CD4+ and CDS+ T cells and is overcome by IL-2,"" Eur J Immunology 32:634-643, Wiley-VCH, Germany (2002).;;Dong, H., et al., ""Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion,"" Nat Med, 8:783-800, Nature, United States (2002).;;Dong, H., Chen, L.,""B7-H1 pathway and its role in the evasion of tumor immunity,"" Journal of Molecular Medicine vol. 81:281-287, Springer Science+ Business Media, Germany (2002).;;Dong, H., et al., ""B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,"" Nature Medicine 5(12):1365-1369, Nature America Inc., United States (1999).;;Exhibit 1, ""Dichotomy of the activity of PD-L1 (B7-4) and how an anti-PD-1 antibody fits into it,"" in Response to Patentee's Aug. 12, 2015 Reply, mailed Dec. 21, 2015 for European Patent No. EP 1537878, filed Jul. 2, 2003, 1 page.;;Freeman, G.J., et al., ""Engagement of the PD-1 immunoinhibitory receptor by a novel B7-family member leads to negative regulation of lymphocyte activation,"", Journal of Experimental Medicine 192(7):1027-1034, Rockefeller University Press, United States (2000).;;Freeman, G.J., et al., ""Engagement of the PD-1 Immunoinhibitory by a Novel B7-Family Member Leads to Negative Regulation of Lymphocyte Activation,"" Blood 96(11):810a-811a (Abstract No. 3502) (2000).;;He, Y.F., et al., ""Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine,"" Journal of Immunology 173: 4919-4928, American Association of Immunologist, United States (2004).;;Hirano, F., et al., ""Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity,"" Cancer Research 65(3): 1089-1096, American Association for Cancer Research, United States (2005).;;Konishi, J., et al., ""B7-H1 Expression on Non-Small Cell Lung Cancer Cells and its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression,"" Clin. Cancer Res 10:5094-5100, American Association for Cancer Research, United States (2004).;;Nagler, A., et al., ""Phase I clinical trial CT-011, a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced hematological malignancies,"" Experimental Hematology, 33:97, Elsevier, Netherlands (2005).;;Nomi, T., et al., ""Clinical significance and therapeutic potential of the programmed death-1 liagnd/programmed death-1 pathway in human pancreatic cancer,"" Clinical Cancer Research 13(7):2151-2157, The Association, United States (2007).;;Tamura, H., et al., ""B7-H1 co-stimulation preferentially enhances CD28-independent T-helper cell function,"" Blood 97(6):1809-1816, American Society of Hematology, United States (2001).;;West, J.H., ""CheckMate-057 Trial: The Future of PD-L1 as a Biomarker,"" medscape.com, accessed at http://www.medscape.com/viewarticle/845926, accessed on Sep. 17, 2015, 1 page (Jun. 5, 2015).;;Yamazaki, T., et al., ""Expression of programmed death 1 ligands by murine T cells and APC,"" Journal of Immunology 169(10):5538-5545, American Association of Immunologist, United States (2002).;;Zou, W. and Chen, L., ""Inhibitory B7-family Molecules in the Tumour Microenvironment,"" Nature Reviews Immunology 8(6):467-477, Nature Publishing Group, England (2008).;;Zuberek, K., et al., ""The role of in vivo PD-1/PD-L1 interactions in syngeneic and allogeneic antitumor responses in murine tumor models,"" Blood 98(11):42B, American Society of Hematology, United States (2001).;;Co-pending Application, U.S. Appl. No. 15/188,860, Korman, A., et al., filed Jun. 21, 2016 (Not Published).",ACTIVE
94,US,B2,US 9492539 B2,100-851-240-022-745,2016-11-15,2016,US 201414248462 A,2014-04-09,US 201414248462 A;;US 201113210137 A;;US 91321706 A;;JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Monoclonal antibodies to Programmed Death 1 (PD-1),"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",SQUIBB & SONS LLC;;ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;ONO PHARMACEUTICAL CO. LTD (2007-12-27);;MEDAREX INC (2012-04-12),https://lens.org/100-851-240-022-745,Granted Patent,yes,89,91,120,125,82,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/00;;A61K39/395;;A61K47/48;;A61K51/10;;C07K16/18;;C07K16/46,,99,20,099-845-492-851-481;;029-890-487-783-799;;074-976-826-866-732;;001-256-484-369-395;;079-214-893-487-418;;034-879-699-905-632;;010-811-198-482-852;;103-897-301-868-65X;;197-193-057-828-756;;001-779-867-387-972;;013-584-945-188-940;;115-398-566-039-426;;135-447-350-940-622;;052-153-724-747-948;;147-888-721-956-877;;166-025-821-402-033;;057-460-007-966-306;;006-463-263-246-432;;013-770-850-974-489;;124-864-341-496-45X,10.1016/j.pharmthera.2014.11.017;;25476108;;11973140;;10.1016/s0952-7915(02)00341-2;;9277127;;11470598;;10.1016/s1367-5931(00)00216-7;;10581077;;10.1038/70932;;7481795;;10.1126/science.270.5238.932;;15785203;;10.1089/hyb.2005.24.1;;pmc4348009;;10.1056/nejmoa1411087;;25482239;;10.1016/s0075-7535(08)70702-2;;10.1006/jmbi.1999.3192;;10543973;;10.1182/blood-2002-06-1761;;12393541;;10.1177/107327481402100112;;24357746;;pmc40169;;8552677;;10.1073/pnas.93.1.7;;16285013;;10.1002/eji.200535232;;10.1093/protein/11.1.65;;9579662;;10.1016/s0958-1669(98)80091-8;;9503595;;10.1016/s1535-6108(04)00083-2;;15093539;;10.2210/pdb1s78/pdb;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;18410894;;10.1016/j.bbmt.2008.02.010;;pmc2423190;;10.1038/78963;;10966641,"Berman, D., et al., ""The Development of Immunomodulatory Monoclonal Antibodies as a New Therapeutic Modality for Cancer: The Bristol-Myers Squibb Experience,"" Pharmacology and Therapeutics 148:132-153, Elsevier, Inc., England (Apr. 2015).;;Complaint, Bristol-Myers Squibb Co, E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Jun. 30, 2015, 49 pages.;;Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Jul. 7, 2015, 48 pages.;;Declaration of James L. Riley, Ph.D., Aug. 10, 2015, 6 pages, submitted with Response to Grounds of Appeal, in European Patent No. 1537878.;;Greenwald, R.J., et al., ""Negative Co-receptors on Lymphocytes,"" Current Opinion in immunology 14(3):391-396, Elsevier Science Ltd., England (Jun. 2002).;;Minutes of the Oral Proceedings of Dec. 17, 2014, in European Patent No. EP 0921183, 3 pages.;;Notice of Pre-grant Opposition mailed Jul. 21, 2015, in IN Patent Application No. 5057/CHENP/2007, Indian Pharmaceuticals Alliance, filed May 2, 2006.;;Response to Grounds of Appeal, dated Aug. 12, 2015, in European Patent No. EP 1537878, 76 pages.;;""Summary of a list of clinical trials available from the website ClinicalTrials.gov of the US National Institutes of Health,"" dated Aug. 10, 2015, 18 pages, submitted with Response to Grounds of Appeal in European Patent No. EP 1537878.;;Brief Supporting Motion to Dismiss, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Aug. 21, 2015, 25 pages.;;Brief Supporting Motion to Dismiss, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Aug. 28, 2015, 24 pages.;;Declaration of Andrew C. Mayo, Aug. 21, 2015, 2 pages.;;Declaration of John G. Day, Aug. 28, 2015, 2 pages.;;Motion to Dismiss, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv-00560-GMS, United States District Court for the District of Delaware , Aug. 21, 2015, 3 pages.;;Motion to Dismiss, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Aug. 28, 2015, 3 pages.;;Nema, S., et al., ""Excipients and Their Use in Injectable Products,"" PDA J Phann Sci Technol. 51(4):166-171, Pda (Parenteral Drug Association), United States (1997).;;Plaintiff's Objections and Responses to Defendants' Second Set of Requests for Admission, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuka Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Jul. 1, 2015, 11 pages.;;Van Dijk, M.A. and Van De Winkel, J.G, ""Human antibodies as next generation therapeutics,"" Curr Opin Chem Biol. 5(4):368-374, Elsevier Ltd., England (2001).;;Office action mailed Nov. 18, 2015, in U.S. Appl. No. 14/227,733, inventors Korman, A., et al., filed Mar. 27, 2014.;;Answering Brief including exhibits A, B and C, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Sep. 25, 2015, 70 pages.;;Answering Brief including exhibits A, B and C, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Sep. 25, 2015, 70 pages.;;Declaration of Andrew C. Mayo including exhibits 12-13, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Oct. 14, 2015, 73 pages.;;Declaration of Andrew C. Mayo including exhibits 12-13, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Oct. 14, 2015, 73 pages.;;Defendants E.R. Squibb & Sons, L.L.C., and Bristol-Myers Squibb, Co.'s Answer, Dana-Farber Cancer Institute, Inc. v. Ono Pharmaceutical Co., Ltd., Tasuku Honjo, E.R. Squibb & Sons L.L.C., and Bristol-Myers Squibb Co., Civil Action No. 1:15-cv-13443-MLW, United States District Court for the District of Massachusetts, Dec. 21, 2015, 15 pages.;;Defendant Tasuku Honjo's Answer, Dana-Farber Cancer Institute, Inc. v. Ono Pharmaceutical Co., Ltd., Tasuku Honjo, E.R. Squibb & Sons L.L.C., and Bristol-Myers Squibb Co., Civil Action No. 1:15-cv-13443-MLW, United States District Court for the District of Massachusetts, Dec. 21, 2015, 15 pages.;;Dong, H., et al., ""B7-H1, a third member, of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,"" Nature Medicine 5(12):1365-1369, Nature America Inc., United States (1999).;;Reply Brief Supporting Their Motion to Dismiss, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co, Inc. and Merck Sharp & Dohme Corp., Civil Action. No. 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Oct. 14, 2015, 14 pages.;;Reply Brief Supporting Their Motion to Dismiss, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Oct. 14, 2015, 14 pages.;;Summons to attend oral proceedings pursuant to Rule 115(1) EPC for EP Application No. 0901367.0, European Patent Office, Munich, Germany, mailed on Dec. 14, 2015, 9 pages.;;Office action mailed Dec. 14, 2015 in U.S. Appl. No. 14/244,405, Korman, A., et al., filed Apr. 3, 2014.;;Allison, J.P., et al., ""CTLA-4 Blockade in Tumor Immunotherapy,"" in Principles and Practice of the Biologic Therapy of Cancer, 3rd edition, Rosenberg, S.A., ed., pp. 890-895, Lippincott Williams & Wilkins, Philadelphia, United States (2000).;;Approved Judgment before Mr. Justice Birss, Case Nos. HP-2014-0000388 and HP14 A 02748, Merck vs. Ono, dated Oct. 22, 2015, Royal Courts of Justice, London, England, 57 pages.;;Communication pursuant to Article 94(3) EPC and Pending Claims for EP Application No. 10075561.1, European Patent Office, Germany, mailed on Jun. 2, 2015, 5 pages.;;Exhibit 1, ""Dichotomy of the activity of PD-L1 (B7-4) and how an anti-PD-1 antibody fits into it,"" in Response to Patentee's Aug. 12, 2015 Reply, mailed Dec. 21, 2015 for European Patent No. EP 1537878, filed Jul. 2, 2003, 1 page.;;West, J.H., ""CheckMate-057 Trial: The Future of PD-L1 as a Biomarker,"" medscape.com, accessed at http://www.medscape.com/viewarticle/845926, accesed on Sep. 17, 2015, (Jun. 5, 2015),.;;Response to Patentee's Aug. 12, 2015 Reply to Grounds of Appeal, mailed Dec. 21, 2015 in European Patent No. EP 1537878, Merck & Co., Inc., filed Jul. 2, 2003, Munchen, Germany, 92 pages.;;Co-pending U.S. Appl. No. 15/000,863, inventors Honjo, T., et al., filed Jan. 19, 2016 (Not Published).;;Co-pending U.S. Appl. No. 15/000,869, inventors Honjo, T., et al., filed Jan. 19, 2016 (Not Published).;;Abbas, A.K., et al., Cellular and Molecular Immunobiology, 2nd ed., pp. 8, 47-50, W.B Saunders Company, United States (1991).;;Alignment of Amino Acid Sequences for Extracellular Domain of Wild-Type (UniProt Q15116) Human PD-1, Wild-Type (MednaBio) PD-1 ECD, C62S Variant of Wild-Type Human PD-1 ECD, and A101L Variant of Wild-Type Human PD-1 ECD, 1 page, submitted with Opposition to EP Pat. No. 2161336 on Apr. 30, 2014.;;Allison, J.P. and Krummel, M.F., ""The Yin and Yang of T Cell Costimulation,"" Science 270(5238):932-933, American Association for the Advancement of Science, United States (1995).;;Amended Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp, C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Nov. 21, 2014, 11 pages.;;Andre, E., et al., ""Precise Characterization of the Epitope Recognized by a Monoclonal Antibody Against Escherichia coli RNA Polymerase,"" Hybridoma 24(1):1-5, Mary Ann Liebert, Inc., United States (Feb. 2005).;;Ansell, S.M., et al., ""PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma,"" The New England Journal of Medicine 372(4):311-319, Massachusetts Medical Society, United States (Jan. 22, 2015).;;Answer to Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Oct. 31, 2014, 15 pages.;;Answer to Plaintiffs' Amended Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Dec. 8, 2014, 17 pages.;;Anti-Human CD279 (PD-1) Datasheet, 14-2799, J105, eBioscience, Sep. 6, 2013, 1 page.;;Anti-Human CD279 (PD-1) Datasheet, 14-9989, J116, eBioscience, Sep. 6, 2013, 1 page.;;Anti-human CD279 (PD-1) Purchase Receipts, eBioscience, Oct. 8, 2013, 4 pages.;;Antonia, S.J., et al., ""Association of tumor PD-L1 Expression and Immune Biomarkers with Clinical Activity in Patients with Non-small Cell Lung Cancer (NSCLC) Treated with Nivolumab (Anti-PD-1; BMS-936558; ONO-4538),"" 15th World Conference on Lung Cancer, Sydney, Australia, 15th WCLC: Best of Posters 1-IASLC Selection, P2.11-035, Oct. 27-30, 2013, accessed at http://web.oncoletter.ch/kongressberichte-videos-slides-Onkologie/id-15th-world-conference-on-lung-cancer-conference/conference-highlights.html, accessed on Jan. 8, 2015, 6 pages.;;Appendix to Declaration of Vassiliki A. Boussiotis, Apr. 28, 2014, Data and Records for Example Experiments 21 and 22, 18 pages.;;Armand, P., et al., ""289 Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma-Preliminary Safety, Efficacy and Biomarker Results of a Phase 1 Study,"" 56th ASH Annual Meeting and Exposition, Abstracts & Program, San Francisco, CA, Dec. 6-9, 2014.;;Berg, J.M., et al., ""The Immune System,"" in Biochemistry 5th ed., pp. 921-950, W.H. Freeman and Company, United States (2002).;;Biacore, ""Application Note 1: Characterization of monoclonal antibody epitope specificity using Biacore's SPR technology,"" Biacore AB, 8 pages (2002).;;Biacore, Sensor Surface Handbook, BR-1005-71, edition AB, pp. 1-98, GE Healthcare (Feb. 2005).;;Biacore, ""The SPR signal,"" ""Interpreting experimental data,"" and ""BIA application areas,"" in BlAtechnology Handbook, version AB, chapters 4-6, 34 pages, Biacore AB (1998).;;Campbell, A.M., ""Characterisation of monoclonal antibodies,"" in Laboratory Techniques in Biochemistry and Molecular Biology, Monoclonal Antibody Technology: The Production and Characterization of Rodent and Human Hybridomas, vol. 13, pp. 186-215, Elsevier, the Netherlands (1984).;;CD279/PD-1, D132-3/J110 Datasheet, MBL Medical & Biological Laboratories Co., Ltd., Sep. 6, 2013, 2 pages.;;Chen, Y., et al., ""Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,"" Journal of Molecular Biology 293(4):865-881, Academic Press, England (1999).;;Communication pursuant to Article 94(3) EPC mailed on Dec. 22, 2014, in European Application No. 11 178 187.8-1410, European Patent Office, Germany.;;Communication pursuant to Article 94(3) EPC mailed on Dec. 22, 2014, in European Application No. 11 178 191.0-1410, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, mailed Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178187, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, mailed Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178188, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, mailed Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178191, European Patent Office, Germany.;;Complaint, Bristol-Myers Squibb Co. and Ono Pharmaceutical Co, Ltd. v. Merck & Co., Inc., 1:14-cv-01131-GMS, filed Sep. 4, 2014, 9 pages.;;Co-pending U.S. Appl. No. 14/547,026, inventors Korman, A.J., et al., filed Nov. 18, 2014 (Not Published).;;Co-pending U.S. Appl. No. 14/638,985, inventors Honjo, T., et al., filed Mar. 4, 2015 (Not Published).;;Cragg, M.S., et al., ""Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts,"" Blood 101(3):1045-1052, American Society of Hematology, United States (2003).;;Creelan, B.C., ""Update on Immune Checkpoint Inhibitors in Lung Cancer,"" Journal of the Moffitt Cancer Center 21(1):80-89, H, Lee Moffitt Cancer Center and Research Institute, United States (2014).;;Cruse, J.M. and Lewis, R.E., ""Antigens and Immunogens,"" in Atlas of Immunology, 2nd ed., pp. 105-126, CRC Press, United States (Dec. 29, 2003).;;Curriculum Vitae of Brian T. Fife, Ph.D., 7 pages, submitted with Response to Oppositions against EP Pat. No. 2161336 on Feb. 16, 2015.;;Curriculum Vitae of Dr. Robert J. Bloch, Apr. 11, 2012, 34 pages, submitted with Opposition to EP Pat. No, 2161336.;;Curriculum Vitae of Vassiliki A. Boussiotis, Nov. 8, 2013, 24 pages, submitted with Opposition to EP Pat. No. 2161336.;;Davies, D.R. and Cohen, G.H., ""Interactions of protein antigens with antibodies,"" Proceedings of the National Academy of Sciences USA 93(1):7-12, National Academy of Sciences, United States (1996).;;Declaration of Dr. Haidong Dong, Mar. 31, 2014, 15 pages, submitted with Opposition to EP Pat. No. 1537878.;;Declaration of Professor Brian T. Fife, Feb. 12, 2015, 4 pages, submitted with Response to Oppositions against EP Pat. No. 2161336.;;Del Rio, M-L., et al., ""Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation,"" European Journal of Immunology 35(12):3545-3560, Wiley-VCH Verlag GmbH & Co. KGaA, Germany (Dec. 2005).;;Dougan, D.A., et al., ""Effects of substitutions in the binding surface of an antibody on antigen affinity,"" Protein Engineering 11(1):65-74, Oxford University Press, England (1998).;;Email from MednaBio to Robert Bloch re: E1951MG1-Sequence Information, Apr. 25, 2014, 1 page.;;ExPASy Bioinformatics Resource Portal calculation based on ECD of UniProt Sequence Q15116, accessed at http://web.expasy.org/cgi-bin/compute-pi/pi-tool, accessed on Apr. 28, 2014, 1 page.;;Extended European Search Report for EP Application No. 06746353.9, European Patent Office, Germany, mailed on Mar. 6, 2009.;;Extended European Search Report for EP Application No. 09013687.0, European Patent Office, Germany, mailed on Jan. 29, 2010.;;Extended European Search Report for EP Application No. 10172772.5, European Patent Office, Netherlands, mailed on Sep. 9, 2010.;;Extended European Search Report for EP Application No. 11178187.8, European Patent Office, Germany, mailed on Jun. 1, 2012.;;Extended European Search Report for EP Application No. 11178188.6, European Patent Office, Germany, mailed on Jun. 27, 2013.;;Extended European Search Report for EP Application No. 11178191.0, European Patent Office, Germany, mailed on Sep. 5, 2012.;;Fivash, M. et al., ""BIAcore for macromolecular interaction,"" Current Opinion in Biotechnology 9(1):97-101, Current Biology, England (1998).;;Franklin, M.C., et al., ""Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex,"" Cancer Cell 5(4):317-328, Cell Press, United States (Apr. 2004).;;Freeman, G.J., et al., ""Engagement of the PD-1 Immunoinhibitory by a Novel B7-Family Member Leads to Negative Regulation of Lymphocyte Activation,"" Blood 96(11):810a-811a, (Abstract No. 3502) (2000).;;Ge, X., et al., ""CD134-Allodepletion Allows Selective Elimination of Alloreactive Human T Cells without Loss of Virus-Specific and Leukemia-Specific Effectors,"" Biology of Blood and Marrow Transplantation 14(5):518-530, American Society for Blood and Marrow Transplantation, United States (2008).;;Greenspan, N.S., ""Epitopes, paratopes and other topes: do immunologists know what they are talking about?"" Bulletin de l'Institut Pasteur 90(4):267-279, Elsevier, France (1992).;;Harlow, E. and Lane, D., ""Using Antibodies: A Laboratory Manual,"" Cold Spring Harbor Laboratory Press, Cold Spring Harbor, United States various pages (1999).;;International Preliminary Report on Patentability for International Application No. PCT/JP2006/309606, The International Bureau of WIPO, Switzerland, issued on Nov. 13, 2007.;;International Search Report for International Application No. PCT/JP03/08420, Japanese Patent Office, Japan, mailed Oct. 21, 2003.;;International Search Report for International Application No. PCT/JP2006/309606, Japanese Patent Office, Japan, mailed on Aug. 15, 2006.;;Ishima, R. and Torchia, D.A., ""Protein Dynamics from NMR,"" Nature Structural Biology 7(9):740-743, Nature Publishing Company, United States (2000).;;J105/D133-3 Datasheet, MBL Medical & Biological Laboratories Co., Ltd., Mar. 20, 2013, 2 pages.;;J105/D133-3 Purchase Order, MBL Medical & Biological Laboratories Co., Ltd., Apr. 11, 2014, 1 page.;;J105/D133-3 Purchase Receipts, Invoice MINV52635, MBL International Corporation, Oct. 2, 2013, 2 pages.",ACTIVE
95,EP,A2,EP 3530736 A2,121-547-273-621-192,2019-08-28,2019,EP 19151041 A,2006-05-02,EP 11178191 A;;EP 09013687 A;;EP 06746353 A;;US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;KORMAN ALAN J;;HUANG HAICHUN,,https://lens.org/121-547-273-621-192,Patent Application,yes,115,0,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;A61P7/06;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,159,119,076-092-237-434-500;;127-416-339-660-812;;117-522-189-960-276;;004-728-346-095-981;;043-645-889-898-36X;;020-766-613-912-972;;006-463-263-246-432;;081-074-583-383-824;;025-182-641-289-850;;076-731-232-972-252;;066-015-167-169-542;;006-568-097-103-41X;;013-122-792-588-081;;062-940-851-081-865;;048-060-748-635-820;;117-415-766-090-626;;038-551-014-784-214;;074-046-354-648-540;;008-208-772-364-327;;020-598-246-146-62X;;074-297-827-128-411;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;026-164-216-541-151;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;042-204-626-457-327;;006-574-964-805-278;;030-323-674-660-051;;092-023-577-402-127;;022-179-293-052-569;;004-458-031-333-650;;024-929-137-199-30X;;003-752-183-823-430;;070-318-112-524-781;;032-624-544-479-82X;;002-264-966-090-625;;030-630-100-818-462;;106-753-778-592-300;;032-820-729-763-323;;083-549-078-331-651;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;033-754-369-798-314;;077-525-954-203-403;;028-969-172-280-017;;060-375-551-951-388;;020-753-772-581-741;;038-613-711-274-229;;047-951-914-695-080;;062-485-301-455-912;;032-820-729-763-323;;023-676-781-371-861;;026-744-100-669-883;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;030-769-003-988-749;;057-971-690-843-179;;145-254-035-276-41X;;026-646-521-253-318;;000-331-240-115-824;;065-438-177-962-139;;006-574-942-364-256;;101-640-792-825-42X;;070-316-527-354-375;;040-550-546-463-785;;046-168-111-025-234;;043-654-077-374-418;;084-388-182-984-099;;005-112-559-456-657;;052-219-543-437-800;;056-942-841-068-650;;039-238-464-990-600;;036-564-551-324-053;;020-123-860-433-320;;011-516-147-270-264;;006-568-097-103-41X;;005-416-473-959-707;;020-986-423-793-233;;067-739-856-772-54X;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;007-709-585-201-038;;042-688-967-632-553;;056-422-417-058-69X;;005-022-447-377-963;;127-416-339-660-812;;098-407-145-404-736;;066-749-017-721-197;;001-467-559-709-949;;078-061-292-153-737;;055-646-175-554-792;;129-390-507-012-794;;008-213-515-306-640;;053-703-232-770-99X;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;112-179-955-215-674;;029-697-384-910-375;;038-613-711-274-229;;062-418-979-939-961,10.4049/jimmunol.170.2.711;;12517932;;9930702;;10.1038/16717;;10.1002/j.1460-2075.1992.tb05481.x;;pmc556898;;1396582;;10.1093/intimm/8.5.765;;8671665;;10.1084/jem.181.6.1953;;7539033;;pmc2192041;;10.1016/s0167-5699(97)80025-4;;9190115;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;11857337;;10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9;;12721664;;10.1007/s00109-003-0430-2;;10.1007/s00262-004-0593-x;;15599732;;10.1158/1078-0432.ccr-04-0428;;15297412;;10.1073/pnas.192461099;;12218188;;pmc129438;;10.4049/jimmunol.170.3.1257;;12538684;;10.1016/s1074-7613(00)80089-8;;10485649;;10.1126/science.291.5502.319;;11209085;;10.1084/jem.20022119;;12847138;;pmc2196082;;14764622;;10.1093/hmg/ddh076;;pmc61133;;10.1073/pnas.231486598;;11698646;;4703766;;10.1093/jnci/50.4.1013;;pmc1866856;;10.1016/s0002-9440(10)65141-3;;10433938;;1330947;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;3382986;;10.1093/bioinformatics/4.1.11;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;3127726;;10.1038/332323a0;;10.1038/321522a0;;3713831;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;11096108;;10.1074/jbc.m009483200;;10.1002/bit.20151;;15352059;;11986321;;10.1074/jbc.m202069200;;10.1038/6179;;10052355;;1201277;;10.1021/bi00696a021;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1038/348552a0;;2247164;;1172191;;10.1038/256495a0;;8159246;;10.1038/368856a0;;10.1007/978-3-642-78432-3_3;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;8144892;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nbt727;;12172556;;8159246;;10.1038/368856a0;;10.1126/science.3929380;;3929380;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;12564977;;10.1016/s0169-409x(02)00179-5;;10.1007/s00262-002-0352-9;;12700948;;12676579;;10.1016/s1535-6108(03)00057-6;;10.1038/nrc903;;12360278;;12186272;;10.1016/s0169-409x(01)00206-x;;11744170;;10.1201/b14193-19;;7042536;;10.1111/j.1600-065x.1982.tb00392.x;;10.4049/jimmunol.155.10.4996;;7594506;;8954257;;1371789;;6239899;;10.1084/jem.160.6.1686;;pmc2187539;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;10.1126/science.3925553;;3925553;;2958547;;10.4049/jimmunol.139.7.2367;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;10.1128/aac.39.1.180;;pmc162506;;7695303;;7907597;;10.1016/s0021-9258(17)37081-3;;10.1016/0014-5793(94)00313-0;;8206150;;7820457;;10.1006/immu.1994.1029;;10.1073/pnas.192461099;;12218188;;pmc129438;;15611321;;10.1093/intimm/dxh194;;15470033;;10.4049/jimmunol.173.8.4919;;10.1016/s0960-7404(97)90012-8;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;9624003;;10.1038/30989;;10.1016/s0171-2985(00)80072-8;;10834311;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;9930702;;10.1038/16717;;10417377;;10.1126/science.285.5427.546;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;pmc15881;;10.1073/pnas.96.6.2982;;10077623;;10.1097/00002371-199601000-00009;;8859727;;10.1038/22124;;10408445;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;9850053;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;8910274;;10.1126/science.274.5291.1363;;10.1002/j.1460-2075.1993.tb05721.x;;pmc413278;;8458339;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1126/science.271.5256.1734;;8596936,"OKAZAKI ET AL., CURL . OPIN. IMMUNOL., vol. 14, 2002, pages 391779 - 82;;BENNETT ET AL., J IMMUNOL, vol. 170, 2003, pages 711 - 8;;HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 263 - 266;;HANSEN ET AL., IMMUNOGENICS, vol. 10, 1980, pages 247 - 260;;ISHIDA ET AL., EMBO J, vol. 11, 1992, pages 3887 - 95;;AGATA ET AL., INT. IMMUNOL, vol. 8, 1996, pages 765 - 72;;THOMAS, M.L., J EXP MED, vol. 181, 1995, pages 1953 - 6;;VIVIER, E; DAERON, M, IMMUNOL TODAY, vol. 18, 1997, pages 286 - 91;;FREEMAN ET AL., JEXP MED, vol. 192, 2000, pages 1027 - 34;;LATCHMAN ET AL., NAT LMN UNOL, vol. 2, 2001, pages 261 - 8;;CARTER ET AL., EUR J IMMUNOL, vol. 32, 2002, pages 634 - 43;;DONG ET AL., NAT. MED, vol. 8, 2002, pages 787 - 9;;DONG ET AL., J. MOL. MED., vol. 81, 2003, pages 281 - 7;;BLANK ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 54, 2005, pages 307 - 314;;KONISHI ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 5094 - 100;;IWAI ET AL., PROC. NATL. ACAD SCI. USA, vol. 99, 2002, pages 12293 - 7;;BROWN ET AL., J. IMMUNOL., vol. 170, 2003, pages 1257 - 66;;OKAZAKI ET AL., CURR OPIN IMMUNOL, vol. 14, 2002, pages 391779 - 82;;NISHIMURA ET AL., IMMUNITY, vol. 11, 1999, pages 141 - 51;;NISHIMURA ET AL., SCIENCE, vol. 291, 2001, pages 319 - 22;;SALAMA, J EXP MED, vol. 198, 2003, pages 71 - 78;;PROKUNINA; ALARCON-RIQUELME, HUM MOL GENET, vol. 13, 2004, pages R143;;NIELSEN ET AL., LUPUS, vol. 13, 2004, pages 510;;OKAZAKI ET AL., PNAS, vol. 98, 2001, pages 13866 - 71;;MURPHY; HRUSHESKY, J. NAT'L. CANCER RES., vol. 50, 1973, pages 1013 - 1025;;MURATA, AM. J. PATHOL., vol. 155, 1999, pages 453 - 460;;BALZANO, INT. J. CANCER SUPPL., vol. 7, 1992, pages 28 - 32;;WARD, NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON, PROC. NATL. ACAD SCI. USA, vol. 85, 1988, pages 5879 - 5883;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services"", vol. 91, 1991, NIH PUBLICATION, article ""E. A."", pages: 3242;;E. MEYERS; W. MILLER, COMPUT. APPL. BIOSCI., vol. 4, 1988, pages 11 - 17;;NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL ET AL., J. MOL. BIO!., vol. 215, 1990, pages 403 - 10;;ALTSCHUL, NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;RIECHMANN, L. ET AL., NATURE, vol. 332, 1998, pages 323 - 327;;JONES, P. ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;QUEEN, C. ET AL., PROC. NATL. ACAD SEE. U.S.A., vol. 86, 1989, pages 10029 - 10033;;KABAT, E. A ET AL.: ""Sequences of Proteins of Immunological Interest"", vol. 91, 1991, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NIH PUBLICATION, pages: 3242;;TOMLINSON, I. M.: ""The Repertoire of Human Germline V Sequences Reveals about Fifty Groups of V Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: doi:10.1016/0022-2836(92)90223-7;;COX, J. P. L. ET AL.: ""A Directory of Human Germ-line V Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;""GenBank"", Database accession no. NG_0010109;;""GenBank"", Database accession no. NT_024637;;""GenBank"", Database accession no. BC070333;;""GenBank"", Database accession no. AJ556644;;""GenBank"", Database accession no. AJ406678;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;YAMANE-OHNUKI ET AL., BIOTECHNOL BIOENG, vol. 87, 2004, pages 614 - 22;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;TARENTINO, A.L., BIOCHEM., vol. 14, 1975, pages 5516 - 23;;""Current Protocols in Molecular Biology"", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;;KABAT, E. A.: ""Sequences of Proteins of Immunological Interest"", vol. 91, 1991, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NΊH PUBLICATION, pages: 3242;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest"", vol. 91, 1991, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NIR PUBLICATION, pages: 3242;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;LONBERG, N., HANDBOOK OF EXPERIMENTAL PHARMACOLOGY, vol. 113, 1994, pages 49 - 101;;LONBERG, N.; HUSZAR, D, INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F.; LONBERG, N., ANN. N.Y. ACA . SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD SCI. USA, vol. 90, 1993, pages 3720 - 3724;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J. ET AL., EMBO J., vol. 12, 1993, pages 821 - 830;;TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;TOMIZUKA ET AL., PROC. NATL. ACAD SCI. USA, vol. 97, 2000, pages 722 - 727;;KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894;;LONBERG, N. ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;MORRISON, S., SCIENCE, vol. 229, 1985, pages 1202;;GOEDDEL: ""Methods in Enzymology 185"", 1990, ACADEMIC PRESS, article ""Gene Expression Technology"";;TALCEBE, Y., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;BOSS, M. A.; WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMAN; P. A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;SAITO, G., ADV. DRUG DELIV. REV., vol. 55, 2003, pages 199 - 215;;TRAIL, P.A. ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 52, 2003, pages 328 - 337;;PAYNE, G., CANCER CELL, vol. 3, 2003, pages 207 - 212;;ALLEN, T.M., NAT. REV. CANCER, vol. 2, 2002, pages 750 - 763;;PASTAN, I.; KREITMAN, R. J., CURR. OPIN. INVESTIG. DRUGS, vol. 3, 2002, pages 1089 - 1091;;SENTER, P.D.; SPRINGER, C.J., ADV. DRUGDELIV. REV., vol. 53, 2001, pages 247 - 264;;ARNON ET AL.: ""Monoclonal Antibodies And Cancer Therapy"", 1985, ALAN R. LISS, INC., article ""Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy"", pages: 243 - 56;;HELLSTROM ET AL.: ""Controlled Drug Delivery"", 1987, MARCEL DEKKER, INC., article ""Antibodies For Drug Delivery"", pages: 623 - 53;;THORPE ET AL.: ""Monoclonal Antibodies '84: Biological And Clinical Applications"", 1985, article ""Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review"", pages: 475 - 506;;""Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin"", 1985, ACADEMIC PRESS, article ""Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy"", pages: 303 - 16;;THORPE: ""The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates"", IMMUNOL. REV., vol. 62, 1982, pages 119 - 58, XP001179872, DOI: doi:10.1111/j.1600-065X.1982.tb00392.x;;GRAZIANO, R.F. ET AL., J. IMMUNOL, vol. 155, no. 10, 1995, pages 4996 - 5002;;MORTON, H.C. ET AL., CRITICAL REVIEWS IN IMMUNOLOGY, vol. 16, 1996, pages 423 - 440;;MONTEIRO, R.C. ET AL., J. IMMUNOL., vol. 148, 1992, pages 1764;;KARPOVSKY ET AL., J. EXP. MED., vol. 160, pages 1686;;LIU, MA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 8648;;""Other methods include those described in Paulus"", BEHRING INS. MITT., vol. 78, 1985, pages 118 - 132;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83;;GLENNIE ET AL., J. IMMUNOL., vol. 139, 1987, pages 2367 - 2375;;WEINTRAUB, B.: ""Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques"", THE ENDOCRINE SOCIETY, March 1986 (1986-03-01);;BERGE, S.M. ET AL., J. .P/M'ΤΤ?7. SCI., vol. 66, 1977, pages 1 - 19;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;V.V. | RANADE, J. CLIN. PHARMACOL., vol. 29, 1989, pages 685;;UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 155, 1988, pages 1038;;P.G. BLOEMAN ET AL., FEBS LETT., vol. 357, 1995, pages 140;;M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 39, 1995, pages 180;;BRISCOE ET AL., AM. J. PHYSIOL., vol. 1233, no. 134, 1995, pages 120;;SCHREIER, J. BIOL. CHEM., vol. 269, 1994, pages 9090;;K. KEINANEN; M.L. LAUKKANEN, FEBS LEFT., vol. 346, 1994, pages 123;;J.J. KILLION; I.J. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273;;DONG ET AL., NAT MED, vol. 8, 2002, pages 787 - 9;;DONG ET AL., JMOLMED, vol. 81, 2003, pages 281 - 7;;IWAI ET AL., PNAS, vol. 99, 2002, pages 12293 - 7;;IWAI ET AL., INT. IMMUNOL., vol. 17, 2005, pages 133 - 144;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;ROSENBERG, S.: ""Development of Cancer Vaccines"", 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 60 - 62;;RESTIFO, N.; SZNOL, M.: ""Cancer Vaccines, Ch."", vol. 61, pages: 3023 - 3043;;""Cancer: Principles and Practice of Oncology"", 1997;;DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, SA, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM, N ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT, R; SRIVASTAVA, P, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA, Y. ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE, F. ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER, A. ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR, M. ET AL., CANCER RESEARCH, vol. 58, pages 5301 - 5304;;KEHRL, J. ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARD, M.; O'GARRA, A., IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;FAS LIGAND; HAHNE, M. ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;RIDGE, J. ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;ITO, N. ET AL., IMMUNOBIOLOGY, vol. 201, no. 5, 2000, pages 527 - 40;;WEINBERG, A. ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO, I. ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF, A. ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;GREENBERG, R.; RIDDELL, S., SCIENCE, vol. 285, 1999, pages 546 - 51;;HOLLIGER, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;OVERWIJK, W. ET AL., PROC. NATL. ACAD SCI. U.S.A., vol. 96, 1999, pages 2982 - 2987;;ROSENBERG, SA; WHITE, DE, J. IMMUNOTHER EMPHASIS TUMOR IMMUNOL, vol. 19, no. 1, 1996, pages 81 - 4;;SCHENK ET AL., NATURE, vol. 400, 1999, pages 173 - 177;;HARLOW; LANE: ""Antibodies, A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY PRESS, COLD SPRING HARBOR;;HURWITZ ET AL., PROC. NATL. ACAD SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071;;CAMACHO ET AL., J. CLIN. ONCOLOGY, vol. 22, 2004, pages 145;;MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304;;HE ET AL., J IMMUNOL., vol. 173, 2004, pages 4919 - 28;;RESTIFO; SZNOL, CANCER VACCINES, CH., vol. 61, pages 3023 - 3043;;ROSENBERG, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT; SRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL, J., J EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HAHNE, M. ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;CHEN ET AL., EMBO J., vol. 12, 1993, pages 811 - 820;;FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;FISHWILD, D. ET AL., BRIEFLY, 1996;;DR. N. RESTIFO, NATIONAL CANCER INSTITUTE;;JEFFREY SCHLOM, NATIONAL INSTITUTES OF HEALTH;;LEACH ET AL., SCIENCE, vol. 271, 1996, pages 1734 - 1736",PENDING
96,PL,T3,PL 2439273 T3,125-168-498-659-728,2019-08-30,2019,PL 11178191 T,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;EP 11178191 A;;EP 09013687 A;;EP 06746353 A;;JP 2006309606 W,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;KORMAN ALAN J;;HUANG HAICHUN,,https://lens.org/125-168-498-659-728,Patent Application,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,PENDING
97,JP,A,JP 2019103504 A,170-470-242-796-816,2019-06-27,2019,JP 2019018345 A,2019-02-05,JP 2016220640 A;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,HUMAN MONOCLONAL ANTIBODY AGAINST PROGRAMMED DEATH 1 (PD-1) AND METHOD FOR TREATING CANCER USING ANTI-PD-1 ANTIBODY ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPY,"To provide an isolated monoclonal antibody specifically binding to Programmed Death 1 (PD-1) with high affinity, particularly a human monoclonal antibody.SOLUTION: The present invention provides an isolated monoclonal antibody or a binding portion thereof, which performs a cross-competition for binding to a reference antibody comprising a human heavy chain and light chain variable regions consisting of specific amino acid sequences and PD-1. According to the present invention, by preparing an immunocomplex, a bispecific molecule, and a pharmaceutical composition, which are comprising the antibody, it is possible to provide a PD-1 detection method and treat various disorders including cancer and infectious diseases. According to the present invention, it is also possible to treat hyperproliferative disorders, such as cancer, using a combination immunotherapy, such as a combination of anti-CTLA-4 and anti-PD-1 antibodies. Adverse treatment-related adverse events by each of such antibodies are altered.SELECTED DRAWING: None",ONO PHARMACEUTICAL CO;;ER SQUIBB & SONS LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/170-470-242-796-816,Patent Application,no,3,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12P21/08;;A61K39/395;;A61P35/00;;A61P35/02;;C07K16/28,,0,0,,,,ACTIVE
98,JP,A,JP 2014077015 A,023-331-070-037-636,2014-05-01,2014,JP 2014010140 A,2014-01-23,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,"HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH 1 (PD-1), AND CANCER THERAPEUTIC METHOD SINGLY USING ANTI-PD-1 ANTIBODY OR CONCURRENTLY USING WITH OTHER IMMUNOTHERAPY","PROBLEM TO BE SOLVED: To provide isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to Programmed Death 1 (PD-1) with high affinity.SOLUTION: There are provided: isolated human monoclonal antibodies cross-competing for binding to a reference antibody including human heavy chain and light chain variable regions composed of specific amino acid sequences, and PD-1; or a binding portion thereof. A method for detecting PD-1 is provided and various diseases including cancer and infectious diseases can be treated by preparing immunocomplexes, bispecific molecules and pharmaceutical compositions containing the antibodies. Furthermore, hyperproliferative diseases such as cancer can also be treated by a combination immunotherapy such as a combination of anti-CTLA-4 and anti-PD-1 antibodies. Adverse events related to treatment with each of the antibodies are altered.",ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/023-331-070-037-636,Patent Application,no,4,6,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395;;A61P35/00;;A61P43/00;;C07K16/18;;C12N15/09,,2,0,,,"庄雅之他, 日本癌学会学術総会記事, 2005 AUG, VOL.64, P.56, W-102, JPN6014051801, ISSN: 0002959254;;庄雅之他, 日本癌治療学会誌, 2005 SEP, VOL.40, NO.2, P.590, PS22-5, JPN6014051802, ISSN: 0002959255",PENDING
99,US,B2,US 8008449 B2,027-027-673-799-743,2011-08-30,2011,US 91321706 A,2006-05-02,US 91321706 A;;US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",MEDAREX INC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;ONO PHARMACEUTICAL CO. LTD (2007-12-27);;MEDAREX INC (2012-04-12),https://lens.org/027-027-673-799-743,Granted Patent,yes,33,1667,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28,530/388.15,37,37,027-477-313-726-928;;062-761-744-997-508;;044-871-232-135-52X;;049-336-842-920-389;;067-760-343-772-225;;022-179-293-052-569;;119-897-745-760-544;;092-023-577-402-127;;004-728-346-095-981;;076-092-237-434-500;;076-731-232-972-252;;013-122-792-588-081;;081-074-583-383-824;;122-644-406-202-233;;025-182-641-289-850;;090-247-610-825-843;;006-463-263-246-432;;041-874-179-970-386;;020-986-423-793-233;;127-416-339-660-812;;117-522-189-960-276;;006-568-097-103-41X;;093-666-562-457-905;;005-416-473-959-707;;066-015-167-169-542;;052-597-675-128-75X;;032-820-729-763-323;;044-695-670-834-937;;062-940-851-081-865;;048-060-748-635-820;;074-046-354-648-540;;023-766-913-246-333;;038-551-014-784-214;;117-415-766-090-626;;060-693-602-478-53X;;043-645-889-898-36X;;020-766-613-912-972,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;17898045;;10.1093/intimm/dxm091;;10.1158/1078-0432.ccr-07-4079;;18483370;;14871849;;10.1158/0008-5472.can-03-3259;;10.1002/eji.1830240409;;8149953;;10.1161/01.atv.0000145015.23656.e4;;15374847;;1404388;;10.1016/0022-2836(92)90223-7;;10.1093/intimm/8.5.765;;8671665;;10.4049/jimmunol.170.2.711;;12517932;;10.1007/s00262-004-0593-x;;15599732;;10.4049/jimmunol.170.3.1257;;12538684;;11857337;;10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9;;12091876;;10.1038/nm730;;12721664;;10.1007/s00109-003-0430-2;;9332365;;10.1016/s0378-1119(97)00260-6;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;10.1007/bf01561573;;15470033;;10.4049/jimmunol.173.8.4919;;9930702;;10.1038/16717;;10.1002/j.1460-2075.1992.tb05481.x;;pmc556898;;1396582;;10.1073/pnas.192461099;;12218188;;pmc129438;;10.1016/s0165-2478(02)00088-3;;12095712;;15611321;;10.1093/intimm/dxh194;;10.1158/1078-0432.ccr-04-0428;;15297412;;11224527;;10.1038/85330;;8159246;;10.1038/368856a0;;15352422;;10.1191/0961203303lu1052oa;;10.1016/s1074-7613(00)80089-8;;10485649;;10.1126/science.291.5502.319;;11209085;;pmc61133;;10.1073/pnas.231486598;;11698646;;12413529;;10.1016/s0952-7915(02)00398-9;;14764622;;10.1093/hmg/ddh076;;10.1084/jem.20022119;;12847138;;pmc2196082;;7851902;;10.1006/geno.1994.1562;;10.1084/jem.181.6.1953;;7539033;;pmc2192041;;10.1016/s0167-5699(97)80025-4;;9190115,"Rudikoff et al. 1982, Proc. Natl. Acad. Sci. USA, , 79: 1979-1983.;;Panka et al., 1988, Proc. Natl. Acad. Sci. USA, 85: 3080-3084.;;Wong RM et al., ""Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs,"" Int Immunol. (2007), 19(10):1223-34.;;Berger et al., ""Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies,"" Clin Cancer Res. (2008); 14(10):3044-51.;;Blank et al., ""PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+T Cells""; Cancer Research; (2004); 64:1140-1145.;;Cox et al., ""A directory of human germ-line Vkappa segments reveals a strong bias in their Usage""; Eur. J. Immunol.; (1994); 24:827-836.;;Koga et al., ""Blockade of the Interaction Between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts""; Arterioscler. Thromb. Vasc. Biol.; (2004); 24(11):2057-2062.;;Tomlinson et al., ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops""; J. Mol. Biol.; (1992); 227:776-798.;;Agata, et al., 1996, ""Expression of the PD-1 antigen on the surface of stimulation mouse T and B lymphocytes,"" Int Immunol, vol. 8: p. 765-772.;;Bennett, et al., 2003, ""Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses,"" J Immunol, vol. 170: p. 711-718.;;Blank, et al., 2005, ""Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy,"" Cancer Immunol. Immunother., vol. 54: p. 307-314.;;Brown, et al., 2003, ""Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production,"" J. Immunol., vol. 170: p. 1257-1266.;;Carter, et al., 2002, ""PD-1: PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2,"" Eur J Immunol, vol. 32: p. 634-643.;;Dong, et al., 2002, ""Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion,"" Nat Med., vol. 8: p. 783-800.;;Dong, H. and Chen, L., 2003, ""B7-H1 pathway and its role in the evasion of tumor immunity,"" J Mol Med, vol. 81: p. 281-287.;;Finger, et al., 1997, ""The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors,"" Gene, vol. 197: p. 177-187.;;Freeman, et al., 2000, ""Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation,"" J Exp Med, vol. 192: p. 1027-1034.;;Hansen, et al., 1980, ""Monoclonal Antibodies Identifying a Novel T-Cell Antigen and Ia Antigens of Human Lymphocytes,"" Immunogenics, vol. 10: p. 247-260.;;He, et al., 2004, ""Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine,"" J. Immunol., vol. 173: p. 4919-4928.;;Hutloff, et al., 1999, ""ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28,"" Nature, vol. 397: p. 263-266.;;Ishida, et al., 1992, ""Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death,"" EMBO J., vol. 11: p. 3887-3895.;;Iwai, et al., 2002, ""Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade,"" Proc. Nat'l. Acad. Sci. USA, vol. 99: p. 12293-12297.;;Iwai, et al., 2002, ""Microanatomical localization of PD-1 in human tonsils,"" Immunology Letters, vol. 83, No. 3: p. 215-220.;;Iwai, et al., 2005, ""PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells,"" Int. Immunol., vol. 17: p. 133-144.;;Konishi, et al., 2004, ""B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression,"" Clin. Cancer Res., vol. 10: p. 5094-5100.;;Latchman, et al., 2001, ""PD-L2 is a second ligand for PD-1 and inhibits T cell activation,"" Nat Immunol, vol. 2: p. 261-268.;;Lonberg, et al., 1994, ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications,"" Nature, vol. 368, No. 6474: p. 856-859.;;Nielsen, et al., 2004, ""A putative regulatory polymorphism in PD-1 is associated with nephropathy in a population-based cohort of systemic lupus erythematosus patients,"" Lupus, vol. 13: p. 510-516.;;Nishimura, et al., 1999, ""Development of Lupus-like Autoimmune Disease by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor,"" Immunity, vol. 11: p. 141-151.;;Nishimura, et al., 2001, ""Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice,"" Science, vol. 291: p. 319-322.;;Okazaki, et al., 2001, ""PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tryosine phosphatase 2 to phosphotyrosine,"" PNAS, vol. 98: p. 13866-13871.;;Okazaki, et al., 2002, ""New regulatory co-receptors: inducible co-stimulator and PD-1,"" Curr. Opin. Immunol., vol. 41, No. 6: p. 779-782.;;Prokunina, L. and Alarcon-Riquelme, M., 2004, ""The genetic basis of systemic lupus erythematosus-knowledge of today and thoughts for tomorrow,"" Hum Mol Genet, vol. 13: p. R143-R148.;;Salama, et al., 2003, ""Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis,"" J Exp Med, vol. 198: p. 71-78.;;Shinohara, et al., 1994, ""Structure and chromosomal localization of the human PD-1 gene (PDCD1),"" Genomics, vol. 23: p. 704-706.;;Thomas, M.L., 1995, ""Of ITAMs and ITIMs: Turning On and Off the B Cell Antigen Receptor,"" J Exp Med, vol. 181: p. 1953-1956.;;Vivier, E. and Daeron, M., ""Immunoreceptor tyrosine-based inhibition motifs,"" Immunol Today, vol. 18: p. 286-291, (1997).",ACTIVE
100,WO,A2,WO 2007/005874 A2,034-573-521-496-251,2007-01-11,2007,US 2006/0026046 W,2006-06-30,US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-Ll antibodies.",MEDAREX INC;;KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/034-573-521-496-251,Patent Application,no,0,1212,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28,,0,0,,,,PENDING
101,JP,A,JP 2016033135 A,077-763-795-658-032,2016-03-10,2016,JP 2015213586 A,2015-10-30,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH 1(PD-1) AND METHOD FOR TREATING CANCER USING ANTI-PD-1 ANTIBODY ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,"PROBLEM TO BE SOLVED: To provide isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to programmed Death 1 (PD-1) with high affinity.SOLUTION: There are provided isolated human monoclonal antibodies cross-competing for binding to a reference antibody including human heavy chain and light chain variable regions composed of specific amino acid sequences and PD-1, or a binding portion thereof. A method for detecting PD-1 is provided and various diseases including cancer and infectious diseases can be treated by preparing immunocomplexes, bispecific molecules and pharmaceutical compositions containing the antibodies. Furthermore, hyperproliferative diseases such as cancer can also be treated by a combination immunotherapy such as a combination of anti-CTLA-4 and anti-PD-1 antibodies. Adverse events related to the treatment with each of such antibodies are altered.SELECTED DRAWING: None",ONO PHARMACEUTICAL CO;;ER SQUIBB & SONS LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/077-763-795-658-032,Patent Application,no,7,0,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395;;A61P35/00;;A61P35/02,,0,0,,,,ACTIVE
102,MX,A,MX 2007015942 A,099-964-915-580-890,2008-03-07,2008,MX 2007015942 A,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1).,"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-Ll antibodies.",MEDAREX INC,HUANG HAICHUN;;SRINIVASAN MOHAN;;WANG CHANGYU;;PASSMORE DAVID B;;KORMAN ALAN J;;SELBY MARK J;;CHEN HAIBIN,,https://lens.org/099-964-915-580-890,Patent Application,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28,,0,0,,,,ACTIVE
103,HK,A1,HK 1140793 A1,158-560-331-304-785,2010-10-22,2010,HK 10107100 A,2008-04-21,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1(PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,,ONO PHARMACEUTICAL CO;;MEDAREX LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/158-560-331-304-785,Patent Application,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N/;;C07K/;;C12P/;;C12Q/,,0,0,,,,PENDING
104,PT,E,PT 2161336 E,183-188-668-406-718,2013-10-03,2013,PT 09013687 T,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1(PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,,ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/183-188-668-406-718,Granted Patent,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
105,US,B2,US 9358289 B2,188-549-392-923-61X,2016-06-07,2016,US 201414227733 A,2014-03-27,US 201414227733 A;;US 201113210137 A;;US 91321706 A;;JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodies,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",SQUIBB & SONS LLC;;ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;ONO PHARMACEUTICAL CO. LTD (2007-12-27);;MEDAREX INC (2012-04-12),https://lens.org/188-549-392-923-61X,Granted Patent,yes,89,112,120,125,82,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395;;A61K39/00;;A61K47/48;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/46,,99,37,034-879-699-905-632;;010-811-198-482-852;;103-897-301-868-65X;;197-193-057-828-756;;001-779-867-387-972;;013-584-945-188-940;;115-398-566-039-426;;135-447-350-940-622;;052-153-724-747-948;;147-888-721-956-877;;166-025-821-402-033;;057-460-007-966-306;;006-463-263-246-432;;013-770-850-974-489;;124-864-341-496-45X;;152-923-894-609-509;;085-413-318-249-981;;063-455-531-393-728;;060-728-367-476-688;;010-097-148-050-263;;031-431-800-409-592;;051-918-569-782-385;;079-083-105-219-723;;042-819-179-681-837;;015-898-381-155-805;;025-253-136-774-180;;014-903-975-216-318;;043-030-710-125-973;;051-224-574-304-090;;083-811-051-643-47X;;064-453-435-140-293;;045-623-729-340-346;;025-493-244-483-981;;006-319-541-331-383;;070-722-893-617-204;;020-043-570-354-456;;049-393-898-856-305,7481795;;10.1126/science.270.5238.932;;15785203;;10.1089/hyb.2005.24.1;;pmc4348009;;10.1056/nejmoa1411087;;25482239;;10.1016/s0075-7535(08)70702-2;;10.1006/jmbi.1999.3192;;10543973;;10.1182/blood-2002-06-1761;;12393541;;10.1177/107327481402100112;;24357746;;pmc40169;;8552677;;10.1073/pnas.93.1.7;;16285013;;10.1002/eji.200535232;;10.1093/protein/11.1.65;;9579662;;10.1016/s0958-1669(98)80091-8;;9503595;;10.1016/s1535-6108(04)00083-2;;15093539;;10.2210/pdb1s78/pdb;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;18410894;;10.1016/j.bbmt.2008.02.010;;pmc2423190;;10.1038/78963;;10966641;;18429302;;9592769;;10.1007/bf02752698;;14530338;;10.4049/jimmunol.171.8.4156;;18059626;;10.1080/02648725.2007.10648092;;10.1089/hyb.1996.15.343;;8913783;;10.1074/jbc.m402194200;;15128741;;10.1038/ni1398;;17013388;;pmc1895332;;10.1182/blood-2005-04-1531;;16020508;;pmc2956066;;20817874;;10.4049/jimmunol.1001536;;16116203;;10.4049/jimmunol.175.5.3133;;19448431;;pmc2737335;;10.4161/cc.8.11.8738;;10.1182/blood-2005-06-2298;;pmc1895337;;16037385;;10.1182/blood-2004-07-2561;;15486062;;10.1016/j.clim.2014.02.015;;24631965;;pmc4082337;;17404099;;10.1158/1078-0432.ccr-06-2746;;9376601;;10.1182/blood.v90.8.3179;;10.1038/nrc3239;;pmc4856023;;22437870;;10.1007/3-540-30683-8_443;;22740686;;10.1126/scisignal.2002796;;pmc5498435;;23732914;;pmc3753920;;10.1128/mcb.00319-13;;pmc3552912;;23032366;;10.4161/cc.22135;;11964291;;10.1182/blood.v99.9.3256;;15353480;;10.1182/blood-2004-04-1596,"Abbas, A.K., et al., Cellular and Molecular Immunobiology, 2nd ed., pp. 8, 47-50, W.B. Saunders Company, United States (1991).;;Alignment of Amino Acid Sequences for Extraceliular Domain of Wild-Type (UniProt Q15116) Human PD-1, Wild-Type (MednaBio) PD-1 ECD, C62S Variant of Wild-Type Human PD-1 ECD, and A101L Variant of Wild-Type Human PD-1 ECD, 1 page, submitted with Opposition to EP Pat. No. 2161336 on Apr. 30, 2014.;;Allison, J.P. and Krummel, M.F., ""The Yin and Yang of T Cell Costimulation,"" Science 270(5238):932-933, American Association for the Advancement of Science, United States (1995).;;Amended Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Nov. 21, 2014, 11 pages.;;Andre, E., et al., ""Precise Characterization of the Epitope Recognized by a Monoclonal Antibody Against Escherichia coli RNA Polymerase,"" Hybridoma 24(1):1-5, Mary Ann Liebert, Inc., United States (Feb. 2005).;;Ansell, S.M., et al., ""PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma,"" The New England Journal of Medicine 372(4):311-319, Massachusetts Medical Society, United States (Jan. 22, 2015).;;Answer to Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Oct. 31, 2014, 15 pages.;;Answer to Plaintiffs' Amended Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Dec. 8, 2014, 17 pages.;;Anti-Human CD279 (PD-1) Datasheet, 14/2799, J105, eBioscience, Sep. 6, 2013, 1 page.;;Anti-Human CD279 (PD-1) Datasheet, 14/9989, J116, eBioscience, Sep. 6, 2013, 1 page.;;Anti-Human CD279 (PD-1) Purchase Receipts, eBioscience, Oct. 8, 2013, 4 pages.;;Antonia, S.J., et al., ""Association of tumor PD-L1 Expression and Immune Biomarkers with Clinical Activity in Patients with Non-small Cell Lung Cancer (NSCLC) Treated with Nivolumab (Anti-PD-1; BMS-936558; ONO-4538),"" 15th World Conference on Lung Cancer Sydney, Australia, 15th WCLC: Best of Posters 1-IASLC Selection, P2.11-035, Oct. 27-30, 2013, accessed at http://web.oncoletter.ch/kongressberichte-videos-slides-Onkologie/id-15th-world-conference-on-lung-cancer-conference/conference-highlights.html, accessed on Jan. 8, 2015, 6 pages.;;Appendix to Declaration of Vassiliki A. Boussiotis, Apr. 28, 2014, Data and Records for Example Experiments 21 and 22, 18 pages.;;Armand, P., et al., ""289 Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma-Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study,"" 56th ASH Annual Meeting and Exposition, Abstracts & Program, San Francisco, CA, Dec. 6-9, 2014.;;Berg, J.M., et al., ""The Immune System,"" in Biochemistry 5th ed., pp. 921-950, W.H. Freeman and Company, United States (2002).;;Biacore, ""Application Note 1: Characterization of monoclonal antibody epitope specificity using Biacore's SPR technology,"" Biacore AB, 8 pages (2002).;;Biacore Sensor Surface Handbook, BR-1005-71, edition AB, pp. 1-98, GE Healthcare (Feb. 2005).;;Biacore, ""The SPR signal,"" ""Interpreting experimental data,"" and ""BIA application areas,"" in BIAtechnology Handbook, version AB, chapters 4-6, 34 pages, Biacore AB (1998).;;Campbell, A.M., ""Characterisation of monoclonal antibodies,"" in Laboratory Techniques in Biochemistry and Molecular Biology, Monoclonal Antibody Technology: The Production and Characterization of Rodent and Human Hybridomas, vol. 13, pp. 186-215, Elsevier, the Netherlands (1984).;;CD279/PD-1, D132-3/J110 Datasheet, MBL Medical & Biological Laboratories Co., Ltd., Sep. 6, 2013, 2 pages.;;Chen, Y., et al., ""Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,"" Journal of Molecular Biology 293(4):865-881, Academic Press, England (1999).;;Communication pursuant to Article 94(3) EPC mailed on Dec. 22, 2014, in European Application No. 11 178 187.8-1410, European Patent Office, Germany.;;Communication pursuant to Article 94(3) EPC mailed on Dec. 22, 2014, in European Application No. 11 178 191.0-1410, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, mailed Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178187, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, mailed Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178188, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, mailed Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178191, European Patent Office, Germany.;;Complaint, Bristol-Myers Squibb Co. and Ono Pharmaceutical Co., Ltd. v. Merck & Co., Inc., 1:14-cv-01131-GMS, filed Sep. 4, 2014, 9 pages.;;Co-pending U.S. Appl. No. 14/547,026, inventors Korman, A.J., et al., filed Nov. 18, 2014 (Not Published).;;Co-pending U.S. Appl. No. 14/638,985, inventors Honjo, T., et al., filed Mar. 4, 2015 (Not Published).;;Cragg, M.S., et al., ""Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts,"" Blood 101(3):1045-1052, American Society of Hematology, United States (2003).;;Creelan, B.C, ""Update on Immune Checkpoint Inhibitors in Lung Cancer,"" Journal of the Moffitt Cancer Center 21(1):80-89, H. Lee Moffitt Cancer Center and Research Institute, United States (2014).;;Cruse, J.M. and Lewis, R.E., ""Antigens and Immunogens,"" in Atlas of Immunology, 2nd ed., pp. 105-126, CRC Press, United States (Dec. 29, 2003).;;Curriculum Vitae of Brian T. Fife, Ph.D., 7 pages, submitted with Response to Oppositions against EP Pat. No. 2161336 on Feb. 16, 2015.;;Curriculum Vitae of Dr. Robert J. Bloch, Apr. 11, 2012, 34 pages, submitted with Opposition to EP Pat. No. 2161336.;;Curriculum Vitae of Vassiliki A. Boussiotis, Nov. 8, 2013, 24 pages, submitted with Opposition to EP Pat. No. 2161336.;;Davies, D.R. and Cohen, G.H., ""Interactions of protein antigens with antibodies,"" Proceedings of the National Academy of Sciences USA 93(1):7-12, National Academy of Sciences, United States (1996).;;Declaration of Dr. Haidong Dong, Mar. 31, 2014, 15 pages, submitted with Opposition to EP Pat. No. 1537878.;;Declaration of Professor Brian T. Fife, Feb. 12, 2015, 4 pages, submitted with Response to Oppositions against EP Pat. No. 2161336.;;Del Rio, M-L., et al., ""Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation,"" European Journal of Immunology 35(12):3545-3560, Wiley-VCH Verlag GmbH & Co. KGaA, Germany (Dec. 2005).;;Dougan, D.A., et al., ""Effects of substitutions in the binding surface of an antibody on antigen affinity,"" Protein Engineering 11(1):65-74, Oxford University Press, England (1998).;;Email from MednaBio to Robert Bloch re: E1951MG1-Sequence Information, Apr. 25, 2014, 1 page.;;ExPASy Bioinformatics Resource Portal calculation based on ECD of UniProt Sequence Q15116, accessed at http://web.expasy.org/egi-bin/compute-pi/pi-tool, accessed on Apr. 28, 2014, 1 page.;;Extended European Search Report for EP Application No. 06746353.9, European Patent Office, Germany, mailed on Mar. 6, 2009.;;Extended European Search Report for EP Application No. 09013687.0, European Patent Office, Germany, mailed on Jan. 29, 2010.;;Extended European Search Report for EP Application No. 10172772.5, European Patent Office, Netherlands, mailed on Sep. 9, 2010.;;Extended European Search Report for EP Application No. 11178187.8, European Patent Office, Germany, mailed on Jun. 1, 2012.;;Extended European Search Report for EP Application No, 11178188.6, European Patent Office, Germany, mailed on Jun. 27, 2013.;;Extended European Search Report for EP Application No. 11178191.0, European Patent Office, Germany, mailed on Sep. 5, 2012.;;Fivash, M., et al., ""BIAcore for macromolecular interaction,"" Current Opinion in Biotechnology 9(1):97-101, Current Biology, England (1998).;;Franklin, M.C., et al., ""Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex,"" Cancer Cell 5(4):317-328, Cell Press, United States (Apr. 2004).;;Freeman, G.J., et al., ""Engagement of the PD-1 Immunoinhibitory by a Novel B7-Family Member Leads to Negative Regulation of Lymphocyte Activation,"" Blood 96(11):810a-811a, (Abstract No. 3502) (2000).;;Ge, X., et al., ""CD134-Allodepletion Allows Selective Elimination of Alloreactive Human T Cells without Loss of Virus-Specific and Leukemia-Specific Effectors,"" Biology of Blood and Marrow Transplantation 14(5):518-530, American Society for Blood and Marrow Transplantation, United States (2008).;;Greenspan, N.S., ""Epitopes, paratopes and other topes: do immunologists know what they are talking about?"" Bulletin de l'Institut Pasteur 90(4):267-279, Elsevier, France (1992).;;Harlow, E. and Lane, D., ""Using Antibodies: A Laboratory Manual,"" Cold Spring Harbor Laboratory Press, Cold Spring Harbor, United States various pages (1999).;;International Preliminary Report on Patentability for International Application No. PCT/JP2006/309606, The International Bureau of WIPO, Switzerland, issued on Nov. 13, 2007.;;International Search Report for International Application No. PCT/JP03/08420, Japanese Patent Office, Japan, mailed Oct. 21, 2003.;;International Search Report for International Application No. PCT/JP2006/309606, Japanese Patent Office, Japan, mailed on Aug. 15, 2006.;;Ishima, R. and Torchia, D.A., ""Protein Dynamics from NMR,"" Nature Structural Biology 7(9):740-743, Nature Publishing Company, United States (2000).;;J105/D133-3 Datasheet, MBL Medical & Biological Laboratories Co. Ltd., Mar. 20, 2013, 2 pages.;;J105/D133-3 Purchase Order, MBL Medical & Biological Laboratories Co, Ltd., Apr. 11, 2014, 1 page.;;J105/D133-3 Purchase Receipts, Invoice MINV52635, MBL International Corporation, Oct. 2, 2013, 2 pages.;;Jason-Moller, L., et al., ""Overview of Biacore Systems and Their Applications,"" Current Protocols in Protein Science S45:19.13.1-19.13.14, John Wiley & Sons, Inc., United States (2006).;;Johne, B., ""Protocol: Epitope Mapping by Surface Plasmon Resonance in the BIAcore,"" Molecular Biotechnology 9(1):65-71, Humana Press, United States (1998).;;Kanai, T., et al., ""Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation,"" The Journal of Immunology 171(8):4156-4163, American Association of Immunologists, Inc., United States (2003).;;Ladner, R.C., ""Mapping the Epitopes of Antibodies,"" Biotechnology and Genetic Engineering Reviews 24(1):1-30, Taylor & Francis, England (2007).;;Laricchia-Robbio, L., et al., ""Mapping of Monoclonal Antibody- and Receptor-Binding Domains on Human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF) Using a Surface Plasmon Resonance-Based Biosensor,"" Hybridoma 15(5):343-350, Mary Ann Liebert, Inc., United States (1996).;;Lesokhin, A.M., et al., ""291 Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed of Refractory Lymphoid Malignancies,"" 56th ASH Annual Meeting and Exposition, Abstracts & Program, San Francisco, CA, United States, Dec. 6-9, 2014.;;Lewis, D.E., et al., ""Tumor Necrosis Factor-alpha and CD80 Modulate CD28 Expression through a Similar Mechanism of T-cell Receptor-Independent Inhibition of Transcription,"" The Journal of Biological Chemistry 279(28):29130-29138, The American Society for Biochemistry and Molecular Biology, Inc., United States (Jul. 2004).;;Li, L., et al., ""A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance,"" Nature Immunology 7(11):1157-1165, Nature Publishing, United States (2006).;;Li, L., et al., ""CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties and T-cell anergy,"" Blood 106(9):3068-3073, American Society of Hematology, United States (Nov. 2005).;;Li, L., et al., ""Il-lbeta-Mediated Signals Preferentially Drive Conversion of Regulatory T Cells but Not Conventional T Cells into IL-17-Producing Cells,"" The Journal of Immunology 185(7):4148-4153, American Association of Immunologists, Inc., United States (2010).;;Li, L., et al., ""Rap1-GTP is a Negative Regulator of Th Cell Function and Promotes the Generation of CD4+CD103+ Regulatory T Cells in Vivo,"" The Journal of Immunology 175(5):3133-3139, American Association of Immunologists, Inc., United States (Sep. 2005).;;Li, L., et al., ""The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD,"" Cell Cycle 8(11):1794-1802, Landes Bioscience, United States (2009).;;""List of Clinical Trials with Nivolumab from the website ClinicalTrials.gov of U.S. National Institutes of Health"" submitted with Response to Oppositions against EP Pat. No. 2161336, mailed on Feb. 16, 2015, 11 pages.;;Lute, K.D., et al., ""Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies,"" Blood 106(9):3127-3133, American Society of Hematology, United States (Nov. 2005).;;May, K.F., Jr., et al., ""Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies,"" Blood 105(3):1114-1120, American Society of Hematology, United States (Feb. 2005).;;Nellore, A., et al., ""The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors,"" Clinical Immunology 152(1-2):48-57 (May-Jun. 2014; Epub Mar. 12, 2014).;;Nomi, T., et al., ""Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer,"" Clinical Cancer Research 13(7):2151-2157, The Association, United States (2007).;;Office Action mailed Apr. 13, 2015, in U.S. Appl. No. 14/638,985, inventors Honjo, T., et al., filed Mar. 4, 2015.;;Office Action mailed Jan. 7, 2015, in U.S. Appl. No. 14/550,585, inventors Honjo, T., et al., filed Nov. 21, 2014.;;Ono Pharmaceutical Co., Ltd Research Center Search Research Institute, Ryoji Yagi (Test Director), ""Study of the Antitumor Effects of Anti-mouse PD-1 (J43) in Mouse J558 Cell (myeloma) Subcutaneous Implantation Methods,"" Final Report, Test No. E03CT011, (planned test period: 2003-2004), 34 pages.;;Ozaki, S., et al., ""Immunotherapy of Multiple Myeloma with a Monoclonal Antibody Directed Against a Plasma Cell-specific Antigen, HM1.24,"" Blood 90(8):3179-3186, American Society of Hematology, United States (1997).;;Pardoll, D.M., ""The blockade of immune checkpoints in cancer immunotherapy,"" Nature Reviews Cancer 12(4):252-264, Nature Publishing Group, England (2012).;;Patent Assignment Abstract of Title for U.S. Pat. No. 8,008,449, USPTO Assignments on the Web, accessed on Apr. 30, 2014, 2 pages.;;Patsoukis, N., et al., ""Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation,"" Science Signaling 5(230): ra46, pp. 1-14, American Association for the Advancement of Science, United States (Jun. 2012).;;Patsoukis, N., et al., ""PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2,"" Molecular and Cellular Biology 33(16):3091-3098, American Society for Microbiology, United States (Aug. 2013).;;Patsoukis, N., et al., ""PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A,"" Cell Cycle 11(23):1-5, Landes Bioscience, United States (Dec. 2012).;;Polyak, M.J. and Deans, J.P., ""Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure,"" Blood 99(9):3256-3262, American Society of Hematology, United States (2002).;;Press Release from Bristol-Myers Squibb, ""Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration,"" Dec. 22, 2014, 6 pages.;;Press Release from ESMO, ""ESMO 2014 Press Release: Nivolumab Shows Signs of Superior Response Rate Compared to Standard Chemotherapy in Advanced Melanoma,"" Sep. 29, 2014, 2 pages.;;Press Release from Ono Pharmaceuticals Co., Ltd., ""Human Anti-human PD-1 Monoclonal Antibody ""OPDIVO(R) Intravenous Infusion 20 mg/100 mg"" Receives Manufacturing and Marketing Approval in Japan for the Treatment of Unresectable Melanoma,"" Jul. 4, 2014, 2 pages.;;Press-Release from Bristol-Myers Squibb, ""CheckMate-017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-small Cell Lung Cancer, Stopped Early,"" Jan. 11, 2015, 5 pages.;;Press-Release from Bristol-Myers Squibb, ""Phase 3 First-Line Melanoma Study of Nivolumab, an Investigational PD-1 Checkpoint Inhibitor, Demonstrates Superior Overall Survival Compared to Dacarbazine; Study Stopped Early,"" Jun. 24, 2014, 3 pages.;;Product Insert for Keytruda(R) (pernbrolizumab), Merck & Co., Inc., United States, issued 2014.;;Product Insert for Opdivo(R) (nivolumab), Bristol-Myers Squibb Company, United States, issued Mar. 2015.;;Product Specifications for AffiniPure Goat Anti-Human IgG, Fcgamma Fragment Specific (minimal cross-reaction to Bovine, Horse, and Mouse Serum Proteins), Code No. 109-005-098, Lot No. 111632, Jackson ImmunoResearch Laboratories, Inc., Sep. 12, 2013, 1 page.;;Product Specifications for AffiniPure Goat Anti-Mouse IgG, Fcgamma Fragment Specific (minimal crossreaction to Human, Bovine, and Horse Serum), Code No. 115-005-071, Lot No. 111143, Jackson ImmunoResearch Laboratories, Inc., Sep. 12, 2013, 1 page.;;Response to Oppositions, mailed Feb. 16, 2015, in European Patent No. EP 2161336, Ono Pharmaceutical Co., Ltd. and Medarex, Inc., 27 pages.;;Riley, J.L. and June, C.H., ""The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation,"" Blood 105(1):13-21, American Society of Hematology, United States (Jan. 2005).",ACTIVE
106,DK,T3,DK 2161336 T3,051-687-310-214-308,2013-10-28,2013,DK 09013687 T,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;EP 06746353 A,2005-05-09,Humane monoklonale antistoffer til programmeret død 1(PD-1) samt fremgangsmåder til behandling af kræft under brug af anti-PD-1 antistoffer alene eller kombineret med andre immunterapier,,MEDAREX INC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/051-687-310-214-308,Granted Patent,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
107,AU,B2,AU 2006/265108 B2,090-610-294-480-938,2012-05-17,2012,AU 2006/265108 A,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,Human monoclonal antibodies to programmed death ligand 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-Ll antibodies.",MEDAREX INC,WANG CHANGYU;;PASSMORE DAVID B;;SRINIVASAN MOHAN;;KORMAN ALAN J;;CHEN HAIBIN;;SELBY MARK J;;HUANG HAICHUN,,https://lens.org/090-610-294-480-938,Granted Patent,no,4,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28,,2,2,067-760-343-772-225;;119-897-745-760-544,14871849;;10.1158/0008-5472.can-03-3259;;10.1161/01.atv.0000145015.23656.e4;;15374847,"Blank, C et al (2004) Cancer Research. v64 pp1140-1145;;Koga, N et al (2004) Arterioscler. Thromb. Vasc. Biol. v24 pp2057-2062",ACTIVE
108,KR,A,KR 20170018085 A,114-950-222-013-716,2017-02-15,2017,KR 20177002976 A,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,1 -1 HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1PD-L1,"본 발명은 분리된 모노클로날 항체, 특히 PD-Ll에 높은 친화도로 특이적으로 결합하는 인간 모노클로날 항체를 제공한다. 본 개시의 항체를 코드하는 핵산 분자, 발현 벡터, 숙주세포 및 본 개시의 항체를 발현하는 방법이 또한 제공된다. 본 발명의 항체를 포함하는 면역컨쥬게이트, 바이스페시픽 분자 및 약학적 조성물이 또한 제공된다. 본 개시는 또한 PD-Ll을 검출하는 방법 뿐 아니라 항-PD-Ll 항체를 사용하여 암과 감염성 질병을 포함하는 다양한 질병을 치료하는 방법을 제공한다.",SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/114-950-222-013-716,Patent Application,no,1,0,74,74,240,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/395;;C07K16/28;;A61K47/50,,1,1,119-897-745-760-544,10.1161/01.atv.0000145015.23656.e4;;15374847,"Arterioscler Thromb Vasc Biol., Vol. 24, pp. 2057-2062 (2004.)",ACTIVE
109,IL,A,IL 208642 A,143-656-901-115-540,2012-08-30,2012,IL 20864210 A,2010-10-12,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,USE OF ANTI-PD-1 AND ANTI-CTLA-4 ANTIBODIES FOR THE PREPARATION OF A MEDICAMENT FOR TREATING DISEASE,,BRISTOL MYERS SQUIBB CO;;SRINIVASAN MOHAN;;ONO PHARMACEUTICAL CO;;KORMAN ALAN J;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,SRINIVASAN MOHAN;;KORMAN ALAN J;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/143-656-901-115-540,Patent Application,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,,,0,0,,,,ACTIVE
110,SI,T1,SI 2439273 T1,164-371-338-444-70X,2019-05-31,2019,SI 200632322 T,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;EP 11178191 A,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;KORMAN ALAN J;;HUANG HAICHUN,,https://lens.org/164-371-338-444-70X,Granted Patent,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/00;;C07K16/00;;C12N5/00;;C12P21/00;;C12Q1/00,,0,0,,,,ACTIVE
111,WO,A3,WO 2007/005874 A3,160-502-623-916-042,2007-07-19,2007,US 2006/0026046 W,2006-06-30,US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-Ll antibodies.",MEDAREX INC;;KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/160-502-623-916-042,Search Report,yes,1,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28,,4,4,119-897-745-760-544;;067-760-343-772-225;;092-023-577-402-127;;022-179-293-052-569,10.1161/01.atv.0000145015.23656.e4;;15374847;;14871849;;10.1158/0008-5472.can-03-3259;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953,"KOGA NORITAKA ET AL: ""Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts"", ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, vol. 24, no. 11, November 2004 (2004-11-01), pages 2057 - 2062, XP002411528, ISSN: 1079-5642;;BLANK CHRISTIAN ET AL: ""PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells."", CANCER RESEARCH, vol. 64, no. 3, 1 February 2004 (2004-02-01), pages 1140 - 1145, XP002411529, ISSN: 0008-5472;;TOMLINSON I M ET AL: ""THE REPERTOIRE OF HUMAN GERMLINE VH SEQUENCES REVEALS ABOUT FIFTY GROUPS OF VH SEGMENTS WITH DIFFERENT HYPERVARIABLE LOOPS"", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 227, 1992, pages 776 - 798, XP000990787, ISSN: 0022-2836;;COX J P L ET AL: ""A directory of human germ-line Vkappa segments reveals a strong bias in their usage"", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 24, 1994, pages 827 - 836, XP003004702, ISSN: 0014-2980",PENDING
112,US,B2,US 7943743 B2,034-901-837-480-512,2011-05-17,2011,US 91772706 A,2006-06-30,US 91772706 A;;US 69642605 P;;US 2006/0026046 W,2005-07-01,Human monoclonal antibodies to programmed death ligand 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",MEDAREX INC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;MEDAREX INC (2008-03-26),https://lens.org/034-901-837-480-512,Granted Patent,yes,34,1173,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/00,530/388.15,10,10,027-477-313-726-928;;062-761-744-997-508;;009-746-604-420-355;;027-960-937-319-909;;116-193-705-533-609;;045-556-293-127-132;;119-897-745-760-544;;067-760-343-772-225;;092-023-577-402-127;;022-179-293-052-569,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;10.1006/jmbi.2000.3512;;10677285;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;10.1016/s1074-7613(00)00006-6;;10933393;;10.1161/01.atv.0000145015.23656.e4;;15374847;;14871849;;10.1158/0008-5472.can-03-3259;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953,"Rudikoff et al. 1982, Proc. Natl. Acad. Sci. USA, , 79: 1979-1983.;;Panka et al., 1988, Proc. Natl. Acad. Sci. USA, 85: 3080-3084.;;Klimka et al. British J. of Cancer (2000);83(2):252-260.;;Beiboer et al. J. Mol. Biol. (2000);296:833-849.;;Rader et al. PNAS USA (1998);95:8910-8915.;;Xu et al. (2000) Immunity, 13: 37-45.;;Koga et al. ""Blockade of the Interaction Between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts""; Arterioscler. Thromb. Vasc. Biol.; (2004); 24(11):2057-2062.;;Blank et al. ""PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells""; Cancer Research; (2004); 64:1140-1145.;;Tomlinson et al. ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops""; J. Mol. Biol.; (1992); 227:776-798.;;Cox et al. ""A directory of human germ-line Vkappa segments reveals a strong bias in their usage""; Eur. J. Immunol.; (1994); 24:827-836.",ACTIVE
113,KR,A,KR 20140002041 A,050-420-123-439-182,2014-01-07,2014,KR 20137029908 A,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1(PD-L1),,MEDAREX LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/050-420-123-439-182,Patent Application,no,0,0,74,74,160,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/395,,0,0,,,,ACTIVE
114,EP,A2,EP 1907424 A2,068-983-304-687-583,2008-04-09,2008,EP 06786260 A,2006-06-30,US 2006/0026046 W;;US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),,MEDAREX INC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,"MEDAREX, L.L.C. (2013-08-14);;E. R. SQUIBB & SONS, L.L.C. (2015-03-04)",https://lens.org/068-983-304-687-583,Patent Application,yes,0,6,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
115,HR,T1,HR P20151102 T1,108-013-082-866-579,2015-11-20,2015,HR P20151102 T,2015-10-19,US 69642605 P;;EP 06786260 A;;US 2006/0026046 W,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),,SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/108-013-082-866-579,Granted Patent,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
116,PL,T3,PL 2161336 T3,111-574-787-991-60X,2014-01-31,2014,PL 09013687 T,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;EP 09013687 A;;EP 06746353 A,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/111-574-787-991-60X,Patent Application,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,PENDING
117,JP,A,JP 2013150606 A,117-150-006-345-533,2013-08-08,2013,JP 2013023278 A,2013-02-08,US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"PROBLEM TO BE SOLVED: To provide isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity.SOLUTION: This method for preparing an anti-PD-L1 antibody includes the following steps: (a) providing a heavy chain variable region antibody sequence comprising a specific CDR3 sequence; and/or a light chain variable region antibody sequence comprising a specific CDR3 sequence; (b) altering at least one amino acid residue within the heavy chain variable region antibody sequence and/or light chain variable region antibody sequence to create at least one altered antibody sequence; and (c) expressing the altered antibody sequence as a protein.",MEDAREX INC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/117-150-006-345-533,Patent Application,no,2,5,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C12N15/09;;A01K67/027;;A61K38/00;;A61K39/00;;A61K39/12;;A61K39/395;;A61K51/00;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P39/02;;A61P43/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/071;;C12N5/10;;C12N15/02;;C12P21/08,,7,6,119-897-745-760-544;;067-760-343-772-225;;050-992-361-999-488;;022-046-054-886-073;;092-023-577-402-127;;022-179-293-052-569,10.1161/01.atv.0000145015.23656.e4;;15374847;;14871849;;10.1158/0008-5472.can-03-3259;;12520872;;10.1080/02648725.2002.10648023;;pmc127659;;11796590;;10.1128/iai.70.2.612-619.2002;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953,"KOGA NORITAKA, ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLIGY, vol. V24 N11, JPN5008009810, November 2004 (2004-11-01), pages 2057 - 2062, ISSN: 0002868861;;BLANK CHRISTIAN, CANCER RESEARCH, vol. V64 N3, JPN5008009811, 1 February 2004 (2004-02-01), pages 1140 - 1145, ISSN: 0002868862;;""Biotechnology & Genetic Engineering Reviews"", 2002, VOL.19, PP.73-82, JPN6011069194, ISSN: 0002868863;;""Infection and Immunity"", 2002, VOL.70, NO.2, PP.612-619, JPN6011069195, ISSN: 0002868864;;""Proceedings of the National Academy of Sciences of USA"", 2000, VOL.97, PP.722-727, JPN6011069197, ISSN: 0002868865;;TOMLINSON I M, JOURNAL OF MOLECULAR BIOLOGY, vol. V227, JPN5008009812, 1992, GB, pages 776 - 798, ISSN: 0003185376;;COX J.P.L., EUROPEAN JOURNAL OF IMMUNOLOGY, vol. V24, JPN5008009813, 1994, DE, pages 827 - 836, ISSN: 0003185377",ACTIVE
118,EP,B1,EP 2439273 B1,129-294-766-661-481,2019-02-27,2019,EP 11178191 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;EP 09013687 A;;EP 06746353 A;;JP 2006309606 W,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;KORMAN ALAN J;;HUANG HAICHUN,"MEDAREX, L.L.C. (2014-04-23);;E. R. SQUIBB & SONS, L.L.C. (2015-03-04);;ONO PHARMACEUTICAL CO., LTD. (2015-03-04);;MEDAREX, INC. (2013-05-29)",https://lens.org/129-294-766-661-481,Granted Patent,yes,3,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,30,25,027-748-683-255-715;;060-310-971-679-125;;030-984-256-000-024;;057-299-748-685-191;;062-418-979-939-961;;020-140-165-898-622;;025-182-641-289-850;;168-544-094-336-881;;052-597-675-128-75X;;145-209-675-614-912;;054-987-730-791-922;;143-679-321-041-17X;;070-035-859-822-533;;033-427-694-478-578;;020-216-126-738-704;;113-346-509-283-257;;013-122-792-588-081;;076-731-232-972-252;;023-222-320-518-73X;;076-092-237-434-500;;053-665-131-053-807;;032-820-729-763-323;;012-369-544-741-057;;073-659-966-706-479;;067-097-843-471-519,10.1038/nbt1137;;16151408;;pmc166236;;12826605;;10.1073/pnas.1533209100;;10.1038/ni0702-611;;12087419;;10.1038/nri727;;11910893;;10.1126/science.271.5256.1734;;8596936;;15122199;;10.1038/nri1349;;12721664;;10.1007/s00109-003-0430-2;;12152031;;10.1038/nm0802-787;;11224527;;10.1038/85330;;12947224;;10.1385/ir:28:1:49;;12962274;;10.1080/08830180305219;;15905503;;10.4049/jimmunol.174.11.6648;;10.1038/ni1165;;15685176;;10.1038/ni0305-227;;15716967;;10.1128/mcb.25.21.9543-9553.2005;;16227604;;pmc1265804;;11861596;;10.1146/annurev.immunol.20.091101.091806;;10.4049/jimmunol.170.3.1257;;12538684;;10.1007/s00262-004-0593-x;;15599732;;10.1084/jem.20022125;;12847137;;pmc2196083;;10.4049/jimmunol.170.2.711;;12517932;;9630891;;10.1038/nbt0396-309;;8159246;;10.1038/368856a0;;10.1016/s0167-5699(00)01668-6;;10916138;;10096554;;10.1517/14712598.4.8.1265;;15268661,"ADAMS ET AL.: ""Monoclonal antibody therapy of cancer"", NATURE BIOTECH, vol. 23, 2005, pages 1147 - 1157, XP002456710, DOI: 10.1038/nbt1137;;PHAN ET AL.: ""Cancer regression and autoimmunity induced by cytotoxic T lymphocyte- associated antigen 4 blockade in patients with metastatic melanoma"", PNAS, vol. 100, no. 14, 8 July 2003 (2003-07-08), pages 8372 - 8377, XP002555771, DOI: 10.1073/pnas.1533209100;;EGEN ET AL.: ""CTLA-4 new insights into its biological function and use in tumor immunotherapy"", NATURE IMMUNOLOGY, vol. 3, no. 7, July 2002 (2002-07-01), pages 611 - 618, XP055661586;;SHARPE ET AL.: ""The B7- CD 28 Superfamily"", NATURE REVIEWS IMMUNOLOGY, vol. 2, no. 2, 2002, pages 116 - 126, XP008018232, DOI: 10.1038/nri727;;LEACH ET AL.: ""Enhancement of Antitumor Immunity by CTLA-4 Blockade"", SCIENCE, vol. 271, 1996, pages 1734 - 1736, XP000986211;;CHEN: ""Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity"", NAT REV IMMUNOLOGY, vol. 4, 2004, pages 336 - 347, XP055141186;;DONG ET AL.: ""B7-H1 pathway and its role in the evasion of tumor immunity"", JOURNAL OF MOLECULAR MEDICINE, vol. 81, no. 5, 2003, pages 281 - 287, XP002520498;;FREEMAN ET AL.: ""Protect the killer: CTLs need defenses against the tumor"", NATURE MEDICINE, vol. 8, no. 8, August 2002 (2002-08-01), pages 787 - 789, XP055661595;;LATCHMAN ET AL.: ""PD-L2 is a second ligand for PD-1 and inhibits T cell activation"", NATURE IMMUNOLOGY, vol. 2, no. 3, March 2001 (2001-03-01), pages 261 - 268, XP001064842;;CARTER ET AL.: ""Cytotoxic T-Lymphocyte Antigen-4 and Programmed Death-1 Function as Negative Regulators of Lymphocyte Activation"", IMMUNOLOGIC RESEARCH, vol. 28, no. 1, 2003, pages 49 - 59, XP009057800, DOI: 10.1385/IR:28:1:49;;EVANS ET AL.: ""Boosting T Cell Costimulation in Cancer: The Possibilities Seem Endless"", INTERNATIONAL REVIEWS OF IMMUNOLOGY, vol. 22, no. 2, 2003, pages 173 - 194, XP055661598;;CHEMNITZ ET AL.: ""CTLA-4 and PD-1 Receptors Inhibit T- Cell Activation by Distinct Mechanisms"", BLOOD, vol. 104, no. 11, 2004, pages 2657, XP055661603;;BLAZAR ET AL.: ""Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism"", J IMMUNOL, vol. 171, 2003, pages 1272 - 1277, XP055661609;;ITO ET AL.: ""Analysis of the Role of Negative T Cell Costimulatory Pathways in CD4 and CD8 T Cell-Mediated Alloimmune Responses In Vivo"", J IMMUNOL, vol. 174, 2005, pages 6648 - 6656, XP055661611;;PROBST ET AL.: ""Resting dendritic cells induce peripheral CD 8+ T cell tolerance through PD-1 and CTLA-4"", NATURE IMMUNOLOGY, vol. 6, no. 3, March 2005 (2005-03-01), pages 280 - 286, XP055661612;;ABBAS ET AL.: ""Dendritic cells giveth and taketh away"", NATURE IMMUNOLOGY, vol. 6, no. 3, March 2005 (2005-03-01), pages 227 - 228, XP055661613;;PARRY ET AL.: ""CTLA-4 and PD-1 Receptors Inhibit T- Cell Activation by Distinct Mechanisms"", MOLECULAR AND CELLULAR BIOLOGY, vol. 25, no. 21, October 2005 (2005-10-01), pages 9543 - 9553, XP003026807, DOI: 10.1128/MCB.25.21.9543-9553.2005;;SANDNER ET AL.: ""Functions of the regulatory T cell costimulatory pathways CTLA-4 and PD-1 in alloreactive CD 4+ T cell responses in vivo"", AMERICAN TRANSPLANT CONGRESS 2003 ABSTRACTS, pages 152, XP055661617;;CARRENO ET AL.: ""The B7 Family of Ligands and Its Receptors: New Pathways for Costimulation and Inhibition of Immune Responses"", ANNU. REV. IMMUNOL., vol. 20, 2002, pages 29 - 53, XP009004805;;BROWN ET AL.: ""Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production"", J IMMUNOL, vol. 170, 2003, pages 1257 - 66, XP002973918;;BLANK ET AL.: ""Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy"", CANCER IMMUNOL IMMUNOTHER, vol. 54, 2005, pages 307 - 314, XP019333106;;ANSARI ET AL.: ""The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice"", J. EXP. MED., vol. 198, 2003, pages 63 - 69, XP055188563;;BENNETT ET AL.: ""Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses"", J IMMUNOL, vol. 170, 2003, pages 711 - 718, XP055048008;;VAUGHAN ET AL.: ""Huinan Antibodies with Sub-nanon1olar Affinities Isolated fron1 a Large Non-in1n1unized Phage Display Library"", NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 309 - 314, XP055661624;;LONBERG ET AL.: ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications"", NATURE, vol. 368, 1994, pages 856 - 859, XP002626115;;HARVARD BUSINESS SCHOOL EXCERPT, 2001;;LITTLE ET AL.: ""Of mice and men: hybridoma and recombinant antibodies"", IMMUNOLOGY TODAY, vol. 21, no. 8, 2000, pages 364 - 370, XP004215163;;YANG X ET AL.: ""Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy"", CANCER RESEARCH, vol. 59, 1999, pages 1236 - 1243, XP008154927;;WAYBACK MACHINE EXCERPT RELATING TO MEDAREX HUMAB-MOUSE, 4 April 2005 (2005-04-04);;SCHULTES ET AL.: ""Using antibodies in tumour immunotherapy"", EXPERT OPINION ON BIOLOGICAL THEORY, vol. 4, no. 8, 2004, pages 1265 - 1284, XP008078858, DOI: 10.1517/14712598.4.8.1265",INACTIVE
119,US,A1,US 2009/0055944 A1,006-124-994-946-751,2009-02-26,2009,US 91772706 A,2006-06-30,US 91772706 A;;US 69642605 P;;US 2006/0026046 W,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO BE PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",MEDAREX INC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;MEDAREX INC (2008-03-26),https://lens.org/006-124-994-946-751,Patent Application,yes,27,221,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/395;;A01K67/027;;A61K51/10;;A61P35/00;;C07H21/00;;C07K16/18;;C12N5/18;;C12N15/64,800/18;;530/388.15;;424/142.1;;424/1.49;;435/320.1;;536/23.53;;435/326,0,0,,,,ACTIVE
120,PT,E,PT 1907424 E,051-278-398-187-545,2015-10-09,2015,PT 06786260 T,2006-06-30,US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),,SQUIBB & SONS LLC,KORMAN ALAN J;;HUANG HAICHUN;;WANG CHANGYU;;SRINIVASAN MOHAN;;SELBY MARK J;;PASSMORE DAVID B;;CHEN HAIBIN,,https://lens.org/051-278-398-187-545,Granted Patent,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
121,US,A1,US 2015/0165025 A1,084-599-312-737-222,2015-06-18,2015,US 201414547026 A,2014-11-18,US 201414547026 A;;US 201414270750 A;;US 201113210137 A;;US 91321706 A;;JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",MEDAREX LLC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;MEDAREX INC (2014-12-02),https://lens.org/084-599-312-737-222,Patent Application,yes,0,50,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395,,0,0,,,,ACTIVE
122,CN,A,CN 105315373 A,156-097-794-843-721,2016-02-10,2016,CN 201510568080 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;CN 200680023860 A,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies,"The invention relates to human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies. The invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, which specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUAN,,https://lens.org/156-097-794-843-721,Patent Application,no,2,6,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/395;;A61P31/04;;A61P31/10;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/08;;A61P35/00;;A61P37/02;;A61P37/04;;C12N5/20;;C12N15/13,,3,0,,,"YOSHIKO IWAI等: ""PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells"", 《INTERNATIONAL IMMUNOLOGY》;;YOSHIKO IWAI等: ""Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade"", 《PNAS》;;毛丽伟等: ""PD-L1 mAb 的制备、鉴定及其特性的研究"", 《免疫学杂志》",ACTIVE
123,KR,A,KR 20080045674 A,165-351-305-515-59X,2008-05-23,2008,KR 20087002586 A,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1(PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-Ll antibodies.",MEDAREX INC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/165-351-305-515-59X,Patent Application,no,0,6,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28,,0,0,,,,ACTIVE
124,PT,T,PT 2439273 T,171-537-839-494-714,2019-05-13,2019,PT 11178191 T,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1(PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,MOHAN SRINIVASAN;;CHANGYU WANG;;BING CHEN;;JOSEPHINE M CARDARELLI;;HAICHUN HUANG;;ALAN J KORMAN;;MARK J SELBY,,https://lens.org/171-537-839-494-714,Patent Application,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,PENDING
125,JP,A,JP 2018027952 A,177-093-589-099-28X,2018-02-22,2018,JP 2017166294 A,2017-08-31,US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"PROBLEM TO BE SOLVED: To provide an isolated monoclonal antibody, particularly human monoclonal antibody, that specifically binds to PD-L1 with high affinity.SOLUTION: A method for preparing an anti-PD-L1 antibody comprises: (a) providing a heavy chain variable region antibody sequence including a specific CDR3 sequence, and/or a light chain variable region antibody sequence including a specific CDR3 sequence; (b) altering at least one amino acid residue within the heavy chain variable region antibody sequence and/or the light chain variable region antibody sequence to create at least one altered antibody sequence; and (c) expressing the altered antibody sequence as a protein.SELECTED DRAWING: Figure 47",E R SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/177-093-589-099-28X,Patent Application,no,2,0,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A61K38/16;;A61K39/00;;A61K39/02;;A61K39/12;;A61K39/395;;A61K50/00;;A61K51/10;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P35/00;;A61P35/02;;A61P39/02;;A61P43/00;;C07K16/46;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N5/18;;C12N15/09,,7,6,119-897-745-760-544;;067-760-343-772-225;;050-992-361-999-488;;022-046-054-886-073;;047-951-914-695-080;;092-023-577-402-127,10.1161/01.atv.0000145015.23656.e4;;15374847;;14871849;;10.1158/0008-5472.can-03-3259;;12520872;;10.1080/02648725.2002.10648023;;pmc127659;;11796590;;10.1128/iai.70.2.612-619.2002;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;1404388;;10.1016/0022-2836(92)90223-7,"""Arteriosclerosis, Thrombosis, and Vascular Biology"", 2004, VOL.24, PP.2057-2062, JPN6011069191, ISSN: 0004072428;;""Cancer Research"", 2004, VOL.64, PP.1140-1145, JPN6011069192, ISSN: 0004072429;;""Biotechnology & Genetic Engineering Reviews"", 2002, VOL.19, PP.73-82, JPN6011069194, ISSN: 0004072430;;""Infection and Immunity"", 2002, VOL.70, NO.2, PP.612-619, JPN6011069195, ISSN: 0004072431;;""Proceedings of the National Academy of Sciences of USA"", 2000, VOL.97, PP.722-727, JPN6011069197, ISSN: 0004072432;;""Journal of Molecular Biology"", 1992, VOL.227, PP.776-798, JPN6011069199, ISSN: 0004072426;;""European Journal of Immunology"", 1994, VOL.24, PP.827-836, JPN6011069200, ISSN: 0004072427",ACTIVE
126,US,B2,US 10441655 B2,018-159-629-422-365,2019-10-15,2019,US 201615288545 A,2016-10-07,US 201615288545 A;;US 201414248462 A;;US 201113210137 A;;US 91321706 A;;JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Monoclonal antibodies to programmed death 1 (PD-1),"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",SQUIBB & SONS LLC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;ONO PHARMACEUTICAL CO. LTD (2007-12-27);;MEDAREX INC (2014-12-02),https://lens.org/018-159-629-422-365,Granted Patent,yes,109,18,120,125,82,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/00;;A61K39/395;;A61K47/68;;A61K51/10;;C07K16/18;;C07K16/46,,316,124,096-836-496-369-605;;031-217-961-878-413;;083-230-750-341-053;;105-890-842-208-495;;082-582-463-785-201;;010-809-130-428-953;;107-025-092-815-187;;119-913-141-042-40X;;004-509-656-230-835;;060-550-110-687-29X;;027-748-683-255-715;;004-728-346-095-981;;034-879-699-905-632;;010-811-198-482-852;;023-222-320-518-73X;;103-897-301-868-65X;;076-092-237-434-500;;049-336-842-920-389;;099-845-492-851-481;;076-731-232-972-252;;067-760-343-772-225;;107-581-406-479-794;;051-040-695-254-214;;074-668-310-987-029;;013-122-792-588-081;;197-193-057-828-756;;113-346-509-283-257;;016-221-116-270-759;;145-209-675-614-912;;081-074-583-383-824;;020-140-165-898-622;;001-779-867-387-972;;022-735-509-615-805;;022-179-293-052-569;;013-584-945-188-940;;115-398-566-039-426;;135-447-350-940-622;;052-153-724-747-948;;025-182-641-289-850;;122-644-406-202-233;;079-214-893-487-418;;147-888-721-956-877;;090-247-610-825-843;;166-025-821-402-033;;057-460-007-966-306;;006-463-263-246-432;;006-463-263-246-432;;013-770-850-974-489;;029-890-487-783-799;;041-874-179-970-386;;020-986-423-793-233;;086-751-695-402-863;;127-672-559-644-411;;127-416-339-660-812;;117-522-189-960-276;;124-864-341-496-45X;;006-568-097-103-41X;;093-666-562-457-905;;005-416-473-959-707;;022-983-190-510-755;;152-923-894-609-509;;085-413-318-249-981;;063-455-531-393-728;;045-008-500-970-273;;063-640-752-709-241;;119-897-745-760-544;;066-015-167-169-542;;060-728-367-476-688;;010-097-148-050-263;;052-597-675-128-75X;;062-418-979-939-961;;051-918-569-782-385;;079-083-105-219-723;;042-819-179-681-837;;015-898-381-155-805;;025-253-136-774-180;;032-820-729-763-323;;014-903-975-216-318;;043-030-710-125-973;;051-224-574-304-090;;074-976-826-866-732;;044-695-670-834-937;;048-060-748-635-820;;062-940-851-081-865;;014-507-730-965-260;;083-811-051-643-47X;;023-766-913-246-333;;074-046-354-648-540;;064-453-435-140-293;;055-448-448-628-332;;062-761-744-997-508;;045-623-729-340-346;;088-474-798-925-827;;025-493-244-483-981;;006-319-541-331-383;;070-722-893-617-204;;020-043-570-354-456;;038-551-014-784-214;;049-393-898-856-305;;027-477-313-726-928;;117-415-766-090-626;;036-186-662-918-414;;060-693-602-478-53X;;040-067-479-003-921;;057-629-746-536-175;;005-582-757-921-579;;043-645-889-898-36X;;092-023-577-402-127;;105-316-448-799-614;;033-159-791-900-680;;074-689-687-510-805;;001-256-484-369-395;;024-639-288-749-529;;037-079-580-129-107;;020-766-613-912-972;;074-162-325-116-113;;181-824-611-800-978;;043-201-846-554-690;;044-871-232-135-52X;;054-644-670-291-744;;078-115-905-519-238;;000-879-055-331-49X;;027-989-490-885-638;;033-225-590-843-088,10.1016/j.molimm.2004.05.004;;15302161;;10.1016/j.cell.2015.05.007;;26004070;;pmc4683157;;10.1038/nm.4224;;27820605;;pmc5301914;;27065089;;10.1016/j.coi.2016.03.008;;pmc5203765;;pmc4966639;;10.1080/19420862.2015.1118596;;26652308;;10.1080/19420862.2016.1276683;;28055305;;pmc5384726;;10.4161/19420862.2015.989047;;pmc4622072;;25530082;;10.1111/imm.12838;;pmc5721244;;28898398;;10.1128/9781555817411.ch6;;10.1128/microbiolspec.aid-0028-2014;;26104550;;10.1016/j.ymeth.2017.01.003;;28088364;;10.1038/nbt1137;;16151408;;10.1093/intimm/8.5.765;;8671665;;7481795;;10.1126/science.270.5238.932;;15785203;;10.1089/hyb.2005.24.1;;10.1084/jem.20022125;;12847137;;pmc2196083;;pmc4348009;;10.1056/nejmoa1411087;;25482239;;10.4049/jimmunol.170.2.711;;12517932;;10.1158/1078-0432.ccr-07-4079;;18483370;;10.1016/j.pharmthera.2014.11.017;;25476108;;10.1007/s00262-004-0593-x;;15599732;;14871849;;10.1158/0008-5472.can-03-3259;;8871619;;10.4049/jimmunol.157.8.3250;;10.1200/jco.2008.26.15_suppl.3006;;pmc4834717;;20516446;;10.1200/jco.2009.26.7609;;10.4049/jimmunol.170.3.1257;;12538684;;10.1016/s0075-7535(08)70702-2;;11861596;;10.1146/annurev.immunol.20.091101.091806;;14552835;;10.1016/j.it.2003.08.005;;12947224;;10.1385/ir:28:1:49;;11857337;;10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9;;15122199;;10.1038/nri1349;;10.1006/jmbi.1999.3192;;10543973;;9801349;;10.1128/cdli.5.6.862-870.1998;;pmc96216;;10.1002/eji.1830240409;;8149953;;10.1182/blood-2002-06-1761;;12393541;;10.1177/107327481402100112;;24357746;;pmc40169;;8552677;;10.1073/pnas.93.1.7;;16285013;;10.1002/eji.200535232;;12721664;;10.1007/s00109-003-0430-2;;12091876;;10.1038/nm730;;10581077;;10.1038/70932;;10.1093/protein/11.1.65;;9579662;;9332365;;10.1016/s0378-1119(97)00260-6;;10.1016/s0958-1669(98)80091-8;;9503595;;10.1016/s1535-6108(04)00083-2;;15093539;;10.2210/pdb1s78/pdb;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;18410894;;10.1016/j.bbmt.2008.02.010;;pmc2423190;;11973140;;10.1016/s0952-7915(02)00341-2;;10.1007/bf01561573;;15470033;;10.4049/jimmunol.173.8.4919;;15705911;;10.1158/0008-5472.1089.65.3;;10882809;;10.1016/s0163-7258(00)00052-8;;9930702;;10.1038/16717;;10.1002/j.1460-2075.1992.tb05481.x;;pmc556898;;1396582;;10.1038/78963;;10966641;;10.1073/pnas.192461099;;12218188;;pmc129438;;10.1016/s0165-2478(02)00088-3;;12095712;;15611321;;10.1093/intimm/dxh194;;10.1084/jem.20022235;;12847136;;pmc2196084;;18429302;;9592769;;10.1007/bf02752698;;14530338;;10.4049/jimmunol.171.8.4156;;20139271;;10.4049/jimmunol.0901652;;7581696;;10.1385/0-89603-275-2:171;;10.1161/01.atv.0000145015.23656.e4;;15374847;;10.1158/1078-0432.ccr-04-0428;;15297412;;18059626;;10.1080/02648725.2007.10648092;;10.1089/hyb.1996.15.343;;8913783;;11224527;;10.1038/85330;;10.1126/science.271.5256.1734;;8596936;;10.1038/ni1398;;17013388;;pmc1895332;;10.1182/blood-2005-04-1531;;16020508;;pmc2956066;;20817874;;10.4049/jimmunol.1001536;;16116203;;10.4049/jimmunol.175.5.3133;;19448431;;pmc2737335;;10.4161/cc.8.11.8738;;8159246;;10.1038/368856a0;;10.1182/blood-2005-06-2298;;pmc1895337;;16037385;;10.1182/blood-2004-07-2561;;15486062;;10.1016/j.clim.2014.02.015;;24631965;;pmc4082337;;9277127;;15352422;;10.1191/0961203303lu1052oa;;10.1126/science.291.5502.319;;11209085;;10.1016/s1074-7613(00)80089-8;;10485649;;9796923;;10.1093/intimm/10.10.1563;;17404099;;10.1158/1078-0432.ccr-06-2746;;12413529;;10.1016/s0952-7915(02)00398-9;;pmc61133;;10.1073/pnas.231486598;;11698646;;9376601;;10.1182/blood.v90.8.3179;;10.4049/jimmunol.169.11.6546;;12444166;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;10.1038/nrc3239;;pmc4856023;;22437870;;10.1007/3-540-30683-8_443;;11329858;;10.1016/s0065-3233(01)56010-6;;22740686;;10.1126/scisignal.2002796;;pmc5498435;;23732914;;pmc3753920;;10.1128/mcb.00319-13;;pmc3552912;;23032366;;10.4161/cc.22135;;11964291;;10.1182/blood.v99.9.3256;;14764622;;10.1093/hmg/ddh076;;15353480;;10.1182/blood-2004-04-1596;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1084/jem.20022119;;12847138;;pmc2196082;;10.1006/gyno.2000.6040;;11161852;;7851902;;10.1006/geno.1994.1562;;11114643;;10.1067/msy.2000.110430;;10.1182/blood.v97.6.1809;;11238124;;15172969;;10.1182/blood-2004-01-0039;;10.1084/jem.181.6.1953;;7539033;;pmc2192041;;1404388;;10.1016/0022-2836(92)90223-7;;23847336;;10.1158/2159-8290.cd-nd2013-016;;22658127;;pmc3544539;;10.1056/nejmoa1200690;;pmc2898650;;19225609;;10.1039/b819720b;;11470598;;10.1016/s1367-5931(00)00216-7;;10.1080/01971520009349530;;10929883;;10.1016/0167-5699(89)90140-0;;2478146;;10.1016/s0167-5699(97)80025-4;;9190115;;10.1200/jco.2013.51.4802;;24145345;;pmc3837092;;10.1016/0959-440x(93)90210-c;;10.1056/nejmoa1302369;;23724867;;pmc5698004;;17898045;;10.1093/intimm/dxm091;;10.1074/jbc.m307776200;;12952958;;12421930;;10.4049/jimmunol.169.10.5538;;10.1074/jbc.m105072200;;11805085;;15030777;;10.1016/s1074-7613(04)00051-2;;18500231;;10.1038/nri2326,"Damschroder et al. Molecular Immunology (2004) 41: 985-1000.;;Khan et al. Sci. Rep. (2017) 7, 45163; doi: 10.1038/srep45163 (12 pages).;;Zhu et al. Cell (2015) 161: 1280-1292.;;Lee et al. Nature Medicine (2016) 22: 1456-1464.;;Boyd et al. Current Opinion in Immunology 2016, 40: 103-109.;;Abdiche et al. mAbs (2016) 8: 264-277.;;Konitzer et al. mAbs (2017) 9: 536-549.;;Ferrara et al. mAbs (2015) 7: 32-41.;;Parola et al. Immunology (2018) 153: 31-41.;;Van Regenmortel MHV. Front. Immunol. (2018) vol. 8, Article 2009 (11 pages).;;Sheehan et al. Microbiol. Spectr. (2015) 3(1): AID-0028-2014; 17 pages.;;Conroy et al. Methods (2017) 116: 12-22.;;Abbas, A.K., et al., Cellular and Molecular Immunobiology, 2nd ed., pp. 8, 47-50, W.B. Saunders Company, United States (1991).;;“About the Internet Archive: General Information,” Internet Archive, 2001, 10 pages, retrieved online from http://www.archive.org/about/about.php on Apr. 5, 2011.;;Adams, G.P. and Weiner, L.M., “Monoclonal Antibody Therapy of Cancer,” Nature Biotechnology 23(9):1147-1157, Nature Publishing Group, United States (2005) (D23 as cited in Opposition of EP 2173379).;;Affidavit of Christopher Butler, Apr. 23, 2014, 8 pages.;;Affinity purified anti-mouse PD-1 (PD1): Archived website information for J43 and J116 antibodies; eBioscience and Waybackmachine/org 2002, accessed on Jun. 14, 2011, 4 pages, accessed from http://web.archive.org/web/20020301031217 and http://ebioscience/specs/antibody14/14-9985.;;Agata, Y., et al., “Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes,” International Immunology 8(5):765-772, Oxford University Press, England (1996).;;Alignment of Amino Acid Sequences for Extracellular Domain of Wild-Type (UniProt Q15116) Human PD-1, Wild-Type (MednaBio) PD-1 ECD, C62S Variant of Wild-Type Human PD-1 ECD, and A101L Variant of Wild-Type Human PD-1 ECD, 1 page, submitted with Opposition to EP Pat. No. 2161336 on Apr. 30, 2014.;;Allison, J.P. and Krummel, M.F., “The Yin and Yang of T Cell Costimulation,” Science 270(5238):932-933, American Association for the Advancement of Science, United States (1995).;;Allison, J.P.,et al., “CTLA-4 Blockade in Tumor Immunotherapy,” inPrinciples and Practice of the Biologic Therapy of Cancer, 3rd edition, Rosenberg, S.A., ed., pp. 890-895, Lippincott Williams & Wilkins, Philadelphia, United States (2000).;;Amended Answer, E.R. Squibb & Sons L.L.C. and Bristol-Myers Squibb Co., C.A. No. 1:15-cv-13443-MLW, United States District Court for the District of Massachusetts, Feb. 3, 2016, 15 pages.;;Amended Answer, Tasuku Honjo, C.A. No. 1:15-cv-13443-MLW, United States District Court for the District of Massachusetts, Feb. 3, 2016, 15 pages.;;Amended Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Nov. 21, 2014, 11 pages.;;Andre, E., et al., “Precise Characterization of the Epitope Recognized by a Monoclonal Antibody Against Escherichia coli RNA Polymerase,” Hybridoma 24(1):1-5, Mary Ann Liebert, Inc., United States (2005).;;Ansari, M.J., et al., “The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice,” The Journal of Experimental Medicine 198(1):63-69, The Rockefeller University Press, United States (2003).;;Ansell, S.M., et al., “PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma,” The New England Journal of Medicine 372(4):311-319, Massachusetts Medical Society, United States (Jan. 22, 2015).;;Answer to Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Oct. 31, 2014, 15 pages.;;Answer to Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Mar. 31, 2016, 16 pages.;;Answer to Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Mar. 31, 2016, 16 pages.;;Answer to Plaintiffs' Amended Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Dec. 8, 2014, 17 pages.;;Answering Brief including exhibits A, B and C, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Sep. 25, 2015, 70 pages.;;Answering Brief including exhibits A, B and C, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Sep. 25, 2015, 70 pages.;;Anti-Human CD279 (PD-1) Datasheet, 14-2799, J105, eBioscience, Sep. 6, 2013, 1 page.;;Anti-Human CD279 (PD-1) Datasheet, 14-9989, J116, eBioscience, Sep. 6, 2013, 1 page.;;Anti-Human CD279 (PD-1) Purchase Receipts, eBioscience, Oct. 8, 2013, 4 pages.;;Antonia, S.J., et al., “Association of tumor PD-L1 Expression and Immune Biomarkers with Clinical Activity in Patients with Non-small Cell Lung Cancer (NSCLC) Treated with Nivolumab (Anti-PD-1; BMS-936558; ONO-4538),” 15th World Conference on Lung Cancer, Sydney, Australia, 15th WCLC: Best of Posters 1—IASLC Selection, P2.11-035, Oct. 27-30, 2013, accessed at http://web.oncoletter.ch/kongressberichte-videos-slides-Onkologie/id-15th-world-conference-on-lung-cancer-conference/conference-highlights.html, accessed on Jan. 8, 2015, 6 pages.;;Appendix to Declaration of Vassiliki A. Boussiotis, Apr. 28, 2014, Data and Records for Example Experiments 21 and 22, 18 pages.;;Approved Judgment before Mr. Justice Birss, Case Nos. HP-2014-0000388 and HP14 A 02748, Merck vs. Ono, dated Oct. 22, 2015, Royal Courts of Justice, London, England, 57 pages.;;Armand, P., et al., “289 Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma—Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study,” 56th ASH Annual Meeting and Exposition, Abstracts & Program, San Francisco, CA, Dec. 6-9, 2014.;;Bennett, F., et al., “Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses,” The Journal of Immunology 170(2):711-718, The American Association of Immunologists, United States (2003).;;Berg, J.M., et al., “The Immune System,” in Biochemistry 5th ed., pp. 921-950, W.H. Freeman and Company, United States (2002).;;Berger, R., et al., “Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies,” Clinical Cancer Research 14(10):3044-3051, American Association for Cancer Research, United States (2008).;;Berman, D., et al., “The Development of Immunomodulatory Monoclonal Antibodies as a New Therapeutic Modality for Cancer: The Bristol-Myers Squibb Experience,” Pharmacology and Therapeutics 148:132-153, Elsevier, Inc., England (Apr. 2015).;;Biacore, “Application Note 1: Characterization of monoclonal antibody epitope specificity using Biacore's SPR technology,” Biacore AB, 8 pages (2002).;;Biacore, Sensor Surface Handbook, BR-1005-71, edition AB, pp. 1-98, GE Healthcare (2005).;;Biacore, “The SPR signal,” “Interpreting experimental data,” and “BIA application areas,” in BIAtechnology Handbook, version AB, chapters 4-6, 34 pages, Biacore AB (1998).;;Blank, C., et al., “Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy,” Cancer Immunology Immunotherapy 54(4):307-314, Springer-Verlag, Germany (2005).;;Blank, C., et al., “PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells,” Cancer Research 64(3):1140-1145, American Association for Cancer Research, United States (2004).;;Blazar, B.R., et al., “Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells,” The Journal of Immunology 157(8):3250-3259, The American Association of Immunologists, United States (1996).;;Brahmer., J.R., et al., “Safety and activity of MDX-1106 (ONO-4538) anti-PD-1 monoclonal antibody in patients with selected refractory or relapsed malignancies,” Journal of Clinical Oncology 26:Abstract No. 3006, American Society of Clinical Oncology, United States (2008).;;Brahmer., J.R., et al., “Phase I Study of Single-agent Anti-programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates,” Journal of Clinical Oncology 28(19):3167-3175, American Society of Clinical Oncology, United States (2010).;;Brief Supporting Motion to Dismiss, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Aug. 21, 2015, 25 pages.;;Brief Supporting Motion to Dismiss, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjov. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Aug. 28, 2015, 24 pages.;;Brown, J.A., et al., “Blockade of PD-1 ligands on dendritic cells enhances T cells activation and cytokine production,” FASEB Journal 16(4):A710-517.4, Federation of American Societies for Experimental Biology, United States (2002).;;Brown, J.A., et al., “Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production,” The Journal of Immunology 170(3):1257-1266, The American Association of Immunologists, United States (2003).;;Brown, J.A., et al., “Expression and functional consequences of PD-1 ligands on natural APCS and tumors,” The FASEB Journal 15(4):A345 (abstract No. 275.23), Federation of American Societies for Experimental Biology, United States (2001).;;Campbell, A.M., “Characterisation of monoclonal antibodies,” in Laboratory Techniques in Biochemistry and Molecular Biology, Monoclonal Antibody Technology: The Production and Characterization of Rodent and Human Hybridomas, vol. 13, pp. 186-215, Elsevier, The Netherlands (1984).;;Carreno, B.M. and Collins, M., “The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses,” Annual Review of Immunology 20:29-53, Annual Reviews, United States (2002).;;Carreno, B.M., “BTLA: a new inhibitory receptor with a B7-like ligand,” Trends in Immunology 24(10):524-527, Elsevier, England (2003).;;Carter, L.L. and Carreno, B.M., et al., “Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation,” Immunologic Research 28(1):49-59, Humana Press, United States (2003).;;Carter, L.L., et al., “PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2,” European Journal of Immunology 32(3):634-643, WILEY-VCH Verlag GmbH, German (2002).;;CD279/PD-1, D132-3/J110 Datasheet, MBL Medical & Biological Laboratories Co., Ltd., Sep. 6, 2013, 2 pages.;;Chen, L., “Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity,” Nature Reviews Immunology 4(5):336-347, Nature Publishing Group, England (2004).;;Chen, Y., et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,” Journal of Molecular Biology 293(4):865-881, Academic Press, England (1999).;;Claim Construction Answering Brief filed by Bristol-Myers Squibb Co., E. R. Squibb & Sons, L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo, including exhibits A through I, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:14-cv-01131-GMS, United States District Court for the District of Delaware, Mar. 28, 2016, 98 pages.;;Claim Construction Answering Brief filed by Bristol-Myers Squibb Co., E. R. Squibb & Sons, L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo, including exhibits A through I, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Mar. 28, 2016, 98 pages.;;Claim Construction Answering Brief filed by Bristol-Myers Squibb Co., E. R. Squibb & Sons, L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo, including exhibits A through I, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Mar. 28, 2016, 98 pages.;;Claim Construction Answering Brief filed by Merck & Co., Inc. and Merck Sharp & Dohme Corp., including exhibit 1, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:14-cv-01131-GMS, United States District Court for the District of Delaware, Mar. 28, 2016, 30 pages.;;Claim Construction Answering Brief filed by Merck & Co., Inc. and Merck Sharp & Dohme Corp., including exhibit 1, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Mar. 28, 2016, 30 pages.;;Claim Construction Answering Brief filed by Merck & Co., Inc. and Merck Sharp & Dohme Corp., including exhibit 1, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Mar. 28, 2016, 30 pages.;;Claim Construction Chart, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:14-cv-01131-GMS, United States District Court for the District of Delaware, Feb. 5, 2016, 21 pages.;;Claim Construction Chart, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Feb. 5, 2016, 21 pages.;;Claim Construction Chart, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Feb. 5, 2016, 21 pages.;;Clark, M.R., “Antibody engineering IgG effector mechanisms,” Chemical Immunology 65:88-110 (1997), reprint from http://www.path.cam.ac.ukfmrc7 /publications/reprints/PP 1997CI6588.pdf.;;Cloeckaert, A., et al., “O-Polysaccharide epitopic heterogeneity at the surface of Brucella spp. studied by enzyme-linked immunosorbent assay and flow cytometry,” Clinical and Diagnostic Laboratory Immunology 5(6):862-870, American Society for Microbiology, United States (1998).;;Communication from the Japanese Patent Office dated Jul. 4, 2012, in Japanese application No. 2009-203514.;;Communication pursuant to Article 94(3) EPC for EP Application No. 10161767.8, European Patent Office, Netherlands, dated Oct. 5, 2010.;;Communication pursuant to Article 94(3) EPC, dated Apr. 23, 2014, in EP Application No. 06786260.7.;;Communication pursuant to Article 94(3) EPC dated Dec. 22, 2014, in European Application No. 11 178 187.8-1410, European Patent Office, Germany.;;Communication pursuant to Article 94(3) EPC dated Dec. 22, 2014, in European Application No. 11 178 191.0-1410, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, dated Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178187, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, dated Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178188, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, dated Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178191, European Patent Office, Germany.;;Communication pursuant to Article 94(3) EPC and Pending Claims for EP Application No. 10075561.1, European Patent Office, Germany, dated Jun. 2, 2015, 5 pages.;;Complaint, Bristol-Myers Squibb Co. and Ono Pharmaceutical Co., Ltd. v. Merck & Co., Inc., 1:14-cv-01131-GMS, filed Sep. 4, 2014, 9 pages.;;Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Jun. 30, 2015, 49 pages.;;Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Case 1:15-cv- 0572-GMS, United States District Court for the District of Delaware, Jul. 7, 2015, 48 pages.;;Complaint, Dana-Farber Cancer Institute, Inc. v. Ono Pharmaceutical Co., Ltd., Tasuku Honjo, E.R. Squibb & Sons, L.L.C., and Bristol-Myers Squibb Co., 1:15-cv-13443-GMS, United States District Court for the District of Massachusetts, filed Sep. 25, 2015, 16 pages.;;Complaint for Declaratory Judgment, Merck Sharp & Dohme Corp. v. Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., and Ono Pharmaceutical Co., Ltd., C.A. No. 2:33-av-00001, United States District Court for the District of New Jersey, Apr. 15, 2016, 21 pages.;;Co-pending U.S. Appl. No. 15/000,863, inventors Honjo, T.et al., filed Jan. 19, 2016 (Not Published).;;Co-pending U.S. Appl. No. 15/000,869, inventors Honjo, T.et al., filed Jan. 19, 2016 (Not Published).;;Cox, J.P., et al., “A Directory of Human Germ-line V kappa Segments Reveals a Strong Bias in their Usage,” European Journal of Immunology 24(4):827-836, Verlag Chemie GmbH, Germany (1994).;;Cragg, M.S., et al., “Complement-mediated Lysis by Anti-CD20 mAb Correlates with Segregation into Lipid Rafts,” Blood 101(3):1045-1052, American Society of Hematology, United States (2003).;;Creelan, B.C., “Update on Immune Checkpoint Inhibitors in Lung Cancer,” Journal of the Moffitt Cancer Center 21(1):80-89, H. Lee Moffitt Cancer Center and Research Institute, United States (2014).;;Cruse, J.M. and Lewis, R.E., “Antigens and Immunogens,” in Atlas of Immunology, 2nd ed., pp. 105-126, CRC Press, United States (2004).;;Curriculum Vitae of Brian T. Fife, Ph.D., 7 pages, submitted with Response to Oppositions against EP Pat. No. 2161336 on Feb. 16, 2015.;;Curriculum Vitae of Dr. Robert J. Bloch, Apr. 11, 2012, 34 pages, submitted with Opposition to EP Pat. No. 2161336.;;Curriculum Vitae of Vassiliki A. Boussiotis, Nov. 8, 2013, 24 pages, submitted with Opposition to EP Pat. No. 2161336.;;Davies, D.R. and Cohen, G.H., “Interactions of protein antigens with antibodies,” Proceedings of the National Academy of Sciences USA 93(1):7-12, National Academy of Sciences, United States (1996).;;Declaration of Andrew C. Mayo, Aug. 21, 2015, 2 pages.;;Declaration of Andrew C. Mayo including exhibits 12-13, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Oct. 14, 2015, 73 pages.;;Declaration of Andrew C. Mayo including exhibits 12-13, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., Civil Action No. 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Oct. 14, 2015, 73 pages.;;Declaration of Dr. Andrea Van Elsas, including Annex A and B, Apr. 29, 2014, 17 pages.;;Declaration of Dr. Haidong Dong, Mar. 31, 2014, 15 pages, submitted with Opposition to EP Pat. No. 1537878.;;Declaration of Dr. Jennifer Mataraza, Apr. 28, 2014, 11 pages.;;Declaration of Dr. Robert J. Bolch, including 2 Annex and 39 exhibits, Apr. 29, 2014, 82 pages.;;Declaration of Dr. Ulrich von Andrian including exhibits A through H, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp, C.A. No. 1:14-cv-01131-GMS, United States District Court for the District of Delaware, Feb. 25, 2016, 437 pages.;;Declaration of Dr. Ulrich von Andrian including exhibits A through H, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 1:14-cv-01131-GMS, United States District Court for the District of Delaware, Mar. 24, 2016, 438 pages.;;Declaration of Dr. Ulrich von Andrian including exhibits A through H, BBristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp, C.A. No. 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Feb. 25, 2016, 437 pages.;;Declaration of Dr. Ulrich von Andrian including exhibits A through H, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Mar. 24, 2016, 438 pages.;;Declaration of Dr. Ulrich von Andrian including exhibits a through H, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Feb. 25, 2016, 437 pages.;;Declaration of Dr. Ulrich von Andrian including exhibits a through H, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Mar. 24, 2016, 438 pages.;;Declaration of James L. Riley, Ph.D., Aug. 10, 2015, 6 pages, submitted with Response to Grounds of Appeal, in European Patent No. EP 1537878.;;Declaration of John G. Day, Aug. 28, 2015, 2 pages.;;Declaration of Professor Brian T. Fife, Feb. 12, 2015, 4 pages, submitted with Response to Oppositions against EP Pat. No. 2161336.;;Declaration of Vassiliki A. Boussiotis, Apr. 28, 2014, 15 pages.;;Defendant Tasuku Honjo's Answer, Dana-Farber Cancer Institute, Inc. v. Ono Pharmaceutical Co., Ltd., Tasuku Honjo, E.R. Squibb & Sons L.L.C., and Bristol-Myers Squibb Co., Civil Action No. 1:15-cv-13443-MLW, United States District Court for the District of Massachusetts, Dec. 21, 2015, 15 pages.;;Defendants E.R. Squibb & Sons, L.L.C., and Bristol-Myers Squibb, Co.'s Answer, Dana-Farber Cancer Institute, Inc. v. Ono Pharmaceutical Co., Ltd., Tasuku Honjo, E.R. Squibb & Sons L.L.C., and Bristol-Myers Squibb Co., Civil Action No. 1:15-cv-13443-MLW, United States District Court for the District of Massachusetts, Dec. 21, 2015, 15 pages.;;Defendants' Claim Construction Opening Brief, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 1:14-cv-01131-GMS, United States District Court for the District of Delaware, Feb. 25, 2016, 23 pages.;;Defendants' Claim Construction Opening Brief, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 1:15-cv-00560-GMS, United States District Court for the District of Delaware, Feb. 25, 2016, 23 pages.;;Defendants' Claim Construction Opening Brief, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 1:15-cv-00572-GMS, United States District Court for the District of Delaware, Feb. 25, 2016, 23 pages.;;Del Rio, M-L., et al., “Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation,” European Journal of Immunology 35(12):3545-3560, Wiley-VCH Verlag GmbH & Co. KGaA, Germany (2005).;;Dong, H. and Chen, L., “B7-H1 pathway and its role in the evasion of tumor immunity,” Journal of Molecular Medicine 81(5):281-287, Springer, Germany (2003).;;Dong, H., et al., “Tumor-associated B7-H1 Promotes T-cell Apoptosis: A Potential Mechanism of Immune Evasion,” Nature Medicine 8(8):793-800, Nature Publishing Company, United States (2002).;;Dong, H., et al., “B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,” Nature Medicine 5(12):1365-1369, Nature America, United States (1999).;;Dougan, D.A., et al., “Effects of substitutions in the binding surface of an antibody on antigen affinity,” Protein Engineering 11(1):65-74, Oxford University Press, England (1998).;;eBioscience, Information Sheet, “Anti-Human CD279 (PD-1) Functional Grade Purified: Murine anti-PD-1 antibody J116,” 2000, 2 pages.;;Email from MednaBio to Robert Bloch re: E1951MG1-Sequence Information, Apr. 25, 2014, 1 page.;;EP Application No. 03741154.3 Notice of Opposition dated Jul. 8, 2011, issued by the EPO in the name of Ono Pharmaceutical Co., Ltd. et al.;;EP Publication No. 1576014, Excerpt from Register of European Patents, retrieved online from https://register.epo.org/espacenet/application?number=EP03780521 accessed on May 27, 2011.;;European Office Action dated Aug. 18, 2011, in European Patent Application No. 10172772.5, Ono Pharmaceutical Co., Ltd.;;Exhibit 1 “Human anti-PD-1 antibodies: binding to PD-1, cross-competition with 5C4 and affinity to PD-1,” 6 pages, in Notice of Opposition mailed Apr. 29, 2014, in EP Patent No. EP 2161336, 4-Antibody AG filed May 2, 2006.;;Exhibit 1, “Dichotomy of the activity of PD-L1 (B7-4) and how an anti-PD-1 antibody fits into it,” in Response to Patentee's Aug. 12, 2015 Reply, dated Dec. 21, 2015 for European Patent No. EP 1537878, filed Jul. 2, 2003, 1 page.;;ExPASy Bioinformatics Resource Portal calculation based on ECD of UniProt Sequence Q15116, accessed at http://web.expasy.org/cgi-bin/compute_pi/pi_tool, accessed on Apr. 28, 2014, 1 page.;;Extended European Search Report for EP Application No. 06746353.9, European Patent Office, Germany, dated Mar. 6, 2009.;;Extended European Search Report for EP Application No. 09013687.0, European Patent Office, Germany, dated Jan. 29, 2010.;;Extended European Search Report for EP Application No. 10161767.8, European Patent Office, Netherlands, dated Jun. 7, 2010.;;Extended European Search Report for EP Application No. 10172772.5, European Patent Office, Netherlands, dated Sep. 9, 2010.;;Extended European Search Report for EP Application No. 11178187.8, European Patent Office, Germany, dated Jun. 1, 2012.;;Extended European Search Report for EP Application No. 11178188.6, European Patent Office, Germany, dated Jun. 27, 2013.;;Extended European Search Report for EP Application No. 11178191.0, European Patent Office, Germany, dated Sep. 5, 2012.;;Finger, L.R., et al., “The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors,” Gene 197(1-2):177-187, Elsevier, United States (1997).;;Fivash, M., et al., “BIAcore for macromolecular interaction,” Current Opinion in Biotechnology 9(1):97-101, Current Biology, England (1998).;;Franklin, M.C., et al., “Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex,” Cancer Cell 5(4):317-328, Cell Press, United States (2004).;;Freeman, G.J., et al., “Engagement of the PD-1 Immunoinhibitory by a Novel B7-Family Member Leads to Negative Regulation of Lymphocyte Activation,” Blood 96(11):810a-811a, (Abstract No. 3502) (2000).;;Freeman, G.J., et al., “Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation,” The Journal of Experimental Medicine 192(7):1027-1034, The Rockefeller University Press, United States (2000).;;Ge, X., et al., “CD134-Allodepletion Allows Selective Elimination of Alloreactive Human T Cells without Loss of Virus-Specific and Leukemia-Specific Effectors,” Biology of Blood and Marrow Transplantation 14(5):518-530, American Society for Blood and Marrow Transplantation, United States (2008).;;Greenspan, N.S., “Epitopes, paratopes and other topes: do immunologists know what they are talking about?” Bulletin de l'Institut Pasteur 90(4):267-279, Elsevier, France (1992).;;Greenwald, R.J., et al., “Negative Co-receptors on Lymphocytes,” Current Opinion in Immunology 14(3):391-396, Elsevier Science Ltd., England (Jun. 2002).;;Hansen, J.A., et al., “Monoclonal Antibodies Identifying a Novel T-Cell Antigen and la Antigens of Human Lymphocytes,” Immunogenetics 10:247-260, Springer-Verlag (1980).;;Harlow, E. and Lane, D., “Using Antibodies: A Laboratory Manual,” Cold Spring Harbor Laboratory Press, Cold Spring Harbor, United States various pages (1999).;;He, Y-F., et al., “Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine,” The Journal of Immunology 173(8):4919-4928, The American Association of Immunologists, United States (2004).;;Hirano, F., et al., “Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity,” Cancer Research 65(3):1089-1096, American Association for Cancer Research, United States (2005).;;Honjo, T., et al., Deposit receipt for Accession No. FERM BP-8392 mentioned in EP-A1537878, Jun. 5, 2003, 1 page.;;Huang, Z., “Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis,” Pharmacology & Therapeutics 86(3):201-215, Pergamon Press, England (2000).;;Hutloff, A., et al., “ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28,” Nature 397(6716):263-266, Nature Publishing Group, England (1999).;;International Preliminary Report on Patentability for International Application No. PCT/JP2006/309606, The International Bureau of WIPO, Switzerland, dated Nov. 13, 2007.;;International Search Report for International Application No. PCT/JP03/08420, Japanese Patent Office, Japan, dated Oct. 21, 2003.;;International Search Report for International Application No. PCT/JP2006/309606, Japanese Patent Office, Japan, dated Aug. 15, 2006.;;Ishida, Y., et al., “Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death,” The EMBO Journal 11(11):3887-3895, Oxford University Press, England (1992).;;Ishima, R. and Torchia, D.A., “Protein Dynamics from NMR,” Nature Structural Biology 7(9):740-743, Nature Publishing Company, United States (2000). et al.",ACTIVE
127,JP,A,JP 2020072712 A,029-210-930-633-401,2020-05-14,2020,JP 2020000605 A,2020-01-07,US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"To provide an isolated monoclonal antibody, particularly human monoclonal antibody, that specifically binds to PD-L1 with high affinity.SOLUTION: A method for preparing an anti-PD-L1 antibody comprises: (a) providing a heavy chain variable region antibody sequence including a specific CDR3 sequence, and/or a light chain variable region antibody sequence including a specific CDR3 sequence; (b) altering at least one amino acid residue within the heavy chain variable region antibody sequence and/or the light chain variable region antibody sequence to create at least one altered antibody sequence; and (c) expressing the altered antibody sequence as a protein.SELECTED DRAWING: Figure 47",E R SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/029-210-930-633-401,Patent Application,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C12N15/13;;A01K67/027;;A61K39/00;;A61K39/02;;A61K39/12;;A61K39/395;;A61K41/00;;A61K45/00;;A61K47/68;;A61K51/10;;A61P1/02;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/02;;C12N15/63,,0,0,,,,PENDING
128,US,B2,US 8383796 B2,107-038-073-941-615,2013-02-26,2013,US 201113091936 A,2011-04-21,US 201113091936 A;;US 91772706 A;;US 2006/0026046 W;;US 69642605 P,2005-07-01,Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",MEDAREX INC;;KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30),https://lens.org/107-038-073-941-615,Granted Patent,yes,38,301,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07H21/04,536/23.1,29,21,027-960-937-319-909;;009-746-604-420-355;;116-193-705-533-609;;045-556-293-127-132;;063-455-531-393-728;;011-092-736-500-72X;;039-555-401-046-267;;067-760-343-772-225;;022-179-293-052-569;;040-950-450-163-406;;009-746-604-420-355;;119-897-745-760-544;;062-761-744-997-508;;116-193-705-533-609;;027-477-313-726-928;;092-023-577-402-127;;050-992-361-999-488;;022-046-054-886-073;;047-951-914-695-080;;074-067-544-364-744;;013-122-792-588-081,10.1006/jmbi.2000.3512;;10677285;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;10.1016/s1074-7613(00)00006-6;;10933393;;14530338;;10.4049/jimmunol.171.8.4156;;10.1021/ja00084a073;;10.1073/pnas.92.7.2529;;pmc42251;;7708679;;14871849;;10.1158/0008-5472.can-03-3259;;10.1002/eji.1830240409;;8149953;;8752924;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;10.1161/01.atv.0000145015.23656.e4;;15374847;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;1404388;;10.1016/0022-2836(92)90223-7;;12520872;;10.1080/02648725.2002.10648023;;pmc127659;;11796590;;10.1128/iai.70.2.612-619.2002;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nature04444;;16382236;;10.4049/jimmunol.170.3.1257;;12538684,"Beiboer et al., J. Mol. Biol. (2000), 296: 833-849.;;Klimka et al., British Journal of Cancer (2000), 83: 252-260.;;Rader et al., Proc. Natl. Acad. Sci. USA (1998), 95: 8910-8915.;;Xu et al., Immunity (2000), 13: 37-45.;;Kanai et al., ""Blockade of B7-H1 suppresses the development of chronic intestinal inflammation"", J. Immunol., (2003); 171:4156-4163.;;U.S. Appl. No. 11/917,727, filed Jun. 9, 2008.;;U.S. Appl. No. 11/917,727, filed Jun. 8, 2010 Non-Final Office Action.;;U.S. Appl. No. 11/917,727, filed Sep. 8, 2010 Response to Non-Final Office Action.;;U.S. Appl. No. 11/917,727, filed Oct. 22, 2010 Final Office Action.;;U.S. Appl. No. 11/917,727, filed Dec. 21, 2010 Response to Final Office Action.;;U.S. Appl. No. 11/917,727, filed Jan. 4, 2011 Notice of Allowance.;;Barbas et al., ""Recognition of DNA SyntheticAntibodies""; J. Am. Chem.Soc.; (1994); 116:2161-2162.;;Barbas et al., ""Human Autoantibody Recognition of DNA""; Proc. Natl. Acad. Sci. USA; (Mar. 1995); 92:2529-2533.;;Beiboer et al., J. Mol. Biol. (2000); 296:833-849.;;Blank et al., ""PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells""; Cancer Research; (2004); 64:1140-1145.;;Cox et al., ""A directory of human germ-line Vkappa segments reveals a strong bias in their usage""; Eur. J. Immunol.; (1994); 24:827-836.;;Ditzel et al., ""Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection"", J. of Immunology (1996); 157; 739-749.;;Klimka et al., British J. of Cancer (2000); 83(2):252-260.;;Koga et al., ""Blockade of the Interaction Between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts""; Arterioscler. Thromb. Vasc. Biol.; (2004); 24(11):2057-2062.;;Panka et al., Proc. Natl. Acad. Sci. USA (1988); 85:3080-3084.;;Rader et al., PNAS USA (1998); 95:8910-8915.;;Rudikoff et al., Proc. Natl. Acad. Sci. USA (1982); 79:1979-1983.;;Tomlinson et al. ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops""; J. Mol. Biol.; (1992); 227:776-798.;;Xu et al., Immunity (2000); 13:37-45.;;Ishida et al., ""TransChromo Mouse"", Biotechnology & Genetic Engineering Reviews, 19: 73-82, 2002.;;Mukherjee et al., ""Human Stx2-Specific Monoclonal Antibodies Prevent Systemic Complications of Escherichia coli O157:H7 Infection"", Infection and Immunity, 70(2): 612-619, 2002.;;Tomizuka et al., ""Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing 1g heavy and kappa loci and expression of fully human antibodies"", Proceedings of the National Academy of Sciences of USA, 97(2):723-727, 2000.;;Barber et al., ""Restoring function in exhausted CD8 T cells during chronic viral infection"", Nature: International Weekly Journal of Science, Nature Publishing Group, 439(7077):682-687, Feb. 2006.;;Brown et al., ""Blockade of programmed death-1 ligands om dendritic cells enhances T cell activation and cytokine production"", Journal of Immunology, American Association of Immunologists, 170(3):1257-1266, Feb. 2003.",ACTIVE
129,RS,B1,RS 54271 B1,143-698-462-388-963,2016-02-29,2016,RS P20150648 A,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"Monoklonsko antitelo, ili njegov deo koji vezuje antigen, koji se specifično vezuje za PD-L1, koje sadrži:(a) CDR1 varijabilnog regiona teškog lanca koji sadrži aminokiseline koje imaju sekvencu datu u SEQ ID NO:22;(b) CDR2 varijabilnog regiona teškog lanca koji sadrži aminokiseline koje imaju sekvencu datu u SEQ ID NO:32;(c) CDR3 varijabilnog regiona teškog lanca koji sadrži aminokiseline koje imaju sekvencu datu u SEQ ID NO:42;(d) CDR1 varijabilnog regiona lakog lanca koji sadrži aminokiseline koje imaju sekvencu datu u SEQ ID NO: 52;(e) CDR2 varijabilnog regiona lakog lanca koji sadrži aminokiseline koje imaju sekvencu datu u SEQ ID NO:62;i(f) CDR3 varijabilnog regiona lakog lanca koji sadrži aminokiseline koje imaju sekvencu datu u SEQ ID NO:72.Prijava sadrži još 31 patentni zahtev.",SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/143-698-462-388-963,Granted Patent,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A61K39/00,,0,0,,,,ACTIVE
130,PL,T5,PL 2161336 T5,054-889-214-320-201,2017-10-31,2017,PL 09013687 T,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;EP 09013687 A;;EP 06746353 A,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/054-889-214-320-201,Unknown,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,PENDING
131,SG,A1,SG 163554 A1,061-538-103-789-436,2010-08-30,2010,SG 2010047355 A,2006-06-30,US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-LI with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-LI, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-LI antibodies. FIGURE 47",MEDAREX INC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/061-538-103-789-436,Patent Application,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,,,0,0,,,,PENDING
132,CA,C,CA 3018525 C,099-675-432-742-372,2023-08-01,2023,CA 3018525 A,2006-06-30,US 69642605 P;;CA 2612241 A,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/099-675-432-742-372,Granted Patent,no,0,0,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A01K67/027;;A61K39/395;;A61P35/00;;A61P37/02;;C07K16/46;;C12N5/16;;C12N15/13;;C12P21/08,,0,0,,,,PENDING
133,US,B2,US 8779105 B2,116-314-428-743-322,2014-07-15,2014,US 201113210137 A,2011-08-15,US 201113210137 A;;US 91321709 A;;JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Monoclonal antibodies to programmed death 1 (PD-1),"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN;;MEDAREX LLC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;ONO PHARMACEUTICAL CO. LTD (2007-12-27);;MEDAREX INC (2012-04-12),https://lens.org/116-314-428-743-322,Granted Patent,yes,55,367,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/00;;C07K16/18,530/388.1,99,60,045-008-500-970-273;;086-751-695-402-863;;004-728-346-095-981;;076-092-237-434-500;;049-336-842-920-389;;067-760-343-772-225;;076-731-232-972-252;;013-122-792-588-081;;081-074-583-383-824;;022-179-293-052-569;;122-644-406-202-233;;025-182-641-289-850;;090-247-610-825-843;;006-463-263-246-432;;041-874-179-970-386;;020-986-423-793-233;;127-416-339-660-812;;117-522-189-960-276;;006-568-097-103-41X;;093-666-562-457-905;;005-416-473-959-707;;119-897-745-760-544;;066-015-167-169-542;;052-597-675-128-75X;;032-820-729-763-323;;044-695-670-834-937;;062-940-851-081-865;;048-060-748-635-820;;074-046-354-648-540;;023-766-913-246-333;;062-761-744-997-508;;038-551-014-784-214;;027-477-313-726-928;;117-415-766-090-626;;060-693-602-478-53X;;043-645-889-898-36X;;092-023-577-402-127;;020-766-613-912-972;;044-871-232-135-52X;;006-463-263-246-432;;055-448-448-628-332;;057-629-746-536-175;;122-644-406-202-233;;014-507-730-965-260;;078-115-905-519-238;;051-040-695-254-214;;127-672-559-644-411;;107-581-406-479-794;;113-346-509-283-257;;062-418-979-939-961;;088-474-798-925-827;;022-983-190-510-755;;027-748-683-255-715;;016-221-116-270-759;;020-140-165-898-622;;145-209-675-614-912;;063-640-752-709-241;;027-989-490-885-638;;023-222-320-518-73X;;022-735-509-615-805,20139271;;10.4049/jimmunol.0901652;;15705911;;10.1158/0008-5472.1089.65.3;;10.1093/intimm/8.5.765;;8671665;;10.4049/jimmunol.170.2.711;;12517932;;10.1158/1078-0432.ccr-07-4079;;18483370;;14871849;;10.1158/0008-5472.can-03-3259;;10.1007/s00262-004-0593-x;;15599732;;10.4049/jimmunol.170.3.1257;;12538684;;11857337;;10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9;;10.1002/eji.1830240409;;8149953;;12091876;;10.1038/nm730;;12721664;;10.1007/s00109-003-0430-2;;9332365;;10.1016/s0378-1119(97)00260-6;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;10.1007/bf01561573;;15470033;;10.4049/jimmunol.173.8.4919;;9930702;;10.1038/16717;;10.1002/j.1460-2075.1992.tb05481.x;;pmc556898;;1396582;;10.1073/pnas.192461099;;12218188;;pmc129438;;10.1016/s0165-2478(02)00088-3;;12095712;;15611321;;10.1093/intimm/dxh194;;10.1161/01.atv.0000145015.23656.e4;;15374847;;10.1158/1078-0432.ccr-04-0428;;15297412;;11224527;;10.1038/85330;;8159246;;10.1038/368856a0;;15352422;;10.1191/0961203303lu1052oa;;10.1016/s1074-7613(00)80089-8;;10485649;;10.1126/science.291.5502.319;;11209085;;pmc61133;;10.1073/pnas.231486598;;11698646;;12413529;;10.1016/s0952-7915(02)00398-9;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;14764622;;10.1093/hmg/ddh076;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1084/jem.20022119;;12847138;;pmc2196082;;7851902;;10.1006/geno.1994.1562;;10.1084/jem.181.6.1953;;7539033;;pmc2192041;;1404388;;10.1016/0022-2836(92)90223-7;;10.1016/s0167-5699(97)80025-4;;9190115;;17898045;;10.1093/intimm/dxm091;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;10.4049/jimmunol.169.11.6546;;12444166;;10.1182/blood.v97.6.1809;;11238124;;12091876;;10.1038/nm730;;9796923;;10.1093/intimm/10.10.1563;;12421930;;10.4049/jimmunol.169.10.5538;;10.1200/jco.2008.26.15_suppl.3006;;10882809;;10.1016/s0163-7258(00)00052-8;;8871619;;10.4049/jimmunol.157.8.3250;;11861596;;10.1146/annurev.immunol.20.091101.091806;;10.1126/science.271.5256.1734;;8596936;;11329858;;10.1016/s0065-3233(01)56010-6;;10.1084/jem.20022235;;12847136;;pmc2196084;;10.1038/nbt1137;;16151408;;14552835;;10.1016/j.it.2003.08.005;;15122199;;10.1038/nri1349;;12947224;;10.1385/ir:28:1:49;;7581696;;10.1385/0-89603-275-2:171;;15030777;;10.1016/s1074-7613(04)00051-2;;10.1084/jem.20022125;;12847137;;pmc2196083;;9801349;;10.1128/cdli.5.6.862-870.1998;;pmc96216,"Kasagi, et al., ""Anti-Programmed Cell Death 1 antibody Reduces CD4+PD-1+T Cells and Relieves the Lupus-Like Nephritis of NZB/W F1 Mice"", The Journal of Immunology, 184:2337-2347 (2010).;;Hirano et al., ""Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity"", Cancer Research, American Association for Cancer Research, 65(3): 1089-1096, Feb. 2005.;;U.S. Appl. No. 11/913,217, filed Apr. 22, 2011 Notice of Allowance.;;U.S. Appl. No. 11/913,217, filed Jan. 25, 2011 Response to Non-Final Office Action.;;U.S. Appl. No. 11/913,217, filed Oct. 25, 2010 Non-Final Office Action.;;Agata, et al., 1996, ""Expression of the PD-1 antigen on the surface of stimulation mouse T and B lymphocytes,"" Int Immunol, vol. 8:p. 765-772.;;Bennett, et al., 2003, ""Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses,"" J Immunol, vol. 170: p. 711-718.;;Berger et al., ""Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies,"" Clin Cancer Res. (2008); 14(10):3044-51.;;Blank et al., ""PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+T Cells""; Cancer Research; (2004); 64:1140-1145.;;Blank, et al., 2005, ""Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy,"" Cancer Immunol. Immunother., vol. 54: p. 307-314.;;Brown, et al., 2003, ""Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production,"" J Immunol., vol. 170: p. 1257-1266.;;Carter, et al., 2002, ""PD-1: PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2,"" Eur J Immunol, vol. 32: p. 634-643.;;Cox et al., ""A directory of human germ-line VK segments reveals a strong bias in their usage""; Eur. J. Immunol.; (1994); 24:827-836.;;Dong, et al., 2002, ""Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion,"" Nat Med., vol. 8: p. 783-800.;;Dong, H. and Chen, L., 2003, ""B7-H1 pathway and its role in the evasion of tumor immunity,""J Mol Med, vol. 81: p. 281-287.;;Finger, et al., 1997, ""The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors,"" Gene, vol. 197: p. 177-187.;;Freeman, et al., 2000, ""Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation,"" J Exp Med, vol. 192: p. 1027-1034.;;Hansen, et al., 1980, ""Monoclonal Antibodies Identifying a Novel T-Cell Antigen and Ia Antigens of Human Lymphocytes,"" Immunogenics, vol. 10: p. 247-260.;;He, et al., 2004, ""Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine,"" J. Immunol., vol. 173: p. 4919-4928.;;Hutloff, et al., 1999, ""ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28,"" Nature, vol. 397: p. 263-266.;;Ishida, et al., 1992, ""Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death,"" EMBO J., vol. 11: p. 3887-3895.;;Iwai, et al., 2002, ""Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade,"" Proc. Nat'l. Acad. Sci. USA, vol. 99: p. 12293-12297.;;Iwai, et al., 2002, ""Microanatomical localization of PD-1 in human tonsils,"" Immunology Letters, vol. 83, No. 3: p. 215-220.;;Iwai, et al., 2005, ""PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells,"" Int. Immunol., vol. 17: p. 133-144.;;Koga et al., ""Blockade of the Interaction Between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts""; Arterioscler. Thromb. Vasc. Biol.; (2004); 24(11):2057-2062.;;Konishi, et al., 2004, ""B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression,"" Clin. Cancer Res., vol. 10: p. 5094-5100.;;Latchman, et al., 2001, ""PD-L2 is a second ligand for PD-1 and inhibits T cell activation,"" Nat Immunol, vol. 2: p. 261-268.;;Lonberg, et al., 1994, ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications,"" Nature, vol. 368, No. 6474: p. 856-859.;;Nielsen, et al., 2004, ""A putative regulatory polymorphism in PD-1 is associated with nephropathy in a population-based cohort of systemic lupus erythematosus patients,"" Lupus, vol. 13: p. 510-516.;;Nishimura, et al., 1999, ""Development of Lupus-like Autoimmune Disease by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor,"" Immunity, vol. 11: p. 141-151.;;Nishimura, et al., 2001, ""Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice,"" Science, vol. 291: p. 319-322.;;Okazaki, et al., 2001, ""PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tryosine phosphatase 2 to phosphotyrosine,"" PNAS, vol. 98: p. 13866-13871.;;Okazaki, et al., 2002, ""New regulatory co-receptors: inducible co-stimulator and PD-1,"" Curr. Opin. Immunol., vol. 41, No. 6: p. 779-782.;;Panka et al., 1988, Proc. Natl. Acad. Sci. USA, 85:3080-3084.;;Prokunina, L. and Alarcon-Riquelme, M., 2004, ""The genetic basis of systemic lupus erythematosus-knowledge of today and thoughts for tomorrow,"" Hum Mol Genet, vol. 13: p. R143-R148.;;Rudikoff et al., 1982, Proc. Natl. Acad. Sci. USA, 79:1979-1983.;;Salama, et al., 2003, ""Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis,"" J Exp Med, vol. 198: p. 71-78.;;Shinohara, et al., 1994, ""Structure and chromosomal localization of the human PD-1 gene (PDCD1),"" Genomics, vol. 23: p. 704-706.;;Thomas, M.L., 1995, ""Of ITAMs and ITIMs: Turning on and off the B Cell Antigen Receptor,"" J Exp Med, vol. 181: p. 1953-1956.;;Tomlinson et al., ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops""; J. Mol. Biol.; (1992); 227:776-798.;;Vivier, E. and Daeron, M., ""Immunoreceptor tyrosine-based inhibition motifs,"" Immunol Today, vol. 18: p. 286-291.;;Wong RM et al., ""Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs,"" Int Immunol. (2007), 19(10):1223-34.;;Singer, et al., Genes and Genomes, University Science Books, 1:63-64 (1998).;;Extended European Search Report issued on Jun. 7, 2010 in counterpart EP application No. 10161767.8.;;Extended European Search Report issued on Oct. 5, 2010 in counterpart EP application No. 10161767.8.;;Communication from the Japanese Patent Office mailed Jul. 10, 2012, in Japanese counterpart application No. 2009-203514.;;European Office Action issued Aug. 18, 2011, in corresponding European Patent Application No. 10172772.5 (in the name of Ono Pharmaceutical Co., Ltd.).;;Partial European Search Report dated Oct. 26, 2006 in EP application No. 03741154.3.;;EP application No. 03741154.3 Notice of Opposition dated Jul. 8, 2011, issued by the EPO in the name of Ono Pharmaceutical Co., Ltd. et al.;;EP application No. 03741154.3 Response to the communication pursuant to Art. 96(2) EPC dated Jun. 25, 2007, 7 pages.;;EP Publication No. 1 576 014, Excerpt from Register of European Patents, retrieved online from https://register.epo.org/espacenet/application?number=EP03780521 on May 27, 2011.;;International Search Report for PCT/JP02/08420, dated Oct. 21, 2003.;;""About the Internet Archive: General Information"", Internet Archive, 2001, 10 pages, retrieved online from http://www.archive.org/about/about.php on Apr. 5, 2011.;;Affinity purified anti-mouse PD-1 (PD1): Archived website information for J43 and J116 antibodies; eBioscience and Waybackmachine/org 2002, 4 pages, retrieved online from http://web.archive.org/web/20020301031217 http://ebioscience/specs/antibody14/14-9985.. on Jun. 14, 2011.;;""Anti-Human CD 279 (PD-1) Functional Grade Purified: Murine anti-PD-1 antibody J116"", eBioscience, Information Sheet, 2000, 2 pages.;;Brown, et al., ""Expression and functional consequences of PD-1 ligands on natural APCS and tumors"", The FASEB Journal, 2001, 15(4):A345 (abstract No. 275.23).;;Freeman, et al., ""Engagement of the PD-1 immunoinhibitory receptor by a novel B7-family member leads to negative regulation of lymphocyte activation"", Blood, 2000, 96(11):810a-811a (Abstract No. 3502).;;Ozkaynak, et al., ""Programmed death-1 targeting can promote allograft survival"", The Journal of Immunology, 2002, 169:6546-6553.;;Tamura, et al., ""B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function"", 2001, Blood, 97(6):1809-1816.;;Dong, et al., ""Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion"", 2002, Nature Medicine, 8(8):793-800.;;Nishimura, et al., ""Immunological studies on PD-1-deficient mice: implication of PD-1 as a negative regulator for B cell responses"", 1998, International Immunology, 10(10):1563-1572.;;Yamazaki, et al., ""Expression of programmed death 1 ligands by murine T cells and APC"", The Journal of Immunology, 169(10):5538-5545.;;Zuberek, et al., ""The role of in vivo PD-1/PD-L1 interactions in syngeneic and allogeneic antitumor responses in murine tumor models"", 2001, Blood, 98(11):42B.;;Brown, et al., Blockade of PD-1 ligands on dendritic cells enhances T cells activation and cytokine production, FASEB Journal, Mar. 2002, 16(4):A710-517.4.;;Brahmer, et al., Safety and activity of MDX-1106 (ONO-4538) anti-PD-1 monoclonal antibody in patients with selected refractory or relapsed malignancies, 2008, J. Clin. Oncol., 26(May 20 Suppl; abstract No. 3006).;;Huang, Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, apoptosis, Pharmacology and Therapeutics, 2000, 86:201-215.;;Blazar, et al., ""Infusion of Anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host-disease lethality in part via direct effects on CD4+ and CD8+ T cells"", J. Immunol., 1996, 157:3250-3259.;;Notice of Opposition to European Patent No. EP 2 161 336, from Novartis AG, dated Apr. 25, 2014.;;Notice of Opposition to European Patent No. EP 2 161 336, from 4-Antibody AG, dated Apr. 29, 2014.;;Notice of Opposition to European Patent No. EP 2 161 336, from Janssen Biotech, Inc., dated Apr. 30, 2014.;;Notice of Opposition to European Patent No. EP 2 161 336, from Merck & Co., Inc., dated Apr. 30, 2014.;;Honjo, et al., Deposit receipt for Accession No. FERM BP-8392 mentioned in EP-A 1 537 878, 1 page (Jun. 5, 2003).;;Carreno, et al., ""The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses"", Annu Rev. Immunol., 20:29-53 (2002).;;Leach, et al., ""Enhancement of antitumor immunity by CTLA-4 blockade"", Science, 271(5256):1734-1736 (1996).;;Declarations by Dr. Robert J. Botch including 2 Annex and 39 exhibits, 82 pages (Apr. 29, 2014).;;Patentee's response to Examination Report dated Nov. 24, 2011 for European Patent Application No. 09013687.0-2405, filed Apr. 4, 2012.;;Witness Statement by Mr. Hiroyuki Yamada including exhibits 1-7, (Apr. 16, 2014) (23 pages).;;Witness Statement of Ms. Masako Ikeda including exhibits A-E, (Apr. 15, 2014) (20 pages).;;Response to request further processing of application dated Jan. 13, 2014, for EP Application No. 11178191.0-1410, filed Mar. 20, 2014. (13 pages).;;Park, et al., ""Monoclonal antibody therapy"", Advances in Protein Chemistry, 56:369-421 (2001).;;Clark, ""Antibody engineering lgG effector Mechanisms"", Chemical Immunology, 65:88-110: enclosed is a reprint from http://www.path.cam.ac.uk/mrc7/publications/reprints/PP1997C165-88.pdf (1997).;;Iwai, et al., ""PD-1 inhibits antiviral immunity at the effector phase on the liver"", The Journal of Experimental Medicine, 198(1):39-50 (2003).;;Adams, et al., ""Monoclonal antibody therapy of cancer"", Nature Biotechnology, 23(9):1147-1157 (2005).;;Affidavit of Christopher Butler, 8 pages (Apr. 23, 2014).;;Declaration of AndreaVan Elsas, Ph.D., in support of the opposition against EP-B1 2 161 336, 197 pages (Apr. 29, 2014).;;Declaration of Vassiliki A. Boussiotis, in connection with the opposition against European Patent No. 2161336B1, 167 pages (Apr. 28, 2014).;;Communication pursuant to Article 94(3) EPC for European Application No. 06786260.7-1412, dated Apr. 23, 2014.;;Carreno, et al., ""BTLA: A new inhibitory receptor with a B7-like ligand"", TRENDS in Immunology, 24(10):524-527 (2003).;;Chen, ""Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity"", Nature, 4:336-347 (2004).;;Shinohara, et al., Structural and chromosomal localization of the human PD-1 GENE (PDCD1), UniProt database entry Q15116, http://www.uniprot.org/uniprot/Q15116.txt. downloaded Apr. 29, 2014.;;Exhibit 1 ""Human anti-PD-1 antibodies: binding to PD-1, cross-competition with 5C4 and affinity to PD-1"", 6 pages.;;Carter, et al., ""Cytotoxic T-Iymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation"", Immunologic Research, 28(1):49-59 (2003).;;Kaveri, ""Epitope and idiotope mapping using monoclonal antibodies"", Antibody Engineering Protocols, Methods if Molecular Biology, 51(Chapter 11):171-181 (2005).;;Zhang, et al., ""Structural and functional analysis of the costimulatory receptor programmed death-1"", Immunity, 20:337-347 (2004).;;Sequence alignments between PD-1 and each of CTLA-4, CD28 and ICOS, retrieved on-line on Apr. 10, 2014, http://www.ebi.ac.uk/Tools/services/web/toolresult.ebi?jobId=clustalo-I20140410-15.;;Ansari, et al., ""The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice"", J. Exp. Med, 198(1):63-69 (2003).;;Janeway, et al., ""Immunobiology: The immune system in health and disease"", New York, Garland Science, Chapter 9: 367-408 (2005).;;Nagler, et al., ""Phase I clinical trial of CT-011, a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced hematological malignancies"", Experimental Hematology, 33:97 (2005).;;Cloeckaert, et al., ""O-Polysaccharide epitopic heterogeneity at the surface of Brucella spp. studied by enzyme-linked immunosorbent assay and flow cytometry"", Clinical and Diagnostic Laboratory Immunology, 5(6):862-870 (1998).",ACTIVE
134,CY,T1,CY 1114506 T1,134-993-759-256-510,2016-06-22,2016,CY 131100915 T,2013-10-17,EP 09013687 A;;US 67946605 A;;US 73843405 A;;US 74891905 A,2005-05-09,ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΘΡΩΠΟΥ ΕΝΑΝΤΙ ΤΗΣ ΠΡΩΤΕΪΝΗΣ ΠΡΟΓΡΑΜΜΑΤΙΣΜΕΝΟΥ ΘΑΝΑΤΟΥ (PD-1) ΚΑΙ ΜΕΘΟΔΟΙ ΑΓΩΓΗΣ ΕΝΑΝΤΙ ΤΟΥ ΚΑΡΚΙΝΟΥ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-PD-1 ΜΕΜΟΝΩΜΕΝΑ Ή ΣΕ ΣΥΝΔΥΑΣΜΟ ΜΕ ΑΛΛΟΥΣ ΑΝΟΣΟΘΕΡΑΠΕΥΤΙΚΟΥΣ ΠΑΡΑΓΟΝΤΕΣ,"Η παρούσα εφεύρεση παρέχει απομονωμένα μονοκλωνικά αντισώματα, ιδιαίτερα μονοκλωνικά αντισώματα ανθρώπου, τα οποία δεσμεύουν ειδικά την ΡD-1 με μεγάλη συγγένεια. Επίσης παρέχονται μόρια νουκλεϊκών οξέων που κωδικοποιούν τα αντισώματα της εφεύρεσης, φορείς έκφρασης, ξενιστικά κύτταρα και μέθοδοι έκφρασης των αντισωμάτων της εφεύρεσης. Ακόμα παρέχονται συζεύγματα μορίων του ανοσοποιητικού, μόρια διπλής ειδικότητας και φαρμακευτικές συνθέσεις που περιλαμβάνουν τα αντισώματα της εφεύρεσης. Η εφεύρεση επίσης παρέχει μεθόδους ανίχνευσης της ΡD-1, καθώς και μεθόδους αγωγής έναντι ποικίλων ασθενειών, συμπεριλαμβανομένων του καρκίνου και λοιμωδών ασθενειών, χρησιμοποιώντας αντισώματα αντι-ΡD-1. Η παρούσα εφεύρεση περαιτέρω παρέχει μεθόδους συνδυαστικής ανοσοθεραπείας, όπως ο συνδυασμός αντισωμάτων αντι-CTLΑ-4 και αντι-ΡD-1 προς αγωγή έναντι ασθένειας υπέρμετρου πολλαπλασιασμού των κυττάρων, όπως ο καρκίνος. Η εφεύρεση επίσης παρέχει μεθόδους μεταβολής δυσμενών συμβάντων που σχετίζονται με την αγωγή η οποία ενέχει τέτοια αντισώματα ξεχωριστά.",ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/134-993-759-256-510,Granted Patent,no,0,0,2,2,0,,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
135,PL,T3,PL 1907424 T3,134-397-989-836-421,2015-12-31,2015,PL 06786260 T,2006-06-30,US 69642605 P;;EP 06786260 A;;US 2006/0026046 W,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),,SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/134-397-989-836-421,Patent Application,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/00;;C07K16/28,,0,0,,,,PENDING
136,JP,A,JP 2012158605 A,134-846-247-376-981,2012-08-23,2012,JP 2012106662 A,2012-05-08,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH 1(PD-1) AND METHOD FOR TREATING CANCER USING ANTI-PD-1 ANTIBODY ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,"PROBLEM TO BE SOLVED: To provide isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to programmed Death 1 (PD-1) with high affinity.SOLUTION: Isolated human monoclonal antibodies cross-competing for binding to a reference antibody including human heavy chain and light chain variable areas composed of specific amino acid sequences, or a binding portion thereof are provided. A method for detecting PD-1 is provided and various diseases including cancer and infectious diseases can be treated by preparing immunocomplexes, bispecific molecules and pharmaceutical compositions containing the antibodies. Furthermore, hyperproliferative diseases such as cancer can also be treated by a combination immunotherapy such as a combination of anti-CTLA-4 and anti-PD-1 antibodies. Adverse events related to treatment with each of the antibodies are altered.",ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/134-846-247-376-981,Patent Application,no,3,6,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395;;A61P35/00;;A61P37/04;;C07K16/28,,5,1,032-820-729-763-323,8159246;;10.1038/368856a0,"庄雅之他, 日本癌学会学術総会記事, 2005 AUG, VOL.64, P.56, W-102, JPN6014051260, ISSN: 0002957133;;庄雅之他, 日本癌治療学会誌, 2005 SEP, VOL.40, NO.2, P.590, PS22-5, JPN6014051261, ISSN: 0002957134;;BLOOD, vol. 105, no. 1, JPN6011058924, January 2005 (2005-01-01), pages 13 - 21, ISSN: 0003220215;;GENE, vol. 197, JPN6011058922, 1997, pages 177 - 187, ISSN: 0003220216;;NATURE, vol. 368, JPN6011058923, 1994, pages 856 - 859, ISSN: 0003220217",ACTIVE
137,EP,A3,EP 3530736 A3,162-052-688-527-192,2019-11-06,2019,EP 19151041 A,2006-05-02,EP 11178191 A;;EP 09013687 A;;EP 06746353 A;;US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;KORMAN ALAN J;;HUANG HAICHUN,,https://lens.org/162-052-688-527-192,Search Report,yes,2,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;A61P7/06;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,3,3,013-122-792-588-081;;032-820-729-763-323;;086-751-695-402-863,10.4049/jimmunol.170.3.1257;;12538684;;8159246;;10.1038/368856a0;;15705911;;10.1158/0008-5472.1089.65.3,"BROWN JULIA A ET AL: ""Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production"", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 170, no. 3, 1 February 2003 (2003-02-01), pages 1257 - 1266, XP002973918, ISSN: 0022-1767;;LONBERG N ET AL: ""ANTIGEN-SPECIFIC HUMAN ANTIBODIES FROM MICE COMPRISING FOUR DISTINCT GENETIC MODIFICATIONS"", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 368, no. 6474, 28 April 1994 (1994-04-28), pages 856 - 859, XP000941636, ISSN: 0028-0836;;HIRANO FUMIYA ET AL: ""Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 65, no. 3, 1 February 2005 (2005-02-01), pages 1089 - 1096, XP002419626, ISSN: 0008-5472",PENDING
138,EP,A1,EP 2982379 A1,153-487-576-868-626,2016-02-10,2016,EP 15172571 A,2006-06-30,US 69642605 P;;EP 06786260 A,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-Ll antibodies.
",SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/153-487-576-868-626,Patent Application,yes,107,4,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/00;;A61K39/395;;C07K16/28,,144,123,006-568-097-103-41X;;058-883-699-331-571;;127-416-339-660-812;;006-463-263-246-432;;052-597-675-128-75X;;081-074-583-383-824;;049-945-161-825-531;;006-568-097-103-41X;;122-644-406-202-233;;063-455-531-393-728;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;009-746-604-420-355;;027-960-937-319-909;;116-193-705-533-609;;011-092-736-500-72X;;039-555-401-046-267;;040-950-450-163-406;;026-164-216-541-151;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;042-204-626-457-327;;006-574-964-805-278;;030-323-674-660-051;;092-023-577-402-127;;022-179-293-052-569;;028-862-168-091-90X;;004-458-031-333-650;;024-929-137-199-30X;;003-752-183-823-430;;070-318-112-524-781;;032-624-544-479-82X;;030-630-100-818-462;;106-753-778-592-300;;032-820-729-763-323;;083-549-078-331-651;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;033-754-369-798-314;;077-525-954-203-403;;028-969-172-280-017;;060-375-551-951-388;;020-753-772-581-741;;038-613-711-274-229;;047-951-914-695-080;;062-485-301-455-912;;032-820-729-763-323;;023-676-781-371-861;;026-744-100-669-883;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;071-163-081-597-04X;;035-135-729-507-737;;094-685-907-794-422;;062-029-719-290-327;;070-624-200-848-669;;012-746-915-512-650;;029-926-264-612-986;;059-499-282-511-358;;038-478-749-169-986;;035-554-935-107-802;;099-647-105-451-350;;009-621-637-014-514;;100-985-030-110-978;;030-769-003-988-749;;057-971-690-843-179;;145-254-035-276-41X;;026-646-521-253-318;;000-331-240-115-824;;065-438-177-962-139;;101-640-792-825-42X;;070-316-527-354-375;;040-550-546-463-785;;046-168-111-025-234;;043-654-077-374-418;;084-388-182-984-099;;042-354-196-879-741;;005-112-559-456-657;;052-219-543-437-800;;007-364-858-655-289;;056-942-841-068-650;;107-302-749-967-437;;039-238-464-990-600;;036-564-551-324-053;;020-123-860-433-320;;011-516-147-270-264;;025-182-641-289-850;;066-015-167-169-542;;013-122-792-588-081;;005-416-473-959-707;;020-986-423-793-233;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;007-709-585-201-038;;042-688-967-632-553;;056-422-417-058-69X;;005-022-447-377-963;;127-416-339-660-812;;028-786-751-528-732;;139-084-139-072-589;;098-407-145-404-736;;066-749-017-721-197;;001-467-559-709-949;;078-061-292-153-737;;055-646-175-554-792;;129-390-507-012-794;;063-455-531-393-728;;100-936-013-609-194;;029-697-384-910-375;;038-613-711-274-229,10.1073/pnas.192461099;;12218188;;pmc129438;;10.1002/ijc.21775;;16482562;;9930702;;10.1038/16717;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;11224527;;10.1038/85330;;11857337;;10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9;;15837746;;10.1158/1078-0432.ccr-04-1469;;10.1073/pnas.192461099;;12218188;;pmc129438;;12091876;;10.1038/nm730;;14530338;;10.4049/jimmunol.171.8.4156;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;10.1006/jmbi.2000.3512;;10677285;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;10.1021/ja00084a073;;10.1073/pnas.92.7.2529;;pmc42251;;7708679;;8752924;;3382986;;10.1093/bioinformatics/4.1.11;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;3127726;;10.1038/332323a0;;10.1038/321522a0;;3713831;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;11096108;;10.1074/jbc.m009483200;;10.1002/bit.20151;;15352059;;11986321;;10.1074/jbc.m202069200;;10.1038/6179;;10052355;;1201277;;10.1021/bi00696a021;;10.1038/348552a0;;2247164;;1172191;;10.1038/256495a0;;8159246;;10.1038/368856a0;;10.1007/978-3-642-78432-3_3;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;8144892;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nbt727;;12172556;;8159246;;10.1038/368856a0;;10.1126/science.3929380;;3929380;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;10.1146/annurev.bi.41.070172.003325;;4563441;;10.4049/jimmunol.172.9.5489;;15100290;;2459288;;pmc2189025;;10.1084/jem.168.3.1099;;12042244;;10.1093/glycob/12.4.43r;;10.1038/316452a0;;3927174;;11275255;;10.1016/s0161-5890(00)00105-x;;10.1002/1522-2683(200206)23:11<1605::aid-elps1605>3.0.co;2-o;;12179978;;9561769;;10.1016/s0021-9673(97)01134-5;;10.2174/1389201023378229;;12463418;;10.1023/b:pham.0000008042.15988.c0;;14725359;;10397155;;10.1016/s0165-2478(99)00029-2;;10.1093/chromsci/40.6.343;;12137207;;8644915;;10.1021/ac00116a002;;12564977;;10.1016/s0169-409x(02)00179-5;;10.1007/s00262-002-0352-9;;12700948;;12676579;;10.1016/s1535-6108(03)00057-6;;10.1038/nrc903;;12360278;;12186272;;10.1016/s0169-409x(01)00206-x;;11744170;;7042536;;10.1111/j.1600-065x.1982.tb00392.x;;10.4049/jimmunol.155.10.4996;;7594506;;8954257;;1371789;;6239899;;10.1084/jem.160.6.1686;;pmc2187539;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;3833240;;10.1126/science.3925553;;3925553;;2958547;;10.4049/jimmunol.139.7.2367;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;3390170;;10.1016/s0006-291x(88)81333-0;;10.1128/aac.39.1.180;;pmc162506;;7695303;;7907597;;10.1016/s0021-9258(17)37081-3;;10.1016/0014-5793(94)00313-0;;8206150;;7820457;;10.1006/immu.1994.1029;;12721664;;10.1007/s00109-003-0430-2;;10.1158/1078-0432.ccr-04-0428;;15297412;;10.4049/jimmunol.170.3.1257;;12538684;;15611321;;10.1093/intimm/dxh194;;15470033;;10.4049/jimmunol.173.8.4919;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;9624003;;10.1038/30989;;10.1016/s0171-2985(00)80072-8;;10834311;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;9930702;;10.1038/16717;;10.1038/ni944;;12796776;;10.1016/s1074-7613(03)00152-3;;12818165;;10417377;;10.1126/science.285.5427.546;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;pmc15881;;10.1073/pnas.96.6.2982;;10077623;;10.1097/00002371-199601000-00009;;8859727;;10.1038/22124;;10408445;;14530338;;10.4049/jimmunol.171.8.4156;;15275969;;10.1016/j.imlet.2004.05.007;;10.1002/j.1460-2075.1993.tb05721.x;;pmc413278;;8458339;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887,"IWAI YOSHIKO ET AL: ""Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 99, no. 19, 17 September 2002 (2002-09-17), pages 12293 - 12297, XP002398159, ISSN: 0027-8424, DOI: 10.1073/PNAS.192461099;;BLANK CHRISTIAN ET AL: ""Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro"", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 119, no. 2, 15 February 2006 (2006-02-15), pages 317 - 327, XP002557386, ISSN: 0020-7136, DOI: 10.1002/IJC.21775;;HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 263 - 266;;HANSEN ET AL., IMMUNOGENICS, vol. 10, 1980, pages 247 - 260;;FREEMAN ET AL., J EXP MED, vol. 192, 2000, pages 1027 - 34;;LATCHMAN ET AL., NAT IMMUNOL, vol. 2, 2001, pages 261 - 8;;CARTER ET AL., EUR J IMMUNOL, vol. 32, 2002, pages 634 - 43;;OHIGASHI ET AL., CLIN CANCER RES, vol. 11, 2005, pages 2947 - 53;;IWAI ET AL., PNAS, vol. 99, 2002, pages 12293 - 7;;DONG ET AL., NAT MED, vol. 8, 2002, pages 793 - 800;;KANAI ET AL., J IMMUNOL, vol. 171, 2003, pages 4156 - 63;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest, 5th ed."", 1991, NIH PUBLICATION NO. 91-3242;;KLIMKA ET AL., BRITISH J. OF CANCER, vol. 83, no. 2, 2000, pages 252 - 260;;BEIBOER ET AL., J. MOL. BIOL., vol. 296, 2000, pages 833 - 849;;RADER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 95, 1998, pages 8910 - 8915;;BARBAS ET AL., J. AM. CHEM. SOC., vol. 116, 1994, pages 2161 - 2162;;BARBAS ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 92, 1995, pages 2529 - 2533;;DITZEL ET AL., J. IMMUNOL., vol. 157, 1996, pages 739 - 749;;E. MEYERS; W. MILLER, COMPUT. APPL. BIOSCI., vol. 4, 1988, pages 11 - 17;;NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;RIECHMANN, L. ET AL., NATURE, vol. 332, 1998, pages 323 - 327;;JONES, P. ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;QUEEN, C ET AL., PROC. NATL. ACAD. SEE. U.S.A., vol. 86, 1989, pages 10029 - 10033;;TOMLINSON, I. M. ET AL.: ""The Repertoire of Human Germline V Sequences Reveals about Fifty Groups of V Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: doi:10.1016/0022-2836(92)90223-7;;COX, J. P. L. ET AL.: ""A Directory of Human Germ-line V Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;ALTSCHUL ET AL., NUCLEIC ACIDS RESEARCH, vol. 25, 1997, pages 3389 - 3402;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;YAMANE-OHNUKI ET AL., BIOTECHNOL BIOENG, vol. 87, 2004, pages 614 - 22;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;TARENTINO, A.L. ET AL., BIOCHEM., vol. 14, 1975, pages 5516 - 23;;F. AUSUBEL, ET AL.: ""Current Protocols in Molecular Biology"", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;LONBERG, N.: ""Handbook of Experimental Pharmacology"", vol. 113, 1994, pages: 49 - 101;;LONBERG, N.; HUSZAR, D., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F.; LONBERG, N., ANN. N.Y. ACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR, L. ET AL., NUCLEIC ACIDS , RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 3720 - 3724;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J ET AL., EMBO J., vol. 12, 1993, pages 821 - 830;;TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;TOMIZUKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727;;KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894;;LONBERG, N. ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;MORRISON, S., SCIENCE, vol. 229, 1985, pages 1202;;GOEDDEL: ""Gene Expression Technology. Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;TAKEBE, Y. ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;BOSS, M. A.; WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. 4CAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMAN; P. A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;MARSHALL ET AL., ANNU REV BIOCHEM, vol. 41, 1972, pages 673 - 702;;GALA FA; MORRISON SL, J IMMUNOL, vol. 172, 2004, pages 5489 - 94;;WALLICK ET AL., J EXP MED, vol. 168, 1988, pages 1099 - 109;;SPIRO RG, GLYCOBIOLOGY, vol. 12, 2002, pages 43R - 56R;;PAREKH ET AL., NATURE, vol. 316, 1985, pages 452 - 7;;MIMURA ET AL., MOL IMMUNOL, vol. 37, 2000, pages 697 - 706;;JANINI ET AL., ELECTROPHORESIS, vol. 23, 2002, pages 1605 - 11;;MA ET AL., CHROMATOGRAPHIA, vol. 53, 2001, pages 75 - 89;;HUNT ET AL., JCHROMATOGRA, vol. 800, 1998, pages 355 - 67;;KRISHNAMURTHY R; MANNING MC, CURR PHARM BIOTECHNOL, vol. 3, 2002, pages 361 - 71;;CHEN ET AL., PHARM RES, vol. 20, 2003, pages 1952 - 60;;GHIRLANDO ET AL., IMMUNOL LETT, vol. 68, 1999, pages 47 - 52;;MURRAY ET AL., J. CHROMATOGR SCI, vol. 40, 2002, pages 343 - 9;;ALEXANDER AJ; HUGHES DE, ANAL CHEM, vol. 67, 1995, pages 3626 - 32;;SAITO, G ET AL., ADV. DNIGDELIV, REV., vol. 55, 2003, pages 199 - 215;;TRAIL, P.A. ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 52, 2003, pages 328 - 337;;PAYNE, G., CANCER CELL, vol. 3, 2003, pages 207 - 212;;ALLEN, T.M., NAT. REV. CANCER, vol. 2, 2002, pages 750 - 763;;PASTAN, 1.; KREITMAN, R. J., CURR. OPIN. INVESTIG. DRUGS, vol. 3, 2002, pages 1089 - 1091;;SENTER, P.D; SPRINGER, C.J., ADV. DRUG DELIV. REV., vol. 53, 2001, pages 247 - 264;;REISFELD ET AL.: ""Monoclonal Antibodies And Cancer Therapy"", 1985, ALAN R. LISS, INC., article ARNON ET AL.: ""Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy"", pages: 243 - 56;;ROBINSON ET AL.: ""Controlled Drug Delivery, 2nd ed."", 1987, MARCEL DEKKER, INC., article HELLSTROM ET AL.: ""Antibodies For Drug Delivery"", pages: 623 - 53;;PINCHERA ET AL.: ""Monoclonal Antibodies '84: Biological And Clinical Applications"", 1985, article THORPE ET AL.: ""Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review"", pages: 475 - 506;;BALDWIN ET AL.: ""Monoclonal Antibodies For Cancer Detection And Therapy"", 1985, ACADEMIC PRESS, article ""Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy"", pages: 303 - 16;;THORPE ET AL.: ""The Preparation And Cytotoxic Properties OfI Antibody-Toxin Conjugates"", IMMUNOL. REV., vol. 62, - 1982, pages 119 - 58, XP001179872, DOI: doi:10.1111/j.1600-065X.1982.tb00392.x;;GRAZIANO, R.F. ET AL., J. IMMUNOL, vol. 155, no. 10, 1995, pages 4996 - 5002;;MORTON, H.C. ET AL., CRITICAL REVIEWS IN IMMUNOLOGY, vol. 16, 1996, pages 423 - 440;;MONTEIRO, R.C. ET AL., J. IMMUNOL., vol. 148, 1992, pages 1764;;KARPOVSKY ET AL., J. EXP. MED., vol. 160, 1984, pages 1686;;LIU, MA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 8648;;PAULUS, BEHRING INS. MITT. NO., vol. 78, 1985, pages 118 - 132;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83;;GLENNIE ET AL., J. IMMUNOL., vol. 139, 1987, pages 2367 - 2375;;WEINTRAUB, B.: ""Principles of Radioimmunoassays"", March 1986, THE ENDOCRINE SOCIETY, article ""Seventh Training Course on Radioligand Assay Techniques"";;BERGE, S.M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;J.R. ROBINSON: ""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;V.V. RANADE, J. CLIN. PHARMACOL., vol. 29, 1989, pages 685;;UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 153, 1988, pages 1038;;P.G. BLOEMAN ET AL., FEBSLETT, vol. 357, 1995, pages 140;;M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 39, 1995, pages 180;;BRISCOE ET AL., AM. J. PHYSIOL., vol. 1233, 1995, pages 134;;SCHREIER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 9090;;K. KEINANEN; M.L. LAUKKANEN, FEBS LETT., vol. 346, 1994, pages 123;;J.J. KILLION; IJ. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273;;DONG ET AL., NAT MED, vol. 8, 2002, pages 787 - 9;;DONG ET AL., JMOL MED, vol. 81, 2003, pages 281 - 7;;BLANK ET AL., CANCER IMMUNOL. IMMUNOTHER, 2004;;KONISHI ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 5094 - 100;;BROWN ET AL., J. IMMUNOL., vol. 170, 2003, pages 1257 - 66;;IWAI ET AL., INT. IMMUNOL., vol. 17, 2005, pages 133 - 144;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;ROSENBERG, S.: ""Development of Cancer Vaccines"", 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 60 - 62;;LOGOTHETIS, C.: ""ASCO Educational Book Spring"", 2000, pages: 300 - 302;;KHAYAT, D., ASCO EDUCATIONAL BOOK SPRING, 2000, pages 414 - 428;;FOON, K, ASCO EDUCATIONAL BOOK SPRING, 2000, pages 730 - 738;;DEVITA, V. ET AL.: ""Cancer: Principles and Practice of Oncology, 5th ed."", 1997, article RESTIFO, N.; SZNOL, M. ET AL.: ""Cancer Vaccines (chapter 61)"", pages: 3023 - 3043;;DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, SA, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM, N ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT, R; SRIVASTAVA, P, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA, Y. ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE, F. ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER, A. ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR, M. ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL, J. ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARD, M.; O'GARRA, A., IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE, M. ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;RIDGE, J. ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;ITO, N. ET AL., IMMUNOBIOLOGY, vol. 201, no. 5, 2000, pages 527 - 40;;WEINBERG, A. ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO, I. ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF, A. ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;WATANABE, N. ET AL., NAT IMMUNOL, vol. 4, 2003, pages 670 - 9;;SICA, GL ET AL., IMMUNITY, vol. 18, 2003, pages 849 - 61;;GREENBERG, R.; RIDDELL, S., SCIENCE, vol. 285, 1999, pages 546 - 51;;HOLLIGER, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;OVERWIJK, W. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 96, 1999, pages 2982 - 2987;;ROSENBERG, SA; WHITE, DE, J. IMMUNOTHER EMPHASIS TUMOR IMMUNOL, vol. 19, no. 1, 1996, pages 81 - 4;;SCHENK ET AL., NATURE, vol. 400, 1999, pages 173 - 177;;KANAI ET AL., J. IMMU OL., vol. 171, 2003, pages 4156 - 63;;YOUNGNAK-PIBOONRATANAKIT ET AL., IMMUNOL LETTERS, vol. 94, 2004, pages 215 - 22;;CHEN ET AL., EMBO J., vol. 12, 1993, pages 811 - 820;;FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851",PENDING
139,US,B2,US 9580505 B2,145-923-981-026-092,2017-02-28,2017,US 201514807522 A,2015-07-23,US 201514807522 A;;US 201313746773 A;;US 201113091936 A;;US 91772708 A;;US 2006/0026046 W;;US 69642605 P,2005-07-01,Human monoclonal antibodies to programmed death ligand 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",SQUIBB & SONS LLC;;SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;MEDAREX INC (2008-03-26),https://lens.org/145-923-981-026-092,Granted Patent,yes,99,33,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A61K39/00;;A61K39/395;;A61K45/06,,77,44,058-883-699-331-571;;006-568-097-103-41X;;039-555-401-046-267;;011-092-736-500-72X;;074-067-544-364-744;;027-960-937-319-909;;067-760-343-772-225;;038-040-632-602-487;;013-122-792-588-081;;022-179-293-052-569;;037-833-888-905-08X;;050-992-361-999-488;;063-455-531-393-728;;009-746-604-420-355;;119-897-745-760-544;;022-046-054-886-073;;062-761-744-997-508;;059-733-201-044-050;;116-193-705-533-609;;027-477-313-726-928;;000-592-435-005-508;;027-727-853-855-594;;012-269-427-021-802;;088-581-950-418-154;;047-951-914-695-080;;092-023-577-402-127;;045-556-293-127-132;;076-731-232-972-252;;113-346-509-283-257;;081-074-583-383-824;;122-644-406-202-233;;025-182-641-289-850;;079-214-893-487-418;;006-463-263-246-432;;006-463-263-246-432;;020-986-423-793-233;;086-751-695-402-863;;066-015-167-169-542;;083-811-051-643-47X;;057-629-746-536-175;;078-115-905-519-238;;033-225-590-843-088;;009-675-556-987-094;;045-113-475-699-403,10.1002/ijc.21775;;16482562;;10.1073/pnas.192461099;;12218188;;pmc129438;;10.1073/pnas.92.7.2529;;pmc42251;;7708679;;10.1021/ja00084a073;;10.1038/nature04444;;16382236;;10.1006/jmbi.2000.3512;;10677285;;14871849;;10.1158/0008-5472.can-03-3259;;10.1056/nejmoa1200694;;pmc3563263;;22658128;;10.4049/jimmunol.170.3.1257;;12538684;;10.1002/eji.1830240409;;8149953;;22588271;;10.1038/mt.2012.98;;pmc3437589;;12520872;;10.1080/02648725.2002.10648023;;14530338;;10.4049/jimmunol.171.8.4156;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;10.1161/01.atv.0000145015.23656.e4;;15374847;;pmc127659;;11796590;;10.1128/iai.70.2.612-619.2002;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;pmc3958087;;10.1128/jvi.02034-13;;24352453;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;22023178;;10.2174/157488712799363262;;pmc3804573;;10.1371/journal.pone.0077780;;24204962;;24739950;;pmc3989168;;10.1371/journal.pone.0092934;;10.4049/jimmunol.164.3.1432;;10640759;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;1404388;;10.1016/0022-2836(92)90223-7;;10.1016/s1074-7613(00)00006-6;;10933393;;10.1007/s00262-004-0593-x;;15599732;;11861596;;10.1146/annurev.immunol.20.091101.091806;;11857337;;10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9;;12091876;;10.1038/nm730;;12721664;;10.1007/s00109-003-0430-2;;10581077;;10.1038/70932;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;15470033;;10.4049/jimmunol.173.8.4919;;15705911;;10.1158/0008-5472.1089.65.3;;10.1158/1078-0432.ccr-04-0428;;15297412;;17404099;;10.1158/1078-0432.ccr-06-2746;;10.1182/blood.v97.6.1809;;11238124;;12421930;;10.4049/jimmunol.169.10.5538;;18500231;;10.1038/nri2326;;14515254;;10.1002/eji.200324228;;10.1093/ndt/gfh423;;15353579,"U.S. Appl. No. 15/188,860, filed Jun. 2016, Korman, A.;;Blank, C., at al., ""Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro,"" International Journal of Cancer 119(2):317-327, International Union Against Cancer, United States (2006).;;Iwai, Y., et al., ""Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade,"" Proceedings of the National Academy of Sciences of the United States of America 99(19):12293-12297, National Academy of Sciences, United States (2002).;;Extended European Search Report and Search Opinion for EP Application No. 15172571.0, European Patent Office, Germany, mailed on Dec. 17, 2015.;;Amendment after Notice of Allowance mailed Jan. 10, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Amendment and Request for Continued Examination (RCE) mailed Aug. 20, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Barbas, S.M., et al., ""Human Autoantibody Recognition of DNA,"" Proceedings of the National Academy of Sciences of the United States of America 92(7):2529-2533, National Academy of Sciences, United States (1995).;;Barbas, S.M., et al., ""Recognition of DNA by Synthetic Antibodies,"" Journal of the American Chemical Society 116(5):2161-2162, American Chemical Society, United States (1994).;;Barber, D.L., et al., ""Restoring Function in Exhausted CD8 T Cells during Chronic Viral Infection,"" Nature 439(7077):682-687, Nature Publishing Group, United States (2006).;;Beiboer, S.H., et al., ""Guided Selection of a Pan Carcinoma Specific Antibody Reveals Similar Binding Characteristics Yet Structural Divergence between the Original Murine Antibody and its Human Equivalent,"" Journal of Molecular Biology 296(3):833-849, Elsevier, England (2000).;;Blank, C., et al., ""PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells,"" Cancer Research 64(3):1140-1145, American Association for Cancer Research, United States (2004).;;Brahmer, J.R., et al., ""Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer,"" The New England Journal of Medicine 366(26):2455-2465, Massachusetts Medical Society, United States (2012).;;Brown, J.A., et al., ""Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production,"" The Journal of Immunology 170(3):1257-1266, The American Association of Immunologists, United States (2003).;;Certificate of Correction mailed Dec. 6, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Certificate of Correction mailed Jul. 9, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Cox, J.P., et al., ""A Directory of Human Germ-Line V kappa Segments Reveals a Strong Bias in their Usage,"" European Journal of Immunology 24(4):827-836, Verlag Chemie GmbH, Germany (1994).;;Dai, B., et al., ""PD-1/PD-L1 Blockade can Enhance HIV-1 Gag-Specific T Cell Immunity Elicited by Dendritic Cell-Directed Lentiviral Vaccines,"" Molecular Therapy 20(9):1800-1809, Academic Press, United States (2012).;;Final Office Action mailed Oct. 22, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;International Preliminary Report on Patenetability for International Application No. PCT/US2006/026046, International Bureau of WIPO, Switzerland, mailed on Jan. 9, 2008,11 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2006/026046, European Patent Office, Netherlands, mailed on Apr. 3, 2007,17 pages.;;Ishida, I., et al., ""TransChromo Mouse,"" Biotechnology & Genetic Engineering Reviews 19:73-82, Taylor & Francis, England (2002).;;Issue Fee payment mailed Apr. 4, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Issue Fee payment mailed Jan. 22, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Kanai, T., et al., ""Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation,"" The Journal of Immunology 171(8):4156-4163, American Association of Immunologists, Inc., United States (2003).;;Klimka, A., et al., ""Human Anti-CD30 Recombinant Antibodies by Guided Phage Antibody Selection Using Cell Panning,"" British Journal of Cancer 83(2):252-260, Cancer Research Campaign, England (2000).;;Koga, N., et al., ""Blockade of the Interaction Between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts,"" Arteriosclerosis, Thrombosis and Vascualr Biology 24(11):2057-2062, American Heart Association, Inc., United States (2004).;;Mukherjee, J., et al., ""Human Stx2-Specific Monoclonal Antibodies Prevent Systemic Complications of Escherichia coli O157:H7 Infection,"" Infection and Immunity 70(2):612-619, American Society for Microbiology, United States (2002).;;Non-Final Office Action mailed Jan. 31, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Non-Final Office Action mailed Jun. 8, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Notice of Allowance mailed Jan. 4, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Notice of Allowance mailed May 2, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Notice of Allowance mailed Oct. 23, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Panka, D.J., et al., ""Variable Region Framework Differences Result in Decreased or Increased Affinity of Variant Anti-digoxin Antibodies,"" Proceedings of the National Academy of Sciences 85(9):3080-3084, National Academy of Sciences, United. States (1988).;;Porichis, F., et al., ""Differential impact PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions,"" Journal of Virology 88(5):2508-2518, American Society for Microbiology, United States (2014).;;Rader, C., et al., ""A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries,"" Proceedings of the National Academy of Sciences of the United States of America 95(15):8910-8915, National Academy of Sciences, United Ststes (1998).;;Request for Certificate of Correction mailed Jun. 13, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Request for Certificate of Correction mailed Nov. 1, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Response to Amendment under Rule 312 mailed Jan. 18, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Response to Final Office Action mailed Dec. 21, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Response to Non-Final Office Action mailed Apr. 9, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Response to Non-Final Office Action mailed Sep. 8, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Response to Restriction Requirement mailed Mar. 15, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Restriction Requirement mailed Dec. 14, 2009, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Rudikoff, S., et al., ""Single Amino Acid Substitution Altering Antigen-Binding Specificity,"" Proceedings of the National Academy of Sciences 79(6):1979-1983, The National Academy of Sciences, United States (1982).;;Sakthivel, P., et al., ""Therapeutic Intervention in Cancer and Chronic Viral Infections: Antibody Mediated Manipulation of PD-1/PD-L1 Interation,"" Reviews on Recent Clinical Trials 7(1):10-23, Bentham Science Pub., United Arab Emirates (2012).;;Seung, E., et al., ""PD-1 Blockade in Chronically HIV-1-Infected Humanized Mice Suppresses Viral Loads,"" PloS One 8(10):e77780, Public Library of Science, United States(Oct. 2013).;;Siewe, B., et al., ""Regulatory B Cells Inhibit Cytotoxic T Lymphocyte (CTL) Activity and Elimination of Infected CD4 T Cells after In Vitro Reactivation of HIV Latent Reservoirs,"" PloS One 9(4):e92934, Public Library of Science, United States (Apr. 2014).;;Tamura, M., et al., ""Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Delevlopment of a Minimally Immunogenic Antibody Variant by Retention of SDRs only,"" Journal of Immunology 164(3):1432-1441, American Association of Immunologist, United States (2000).;;Tomizuka, K., et al., ""Double Trans-Chromosomic Mice: Maintenance of Two Individual Human Chromosome Fragments Containing Ig Heavy and Kappa loci and Expression of Fully Human Antibodies,"" Proceedings of the National Academy of Sciences of the United States of America 97(2):722-727, National Academy of Sciences, United States (2000).;;Tomlinson, I.M., et al., ""The Repertoire of Human Germline VH Sequences Reveals About Fifty Groups of VH segments with Different Hypervariable Loops,"" Journal of Molecular Biology 227(3):776-798, Elsevier, Netherlands (1992).;;Xu, J.L. and Davis, M.M., ""Diversity in the CDR3 Region of V(H) is Sufficient for Most Antibody Specificities,"" Immunity 13(1):37-45, Cell Press, United States (2000).;;Antonia, S.J., et al., ""Association of tumor PD-L1 Expression and Immune Biomarkers with Clinical Activity in Patients with Non-small Cell Lung Cancer (NSCLC) Treated with Nivolumab (Anti-PD-1; BMS-936558; ONO-4538),"" 15th World Conference on Lung Cancer, Sydney, Australia, 15th WCLC: Best of Posters 1-IASLC Selection, P2.11-035, Oct. 27-30, 2013, accessed at http://web.oncoletter.ch/kongressberichte-videos-slides-Onkologie/id-15th-world-conference-on-lung-cancer-conference/conference-highlights.html, accessed on Jan. 8, 2015, 6 pages.;;Blank, C., et al., ""Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy,"" Cancer Immunology, Immunotherapy 54:307-314, Springer Science+ Business Media, Germany (2005).;;Brown, J.A., et al., ""Expression and functional consequences of PD-1 ligands on natural APCS and tumors,"" The FASEB Journal 15(4):A345 (abstract No. 275.23), Federation of American Societies for Experimental Biology, United States (2001).;;Brown, J.A., et al., ""Blockade of PD-1 ligands on dendritic cells enhances T cells activation and cytokine production,"" FASEB Journal 16(4):710-517.4, Federation of American Societies for Experimental Biology, United States (2002).;;Carreno, B.M., et al., ""The B7 family of ligands and its receptors: New pathways for co-stimulation and inhibition of immune responses,"" Annu Rev. Immunol, 20:29-53, Annual reviews, United States (2002).;;Carter, L., et al., ""PD-1: PD-L inhibitory pathway affects both CD4+ and CDS+ T cells and is overcome by IL-2,"" Eur J Immunology 32:634-643, Wiley-VCH, Germany (2002).;;Dong, H., et al., ""Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion,"" Nat Med, 8:783-800, Nature, United States (2002).;;Dong, H., Chen, L.,""B7-H1 pathway and its role in the evasion of tumor immunity,"" Journal of Molecular Medicine vol. 81:281-287, Springer Science+ Business Media, Germany (2002).;;Dong, H., et al., ""B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,"" Nature Medicine 5(12):1365-1369, Nature America Inc., United States (1999).;;Exhibit 1, ""Dichotomy of the activity of PD-L1 (B7-4) and how an anti-PD-1 antibody fits into it,"" in Response to Patentee's Aug. 12, 2015 Reply, mailed Dec. 21, 2015 for European Patent No. EP 1537878, filed Jul. 2, 2003, 1 page.;;Freeman, G.J., et al., ""Engagement of the PD-1 immunoinhibitory receptor by a novel B7-family member leads to negative regulation of lymphocyte activation,"", Journal of Experimental Medicine 192(7):1027-1034, Rockefeller University Press, United States (2000).;;Freeman, G.J., et al., ""Engagement of the PD-1 Immunoinhibitory by a Novel B7-Family Member Leads to Negative Regulation of Lymphocyte Activation,"" Blood 96(11):810a-811a (Abstract No. 3502) (2000).;;He, Y.F., et al., ""Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine,"" Journal of Immunology 173: 4919-4928, American Association of Immunologist, United States (2004).;;Hirano, F., et al., ""Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity,"" Cancer Research 65(3): 1089-1096, American Association for Cancer Research, United States (2005).;;Konishi, J., et al., ""B7-H1 Expression on Non-Small Cell Lung Cancer Cells and its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression,"" Clin. Cancer Res 10:5094-5100, American Association for Cancer Research, United States (2004).;;Nagler, A., et al., ""Phase I clinical trial CT-011, a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced hematological malignancies,"" Experimental Hematology, 33:97, Elsevier, Netherlands (2005).;;Nomi, T., et al., ""Clinical significance and therapeutic potential of the programmed death-1 liagnd/programmed death-1 pathway in human pancreatic cancer,"" Clinical Cancer Research 13(7):2151-2157, The Association, United States (2007).;;Tamura, H., et al., ""B7-H1 co-stimulation preferentially enhances CD28-independent T-helper cell function,"" Blood 97(6):1809-1816, American Society of Hematology, United States (2001).;;West, J.H., ""CheckMate-057 Trial: The Future of PD-L1 as a Biomarker,"" medscape.com, accessed at http://www.medscape.com/viewarticle/845926, accessed on Sep. 17, 2015, 1 page (Jun. 5, 2015).;;Yamazaki, T., et al., ""Expression of programmed death 1 ligands by murine T cells and APC,"" Journal of Immunology 169(10):5538-5545, American Association of Immunologist, United States (2002).;;Zou, W. and Chen, L., ""Inhibitory B7-family Molecules in the Tumour Microenvironment,"" Nature Reviews Immunology 8(6):467-477, Nature Publishing Group, England (2008).;;Zuberek, K., et al., ""The role of in vivo PD-1/PD-L1 interactions in syngeneic and allogeneic antitumor responses in murine tumor models,"" Blood 98(11):42B, American Society of Hematology, United States (2001).;;Co-pending Application, U.S. Appl. No. 15/188,860, Korman, A., et al., filed Jun. 21, 2016 (Not Published).;;Liang, S.C., et al., ""Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses,"" Eur J Immunol 33:2706-2716, Wiley-VCH Verlag GmbH & Co. KGaA, Germany (2003).;;Schoop, R., et al., ""Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells,"" Nephrol Dial Transplant 19:2713-2720, Springer International, England (2004).;;English Translation of Search Report dated Dec. 5, 2016, in Chinese Patent Application No. 201410639719.X.",ACTIVE
140,US,A1,US 2014/0212422 A1,150-129-841-458-355,2014-07-31,2014,US 201414227733 A,2014-03-27,US 201414227733 A;;US 201113210137 A;;US 91321706 A;;JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES IN COMBINATION WITH ANTI-CTLA-4 ANTIBODIES,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;ONO PHARMACEUTICAL CO. LTD (2007-12-27);;MEDAREX INC (2012-04-12),https://lens.org/150-129-841-458-355,Patent Application,yes,1,61,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395,424/135.1;;424/173.1;;424/152.1;;424/133.1;;424/144.1,0,0,,,,ACTIVE
141,HR,A2,HR P20080053 A2,004-725-171-053-355,2009-08-31,2009,HR P20080053 A,2008-01-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"Predmet ovog izuma su izolirana monoklonska protutijela, posebice ljudska monoklonska protutijela, koja se visokim afinitetom vežu na PD-L1. Otkrivaju se i molekule nukleinskih kiselina koje kodiraju sintezu protutijela koja su predmetom ovog izuma, ekspresijski vektori, stanice-domaćini i metode za ekspresiju protutijela. Otkrivaju se i imunokonjugati, bispecifične molekule i farmaceutske sastavine koje sadrže protutijela koja su predmetom ovog izuma. Otkrivaju se i metode detekcije PD-L1, kao i metode liječenja različitih bolesti, uključivši rak i infektivne bolesti s pomoću anti-PD-L1 protutijela.",MEDAREX,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,"MEDAREX, L.L.C., US (2013-07-25)",https://lens.org/004-725-171-053-355,Patent Application,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28,,0,0,,,,DISCONTINUED
142,EP,A2,EP 2439272 A2,051-629-639-096-890,2012-04-11,2012,EP 11178188 A,2006-05-02,EP 09013687 A;;EP 06746353 A;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX INC,SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;KORMAN ALAN J;;HUANG HAICHUN,"MEDAREX, L.L.C. (2014-04-23);;E. R. SQUIBB & SONS, L.L.C. (2015-03-04);;ONO PHARMACEUTICAL CO., LTD. (2015-03-04);;MEDAREX, INC. (2013-05-29)",https://lens.org/051-629-639-096-890,Patent Application,yes,115,13,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/18;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,157,119,076-092-237-434-500;;127-416-339-660-812;;117-522-189-960-276;;004-728-346-095-981;;043-645-889-898-36X;;020-766-613-912-972;;006-463-263-246-432;;052-597-675-128-75X;;081-074-583-383-824;;025-182-641-289-850;;076-731-232-972-252;;066-015-167-169-542;;006-568-097-103-41X;;013-122-792-588-081;;062-940-851-081-865;;048-060-748-635-820;;117-415-766-090-626;;038-551-014-784-214;;074-046-354-648-540;;008-208-772-364-327;;020-598-246-146-62X;;074-297-827-128-411;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;026-164-216-541-151;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;042-204-626-457-327;;006-574-964-805-278;;030-323-674-660-051;;092-023-577-402-127;;022-179-293-052-569;;004-458-031-333-650;;024-929-137-199-30X;;003-752-183-823-430;;070-318-112-524-781;;032-624-544-479-82X;;030-630-100-818-462;;106-753-778-592-300;;032-820-729-763-323;;083-549-078-331-651;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;033-754-369-798-314;;077-525-954-203-403;;028-969-172-280-017;;060-375-551-951-388;;020-753-772-581-741;;038-613-711-274-229;;047-951-914-695-080;;062-485-301-455-912;;032-820-729-763-323;;023-676-781-371-861;;026-744-100-669-883;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;030-769-003-988-749;;057-971-690-843-179;;145-254-035-276-41X;;026-646-521-253-318;;000-331-240-115-824;;065-438-177-962-139;;101-640-792-825-42X;;070-316-527-354-375;;040-550-546-463-785;;046-168-111-025-234;;043-654-077-374-418;;084-388-182-984-099;;005-112-559-456-657;;052-219-543-437-800;;007-364-858-655-289;;056-942-841-068-650;;107-302-749-967-437;;039-238-464-990-600;;036-564-551-324-053;;020-123-860-433-320;;011-516-147-270-264;;076-731-232-972-252;;006-568-097-103-41X;;005-416-473-959-707;;020-986-423-793-233;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;007-709-585-201-038;;056-422-417-058-69X;;005-022-447-377-963;;127-416-339-660-812;;098-407-145-404-736;;066-749-017-721-197;;001-467-559-709-949;;078-061-292-153-737;;055-646-175-554-792;;129-390-507-012-794;;008-213-515-306-640;;053-703-232-770-99X;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;042-688-967-632-553;;005-022-447-377-963;;029-697-384-910-375;;038-613-711-274-229;;062-418-979-939-961;;093-666-562-457-905,10.4049/jimmunol.170.2.711;;12517932;;9930702;;10.1038/16717;;10.1002/j.1460-2075.1992.tb05481.x;;pmc556898;;1396582;;10.1093/intimm/8.5.765;;8671665;;10.1084/jem.181.6.1953;;7539033;;pmc2192041;;10.1016/s0167-5699(97)80025-4;;9190115;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;11224527;;10.1038/85330;;11857337;;10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9;;12721664;;10.1007/s00109-003-0430-2;;10.1007/s00262-004-0593-x;;15599732;;10.1158/1078-0432.ccr-04-0428;;15297412;;10.1073/pnas.192461099;;12218188;;pmc129438;;10.4049/jimmunol.170.3.1257;;12538684;;10.1016/s1074-7613(00)80089-8;;10485649;;10.1126/science.291.5502.319;;11209085;;10.1084/jem.20022119;;12847138;;pmc2196082;;14764622;;10.1093/hmg/ddh076;;pmc61133;;10.1073/pnas.231486598;;11698646;;4703766;;10.1093/jnci/50.4.1013;;pmc1866856;;10.1016/s0002-9440(10)65141-3;;10433938;;1330947;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;3382986;;10.1093/bioinformatics/4.1.11;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;3127726;;10.1038/332323a0;;10.1038/321522a0;;3713831;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;11096108;;10.1074/jbc.m009483200;;10.1002/bit.20151;;15352059;;11986321;;10.1074/jbc.m202069200;;10.1038/6179;;10052355;;1201277;;10.1021/bi00696a021;;10.1038/348552a0;;2247164;;1172191;;10.1038/256495a0;;8159246;;10.1038/368856a0;;10.1007/978-3-642-78432-3_3;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;8144892;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nbt727;;12172556;;8159246;;10.1038/368856a0;;10.1126/science.3929380;;3929380;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;12564977;;10.1016/s0169-409x(02)00179-5;;10.1007/s00262-002-0352-9;;12700948;;12676579;;10.1016/s1535-6108(03)00057-6;;10.1038/nrc903;;12360278;;12186272;;10.1016/s0169-409x(01)00206-x;;11744170;;7042536;;10.1111/j.1600-065x.1982.tb00392.x;;10.4049/jimmunol.155.10.4996;;7594506;;8954257;;1371789;;6239899;;10.1084/jem.160.6.1686;;pmc2187539;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;10.1126/science.3925553;;3925553;;2958547;;10.4049/jimmunol.139.7.2367;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;3390170;;10.1016/s0006-291x(88)81333-0;;10.1128/aac.39.1.180;;pmc162506;;7695303;;7907597;;10.1016/s0021-9258(17)37081-3;;10.1016/0014-5793(94)00313-0;;8206150;;7820457;;10.1006/immu.1994.1029;;10.1007/s00262-004-0593-x;;15599732;;10.1073/pnas.192461099;;12218188;;pmc129438;;15611321;;10.1093/intimm/dxh194;;15470033;;10.4049/jimmunol.173.8.4919;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;9624003;;10.1038/30989;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;9930702;;10.1038/16717;;10417377;;10.1126/science.285.5427.546;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;pmc15881;;10.1073/pnas.96.6.2982;;10077623;;10.1097/00002371-199601000-00009;;8859727;;10.1038/22124;;10408445;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;9850053;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;10.1016/s0171-2985(00)80072-8;;10834311;;9176498;;10.1038/nm0697-682;;10.1002/j.1460-2075.1993.tb05721.x;;pmc413278;;8458339;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1126/science.271.5256.1734;;8596936;;10.1016/s0165-2478(02)00088-3;;12095712,"OKAZAKI ET AL., CURR. OPIN. IMMUNOL., vol. 14, 2002, pages 391779 - 82;;BENNETT ET AL., J IMMUNOL, vol. 170, 2003, pages 711 - 8;;HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 263 - 266;;HANSEN ET AL., 1MMUNOGENICS, vol. 10, 1980, pages 247 - 260;;ISHIDA ET AL., EMBO J, vol. 11, 1992, pages 3887 - 95;;AGATA ET AL., INT IMMUNOL, vol. 8, 1996, pages 765 - 72;;THOMAS, M.L., J EXP MED, vol. 181, 1995, pages 1953 - 6;;VIVIER, E, DAERON, M, IMMUNOL TODAY, vol. 18, 1997, pages 286 - 91;;FREEMAN ET AL., JEXP MED, vol. 192, 2000, pages 1027 - 34;;LATCHMAN ET AL., NAT IMMUNOL, vol. 2, 2001, pages 261 - 8;;CARTER ET AL., EUR J IMMUNOL, vol. 32, 2002, pages 634 - 43;;DONG ET AL., NAT. MED, vol. 8, 2002, pages 787 - 9;;DONG ET AL., J. MOL. MED., vol. 81, 2003, pages 281 - 7;;BLANK ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 54, 2005, pages 307 - 314;;KONISHI ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 5094 - 100;;IWAI ET AL., PROC. NAT.'L ACAD SCI. USA, vol. 99, 2002, pages 12293 - 7;;BROWN ET AL., J IMMUNOL., vol. 170, 2003, pages 1257 - 66;;OKAZAKI ET AL., CURR OPIN IMMUNOL, vol. 14, 2002, pages 391779 - 82;;NISHIMURA ET AL., IMMUNITY, vol. 11, 1999, pages 141 - 51;;NISHIMURA ET AL., SCIENCE, vol. 291, 2001, pages 319 - 22;;SALAMA ET AL., JEXP MED, vol. 198, 2003, pages 71 - 78;;PROKUNINA, ALARCON-RIQUELME, HUM MOL GENET, vol. 13, 2004, pages R143;;NIELSEN ET AL., LUPUS, vol. 13, 2004, pages 510;;OKAZAKI, PNAS, vol. 98, 2001, pages 13866 - 71;;MURPHY, HRUSHESKY, J. NAT.'L. CANCER RES., vol. 50, 1973, pages 1013 - 1025;;MURATA, AM. J PATHOL., vol. 155, 1999, pages 453 - 460;;BALZANO, INT. J CANCER, vol. 7, 1992, pages 28 - 32;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD SCI. USA, vol. 85, 1988, pages 5879 - 5883;;E. MEYERS, W. MILLER, COMPUT. APPL. BIOSCI., vol. 4, 1988, pages 11 - 17;;NEEDLEMAN, WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL, J. MOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;RIECHMANN, L. ET AL., NATURE, vol. 332, 1998, pages 323 - 327;;JONES, P. ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;QUEEN, C., PROC. NATL. ACAD SEE. U.S.A., vol. 86, 1989, pages 10029 - 10033;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest, Fifth Edition,"", 1991, NIH PUBLICATION NO. 91-3242;;TOMLINSON, I. M. ET AL.: ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: doi:10.1016/0022-2836(92)90223-7;;COX, J. P. L. ET AL.: ""A Directory of Human Germ-line VH Segments Reveals a Strong Bias in their Usage"", EUR.J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;SHIELDS, R.L. ET AL., J BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;YAMANE-OHNUKI ET AL., BIOTECHNOL BIOENG, vol. 87, 2004, pages 614 - 22;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;TARENTINO, A.L. ET AL., BIOCHEM., vol. 14, 1975, pages 5516 - 23;;F. AUSUBEL, ET AI.,: ""Current Protocols in Molecular Biology"", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;KOHLER, MILSTEIN, NATURE, vol. 256, 1975, pages 495;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;LONBERG, N., HANDBOOK OFEXPERIMENTAL PHARMACOLOGY, vol. 113, 1994, pages 49 - 101;;LONBERG, N., HUSZAR, D., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F., LONBERG, N., ANN. N.Y. ACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 2, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD SCI. USA, vol. 90, 1993, pages 3720 - 3724;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J. ET AL., EMBO J., vol. 12, 1993, pages 821 - 830;;TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;TOMIZUKA ET AL., PROC. NATL. ACAD SCI. USA, vol. 97, 2000, pages 722 - 727;;KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894;;LONBERG, N. ET AL., NATURE, vol. 3 68, no. 6474, 1994, pages 856 - 859;;MORRISON, S., SCIENCE, vol. 229, 1985, pages 1202;;GOEDDEL: ""Gene Expression Technology. Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;TALCEBE, Y., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;BOSS, M. A., WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB, CHASIN, PROC. NATL. ACAD SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMAN, P. A. SHARP, MOL. BIOI., vol. 159, 1982, pages 601 - 621;;SAITO, G. ET AL., ADV. DRUG DELIV. REV., vol. 55, 2003, pages 199 - 215;;TRAIL, P.A. ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 52, 2003, pages 328 - 337;;PAYNE, G., CANCER CELL, vol. 3, 2003, pages 207 - 212;;ALLEN, T.M., NAT. REV. CANCER, vol. 2, 2002, pages 750 - 763;;PASTAN, I., KREITMAN, R. J., CURR. OPIN. INVESTIG. DRUGS, vol. 3, 2002, pages 1089 - 1091;;SENTER, P.D., SPRINGER, C.J., ADV. DRUG DELIV. REV, vol. 53, 2001, pages 247 - 264;;ARNON ET AL.: ""Monoclonal Antibodies And Cancer Therapy"", 1985, ALAN R. LISS, INC., article ""Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy"", pages: 243 - 56;;ROBINSON ET AL.: ""Controlled Drug Delivery(2nd Ed.)"", 1987, MARCEL DEKKER, INC., article HELLSTROM ET AL.: ""Antibodies For Drug Delivery"", pages: 623 - 53;;PINCHERA ET AL.: ""Monoclonal Antibodies '84: Biological And Clinical Applications"", 1985, article THORPE ET AL.: ""Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review"", pages: 475 - 506;;BALDWIN ET AL.: ""Monoclonal Antibodies For Cancer Detection And Therapy"", 1985, ACADEMIC PRESS, article ""Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy"", pages: 303 - 16;;THORPE ET AL.: ""The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates"", IMMUNOL. REV., vol. 62, 1982, pages 119 - 5,8;;GRAZIANO, R.F. ET AL., J. IMMUNOL, vol. 155, no. 10, 1995, pages 4996 - 5002;;MORTON, H.C. ET AL., CRITICAL REVIEWS IN IMMUNOLOGY, vol. 16, 1996, pages 423 - 440;;MONTEIRO, RC. ET AL., J. IMMUNOL., vol. 148, 1992, pages 1764;;KARPOVSKY ET AL., J. EXP. MED., vol. 160, 1984, pages 1686;;LIU, MA ET AL., PROC. NATL. ACAD SCI. USA, vol. 82, 1985, pages 8648;;BEHRING INS. MITT., pages 118 - 132;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83;;GLENNIE ET AL., J. 1MMUNOL, vol. 139, 1987, pages 2367 - 2375;;WEINTRAUB, B.: ""Principles ofRadioimmunoassays, Seventh Training Course on Radioligand Assay Techniques"", THE ENDOCRINE SOCIETY, March 1986 (1986-03-01);;BERGE, S.M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;J.R. ROBINSON: ""Sustained and ControlledRelease Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;V.V. RANADE, J CLIN PHARMACOL., vol. 29, 1989, pages 685;;UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 153, 1988, pages 1038;;P.G. BLOEMAN, FEBS LEFT., vol. 357, 1995, pages 140;;M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 39, 1995, pages 180;;BRISCOE ET AL., AM. J. PHYSIOL., vol. 1233, 1995, pages 134;;SCHREIER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 9090;;K. KEINANEN, M.L. LAUKKANEN, FEBSLETT., vol. 346, 1994, pages 123;;J.J. KILLION, I.J. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273;;DONG ET AL., NATMED, vol. 8, 2002, pages 787 - 9;;DONG ET AL., J MOL MED, vol. 81, 2003, pages 281 - 7;;BLANK ET AL., CANCER IMMUNOL. IMMUNOFHER., vol. 54, 2005, pages 307 - 314;;IWAI ET AL., PNAS, vol. 99, 2002, pages 12293 - 7;;IWAI ET AL., INT. IMMUNOL., vol. 17, 2005, pages 133 - 144;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;ROSENBERG, S.: ""ASCO Educational Book"", 2000, SPRING, article ""Development of Cancer Vaccines"", pages: 60 - 62;;LOGOTHETIS, C.: ""ASCO Educational Book"", 2000, SPRING, pages: 300 - 302;;KHAYAT, D.: ""ASCO Educational Book"", 2000, SPRING, pages: 414 - 428;;FOON, K.: ""ASCO Educational Book"", 2000, SPRING, pages: 730 - 738;;RESTIFO, N., SZNOL, M.: ""Cancer Vaccines"", pages: 3023 - 3043;;DEVITA, V.: ""Cancer: Principles and Practice of Oncology. Fifth Edition"", 1997;;DRANOFF ET AL., PROC. NAFL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, SA, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM, NET, SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT, R, SRIVASTAVA, P, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA, Y. ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE, F. ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER, A. ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR, M. ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL, J. ET AL., J EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARD, M., O'GARRA, A., IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE, M. ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;RIDGE, J. ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;ITO, N. ET AL., INIMUNOBIOLOGY, vol. 201, no. 5, 2000, pages 527 - 40;;WEINBERG, A. ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO, 1. ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF A. ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;GREENBERG, R., RIDDELL, S., SCIENCE, vol. 285, 1999, pages 546 - 51;;HOLLIGER, PROC. NAFL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;OVERWIJK, W. ET AL., PROC. NATL. ACAD SCI. U.S.A., vol. 96, 1999, pages 2982 - 2987;;ROSENBERG, SA, WHITE, DE, J. IMMUNOTHER EMPHASIS TUMOR IMMUNOL, vol. 19, no. 1, 1996, pages 81 - 4;;SCHENK ET AL., NATURE, vol. 400, 1999, pages 173 - 177;;HARLOW, LANE: ""Antibodies, A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY PRESS;;HURWITZ ET AL., PROC. NATL. ACAD SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071;;CAMACHO ET AL., J CLIN. ONCOLOGY, vol. 22, no. 145, 2004;;MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304;;HE ET AL., J IMMUNOL., vol. 173, 2004, pages 4919 - 28;;DRANOFF ET AL., PROC. NAFL. ACAD SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT, SRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;ITO, N. ET AL., IMMUNOBIOLOGY, vol. 201, no. 5, 2000, pages 527 - 40;;MELERO, I. ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF, A. ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;""PDR 58th ed."", 2004, pages: 608 - 610;;CHEN ET AL., EMBO 1., vol. 12, 1993, pages 811 - 820;;FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;LONBERG, N. ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;HARLOW, LANE: ""Antibodies A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY PRESS;;LEACH ET AL., SCIENCE, vol. 271, 1996, pages 1734 - 1736;;WAI Y; ET AL: ""MICROANATOMICAL LOCALIZATION OF PD-1 IN HUMAN TONSILS"", IMMUNOLOGY LETTERS,, vol. 83, no. 3, 1 January 2002 (2002-01-01), pages 215 - 220, XP003007112",DISCONTINUED
143,ES,T5,ES 2427646 T5,066-773-043-494-32X,2017-08-22,2017,ES 09013687 T,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos,,ONO PHARMACEUTICAL CO;;MEDAREX LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/066-773-043-494-32X,Amended Patent,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
144,CN,A,CN 105330741 A,064-567-776-246-155,2016-02-17,2016,CN 201510505393 A,2006-06-30,US 69642605 P;;CN 200680028238 A,2005-07-01,Human monoclonal antibodies to programmed death ligand 1 (pd-l1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-Ll antibodies.",SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/064-567-776-246-155,Patent Application,no,1,6,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A61K39/395;;A61P31/00;;A61P35/00,,3,2,067-760-343-772-225;;006-568-097-103-41X,14871849;;10.1158/0008-5472.can-03-3259;;10.1073/pnas.192461099;;12218188;;pmc129438,"CHRISTIAN BLANK，ET AL.: ""PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor(TCR) Transgenic CD8+ T Cells"", 《CANCER RESEARCH》;;YOSHIKO IWAI,ET AL.: ""Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade"", 《PNAS》;;陈永井等: ""人PD-L1(B7-H1)基因克隆及其逆转录病毒载体的构建和稳定表达"", 《中国肿瘤生物治疗杂志》",ACTIVE
145,US,A1,US 2015/0337038 A1,070-990-140-286-974,2015-11-26,2015,US 201514796956 A,2015-07-10,US 201514796956 A;;US 201313746773 A;;US 201113091936 A;;US 91772706 A;;US 2006/0026046 W;;US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;MEDAREX INC (2008-03-26),https://lens.org/070-990-140-286-974,Patent Application,yes,0,23,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A61K39/395,,0,0,,,,ACTIVE
146,EP,B1,EP 2161336 B1,075-008-177-287-383,2013-07-31,2013,EP 09013687 A,2006-05-02,EP 06746353 A;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,,ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,"ONO PHARMACEUTICAL CO., LTD., US (2015-01-30);;MEDAREX, L.L.C. (2014-03-03);;MEDAREX, L.L.C., PRINCETON, US (2014-04-01);;E.R. SQUIBB & SONS, L.L.C., PRINCETON, NJ, US (2015-07-15);;ONO PHARMACEUTICAL CO., LTD., OSAKA-SHI, OSAKA, JP (2015-07-15);;MEDAREX, L.L.C., PRINCETON, NEW JERSEY, US (2014-06-05);;MEDAREX, L.L.C., US (2014-04-01);;E. R. SQUIBB & SONS, L.L.C. (2015-04-22);;E. R. SQUIBB & SONS, L.L.C. (N.D.GES.D. STAATE, US (2015-02-05);;ONO PHARMACEUTICAL CO., LTD., JP (2016-04-19);;ONO PHARMACEUTICAL CO., LTD. (2015-04-22);;E. R. SQUIBB & SONS, L.L.C., US (2016-04-19);;MEDAREX, INC. (2013-05-29);;ONO PHARMACEUTICAL CO., LTD.; US (2015-02-13)",https://lens.org/075-008-177-287-383,Granted Patent,yes,0,15,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,2,0,,,"BROWN JULIA A ET AL: ""Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production"" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 170, no. 3, 1 February 2003 (2003-02-01), pages 1257-1266, XP002973918 ISSN: 0022-1767;;LONBERG N ET AL: ""ANTIGEN-SPECIFIC HUMAN ANTIBODIES FROM MICE COMPRISING FOUR DISTINCT GENETIC MODIFICATIONS"" NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 368, no. 6474, 28 April 1994 (1994-04-28), pages 856-859, XP000941636 ISSN: 0028-0836",ACTIVE
147,US,B2,US 9546216 B2,116-108-530-360-056,2017-01-17,2017,US 14807522,2015-07-23,,,Human monoclonal antibodies to programmed death ligand 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.","E. R. Squibb & Sons, L. L. C.",Alan J. Korman;;Mark J. Selby;;Changyu Wang;;Mohan Srinivasan;;David B. Passmore;;Haichun Huang;;Haibin Chen,,https://lens.org/116-108-530-360-056,Granted Patent,yes,104,0,1,1,120,C07K16/2803;;A61K39/3955;;A61K47/48438;;A61K47/48469;;A61K47/48561;;C07K16/28;;C07K16/2827;;A61K2039/505;;A61K2039/507;;A61K2039/575;;C07K2316/96;;C07K2317/21;;C07K2317/41;;C07K2317/51;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/77;;C07K2317/92,C07K16/28;;A61K39/395;;A61K47/48;;A61K39/00,,74,0,,,"U.S. Appl. No. 15/188,860, filed Jun. 2016, Korman, A.;;Blank, C., at al., “Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro,” International Journal of Cancer 119(2):317-327, International Union Against Cancer, United States (2006).;;Iwai, Y., et al., “Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade,” Proceedings of the National Academy of Sciences of the United States of America 99(19):12293-12297, National Academy of Sciences, United States (2002).;;Extended European Search Report and Search Opinion for EP Application No. 15172571.0, European Patent Office, Germany, mailed on Dec. 17, 2015.;;Amendment after Notice of Allowance mailed Jan. 10, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Amendment and Request for Continued Examination (RCE) mailed Aug. 20, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Barbas, S.M., et al., “Human Autoantibody Recognition of DNA,” Proceedings of the National Academy of Sciences of the United States of America 92(7):2529-2533, National Academy of Sciences, United States (1995).;;Barbas, S.M., et al., “Recognition of DNA by Synthetic Antibodies,” Journal of the American Chemical Society 116(5):2161-2162, American Chemical Society, United States (1994).;;Barber, D.L., et al., “Restoring Function in Exhausted CD8 T Cells during Chronic Viral Infection,” Nature 439(7077):682-687, Nature Publishing Group, United States (2006).;;Beiboer, S.H., et al., “Guided Selection of a Pan Carcinoma Specific Antibody Reveals Similar Binding Characteristics Yet Structural Divergence between the Original Murine Antibody and its Human Equivalent,” Journal of Molecular Biology 296(3):833-849, Elsevier, England (2000).;;Blank, C., et al., “PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells,” Cancer Research 64(3):1140-1145, American Association for Cancer Research, United States (2004).;;Brahmer, J.R., et al., “Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer,” The New England Journal of Medicine 366(26):2455-2465, Massachusetts Medical Society, United States (2012).;;Brown, J.A., et al., “Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production,” The Journal of Immunology 170(3):1257-1266, The American Association of Immunologists, United States (2003).;;Certificate of Correction mailed Dec. 6, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Certificate of Correction mailed Jul. 9, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Cox, J.P., et al., “A Directory of Human Germ-Line V kappa Segments Reveals a Strong Bias in their Usage,” European Journal of Immunology 24(4):827-836, Verlag Chemie GmbH, Germany (1994).;;Dai, B., et al., “PD-1/PD-L1 Blockade can Enhance HIV-1 Gag-Specific T Cell Immunity Elicited by Dendritic Cell-Directed Lentiviral Vaccines,” Molecular Therapy 20(9):1800-1809, Academic Press, United States (2012).;;Final Office Action mailed Oct. 22, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;International Preliminary Report on Patenetability for International Application No. PCT/US2006/026046, International Bureau of WIPO, Switzerland, mailed on Jan. 9, 2008,11 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2006/026046, European Patent Office, Netherlands, mailed on Apr. 3, 2007,17 pages.;;Ishida, I., et al., “TransChromo Mouse,” Biotechnology & Genetic Engineering Reviews 19:73-82, Taylor & Francis, England (2002).;;Issue Fee payment mailed Apr. 4, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Issue Fee payment mailed Jan. 22, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Kanai, T., et al., “Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation,” The Journal of Immunology 171(8):4156-4163, American Association of Immunologists, Inc., United States (2003).;;Klimka, A., et al., “Human Anti-CD30 Recombinant Antibodies by Guided Phage Antibody Selection Using Cell Panning,” British Journal of Cancer 83(2):252-260, Cancer Research Campaign, England (2000).;;Koga, N., et al., “Blockade of the Interaction Between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts,” Arteriosclerosis, Thrombosis and Vascualr Biology 24(11):2057-2062, American Heart Association, Inc., United States (2004).;;Mukherjee, J., et al., “Human Stx2-Specific Monoclonal Antibodies Prevent Systemic Complications of Escherichia coli O157:H7 Infection,” Infection and Immunity 70(2):612-619, American Society for Microbiology, United States (2002).;;Non-Final Office Action mailed Jan. 31, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Non-Final Office Action mailed Jun. 8, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Notice of Allowance mailed Jan. 4, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Notice of Allowance mailed May 2, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Notice of Allowance mailed Oct. 23, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Panka, D.J., et al., “Variable Region Framework Differences Result in Decreased or Increased Affinity of Variant Anti-digoxin Antibodies,” Proceedings of the National Academy of Sciences 85(9):3080-3084, National Academy of Sciences, United. States (1988).;;Porichis, F., et al., “Differential impact PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions,” Journal of Virology 88(5):2508-2518, American Society for Microbiology, United States (2014).;;Rader, C., et al., “A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries,” Proceedings of the National Academy of Sciences of the United States of America 95(15):8910-8915, National Academy of Sciences, United Ststes (1998).;;Request for Certificate of Correction mailed Jun. 13, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Request for Certificate of Correction mailed Nov. 1, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Response to Amendment under Rule 312 mailed Jan. 18, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Response to Final Office Action mailed Dec. 21, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Response to Non-Final Office Action mailed Apr. 9, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Response to Non-Final Office Action mailed Sep. 8, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Response to Restriction Requirement mailed Mar. 15, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Restriction Requirement mailed Dec. 14, 2009, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Rudikoff, S., et al., “Single Amino Acid Substitution Altering Antigen-Binding Specificity,” Proceedings of the National Academy of Sciences 79(6):1979-1983, The National Academy of Sciences, United States (1982).;;Sakthivel, P., et al., “Therapeutic Intervention in Cancer and Chronic Viral Infections: Antibody Mediated Manipulation of PD-1/PD-L1 Interation,” Reviews on Recent Clinical Trials 7(1):10-23, Bentham Science Pub., United Arab Emirates (2012).;;Seung, E., et al., “PD-1 Blockade in Chronically HIV-1-Infected Humanized Mice Suppresses Viral Loads,” PloS One 8(10):e77780, Public Library of Science, United States(Oct. 2013).;;Siewe, B., et al., “Regulatory B Cells Inhibit Cytotoxic T Lymphocyte (CTL) Activity and Elimination of Infected CD4 T Cells after In Vitro Reactivation of HIV Latent Reservoirs,” PloS One 9(4):e92934, Public Library of Science, United States (Apr. 2014).;;Tamura, M., et al., “Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Delevlopment of a Minimally Immunogenic Antibody Variant by Retention of SDRs only,” Journal of Immunology 164(3):1432-1441, American Association of Immunologist, United States (2000).;;Tomizuka, K., et al., “Double Trans-Chromosomic Mice: Maintenance of Two Individual Human Chromosome Fragments Containing Ig Heavy and Kappa loci and Expression of Fully Human Antibodies,” Proceedings of the National Academy of Sciences of the United States of America 97(2):722-727, National Academy of Sciences, United States (2000).;;Tomlinson, I.M., et al., “The Repertoire of Human Germline VH Sequences Reveals About Fifty Groups of VH segments with Different Hypervariable Loops,” Journal of Molecular Biology 227(3):776-798, Elsevier, Netherlands (1992).;;Xu, J.L. and Davis, M.M., “Diversity in the CDR3 Region of V(H) is Sufficient for Most Antibody Specificities,” Immunity 13(1):37-45, Cell Press, United States (2000).;;Antonia, S.J., et al., “Association of tumor PD-L1 Expression and Immune Biomarkers with Clinical Activity in Patients with Non-small Cell Lung Cancer (NSCLC) Treated with Nivolumab (Anti-PD-1; BMS-936558; ONO-4538),” 15th World Conference on Lung Cancer, Sydney, Australia, 15th WCLC: Best of Posters 1—IASLC Selection, P2.11-035, Oct. 27-30, 2013, accessed at http://web.oncoletter.ch/kongressberichte-videos-slides-Onkologie/id-15th-world-conference-on-lung-cancer-conference/conference-highlights.html, accessed on Jan. 8, 2015, 6 pages.;;Blank, C., et al., “Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy,” Cancer Immunology, Immunotherapy 54:307-314, Springer Science+ Business Media, Germany (2005).;;Brown, J.A., et al., “Expression and functional consequences of PD-1 ligands on natural APCS and tumors,” The FASEB Journal 15(4):A345 (abstract No. 275.23), Federation of American Societies for Experimental Biology, United States (2001).;;Brown, J.A., et al., “Blockade of PD-1 ligands on dendritic cells enhances T cells activation and cytokine production,” FASEB Journal 16(4):710-517.4, Federation of American Societies for Experimental Biology, United States (2002).;;Carreno, B.M., et al., “The B7 family of ligands and its receptors: New pathways for co-stimulation and inhibition of immune responses,” Annu Rev. Immunol, 20:29-53, Annual reviews, United States (2002).;;Carter, L., et al., “PD-1: PD-L inhibitory pathway affects both CD4+ and CDS+ T cells and is overcome by IL-2,” Eur J Immunology 32:634-643, Wiley-VCH, Germany (2002).;;Dong, H., et al., “Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion,” Nat Med, 8:783-800, Nature, United States (2002).;;Dong, H., Chen, L.,“B7-H1 pathway and its role in the evasion of tumor immunity,” Journal of Molecular Medicine vol. 81:281-287, Springer Science+ Business Media, Germany (2002).;;Dong, H., et al., “B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,” Nature Medicine 5(12):1365-1369, Nature America Inc., United States (1999).;;Exhibit 1, “Dichotomy of the activity of PD-L1 (B7-4) and how an anti-PD-1 antibody fits into it,” in Response to Patentee's Aug. 12, 2015 Reply, mailed Dec. 21, 2015 for European Patent No. EP 1537878, filed Jul. 2, 2003, 1 page.;;Freeman, G.J., et al., “Engagement of the PD-1 immunoinhibitory receptor by a novel B7-family member leads to negative regulation of lymphocyte activation,”, Journal of Experimental Medicine 192(7):1027-1034, Rockefeller University Press, United States (2000).;;Freeman, G.J., et al., “Engagement of the PD-1 Immunoinhibitory by a Novel B7-Family Member Leads to Negative Regulation of Lymphocyte Activation,” Blood 96(11):810a-811a (Abstract No. 3502) (2000).;;He, Y.F., et al., “Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine,” Journal of Immunology 173: 4919-4928, American Association of Immunologist, United States (2004).;;Hirano, F., et al., “Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity,” Cancer Research 65(3): 1089-1096, American Association for Cancer Research, United States (2005).;;Konishi, J., et al., “B7-H1 Expression on Non-Small Cell Lung Cancer Cells and its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression,” Clin. Cancer Res 10:5094-5100, American Association for Cancer Research, United States (2004).;;Nagler, A., et al., “Phase I clinical trial CT-011, a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced hematological malignancies,” Experimental Hematology, 33:97, Elsevier, Netherlands (2005).;;Nomi, T., et al., “Clinical significance and therapeutic potential of the programmed death-1 liagnd/programmed death-1 pathway in human pancreatic cancer,” Clinical Cancer Research 13(7):2151-2157, The Association, United States (2007).;;Tamura, H., et al., “B7-H1 co-stimulation preferentially enhances CD28-independent T-helper cell function,” Blood 97(6):1809-1816, American Society of Hematology, United States (2001).;;West, J.H., “CheckMate-057 Trial: The Future of PD-L1 as a Biomarker,” medscape.com, accessed at http://www.medscape.com/viewarticle/845926, accessed on Sep. 17, 2015, 1 page (Jun. 5, 2015).;;Yamazaki, T., et al., “Expression of programmed death 1 ligands by murine T cells and APC,” Journal of Immunology 169(10):5538-5545, American Association of Immunologist, United States (2002).;;Zou, W. and Chen, L., “Inhibitory B7-family Molecules in the Tumour Microenvironment,” Nature Reviews Immunology 8(6):467-477, Nature Publishing Group, England (2008).;;Zuberek, K., et al., “The role of in vivo PD-1/PD-L1 interactions in syngeneic and allogeneic antitumor responses in murine tumor models,” Blood 98(11):42B, American Society of Hematology, United States (2001).;;Co-pending Application, U.S. Appl. No. 15/188,860, Korman, A., et al., filed Jun. 21, 2016 (Not Published).",UNKNOWN
148,AU,C1,AU 2006/265108 C1,116-893-185-943-440,2013-01-17,2013,AU 2006/265108 A,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,Human monoclonal antibodies to programmed death ligand 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-Ll antibodies.",SQUIBB & SONS LLC,WANG CHANGYU;;KORMAN ALAN J;;PASSMORE DAVID B;;CHEN HAIBIN;;HUANG HAICHUN;;SRINIVASAN MOHAN;;SELBY MARK J,,https://lens.org/116-893-185-943-440,Amended Patent,no,4,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28,,2,2,067-760-343-772-225;;119-897-745-760-544,14871849;;10.1158/0008-5472.can-03-3259;;10.1161/01.atv.0000145015.23656.e4;;15374847,"Blank, C et al (2004) Cancer Research. v64 pp1140-1145;;Koga, N et al (2004) Arterioscler. Thromb. Vasc. Biol. v24 pp2057-2062",ACTIVE
149,US,A1,US 2023/0061544 A1,167-407-939-615-018,2023-03-02,2023,US 202217842540 A,2022-06-16,US 202217842540 A;;US 201916448721 A;;US 201715413244 A;;US 201615188860 A;;US 201514807522 A;;US 201313746773 A;;US 201113091936 A;;US 91772708 A;;US 2006/0026046 W;;US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/167-407-939-615-018,Patent Application,yes,0,0,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A61K45/06;;A61K47/68,,0,0,,,,PENDING
150,US,B2,US 9387247 B2,036-248-532-066-269,2016-07-12,2016,US 201414244405 A,2014-04-03,US 201414244405 A;;US 201113210137 A;;US 91321706 A;;JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Monoclonal antibodies to programmed death 1 (PD-1),"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",SQUIBB & SONS LLC;;ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;ONO PHARMACEUTICAL CO. LTD (2007-12-27);;MEDAREX INC (2012-04-12),https://lens.org/036-248-532-066-269,Granted Patent,yes,89,96,120,125,82,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/00;;A61K39/395;;A61K47/48;;A61K51/10;;C07K16/18;;C07K16/46,,99,32,113-346-509-283-257;;062-418-979-939-961;;088-474-798-925-827;;022-983-190-510-755;;027-748-683-255-715;;016-221-116-270-759;;020-140-165-898-622;;145-209-675-614-912;;063-640-752-709-241;;027-989-490-885-638;;023-222-320-518-73X;;022-735-509-615-805;;074-668-310-987-029;;034-879-699-905-632;;010-811-198-482-852;;103-897-301-868-65X;;197-193-057-828-756;;001-779-867-387-972;;013-584-945-188-940;;115-398-566-039-426;;135-447-350-940-622;;052-153-724-747-948;;147-888-721-956-877;;166-025-821-402-033;;057-460-007-966-306;;006-463-263-246-432;;013-770-850-974-489;;124-864-341-496-45X;;152-923-894-609-509;;085-413-318-249-981;;063-455-531-393-728;;060-728-367-476-688,11861596;;10.1146/annurev.immunol.20.091101.091806;;10.1126/science.271.5256.1734;;8596936;;11329858;;10.1016/s0065-3233(01)56010-6;;10.1084/jem.20022235;;12847136;;pmc2196084;;10.1038/nbt1137;;16151408;;14552835;;10.1016/j.it.2003.08.005;;15122199;;10.1038/nri1349;;12947224;;10.1385/ir:28:1:49;;7581696;;10.1385/0-89603-275-2:171;;15030777;;10.1016/s1074-7613(04)00051-2;;10.1084/jem.20022125;;12847137;;pmc2196083;;9801349;;10.1128/cdli.5.6.862-870.1998;;pmc96216;;pmc4834717;;20516446;;10.1200/jco.2009.26.7609;;7481795;;10.1126/science.270.5238.932;;15785203;;10.1089/hyb.2005.24.1;;pmc4348009;;10.1056/nejmoa1411087;;25482239;;10.1016/s0075-7535(08)70702-2;;10.1006/jmbi.1999.3192;;10543973;;10.1182/blood-2002-06-1761;;12393541;;10.1177/107327481402100112;;24357746;;pmc40169;;8552677;;10.1073/pnas.93.1.7;;16285013;;10.1002/eji.200535232;;10.1093/protein/11.1.65;;9579662;;10.1016/s0958-1669(98)80091-8;;9503595;;10.1016/s1535-6108(04)00083-2;;15093539;;10.2210/pdb1s78/pdb;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;18410894;;10.1016/j.bbmt.2008.02.010;;pmc2423190;;10.1038/78963;;10966641;;18429302;;9592769;;10.1007/bf02752698;;14530338;;10.4049/jimmunol.171.8.4156;;18059626;;10.1080/02648725.2007.10648092,"Notice of Opposition to European Patent No. EP 2 161 336, from Novartis AG, dated Apr. 25, 2014.;;Notice of Opposition to European Patent No. EP 2 161 336, from 4-Antibody AG, dated Apr. 29, 2014.;;Notice of Opposition to European Patent No. EP 2 161 336, from Janssen Biotech, Inc., dated Apr. 30, 2014.;;Notice of Opposition to European Patent No. EP 2 161 336, from Merck & Co., Inc., dated Apr. 30, 2014.;;Honjo, et al., Deposit receipt for Accession No. FERM BP-8392 mentioned in EP-A 1 537 878, 1 page (Jun. 5, 2003).;;Carreno, et al., ""The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses"", Annu Rev. Immunol., 20:29-53 (2002).;;Leach, et al., ""Enhancement of antitumor immunity by CTLA-4 blockade"", Science, 271(5256):1734-1736 (1996).;;Declarations by Dr. Robert J. Bolch including 2 Annex and 39 exhibits, 82 pages (Apr. 29, 2014).;;Patentee's response to Examination Report dated Nov. 24, 2011 for European Patent Application No. 09013687.0-2405, filed Apr. 4, 2012.;;Witness Statement by Mr. Hiroyuki Yamada including exhibits 1-7, (Apr. 16, 2014) (23 pages).;;Witness Statement of Ms. Masako Ikeda including exhibits A-E, (Apr. 15, 2014) (20 pages).;;Response to request further processing of application dated Jan. 13, 2014, for EP Application No. 11178191.0-1410, filed Mar. 20, 2014. (13 pages).;;Park, et al., ""Monoclonal antibody therapy"", Advances in Protein Chemistry, 56:369-421 (2001).;;Clark, ""Antibody engineering IgG effector Mechanisms"", Chemical Immunology, 65:88-110: enclosed is a reprint from http://www.path.cam.ac.uk/mrc7/publications/reprints/PP1997CI65-88.pdf (1997).;;Iwai, et al., ""PD-1 inhibits antiviral immunity at the effector phase on the liver"", The Journal of Experimental Medicine, 198(1):39-50 (2003).;;Adams, et al., ""Monoclonal antibody therapy of cancer"", Nature Biotechnology, 23(9):1147-1157 (2005).;;Affidavit of Christopher Butler, 8 pages (Apr. 23, 2014).;;Declaration of AndreaVan Elsas, Ph.D., in support of the opposition against EP-B1 2 161 336, 197 pages (Apr. 29, 2014).;;Declaration of Vassiliki A. Boussiotis, in connection with the opposition against European Patent No. 2161336B1, 167 pages (Apr. 28, 2014).;;Communication pursuant to Article 94(3) EPC for European Application No. 06786260.7-1412, dated Apr. 23, 2014.;;Carreno, et al., ""BTLA: A new inhibitory receptor with a B7-like ligand"", Trends in Immunology, 24(10):524-527 (2003).;;Chen, ""Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity"", Nature, 4:336-347 (2004).;;Shinohara, et al., Structural and chromosomal localization of the human PD-1 Gene (PDCD1), UniProt database entry Q15116, http://www.uniprot.org/uniprot/Q15116.txt. downloaded Apr. 29, 2014.;;Exhibit 1 ""Human anti-PD-1 antibodies: binding to PD-1, cross-competition with 5C4 and affinity to PD-1"", 6 pages.;;Carter, et al., ""Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation"", Immunologic Research, 28(1):49-59 (2003).;;Kaveri, ""Epitope and idiotope mapping using monoclonal antibodies"", Antibody Engineering Protocols, Methods if Molecular Biology, 51(Chapter 11):171-181 (2005).;;Zhang, et al., ""Structural and functional analysis of the costimulatory receptor programmed death-1"", Immunity, 20:337-347 (2004).;;Sequence alignments between PD-1 and each of CTLA-4, CD28 and ICOS, retrieved on-line on Apr. 10, 2014, http://www.ebi.ac.uk/Tools/services/web/toolresult.ebi?jobId=clustalo-I20140410-15.;;Ansari, et al., ""The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice"", J. Exp. Med, 198(1):63-69 (2003).;;Janeway, et al., ""Immunobiology: The immune system in health and disease"", New York, Garland Science, Chapter 9: 367-408 (2005).;;Nagler, et al., ""Phase I clinical trial of CT-011, a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced hematological malignancies"", Experimental Hematology, 33:97 (2005).;;Cloeckaert, et al., ""O-Polysaccharide epitopic heterogeneity at the surface of Brucella spp. studied by enzyme-linked immunosorbent assay and flow cytometry"", Clinical and Diagnostic Laboratory Immunology, 5(6);862-870 (1998).;;Brahmer, et al., ""Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates"", Journal of Clinical Oncology, 28(19):3167-3175 (2005).;;Declaration from Dr. Jennifer Mataraza, 11 pages (Apr. 28, 2014).;;Abbas, A.K., et al., Cellular and Molecular Immunobiology, 2nd ed., pp. 8, 47-50, W.B. Saunders Company, United States (1991).;;Alignment of Amino Acid Sequences for Extracellular Domain of Wild-Type (UniProt Q15116) Human PD-1, Wild-Type (MednaBio) PD-1 ECD, C62S Variant of Wild-Type Human PD-1 ECD, and A101L Variant of Wild-Type Human PD-1 ECD, 1 page, submitted with Opposition to EP Pat. No. 2161336 on Apr. 30, 2014.;;Allison, J.P. and Krummel, M.F., ""The Yin and Yang of T Cell Costimulation,"" Science 270(5238):932-933, American Association for the Advancement of Science, United States (1995).;;Amended Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Nov. 21, 2014, 11 pages.;;Andre, E., et al, ""Precise Characterization of the Epitope Recognized by a Monoclonal Antibody Against Escherichia coli RNA Polymerase,"" Hybridoma 24(1):1-5, Mary Ann Liebert, Inc., United States (Feb. 2005).;;Ansell, S.M., et al., ""PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma,"" The New England Journal of Medicine 372(4):311-319, Massachusetts Medical Society, United States (Jan. 22, 2015).;;Answer to Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C, Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Oct. 31, 2014, 15 pages.;;Answer to Plaintiffs' Amended Complaint, Bristol-Myers Squibb Co., E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co., Ltd., and Tasuku Honjo v. Merck & Co., Inc. and Merck Sharp & Dohme Corp., C.A. No. 14-cv-1131-GMS, United States District Court for the District of Delaware, Dec. 8, 2014, 17 pages.;;Anti-Human CD279 (PD-1) Datasheet, 14-2799, J105, eBioscience, Sep. 6, 2013, 1 page.;;Anti-Human CD279 (PD-1) Datasheet, 14-9989, J116, eBioscience, Sep. 6, 2013, 1 page.;;Anti-Human CD279 (PD-1) Purchase Receipts, eBioscience, Oct. 8, 2013, 4 pages.;;Antonia, S.J., et al., ""Association of tumor PD-L1 Expression, and Immune Biomarkers with Clinical Activity in Patients with Non-small Cell Lung Cancer (NSCLC) Treated with Nivolumab (Anti-PD-1; BMS-936558; ONO-4538),"" 15th World Conference on Lung Cancer, Sydney, Australia, 15th WCLC: Best of Posters 1-IASLC Selection, P2.11-035, Oct. 27-30, 2013, accessed at http://web.oncoletter.ch/kongressberichte-videos-slides-Onkologie/id-15th-world-conference-on-lung-cancer-conference/conference-highlights.html, accessed on Jan. 8, 2015, 6 pages.;;Appendix to Declaration of Vassiliki A. Boussiotis, Apr. 28, 2014, Data and Records for Example Experiments 21 and 22, 18 pages.;;Armand, P., et al., ""289 Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma-Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study,"" 56th ASH Annual Meeting and Exposition, Abstracts & Program, San Francisco, CA, Dec. 6-9, 2014.;;Berg, J.M., et al., ""The Immune System,"" in Biochemistry 5th ed., pp. 921-950, W.H. Freeman and Company, United States (2002).;;Biacore, ""Application Note I: Characterization of monoclonal antibody epitope specificity using Biacore's SPR technology,"" Biacore AB, 8 pages (2002).;;Biacore, Sensor Surface Handbook, BR-1005-71, edition AB, pp. 1-98, GE Healthcare (Feb. 2005).;;Biacore, ""The SPR signal,"" ""Interpreting experimental data,"" and ""BIA application areas,"" in BIAtechnology Handbook, version AB, chapters 4-6, 34 pages, Biacore AB (1998).;;Campbell, A.M., ""Characterisation of monoclonal antibodies,"" in Laboratory Techniques in Biochemistry and Molecular Biology, Monoclonal Antibody Technology: The Production and Characterization of Rodent and Human Hybridomas, vol. 13, pp. 186-215, Elsevier, the Netherlands (1984).;;CD279/PD-1, D132-3/J110 Datasheet, MBL Medical & Biological Laboratories Co., Ltd., Sep. 6, 2013, 2 pages.;;Chen, Y., et al., ""Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,"" Journal of Molecular Biology 293(4):865-881, Academic Press, England (1999).;;Communication pursuant to Article 94(3) EPC mailed on Dec. 22, 2014, in European Application No. 11 178 187.8-1410, European Patent Office, Germany.;;Communication pursuant to Article 94(3) EPC mailed on Dec. 22, 2014, in European Application No. 11 178 191.0-1410, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, mailed Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178187, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, mailed Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178188, European Patent Office, Germany.;;Communication pursuant to Rule 114(2) EPC, mailed Jul. 17, 2014, Third Party Observations (Article 115 EPC) for Application No. EP20110178191, European Patent Office, Germany.;;Complaint, Bristol-Myers Squibb Co. and Ono Pharmaceutical Co., Ltd. v. Merck & & Co., Inc., 1:14-cv-01131-GMS, filed Sep. 4, 2014, 9 pages.;;Co-pending U.S. Appl. No. 14/547,026, inventors Korman, A.J., et al., filed Nov. 18, 2014 (Not Published).;;Co-pending U.S. Appl. No. 14/638,985, inventors Honjo, T., et al., filed Mar. 4, 2015 (Not Published).;;Cragg, M.S., et al., ""Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts,"" Blood 101(3):1045-1052, American Society of Hematology, United States (2003).;;Creelan, B.C., ""Update on Immune Checkpoint Inhibitors in Lung Cancer,"" Journal of the Moffitt Cancer Center 21(1):80-89, H. Lee Moffitt Cancer Center and Research Institute, United States (2014).;;Cruse, J.M. and Lewis, R.E., ""Antigens and Immunogens,"" in Atlas of Immunology, 2nd ed., pp. 105-126, CRC Press, United States (Dec. 29, 2003).;;Curriculum Vitae of Brian T. Fife, Ph.D., 7 pages, submitted with Response to Oppositions against EP Pat. No. 2161336 on Feb. 16, 2015.;;Curriculum Vitae of Dr. Robert J. Bloch, Apr. 11, 2012, 34 pages, submitted with Opposition to EP Pat. No. 2161336.;;Curriculum Vitae of Vassiliki A. Boussiotis, Nov. 8, 2013, 24 pages, submitted with Opposition to EP Pat. No. 2161336.;;Davies, D.R. and Cohen, G.H., ""Interactions of protein antigens with antibodies,"" Proceedings of the National Academy of Sciences USA 93(1):7-12, National Academy of Sciences, United States (1996).;;Declaration of Dr. Haidong Dong, Mar. 31, 2014, 15 pages, submitted with Opposition to EP Pat. No. 1537878.;;Declaration of Professor Brian T. Fife, Feb. 12, 2015, 4 pages, submitted with Response to Feb. Oppositions against EP Pat. No. 2161336.;;Del Rio, M-L., et al., ""Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation,"" European Journal of Immunology 35(12):3545-3560, Wiley-VCH Verlag GmbH & Co. KGaA, Germany (Dec. 2005).;;Dougan, D.A., at al., ""Effects of substitutions in the binding surface of an antibody on antigen affinity,"" Protein Engineering 11(1):65-74, Oxford University Press, England (1998).;;Email from MednaBio to Robert Bloch re: E1951MG1-Sequence Information, Apr. 25, 2014, 1 page.;;ExPASy Bioinformatics Resource Portal calculation based on ECD of UniProt Sequence Q15116, accessed at http://web.expasy.org/cgi-bin/compute-pi/pi-tool, accessed on Apr. 28, 2014, 1 page.;;Extended European Search Report, for EP Application No. 06746353.9, European Patent Office, Germany, mailed on Mar. 6, 2009.;;Extended European Search Report for EP Application No. 09013687.0, European Patent Office, Germany, mailed on Jan. 29, 2010.;;Extended European Search Report for EP Application No. 10172772.5, European Patent Office, Netherlands, mailed on Sep. 9, 2010.;;Extended European Search Report for EP Application No. 11178187.8, European Patent Office, Germany, mailed on Jun. 1, 2012.;;Extended European Search Report for EP Application No. 11178188.6, European Patent Office, Germany, mailed on Jun. 27, 2013.;;Extended European Search Report for EP Application No. 11178191.0, European Patent Office, Germany, mailed on Sep. 5, 2012.;;Fivash, M., et al., ""BIAcore for macromolecular interaction,"" Current Opinion in Biotechnology 9(1):97-101, Current Biology, England (1998).;;Franklin, M.C., et al., ""Insights into ErbB signaling from the structure of the ErbB2-pertuzumah complex,"" Cancer Cell 5(4):317-328, Cell Press, United States (Apr. 2004).;;Freeman, G.J., et al., ""Engagement of the PD-1 Immunoinhibitory by a Novel B7-Family Member Leads to Negative Regulation of Lymphocyte Activation,"" Blood 96(11):810a-811a, (Abstract No. 3502) (2000).;;Ge, X., at al., ""CD134-Allodepletion Allows Selective Elimination of Alloreactive Human T Cells without Loss of Virus-Specific and Leukemia-Specific Effectors,"" Biology of Blood and Marrow Transplantation 14(5):518-530, American Society for Blood and Marrow Transplantation, United States (2008).;;Greenspan, N.S., ""Epitopes, paratopes and other topes: do immunologists know what they are talking about?"" Bulletin de l'Institut Pasteur 90(4):267-279, Elsevier, France (1992).;;Harlow, E. and Lane, D., ""Using Antibodies: A Laboratory Manual,"" Cold Spring Harbor Laboratory Press, Cold Spring Harbor, United States various pages. (1999).;;International Preliminary Report on Patentability for International Application No. PCT/JP2006/309606, The International Bureau of WIPO, Switzerland, issued on Nov. 13, 2007.;;International Search Report for International Application No. PCT/JP03/08420, Japanese Patent Office, Japan, mailed Oct. 21, 2003.;;International Search Report for International Application No. PCT/JP2006/309606, Japanese Patent Office, Japan, mailed on Aug. 15, 2006.;;Ishima, R. and Torchia, D.A , ""Protein Dynamics from NMR,"" Nature Structural Biology 7(9):740-743, Nature Publishing Company, United States (2000).;;J105/D133-3 Datasheet, MBL Medical & Biological Laboratories Co., Ltd., Mar. 20, 2013, 2 pages.;;J105/D133-3 Purchase Order, MBL Medical & Biological Laboratories Co., Ltd., Apr. 11, 2014, 1 page.;;J105/D133-3 Purchase Receipts, Invoice MINV52635, MBL International Corporation, Oct. 2, 2013, 2 pages.;;Jason-Moller, L., et al., ""Overview of Biacore Systems and Their Applications,"" Current Protocols in Protein Science S45:19,13.1-19.13.14, John Wiley & Sons, Inc., United States (2006).;;Johne, B., ""Protocol: Epitope Mapping by Surface Plasmon Resonance in the BIAcore,"" Molecular Biotechnology 9(1):65-71, Humana Press, United States (1998).;;Kanai, T., et al., ""Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation,"" The Journal of Immunology 171(8):4156-4163, American Association of Immunologists, Inc., United States (2003).;;Ladner, R.C., ""Mapping the Epitopes of Antibodies,"" Biotechnology and Genetic Engineering Reviews 24(1):1-30, Taylor & Francis, England (2007).",ACTIVE
151,EP,A2,EP 2439273 A2,056-147-565-593-439,2012-04-11,2012,EP 11178191 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;EP 09013687 A;;EP 06746353 A;;JP 2006309606 W,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX INC,SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;KORMAN ALAN J;;HUANG HAICHUN,"MEDAREX, L.L.C. (2014-04-23);;E. R. SQUIBB & SONS, L.L.C. (2015-03-04);;ONO PHARMACEUTICAL CO., LTD. (2015-03-04);;MEDAREX, INC. (2013-05-29)",https://lens.org/056-147-565-593-439,Patent Application,yes,114,14,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,158,125,076-092-237-434-500;;127-416-339-660-812;;117-522-189-960-276;;004-728-346-095-981;;043-645-889-898-36X;;020-766-613-912-972;;006-463-263-246-432;;052-597-675-128-75X;;081-074-583-383-824;;025-182-641-289-850;;076-731-232-972-252;;066-015-167-169-542;;006-568-097-103-41X;;076-092-237-434-500;;062-940-851-081-865;;048-060-748-635-820;;117-415-766-090-626;;038-551-014-784-214;;074-046-354-648-540;;008-208-772-364-327;;020-598-246-146-62X;;074-297-827-128-411;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;026-164-216-541-151;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;042-204-626-457-327;;006-574-964-805-278;;030-323-674-660-051;;092-023-577-402-127;;022-179-293-052-569;;004-458-031-333-650;;024-929-137-199-30X;;003-752-183-823-430;;070-318-112-524-781;;032-624-544-479-82X;;030-630-100-818-462;;106-753-778-592-300;;032-820-729-763-323;;083-549-078-331-651;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;033-754-369-798-314;;077-525-954-203-403;;028-969-172-280-017;;060-375-551-951-388;;020-753-772-581-741;;038-613-711-274-229;;047-951-914-695-080;;062-485-301-455-912;;032-820-729-763-323;;023-676-781-371-861;;026-744-100-669-883;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;030-769-003-988-749;;057-971-690-843-179;;145-254-035-276-41X;;026-646-521-253-318;;000-331-240-115-824;;065-438-177-962-139;;006-574-942-364-256;;101-640-792-825-42X;;070-316-527-354-375;;040-550-546-463-785;;046-168-111-025-234;;043-654-077-374-418;;084-388-182-984-099;;042-354-196-879-741;;005-112-559-456-657;;052-219-543-437-800;;007-364-858-655-289;;056-942-841-068-650;;107-302-749-967-437;;039-238-464-990-600;;036-564-551-324-053;;020-123-860-433-320;;011-516-147-270-264;;025-182-641-289-850;;076-731-232-972-252;;006-568-097-103-41X;;013-122-792-588-081;;005-416-473-959-707;;020-986-423-793-233;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;007-709-585-201-038;;042-688-967-632-553;;056-422-417-058-69X;;005-022-447-377-963;;127-416-339-660-812;;098-407-145-404-736;;066-749-017-721-197;;001-467-559-709-949;;078-061-292-153-737;;129-390-507-012-794;;008-213-515-306-640;;053-703-232-770-99X;;020-986-423-793-233;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;056-422-417-058-69X;;029-697-384-910-375;;038-613-711-274-229;;062-418-979-939-961;;093-666-562-457-905,10.4049/jimmunol.170.2.711;;12517932;;9930702;;10.1038/16717;;10.1002/j.1460-2075.1992.tb05481.x;;pmc556898;;1396582;;10.1093/intimm/8.5.765;;8671665;;10.1084/jem.181.6.1953;;7539033;;pmc2192041;;10.1016/s0167-5699(97)80025-4;;9190115;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;11224527;;10.1038/85330;;11857337;;10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9;;12721664;;10.1007/s00109-003-0430-2;;10.1007/s00262-004-0593-x;;15599732;;10.1158/1078-0432.ccr-04-0428;;15297412;;10.1073/pnas.192461099;;12218188;;pmc129438;;10.4049/jimmunol.170.2.711;;12517932;;10.1016/s1074-7613(00)80089-8;;10485649;;10.1126/science.291.5502.319;;11209085;;10.1084/jem.20022119;;12847138;;pmc2196082;;14764622;;10.1093/hmg/ddh076;;pmc61133;;10.1073/pnas.231486598;;11698646;;4703766;;10.1093/jnci/50.4.1013;;pmc1866856;;10.1016/s0002-9440(10)65141-3;;10433938;;1330947;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;3382986;;10.1093/bioinformatics/4.1.11;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;3127726;;10.1038/332323a0;;10.1038/321522a0;;3713831;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;11096108;;10.1074/jbc.m009483200;;10.1002/bit.20151;;15352059;;11986321;;10.1074/jbc.m202069200;;10.1038/6179;;10052355;;1201277;;10.1021/bi00696a021;;10.1038/348552a0;;2247164;;1172191;;10.1038/256495a0;;8159246;;10.1038/368856a0;;10.1007/978-3-642-78432-3_3;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;8144892;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nbt727;;12172556;;8159246;;10.1038/368856a0;;10.1126/science.3929380;;3929380;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;12564977;;10.1016/s0169-409x(02)00179-5;;10.1007/s00262-002-0352-9;;12700948;;12676579;;10.1016/s1535-6108(03)00057-6;;10.1038/nrc903;;12360278;;12186272;;10.1016/s0169-409x(01)00206-x;;11744170;;10.1201/b14193-19;;7042536;;10.1111/j.1600-065x.1982.tb00392.x;;10.4049/jimmunol.155.10.4996;;7594506;;8954257;;1371789;;6239899;;10.1084/jem.160.6.1686;;pmc2187539;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;3833240;;10.1126/science.3925553;;3925553;;2958547;;10.4049/jimmunol.139.7.2367;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;3390170;;10.1016/s0006-291x(88)81333-0;;10.1128/aac.39.1.180;;pmc162506;;7695303;;7907597;;10.1016/s0021-9258(17)37081-3;;10.1016/0014-5793(94)00313-0;;8206150;;7820457;;10.1006/immu.1994.1029;;12721664;;10.1007/s00109-003-0430-2;;10.1007/s00262-004-0593-x;;15599732;;10.1073/pnas.192461099;;12218188;;pmc129438;;10.4049/jimmunol.170.3.1257;;12538684;;15611321;;10.1093/intimm/dxh194;;15470033;;10.4049/jimmunol.173.8.4919;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;9624003;;10.1038/30989;;10.1016/s0171-2985(00)80072-8;;10834311;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;9930702;;10.1038/16717;;10417377;;10.1126/science.285.5427.546;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;pmc15881;;10.1073/pnas.96.6.2982;;10077623;;10.1038/22124;;10408445;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;9850053;;15470033;;10.4049/jimmunol.173.8.4919;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10657670;;10.4049/jimmunol.164.4.2160;;10.1002/j.1460-2075.1993.tb05721.x;;pmc413278;;8458339;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1126/science.271.5256.1734;;8596936;;10.1016/s0165-2478(02)00088-3;;12095712,"OKAZAKI ET AL., CURR. OPIN. IMMUNOL., vol. 14, 2002, pages 391779 - 82;;BENNETT ET AL., J LMMUNOL, vol. 170, 2003, pages 711 - 8;;HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 263 - 266;;HANSEN ET AL., IMMUNOGENICS, vol. 10, 1980, pages 247 - 260;;ISHIDA ET AL., EMBO J, vol. 11, 1992, pages 3887 - 95;;AGATA ET AL., INT. IMMUNOL, vol. 8, 1996, pages 765 - 72;;THOMAS, M.L., J EXP MED, vol. 181, 1995, pages 1953 - 6;;VIVIER, E, DAERON, M, IMMUNOL TODAY, vol. 18, 1997, pages 286 - 91;;FREEMAN ET AL., JEXP MED, vol. 192, 2000, pages 1027 - 34;;LATCHMAN ET AL., NAT IMMUNOL, vol. 2, 2001, pages 261 - 8;;CARTER ET AL., EUR JIMMUNOL, vol. 32, 2002, pages 634 - 43;;DONG ET AL., NAT. MED, vol. 8, 2002, pages 787 - 9;;DONG ET AL., J. MOL. MED., vol. 81, 2003, pages 281 - 7;;BLANK ET AL., CANCER IMMUNOL. IMMUNOTHER, vol. 54, 2005, pages 307 - 314;;KONISHI ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 5094 - 100;;IWAI ET AL., PROC. NAT.'L. ACAD SCI. USA, vol. 99, 2002, pages 1.2293 - 7;;BROWN ET AL., J IMMUNOL., vol. 170, 2003;;OKAZAKI ET AL., CURR OPIN IMMUNOL, vol. 14, 2002, pages 391779 - 82;;BENNETT ET AL., IMMUNOL, vol. 170, 2003, pages 711 - 8;;NISHIMURA ET AL., IMMUNITY, vol. 11, 1999, pages 141 - 51;;NISHIMURA ET AL., SCIENCE, vol. 291, 2001, pages 319 - 22;;SALAMA, JEXP MED, vol. 198, 2003, pages 71 - 78;;PROKUNINA, ALARCON-RIQUELME, HUM MOL GENET, vol. 13, 2004, pages R143;;NIELSEN ET AL., LUPUS, vol. 13, 2004, pages 10;;OKAZAKI, PNAS, vol. 98, 2001, pages 13866 - 71;;MURPHY, HRUSHESKY, J: NAT'L. CANCER RES., vol. 50, 1973, pages 1013 - 1025;;MURATA, AM. J. PATHOL., vol. 155, 1999, pages 453 - 460;;BALZANO, INT. J CANCER SUPPL., vol. 7, 1992, pages 28 - 32;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD SCI. USA, vol. 85, 1988, pages 5879 - 5883;;E. MEYERS, W. MILLER, COMPUT APPL. BIOSCI., vol. 4, 1988, pages 11 - 17;;NEEDLEMAN, WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL. ET AL., J. MOL. BIOL.., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;RIECHMANN, L. ET AL., NATURE, vol. 332, 1998, pages 323 - 327;;JONES, P. ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;QUEEN, C. ET AL., PROC. NATL. ACAD SEE. USA, vol. 86, 1989, pages 10029 - 10033;;KABAT, E. A ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, NIH PUBLICATION NO. 91-3242;;TOMLINSON, I. M: ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: doi:10.1016/0022-2836(92)90223-7;;COX, J. P. L. ET AL.: ""A Directory of Human Germ-line VH Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;YAMANE-OHNUKI ET AL., BIOTECHNOL BIOENG, vol. 87, 2004, pages 614 - 22;;SHIELDS, R.L. ET AL., J BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;TARENTINO, A.L., BIOCHEM., vol. 14, 1975, pages 5516 - 23;;""Current Protocols in Molecular Biology"", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, NIH PUBLICATION NO. 91-3242;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;KOHLER, MILSTEIN, NATURE, vol. 256, 1975, pages 495;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;LONBERG, N.: ""Handbook ofExperimental Pharmacology"", vol. 113, 1994, pages: 49 - 101;;LONBERG, N., HUSZAR, D., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F., LONBERG, N., ANN. N.Y. ACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 2, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD SCI. USA, vol. 90, 1993, pages 3720 - 3724;;CHOI, NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J. ET AL., EMBOJ., vol. 12, 1993, pages 821 - 830;;TUAILLON ET AL., J IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;TOMIZUKA ET AL., PROC. NATL. ACAD SCI. USA, vol. 97, 2000, pages 722 - 727;;KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894;;LONBERG, N. ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;MORRISON, S., SCIENCE, vol. 229, 1985, pages 1202;;GOEDDEL: ""Gene Expression Technology. Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;TAKEBE, Y., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;BOSS, M. A., WOOD, C. R, IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB, CHASIN, PROC. NATL. ACAD SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMAN, P. A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;SAITO, G., ADV. DRUG DELIV. REV., vol. 55, 2003, pages 199 - 215;;TRAIL, P.A. ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 52, 2003, pages 328 - 337;;PAYNE, G., CANCER CELL, vol. 3, 2003, pages 207 - 212;;ALLEN, T.M., NAT. REV. CANCER, vol. 2, 2002, pages 750 - 763;;PASTAN, I., KREITMAN, R. J., CURR. OPIN. INVESTIG. DRUGS, vol. 3, 2002, pages 1089 - 1091;;SENTER, P.D., SPRINGER, C.J., ADV. DRUGDELIV. REV., vol. 53, 2001, pages 247 - 264;;ARNON ET AL.: ""Monoclonal Antibodies And Cancer Therapy"", 1985, ALAN R. LISS, INC., article ""Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy"", pages: 243 - 56;;HELLSTROM ET AL.: ""Controlled Drug Delivery"", 1987, MARCEL DEKKER, INC., article ""Antibodies For Drug Delivery"", pages: 623 - 53;;THORPE: ""Monoclonal Antibodies '84: Biological And Clinical Applications"", 1985, article ""Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review"", pages: 475 - 506;;""Monoclonal Antibodies For Cancer Detection And Therapy"", 1985, ACADEMIC PRESS, article ""Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy"", pages: 303 - 16;;THORPE: ""The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates"", IMMUNOL. REV., vol. 62, 1982, pages 119 - 58, XP001179872, DOI: doi:10.1111/j.1600-065X.1982.tb00392.x;;GRAZIANO, R.F. ET AL., J IMMUNOL, vol. 155, no. 10, 1995, pages 4996 - 5002;;MORTON, H.C. ET AL., CRITICAL REVIEWS IN IMMUNOLOGY, vol. 16, 1996, pages 423 - 440;;MONTEIRO, R.C., J. IMMUNOL.., vol. 148, 1992, pages 1764;;KARPOVSKY ET AL., J. EXP. MED., vol. 160, 1984, pages 1686;;LIU, MA ET AL., PROC. NATL. ACAD SCI. USA, vol. 82, 1985, pages 8648;;PAULUS, BEHRING INS. MITT., 1985, pages 118 - 132;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83;;GLENNIE ET AL., J. 1MMUNOL, vol. 139, 1987, pages 2367 - 2375;;WEINTRAUB, B.: ""Principles ofRadioimmunoassays, Seventh Training Course on Radioligand Assay Techniques"", March 1986, THE ENDOCRINE SOCIETY;;BERGE, S.M., J PHARM. SCI., vol. 66, 1977, pages 1 - 19;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;V.V. RANADE, J CLIN. PHARMACOL., vol. 29, 1989, pages 685;;UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 153, 1988, pages 1038;;P.G. BLOEMAN ET AL., FEBS LETT., vol. 357, 1995, pages 140;;M. OWAIS ET AL., ANTIMICROB AGENTS CHEMOTHER., vol. 39, 1995, pages 180;;BRISCOE ET AL., AM. J PHYSIOL., vol. 1233, 1995, pages 134;;SCHREIER ET AL., J BIOL. CHEM., vol. 269, 1994, pages 9090;;K. KEINANEN, M.L. LAUKKANEN, FEBS LETT.., vol. 346, 1994, pages 123;;J.J. KILLION, I.J. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273;;DONG ET AL., NAT MED, vol. 8, 2002, pages 787 - 9;;DONG, J MOL MED, vol. 81, 2003, pages 281 - 7;;BLANK, CANCER IMMUNOL IMMUNOFHER., vol. 54, 2005, pages 307 - 314;;IWAI ET AL., PNAS, vol. 99, 2002, pages 12293 - 7;;BROWN ET AL., J. IMMUNOL., vol. 170, 2003, pages 1257 - 66;;IWAI ET AL., INT. IMMUNOL., vol. 17, 2005, pages 133 - 144;;HE ET AL., J IMMUNOL., vol. 173, 2004, pages 4919 - 28;;ROSENBERG, S.: ""Development of Cancer Vaccines"", 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 60 - 62;;LOGOTHETIS, C.: ""ASCO"", 2000, EDUCATIONAL BOOK SPRING, pages: 300 - 302;;KHAYAT, D.: ""ASCO"", 2000, EDUCATIONAL BOOK SPRING, pages: 414 - 428;;FOON, K.: ""ASCO"", 2000, EDUCATIONAL BOOK SPRING, pages: 730 - 738;;RESTIFO, N., SZNOL, M. ET AL.: ""Cancer: Principles and Practice of Oncology"", 1997, article ""Cancer Vaccines"", pages: 3023 - 3043;;DRANOFF ET AL., PROC. NAFL. ACAD SCI US.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, SA, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM, N ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT, R, SRIVASTAVA, P, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA, Y. ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE, F. ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER, A., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR, M. ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL, J., J EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARD, M., O'GARRA, A., IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE, M. ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;RIDGE, J. ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;ITO, N. ET AL., IMMUNOBIOLOGY, vol. 201, no. 5, 2000, pages 527 - 40;;WEINBERG, A., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO, I. ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF, A. ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;GREENBERG, R., RIDDELL, S., SCIENCE, vol. 285, 1999, pages 546 - 51;;HOLLIGER, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;OVERWIJK, W. ET AL., PROC. NATL. ACAD SCI. U.S.A., vol. 96, 1999, pages 2982 - 2987;;SCHENK, NATURE, vol. 400, 1999, pages 173 - 177;;HARLOW, LANE: ""Antibodies, A Laboratoy Manual"", 1988, COLD SPRING HARBOR LABORATORY PRESS;;HURWITZ ET AL., PROC. NATL. ACAD SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071;;CAMACHO ET AL., J CLIN. ONCOLOGY, vol. 22, no. 145, 2004;;MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304;;HE, J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;ROSENBERG, S.: ""Development of Cancer Vaccines, ASCO"", 2000, EDUCATIONAL BOOK SPRING, pages: 60 - 62;;RESTIFO, SZNOL ET AL.: ""Cancer: Principles and Practice of Oncology"", 1997, article ""Cancer Vaccines"", pages: 3023 - 3043;;DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT, SRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE, NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL, J. ET AL., 1. EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARD, M, O'GARRA, A, IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;WEINBERG, A. ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;CHEN ET AL., EMBO J., vol. 12, 1993, pages 811 - 820;;FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;HARLOW, LANE: ""Antibodies, A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY PRESS;;LEACH ET AL., SCIENCE, vol. 271, 1996, pages 1734 - 1736;;IWAI Y; ET AL: ""MICROANATOMICAL LOCALIZATION OF PD-1 IN HUMAN TONSILS"", IMMUNOLOGY LETTERS, vol. 83, no. 3, January 2002 (2002-01-01), pages 215 - 220, XP003007112",INACTIVE
152,JP,A,JP 2021191793 A,097-254-658-813-067,2021-12-16,2021,JP 2021149019 A,2021-09-14,JP 2019018345 A;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,HUMAN MONOCLONAL ANTIBODY AGAINST PROGRAMMED DEATH 1 (PD-1) AND METHOD FOR TREATING CANCER USING ANTI-PD-1 ANTIBODY ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPY,"To provide an isolated monoclonal antibody specifically binding to Programmed Death 1 (PD-1) with high affinity, particularly a human monoclonal antibody.SOLUTION: The present invention provides an isolated monoclonal antibody or a binding portion thereof, which performs a cross-competition for binding to a reference antibody comprising a human heavy chain and light chain variable regions consisting of specific amino acid sequences and PD-1. According to the present invention, by preparing an immunocomplex, a bispecific molecule, and a pharmaceutical composition, which are comprising the antibody, it is possible to provide a PD-1 detection method and treat various disorders including cancer and infectious diseases. According to the present invention, it is also possible to treat hyperproliferative disorders, such as cancer, using a combination immunotherapy, such as a combination of anti-CTLA-4 and anti-PD-1 antibodies. Adverse treatment-related adverse events by each of such antibodies are altered.SELECTED DRAWING: None",ONO PHARMACEUTICAL CO;;ER SQUIBB & SONS LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/097-254-658-813-067,Patent Application,no,3,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/395;;A61P35/00;;A61P35/02;;C12P21/08,,0,0,,,,PENDING
153,EP,A3,EP 2439272 A3,133-806-391-961-496,2013-07-31,2013,EP 11178188 A,2006-05-02,EP 09013687 A;;EP 06746353 A;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;MEDAREX INC,SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;KORMAN ALAN J;;HUANG HAICHUN,"MEDAREX, L.L.C. (2014-04-23);;E. R. SQUIBB & SONS, L.L.C. (2015-03-04);;ONO PHARMACEUTICAL CO., LTD. (2015-03-04);;MEDAREX, INC. (2013-05-29)",https://lens.org/133-806-391-961-496,Search Report,yes,3,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/18;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,5,5,013-122-792-588-081;;032-820-729-763-323;;086-751-695-402-863;;117-415-766-090-626;;045-008-500-970-273,10.4049/jimmunol.170.3.1257;;12538684;;8159246;;10.1038/368856a0;;15705911;;10.1158/0008-5472.1089.65.3;;10.1084/jem.20022119;;12847138;;pmc2196082;;20139271;;10.4049/jimmunol.0901652,"BROWN JULIA A ET AL: ""Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production"", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 170, no. 3, 1 February 2003 (2003-02-01), pages 1257 - 1266, XP002973918, ISSN: 0022-1767;;LONBERG N ET AL: ""ANTIGEN-SPECIFIC HUMAN ANTIBODIES FROM MICE COMPRISING FOUR DISTINCT GENETIC MODIFICATIONS"", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 368, no. 6474, 28 April 1994 (1994-04-28), pages 856 - 859, XP000941636, ISSN: 0028-0836;;HIRANO FUMIYA ET AL: ""Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 65, no. 3, 1 February 2005 (2005-02-01), pages 1089 - 1096, XP002419626, ISSN: 0008-5472;;A. D. SALAMA ET AL: ""Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis"", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 198, no. 1, 1 January 2003 (2003-01-01), pages 71 - 78, XP055014704, ISSN: 0022-1007, DOI: 10.1084/jem.20022119;;S. KASAGI ET AL: ""Anti-Programmed Cell Death 1 Antibody Reduces CD4+PD-1+ T Cells and Relieves the Lupus-Like Nephritis of NZB/W F1 Mice"", THE JOURNAL OF IMMUNOLOGY, vol. 184, no. 5, 1 March 2010 (2010-03-01), pages 2337 - 2347, XP055067100, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0901652",DISCONTINUED
154,HU,T2,HU E026039 T2,130-985-343-822-958,2016-05-30,2016,HU E06786260 A,2006-06-30,US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),,SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/130-985-343-822-958,Amended Patent,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/00;;C07K16/28,,0,0,,,,PENDING
155,CN,A,CN 104356236 A,141-597-699-372-841,2015-02-18,2015,CN 201410639719 A,2006-06-30,US 69642605 P;;CN 200680028238 A,2005-07-01,Human Monoclonal Antibodies To Programmed Death Ligand 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-Ll antibodies.",MEDAREX INC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,E. R. SQUIBB SAINS LLC (2015-03-11),https://lens.org/141-597-699-372-841,Patent Application,no,0,14,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A61K39/395;;A61P31/00;;A61P35/00,,0,0,,,,ACTIVE
156,NO,L,NO 20080590 L,018-327-207-059-949,2008-03-31,2008,NO 20080590 A,2008-01-31,US 69642605 P;;US 2006/0026046 W,2005-07-01,"Humane, monoklonale antistoffer mot programmert dodsligand (PD-L1)","Sammendrag Den foreliggende beskrivelse tilveiebringer isolerte monoklonale antistoffer, fortrinnsvis humane monoklonale antistoffer, som spesifikt bindes til PD-LI med høy affinitet. Nukleinsyremolekyler som koder for antistoffene ifølge den foreliggende beskrivelse, ekspresjonsvektorer, vertseeller og fremgangsmåter for ekspresjon av antistoffene ifølge den foreliggende beskrivelse tilveiebringes også. Immunkonjugater, bispesifikke molekyler og fannasøytiske preparater som omfatter antistoffene ifølge oppfinnelsen tilveiebringes også. Beskrivelsen tilveiebringer også fremgangsmåter for påvisning av PD-LI, så vel som fremgangsmåter for behandling av forskjellige sykdommer, innbefattet . kreft og infeksjonssykdommer, ved anvendelse av antiPD-Ll-antistoffer.",MEDAREX LLC,WANG CHANGYU;;SRINIVASAN MOHAN;;HUANG HAICHUN;;KORMAN ALAN J;;SELBY MARK J;;PASSMORE DAVID B;;CHEN HAIBIN,"MEDAREX LLC, US (2013-06-03);;E. R. SQUIBB & SONS, US (2015-11-16)",https://lens.org/018-327-207-059-949,Abstract,no,0,0,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A61K39/395;;A61P37/04;;C07K16/18;;C12P21/08,,0,0,,,,DISCONTINUED
157,SI,T2,SI 2161336 T2,037-615-210-811-703,2017-07-31,2017,SI 200631652 A,2006-05-02,US 67946605 A;;US 73843405 A;;US 74891905 A;;EP 09013687 A,2005-05-09,Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,,ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/037-615-210-811-703,Amended Patent,no,0,0,2,2,0,,C12N15/00;;C07K16/00;;C12N5/00;;C12P21/00;;C12Q1/00,,0,0,,,,PENDING
158,ES,T3,ES 2427646 T3,029-689-543-467-121,2013-10-31,2013,ES 09013687 T,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos,"Un anticuerpo monoclonal aislado, o porción de unión a antígeno del mismo, que comprende: a) una CDR1 de la región variable de la cadena pesada que comprende los aminoácidos que tienen lasecuencia mostrada en el SEC ID NO: 18; b) una CDR2 de la región variable de la cadena pesada que comprende los aminoácidos que tienen lasecuencia mostrada en el SEC ID NO: 25; c) una CDR3 de la región variable de cadena pesada que comprende aminoácidos que tienen la secuenciamostrada en el SEC ID NO: 32; d) una CDR1 de la región variable de la cadena ligera que comprende los aminoácidos que tienen lasecuencia mostrada en el SEC ID NO: 39; e) una CDR2 de la región variable de la cadena ligera que comprende los aminoácidos que tienen lasecuencia mostrada en el SEC ID NO: 46; y f) una CDR3 de la región variable de la cadena ligera que comprende los aminoácidos que tienen lasecuencia mostrada en el SEC ID NO: 53; en donde el anticuerpo se une específicamente a la proteína Muerte Programada 1 (PD-1) humana.",ONO PHARMACEUTICAL CO;;MEDAREX INC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/029-689-543-467-121,Granted Patent,no,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C12N15/09;;C07K16/28;;C12N5/00;;C12P21/08;;C12Q1/02,,0,0,,,,ACTIVE
159,US,A1,US 2013/0122014 A1,044-761-442-462-265,2013-05-16,2013,US 201313746773 A,2013-01-22,US 201313746773 A;;US 201113091936 A;;US 91772706 A;;US 2006/0026046 W;;US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",MEDAREX INC;;MEDAREX INC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30),https://lens.org/044-761-442-462-265,Patent Application,yes,1,38,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28,424/143.1;;530/388.22;;530/387.3;;536/23.53;;800/18;;435/69.6,5,5,037-833-888-905-08X;;000-592-435-005-508;;027-727-853-855-594;;059-733-201-044-050;;012-269-427-021-802,22588271;;10.1038/mt.2012.98;;pmc3437589;;22023178;;10.2174/157488712799363262;;pmc3804573;;10.1371/journal.pone.0077780;;24204962;;pmc3958087;;10.1128/jvi.02034-13;;24352453;;24739950;;pmc3989168;;10.1371/journal.pone.0092934,"Dai et al., Molecular Therapy, 2012; 20(9): 1800-1809.;;Sakthivel et al., Reviews on Recent clinical trials, 2012; 7: 10-23.;;Seung et al., 2013; PLoS ONE 8(10):e77780. doi:10.1371/journal.pone.0077780.;;Porichis et al., Journal of Virology, 2014; 88(5): 2508-2518.;;Siewe et al., 2014; PLoS ONE 9(4):e92934. doi:10.1371/journal.pone.0092934.",ACTIVE
160,US,A1,US 2017/0088615 A1,166-170-532-535-64X,2017-03-30,2017,US 201615288545 A,2016-10-07,US 201615288545 A;;US 201414248462 A;;US 201113210137 A;;US 91321706 A;;JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Monoclonal Antibodies to Programmed Death 1 (PD-1),"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",SQUIBB & SONS LLC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;ONO PHARMACEUTICAL CO. LTD (2007-12-27);;MEDAREX INC (2014-12-02),https://lens.org/166-170-532-535-64X,Patent Application,yes,0,53,120,125,82,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/00;;A61K39/395,,0,0,,,,ACTIVE
161,CN,A,CN 109485727 A,012-376-705-942-999,2019-03-19,2019,CN 201811213609 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;CN 200680023860 A,2005-05-09,Human monoclonal antibodies to programmed death-1(PD-1) and methods for treating cancer using anti-PD-1 antibodies,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositionscomprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectiousdiseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",ONO PHARMACEUTICAL CO;;SQUIBB & SONS LLC,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/012-376-705-942-999,Patent Application,no,2,2,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A01K67/027;;A61K39/395;;A61P31/00;;A61P33/00;;A61P35/00;;A61P37/04;;C07K16/46;;C12N5/20;;C12N15/13,,2,1,086-751-695-402-863,15705911;;10.1158/0008-5472.1089.65.3,"FUMIYA HIRANO ET AL.: ""Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity"", 《CANCER RESEARCH》;;毛丽伟等: ""PD-L1 mAb的制备、鉴定及其特性的研究"", 《免疫学杂志》",PENDING
162,BR,A2,BR PI0613361 A2,028-341-207-426-781,2011-01-04,2011,BR PI0613361 A,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,"anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1","ANTICORPO MONOCLONAL HUMANO ISOLADO, COMPOSIçãO, IMUNOCONJUGADO, MOLéCULA BIESPECìFICA, MOLéCULA DE ACIDO NUCLEICO ISOLADA, VETOR DE EXPRESSãO, CéLULA HOSPEDEIRA, CAMUNDONGO TRANSCêNICO, MéTODO PARA MODULAR UMA RESPOSTA IMUNE NUM INDIVìDUO, MéTODO PARA INIBIR CRESCIMENTO DE CéLULAS TUMORAIS NUM INDIVìDUO, MéTODO PARA TRATAR UMA DOENçA INFECCIOSA NUM INDIVìDUO, MéTODO PARA AUMENTAR UMA RESPOSTA IMUNE A UM ANTìGENO NUM INDIVìDUO, MéTODO PARA TRATAR OU PREVENIR UMA DOENçA INFLAMATóRIA NUM INDIVìDUO E MéTODO PARA PREPARAR O ANTICORPO ANTI-PD-L1"". A presente descrição provê anticorpos monoclonais isolados, especialmente anticorpos monoclonais humanos que ligam-se especificamente a PD-L1 com alta afinidade. Moléculas de ácido nucleico que codificam os anticorpos da presente descrição, vetores de expressão, células hospedeiras e métodos para expressar os anticorpos da presente descrição são também providos. Imunoconjugados, moléculas biespecíficas e composições farmacêuticas compreendendo os anticorpos da invenção são também providos. A descrição também provê métodos para detectar PD-L1, bem como métodos para tratar diversas doenças, inclusive o câncer e doenças infecciosas, utilizando anticorpos anti-PD-L1.",MEDAREX INC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,"MEDAREX, L.L.C. (US) (2018-10-23)",https://lens.org/028-341-207-426-781,Patent Application,no,0,1,74,74,0,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28,,0,0,,,,PENDING
163,KR,A,KR 20150082674 A,024-173-280-956-097,2015-07-15,2015,KR 20157017089 A,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1(PD-L1),"본 발명은 분리된 모노클로날 항체, 특히 PD-Ll에 높은 친화도로 특이적으로 결합하는 인간 모노클로날 항체를 제공한다. 본 개시의 항체를 코드하는 핵산 분자, 발현 벡터, 숙주세포 및 본 개시의 항체를 발현하는 방법이 또한 제공된다. 본 발명의 항체를 포함하는 면역컨쥬게이트, 바이스페시픽 분자 및 약학적 조성물이 또한 제공된다. 본 개시는 또한 PD-Ll을 검출하는 방법 뿐 아니라 항-PD-Ll 항체를 사용하여 암과 감염성 질병을 포함하는 다양한 질병을 치료하는 방법을 제공한다.",MEDAREX LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/024-173-280-956-097,Patent Application,no,2,0,74,74,240,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,A61K39/395;;A61K47/48,,2,2,119-897-745-760-544;;067-760-343-772-225,10.1161/01.atv.0000145015.23656.e4;;15374847;;14871849;;10.1158/0008-5472.can-03-3259,"Arterioscler Thromb Vasc Biol. 2004, Vol. 24, pp.2057-2062.;;Cancer Research. 2004, Vol. 64, No. 3, pp.1140-1145.",ACTIVE
164,US,A1,US 2020/0062848 A1,044-664-994-216-068,2020-02-27,2020,US 201916448721 A,2019-06-21,US 201916448721 A;;US 201715413244 A;;US 201615188860 A;;US 201514807522 A;;US 201313746773 A;;US 201113091936 A;;US 91772708 A;;US 2006/0026046 W;;US 69642605 P,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,,https://lens.org/044-664-994-216-068,Patent Application,yes,0,13,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A61K45/06;;A61K47/68,,0,0,,,,DISCONTINUED
165,CA,A1,CA 2612241 A1,062-682-716-029-344,2007-01-11,2007,CA 2612241 A,2006-06-30,US 69642605 P;;US 2006/0026046 W,2005-07-01,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules an d pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectio us diseases, using anti-PD-Ll antibodies.",MEDAREX INC,SELBY MARK J;;KORMAN ALAN J;;CHEN HAIBIN;;HUANG HAICHUN;;PASSMORE DAVID B;;SRINIVASAN MOHAN;;WANG CHANGYU,,https://lens.org/062-682-716-029-344,Patent Application,no,0,1,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C12N15/13;;A01K67/027;;A61K39/395;;A61K47/48;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;C07K14/705;;C07K16/28;;C07K16/46;;C12N5/18;;C12N15/63,,0,0,,,,ACTIVE
166,US,B2,US 9580507 B2,044-956-061-316-133,2017-02-28,2017,US 201615188860 A,2016-06-21,US 201615188860 A;;US 201514807522 A;;US 201313746773 A;;US 201113091936 A;;US 91772708 A;;US 2006/0026046 W;;US 69642605 P,2005-07-01,Human monoclonal antibodies to programmed death ligand 1 (PD-L1),"The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.",SQUIBB & SONS LLC,KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;SRINIVASAN MOHAN;;PASSMORE DAVID B;;HUANG HAICHUN;;CHEN HAIBIN,MEDAREX L.L.C (2012-12-31);;E. R. SQUIBB & SONS L.L.C (2014-09-30);;MEDAREX INC (2008-03-26),https://lens.org/044-956-061-316-133,Granted Patent,yes,99,102,74,74,120,A61K2039/505;;C07K2317/21;;C07K2317/92;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K47/6817;;A61K47/6825;;A61K47/6849;;C07K16/2803;;C07K16/2827;;A61P1/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/04;;A61P33/06;;A61P33/10;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/04;;A61P39/02;;A61P43/00;;A61K47/68;;A61K39/395;;C07K16/28;;C07K2317/565;;C07K16/2803;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/41;;C07K2317/732;;C07K2317/77;;A61K2039/505;;C07K2317/21;;C07K2317/92;;A61K47/6849;;A61K47/6817;;A61K47/6825;;Y02A50/30;;C07K16/2827;;C07K16/28;;A61K45/06;;C07K16/2818;;C07K2317/56;;C07K2317/567,C07K16/28;;A61K39/00;;A61K39/395;;A61K45/06,,75,44,039-555-401-046-267;;011-092-736-500-72X;;074-067-544-364-744;;027-960-937-319-909;;067-760-343-772-225;;038-040-632-602-487;;013-122-792-588-081;;022-179-293-052-569;;037-833-888-905-08X;;050-992-361-999-488;;063-455-531-393-728;;009-746-604-420-355;;119-897-745-760-544;;022-046-054-886-073;;062-761-744-997-508;;059-733-201-044-050;;116-193-705-533-609;;027-477-313-726-928;;000-592-435-005-508;;027-727-853-855-594;;012-269-427-021-802;;088-581-950-418-154;;047-951-914-695-080;;092-023-577-402-127;;045-556-293-127-132;;058-883-699-331-571;;006-568-097-103-41X;;076-731-232-972-252;;113-346-509-283-257;;081-074-583-383-824;;122-644-406-202-233;;025-182-641-289-850;;079-214-893-487-418;;006-463-263-246-432;;006-463-263-246-432;;020-986-423-793-233;;086-751-695-402-863;;066-015-167-169-542;;083-811-051-643-47X;;057-629-746-536-175;;078-115-905-519-238;;033-225-590-843-088;;009-675-556-987-094;;045-113-475-699-403,10.1073/pnas.92.7.2529;;pmc42251;;7708679;;10.1021/ja00084a073;;10.1038/nature04444;;16382236;;10.1006/jmbi.2000.3512;;10677285;;14871849;;10.1158/0008-5472.can-03-3259;;10.1056/nejmoa1200694;;pmc3563263;;22658128;;10.4049/jimmunol.170.3.1257;;12538684;;10.1002/eji.1830240409;;8149953;;22588271;;10.1038/mt.2012.98;;pmc3437589;;12520872;;10.1080/02648725.2002.10648023;;14530338;;10.4049/jimmunol.171.8.4156;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;10.1161/01.atv.0000145015.23656.e4;;15374847;;pmc127659;;11796590;;10.1128/iai.70.2.612-619.2002;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;pmc3958087;;10.1128/jvi.02034-13;;24352453;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;22023178;;10.2174/157488712799363262;;pmc3804573;;10.1371/journal.pone.0077780;;24204962;;24739950;;pmc3989168;;10.1371/journal.pone.0092934;;10.4049/jimmunol.164.3.1432;;10640759;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;1404388;;10.1016/0022-2836(92)90223-7;;10.1016/s1074-7613(00)00006-6;;10933393;;10.1002/ijc.21775;;16482562;;10.1073/pnas.192461099;;12218188;;pmc129438;;10.1007/s00262-004-0593-x;;15599732;;11861596;;10.1146/annurev.immunol.20.091101.091806;;11857337;;10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9;;12091876;;10.1038/nm730;;12721664;;10.1007/s00109-003-0430-2;;10581077;;10.1038/70932;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;11015443;;10.1084/jem.192.7.1027;;pmc2193311;;15470033;;10.4049/jimmunol.173.8.4919;;15705911;;10.1158/0008-5472.1089.65.3;;10.1158/1078-0432.ccr-04-0428;;15297412;;17404099;;10.1158/1078-0432.ccr-06-2746;;10.1182/blood.v97.6.1809;;11238124;;12421930;;10.4049/jimmunol.169.10.5538;;18500231;;10.1038/nri2326;;14515254;;10.1002/eji.200324228;;10.1093/ndt/gfh423;;15353579,"Amendment after Notice of Allowance mailed Jan. 10, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Amendment and Request for Continued Examination (RCE) mailed Aug. 20, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Barbas, S.M., et al., ""Human Autoantibody Recognition of DNA,"" Proceedings of the National Academy of Sciences of the United States of America 92(7):2529-2533, National Academy of Sciences, United States (1995).;;Barbas, S.M., et al., ""Recognition of DNA by Synthetic Antibodies,"" Journal of the American Chemical Society 116(5):2161-2162, American Chemical Society, United States (1994).;;Barber, D.L., et al., ""Restoring Function in Exhausted CD8 T Cells during Chronic Viral Infection,"" Nature 439(7077):682-687, Nature Publishing Group, United States (2006).;;Beiboer, S.H., et al., ""Guided Selection of a Pan Carcinoma Specific Antibody Reveals Similar Binding Characteristics Yet Structural Divergence between the Original Murine Antibody and its Human Equivalent,"" Journal of Molecular Biology 296(3):833-849, Elsevier, England (2000).;;Blank, C., et al., ""PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells,"" Cancer Research 64(3):1140-1145, American Association for Cancer Research, United States (2004).;;Brahmer, J.R., et al., ""Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer,"" The New England Journal of Medicine 366(26):2455-2465, Massachusetts Medical Society, United States (2012).;;Brown, J.A., et al., ""Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production,"" The Journal of Immunology 170(3):1257-1266, The American Association of Immunologists, United States (2003).;;Certificate of Correction mailed Dec. 6, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Certificate of Correction mailed Jul. 9, 2013, in United States Patent Application No. 13/091,936, Alan, J , et al., filed Apr. 21, 2011.;;Cox, J.P., et al., ""A Directory of Human Germ-line V kappa Segments Reveals a Strong Bias in their Usage,"" European Journal of Immunology 24(4):827-836, Verlag Chemie GmbH, Germany (1994).;;Dai, B., et al., ""PD-1/PD-L1 Blockade can Enhance HIV-1 Gag-Specific T Cell Immunity Elicited by Dendritic Cell-Directed Lentiviral Vaccines,"" Molecular Therapy 20(9):1800-1809, Academic Press, United States (2012).;;Final Office Action mailed Oct. 22, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;International Preliminary Report on Patentability for International Application No. PCT/US2006/026046, International Bureau of WIPO, Switzerland, mailed on Jan. 9, 2008,11 pages.;;International Search Report and Written Opinion for International Application No. PCT/US2006/026046, European Patent Office, Netherlands, mailed on Apr. 3, 2007,17 pages.;;Ishida, I., et al., ""TransChromo Mouse,"" Biotechnology & Genetic Engineering Reviews 19:73-82, Taylor & Francis, England (2002).;;Issue Fee payment mailed Apr. 4, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Issue Fee payment mailed Jan. 22, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Kanai, T., et al., ""Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation,"" The Journal of Immunology 171(8):4156-4163, American Association of Immunologists, Inc., United States (2003).;;Klimka, A., et al., ""Human Anti-CD30 Recombinant Antibodies by Guided Phage Antibody Selection Using Cell Panning,"" British Journal of Cancer 83(2):252-260, Cancer Research Campaign, England (2000).;;Koga, N., et al., ""Blockade of the Interaction Between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts,"" Arteriosclerosis, Thrombosis and Vascular Biology 24(11):2057-2062, American Heart Association, Inc., United States (2004).;;Mukherjee, J., et al., ""Human Stx2-Specific Monoclonal Antibodies Prevent Systemic Complications of Escherichia coli O157:H7 Infection,"" Infection and Immunity 70(2):612-619, American Society for Microbiology, United States (2002).;;Non-Final Office Action mailed Jan. 31, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Non-Final Office Action mailed Jun. 8, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Notice of Allowance mailed Jan. 4, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Notice of Allowance mailed May 2, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Notice of Allowance mailed Oct. 23, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Panka, D.J., et al., ""Variable Region Framework Differences Result in Decreased or Increased Affinity of Variant Anti-digoxin Antibodies,"" Proceedings of the National Academy of Sciences 85(9):3080-3084, National Academy of Sciences, United States (1988).;;Porichis, F., et al., ""Differential impact PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions,"" Journal of Virology 88(5):2508-2518, American Society for Microbiology, United States (2014).;;Rader, C., et al., ""A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries,"" Proceedings of the National Academy of Sciences of the United States of America 95(15):8910-8915, National Academy of Sciences, United States (1998).;;Request for Certificate of Correction mailed Jun. 13, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Request for Certificate of Correction mailed Nov. 1, 2011, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Response to Amendment under Rule 312 mailed Jan. 18, 2013, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Response to Final Office Action mailed Dec. 21, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Response to Non-Final Office Action mailed Apr. 9, 2012, in U.S. Appl. No. 13/091,936, Alan, J., et al., filed Apr. 21, 2011.;;Response to Non-Final Office Action mailed Sep. 8, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Response to Restriction Requirement mailed Mar. 15, 2010, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Restriction Requirement mailed Dec. 14, 2009, in U.S. Appl. No. 11/917,727, Alan, J., et al., filed Jun. 9, 2008.;;Rudikoff, S., et al., ""Single Amino Acid Substitution Altering Antigen-Binding Specificity,"" Proceedings of the National Academy of Sciences 79(6):1979-1983, The National Academy of Sciences, United States (1982).;;Sakthivel, P., et al., ""Therapeutic Intervention in Cancer and Chronic Viral Infections: Antibody Mediated Manipulation of PD-1/PD-L1 Interaction,"" Reviews on Recent Clinical Trials 7(1):10-23, Bentham Science Pub., United Arab Emirates (2012).;;Seung, E., et al., ""PD-1 Blockade in Chronically HIV-1-Infected Humanized Mice Suppresses Viral Loads,"" PloS One 8(10):e77780, Public Library of Science, United States(Oct. 2013).;;Siewe, B., et al., ""Regulatory B Cells Inhibit Cytotoxic T Lymphocyte (CTL) Activity and Elimination of Infected CD4 T Cells after In Vitro Reactivation of HIV Latent Reservoirs,"" PloS One 9(4):e92934, Public Library of Science, United States (Apr. 2014).;;Tamura, M., et al., ""Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs only,"" Journal of Immunology 164(3):1432-1441, American Association of Immunologists, United States (2000).;;Tomizuka, K., et al., ""Double Trans-Chromosomic Mice: Maintenance of Two Individual Human Chromosome Fragments Containing Ig Heavy and Kappa loci and Expression of Fully Human Antibodies,"" Proceedings of the National Academy of Sciences of the United States of America 97(2):722-727, National Academy of Sciences, United States (2000).;;Tomlinson, I.M., et al., ""The Repertoire of Human Germline VH Sequences Reveals About Fifty Groups of VH segments with Different Hypervariable Loops,"" Journal of Molecular Biology 227(3):776-798, Elsevier, Netherlands (1992).;;Xu, J.L. and Davis, M.M., ""Diversity in the CDR3 Region of V(H) is Sufficient for Most Antibody Specificities,"" Immunity 13(1):37-45, Cell Press, United States (2000).;;Blank, C., et al., ""Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro,"" International Journal of Cancer 119(2):317-327, International Union Against Cancer, United States (2006).;;Iwai, Y., et al., ""Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade,"" Proceedings of the National Academy of Sciences of the United States of America 99(19):12293-12297, National Academy of Sciences, United States (2002).;;Extended European Search Report and Search Opinion for EP Application No. 15172571.0, European Patent Office, Germany, mailed on Dec. 17, 2015.;;Antonia, S.J., et al.,""Association of tumor PD-L1 Expression and Immune Biomarkers with Clinical Activity in Patients with Non-small Cell Lung Cancer (NSCLC) Treated with Nivolumab (Anti-PD-1; BMS-936558; ONO-4538),"" 15th World Conference on Lung Cancer, Sydney, Australia, 15th WCLC: Best of Posters 1-IASLC Selection, P2.11-035, Oct. 27-30, 2013, accessed at http://web.oncoletter.ch/kongressberichte-videos-slides-Onkologie/id-15th-world-conference-on-lung-cancer-conference/conference-highlights.html, accessed on Jan. 8, 2015, 6 pages.;;Blank, C., et al., ""Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy,"" Cancer Immunology, Immunotherapy 54:307-314, Springer Science+ Business Media, Germany (2005).;;Brown, J.A., et al., ""Expression and functional consequences of PD-1 ligands on natural APCS and tumors,"" The FASEB Journal 15(4):A345 (abstract No. 275.23), Federation of American Societies for Experimental Biology, United States (2001).;;Brown, J.A., et al., ""Blockade of PD-1 ligands on dendritic cells enhances T cells activation and cytokine production,"" FASEB Journal 16(4):710-517.4, Federation of American Societies for Experimental Biology, United States (2002).;;Carreno, B.M., et al., ""The B7 family of ligands and its receptors: New pathways for co-stimulation and inhibition of immune responses,"" Annu Rev. lmmunol, 20:29-53, Annual reviews, United States (2002).;;Carter, L., et al., ""PD-1: PD-L inhibitory pathway affects both CD4+ and CDS+ T cells and is overcome by IL-2,"" Eur J Immunology 32:634-643, Wiley-VCH, Germany (2002).;;Dong, H., et al., ""Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion,"" Nat Med, 8:783-800, Nature, United States (2002).;;Dong, H., Chen, L.,""B7-H1 pathway and its role in the evasion of tumor immunity,"" Journal of Molecular Medicine vol. 81:281-287, Springer Science+ Business Media, Germany (2002).;;Dong, H., et al., ""B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,"" Nature Medicine 5(12):1365-1369, Nature America Inc., United States (1999).;;Exhibit 1, ""Dichotomy of the activity of PD-L1 (B7-4) and how an anti-PD-1 antibody fits into it,"" in Response to Patentee's Aug. 12, 2015 Reply, mailed Dec. 21, 2015 for European Patent No. EP 1537878, filed Jul. 2, 2003, 1 page.;;Freeman, G.J., et al., ""Engagement of the PD-1 immunoinhibitory receptor by a novel B7-family member leads to negative regulation of lymphocyte activation,"",Journal of Experimental Medicine 192(7):1027-1034, Rockefeller University Press, United States (2000).;;Freeman, G.J., et al., ""Engagement of the PD-1 Immunoinhibitory by a Novel B7-Family Member Leads to Negative Regulation of Lymphocyte Activation,"" Blood 96(11):810a-811a (Abstract No. 3502) (2000).;;He, Y.F., et al., ""Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine,"" Journal of Immunology 173: 4919-4928, American Association of Immunologist, United States (2004).;;Hirano, F., et al., ""Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity,"" Cancer Research 65(3): 1089-1096, American Association for Cancer Research, United States (2005).;;Konishi, J., et al., ""B7-H1 Expression on Non-Small Cell Lung Cancer Cells and its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression,"" Clin. Cancer Res 10:5094-5100, American Association for Cancer Research, United States (2004).;;Nagler, A., et al., ""Phase I clinical trial of CT-011, a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced hematological malignancies,"" Experimental Hematology, 33:97, Elsevier, Netherlands (2005).;;Nomi, T., et al., ""Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer,"" Clinical Cancer Research 13(7):2151-2157, The Association, United States (2007).;;Tamura, H., et al., ""B7-H1 co-stimulation preferentially enhances CD28-independent T-helper cell function,"" Blood 97(6):1809-1816, American Society of Hematology, United States (2001).;;West, J.H., ""CheckMate-057 Trial: The Future of PD-Ll as a Biomarker,"" medscape.com, accessed at http://www.medscape.com/viewarticle/845926, accessed on Sep. 17, 2015, 1 page (Jun. 5, 2015).;;Yamazaki, T., et al., ""Expression of programmed death 1 ligands by murine T cells and APC,"" Journal of Immunology 169(10):5538-5545, American Association of Immunologist, United States (2002).;;Zou, W. and Chen, L., ""Inhibitory B7-family Molecules in the Tumour Microenvironment,"" Nature Reviews Immunology 8(6):467-477, Nature Publishing Group, England (2008).;;Zuberek, K., et al., ""The role of in vivo PD-1/PD-L1 interactions in syngeneic and allogeneic antitumor responses in murine tumor models,"" Blood 98(11): 42B, American Society of Hematology, United States (2001).;;Liang, S.C., et al., ""Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmunue responses,"" Eur J Immunol 33:2706-2716, Wiley-VCH Verlag GmbH & Co. KGaA, Germany (2003).;;Schoop, R., et al., ""Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells,"" Nephrol Dial Transplant 19:2713-2720, Springer International, England (2004).;;English Translation of Search Report dated Dec. 5, 2016, in Chinese Patent Application No. 201410639719.X.",ACTIVE
167,US,A1,US 2023/0272079 A1,112-663-153-121-398,2023-08-31,2023,US 202318167012 A,2023-02-09,US 202318167012 A;;US 201916600272 A;;US 201615288545 A;;US 201414248462 A;;US 201113210137 A;;US 91321709 A;;JP 2006309606 W;;US 67946605 P;;US 73843405 P;;US 74891905 P,2005-05-09,Monoclonal Antibodies to Programmed Death 1 (PD-1),"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",SQUIBB & SONS LLC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BINGLIANG;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/112-663-153-121-398,Patent Application,yes,0,0,120,125,0,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/00;;A61K39/395;;A61K47/68;;A61K51/10;;A61P7/06;;C07K16/18;;C07K16/46,,0,0,,,,PENDING
168,KR,A,KR 20130032908 A,137-732-669-229-985,2013-04-02,2013,KR 20137004055 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;JP 2006309606 W,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,,MEDAREX INC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN,,https://lens.org/137-732-669-229-985,Patent Application,no,0,1,120,125,84,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,A61K39/395;;A61P35/00,,0,0,,,,ACTIVE
169,JP,A,JP 2020129001 A,032-389-655-125-795,2020-08-27,2020,JP 2020083351 A,2020-05-11,US 201562139183 P,2015-03-27,HCV NS4A/MODIFIED NS3 POLYPEPTIDES AND USES THEREOF,"To provide modified hepatitis-C virus polypeptides.SOLUTION: A method of detecting antibodies to hepatitis C virus including the HCV NS4a domain and modified NS3 domain in a biological sample is provided, the method comprising: (a) providing an immunoassay reagent; (b) binding HCV antibodies, if present in the biological sample, to a polypeptide to form a first immune complex; (c) adding a labeled detector to the first immune complex obtained in the step (b), the labeled detector being reactive with the first immune complex; and (d) detecting second immune complexes formed between the labeled detector and the first immune complex, if present, as an indication of the presence of antibodies to hepatitis C virus in the biological sample.SELECTED DRAWING: Figure 7",ORTHO CLINICAL DIAGNOSTICS INC;;ORTHO CLINICAL DIAGNOSTICS KK;;GRIFOLS WORLDWIDE OPERATIONS LTD,Y CHIEN DAVID;;DORIS GUENZI COIT;;FUJIWARA TOSHIYA;;ALEXANDER GYENES;;JOHN ANDREW HALL;;ANGELICA MEDINA-SELBY;;CHEN JIAN,,https://lens.org/032-389-655-125-795,Patent Application,no,6,0,23,23,0,C12Q1/70;;G01N2469/20;;C07K14/005;;C07K2319/00;;C12N2770/24222;;G01N33/5767;;C12Q1/70;;G01N2469/20;;C07K14/005;;C07K2319/00;;C12N2770/24222;;C07K14/02;;G01N33/5767;;G01N2333/186,G01N33/576;;G01N33/53;;G01N33/543,,0,0,,,,PENDING
170,CA,A1,CA 2970873 A1,009-306-586-513-638,2006-11-16,2006,CA 2970873 A,2006-05-02,US 67946605 P;;US 73843405 P;;US 74891905 P;;CA 2607147 A,2005-05-09,HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS,"The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti- CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.",SQUIBB & SONS LLC;;ONO PHARMACEUTICAL CO,KORMAN ALAN J;;SRINIVASAN MOHAN;;WANG CHANGYU;;SELBY MARK J;;CHEN BING;;CARDARELLI JOSEPHINE M;;HUANG HAICHUN;;HUANG HAICHUN,,https://lens.org/009-306-586-513-638,Patent Application,no,0,1,120,125,74,A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;C07K2317/52;;C07K2317/74;;C07K2317/75;;C07K2317/76;;A61K47/6849;;A61P7/06;;C07K2317/73;;C07K16/2818;;Y02A50/30;;A61K39/00;;C07K16/28;;A61K39/00;;A61K39/39533;;C07K16/28;;A61K39/00;;A61K39/39558;;A61K51/10;;C07K16/18;;C07K16/28;;C07K16/468;;C07K16/2818;;A61K39/00;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/732;;A61P7/06;;A61K47/6849;;Y02A50/30;;C07K16/2818;;C07K16/18;;A61K39/3955;;C07K16/468;;A61K51/10;;C07K16/28;;C07K2317/73;;A61K39/39558;;A61K39/00;;A61K2039/507;;C07K16/2803;;C07K2317/33;;C07K2317/92;;C07K2317/94,C07K16/28;;A01K67/027;;C07K16/46;;C12N5/16;;C12N15/13,,0,0,,,,PENDING
171,US,A1,US 2007/0035516 A1,173-393-992-357-815,2007-02-15,2007,US 19963005 A,2005-08-09,US 19963005 A,2005-08-09,Joystick sensor with light detection,"The present invention creates a virtual sensor plane by arraying two one-dimensional light sensors at right angles to one another wherein the shaft of a joystick extends perpendicularly through the virtual sensor plane. With this configuration, the sensor plane can detect traditional joystick rotation around a point along its axis as well as a herein-disclosed true rotation of the joystick around the joystick axis itself. Between the light sources and lenses which enable light detection and the optical, rather than mechanical or electromechanical, nature of the light sensors, wear surfaces in the joystick are minimized or eliminated everywhere except, where applicable, in the universal joint at the base of joystick configurations which include such a universal joint.",DELPHI TECH INC,VOTO ANDREW M;;SELBY RONALD K;;PERRY KENNETH D;;ROSS DAVID A;;DUMSA ALFRED V JR;;LIPPMANN RAY;;CHEN YANSONG,DELPHI TECHNOLOGIES INC (2005-06-15),https://lens.org/173-393-992-357-815,Patent Application,yes,18,23,3,3,0,G05G9/047;;G05G2009/04759;;G05G9/047;;G05G2009/04759,G09G5/08,345/161,0,0,,,,DISCONTINUED
172,EP,A2,EP 1752854 A2,177-605-845-227-17X,2007-02-14,2007,EP 06076361 A,2006-07-05,US 19963005 A,2005-08-09,Joystick sensor with light detection,"The present invention creates a virtual sensor plane by arraying two one-dimensional light sensors (24) at right angles to one another wherein the shaft of a joystick (10) extends perpendicularly through the virtual sensor plane. With this configuration, the sensor plane can detect traditional joystick (10) rotation around a point along its axis as well as a herein-disclosed true rotation of the joystick (10) around the joystick axis itself. Between the light sources (26) and lenses which enable light detection and the optical, rather than mechanical or electromechanical, nature of the light sensors, wear surfaces in the joystick are minimized or eliminated everywhere except, where applicable, in the universal joint at the base of joystick configurations which include such a universal joint.",DELPHI TECH INC,VOTO ANDREW M;;SELBY RONALD K;;PERRY KENNETH D;;ROSS DAVID A;;DUMSA JR ALFRED V;;LIPPMANN RAYMOND;;CHEN YANSONG,,https://lens.org/177-605-845-227-17X,Patent Application,yes,8,0,3,3,0,G05G9/047;;G05G2009/04759;;G05G9/047;;G05G2009/04759,G05G9/047,,0,0,,,,DISCONTINUED
173,EP,A3,EP 1752854 A3,160-104-494-893-505,2009-01-07,2009,EP 06076361 A,2006-07-05,US 19963005 A,2005-08-09,Joystick sensor with light detection,"The present invention creates a virtual sensor plane by arraying two one-dimensional light sensors (24) at right angles to one another wherein the shaft of a joystick (10) extends perpendicularly through the virtual sensor plane. With this configuration, the sensor plane can detect traditional joystick (10) rotation around a point along its axis as well as a herein-disclosed true rotation of the joystick (10) around the joystick axis itself. Between the light sources (26) and lenses which enable light detection and the optical, rather than mechanical or electromechanical, nature of the light sensors, wear surfaces in the joystick are minimized or eliminated everywhere except, where applicable, in the universal joint at the base of joystick configurations which include such a universal joint.",DELPHI TECH INC,VOTO ANDREW M;;SELBY RONALD K;;PERRY KENNETH D;;ROSS DAVID A;;DUMSA JR ALFRED V;;LIPPMANN RAYMOND;;CHEN YANSONG,,https://lens.org/160-104-494-893-505,Search Report,yes,7,0,3,3,0,G05G9/047;;G05G2009/04759;;G05G9/047;;G05G2009/04759,G05G9/047,,0,0,,,,DISCONTINUED
174,WO,A1,WO 2019/195452 A1,107-180-887-658-242,2019-10-10,2019,US 2019/0025623 W,2019-04-03,US 201862652790 P,2018-04-04,ANTI-CD27 ANTIBODIES AND USES THEREOF,"This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.",BRISTOL MYERS SQUIBB CO,LU LI-SHENG;;SELBY MARK J;;KORMAN ALAN J;;DESHPANDE SHRIKANT;;SRINIVASAN MOHAN;;ZHANG JUN;;HUANG HAICHUN;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA,,https://lens.org/107-180-887-658-242,Patent Application,yes,46,7,6,6,21,C07K16/2878;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/75;;C07K2317/92;;A61P35/00;;C07K16/2878;;A61P35/00;;C07K2317/565;;C07K2317/24;;C07K2317/75;;C07K2317/92;;A61K2039/505;;A61P35/00;;A61K39/39541;;A61K45/06;;A61K2039/505;;A61K2039/507;;C07K16/2878;;C07K2317/33;;C07K2317/34;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/92;;C07K2317/94,C07K16/28;;A61P35/00,,71,64,047-931-357-777-682;;002-879-881-600-068;;117-139-548-093-070;;111-853-877-209-361;;032-720-983-972-675;;032-607-822-990-069;;074-668-310-987-029;;052-913-173-810-208;;038-040-632-602-487;;057-014-871-705-328;;075-995-902-619-937;;051-342-928-187-07X;;100-183-873-028-783;;022-567-239-000-412;;043-812-256-401-101;;049-134-753-209-354;;024-995-475-936-443;;008-286-491-619-040;;090-449-093-594-607;;068-945-392-083-431;;044-344-815-519-299;;017-264-721-007-699;;066-965-839-246-707;;043-212-741-972-267;;023-684-363-686-73X;;050-208-353-729-638;;077-532-829-551-519;;077-663-157-776-490;;116-852-773-281-868;;097-770-521-003-814;;049-768-613-060-097;;032-075-442-654-704;;029-667-686-534-996;;039-515-794-348-090;;022-703-574-575-508;;030-147-307-308-064;;052-660-996-132-29X;;002-852-159-123-460;;023-868-377-007-810;;095-334-545-560-259;;018-477-612-366-268;;096-300-656-247-223;;092-273-064-168-541;;058-199-318-751-580;;045-623-729-340-346;;017-850-333-220-676;;093-180-432-524-890;;066-998-609-716-022;;048-865-812-223-66X;;007-344-239-700-062;;043-500-509-143-751;;141-233-903-470-987;;084-861-511-117-30X;;072-475-603-264-541;;061-853-994-914-594;;100-189-413-960-390;;051-218-620-433-15X;;042-544-790-348-596;;041-698-857-198-939;;026-701-180-749-292;;043-114-291-493-998;;083-642-669-474-327;;035-305-977-167-611;;147-864-247-924-432,10.1016/j.molimm.2017.01.005;;28119207;;pmc5417320;;28471362;;10.1107/s2053230x17005957;;18614234;;10.1016/j.molimm.2008.05.022;;10.1158/0008-5472.can-15-3130;;27020860;;10.1006/jmbi.1997.1354;;9367782;;10.1371/journal.pone.0030852;;22347406;;pmc3275569;;pmc4834717;;20516446;;10.1200/jco.2009.26.7609;;25798726;;10.2217/fon.15.52;;10.1056/nejmoa1200694;;pmc3563263;;22658128;;25404365;;pmc4272895;;10.4049/jimmunol.1401644;;29514845;;10.1158/1078-0432.ccr-17-3057;;pmc5959006;;10.1186/2051-1426-2-s3-p100;;27192570;;10.1016/j.immuni.2016.04.023;;10.1016/j.ajpath.2016.02.023;;pmc4929396;;27338107;;23890059;;10.1016/j.immuni.2013.07.012;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/342877a0;;2687698;;10.1038/icb.2010.171;;21283110;;pmc2931327;;10.4049/jimmunol.180.5.2912;;18292513;;10.1186/s12916-016-0623-5;;pmc4858828;;27151159;;17311995;;10.1182/blood-2006-11-057216;;10.1158/1538-7445.am2017-4606;;10.7150/jca.17144;;pmc5332892;;28261342;;10.4049/jimmunol.1300409;;24026078;;10.1038/80877;;11062504;;25428504;;pmc4836193;;10.1038/nature14011;;10.1038/nbt1142;;16151406;;pmc4084782;;23677477;;10.4049/jimmunol.1300022;;10.1007/s00216-014-7924-3;;24948090;;pmc5381059;;10.1186/s12929-017-0329-9;;28376884;;21894996;;10.1021/ac2007366;;pmc3193551;;10.3389/fonc.2017.00064;;28459041;;pmc5394116;;6292436;;10.1016/0022-2836(82)90103-6;;10.1016/s0145-305x(02)00039-3;;12477501;;25810313;;10.1126/scitranslmed.3010274;;10.1158/1078-0432.ccr-12-2625;;pmc3548952;;23169436;;28679395;;pmc5499002;;10.1186/s13045-017-0506-z;;26228759;;10.1038/nrd4591;;2594766;;pmc298475;;10.1073/pnas.86.23.9268;;10.1006/jmbi.1996.0548;;8876650;;22193102;;pmc3967235;;10.1038/nature10673;;pmc3552005;;23269247;;10.4049/jimmunol.1202353;;20350626;;10.1053/j.semnuclmed.2009.12.005;;pmc2853948;;10.1186/s40425-017-0218-5;;28239469;;pmc5319100;;10.1038/nrc3239;;pmc4856023;;22437870;;10.1007/3-540-30683-8_443;;10.21037/sci.2017.03.04;;pmc5420526;;28529947;;pmc4619281;;26500773;;10.1186/s40425-015-0080-2;;pmc2955154;;20842060;;10.1097/cji.0b013e3181ee238f;;10.1016/j.bbrc.2010.02.092;;20171165;;10.3324/haematol.2012.068791;;pmc3659923;;22801960;;17237405;;10.4049/jimmunol.178.3.1564;;10.1200/jco.2017.35.15_suppl.3007;;10.4049/jimmunol.173.11.6542;;15557144;;10.1016/j.immuni.2011.04.020;;21763160;;10.1016/j.jaci.2011.11.013;;22197273;;pmc3294016;;10.1517/14728222.2016.1158812;;26914723;;24872026;;10.1158/2326-6066.cir-14-0040;;10.1053/j.seminoncol.2010.09.005;;21074057;;pmc4081482;;23928097;;10.1016/j.drudis.2013.07.019;;pmc4081656;;10.1093/annonc/mdt161;;23666915;;pmc2138737;;5508247;;10.1084/jem.132.2.211;;pmc4224620;;10.1007/s13361-014-0993-x;;25267085;;10.1038/nrd3877;;23370250;;pmc3698571;;pmc5341541;;10.1038/celldisc.2017.4;;28280600,"OBMOLOVA GALINA ET AL: ""Epitope-dependent mechanisms of CD27 neutralization revealed by X-ray crystallography"", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 83, 21 January 2017 (2017-01-21), pages 92 - 99, XP029925306, ISSN: 0161-5890, DOI: 10.1016/J.MOLIMM.2017.01.005;;ALEXEY TEPLYAKOV ET AL: ""Crystal structure of CD27 in complex with a neutralizing noncompeting antibody"", ACTA CRYSTALLOGRAPHICA SECTION F STRUCTURAL BIOLOGY COMMUNICATIONS, vol. 73, no. 5, 1 May 2017 (2017-05-01), pages 294 - 299, XP055435718, DOI: 10.1107/S2053230X17005957;;""Concise Dictionary of Biomedicine and Molecular Biology"", 2002, CRC PRESS;;""The Dictionary of Cell and Molecular Biology"", 1999, ACADEMIC PRESS;;""Oxford Dictionary Of Biochemistry And Molecular Biology, Revised"", 2000, OXFORD UNIVERSITY PRESS;;ABHINANDAN KR; MARTIN AC: ""Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains"", MOL IMMUNOL, vol. 45, 2008, pages 3832 - 9, XP023437109, DOI: doi:10.1016/j.molimm.2008.05.022;;AHRENDS T; BABALA N; XIAO Y ET AL.: ""CD27 agonism plus PD-1 blockade recapitulates CD4+ T cell help in therapeutic anti-cancer vaccination"", CANCER RES, vol. 76, no. 10, 2016, pages 2921 - 31;;AL-LAZIKANI, LESK AM; CHOTHIA C: ""Standard conformations for the canonical structures of immunoglobulins"", J MOL BIOL, vol. 273, no. 4, 1997, pages 927 - 48, XP004461383, DOI: doi:10.1006/jmbi.1997.1354;;BAITSCH L; LEGAT A; BARBA L; FUERTES MARRACO SA; RIVALS JP ET AL.: ""Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization"", PLOS ONE, vol. 7, no. 2, 2012, pages e30852;;BRAHMER JR; DRAKE CG; WOLLNER I; POWDERLY JD; PICUS J ET AL.: ""Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates"", J CLIN ONCOL, vol. 28, 2010, pages 3167 - 75, XP055124332, DOI: doi:10.1200/JCO.2009.26.7609;;BRAHMER JR; HAMMERS H; LIPSON EJ: ""Nivolumab: targeting PD-1 to bolster antitumor immunity"", FUTURE ONCOL, vol. 11, no. 9, 2015, pages 1307 - 26, XP055198599, DOI: doi:10.2217/fon.15.52;;BRAHMER JR; TYKODI SS; CHOW LQ; HWU WJ; TOPALIAN SL ET AL.: ""Safety and activity of anti-PD-Ll antibody in patients with advanced cancer"", NENGL J MED, vol. 366, 2012, pages 2455 - 65, XP002685330, DOI: doi:10.1056/NEJMoa1200694;;BUCHAN SL; MANZO T; FLUTTER B ET AL.: ""OX40- and CD27-mediated costimulation synergizes with anti-PD-Ll blockade by forcing exhausted CD8+ T cells to exit quiescence"", J, vol. 194, 2015, pages 125 - 33, XP055413464, DOI: doi:10.4049/jimmunol.1401644;;BUCHAN SL; FALLATAH M; THIRDBOROUGH SM; TARABAN VY; ROGEL A ET AL.: ""PD-1 blockade and CD27 stimulation activate distinct transcriptional programs that synergize for CD8+ T-cell driven anti-tumor immunity"", CLIN CANCER RES, vol. 24, no. 10, 2018, pages 2383 - 94;;BULLOCK T; MCCLINTIC H; JEONG S ET AL.: ""Immune correlates of varlilumab (CDX-1127) treated cancer patients are consistent with CD27 costimulatory activity"", SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 29TH ANNUAL MEETING, 2014;;CALLAHAN M; POSTOW MA; WOLCHOK JD: ""Targeting T cell co-receptors for cancer therapy"", IMMUNITY, vol. 44, no. 5, 2016, pages 1069 - 78, XP029537989, DOI: doi:10.1016/j.immuni.2016.04.023;;CHAKRAVARTHI BVSK; NEPAL S; VARAMBALLY S: ""Genomic and epigenomic alterations in cancer"", AM JPATHOL, vol. 186, no. 7, 2016, pages 1724 - 35;;CHEN DS; MELLMAN I: ""Oncology meets immunology: the cancer-immunity cycle"", IMMUNITY, vol. 39, no. 1, 2013, pages 1 - 10, XP002742399, DOI: doi:10.1016/j.immuni.2013.07.012;;CHOTHIA C; LESK AM: ""Canonical structures for the hypervariable regions of immunoglobulins"", JMOLBIOL, vol. 196, 1987, pages 901 - 17, XP024010426, DOI: doi:10.1016/0022-2836(87)90412-8;;CHOTHIA C; LESK AM; TRAMONTANO A; LEVITT M; SMITH-GILL JS ET AL.: ""Conformations of immunoglobulin hypervariable regions"", NATURE, vol. 342, 1989, pages 877 - 83, XP002030586, DOI: doi:10.1038/342877a0;;DE COLVENAER V; TAVEIRNE S; DELFORCHE M ET AL.: ""CD27-deficient mice show normal NK-cell differentiation but impaired function upon stimulation"", IMMUNOL CELL BIOL, vol. 89, 2011, pages 803 - 11;;DOLFI DV; BOESTEANU AC; PETROVAS C ET AL.: ""Late signals from CD27 prevent Fas-dependent apoptosis of primary CD8+T cells"", J. IMMUNOL, vol. 180, 2008, pages 2912 - 21;;DRUGS.COM - OPDIVO APPROVAL HISTORY, 1 April 2019 (2019-04-01), Retrieved from the Internet <URL:https://www.drugs.com/history/opdivo.html>;;FARKONA ET AL.: ""Cancer immunotherapy: the beginning of the end of cancer?"", BMC MEDICINE, vol. 14, 2016, pages 73;;FRENCH RR; TARABAN VY; CROWTHER GR ET AL.: ""Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation"", BLOOD, vol. 109, 2007, pages 4810 - 5, XP002582844, DOI: doi:10.1182/BLOOD-2006-11-057216;;GORELIK L; AVGERINOS G; KUNES Y; MARASCO WA: ""Preclinical characterization of a novel fully human IgGl anti-PD-Ll mAb CK-301"", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING, vol. 77, no. 13, 2017;;GUO L; ZHANG H; CHEN B: ""Nivolumab as Programmed Death-1 (PD-1) inhibitor for targeted immunotherapy in tumor"", J CANCER, vol. 8, no. 3, 2017, pages 410 - 6;;HE LZ; PROSTAK N; THOMAS LJ ET AL.: ""Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice"", J IMMUNOL, vol. 191, 2013, pages 4174 - 83, XP055496515, DOI: doi:10.4049/jimmunol.1300409;;HENDRIKS J; GRAVESTEIN LA; TESSELAAR K ET AL.: ""CD27 is required for generation and long-term maintenance of T cell immunity"", NAT IMMUNOL, vol. 1, 2000, pages 433 - 40, XP002267541, DOI: doi:10.1038/80877;;HERBST RS; SORIA JC; KOWANETZ M; FINE GD; HAMID O ET AL.: ""Predictive correlates of response to the anti-PD-Ll antibody MPDL3280A in cancer patients"", NATURE, vol. 515, 2014, pages 563 - 7, XP055262130, DOI: doi:10.1038/nature14011;;HOLLINGER P; HUDSON PJ: ""Engineered antibody fragments and the rise of single domains"", NATURE BIOTECH, vol. 23, no. 9, 2005, pages 1126 - 36, XP008076746, DOI: doi:10.1038/nbt1142;;HUANG J; JOCHEMS C; ANDERSON AM ET AL.: ""Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity"", J. IMMUNOL., vol. 190, 2013, pages 6250 - 8, XP055132835, DOI: doi:10.4049/jimmunol.1300022;;HUANG R; CHEN G: ""Higher order structure characterization of protein therapeutics by hydrogen/deuterium exchange mass spectrometry"", ANALYTICAL AND BIOANALYTICAL CHEMISTRY, vol. 406, 2014, pages 6541 - 58, XP035401219, DOI: doi:10.1007/s00216-014-7924-3;;IWAI Y; HAMANISHI J; CHAMOTO K; HONJO T: ""Cancer immunotherapies targeting the PD-1 signaling pathway"", JBIOMED SCI, vol. 24, no. 1, 2017, pages 26, XP002771345, DOI: doi:10.1186/s12929-017-0329-9;;JONES LM; SPERRY JB; CARROLL JA; GROSS ML: ""Fast photochemical oxidation of proteins for epitope mapping"", ANAL CHEM, vol. 83, 2011, pages 7657 - 61;;KABAT EA; WU TT; BILOFSKY H; REID-MILLER M; PERRY H: ""Sequences of Proteins of Immunological Interest"", 1983, NATIONAL INSTITUTE OF HEALTH, pages: 323;;KABAT EA; WU TT; PERRY H; GOTTESMAN K; FOELLER C: ""Sequences of Proteins of Immunological Interest"", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES;;KABAT EA; WU TT; REID-MILLER M; PERRY H; GOTTESMAN K: ""Sequences of Proteins of Immunological Interest"", 1987, U.S. GOVERNMENT PRINTING OFFICE;;KAMTA J; CHAAR M; ANDE A; ALTOMARE DA; AIT-OUDHIA S: ""Advancing cancer therapy with present and emerging immuno-oncology approaches"", FRONT ONCOL, vol. 18, no. 7, 2017, pages 64;;KAUFMAN RJ; SHARP PA: ""Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary DNA gene"", MOL BIOL, vol. 159, 1982, pages 601 - 21, XP024012279, DOI: doi:10.1016/0022-2836(82)90103-6;;LEFRANC MP; POMMIE C; RUIZ M; GIUDICELLI V; FOULQUIER E ET AL.: ""IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains"", DEV COMP IMMUNOL, vol. 27, 2003, pages 55 - 77, XP055144492, DOI: doi:10.1016/S0145-305X(02)00039-3;;LESOKHIN AM; CALLAHAN MK; POSTOW MA; WOLCHOK JD: ""On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation"", SCI TRANSL MED, vol. 7, no. 280, 2015, pages 280srl;;LIPSON EJ; SHARFMAN WH; DRAKE CG; WOLLNER I; TAUBE JM ET AL.: ""Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody"", CLIN CANCER RES, vol. 19, 2013, pages 462 - 8, XP055296771, DOI: doi:10.1158/1078-0432.CCR-12-2625;;LIU SY; WU YL: ""Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China"", J HEMATOL ONCOL, vol. 10, no. 1, 2017, pages 136;;MAHONEY KM; RENNERT PD; FREEMAN GJ: ""Combination cancer immunotherapy and new immunomodulatory targets"", NAT REV DRUG DISCOV, vol. 14, no. 8, 2015, pages 561 - 84, XP055240362, DOI: doi:10.1038/nrd4591;;MARTIN A; CHEETHAM JC; REES AR: ""Modeling antibody hypervariable loops: a combined algorithm"", PROC NATL ACAD SCI USA, vol. 86, no. 23, 1989, pages 9268 - 72, XP000165667, DOI: doi:10.1073/pnas.86.23.9268;;MACCALLUM RM.; MARTIN ACR; THORNTON JT: ""Antibody-antigen interactions: contact analysis and binding site topography"", JMOLBIOL, vol. 262, 1996, pages 732 - 45, XP002242391, DOI: doi:10.1006/jmbi.1996.0548;;MELLMAN I; COUKOS G; DRANOFF: ""Cancer immunotherapy comes of age"", NATURE, vol. 480, 2011, pages 480 - 9, XP055054665, DOI: doi:10.1038/nature10673;;MUNITIC I; KUKA M; ALLAM A ET AL.: ""CD70 deficiency impairs effector CD8 T cell generation and viral clearance but is dispensable for the recall response to lymphocytic choriomeningitis virus"", J, vol. 190, 2013, pages 1169 - 79;;OLAFSEN T; WU AM: ""Antibody vectors for imaging"", SEMIN NUCL MED, vol. 40, no. 3, 2010, pages 167 - 81;;OTT PA; HODI FS; KAUFMAN HL; WIGGINTON JM; WOLCHOK JD: ""Combination immunotherapy: a road map"", JIMMUNOTHER CANCER, vol. 5, 2017, pages 16;;PARDOLL DM: ""The blockage of immune checkpoints in cancer immunotherapy"", NAT REV CANCER, vol. 12, 2012, pages 252 - 64;;PIANKO MJ; LIU Y; BAGCHI S; LESOKHIN AM: ""Immune checkpoint blockade for hematologic malignancies: a review"", STEM CELL INVESTIG, vol. 4, 2017, pages 32;;RAMAKRISHNA V; SUNDARAPANDIYAN K; ZHAO B ET AL.: ""Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab"", JIMMUNOTHER CANCER, vol. 3, 2015, pages 37, XP055414303, DOI: doi:10.1186/s40425-015-0080-2;;ROBERTS DJ; FRANKLIN NA; KINGETER LM ET AL.: ""Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression, of tumor infiltrating CD8+ T cells"", J IMMUNOTHER, vol. 33, 2010, pages 769 - 79, XP055505951, DOI: doi:10.1097/CJI.0b013e3181ee238f;;SAKANISHI T; YAGITA H: ""Anti-tumor effects of depleting and non-depleting anti-CD27 mAbs in immune-competent mice"", BIOCHEM BIOPHYS RES COMMUN, vol. 393, 2010, pages 829 - 35, XP026970765, DOI: doi:10.1016/j.bbrc.2010.02.092;;SALZER E; DASCHKEY S; CHOO S ET AL.: ""Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27"", HAEMATOLOGICA, vol. 98, 2013, pages 473 - 8;;SANCHEZ PJ; MCWILLIAMS JA; HALUSZCZAK C ET AL.: ""Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo"", J IMMUNOL, vol. 178, 2007, pages 1564 - 72;;SANBORN RE; PISHVAIAN MJ; KLUGER HM; CALLAHAN MK ET AL.: ""Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PDl antibody nivolumab in advanced cancer patients"", J CLIN ONCOL, vol. 35, no. 15, 2017, pages 3007;;TARABAN VY; ROWLEY TF; AL-SHAMKHANI A: ""Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs"", J IMMUNOL, vol. 173, 2004, pages 6542 - 6, XP008099518;;VAN GISBERGEN KP; KLARENBEEK PL; KRAGTEN NA ET AL.: ""The costimulatory molecule CD27 maintains clonally diverse CD8 (+) T cell responses of low antigen affinity to protect against viral variants"", IMMUNITY, vol. 35, 2011, pages 97 - 108, XP028381702, DOI: doi:10.1016/j.immuni.2011.04.020;;VAN MONTFRANS JM; HOEPELMAN AI; OTTO S ET AL.: ""CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia"", ALLERGY CLIN IMMUNOL, vol. 129, 2012, pages 787 - 93;;WAJ ANT H: ""Therapeutic targeting of CD70 and CD27"", EXPERT OPIN THER TARGETS, vol. 15, 2016, pages 1 - 15;;WANG C; THUDIUM KB; HAN M; WANG XT ET AL.: ""In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates"", CANCER IMM RES, vol. 2, no. 9, 2014, pages 846 - 56, XP055537674, DOI: doi:10.1158/2326-6066.CIR-14-0040;;WEBER J: ""Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade"", SEMIN ONCOL, vol. 37, no. 5, 2010, pages 430 - 9, XP009177527, DOI: doi:10.1053/j.seminoncol.2010.09.005;;WEI H; MO J; TAO L; RUSSELL RG; TYMIAK AA ET AL.: ""Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications"", DRUGDISCOV TODAY, vol. 19, 2014, pages 95 - 102;;WOLCHOK JD; WEBER JS; MAIO M; NEYNS B; HARMANKAYA K ET AL.: ""Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials"", ANN ONCOL, vol. 24, no. 8, 2013, pages 2174 - 80;;WU TT; KABAT EA: ""An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity"", JEXP MED, vol. 132, 1970, pages 211 - 50;;YAN Y; CHEN G; WEI H; HUANG R; MO J ET AL.: ""Fast photochemical oxidation of proteins (FPOP) maps the epitope of EGFR binding to adnectin"", JAM SOC MASS SPEC, vol. 25, 2014, pages 2084 - 92;;YAO S; ZHU Y; CHEN L: ""Advances in targeting cell surface signalling molecules for immune modulation"", NATURE REV DRUG DISCOV, vol. 12, 2013, pages 130 - 46, XP055157248, DOI: doi:10.1038/nrd3877;;ZHANG F; WEI H; WANG X; BAI Y; WANG P ET AL.: ""Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade"", CELL DISCOV, vol. 3, 2017, pages 17004",PENDING
175,CN,A,CN 112292399 A,013-785-401-988-633,2021-01-29,2021,CN 201980024528 A,2019-04-03,US 201862652790 P;;US 2019/0025623 W,2018-04-04,ANTI-CD27 ANTIBODIES AND USES THEREOF,"This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administeringto the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.",BRISTOL MYERS SQUIBB CO,LU LI-SHENG;;SELBY MARK J;;KORMAN ALAN J;;DESHPANDE SHRIKANT;;SRINIVASAN MOHAN;;ZHANG JIM;;HUANG HAICHUN;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA,,https://lens.org/013-785-401-988-633,Patent Application,no,4,0,6,6,0,C07K16/2878;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/75;;C07K2317/92;;A61P35/00;;C07K16/2878;;A61P35/00;;C07K2317/565;;C07K2317/24;;C07K2317/75;;C07K2317/92;;A61K2039/505;;A61P35/00;;A61K39/39541;;A61K45/06;;A61K2039/505;;A61K2039/507;;C07K16/2878;;C07K2317/33;;C07K2317/34;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/92;;C07K2317/94,C07K16/28;;A61P35/00,,2,1,100-189-413-960-390,10.1517/14728222.2016.1158812;;26914723,"HARALD WAJANT: ""Therapeutic targeting of CD70 and CD27"", 《EXPERT OPIN THER TARGETS . 》, vol. 20, no. 8, pages 959 - 973, XP055289722, DOI: 10.1517/14728222.2016.1158812;;GENBANK: ""Accession No.:CEF90812.1, immunoglobulin heavy chain variable region, partial [Homo sapiens]"", 《GENBANK》",PENDING
176,EP,A1,EP 3774903 A1,141-183-170-196-091,2021-02-17,2021,EP 19717731 A,2019-04-03,US 201862652790 P;;US 2019/0025623 W,2018-04-04,ANTI-CD27 ANTIBODIES AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,LU LI-SHENG;;SELBY MARK J;;KORMAN ALAN J;;DESHPANDE SHRIKANT;;SRINIVASAN MOHAN;;ZHANG JUN;;HUANG HAICHUN;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA,,https://lens.org/141-183-170-196-091,Patent Application,yes,0,0,6,6,0,C07K16/2878;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/75;;C07K2317/92;;A61P35/00;;C07K16/2878;;A61P35/00;;C07K2317/565;;C07K2317/24;;C07K2317/75;;C07K2317/92;;A61K2039/505;;A61P35/00;;A61K39/39541;;A61K45/06;;A61K2039/505;;A61K2039/507;;C07K16/2878;;C07K2317/33;;C07K2317/34;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/92;;C07K2317/94,C07K16/28;;A61P35/00,,0,0,,,,PENDING
177,KR,A,KR 20200140315 A,043-273-424-146-593,2020-12-15,2020,KR 20207031468 A,2019-04-03,US 201862652790 P;;US 2019/0025623 W,2018-04-04,항-CD27 항체 및 그의 용도,"본 개시내용은 높은 친화도로 CD27에 특이적으로 결합하는 단리된 항체를 제공한다. 본 개시내용은 암을 앓는 대상체에게 치료 유효량의 항-CD27 항체를 단독요법으로서 또는 체크포인트 억제제 예컨대 항-PD-1, 항-PD-L1, 또는 항-CTLA-4 항체와 조합하여 투여하는 것을 포함하는, 암을 앓는 대상체를 치료하는 방법을 제공한다.",BRISTOL MYERS SQUIBB CO,LU LI SHENG;;SELBY MARK J;;KORMAN ALAN J;;DESHPANDE SHRIKANT;;SRINIVASAN MOHAN;;ZHANG JUN;;HUANG HAICHUN;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA,,https://lens.org/043-273-424-146-593,Patent Application,no,0,0,6,6,42,C07K16/2878;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/75;;C07K2317/92;;A61P35/00;;C07K16/2878;;A61P35/00;;C07K2317/565;;C07K2317/24;;C07K2317/75;;C07K2317/92;;A61K2039/505;;A61P35/00;;A61K39/39541;;A61K45/06;;A61K2039/505;;A61K2039/507;;C07K16/2878;;C07K2317/33;;C07K2317/34;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/00;;A61P35/00,,0,0,,,,PENDING
178,US,A1,US 2021/0155703 A1,023-233-202-221-242,2021-05-27,2021,US 201917045143 A,2019-04-03,US 201917045143 A;;US 201862652790 P;;US 2019/0025623 W,2018-04-04,ANTI-CD27 ANTIBODIES AND USES THEREOF,"This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.",BRISTOL MYERS SQUIBB CO,LU LI-SHENG;;SELBY MARK J;;KORMAN ALAN J;;DESHPANDE SHRIKANT;;SRINIVASAN MOHAN;;ZHANG JUN;;HUANG HAICHUN;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G,BRISTOL-MYERS SQUIBB COMPANY (2019-06-28),https://lens.org/023-233-202-221-242,Patent Application,yes,0,1,6,6,21,C07K16/2878;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/75;;C07K2317/92;;A61P35/00;;C07K16/2878;;A61P35/00;;C07K2317/565;;C07K2317/24;;C07K2317/75;;C07K2317/92;;A61K2039/505;;A61P35/00;;A61K39/39541;;A61K45/06;;A61K2039/505;;A61K2039/507;;C07K16/2878;;C07K2317/33;;C07K2317/34;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/395;;A61K45/06;;A61P35/00,,11,8,028-083-561-590-85X;;093-895-333-641-580;;095-334-545-560-259;;047-940-327-709-894;;020-488-119-185-469;;032-232-040-336-734;;091-637-220-567-447;;033-340-898-477-153,9040002;;10.1093/intimm/9.2.201;;11859128;;10.4049/jimmunol.168.5.2371;;10.1006/jmbi.1996.0548;;8876650;;7796805;;10.1002/j.1460-2075.1995.tb07278.x;;pmc398397;;10.1038/s41598-017-12519-9;;pmc5613017;;28947772;;22383868;;pmc3285572;;10.1371/journal.pcbi.1002388;;24115948;;pmc3792396;;10.3389/fimmu.2013.00302;;25496223;;10.1186/s12967-014-0343-6;;pmc4269866,"GenBank Database, Accession No: NP_001400196.1, CD27 antigen isoform e [Homo sapiens], Retrieved online: <URL:<span style=""font-family: ""Windows Arial Unicode"";"">https://www.ncbi.nlm.nih.gov/protein/NP_001400196.1> [retrieved 02/21/2023], 01. Jan 2023.</span>;;GenBank Database, Accession No: XP_047285856.1, <span style=""font-family: ""Windows Arial Unicode"";"">CD27 antigen isoform X2 [Homo sapiens]</span> Retrieved online: <URL:https://www.https://www.ncbi.nlm.nih.gov/protein/XP_047285856.1> [retrieved 02/21/2023], 05 Apr 2022.;;GenBank Database, Accession No: AAH12160.1, CD27 antigen isoform e [Homo sapiens], Retrieved online: <URL:https://www.ncbi.nlm.nih.gov/protein/AAH12160.1> [retrieved 02/21/2023], 07 Nov 2006.;;<p class=""MsoNormal"" style=""line-height:150%;mso-layout-grid-align:none; text-autospace:none""><span style=""mso-bidi-font-size:12.0pt;line-height:150%; color:windowtext"">Fadeel et al., Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects in vitro, Intl.;;Nair et al., Epitope Recognition by Diverse Antibodies Suggests Conformational Convergence in an Antibody Response, J. Immunol. 168:2371-2382, 2002.;;MacCallum et al.,Antibody-antigen interactions: contact analysis and binding site topography, J. Mol. Biol. 262:732-745, 1996.;;Chen et al., Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations, EMBO J. 14(12):2784-2794, 1995.;;Herold et al., Determinants of the assembly and function of antibody variable domains, Scientific Reports, 7:12276, 17 pages, DOI:10.1038/s41598-017-12519-9, Sept. 2017.;;Kunik et al., Structural consensus among antibodies defines the antigen binding site, PLoS Comput. Biol. 8(2):e1002388, 12 pages, doi:10.1371/journal.pcbi.1002388, 2012.;;Sela-Culang et al., The structural basis of antibody-antigen recognition, Front. Immunol. 4:302, 13 pages, doi:10.3389/fimmu.2013.00302, Oct. 2018.;;Yan et al., Construction of a synthetic phage-displayed Nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic J.Translational Med.12:343, 12 pages, http://www.translational-medicine.com/content/12/1/343, 2014.",PENDING
179,ES,T3,ES 2755395 T3,119-526-586-680-893,2020-04-22,2020,ES 15742414 T,2015-06-03,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W,2014-06-06,Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos,"Un anticuerpo monoclonal aislado, que se une al receptor de TNF inducible por glucocorticoides humano (GITR), que comprende secuencias de CDR1, CDR2 y CDR3 de cadena pesada que comprenden las SEQ ID NO: 20, 21 y 22, respectivamente y secuencias de CDR1, CDR2 y CDR3 de cadena ligera que comprenden las SEQ ID NO: 23, 24 y 25, respectivamente.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/119-526-586-680-893,Granted Patent,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
180,LT,T,LT 3151921 T,093-342-506-191-515,2019-12-10,2019,LT 15742414 T,2015-06-03,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/093-342-506-191-515,Unknown,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/28,,0,0,,,,PENDING
181,HU,T2,HU E047385 T2,151-912-622-632-051,2020-04-28,2020,HU E15742414 A,2015-06-03,US 201462008945 P;;US 201462082980 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/151-912-622-632-051,Amended Patent,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/28,,0,0,,,,PENDING
182,SG,A,SG 10201810507W A,104-053-637-967-076,2018-12-28,2018,SG 10201810507W A,2015-06-03,US 201462008945 P;;US 201462082980 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies. [No Figure]",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/104-053-637-967-076,Unknown,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,,,0,0,,,,PENDING
183,MA,A1,MA 39559 A1,034-556-598-323-717,2018-08-31,2018,MA 39559 A,2015-06-03,US 201462008945 P;;US 2015/0033991 W,2014-06-06,Anticorps anti récepteur du facteur de nécrose tumorale induit par glucocorticoïdes (gitr) et leurs utilisations,"L'invention concerne des anticorps ou des parties de liaison à l''antigène de ceux-ci, qui se lient au récepteur du tnf pouvant être induit par glucocorticoïdes (gitr) l'invention concerne également des utilisations de ces protéines dans des applications thérapeutiques, telles que dans le traitement du cancer. En outre, l'invention concerne des cellules qui produisent lesdits anticorps, des polynucléotides codant pour la région variable de chaîne lourde et/ou légère desdits anticorps ainsi que des vecteurs comprenant les polynucléotides codant pour la région variable de chaîne lourde et/ou légère desdits anticorps.",BRISTOL MYERS SQUIBB CO,HUANG RICHARD;;WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE;;CHEN GUODONG;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/034-556-598-323-717,Patent Application,no,0,0,2,65,0,,A61K39/00;;A61P35/00;;C07K16/28,,0,0,,,,PENDING
184,PE,A1,PE 20211604 A1,156-205-376-815-002,2021-08-23,2021,PE 2021000028 A,2019-07-08,US 201862695600 P;;US 201862744611 P;;US 2019/0040820 W,2018-07-09,ANTICUERPOS DE UNION A ILT4,"La presente invencion se refiere a anticuerpos que se unen especificamente a la proteina de transcripcion de tipo inmunoglobulina 4 (ILT4), que tambien se denomina LILRB2, LIR2, MIR10 y CD85d, caracterizado porque comprende una cadena pesada y una cadena ligera, donde la cadena pesada comprende CDR1, CDR2 y CDR3 VH del anticuerpo anti-ILT4 9G4 (SEQ ID NOs: 125-127), 9C8 (SEQ ID NOs: 131-133), 2H2 (SEQ ID NOs: 137-139), 2E5 (SEQ ID NOs: 143-145), 24E5 (SEQ ID NOs: 149-151), 21D9 (SEQ ID NOs: 155-157), 21A5 (SEQ ID NOs: 161-163), o 10F10 (SEQ ID NOs: 167-169); y donde la cadena ligera comprende CDR1, CDR2 y CDR3 VL del anticuerpo anti-ILT4 9G4 (SEQ ID NOs: 128-130), 9C8 (SEQ ID NOs: 134-136), 2H2 (SEQ ID NOs: 140-142), 2E5 (SEQ ID NOs: 146-148), 24E5 (SEQ ID NOs: 152-154), 21D9 (SEQ ID NOs: 158-160), 21A5 (SEQ ID NOs: 164-166), o 10F10 (SEQ ID NOs: 170-172). Tambien se refiere a acidos nucleicos, celulas hospedadoras, composiciones, metodos de preparacion y deteccion que comprenden a los anticuerpos o sus asociados. Los anticuerpos de la invencion se unen e inhiben a ILT4, la cual se expresa en celulas mieloides, tales como monocitos, macrofagos y celulas dendriticas, dichos anticuerpos no se unen de manera significativa a ILT2, ILT3, o ILT5, o a otros miembros de las familias LILRA o LILRB, siendo utiles en el tratamiento del cancer.",FIVE PRIME THERAPEUTICS INC;;BRISTOL MYERS SQUIBB CO,CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LINDA;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;TRUONG HONG-AN;;SELBY MARK J;;KORMAN ALAN J;;LONBERG NILS;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G,,https://lens.org/156-205-376-815-002,Patent Application,no,0,0,21,23,0,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,C07K16/28;;A61K39/395,,0,0,,,,PENDING
185,CA,A1,CA 2951234 A1,065-203-778-020-650,2015-12-10,2015,CA 2951234 A,2015-06-03,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid- inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/065-203-778-020-650,Patent Application,no,0,0,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61P35/00;;C07K16/46;;C12N15/13,,0,0,,,,ACTIVE
186,EA,B1,EA 037006 B1,083-296-735-203-244,2021-01-26,2021,EA 201692459 A,2015-06-03,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"The invention relates to antibodies that bind to human glucocorticoid-inducible TNF receptor (GITR). The antibodies or compositions comprising the same can be used to stimulate antigen-specific T cell responses, to activate or co-stimulate an effector T cell, to increase IL-2 and/or IFN- production in a T cell, and to stimulate an immune response and treat cancer. Described are cells that produce the antibodies, a nucleic acid encoding heavy and light chains of the antibodies or variable regions thereof, and vectors comprising the nucleic acid.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/083-296-735-203-244,Granted Patent,no,5,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/28,,2,2,029-382-279-785-035;;051-374-571-260-065,10.1084/jem.20130573;;23897982;;pmc3754864;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001,"BULLIARD YANNICK; JOLICOEUR ROSE; WINDMAN MAURICE; RUE SARAH M; ETTENBERG SETH; KNEE DEBORAH A; WILSON NICHOLAS S; DRANOFF GLENN; : ""Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies"", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 210, no. 9, 26 August 2013 (2013-08-26), US, pages 1685 - 1693, XP009176020, ISSN: 0022-1007, DOI: 10.1084/jem.20130573;;ANN�L. WHITE, H.T.�CLAUDE CHAN, RUTH�R. FRENCH, JANE WILLOUGHBY, C.�IAN MOCKRIDGE, ALI ROGHANIAN, CHRISTINE�A. PENFOLD, STEVEN�G. : ""Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies"", CANCER CELL, CELL PRESS, vol. 27, no. 1, 1 January 2015 (2015-01-01), pages 138 - 148, XP055193819, ISSN: 15356108, DOI: 10.1016/j.ccell.2014.11.001",ACTIVE
187,CL,A1,CL 2016003136 A1,073-617-497-750-737,2017-09-08,2017,CL 2016003136 A,2016-12-05,US 201462008945 P;;US 201462082980 P,2014-06-06,Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos,,BRISTOL MYERS SQUIBB CO,LONBERG NILS;;SRINIVASAN MOHAN;;KORMAN ALAN J;;WANG CHANGYU;;SELBY MARK J;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/073-617-497-750-737,Patent Application,no,0,1,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61K39/00;;A61P35/00;;C07K16/28,,0,0,,,,PENDING
188,AU,A1,AU 2015/271709 A1,127-112-500-066-615,2016-12-08,2016,AU 2015/271709 A,2015-06-03,US 201462082980 P;;US 201462008945 P;;US 2015/0033991 W,2014-06-06,Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid- inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/127-112-500-066-615,Patent Application,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/00;;A61P35/00,,0,0,,,,ACTIVE
189,EP,A1,EP 3998079 A1,012-059-902-835-659,2022-05-18,2022,EP 21199061 A,2015-06-03,US 201462008945 P;;US 201462082980 P;;EP 19184566 A;;EP 15742414 A;;US 2015/0033991 W,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/012-059-902-835-659,Patent Application,yes,214,0,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61K39/00;;A61P35/00;;C07K16/28,,144,116,029-382-279-785-035;;051-374-571-260-065;;045-714-831-915-963;;075-363-665-052-387;;079-191-303-518-861;;039-943-095-184-294;;073-108-237-457-07X;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;040-577-067-037-463;;104-212-297-137-759;;010-953-281-569-514;;013-795-151-218-458;;068-238-957-669-243;;014-277-808-472-992;;061-754-151-573-898;;113-327-994-370-771;;006-553-734-546-212;;105-316-874-895-908;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;104-557-841-648-936;;034-441-292-442-799;;038-895-768-831-047;;132-281-029-747-299;;087-667-912-261-011;;001-835-514-097-551;;002-377-881-851-166;;022-179-293-052-569;;030-049-949-326-687;;038-595-729-934-153;;007-709-585-201-038;;006-574-964-805-278;;030-323-674-660-051;;092-023-577-402-127;;088-086-720-613-343;;070-318-112-524-781;;010-488-381-022-259;;082-210-673-349-152;;004-458-031-333-650;;041-909-244-299-232;;078-432-639-041-575;;042-740-484-382-110;;004-458-031-333-650;;003-752-183-823-430;;071-163-081-597-04X;;035-135-729-507-737;;094-685-907-794-422;;062-029-719-290-327;;070-624-200-848-669;;012-746-915-512-650;;038-478-749-169-986;;035-554-935-107-802;;099-647-105-451-350;;009-621-637-014-514;;100-985-030-110-978;;030-630-100-818-462;;106-753-778-592-300;;032-820-729-763-323;;083-549-078-331-651;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;077-525-954-203-403;;028-969-172-280-017;;060-375-551-951-388;;020-753-772-581-741;;038-613-711-274-229;;047-951-914-695-080;;062-485-301-455-912;;026-744-100-669-883;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;012-300-595-074-789;;031-815-870-004-331;;040-841-912-862-912;;011-583-491-184-648;;126-659-091-098-052;;038-166-075-279-931;;083-079-509-375-354;;043-654-077-374-418;;084-388-182-984-099;;042-354-196-879-741;;020-986-423-793-233;;007-364-858-655-289;;056-942-841-068-650;;107-302-749-967-437;;039-238-464-990-600;;036-564-551-324-053;;020-123-860-433-320;;011-516-147-270-264;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;056-422-417-058-69X;;005-022-447-377-963;;098-407-145-404-736;;001-467-559-709-949;;049-089-244-500-629;;078-061-292-153-737;;055-646-175-554-792;;008-213-515-306-640;;053-703-232-770-99X;;033-109-855-318-388;;030-249-121-435-10X;;001-091-081-800-619,10.1084/jem.20130573;;23897982;;pmc3754864;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001;;pmc21029;;9177197;;10.1073/pnas.94.12.6216;;pmc299905;;14608036;;10.1073/pnas.2334901100;;15771565;;10.1146/annurev.immunol.23.021704.115839;;10.1038/ni759;;11812990;;16140769;;pmc1212625;;10.1128/jvi.79.18.11935-11942.2005;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1038/nbt1135;;16151405;;9780179;;10.4049/jimmunol.161.8.4083;;10556249;;10.1093/protein/12.10.879;;10.4049/jimmunol.137.11.3614;;2431039;;10.1016/0042-6822(90)90025-m;;1693247;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;8424945;;10.1021/bi00055a024;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;16263307;;10.1016/j.jasms.2005.09.008;;10.1021/bi00161a011;;1332755;;10.1021/bi00078a011;;7687462;;15299382;;10.1107/s0907444994001344;;2185018;;10.1111/j.1432-1033.1990.tb15454.x;;9351804;;10.1016/s0969-2126(97)00279-7;;977570;;10.1016/s0021-9258(20)81858-4;;10.1002/eji.1830240409;;8149953;;9311915;;10.1126/science.278.5335.117;;15299544;;10.1107/s0907444992010400;;9624003;;10.1038/30989;;10.1038/321522a0;;3713831;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;1404388;;10.1016/0022-2836(92)90223-7;;19896358;;10.1016/j.copbio.2009.10.011;;10.1038/6179;;10052355;;14699147;;10.1074/jbc.c300470200;;10.4049/jimmunol.176.1.346;;16365427;;11096108;;10.1074/jbc.m009483200;;12391234;;10.4049/jimmunol.169.9.5171;;10.1074/jbc.m604292200;;16793771;;10.4049/jimmunol.0804182;;19494290;;11096108;;10.1074/jbc.m009483200;;11986321;;10.1074/jbc.m202069200;;10.1146/annurev.bi.41.070172.003325;;4563441;;10.4049/jimmunol.172.9.5489;;15100290;;2459288;;pmc2189025;;10.1084/jem.168.3.1099;;12042244;;10.1093/glycob/12.4.43r;;10.1038/316452a0;;3927174;;11275255;;10.1016/s0161-5890(00)00105-x;;10.2174/1389201023378229;;12463418;;10.1023/b:pham.0000008042.15988.c0;;14725359;;10397155;;10.1016/s0165-2478(99)00029-2;;10.1093/chromsci/40.6.343;;12137207;;8644915;;10.1021/ac00116a002;;10.1038/348552a0;;2247164;;1172191;;10.1038/256495a0;;8159246;;10.1038/368856a0;;10.1007/978-3-642-78432-3_3;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;8144892;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nbt727;;12172556;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;10.1016/j.cbpa.2009.03.023;;19414278;;10.1002/anie.200801313;;19072788;;10.1039/b908687k;;19675886;;10.1002/cbic.200800801;;19130455;;10.1016/j.chembiol.2008.01.007;;18291317;;19924746;;pmc4878437;;10.1002/anie.200903627;;10.1021/bc800294a;;19191567;;6239899;;10.1084/jem.160.6.1686;;pmc2187539;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;3833240;;15470033;;10.4049/jimmunol.173.8.4919;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;3390170;;10.1016/s0006-291x(88)81333-0;;10.1128/aac.39.1.180;;pmc162506;;7695303;;7907597;;10.1016/s0021-9258(17)37081-3;;10.1016/0014-5793(94)00313-0;;8206150;;7820457;;10.1006/immu.1994.1029;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;10417377;;10.1126/science.285.5427.546;;10.1016/s0969-2126(94)00113-8;;7704521;;11514604;;10.3410/f.1000338.7202;;pmc2193490;;10.1084/jem.194.4.481;;pmc15881;;10.1073/pnas.96.6.2982;;10077623;;10.1097/00002371-199601000-00009;;8859727;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;9850053;;10.1038/nm735;;12118245;;10.3410/f.1008846.113460;;15930300;;10.1158/0008-5472.can-04-3319;;22918247;;10.4161/cc.21842;;pmc3466534,"BULLIARD YANNICK ET AL: ""Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies"", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 210, no. 9, 26 August 2013 (2013-08-26), pages 1685 - 1693, XP009176020, ISSN: 0022-1007;;ANN L. WHITE ET AL: ""Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies"", CANCER CELL, vol. 27, no. 1, 1 January 2015 (2015-01-01), pages 138 - 148, XP055193819, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2014.11.001;;NOCENTINI ET AL., PNAS, vol. 94, 1997, pages 6216 - 21;;TONE ET AL., PNAS, vol. 100, 2003, pages 15059 - 64;;WATTS, ANNUAL REVIEWS IN IMMUNOLOGY, vol. 23, 2005, pages 23 - 68;;SHIMIZU ET AL., NATURE IMMUNOLOGY, vol. 3, 2002, pages 135 - 42;;STEPHANS ET AL., JI, vol. 173, no. 8, pages 5008 - 20;;SUVAS ET AL., J VIROL, vol. 79, 2005, pages 11935 - 42;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;SONGSIVILAILACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;LONBERG, NATURE BIOTECH., vol. 23, no. 9, 2005, pages 1117 - 1125;;JEFFERIS ET AL., MABS, vol. 1, 2009, pages 1;;ROUX ET AL., J. IMMUNOL., vol. 161, 1998, pages 4083;;ROUX ET AL., J IMMUNOL, vol. 161, 1998, pages 4083;;EPITOPE MAPPING PROTOCOLS IN METHODS IN MOLECULAR BIOLOGY, vol. 66, 1996;;KOBAYASHI ET AL., PROTEIN ENG, vol. 12, no. 10, 1999, pages 879 - 884;;STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 9, 1983, pages 242;;KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614;;MOREL ET AL., MOL. IMMUNOL., vol. 25, no. 1, 1988, pages 7;;CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546;;MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77;;BRUMMELL ET AL., BIOCHEM, vol. 32, 1993, pages 1180 - 1187;;BURKS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 412 - 417;;E. MEYERSW. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17;;NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;""Current Protocols in Molecular Biology"", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;;""GENBANKO"", Database accession no. AAA58637;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES;;WEI ET AL., DRUG DISCOVERY TODAY, vol. 19, 2014, pages 95;;HAMBLEYGROSS, J. AMERICAN SOC. MASS SPECTROMETRY, vol. 16, 2005, pages 2057;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 31, 1992, pages 11335 - 11347;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 32, 1993, pages 6884 - 6891;;GIEGE ET AL., ACTA CRYSTALLOGR., vol. D50, 1994, pages 339 - 350;;MCPHERSON, EUR. J. BIOCHEM., vol. 189, 1990, pages 1 - 23;;CHAYEN, STRUCTURE, vol. 5, 1997, pages 1269 - 1274;;MCPHERSON, J. BIOL. CHEM., vol. 251, 1976, pages 6300 - 6303;;COX, J. P. L. ET AL.: ""A Directory of Human Germ-line V Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: 10.1002/eji.1830240409;;TAMURA ET AL., SCIENCE, vol. 276A, 1997, pages 117 - 120;;BRICOGNE, ACTA CRYST, vol. D49, 1993, pages 37 - 60;;ROVERSI ET AL., ACTA CRYST., vol. D56, 2000, pages 1313 - 1323;;RIECHMANN, L ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;JONES, P ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;QUEEN, C ET AL., PROC. NATL. ACAD. SEE. U.S.A., vol. 86, 1989, pages 10029 - 10033;;TOMLINSON, I. M. ET AL.: ""The Repertoire of Human Germline V Sequences Reveals about Fifty Groups of V Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: 10.1016/0022-2836(92)90223-7;;MOLEC. IMMUNOL., vol. 29, no. 5, 1992, pages 633 - 9;;STROHL, CURRENT OPINION IN BIOTECHNOLOGY, vol. 20, 2009, pages 685 - 691;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;HINTON ET AL., J. BIOL. CHEM., vol. 279, no. 8, 2004, pages 6213 - 6216;;HINTON ET AL., JOURNAL OF IMMUNOLOGY, vol. 176, 2006, pages 346 - 356;;SHIELDS ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 9, 2001, pages 6591 - 6604;;DALL ACQUA ET AL., JOURNAL OF IMMUNOLOGY, vol. 169, 2002, pages 5171 - 5180;;DALL'ACQUA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, 2006, pages 23514 - 23524;;YEUNG ET AL., J IMMUNOL, vol. 182, 2010, pages 7663 - 7671;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;MARSHALL ET AL., ANNU REV BIOCHEM, vol. 41, 1972, pages 673 - 702;;GALAMORRISON, J. IMMUNOL, vol. 172, 2004, pages 5489 - 94;;WALLICK ET AL., J EXP MED, vol. 168, 1988, pages 1099 - 109;;SPIRO, GLYCOBIOLOGY, vol. 12, 2002, pages 43R - 56R;;PAREKH ET AL., NATURE, vol. 316, 1985, pages 452 - 7;;MIMURA ET AL., MOL IMMUNOL, vol. 37, 2000, pages 697 - 706;;KRISHNAMURTHY RMANNING M C, CURR PHARM BIOTECHNOL, vol. 3, 2002, pages 361 - 71;;CHEN ET AL., PHARM RES, vol. 20, 2003, pages 1952 - 60;;GHIRLANDO ET AL., IMMUNOL LETT, vol. 68, 1999, pages 47 - 52;;MURRAY ET AL., J. CHROMATOGR SCI, vol. 40, 2002, pages 343 - 9;;ALEXANDER A JHUGHES D E, ANAL CHEM, vol. 67, 1995, pages 3626 - 32;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;LONBERG, N., HANDBOOK OF EXPERIMENTAL PHARMACOLOGY, vol. 113, 1994, pages 49 - 101;;LONBERG, N.HUSZAR, D., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F.LONBERG, N., ANN. N.Y. ACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J. ET AL., EMBO J, vol. 12, 1993, pages 821 - 830;;TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;TOMIZUKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727;;KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 1202 - 83;;GOEDDEL: ""Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS, article ""Gene Expression Technology"";;TAKEBE, Y. ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;BOSS, M. A.WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUBCHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMANP. A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;SENTER, P. D., CURR. OPIN. CHEM. BIOL., vol. 13, 2009, pages 235 - 244;;HACKENBERGER, C. P. R.SCHWARZER, D., ANGEW. CHEM. INT. ED. ENGL., vol. 47, 2008, pages 10030 - 10074;;SUNBUL, M.YIN, J., ORG. BIOMOL. CHEM., vol. 7, 2009, pages 3361 - 3371;;FRESE, M. A.DIERKS, T., CHEMBIOCHEM, vol. 10, 2009, pages 425 - 427;;TAKI, M. ET AL., PROT. ENG. DES. SEL., vol. 17, 2004, pages 119 - 126;;GAUTIER, A. ET AL., CHEM. BIOL., vol. 15, 2008, pages 128 - 136;;BORDUSA, F., HIGHLIGHTS IN BIOORGANIC CHEMISTRY, 2004, pages 389 - 403;;REN, H. ET AL., ANGEW. CHEM. INT. ED. ENGL., vol. 48, 2009, pages 9658 - 9662;;TAYLOR, E. VOGELIMPERIALI, B: ""Protein Engineering"", NUCLEIC ACIDS AND MOLECULAR BIOLOGY, vol. 22, 2009, pages 65 - 96;;DE GRAAF, A. J. ET AL., BIOCONJUG. CHEM., vol. 20, 2009, pages 1281 - 1295;;KARPOVSKY ET AL., J. EXP. MED., vol. 160, 1984, pages 1686;;LIU, MA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 8648;;PAULUS, BEHRING INS. MITT. NO., vol. 78, 1985, pages 118 - 132;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 2375;;BERGE, S.M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;V.V. RANADE, J. CLIN. PHARMACOL., vol. 29, 1989, pages 685;;UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 153, 1988, pages 1038;;P.G. BLOEMAN ET AL., FEBS LETT., vol. 357, 1995, pages 140;;M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 39, 1995, pages 180;;BRISCOE ET AL., AM. J. PHYSIOL., vol. 1233, 1995, pages 134;;SCHREIER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 9090;;K. KEINANENM.L. LAUKKANEN, FEBS LETT., vol. 346, 1994, pages 123;;J.J. KILLIONI.J. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273;;ROSENBERG, S.: ""Development of Cancer Vaccines"", ASCO EDUCATIONAL BOOK SPRING, 2000, pages 60 - 62;;LOGOTHETIS, C., ASCO EDUCATIONAL BOOK SPRING, 2000, pages 730 - 738;;RESTIFO, N.SZNOL, M., CANCER VACCINES, pages 3023 - 3043;;DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, S A, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOTSRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARDO'GARRA, IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;WEINBERG ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF ET AL., NATURE, vol. 400, 1999, pages 173 - 177;;GREENBERGRIDDELL, SCIENCE, vol. 285, 1999, pages 546 - 51;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;VAN ELSAS ET AL., J. EXP. MED., vol. 194, 2001, pages 481 - 489;;OVERWIJK ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 96, 1999, pages 2982 - 2987;;ROSENBERGWHITE, J. IMMUNOTHER EMPHASIS TUMOR IMMUNOL, vol. 19, no. 1, 1996, pages 81 - 4;;HURWITZ ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071;;CAMACHO ET AL., J. CLIN. ONCOLOGY, vol. 22, no. 145, 2004;;MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304;;FULDA ET AL., NAT MED, vol. 8, 2002, pages 808 - 15;;HYER ET AL., CANCER RESEARCH, vol. 65, 2005, pages 4799 - 808;;LI ET AL., CELL CYCLE, vol. 11, 2012, pages 3343 - 3344",PENDING
190,CY,T1,CY 1122389 T1,014-794-173-045-377,2021-01-27,2021,CY 191101246 T,2019-11-27,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W,2014-06-06,ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙ ΔΙΕΓΕΙΡΟΜΕΝΟΥ ΜΕ ΓΛΥΚΟΚΟΡΤΙΚΟΕΙΔΕΣ ΥΠΟΔΟΧΕΑ ΠΑΡΑΓΟΝΤΑ ΝΕΚΡΩΣΗΣ ΟΓΚΟΥ (GITR) ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ,"Παρεχόμενα στο παρόν είναι αντισώματα ή τμήματα σύνδεσης αντιγόνου αυτών, που συνδέονται σε διεγειρόμενο με γλυκοκορτικοειδές υποδοχέα TNF (GITR). Επίσης παρεχόμενες είναι χρήσεις αυτών των πρωτεϊνών σε θεραπευτικές εφαρμογές, όπως στη θεραπεία καρκίνου. Περαιτέρω παρεχόμενα είναι κύτταρα που παράγουν τα αντισώματα, πολυνουκλεοτίδια που κωδικοποιούν τη μεταβλητή περιοχή βαριάς ή/και ελαφράς αλύσου των αντισωμάτων και φορείς που περιλαμβάνουν τα πολυνουκλεοτίδια που κωδικοποιούν τη μεταβλητή περιοχή βαριάς ή/και ελαφράς αλύσου των αντισωμάτων.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/014-794-173-045-377,Granted Patent,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
191,US,A1,US 2023/0050665 A1,117-853-084-699-039,2023-02-16,2023,US 202117364107 A,2021-06-30,US 202117364107 A;;US 2015/0033991 W;;US 201916578987 A;;US 201715646558 A;;US 201514949424 A;;US 201514732082 A;;US 201462082980 P;;US 201462008945 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2015-07-22),https://lens.org/117-853-084-699-039,Patent Application,yes,0,1,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/395;;G01N33/574;;G01N33/68,,0,0,,,,PENDING
192,SI,T1,SI 3151921 T1,150-210-332-677-267,2019-12-31,2019,SI 201530955 T,2015-06-03,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W;;EP 15742414 A,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/150-210-332-677-267,Granted Patent,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/00,,0,0,,,,ACTIVE
193,DK,T3,DK 3151921 T3,138-623-015-274-561,2019-12-02,2019,DK 15742414 T,2015-06-03,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W,2014-06-06,ANTISTOFFER MOD GLUCOCORTICOID-INDUCERET TUMORNEKROSEFAKTOR- RECEPTORER (GITR) OG ANVENDELSER DERAF,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/138-623-015-274-561,Granted Patent,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
194,RS,B1,RS 59643 B1,157-341-643-052-330,2020-01-31,2020,RS P20191521 A,2015-06-03,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W;;EP 15742414 A,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/157-341-643-052-330,Granted Patent,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
195,HR,T1,HR P20192098 T1,193-056-019-479-077,2020-02-21,2020,HR P20192098 T,2019-11-22,US 201462008945 P;;US 201462082980 P;;EP 15742414 A;;US 2015/0033991 W,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/193-056-019-479-077,Granted Patent,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
196,JP,A,JP 2021119173 A,063-981-582-979-948,2021-08-12,2021,JP 2021076131 A,2021-04-28,JP 2018228384 A;;US 201462082980 P;;US 201462008945 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"To provide an agent for enhancing immune responses, in particular for stimulating T cell responses, to control glucocorticoid-induced tumor necrosis factor receptor (GITR).SOLUTION: An agent for stimulating a T cell response comprises an isolated antibody binding to human glucocorticoid-induced TNF receptor (GITR) and comprising: heavy chain CDR1, CDR2 and CDR3 sequences respectively comprising SYGMH, VIWYEGSNKYYADSVKG and GGSMVRGDYYYGMDV; and light chain CDR1, CDR2, and CDR3 sequences respectively comprising RASQGISSALA, DASSLES and QQFNSYPYT.SELECTED DRAWING: None",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;NILS LONBERG;;ALAN J KORMAN;;MARK J SELBY;;MOHAN SRINIVASAN;;KARLA HENNING;;MICHELLE MINHUA HAN;;CHEN GUODONG;;RICHARD HUANG;;INDRANI CHAKRABORTY;;HUANG HAICHUN;;SUSAN WONG;;LI HUIMING,,https://lens.org/063-981-582-979-948,Patent Application,no,3,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61K39/395;;A61P31/12;;A61P35/00;;A61P43/00;;C07K16/28;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/63,,0,0,,,,ACTIVE
197,ES,T3,ES 2901705 T3,127-496-565-360-140,2022-03-23,2022,ES 19184566 T,2015-06-03,US 201462008945 P;;US 201462082980 P,2014-06-06,Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos,"Un anticuerpo monoclonal aislado, que se une al receptor de TNF inducible por glucocorticoides humano (GITR), que comprende dos cadenas pesadas y dos cadenas ligeras, en donde cada una de las cadenas pesadas comprende una región variable de cadena pesada que consiste en la secuencia de aminoácidos expuesta en el SEQ ID NO: 13 y cada una de las cadenas ligeras comprende una región variable de cadena ligera que consiste en la secuencia de aminoácidos expuesta en el SEQ ID NO: 14.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/127-496-565-360-140,Granted Patent,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
198,CN,A,CN 106459203 A,133-372-050-958-031,2017-02-22,2017,CN 201580030121 A,2015-06-03,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W,2014-06-06,Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid- inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/133-372-050-958-031,Patent Application,no,2,12,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/395;;A61P35/00;;G01N33/574;;G01N33/68,,0,0,,,,ACTIVE
199,PE,A1,PE 20170441 A1,079-395-197-301-486,2017-04-26,2017,PE 2016002515 A,2015-06-03,US 201462008945 P;;US 201462082980 P,2014-06-06,ANTICUERPOS CONTRA EL RECEPTOR DEL FACTOR DE NECROSIS TUMORAL INDUCIDO POR GLUCOCORTICOIDES (GITR) Y SUS USOS,"Anticuerpos, o porciones de fijacion al antigeno de estos, que se fijan al receptor de TNF inducible por glucocorticoides (GITR). Tambien, usos de estas proteinas en aplicaciones terapeuticas, tales como el tratamiento del cancer. Ademas, celulas que producen los anticuerpos, polinucleotidos que codifican la region variable de la cadena pesada y/o liviana y vectores que comprenden los polinucleotidos que codifican la region variable de la cadena pesada y/o liviana de los anticuerpos",BRISTOL MYERS SQUIBB CO,CHAKRABORTY INDRANI;;CHEN GUODONG;;HAN MICHELLE MINHUA;;HENNING KARLA;;HUANG HAICHUN;;HUANG RICHARD;;WONG SUSAN;;LI HUIMING;;LONBERG NILS;;SELBY MARK J;;SRINIVASAN MOHAN;;WANG CHANGYU;;KORMAN ALAN J,,https://lens.org/079-395-197-301-486,Patent Application,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61K39/00;;A61P35/00;;C07K16/28,,0,0,,,,PENDING
200,US,A1,US 2016/0145342 A1,095-594-335-411-686,2016-05-26,2016,US 201514949424 A,2015-11-23,US 201514949424 A;;US 2015/0033991 W;;US 201514732082 A;;US 201462082980 P;;US 201462008945 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2015-07-22),https://lens.org/095-594-335-411-686,Patent Application,yes,0,16,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/395;;G01N33/574,,0,0,,,,ACTIVE
201,WO,A3,WO 2015/187835 A3,112-174-322-423-518,2016-01-28,2016,US 2015/0033991 W,2015-06-03,US 201462008945 P;;US 201462082980 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid- inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/112-174-322-423-518,Search Report,yes,5,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61K39/00;;A61P35/00;;C07K16/28,,2,2,029-382-279-785-035;;051-374-571-260-065,10.1084/jem.20130573;;23897982;;pmc3754864;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001,"BULLIARD YANNICK ET AL: ""Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies"", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 210, no. 9, 26 August 2013 (2013-08-26), pages 1685 - 1693, XP009176020, ISSN: 0022-1007;;ANN L. WHITE ET AL: ""Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies"", CANCER CELL, vol. 27, no. 1, 1 January 2015 (2015-01-01), pages 138 - 148, XP055193819, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2014.11.001",PENDING
202,MY,A,MY 181896 A,163-343-155-163-708,2021-01-12,2021,MY PI2016704509 A,2015-06-03,US 2015/0033991 W;;US 201462008945 P;;US 201462082980 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/163-343-155-163-708,Granted Patent,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/00;;A61P35/00,,0,0,,,,ACTIVE
203,CA,C,CA 2951234 C,185-736-877-011-920,2022-05-31,2022,CA 2951234 A,2015-06-03,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid- inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/185-736-877-011-920,Granted Patent,no,0,0,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61P35/00;;C07K16/46;;C12N15/13,,0,0,,,,ACTIVE
204,US,A1,US 2015/0353637 A1,093-800-721-314-077,2015-12-10,2015,US 201514732082 A,2015-06-05,US 201514732082 A;;US 2015/0033991 W;;US 201462082980 P;;US 201462008945 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2015-07-22),https://lens.org/093-800-721-314-077,Patent Application,yes,0,33,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/395;;G01N33/574;;G01N33/68,,0,0,,,,ACTIVE
205,PL,T3,PL 3151921 T3,095-505-591-992-531,2020-02-28,2020,PL 15742414 T,2015-06-03,US 201462008945 P;;US 201462082980 P;;EP 15742414 A;;US 2015/0033991 W,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/095-505-591-992-531,Patent Application,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/28,,0,0,,,,PENDING
206,SG,A,SG 11201610074Y A,048-323-413-528-910,2016-12-29,2016,SG 11201610074Y A,2015-06-03,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/048-323-413-528-910,Unknown,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61K39/00;;A61P35/00;;C07K16/28,,0,0,,,,PENDING
207,PT,T,PT 3151921 T,179-631-605-800-645,2019-11-21,2019,PT 15742414 T,2015-06-03,US 201462008945 P;;US 201462082980 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,CHANGYU WANG;;NILS LONBERG;;ALAN J KORMAN;;MARK J SELBY;;MOHAN SRINIVASAN;;KARLA HENNING;;MICHELLE MINHUA HAN;;GUODONG CHEN;;RICHARD HUANG;;INDRANI CHAKRABORTY;;HAICHUN HUANG;;SUSAN WONG;;HUIMING LI,,https://lens.org/179-631-605-800-645,Patent Application,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/28,,0,0,,,,PENDING
208,UY,A,UY 36154 A,162-020-585-739-989,2016-01-08,2016,UY 36154 A,2015-06-04,US 201462008945 P;;US 201462082980 P,2014-06-06,ANTICUERPOS CONTRA EL RECEPTOR DEL FACTOR DE NECROSIS TUMORAL INDUCIDO POR GLUCOCORTICOIDES (GITR) Y SUS USOS,"En la presente, se proporcionan anticuerpos, o porciones de fijación al antígeno de estos, que se fijan al receptor de TNF inducible por glucocorticoides (GITR). También se proporcionan usos de estas proteínas en aplicaciones terapéuticas, tales como el tratamiento del cáncer. Además, se proporcionan células que producen los anticuerpos, polinucleótidos que codifican la región variable de la cadena pesada y/o liviana y vectores que comprenden los polinucleótidos que codifican la región variable de la cadena pesada y/o liviana de los anticuerpos.",BRISTOL MYERS SQUIBB COMPANY UNA CORPORACIÓN DEL ESTADO DE DELAWARE,CHANGYU WANG;;NILS LONBERG;;KORMAN ALAN J;;SELBY MARK J;;MOHAN SRINIVASAN;;KARLA HENNING;;HAN MICHELLE MINHUA;;GUODONG CHEN;;RICHARD HUANG;;INDRANI CHAKRABORTY;;HAICHUN HUANG;;SUSAN WONG;;HUIMING LI,,https://lens.org/162-020-585-739-989,Patent Application,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/395;;A61P37/02;;C07K16/28;;C07K16/30;;C07K16/46;;C12N5/10;;C12N15/11;;C12N15/13;;C12N15/85;;C12P21/08,,0,0,,,,PENDING
209,AU,B2,AU 2015/271709 B2,101-100-997-216-954,2020-11-26,2020,AU 2015/271709 A,2015-06-03,US 201462082980 P;;US 201462008945 P;;US 2015/0033991 W,2014-06-06,Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid- inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/101-100-997-216-954,Granted Patent,no,1,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/00;;A61P35/00,,0,0,,,,ACTIVE
210,EP,A2,EP 3151921 A2,144-292-507-514-115,2017-04-12,2017,EP 15742414 A,2015-06-03,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/144-292-507-514-115,Patent Application,yes,0,2,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
211,US,B2,US 11084881 B2,073-528-240-424-026,2021-08-10,2021,US 201916578987 A,2019-09-23,US 201916578987 A;;US 2015/0033991 W;;US 201715646558 A;;US 201514949424 A;;US 201514732082 A;;US 201462082980 P;;US 201462008945 P,2014-06-06,Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2015-07-22),https://lens.org/073-528-240-424-026,Granted Patent,yes,97,3,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C12N15/13;;A61K39/00;;A61K39/395;;A61K47/68;;C07K16/28;;G01N33/574;;G01N33/68,,106,62,171-614-306-115-108;;086-268-955-647-163;;136-116-610-765-69X;;084-334-863-236-818;;019-741-156-878-521;;029-382-279-785-035;;009-483-512-107-343;;019-459-691-036-036;;087-404-567-384-381;;128-554-308-094-91X;;020-296-196-517-635;;055-706-543-681-974;;044-673-845-363-528;;056-584-393-786-220;;070-164-938-901-37X;;005-119-615-003-591;;013-323-148-570-367;;022-259-501-579-745;;055-329-732-668-508;;011-405-827-983-549;;141-244-428-002-001;;143-287-907-926-845;;124-353-299-096-166;;012-369-544-741-057;;055-677-065-531-946;;010-916-105-450-247;;019-791-912-221-046;;078-111-385-767-730;;017-588-579-721-840;;016-276-447-231-541;;045-714-831-915-963;;071-886-484-965-256;;145-500-434-317-873;;012-108-483-329-37X;;083-410-991-104-604;;013-888-189-100-394;;112-871-461-451-205;;110-748-788-527-236;;082-582-794-395-339;;124-668-123-456-128;;039-943-095-184-294;;050-463-287-173-296;;051-374-571-260-065;;004-189-544-863-902;;043-054-515-242-505;;055-904-468-981-551;;008-019-042-176-997;;027-477-313-726-928;;039-634-532-775-166;;045-706-253-475-176;;048-960-656-989-289;;030-950-631-666-077;;032-391-642-770-202;;097-339-730-628-695;;008-117-373-727-019;;005-086-269-055-082;;037-103-075-806-573;;120-141-881-915-542;;030-052-818-943-711;;008-727-266-329-179;;076-840-039-480-531;;035-924-762-030-733,21304271;;10.4161/mabs.3.2.14939;;pmc3092615;;20563707;;10.1007/82_2010_49;;pmc4060248;;12444126;;10.4049/jimmunol.169.11.6210;;7506686;;10.1016/0378-1119(93)90258-5;;15484187;;10.1002/eji.200324632;;10.1084/jem.20130573;;23897982;;pmc3754864;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;20480365;;10.1007/s00262-010-0866-5;;20454651;;pmc2862699;;10.1371/journal.pone.0010436;;10.1158/0008-5472.can-05-2813;;16651447;;pmc2242844;;9373310;;10.1016/s1380-2933(96)00045-0;;10.1016/s1074-7613(04)00054-8;;15030773;;15374887;;10.1182/blood-2004-06-2467;;10.3410/f.1001160.6701;;11520463;;10.1016/s1074-7613(01)00183-2;;10074428;;10.1016/s0960-9822(99)80093-1;;10.1016/0022-2836(92)90639-2;;1507232;;14573361;;10.1016/j.tibtech.2003.08.007;;10.1182/blood-2008-07-170274;;pmc2668854;;18941113;;10.4049/jimmunol.172.12.7306;;15187106;;23980122;;pmc3754862;;10.1084/jem.20131625;;17671218;;10.1158/0008-5472.can-06-4639;;10.1084/jem.20050940;;pmc2213162;;10.1084/jem.200509402092c;;16186187;;10.3410/f.1028385.337176;;10037686;;10.1074/jbc.274.10.6056;;10.1016/s0167-5699(00)01668-6;;10916138;;10.1186/1479-5876-12-36;;24502656;;pmc4104995;;10.1038/nbt0792-779;;1368267;;10.1016/s1074-7613(02)00280-7;;11869690;;pmc4397897;;23460535;;10.1158/1078-0432.ccr-13-0598;;10.1158/1078-0432.ccr-12-2065;;10.1158/1078-0432.ccr-12-2214;;23460531;;10.1158/1078-0432.ccr-09-3243;;20460483;;pmc21029;;9177197;;10.1073/pnas.94.12.6216;;10.1002/eji.200425818;;15770698;;10836847;;10.1038/sj.cdd.4400670;;10.1186/s40425-016-0132-2;;27822377;;pmc5096004;;27190629;;10.1186/s40425-016-0181-6;;pmc4869343;;10.1111/j.1365-2567.2009.03228.x;;20201988;;pmc2878467;;11533635;;10.1038/nbt0901-819;;10.1002/eji.200324804;;14991590;;10.1016/j.clim.2010.03.288;;21154120;;pmc3413251;;22245556;;10.1016/j.coi.2011.12.011;;10.1038/ni759;;11812990;;10.1084/jem.20041130;;15381730;;pmc2211964;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001;;9299585;;10.1006/scbi.1997.0058;;7490758;;10.1006/jmbi.1995.0626;;10.1002/jmr.679;;15227640;;15185369;;10.1002/cbic.200300806;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;17360848;;10.1096/fj.06-7724com;;20734397;;10.1002/cncr.25371;;20012605;;10.1007/s00262-009-0803-7;;26216629;;10.1016/s0065-230x(15)00083-4;;10.1016/bs.acr.2015.04.010;;10.1038/nrclinonc.2016.25;;26977780;;pmc5551685;;10.1155/2016/4683607;;26881264;;pmc4736366;;10.1016/j.ejca.2016.06.028;;27591414;;10.1016/j.pharmthera.2017.03.008;;pmc5600680;;28322974;;23856878;;10.1590/0037-8682-0029-2013;;10.1016/j.bbcan.2017.10.007;;29126881;;28187290;;10.1016/j.cell.2017.01.017;;pmc5391692;;27511159;;10.1016/s1470-2045(16)30123-1;;26239999;;10.1002/ijc.29713;;20197484;;10.1158/1078-0432.ccr-09-2425,"Arnett, S. et al., “IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of The Antibody Society,” Dec. 5-9, 2010, San Diego, CA USA, mAbs, vol. 3 (2), Mar./Apr. 2011, 133-152.;;Avogadri, F. et al., “Modulation of CTLA-4 and GITR for Cancer Immunotherapy,” Curr Top Microbiol Immunol, vol. 344: 211-244 (2011).;;Baecher-Allan, B. et al., “Inhibition of Human CD4+CD25+ high Regulatory T Cell Function,” J. Immunol., vol. 169: , 6210-6217 (2002).;;Balint, R. et al., “Antibody Engineering by Parsimonious Mutagenesis,” Gene, vol. 137: 109-118 (1993).;;Birebent, B. et al., “Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression,” Eur. J. Immunol., vol. 34:3485-3496 (2004).;;Bulliard, Y. et al., “Activating Fc y receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies,” JEM, vol. 210 (9), 1685-1693 (2013).;;Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” PNAS, vol. 89, 4285-4289 (1992).;;Coe, D. et al., “Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy,” Cancer Immunol Immunother, vol. 59, 1367-1377 (2010).;;Cohen et al., “Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation,” PLoS, vol. 5, Iss. 5, 1-12 (2010).;;Cohen et al., “Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody,” Blood, ASH Annual Meeting Abstracts, Dec. 8-11, 2007, vol. 110 (11), 1788.;;Cohen, et al., “Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity,” Cancer Res., vol. 66: (9):4904-4912 (2006).;;Davies et al., “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen bnding,” Immunotechnology, vol. 2, 169-179 (1996).;;Dittmer et al., “Functional impairment of CD8+ T cellls by regulatory T cells during persistent retroviral infection,” Immunirty, vol. 20, 293-303 (2004).;;Glaus et al., “In vivo SPECT/CT imaging of an anti-GITR antibody: A novel cancer immunotherapeutic,” J Nucl Med., vol. 54 (Supplement 2):327 (2013).;;Godrey et al., “Cord blood CD4+ CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function,” Blood, vol. 105 No. 2, 750-758 (2005).;;Gross et al., “TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease: Impaired B Cell Maturation in Mice Lacking BLyS,” Immunity, vol. 15:289-302 (2001).;;Gurney et al., “Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR,” Current Biology, vol. 9 (4), 215-218 (1999).;;Hawkins, R.E. et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,” J. Mol. Biol., vol. 226(3): 889-896 (1992).;;Hiroyoshi Nishikawa, “Application of Modulators of Cancer Immunosuppression for Immunotherapy—GITR and CTLA-4,” The Medical Frontline, vol. 64 (11): 100-105 (2009).;;Holt, L. et al., “Domain antibodies: proteins for therapy,” Trends in Biotechnology, vol. 21 (11): 484-490 (2003).;;Houot et al., “T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need or chemotherapy,” Blood, vol. 113 (15):3546-3552 (2009).;;International Preliminary Report on Patentability, PCT/US2015/033991, dated Dec. 6, 2016, 11 pages.;;International Search Report and Written Opinion for Application No. PCT/US2015/033991, 19 pages, dated Dec. 8, 2015.;;Kanamaru et al., “Costimulation via Glucocorticoid-Induced TNF Receptor in Both Conventional and CD25+ Regulatory CD4+ T Cells,” The Journal of Immunology, 7306-7314 (2004).;;Kim et al., “Fcy receptors enable anticancer action of proapoptotic and immune-modulatory antibodies,” J Exp Med., vol. 210 (9) 1647-1657 (2013).;;Ko et al., “A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model,” Cancer Research, vol. 67 (15) 7477-7486 (2007).;;Ko et al., “Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+ CD4+ regulatory T cells,” JEM, vol. 202 (7), 885-891 (2005).;;Kwon et al., “Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand,” Journal of Biol Chem, vol. 274 (10) 6056-6061 (1999).;;Little et al., “Of Mice and Men: hybridoma and recombinant antibodies,” Immunology Today, vol. 21(8): 364-370 (2000).;;Lu et al. “Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs,” Journal of Translational Medicine, vol. 12 (36), 1-11 (2014).;;Marks, J. et al, “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,” Biotechnology, vol. 10(7): 779-783 (1992).;;McHugh et al., “CD4+CD25+ Immunoregulatory T Cells: Gene Expression Analysis Reveals a Functional Role for the Glucocorticoid-Induced TNF Receptor,” Immunity, vol. 16, 311-323 (2002).;;Melero et al., “Agonist Antibodies to TNFR Molecules That Costimulate Tand NK Cells,” Clinical Cancer Research, vol. 19 (5): 1044-1053, 1913 (2013).;;Melero et al., “Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination,” Clinical Cancer Research, vol. 19(5), 997-1008 (2013).;;Melero, I., “Immunological targets: Basic aspects,” IL29, Annals of Oncology, vol. 22 (Supplement 3), 8 pages, (2011) doi:10.1093/annonc/mdr103.;;Mitsui et al, “Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals,” Clinical Cancer Res, vol. 16, 2781-2791(2010).;;National Cancer Institute, Immunotherapy Agent Workshop Jul. 12, 2007, 1-77.;;Nocentini et al., “A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis,” PNAS, vol. 94, 6216-6221 (1997).;;Nocentini et al., “GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily,” Eur J of Immunol, vol. 35 Iss 4, 1016-1022 (2005).;;Nocentini et al., “Identification of three novel mRNA splice variants of GITR,”Cell Death and Differentiation, vol. 7, 408-410 (2000).;;Patel, M. et al., “Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma,” Journal for ImmunoTherapy of Cancer, vol. 4(28)13 pages (2007).;;Ponte et al., “Enhancement of humoral and cellular immunity with an antiglucocorticoid-induced tumour necrosis factor receptor monoclonal antibody,” Immunology, vol. 130, 231-242 (2010).;;Press Release, Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting, Cambridge, MA, Jun. 25, 2015, PR Newswire, 1-3.;;Printout from the R&D Systems website showing a list of available anti-GITR antibodies, Jul. 2, 2014, 1-2.;;Reichert, J. et al., “Monoclonal antibodies in the clinic,” Nat. Biotech, vol. 19, 819-822 (2001).;;Ronchetti et al., “GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations,” Eur J Immunol, vol. 34, 613-622 (2004).;;Rosenzweig et al., “Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR.,” ASCO Meeting Library 2010 Annual Meeting, 1-2.;;Schaer et al., “Anti-GITR antibodies—Potential Clinical applications for tumor immunotherapy,” Curr Opin in Investigational Drugs, vol. 11 (12), 1378-1386 (2010).;;Schaer, et al. “Modulation of GITR for cancer immunotherapy,” Curr Opin in Immunol, vol. 24, 217-224 (2012).;;Schimizu et al., “Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance,” Nature Immunol, vol. 3 (2), 135-142 (2002).;;Turk, et al., “Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells,” Journal of Exp Medicine, vol. 200 (6) 771-782 (2004).;;U.S. Appl. No. 60/665,322, filed Mar. 25, 2005, 62 pages.;;U.S. Appl. No. 60/687,265, filed Jun. 3, 2005, 71 pages.;;Website Information for human GITR/TNFRSF 18 MAb (Clone 110416), Catalog No. MAB589, 1-2.;;White, A. et al., “Conformation of the Human Immunoglobulin G2 Hing Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies,” Cancer Cell, vol. 27(1):138-148 (2015).;;Whiteside, S. et al., “IkB proteins: structure, function and regulation,” Seminars in Cancer Biology, vol. 8, 75-82 (1997).;;Yang, W. et al., “CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range,” J. Mol. Biol., vol. 254 (3): 392-403 (1995).;;Barrios, Y. et al., “Length of the antibody heavy chain complementarity determining region 3 as a specificity determining factor,” J Molecular Recognition, vol. 17: 332-338 (2004).;;Piatesi, A. et al., “Immunological Optimization of a Generic Hydrophobic Pocket for High Affinity Hapten Binding and Diets-Alder Activity,” ChemBio Chem., vol. 5: 460-466 (2004).;;Rudikoff, S. et al., “Single amino acid substitution altering antigen-binding specificity,” PNAS, vol. 79: 1979-1983 (1982).;;U.S. Appl. No. 14/732,082, filed Jun. 5, 2015, Changyu Wang.;;U.S. Appl. No. 14/949,424, filed Nov. 23, 2015, Changyu Wang.;;U.S. Appl. No. 15/646,558, filed Jul. 11, 2017, Changyu Wang.;;U.S. Appl. No. 15/369,290, filed Dec. 5, 2016, Changyu Wang.;;U.S. Appl. No. 16/663,583, filed Oct. 25, 2019, Changyu Wang.;;U.S. Appl. No. 15/264,266, filed Sep. 13, 2016, Suba Krishnan.;;U.S. Appl. No. 16/133,418, Sep. 17, 2018, Suba Krishnan.;;U.S. Appl. No. 15/776,591, filed May 16, 2018, Changyu Wang.;;U.S. Appl. No. 14/732,082, Aug. 24, 2015.;;U.S. Appl. No. 14/732,082, Jul. 13, 2015.;;U.S. Appl. No. 14/949,424, Apr. 20, 2017.;;U.S. Appl. No. 14/949,424, Apr. 13, 2017.;;U.S. Appl. No. 14/949,424, Jan. 25, 2017.;;U.S. Appl. No. 14/949,424, Nov. 4, 2016.;;U.S. Appl. No. 15/646,558, Jun. 21, 2019.;;U.S. Appl. No. 15/646,558, Feb. 4, 2019.;;U.S. Appl. No. 15/646,558, Sep. 26, 2018.;;U.S. Appl. No. 15/646,558, May 30, 2018.;;U.S. Appl. No. 15/369,290, Jul. 25, 2019.;;U.S. Appl. No. 15/369,290, Nov. 8, 2018.;;U.S. Appl. No. 15/369,290, Jul. 16, 2018.;;U.S. Appl. No. 15/369,290, Feb. 8, 2018.;;U.S. Appl. No. 15/776,591, Nov. 4, 2019.;;U.S. Appl. No. 15/776,591, Jan. 29, 2020.;;An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread, NIH U.S. National Library of Medicine ClinicalTrails.gov, Nov. 6, 2015 Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/NCT02598960 [retrieved on Aug. 10, 2018].;;Baltz, K. et al., “Cancer immunoediting by GITR (glucocorticoidinduced TNF-related protein) ligand in humans: NK cell/tumor cell interactions,” The FASEB Journal, Research Communication, vol. 21(8): 2442-2454 (2007).;;Chang, W. et al., “Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma,” Cancer, vol. 116 (24): 5777-5788 (2010).;;Gasparoto, T. et al., “Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment,” Cancer Immunology, Immunotherapy, vol. 59: 819-828 (2010).;;International Preliminary Report on Patentability, PCT/US2018/032750, dated Nov. 19, 2019, 14 pages.;;International Search Report and Written Opinion, PCT/US2018/032750, dated Oct. 31, 2018, 24 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, PCT/US2018/032750, dated Aug. 24, 2018, 21 pages.;;Khalil D. et al., “The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy,” Immunotherapy Of Cancer in: Advances In Cancer Research, vol. 128, 1-68 (2015).;;Khalil, D. et al., “The future of cancer treatment: immunomodulation,” CARs and combi-nation immunotherapy, Nature Reviews Clinical Oncology, vol. 13(5): 15 pages,273-290(2016).;;Kim E. et al., “Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium,” Journal of Immunology Research, (2016).;;Knee D. et al., “Rationale for anti-GITR cancer immunotherapy,” European Journal of Can-cer, vol. 67: 10 pages (2016).;;Lohmueller J. et al., “Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines,” Pharmacology and Therapeutics, vol. 178: 31-47 (2017).;;NIH U.S. National Library of Medicine: “Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastat-ic Malignancies,” ClinincalTrials.gov, (2017) Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/NCT03126110 [retrieved on Aug. 9, 2018].;;Padovani, C. et al., “Glucocorticoid-induced tumor necrosis factor receptor expression in patients with cervical human papillomavirus infection,” Revista DA Sociedada Brasileira De Medicina Tropical, vol. 46(3):288-292 :(2013).;;Santoni, M. et al., “Triple negative breast cancer: Key role of Tumor-Associated Macro-phages in regulating the activity of anti-PD-1/PD-L1 agents,” BBA—Reviews on Cancer, vol. 1869(1):78-84 (2017).;;Sharma P. et al., “Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy,” Cell, Cell Press, vol. 168(4):707-723 (2017).;;Tan, W-L., et al., “Novel therapeutic targets on the horizon for lung cancer,” The Lancet Oncology, vol. 17(8): e347:16 pages (2016).;;Yu, N. et al., “Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma,” International Journal of Cancer, vol. 138(2): 451-462 (2015).;;Kuenen, B. et al., “A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgGi Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies,” Clin Cancer Res vol. 16(6):1915-23 (2010).;;U.S. Appl. No. 16/793,737, filed Feb. 18, 2020, Suba Krishnan.;;U.S. Appl. No. 15/776,591, Jan. 1, 2021.;;U.S. Appl. No. 15/776,591, Sep. 29, 2020.",ACTIVE
212,JP,A,JP 2019058181 A,085-288-713-239-468,2019-04-18,2019,JP 2018228384 A,2018-12-05,US 201462082980 P;;US 201462008945 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"To provide isolated antibodies that specifically bind to glucocorticoid-induced TNF receptor (GITR) and have desirable functional properties.SOLUTION: Disclosed herein is an isolated antibody or antigen-binding fraction thereof that binds to human GITR with the following properties: (a) binding to a soluble human GITR; (b) binding to membrane bound human GITR; (c) binding to cynomolgus GITR; (d) inducing or promoting T cell activation; (e) inhibiting the binding of a GITR ligand to GITR on 3A9-hGITR cells; (f) at most partially inhibiting the binding of GITR ligand to GITR on activated T cells; (g) binding to s conformational epitope on mature human GITR; (h) binding to both O-linked and N-glycosylated and non glycosylated human GITR; (i) having agonist activity without binding to a Fc receptor, wherein binding to a Fc receptor further enhances the agonist activity.SELECTED DRAWING: None",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;NILS LONBERG;;ALAN J KORMAN;;MARK J SELBY;;MOHAN SRINIVASAN;;KARLA HENNING;;MICHELLE MINHUA HAN;;CHEN GUODONG;;RICHARD HUANG;;INDRANI CHAKRABORTY;;HUANG HAICHUN;;SUSAN WONG;;LI HUIMING,,https://lens.org/085-288-713-239-468,Patent Application,no,1,0,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C12N15/13;;A61K39/395;;A61K45/00;;A61K47/68;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/04;;A61P43/00;;C07K16/28;;C07K16/46;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/62;;C12N15/63;;C12P21/08;;G01N33/574,,2,0,,,"JOURNAL OF TRANSLATIONAL MEDICINE, vol. Vol. 12, 36, JPN6017049851, 7 February 2014 (2014-02-07), pages 1 - 11, ISSN: 0004376595;;最新医学, vol. 64, no. 11, JPN6017049849, November 2009 (2009-11-01), JP, pages 100 - 105, ISSN: 0004376596",ACTIVE
213,PH,A1,PH 12016502267 A1,189-644-790-413-473,2017-02-06,2017,PH 12016502267 A,2016-11-15,US 201462082980 P;;US 201462008945 P;;US 2015/0033991 W,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid- inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MEYERS SQUIBB CO,CHANGYU WANG;;NILS LONBERG;;KORMAN ALAN J;;SELBY MARK J;;MOHAN SRINIVASAN;;KARLA HENNING;;MINHUA HAN MICHELLE;;GUODONG CHEN;;RICHARD HUANG;;INDRANI CHAKRABORTY;;HAICHUN HUANG;;SUSAN WONG;;HUIMING LI,,https://lens.org/189-644-790-413-473,Patent Application,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/00;;A61P35/00,,0,0,,,,PENDING
214,ZA,B,ZA 202003741 B,124-094-545-640-89X,2023-03-29,2023,ZA 202003741 A,2020-06-22,US 201462008945 P;;US 201462082980 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/124-094-545-640-89X,Granted Patent,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,,,0,0,,,,ACTIVE
215,US,B2,US 9745379 B2,158-551-628-823-231,2017-08-29,2017,US 201514949424 A,2015-11-23,US 201514949424 A;;US 2015/0033991 W;;US 201514732082 A;;US 201462082980 P;;US 201462008945 P,2014-06-06,Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2015-07-22),https://lens.org/158-551-628-823-231,Granted Patent,yes,75,10,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/00;;A61K39/00;;A61K39/395;;C07H21/00;;C07K16/28;;G01N33/574;;G01N33/68,,60,45,012-108-483-329-37X;;051-374-571-260-065;;004-189-544-863-902;;043-054-515-242-505;;171-614-306-115-108;;086-268-955-647-163;;136-116-610-765-69X;;084-334-863-236-818;;019-741-156-878-521;;029-382-279-785-035;;009-483-512-107-343;;019-459-691-036-036;;087-404-567-384-381;;128-554-308-094-91X;;020-296-196-517-635;;055-706-543-681-974;;044-673-845-363-528;;056-584-393-786-220;;070-164-938-901-37X;;005-119-615-003-591;;013-323-148-570-367;;022-259-501-579-745;;055-329-732-668-508;;011-405-827-983-549;;141-244-428-002-001;;143-287-907-926-845;;124-353-299-096-166;;012-369-544-741-057;;055-677-065-531-946;;010-916-105-450-247;;019-791-912-221-046;;078-111-385-767-730;;017-588-579-721-840;;016-276-447-231-541;;045-714-831-915-963;;071-886-484-965-256;;145-500-434-317-873;;083-410-991-104-604;;013-888-189-100-394;;112-871-461-451-205;;110-748-788-527-236;;082-582-794-395-339;;124-668-123-456-128;;039-943-095-184-294;;050-463-287-173-296,10.1186/s40425-016-0132-2;;27822377;;pmc5096004;;27190629;;10.1186/s40425-016-0181-6;;pmc4869343;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001;;9299585;;10.1006/scbi.1997.0058;;7490758;;10.1006/jmbi.1995.0626;;21304271;;10.4161/mabs.3.2.14939;;pmc3092615;;20563707;;10.1007/82_2010_49;;pmc4060248;;12444126;;10.4049/jimmunol.169.11.6210;;7506686;;10.1016/0378-1119(93)90258-5;;15484187;;10.1002/eji.200324632;;10.1084/jem.20130573;;23897982;;pmc3754864;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;20480365;;10.1007/s00262-010-0866-5;;20454651;;pmc2862699;;10.1371/journal.pone.0010436;;10.1158/0008-5472.can-05-2813;;16651447;;pmc2242844;;9373310;;10.1016/s1380-2933(96)00045-0;;10.1016/s1074-7613(04)00054-8;;15030773;;15374887;;10.1182/blood-2004-06-2467;;10.3410/f.1001160.6701;;11520463;;10.1016/s1074-7613(01)00183-2;;10074428;;10.1016/s0960-9822(99)80093-1;;10.1016/0022-2836(92)90639-2;;1507232;;14573361;;10.1016/j.tibtech.2003.08.007;;10.1182/blood-2008-07-170274;;pmc2668854;;18941113;;10.4049/jimmunol.172.12.7306;;15187106;;23980122;;pmc3754862;;10.1084/jem.20131625;;17671218;;10.1158/0008-5472.can-06-4639;;10.1084/jem.20050940;;pmc2213162;;10.1084/jem.200509402092c;;16186187;;10.3410/f.1028385.337176;;10037686;;10.1074/jbc.274.10.6056;;10.1016/s0167-5699(00)01668-6;;10916138;;10.1186/1479-5876-12-36;;24502656;;pmc4104995;;10.1038/nbt0792-779;;1368267;;10.1016/s1074-7613(02)00280-7;;11869690;;pmc4397897;;23460535;;10.1158/1078-0432.ccr-13-0598;;10.1158/1078-0432.ccr-12-2065;;10.1158/1078-0432.ccr-12-2214;;23460531;;10.1158/1078-0432.ccr-09-3243;;20460483;;pmc21029;;9177197;;10.1073/pnas.94.12.6216;;10.1002/eji.200425818;;15770698;;10836847;;10.1038/sj.cdd.4400670;;10.1111/j.1365-2567.2009.03228.x;;20201988;;pmc2878467;;11533635;;10.1038/nbt0901-819;;10.1002/eji.200324804;;14991590;;10.1016/j.clim.2010.03.288;;21154120;;pmc3413251;;22245556;;10.1016/j.coi.2011.12.011;;10.1038/ni759;;11812990;;10.1084/jem.20041130;;15381730;;pmc2211964,"U.S. Appl. No. 14/732,082, filed Jun. 5, 2015, Changyu Wang.;;U.S. Appl. No. 14/732,082, Aug. 24, 2015.;;U.S. Appl. No. 14/732,082, Jul. 13, 2015.;;International Search Report and Written Opinion for Application No. PCT/US2015/033991, 19 pages, dated Dec. 8, 2015.;;International Preliminary Report on Patentability, PCT/US2015/033991, dated Dec. 6, 2016, 11 pages.;;Patel, M. et al., “Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma,” Journal for ImmunoTherapy of Cancer, vol. 4(28):14 pages (2016).;;White, A. et al., “Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies,” Cancer Cell, vol. 27(1), pp. 138-148 (2015).;;Whiteside, S. et al., “IkB proteins: structure, function and regulation,” Seminars in Cancer Biology, 1997, vol. 8, 75-82.;;Yang, W. et al., “CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range,” J. Mol. Biol., 1995, vol. 254 (3), 392-403.;;Arnett, S. et al., “IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society,” Dec. 5-9, 2010, San Diego, CA USA, mAbs, vol. 3 (2), Mar./Apr. 2011, 133-152.;;Avogadri, F. et al., “Modulation of CTLA-4 and GITR for Cancer Immunotherapy,” Curr Top Microbiol Immunol, vol. 344, 2011, 211-244.;;Baecher-Allan, B. et al., “Inhibition of Human CD4+CD25+ high Regulatory T Cell Function,” J. Immunol., 2002, vol. 169, 6210-6217.;;Balint, R. et al., “Antibody Engineering by Parsimonious Mutagenesis,” Gene, 1993, vol. 137, 109-118.;;Birebent, B. et al., “Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression,” Eur. J. Immunol., 2004, vol. 34, 3485-3496.;;Bulliard, et al., “Activating Fc y receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies,” JEM , Aug. 2013, vol. 210 (9), 1685-1693.;;Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” PNAS, 1992, vol. 89, 4285-4289.;;Coe, D. et al., “Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy,” Cancer Immunol Immunother, 2010,vol. 59, 1367-1377.;;Cohen et al., “Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation,” PLoS, May 2010, vol. 5 Iss. 5, 1-12.;;Cohen et al., “Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody,” Blood, ASH Annual Meeting Abstracts, Dec. 8-11, 2007, vol. 110 (11), 1788.;;Cohen, et al., “Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+; T-Cell Responses and Tumor Immunity,” Cancer Res, 2006; vol. 66: (9), 4904-4912.;;Davies et al., “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen bnding,” Immunotechnology, 1996, vol. 2, 169-179.;;Dittmer et al., “Functional impairment of CD8+ T cellls by regulatory T cells during persistent retroviral infection,” Immunirty, 2004, vol. 20, 293-303.;;Glaus et al., “In vivo SPECT/CT imaging of an anti-GITR antibody: A novel cancer immunotherapeutic,” J Nucl Med. 2013; 54 (Supplement 2):327.;;Godrey et al., “Cord blood CD4+ CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function,” Blood, Jan. 15, 2005, vol. 105 No. 2, 750-758.;;Gross et al., TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease: Impaired B Cell Maturation in Mice Lacking BLyS, (2001) Immunity vol. 15:289-302.;;Gurney et al., “Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR,” Current Biology, Feb. 25, 1999, vol. 9 (4), 215-218.;;Hawkins, R.E. et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,” J. Mol. Biol., 1992, vol. 226(3), 889-896.;;Holt, L. et al., “Domain antibodies: proteins for therapy,” Trends in Biotechnology, 2003, vol. 21 (11), 484-490.;;Houot et al., “T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy,” Blood, Apr. 9, 2009, vol. 113 (15), 3546-3552.;;Kanamaru et al., “Costimulation via Glucocorticoid-Induced TNF Receptor in Both Conventional and CD25+ Regulatory CD4+ T Cells,” The Journal of Immunology, 2004, 7306-7314.;;Kim et al., “Fcy receptors enable anticancer action of proapoptotic and immune-modulatory antibodies,” J Exp Med Aug. 26, 2013, vol. 210 (9) 1647-1657.;;Ko et al., “A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model,” Cancer Research, Aug. 1, 2007, vol. 67 (15) 7477-7486.;;Ko et al., “Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+ CD4+ regulatory T cells,” JEM, Oct. 3, 2005, vol. 202 (7), 885-891.;;Kwon et al., “Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand,” Journal of Biol Chem, Mar. 5, 1999, vol. 274 (10) 6056-6061.;;Little et al., “Of Mice and Men: hybridoma and recombinant antibodies,” Immunology Today, 2000, vol. 21, (8), 364-370.;;Lu et al. “Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs,” Journal of Translational Medicine, 2014, vol. 12 (36), 1-11.;;Marks, J. et al, “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,” Biotechnology, 1992, vol. 10(7) 779-783.;;McHugh et al., “CD4+CD25+ Immunoregulatory T Cells: Gene Expression Analysis Reveals a Functional Role for the Glucocorticoid-Induced TNF Receptor,” Immunity, Feb. 16, 2002, vol. 16, 311-323.;;Melero et al., “Agonist Antibodies to TNFR Molecules That Costimulate Tand NK Cells,” Clinical Cancer Research, Mar. 1, 2013, vol. 19 (5), 1044-1053, 1913.;;Melero et al., “Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination,” Clinical Cancer Research, Mar. 1, 2013, vol. 19 (5), 997-1008.;;Melero, I., “Immunological targets: Basic aspects,” IL29, Annals of Oncology, vol. 22 (Supplement 3), 1 page, (2011) doi:10.1093/annonc/mdr103.;;Mitsui et al, “Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals,” Clinical Cancer Res, May 11, 2010, vol. 16, 2781-2791.;;National Cancer Institute, Immunotherapy Agent Workshop Jul. 12, 2007, 1-77.;;Nocentini et al., “A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis,” PNAS, Jun. 10, 1997, vol. 94, 6216-6221.;;Nocentini et al., “GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily,” Eur J of Immunol, Apr. 2005, vol. 35 Iss 4, 1016-1022.;;Nocentini et al., “Identification of three novel mRNA splice variants of GITR,” Cell Death and Differentiation, Apr. 2000, vol. 7, 408-410.;;Ponte et al., “Enhancement of humoral and cellular immunity with an antiglucocorticoid-induced tumour necrosis factor receptor monoclonal antibody,” Immunology, Jun. 2010, vol. 130, 231-242.;;Press Release, Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting, Cambridge, MA, Jun. 25, 2015, PR Newswire, 1-3.;;Printout from the R&D Systems website showing a list of available anti-GITR antibodies, Jul. 2, 2014, 1-2.;;Reichert, J. et al., “Monoclonal antibodies in the clinic,” Nat. Biotech, 2001, vol. 19, 819-822.;;Ronchetti et al., “GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations,” Eur J Immunol, 2004 vol. 34, 613-622.;;Rosenzweig et al., “Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR.,” ASCO Meeting Library 2010 Annual Meeting, 1-2.;;Schaer et al., “Anti-GITR antibodies—Potential Clinical applications for tumor immunotherapy,” Curr Opin in Investigational Drugs, 2010, vol. 11 (12), 1378-1386.;;Schaer, et al. “Modulation of GITR for cancer immunotherapy,” Curr Opin in Immunol, Apr. 2012, vol. 24, 217-224.;;Shimizu et al., “Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance,” Nature Immunol, Feb. 2002, vol. 3 (2), 135-142.;;Turk, et al., “Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells,” Journal of Exp Medicine, Sep. 20, 2004, vol. 200 (6) 771-782.;;U.S. Appl. No. 60/665,322, filed Mar. 25, 2005, 62 pages.;;U.S. Appl. No. 60/687,265, filed Jun. 3, 2005, 71 pages.;;Website Information for human GITR/TNFRSF 18 MAb (Clone 110416), Catalog No. MAB589, 1-2.;;U.S. Appl. No. 15/369,290, filed Dec. 5, 2016, Changyu Wang.",ACTIVE
216,US,B2,US 9228016 B2,013-898-414-088-184,2016-01-05,2016,US 201514732082 A,2015-06-05,US 201514732082 A;;US 2015/0033991 W;;US 201462082980 P;;US 201462008945 P,2014-06-06,Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2015-07-22),https://lens.org/013-898-414-088-184,Granted Patent,yes,71,80,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/00;;A61K39/00;;A61K39/395;;C07H21/00;;C07K16/28;;G01N33/574;;G01N33/68,,52,44,171-614-306-115-108;;086-268-955-647-163;;136-116-610-765-69X;;084-334-863-236-818;;019-741-156-878-521;;029-382-279-785-035;;029-382-279-785-035;;009-483-512-107-343;;019-459-691-036-036;;087-404-567-384-381;;128-554-308-094-91X;;020-296-196-517-635;;055-706-543-681-974;;044-673-845-363-528;;056-584-393-786-220;;070-164-938-901-37X;;005-119-615-003-591;;013-323-148-570-367;;022-259-501-579-745;;055-329-732-668-508;;011-405-827-983-549;;141-244-428-002-001;;143-287-907-926-845;;124-353-299-096-166;;012-369-544-741-057;;055-677-065-531-946;;010-916-105-450-247;;019-791-912-221-046;;078-111-385-767-730;;017-588-579-721-840;;016-276-447-231-541;;045-714-831-915-963;;071-886-484-965-256;;145-500-434-317-873;;083-410-991-104-604;;013-888-189-100-394;;112-871-461-451-205;;110-748-788-527-236;;082-582-794-395-339;;124-668-123-456-128;;039-943-095-184-294;;050-463-287-173-296;;004-189-544-863-902;;043-054-515-242-505,21304271;;10.4161/mabs.3.2.14939;;pmc3092615;;20563707;;10.1007/82_2010_49;;pmc4060248;;12444126;;10.4049/jimmunol.169.11.6210;;7506686;;10.1016/0378-1119(93)90258-5;;15484187;;10.1002/eji.200324632;;10.1084/jem.20130573;;23897982;;pmc3754864;;10.1084/jem.20130573;;23897982;;pmc3754864;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;20480365;;10.1007/s00262-010-0866-5;;20454651;;pmc2862699;;10.1371/journal.pone.0010436;;10.1158/0008-5472.can-05-2813;;16651447;;pmc2242844;;9373310;;10.1016/s1380-2933(96)00045-0;;10.1016/s1074-7613(04)00054-8;;15030773;;15374887;;10.1182/blood-2004-06-2467;;10.3410/f.1001160.6701;;11520463;;10.1016/s1074-7613(01)00183-2;;10074428;;10.1016/s0960-9822(99)80093-1;;10.1016/0022-2836(92)90639-2;;1507232;;14573361;;10.1016/j.tibtech.2003.08.007;;10.1182/blood-2008-07-170274;;pmc2668854;;18941113;;10.4049/jimmunol.172.12.7306;;15187106;;23980122;;pmc3754862;;10.1084/jem.20131625;;17671218;;10.1158/0008-5472.can-06-4639;;10.1084/jem.20050940;;pmc2213162;;10.1084/jem.200509402092c;;16186187;;10.3410/f.1028385.337176;;10037686;;10.1074/jbc.274.10.6056;;10.1016/s0167-5699(00)01668-6;;10916138;;10.1186/1479-5876-12-36;;24502656;;pmc4104995;;10.1038/nbt0792-779;;1368267;;10.1016/s1074-7613(02)00280-7;;11869690;;pmc4397897;;23460535;;10.1158/1078-0432.ccr-13-0598;;10.1158/1078-0432.ccr-12-2065;;10.1158/1078-0432.ccr-12-2214;;23460531;;10.1158/1078-0432.ccr-09-3243;;20460483;;pmc21029;;9177197;;10.1073/pnas.94.12.6216;;10.1002/eji.200425818;;15770698;;10836847;;10.1038/sj.cdd.4400670;;10.1111/j.1365-2567.2009.03228.x;;20201988;;pmc2878467;;11533635;;10.1038/nbt0901-819;;10.1002/eji.200324804;;14991590;;10.1016/j.clim.2010.03.288;;21154120;;pmc3413251;;22245556;;10.1016/j.coi.2011.12.011;;10.1038/ni759;;11812990;;10.1084/jem.20041130;;15381730;;pmc2211964;;9299585;;10.1006/scbi.1997.0058;;7490758;;10.1006/jmbi.1995.0626,"U.S. Appl. No. 60/687,265, filed Jun. 3, 2005, 71 pages.;;U.S. Appl. No. 60/665,322, filed Mar. 25, 2005, 62 pages.;;Arnett, S. et al., ""IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society,"" Dec. 5-9, 2010, San Diego, CA USA, mAbs, vol. 3 (2), Mar./Apr. 2011, 133-152.;;Avogadri, F. et al., ""Modulation of CTLA-4 and GITR for Cancer Immunotherapy,"" Curr Top Microbiol Immunol, vol. 344, 2011, 211-244.;;Baecher-Allan, B. et al., ""Inhibition of Human CD4+CD25+ high Regulatory T Cell Function,"" J. Immunol., 2002, vol. 169, 6210-6217.;;Balint, R. et al., ""Antibody Engineering by Parsimonious Mutagenesis,"" Gene, 1993, vol. 137, 109-118.;;Birebent, B. et al., ""Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression,"" Eur. J. Immunol., 2004, vol. 34, 3485-3496.;;Bulliard, et al., ""Activating Fc y receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies,"" JEM , Aug. 2013, vol. 210 (9), 1685-1693.;;Bulliard, et al., ""Activating Fc y receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies,"" Novartis Institutes for Biomedical Research and Dana Farber Cancer Institutes USA, No date, 1-3.;;Carter et al., ""Humanization of an anti-p185HER2 antibody for human cancer therapy,"" PNAS, 1992, vol. 89, 4285-4289.;;Coe, D. et al., ""Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy,"" Cancer Immunol Immunother, 2010,vol. 59, 1367-1377.;;Cohen et al., ""Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation,"" PLoS, May 2010, vol. 5 Iss. 5, 1-12.;;Cohen et al., ""Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody,"" Blood, ASH Annual Meeting Abstracts, Dec. 8-11, 2007, vol. 110 (11), 1788.;;Cohen, et al., ""Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+; T-Cell Responses and Tumor Immunity,"" Cancer Res, 2006; vol. 66: (9), 4904-4912.;;Davies et al., ""Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen bnding,"" Immunotechnology, 1996, vol. 2, 169-179.;;Dittmer et al., ""Functional impairment of CD8+ T cellls by regulatory T cells during persistent retroviral infection,"" Immunirty, 2004, vol. 20, 293-303.;;Glaus et al., ""In vivo SPECT/CT imaging of an anti-GITR antibody: A novel cancer immunotherapeutic,"" J Nucl Med. 2013; 54 (Supplement 2):327.;;Godrey et al., ""Cord blood CD4+ CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function,"" Blood, Jan. 15, 2005, vol. 105 No. 2, 750-758.;;Gross et al., TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease: Impaired B Cell Maturation in Mice Lacking BLyS, (2001) Immunity vol. 15:289-302.;;Gurney et al., ""Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR,"" Current Biology, Feb. 25, 1999, vol. 9 (4), 215-218.;;Hawkins, R.E. et al., ""Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,"" J. Mol. Biol., 1992, vol. 226(3), 889-896.;;Holt, L. et al., ""Domain antibodies: proteins for therapy,""Trends in Biotechnology, 2003, vol. 21 (11), 484-490.;;Houot et al., ""T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy,"" Blood, Apr. 9, 2009, vol. 113 (15), 3546-3552.;;Kanamaru et al., ""Costimulation via Glucocorticoid-Induced TNF Receptor in Both Conventional and CD25+ Regulatory CD4+ T Cells,"" The Journal of Immunology, 2004, 7306-7314.;;Kim et al., ""Fcy receptors enable anticancer action of proapoptotic and immune-modulatory antibodies,"" J Exp Med Aug. 26, 2013, vol. 210 (9) 1647-1657.;;Ko et al., ""A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model,"" Cancer Research, Aug. 1, 2007, vol. 67 (15) 7477-7486.;;Ko et al., ""Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+ CD4+ regulatory T cells,"" JEM, Oct. 3, 2005, vol. 202 (7), 885-891.;;Kwon et al., ""Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand,"" Journal of Biol Chem, Mar. 5, 1999, vol. 274 (10) 6056-6061.;;Little et al., ""Of Mice and Men: hybridoma and recombinant antibodies,"" Immunology Today, 2000, vol. 21, (8), 364-370.;;Lu et al. ""Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs,"" Journal of Translational Medicine, 2014, vol. 12 (36), 1-11.;;Marks, J. et al, ""By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,"" Biotechnology, 1992, vol. 10(7) 779-783.;;McHugh et al., ""CD4+CD25+ Immunoregulatory T Cells: Gene Expression Analysis Reveals a Functional Role for the Glucocorticoid-Induced TNF Receptor,"" Immunity, Feb. 16, 2002, vol. 16, 311-323.;;Melero et al., ""Agonist Antibodies to TNFR Molecules That Costimulate Tand NK Cells,"" Clinical Cancer Research, Mar. 1, 2013, vol. 19 (5), 1044-1053, 1913.;;Melero et al., ""Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination,"" Clinical Cancer Research, Mar. 1, 2013, vol. 19 (5), 997-1008.;;Mitsui et al, ""Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals,"" Clinical Cancer Res, May 11, 2010, vol. 16, 2781-2791.;;National Cancer Institute, Immunotherapy Agent Workshop Jul. 12, 2007, 1-77.;;Nocentini et al., ""A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis,"" PNAS, Jun. 10, 1997, vol. 94, 6216-6221.;;Nocentini et al., ""GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily,"" Eur J of Immunol, Apr. 2005, vol. 35 Iss 4, 1016-1022.;;Nocentini et al., ""Identification of three novel mRNA splice variants of GITR,""Cell Death and Differentiation, Apr. 2000, vol. 7, 408-410.;;Ponte et al., ""Enhancement of humoral and cellular immunity with an antiglucocorticoid-induced tumour necrosis factor receptor monoclonal antibody,"" Immunology, Jun. 2010, vol. 130, 231-242.;;Press Release, Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting, Cambridge, MA, Jun. 25, 2015, PR Newswire, 1-3.;;Printout from the R&D Systems website showing a list of available anti-GITR antibodies, Jul. 2, 2014, 1-2.;;Reichert, J. et al., ""Monoclonal antibodies in the clinic,"" Nat. Biotech, 2001, vol. 19, 819-822.;;Ronchetti et al., ""GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations,"" Eur J Immunol, 2004 vol. 34, 613-622.;;Rosenzweig et al., ""Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR.,"" ASCO Meeting Library 2010 Annual Meeting, 1-2.;;Schaer et al., ""Anti-GITR antibodies-Potential Clinical applications for tumor immunotherapy,"" Curr Opin in Investigational Drugs, 2010, vol. 11 (12), 1378-1386.;;Schaer, et al. ""Modulation of GITR for cancer immunotherapy,"" Curr Opin in Immunol, Apr. 2012, vol. 24, 217-224.;;Shimizu et al., ""Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance,"" Nature Immunol, Feb. 2002, vol. 3 (2), 135-142.;;Turk, et al., ""Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells,"" Journal of Exp Medicine, Sep. 20, 2004, vol. 200 (6) 771-782.;;Website Information for human GITR/TNFRSF 18 MAb (Clone 110416), Catalog No. MAB589, 1-2.;;Whiteside, S. et al., ""IkB proteins: structure, function and regulation,"" Seminars in Cancer Biology, 1997, vol. 8, 75-82.;;Yang, W. et al., ""CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range,"" J. Mol. Biol., 1995, vol. 254 (3), 392-403.",ACTIVE
217,KR,A,KR 20170010438 A,010-353-002-069-746,2017-01-31,2017,KR 20177000107 A,2015-06-03,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W,2014-06-06,- GITR ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR GITR AND USES THEREOF,"글루코코르티코이드-유도성 TNF 수용체 (GITR)와 결합하는 항체, 또는 그의 항원 결합 부분이 본원에 제공된다. 또한, 치료적 적용분야, 예컨대 암의 치료에서의 이들 단백질의 용도가 제공된다. 항체를 생성하는 세포, 항체의 중쇄 및/또는 경쇄 가변 영역을 코딩하는 폴리뉴클레오티드, 및 항체의 중쇄 및/또는 경쇄 가변 영역을 코딩하는 폴리뉴클레오티드를 포함하는 벡터가 추가로 제공된다.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/010-353-002-069-746,Patent Application,no,0,1,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/00;;A61K39/395;;C12N5/0783;;G01N33/574;;G01N33/68,,0,0,,,,ACTIVE
218,AR,A1,AR 100744 A1,123-453-294-637-009,2016-10-26,2016,AR P150101787 A,2015-06-04,US 201462008945 P,2014-06-06,ANTICUERPOS CONTRA EL RECEPTOR DEL FACTOR DE NECROSIS TUMORAL INDUCIDO POR GLUCOCORTICOIDES (GITR) Y SUS USOS,"Anticuerpos, o porciones de fijación al antígeno de estos, que se fijan al receptor de TNF (factor de necrosis tumoral) inducible por glucocorticoides (GITR). También, usos de estas proteínas en aplicaciones terapéuticas, tales como el tratamiento del cáncer. Además, células que producen los anticuerpos, polinucleótidos que codifican la región variable de la cadena pesada y/o liviana y vectores que comprenden los polinucleótidos que codifican la región variable de la cadena pesada y/o liviana de los anticuerpos. Molécula biespecífica, composición, kit, método.",BRISTOL MYERS SQUIBB CO,HUIMING LI;;SUSAN WONG;;RICHARD HUANG;;GUODONG CHEN;;HAICHUN HUANG;;INDRANI CHAKRABORTY;;MICHELLE MINHUA HAN;;KARLA HENNING;;MOHAN SRINIVASAN;;MARK J SELBY;;ALAN J KORMAN;;NILS LONBERG;;CHANGYU WANG,,https://lens.org/123-453-294-637-009,Patent Application,no,0,0,2,65,0,,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C12N5/10;;C12N15/13;;C12N15/85;;C12P21/02;;G01N33/574;;G01N33/68,,0,0,,,,PENDING
219,BR,A2,BR 112016028378 A2,142-253-856-527-841,2017-10-24,2017,BR 112016028378 A,2015-06-03,US 2015/0033991 W;;US 201462008945 P;;US 201462082980 P,2014-06-06,anticorpos contra o receptor do fator de necrose tumoral induzido por glicocorticoide (gitr) e usos dos mesmos,"a presente invenção refere-se a anticorpos, ou porções de ligação ao antígeno dos mesmos, que se ligam ao receptor de tnf que pode ser induzido por glicocorticoide (gitr). também são providos os usos destas proteínas em aplicações terapêuticas, tais como no tratamento de câncer. são adicionalmente providas células que produzem anticorpos, polinucleotídeos que codificam a região variável de cadeia pesada e/ou leve dos anticorpos, e vetores compreendendo os polinucleotídeos que codificam a região variável de cadeia pesada e/ou leve dos anticorpos.",BRISTOL MYERS SQUIBB CO,ALAN J KORMAN;;CHANGYU WANG;;GUODONG CHEN;;HAICHUN HUANG;;HUIMING LI;;INDRANI CHAKRABORTY;;KARLA HENNING;;MARK J SELBY;;MICHELLE MINHUA HAN;;MOHAN SRINIVASAN;;NILS LONBERG;;RICHARD HUANG;;SUSAN WONG,,https://lens.org/142-253-856-527-841,Patent Application,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/00;;A61P35/00,,0,0,,,,PENDING
220,US,A1,US 2018/0002432 A1,043-111-383-698-305,2018-01-04,2018,US 201715646558 A,2017-07-11,US 201715646558 A;;US 2015/0033991 W;;US 201514949424 A;;US 201514732082 A;;US 201462082980 P;;US 201462008945 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2015-07-22),https://lens.org/043-111-383-698-305,Patent Application,yes,0,9,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/00;;A61K39/395;;A61K47/68;;G01N33/574;;G01N33/68,,0,0,,,,ACTIVE
221,EP,B1,EP 3151921 B1,103-731-412-562-477,2019-08-28,2019,EP 15742414 A,2015-06-03,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/103-731-412-562-477,Granted Patent,yes,5,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/28,,2,0,,,"BULLIARD YANNICK ET AL: ""Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies"", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 210, no. 9, 26 August 2013 (2013-08-26), pages 1685-1693, XP009176020, ISSN: 0022-1007;;ANN L. WHITE ET AL: ""Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies"", CANCER CELL, vol. 27, no. 1, 1 January 2015 (2015-01-01), pages 138-148, XP055193819, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2014.11.001",ACTIVE
222,WO,A2,WO 2015/187835 A2,117-553-557-407-522,2015-12-10,2015,US 2015/0033991 W,2015-06-03,US 201462008945 P;;US 201462082980 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid- inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/117-553-557-407-522,Patent Application,yes,210,76,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00,,159,126,045-714-831-915-963;;075-363-665-052-387;;079-191-303-518-861;;039-943-095-184-294;;073-108-237-457-07X;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;040-577-067-037-463;;104-212-297-137-759;;010-953-281-569-514;;013-795-151-218-458;;092-334-939-903-42X;;014-277-808-472-992;;061-754-151-573-898;;113-327-994-370-771;;006-553-734-546-212;;068-238-957-669-243;;105-316-874-895-908;;056-201-471-905-934;;028-862-168-091-90X;;040-701-579-915-050;;018-694-084-068-187;;104-557-841-648-936;;034-441-292-442-799;;038-895-768-831-047;;132-281-029-747-299;;087-667-912-261-011;;001-835-514-097-551;;002-377-881-851-166;;038-595-729-934-153;;065-102-359-566-736;;042-204-626-457-327;;006-574-964-805-278;;030-323-674-660-051;;092-023-577-402-127;;022-179-293-052-569;;088-086-720-613-343;;010-488-381-022-259;;082-210-673-349-152;;004-458-031-333-650;;041-909-244-299-232;;078-432-639-041-575;;042-740-484-382-110;;004-458-031-333-650;;003-752-183-823-430;;070-318-112-524-781;;071-163-081-597-04X;;035-135-729-507-737;;094-685-907-794-422;;062-029-719-290-327;;070-624-200-848-669;;012-746-915-512-650;;038-478-749-169-986;;035-554-935-107-802;;099-647-105-451-350;;009-621-637-014-514;;100-985-030-110-978;;030-630-100-818-462;;106-753-778-592-300;;032-820-729-763-323;;083-549-078-331-651;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;033-754-369-798-314;;077-525-954-203-403;;028-969-172-280-017;;060-375-551-951-388;;020-753-772-581-741;;038-613-711-274-229;;047-951-914-695-080;;062-485-301-455-912;;038-613-711-274-229;;023-676-781-371-861;;026-744-100-669-883;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;012-300-595-074-789;;031-815-870-004-331;;040-841-912-862-912;;011-583-491-184-648;;126-659-091-098-052;;038-166-075-279-931;;083-079-509-375-354;;043-654-077-374-418;;084-388-182-984-099;;042-354-196-879-741;;005-112-559-456-657;;052-219-543-437-800;;007-364-858-655-289;;056-942-841-068-650;;107-302-749-967-437;;039-238-464-990-600;;036-564-551-324-053;;020-123-860-433-320;;011-516-147-270-264;;020-986-423-793-233;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;007-709-585-201-038;;056-422-417-058-69X;;005-022-447-377-963;;127-416-339-660-812;;098-407-145-404-736;;066-749-017-721-197;;001-467-559-709-949;;049-089-244-500-629;;078-061-292-153-737;;055-646-175-554-792;;129-390-507-012-794;;008-213-515-306-640;;053-703-232-770-99X;;033-109-855-318-388;;030-249-121-435-10X;;001-091-081-800-619,pmc21029;;9177197;;10.1073/pnas.94.12.6216;;pmc299905;;14608036;;10.1073/pnas.2334901100;;15771565;;10.1146/annurev.immunol.23.021704.115839;;10.1038/ni759;;11812990;;16140769;;pmc1212625;;10.1128/jvi.79.18.11935-11942.2005;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1038/nbt1135;;16151405;;9780179;;10.4049/jimmunol.161.8.4083;;10.1385/0896033759;;10.4049/jimmunol.137.11.3614;;2431039;;10.1016/0042-6822(90)90025-m;;1693247;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;8424945;;10.1021/bi00055a024;;10556249;;10.1093/protein/12.10.879;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;7521646;;10.1038/nbt0994-899;;10.1126/science.2471267;;2471267;;16263307;;10.1016/j.jasms.2005.09.008;;10.1021/bi00161a011;;1332755;;10.1021/bi00078a011;;7687462;;15299382;;10.1107/s0907444994001344;;2185018;;10.1111/j.1432-1033.1990.tb15454.x;;9351804;;10.1016/s0969-2126(97)00279-7;;977570;;10.1016/s0021-9258(20)81858-4;;15299544;;10.1107/s0907444992010400;;27799107;;10.1016/s0076-6879(97)76070-1;;3127726;;10.1038/332323a0;;10.1038/321522a0;;3713831;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;19896358;;10.1016/j.copbio.2009.10.011;;14699147;;10.1074/jbc.c300470200;;10.4049/jimmunol.176.1.346;;16365427;;11096108;;10.1074/jbc.m009483200;;12391234;;10.4049/jimmunol.169.9.5171;;10.1074/jbc.m604292200;;16793771;;10.4049/jimmunol.0804182;;19494290;;11096108;;10.1074/jbc.m009483200;;11986321;;10.1074/jbc.m202069200;;10.1038/6179;;10052355;;10.1146/annurev.bi.41.070172.003325;;4563441;;10.4049/jimmunol.172.9.5489;;15100290;;2459288;;pmc2189025;;10.1084/jem.168.3.1099;;12042244;;10.1093/glycob/12.4.43r;;10.1038/316452a0;;3927174;;11275255;;10.1016/s0161-5890(00)00105-x;;10.2174/1389201023378229;;12463418;;10.1023/b:pham.0000008042.15988.c0;;14725359;;10397155;;10.1016/s0165-2478(99)00029-2;;10.1093/chromsci/40.6.343;;12137207;;8644915;;10.1021/ac00116a002;;10.1038/348552a0;;2247164;;1172191;;10.1038/256495a0;;8159246;;10.1038/368856a0;;10.1007/978-3-642-78432-3_3;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;8144892;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nbt727;;12172556;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1126/science.3929380;;3929380;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;10.1016/j.cbpa.2009.03.023;;19414278;;10.1002/anie.200801313;;19072788;;10.1039/b908687k;;19675886;;10.1002/cbic.200800801;;19130455;;10.1016/j.chembiol.2008.01.007;;18291317;;19924746;;pmc4878437;;10.1002/anie.200903627;;10.1021/bc800294a;;19191567;;6239899;;10.1084/jem.160.6.1686;;pmc2187539;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;3833240;;10.1126/science.3925553;;3925553;;2958547;;10.4049/jimmunol.139.7.2367;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;3390170;;10.1016/s0006-291x(88)81333-0;;10.1128/aac.39.1.180;;pmc162506;;7695303;;7907597;;10.1016/s0021-9258(17)37081-3;;10.1016/0014-5793(94)00313-0;;8206150;;7820457;;10.1006/immu.1994.1029;;15470033;;10.4049/jimmunol.173.8.4919;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;9624003;;10.1038/30989;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;9930702;;10.1038/16717;;10417377;;10.1126/science.285.5427.546;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;11514604;;10.3410/f.1000338.7202;;pmc2193490;;10.1084/jem.194.4.481;;pmc15881;;10.1073/pnas.96.6.2982;;10077623;;10.1097/00002371-199601000-00009;;8859727;;10.1038/22124;;10408445;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;9850053;;10.1038/nm735;;12118245;;10.3410/f.1008846.113460;;15930300;;10.1158/0008-5472.can-04-3319;;22918247;;10.4161/cc.21842;;pmc3466534,"NOCENTINI ET AL., PNAS, vol. 94, 1997, pages 6216 - 21;;TONE ET AL., PNAS, vol. 100, 2003, pages 15059 - 64;;WATTS, ANNUAL REVIEWS IN IMMUNOLOGY, vol. 23, 2005, pages 23 - 68;;SHIMIZU ET AL., NATURE IMMUNOLOGY, vol. 3, 2002, pages 135 - 42;;STEPHANS ET AL., JI, vol. 173, no. 8, 15 December 2003 (2003-12-15), pages 5008 - 20;;SUVAS ET AL., J VIROL., vol. 79, 2005, pages 11935 - 42;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;SONGSIVILAI; LACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;LONBERG, NATURE BIOTECH., vol. 23, no. 9, 2005, pages 1117 - 1125;;JEFFERIS ET AL., MABS, vol. 1, 2009, pages 1;;ROUX ET AL., J. IMMUNOL., vol. 161, 1998, pages 4083;;ROUX ET AL., J IMMUNOL, vol. 161, 1998, pages 4083;;G. E. MORRIS,: ""Epitope Mapping Protocols in Methods in Molecular Biology"", vol. 66, 1996;;ED HARLOW; DAVID LANE: ""Using Antibodies"", 1999, COLD SPRING HARBOR LABORATORY PRESS;;STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 9, 1983, pages 242;;KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR PRESS;;MOREL ET AL., MOL. IMMUNOL., vol. 25, no. 1, 1988, pages 7;;CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546;;MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77;;BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187;;KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999, pages 879 - 884;;BURKS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 412 - 417;;E. MEYERS; W. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;F. AUSUBEL, ET AL.,: ""Current Protocols in Molecular Biology"", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;;JESPERS ET AL., BIOTECHNOLOGY, vol. 12, 1994, pages 899;;CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;WEI ET AL., DRUG DISCOVERY TODAY, vol. 19, 2014, pages 95;;HAMBLEY; GROSS, J. AMERICAN SOC. MASS SPECTROMETRY, vol. 16, 2005, pages 2057;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 31, 1992, pages 11335 - 11347;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 32, 1993, pages 6884 - 6891;;GIEGE ET AL., ACTA CRYSTALLOGR., vol. D50, 1994, pages 339 - 350;;MCPHERSON, EUR. J. BIOCHEM., vol. 189, 1990, pages 1 - 23;;CHAYEN, STRUCTURE, vol. 5, 1997, pages 1269 - 1274;;MCPHERSON, J. BIOL. CHEM., vol. 251, 1976, pages 6300 - 6303;;SCOPES: ""Protein Purification: Principles and Practice, Third ed.,"", 1994, SPRINGER-VERLAG;;BLUNDELL; JOHNSON ET AL.: ""Meth. Enzymol."", 1985, ACADEMIC PRESS, pages: 114,115;;BRICOGNE, ACTA CRYST., vol. D49, 1993, pages 37 - 60;;BRICOGNE: ""Meth. Enzymol."", vol. 276A, 1997, pages: 361 - 423;;ROVERSI ET AL., ACTA CRYST., vol. D56, 2000, pages 1313 - 1323;;RIECHMANN, L. ET AL., NATURE, vol. 332, 1998, pages 323 - 327;;JONES, P. ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;QUEEN, C. ET AL., PROC. NATL. ACAD. SEE. U.S.A., vol. 86, 1989, pages 10029 - 10033;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest, Fifth Edition,"", 1991;;TOMLINSON, I. M. ET AL.: ""The Repertoire of Human Germline V Sequences Reveals about Fifty Groups of V Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: doi:10.1016/0022-2836(92)90223-7;;COX, J. P. L. ET AL.: ""A Directory of Human Germ-line V Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;MOLEC. IMMUNOL, vol. 29, no. 5, 1992, pages 633 - 9;;STROHL, CURRENT OPINION IN BIOTECHNOLOGY, vol. 20, 2009, pages 685 - 691;;PAUL, W. E.,: ""Fundamental Immunology, 4th Ed.,"", 1999, LIPPINCOTT-RAVEN;;HINTON ET AL., J, BIOL. CHEM., vol. 279, no. 8, 2004, pages 6213 - 6216;;HINTON ET AL., JOURNAL OF IMMUNOLOGY, vol. 176, 2006, pages 346 - 356;;SHIELDS ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 9, 2001, pages 6591 - 6604;;DALL ACQUA ET AL., JOURNAL OF IMMUNOLOGY, vol. 169, 2002, pages 5171 - 5180;;DALL'ACQUA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, 2006, pages 23514 - 23524;;YEUNG ET AL., J IMMUNOL, vol. 182, 2010, pages 7663 - 7671;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;SHIELDS, R.L ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;MARSHALL ET AL., ANNU REV BIOCHEM, vol. 41, 1972, pages 673 - 702;;GALA; MORRISON, J. IMMUNOL, vol. 172, 2004, pages 5489 - 94;;WALLICK ET AL., J EXP MED, vol. 168, 1988, pages 1099 - 109;;SPIRO, GLYCOBIOLOGY, vol. 12, 2002, pages 43R - 56R;;PAREKH ET AL., NATURE, vol. 316, 1985, pages 452 - 7;;MIMURA ET AL., MOL IMMUNOL, vol. 37, 2000, pages 697 - 706;;KRISHNAMURTHY R; MANNING M C, CURR PHARM BIOTECHNOL, vol. 3, 2002, pages 361 - 71;;CHEN ET AL., PHARM RES, vol. 20, 2003, pages 1952 - 60;;GHIRLANDO ET AL., IMMUNOL LETT, vol. 68, 1999, pages 47 - 52;;MURRAY ET AL., J. CHROMATOGR SCI, vol. 40, 2002, pages 343 - 9;;ALEXANDER A J; HUGHES D E, ANAL CHEM, vol. 67, 1995, pages 3626 - 32;;KABAT, E. A.: ""Sequences of Proteins of Immunological Interest Fifth Edition,"", 1991, NIH PUBLICATION NO. 91-3242;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest Fifth Edition,"", 1991, NIH PUBLICATION NO. 91-3242;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;LONBERG, N.: ""Handbook of Experimental Pharmacology"", vol. 113, 1994, pages: 49 - 101;;LONBERG, N.; HUSZAR, D., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F.; LONBERG, N., ANN. N.Y. ACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 3720 - 3724;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J ET AL., EMBO J., vol. 12, 1993, pages 821 - 830;;TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;TOMIZUKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727;;KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894;;FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;MORRISON, S, SCIENCE, vol. 229, 1985, pages 1202;;GOEDDEL: ""Gene Expression Technology. Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;TAKEBE, Y. ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;BOSS, M. A; WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMAN; P. A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;SENTER, P. D., CURR. OPIN. CHEM. BIOL., vol. 13, 2009, pages 235 - 244;;HACKENBERGER, C. P. R.; SCHWARZER, D., ANGEW. CHEM. INT. ED. ENGL., vol. 47, 2008, pages 10030 - 10074;;SUNBUL, M.; YIN, J., ORG. BIOMOL. CHEM., vol. 7, 2009, pages 3361 - 3371;;FRESE, M. A.; DIERKS, T., CHEMBIOCHEM., vol. 10, 2009, pages 425 - 427;;TAKI, M. ET AL., PROT. ENG. DES. SEL, vol. 17, 2004, pages 119 - 126;;GAUTIER, A. ET AL., CHEM. BIOL., vol. 15, 2008, pages 128 - 136;;BORDUSA, F., HIGHLIGHTS IN BIOORGANIC CHEMISTRY, 2004, pages 389 - 403;;REN, H. ET AL., ANGEW. CHEM. INT. ED. ENGL., vol. 48, 2009, pages 9658 - 9662;;DE GRAAF, A. J ET AL., BIOCONJUG. CHEM., vol. 20, 2009, pages 1281 - 1295;;KARPOVSKY ET AL., J. EXP. MED., vol. 160, 1984, pages 1686;;LIU, MA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 8648;;PAULUS, BEHRING INS. MITT. NO. 78, 1985, pages 118 - 132;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83;;GLENNIE ET AL., J. IMMUNOL., vol. 139, 1987, pages 2367 - 2375;;BERGE, S.M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;J.R. ROBINSON,: ""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;V.V. RANADE, J. CLIN. PHARMACOL, vol. 29, 1989, pages 685;;UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN, vol. 153, 1988, pages 1038;;P.G. BLOEMAN ET AL., FEBS LETT., vol. 357, 1995, pages 140;;M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 39, 1995, pages 180;;BRISCOE ET AL., AM. J. PHYSIOL., vol. 1233, 1995, pages 134;;SCHREIER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 9090;;K. KEINANEN; M.L. LAUKKANEN, FEBS LETT., vol. 346, 1994, pages 123;;J.J. KILLION; I.J. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;ROSENBERG, S.: ""Development of Cancer Vaccines"", ASCO EDUCATIONAL BOOK SPRING, 2000, pages 60 - 62;;LOGOTHETIS, C., ASCO EDUCATIONAL BOOK SPRING, 2000, pages 300 - 302;;KHAYAT, D.: ""ASCO Educational Book Spring"", 2000, pages: 414 - 428;;FOON, K.: ""ASCO Educational Book Spring"", 2000, pages: 730 - 738;;RESTIFO, N.; SZNOL, M. ET AL.: ""Cancer Vaccines"", 1997, pages: 3023 - 3043;;DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, S A, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT; SRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARD; O'GARRA, IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;RIDGE ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;WEINBERG ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;GREENBERG; RIDDELL, SCIENCE, vol. 285, 1999, pages 546 - 51;;HOLLIGER, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;VAN ELSAS ET AL., J. EXP. MED., vol. 194, 2001, pages 481 - 489;;OVERWIJK ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 96, 1999, pages 2982 - 2987;;ROSENBERG; WHITE, J. IMMUNOTHER EMPHASIS TUMOR IMMUNOL, vol. 19, no. 1, 1996, pages 81 - 4;;SCHENK ET AL., NATURE, vol. 400, 1999, pages 173 - 177;;TANSEY, DRUG DISCOVERY TODAY, 2009, pages 1;;HURWITZ ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071;;CAMACHO ET AL., J. CLIN. ONCOLOGY, vol. 22, no. 145, 2004;;MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304;;FULDA ET AL., NAT MED, vol. 8, 2002, pages 808 - 15;;HYER ET AL., CANCER RESEARCH, vol. 65, 2005, pages 4799 - 808;;""Physicians' Desk Reference (PDR)"", 1996, MEDICAL ECONOMICS COMPANY;;LI ET AL., CELL CYCLE, vol. 11, 2012, pages 3343 - 3344",PENDING
223,MX,A,MX 2016015456 A,127-992-238-453-369,2017-02-23,2017,MX 2016015456 A,2015-06-03,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF.,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid- inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,HAICHUN HUANG;;NILS LONBERG;;ALAN J KORMAN;;MARK J SELBY;;KARLA HENNING;;CHANGYU WANG;;MOHAN SRINIVASAN;;MICHELLE MINHUA HAN;;INDRANI CHAKRABORTY;;SUSAN WONG;;GUODONG CHEN;;RICHARD HUANG;;HUIMING LI,,https://lens.org/127-992-238-453-369,Patent Application,no,0,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61K39/00;;C07K16/28;;A61P35/00,,0,0,,,,ACTIVE
224,US,A1,US 2020/0079865 A1,003-311-189-401-235,2020-03-12,2020,US 201916578987 A,2019-09-23,US 201916578987 A;;US 2015/0033991 W;;US 201715646558 A;;US 201514949424 A;;US 201514732082 A;;US 201462082980 P;;US 201462008945 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2015-07-22),https://lens.org/003-311-189-401-235,Patent Application,yes,0,8,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61K39/395;;C07K16/28;;G01N33/574;;G01N33/68,,0,0,,,,ACTIVE
225,US,B2,US 10465010 B2,094-275-667-148-314,2019-11-05,2019,US 201715646558 A,2017-07-11,US 201715646558 A;;US 2015/0033991 W;;US 201514949424 A;;US 201514732082 A;;US 201462082980 P;;US 201462008945 P,2014-06-06,Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2015-07-22),https://lens.org/094-275-667-148-314,Granted Patent,yes,80,5,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/00;;A61K39/00;;A61K39/395;;A61K47/68;;C07H21/00;;C07K16/28;;G01N33/574;;G01N33/68,,72,45,171-614-306-115-108;;086-268-955-647-163;;136-116-610-765-69X;;084-334-863-236-818;;019-741-156-878-521;;029-382-279-785-035;;009-483-512-107-343;;019-459-691-036-036;;087-404-567-384-381;;128-554-308-094-91X;;020-296-196-517-635;;055-706-543-681-974;;044-673-845-363-528;;056-584-393-786-220;;070-164-938-901-37X;;005-119-615-003-591;;013-323-148-570-367;;022-259-501-579-745;;055-329-732-668-508;;011-405-827-983-549;;141-244-428-002-001;;143-287-907-926-845;;124-353-299-096-166;;012-369-544-741-057;;055-677-065-531-946;;010-916-105-450-247;;019-791-912-221-046;;078-111-385-767-730;;017-588-579-721-840;;016-276-447-231-541;;045-714-831-915-963;;071-886-484-965-256;;145-500-434-317-873;;012-108-483-329-37X;;083-410-991-104-604;;013-888-189-100-394;;112-871-461-451-205;;110-748-788-527-236;;082-582-794-395-339;;124-668-123-456-128;;039-943-095-184-294;;050-463-287-173-296;;051-374-571-260-065;;004-189-544-863-902;;043-054-515-242-505,21304271;;10.4161/mabs.3.2.14939;;pmc3092615;;20563707;;10.1007/82_2010_49;;pmc4060248;;12444126;;10.4049/jimmunol.169.11.6210;;7506686;;10.1016/0378-1119(93)90258-5;;15484187;;10.1002/eji.200324632;;10.1084/jem.20130573;;23897982;;pmc3754864;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;20480365;;10.1007/s00262-010-0866-5;;20454651;;pmc2862699;;10.1371/journal.pone.0010436;;10.1158/0008-5472.can-05-2813;;16651447;;pmc2242844;;9373310;;10.1016/s1380-2933(96)00045-0;;10.1016/s1074-7613(04)00054-8;;15030773;;15374887;;10.1182/blood-2004-06-2467;;10.3410/f.1001160.6701;;11520463;;10.1016/s1074-7613(01)00183-2;;10074428;;10.1016/s0960-9822(99)80093-1;;10.1016/0022-2836(92)90639-2;;1507232;;14573361;;10.1016/j.tibtech.2003.08.007;;10.1182/blood-2008-07-170274;;pmc2668854;;18941113;;10.4049/jimmunol.172.12.7306;;15187106;;23980122;;pmc3754862;;10.1084/jem.20131625;;17671218;;10.1158/0008-5472.can-06-4639;;10.1084/jem.20050940;;pmc2213162;;10.1084/jem.200509402092c;;16186187;;10.3410/f.1028385.337176;;10037686;;10.1074/jbc.274.10.6056;;10.1016/s0167-5699(00)01668-6;;10916138;;10.1186/1479-5876-12-36;;24502656;;pmc4104995;;10.1038/nbt0792-779;;1368267;;10.1016/s1074-7613(02)00280-7;;11869690;;pmc4397897;;23460535;;10.1158/1078-0432.ccr-13-0598;;10.1158/1078-0432.ccr-12-2065;;10.1158/1078-0432.ccr-12-2214;;23460531;;10.1158/1078-0432.ccr-09-3243;;20460483;;pmc21029;;9177197;;10.1073/pnas.94.12.6216;;10.1002/eji.200425818;;15770698;;10836847;;10.1038/sj.cdd.4400670;;10.1186/s40425-016-0132-2;;27822377;;pmc5096004;;27190629;;10.1186/s40425-016-0181-6;;pmc4869343;;10.1111/j.1365-2567.2009.03228.x;;20201988;;pmc2878467;;11533635;;10.1038/nbt0901-819;;10.1002/eji.200324804;;14991590;;10.1016/j.clim.2010.03.288;;21154120;;pmc3413251;;22245556;;10.1016/j.coi.2011.12.011;;10.1038/ni759;;11812990;;10.1084/jem.20041130;;15381730;;pmc2211964;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001;;9299585;;10.1006/scbi.1997.0058;;7490758;;10.1006/jmbi.1995.0626,"U.S. Appl. No. 14/949,424, filed Nov. 23, 2015, Changyu Wang.;;U.S. Appl. No. 15/369,290, filed Dec. 5, 2016, Changyu Wang.;;U.S. Appl. No. 14/732,082, filed Jun. 5, 2015, Changyu Wang.;;U.S. Appl. No. 14/949,424, Apr. 20, 2017, S. Shafer.;;U.S. Appl. No. 14/949,424, Apr. 13, 2017, S. Shafer.;;U.S. Appl. No. 14/949,424, Jan. 25, 2017, S. Shafer.;;U.S. Appl. No. 14/949,424, Nov. 4, 2016, S. Shafer.;;U.S. Appl. No. 14/732,082, Aug. 24, 2015, S. Shafer.;;U.S. Appl. No. 14/732,082, Jul. 13, 2015, S. Shafer.;;Hiroyoshi Nishikawa, “Application of Modulators of Cancer Immunosuppression for Immunotherapy—GITR and CTLA-4,” The Medical Frontline, vol. 64 (11): 100-105 (2009).;;Arnett, S. et al., “IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society,” Dec. 5-9, 2010, San Diego, CA USA, mAbs, vol. 3 (2), Mar./Apr. 2011, 133-152.;;Avogadri, F. et al., “Modulation of CTLA-4 and GITR for Cancer Immunotherapy,” Curr Top Microbiol Immunol, vol. 344, 2011, 211-244.;;Baecher-Allan, B. et al., “Inhibition of Human CD4+CD25+ high Regulatory T Cell Function,” J. Immunol., 2002, vol. 169, 6210-6217.;;Balint, R. et al., “Antibody Engineering by Parsimonious Mutagenesis,” Gene, 1993, vol. 137, 109-118.;;Birebent, B. et al., “Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression,” Eur. J. Immunol., 2004, vol. 34, 3485-3496.;;Bulliard, et al., “Activating Fc y receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies,” JEM , Aug. 2013, vol. 210 (9), 1685-1693.;;Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” PNAS, 1992, vol. 89, 4285-4289.;;Coe, D. et al., “Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy,” Cancer Immunol Immunother, 2010,vol. 59, 1367-1377.;;Cohen et al., “Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation,” PLoS, May 2010, vol. 5 Iss. 5, 1-12.;;Cohen et al., “Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody,” Blood, ASH Annual Meeting Abstracts, Dec. 8-11, 2007, vol. 110 (11), 1788.;;Cohen, et al., “Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+; T-Cell Responses and Tumor Immunity,” Cancer Res, 2006; vol. 66: (9), 4904-4912.;;Davies et al., “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen bnding,” Immunotechnology, 1996, vol. 2, 169-179.;;Dittmer et al., “Functional impairment of CD8+ T cellls by regulatory T cells during persistent retroviral infection,” Immunirty, 2004, vol. 20, 293-303.;;Glaus et al., “In vivo SPECT/CT imaging of an anti-GITR antibody: A novel cancer immunotherapeutic,” J Nucl Med. 2013; 54 (Supplement 2):327.;;Godrey et al., “Cord blood CD4+CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function,” Blood, Jan. 15, 2005, vol. 105 No. 2, 750-758.;;Gross et al., TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease: Impaired B Cell Maturation in Mice Lacking BLyS, (2001) Immunity vol. 15:289-302.;;Gurney et al., “Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR,” Current Biology, Feb. 25, 1999, vol. 9 (4), 215-218.;;Hawkins, R.E. et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,” J. Mol. Biol., 1992, vol. 226(3), 889-896.;;Holt, L. et al., “Domain antibodies: proteins for therapy,” Trends in Biotechnology, 2003, vol. 21 (11), 484-490.;;Houot et al., “T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy,” Blood, Apr. 9, 2009, vol. 113 (15), 3546-3552.;;International Preliminary Report on Patentability, PCT/US2015/033991, dated Dec. 6, 2016, 11 pages.;;International Search Report and Written Opinion for Application No. PCT/US2015/033991, 19 pages, dated Dec. 8, 2015.;;Kanamaru et al., “Costimulation via Glucocorticoid-Induced TNF Receptor in Both Conventional and CD25+ Regulatory CD4+ T Cells,” The Journal of Immunology, 2004, 7306-7314.;;Kim et al., “Fcy receptors enable anticancer action of proapoptotic and immune-modulatory antibodies,” J Exp Med Aug. 26, 2013, vol. 210 (9) 1647-1657.;;Ko et al., “A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model,” Cancer Research, Aug. 1, 2007, vol. 67 (15) 7477-7486.;;Ko et al., “Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+ CD4+ regulatory T cells,” JEM, Oct. 3, 2005, vol. 202 (7), 885-891.;;Kwon et al., “Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand,” Journal of Biol Chem, Mar. 5, 1999, vol. 274 (10) 6056-6061.;;Little et al., “Of Mice and Men: hybridoma and recombinant antibodies,” Immunology Today, 2000, vol. 21, (8), 364-370.;;Lu et al. “Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs,” Journal of Translational Medicine, 2014, vol. 12 (36), 1-11.;;Marks, J. et al, “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,” Biotechnology, 1992, vol. 10(7) 779-783.;;McHugh et al., “CD4+CD25+ Immunoregulatory T Cells: Gene Expression Analysis Reveals a Functional Role for the Glucocorticoid-Induced TNF Receptor,” Immunity, Feb. 16, 2002, vol. 16, 311-323.;;Melero et al., “Agonist Antibodies to TNFR Molecules That Costimulate Tand NK Cells,” Clinical Cancer Research, Mar. 1, 2013, vol. 19 (5), 1044-1053, 1913.;;Melero et al., “Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination,” Clinical Cancer Research, Mar. 1, 2013, vol. 19 (5), 997-1008.;;Melero, I., “Immunological targets: Basic aspects,” IL29, Annals of Oncology, vol. 22 (Supplement 3), 1 page, (2011) doi:10.1093/annonc/mdr103.;;Mitsui et al, “Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals,” Clinical Cancer Res, May 11, 2010, vol. 16, 2781-2791.;;National Cancer Institute, Immunotherapy Agent Workshop Jul. 12, 2007, 1-77.;;Nocentini et al., “A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis,” PNAS, Jun. 10, 1997, vol. 94, 6216-6221.;;Nocentini et al., “GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily,” Eur J of Immunol, Apr. 2005, vol. 35 Iss 4, 1016-1022.;;Nocentini et al., “Identification of three novel mRNA splice variants of GITR,” Cell Death and Differentiation, Apr. 2000, vol. 7, 408-410.;;Patel, M. et al., “Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma,” Journal for ImmunoTherapy of Cancer, vol. 4(28):14 pages (2016).;;Ponte et al., “Enhancement of humoral and cellular immunity with an antiglucocorticoid-induced tumour necrosis factor receptor monoclonal antibody,” Immunology, Jun. 2010, vol. 130, 231-242.;;Press Release, Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting, Cambridge, MA, Jun. 25, 2015, PR Newswire, 1-3.;;Printout from the R&D Systems website showing a list of available anti-GITR antibodies, Jul. 2, 2014, 1-2.;;Reichert, J. et al., “Monoclonal antibodies in the clinic,” Nat. Biotech, 2001, vol. 19, 819-822.;;Ronchetti et al., “GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations,” Eur J Immunol, 2004 vol. 34, 613-622.;;Rosenzweig et al., “Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR.,” ASCO Meeting Library 2010 Annual Meeting, 1-2.;;Schaer et al., “Anti-GITR antibodies—Potential Clinical applications for tumor immunotherapy,” Curr Opin in Investigational Drugs, 2010, vol. 11 (12), 1378-1386.;;Schaer, et al. “Modulation of GITR for cancer immunotherapy,” Curr Opin in Immunol, Apr. 2012, vol. 24, 217-224.;;Shimizu et al., “Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance,” Nature Immunol, Feb. 2002, vol. 3 (2), 135-142.;;Turk, et al., “Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma is Prevented by Regulatory T Cells,” Journal of Exp Medicine, Sep. 20, 2004, vol. 200 (6) 771-782.;;U.S. Appl. No. 15/264,266, filed Sep. 13, 2016, Suba Krishnan.;;U.S. Appl. No. 15/369,290, Feb. 8, 2018, J. Roark.;;U.S. Appl. No. 60/665,322, filed Mar. 25, 2005, 62 pages.;;U.S. Appl. No. 60/687,265, filed Jun. 3, 2005, 71 pages.;;Website Information for human GITR/TNFRSF 18 MAb (Clone 110416), Catalog No. MAB589, 1-2.;;White, A. et al., “Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies,” Cancer Cell, vol. 27(1), pp. 138-148 (2015).;;Whiteside, S. et al., “IkB proteins: structure, function and regulation,” Seminars in Cancer Biology, 1997, vol. 8, 75-82.;;Yang, W. et al., “CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range,” J. Mol. Biol., 1995, vol. 254 (3), 392-403.;;U.S. Appl. No. 16/133,418, filed Sep. 17, 2018, Suba Krishnan.;;U.S. Appl. No. 15/776,591, filed May 16, 2018, Changyu Wang.;;U.S. Appl. No. 15/369,290, Nov. 8, 2018, J. Roark.;;U.S. Appl. No. 15/369,290, Jul. 16, 2018, J. Roark.",ACTIVE
226,KR,A,KR 20180127541 A,101-646-319-341-953,2018-11-28,2018,KR 20187033666 A,2015-06-03,US 201462008945 P;;US 201462082980 P;;US 2015/0033991 W,2014-06-06,- GITR ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR GITR AND USES THEREOF,"글루코코르티코이드-유도성 TNF 수용체 (GITR)와 결합하는 항체, 또는 그의 항원 결합 부분이 본원에 제공된다. 또한, 치료적 적용분야, 예컨대 암의 치료에서의 이들 단백질의 용도가 제공된다. 항체를 생성하는 세포, 항체의 중쇄 및/또는 경쇄 가변 영역을 코딩하는 폴리뉴클레오티드, 및 항체의 중쇄 및/또는 경쇄 가변 영역을 코딩하는 폴리뉴클레오티드를 포함하는 벡터가 추가로 제공된다.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/101-646-319-341-953,Patent Application,no,4,1,63,65,762,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/00;;A61K39/395;;C12N5/0783;;G01N33/574;;G01N33/68,,0,0,,,,ACTIVE
227,EP,A1,EP 3610924 A1,131-886-199-902-453,2020-02-19,2020,EP 19184566 A,2015-06-03,US 201462008945 P;;US 201462082980 P;;EP 15742414 A;;US 2015/0033991 W,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/131-886-199-902-453,Patent Application,yes,217,0,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/28,,145,117,029-382-279-785-035;;051-374-571-260-065;;045-714-831-915-963;;075-363-665-052-387;;079-191-303-518-861;;039-943-095-184-294;;073-108-237-457-07X;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;040-577-067-037-463;;104-212-297-137-759;;010-953-281-569-514;;013-795-151-218-458;;038-613-711-274-229;;068-238-957-669-243;;014-277-808-472-992;;061-754-151-573-898;;113-327-994-370-771;;006-553-734-546-212;;105-316-874-895-908;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;052-219-543-437-800;;040-701-579-915-050;;018-694-084-068-187;;104-557-841-648-936;;034-441-292-442-799;;038-895-768-831-047;;132-281-029-747-299;;087-667-912-261-011;;001-835-514-097-551;;002-377-881-851-166;;022-179-293-052-569;;038-595-729-934-153;;007-709-585-201-038;;006-574-964-805-278;;030-323-674-660-051;;092-023-577-402-127;;088-086-720-613-343;;070-318-112-524-781;;010-488-381-022-259;;082-210-673-349-152;;004-458-031-333-650;;041-909-244-299-232;;078-432-639-041-575;;042-740-484-382-110;;004-458-031-333-650;;003-752-183-823-430;;071-163-081-597-04X;;035-135-729-507-737;;094-685-907-794-422;;062-029-719-290-327;;070-624-200-848-669;;012-746-915-512-650;;038-478-749-169-986;;035-554-935-107-802;;099-647-105-451-350;;009-621-637-014-514;;100-985-030-110-978;;030-630-100-818-462;;106-753-778-592-300;;032-820-729-763-323;;060-375-551-951-388;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;077-525-954-203-403;;028-969-172-280-017;;020-753-772-581-741;;047-951-914-695-080;;062-485-301-455-912;;026-744-100-669-883;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;012-300-595-074-789;;031-815-870-004-331;;040-841-912-862-912;;011-583-491-184-648;;126-659-091-098-052;;038-166-075-279-931;;083-079-509-375-354;;043-654-077-374-418;;084-388-182-984-099;;042-354-196-879-741;;007-364-858-655-289;;056-942-841-068-650;;107-302-749-967-437;;039-238-464-990-600;;036-564-551-324-053;;020-123-860-433-320;;011-516-147-270-264;;020-986-423-793-233;;029-750-154-523-855;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;090-774-193-364-453;;053-703-232-770-99X;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;056-422-417-058-69X;;005-022-447-377-963;;098-407-145-404-736;;001-467-559-709-949;;049-089-244-500-629;;078-061-292-153-737;;055-646-175-554-792;;008-213-515-306-640;;053-703-232-770-99X;;033-109-855-318-388;;030-249-121-435-10X;;001-091-081-800-619,10.1084/jem.20130573;;23897982;;pmc3754864;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001;;pmc21029;;9177197;;10.1073/pnas.94.12.6216;;pmc299905;;14608036;;10.1073/pnas.2334901100;;15771565;;10.1146/annurev.immunol.23.021704.115839;;10.1038/ni759;;11812990;;16140769;;pmc1212625;;10.1128/jvi.79.18.11935-11942.2005;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1038/nbt1135;;16151405;;9780179;;10.4049/jimmunol.161.8.4083;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10556249;;10.1093/protein/12.10.879;;10.4049/jimmunol.137.11.3614;;2431039;;10.1016/0042-6822(90)90025-m;;1693247;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;8424945;;10.1021/bi00055a024;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;2958547;;10.4049/jimmunol.139.7.2367;;7521646;;10.1038/nbt0994-899;;10.1126/science.2471267;;2471267;;16263307;;10.1016/j.jasms.2005.09.008;;10.1021/bi00161a011;;1332755;;10.1021/bi00078a011;;7687462;;15299382;;10.1107/s0907444994001344;;2185018;;10.1111/j.1432-1033.1990.tb15454.x;;9351804;;10.1016/s0969-2126(97)00279-7;;977570;;10.1016/s0021-9258(20)81858-4;;10.1002/eji.1830240409;;8149953;;15299544;;10.1107/s0907444992010400;;9624003;;10.1038/30989;;10.1038/321522a0;;3713831;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;1404388;;10.1016/0022-2836(92)90223-7;;19896358;;10.1016/j.copbio.2009.10.011;;10.1038/6179;;10052355;;14699147;;10.1074/jbc.c300470200;;10.4049/jimmunol.176.1.346;;16365427;;11096108;;10.1074/jbc.m009483200;;12391234;;10.4049/jimmunol.169.9.5171;;10.1074/jbc.m604292200;;16793771;;10.4049/jimmunol.0804182;;19494290;;11096108;;10.1074/jbc.m009483200;;11986321;;10.1074/jbc.m202069200;;10.1146/annurev.bi.41.070172.003325;;4563441;;10.4049/jimmunol.172.9.5489;;15100290;;2459288;;pmc2189025;;10.1084/jem.168.3.1099;;12042244;;10.1093/glycob/12.4.43r;;10.1038/316452a0;;3927174;;11275255;;10.1016/s0161-5890(00)00105-x;;10.2174/1389201023378229;;12463418;;10.1023/b:pham.0000008042.15988.c0;;14725359;;10397155;;10.1016/s0165-2478(99)00029-2;;10.1093/chromsci/40.6.343;;12137207;;8644915;;10.1021/ac00116a002;;10.1038/348552a0;;2247164;;1172191;;10.1038/256495a0;;8159246;;10.1038/368856a0;;8144892;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;10.1093/intimm/6.4.579;;8018598;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nbt727;;12172556;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;10.1016/j.cbpa.2009.03.023;;19414278;;10.1002/anie.200801313;;19072788;;10.1039/b908687k;;19675886;;10.1002/cbic.200800801;;19130455;;10.1016/j.chembiol.2008.01.007;;18291317;;19924746;;pmc4878437;;10.1002/anie.200903627;;10.1021/bc800294a;;19191567;;6239899;;10.1084/jem.160.6.1686;;pmc2187539;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;3833240;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;3390170;;10.1016/s0006-291x(88)81333-0;;10.1128/aac.39.1.180;;pmc162506;;7695303;;7907597;;10.1016/s0021-9258(17)37081-3;;10.1016/0014-5793(94)00313-0;;8206150;;7820457;;10.1006/immu.1994.1029;;15470033;;10.4049/jimmunol.173.8.4919;;10700237;;10.1038/73193;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9500607;;10.1038/nm0398-328;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;10417377;;10.1126/science.285.5427.546;;10.1016/s0969-2126(94)00113-8;;7704521;;11514604;;10.3410/f.1000338.7202;;pmc2193490;;10.1084/jem.194.4.481;;pmc15881;;10.1073/pnas.96.6.2982;;10077623;;10.1097/00002371-199601000-00009;;8859727;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;9850053;;10.1038/nm735;;12118245;;10.3410/f.1008846.113460;;15930300;;10.1158/0008-5472.can-04-3319;;22918247;;10.4161/cc.21842;;pmc3466534,"BULLIARD YANNICK ET AL: ""Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies"", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 210, no. 9, 26 August 2013 (2013-08-26), pages 1685 - 1693, XP009176020, ISSN: 0022-1007;;ANN L. WHITE ET AL: ""Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies"", CANCER CELL, vol. 27, no. 1, 1 January 2015 (2015-01-01), pages 138 - 148, XP055193819, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2014.11.001;;NOCENTINI ET AL., PNAS, vol. 94, 1997, pages 6216 - 21;;TONE ET AL., PNAS, vol. 100, 2003, pages 15059 - 64;;WATTS, ANNUAL REVIEWS IN IMMUNOLOGY, vol. 23, 2005, pages 23 - 68;;SHIMIZU ET AL., NATURE IMMUNOLOGY, vol. 3, 2002, pages 135 - 42;;STEPHANS ET AL., JI2004, vol. 173, no. 8, pages 5008 - 20;;SUVAS ET AL., J VIROL, vol. 79, 2005, pages 11935 - 42;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;SONGSIVILAILACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;LONBERG, NATURE BIOTECH, vol. 23, no. 9, 2005, pages 1117 - 1125;;JEFFERIES ET AL., MABS, vol. 1, 2009, pages 1;;ROUX ET AL., J. IMMUNOL., vol. 161, 1998, pages 4083;;ROUX ET AL., J IMMUNOL, vol. 161, 1998, pages 4083;;FISHWILD, D ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;ED HARLOWDAVID LANE, COLD SPRING HARB PROTOC, 2006;;KOBAYASHI ET AL., PROTEIN ENG, vol. 12, no. 10, 1999, pages 879 - 884;;STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 9, 1983, pages 242;;KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614;;MOREL ET AL., MOL. IMMUNOL., vol. 25, no. 1, 1988, pages 7;;CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546;;MOLDENHAUER ET AL.: ""32"", SCAND. J. IMMUNOL., 1990, pages 77;;BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187;;BURKS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 412 - 417;;E. MEYERSW. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17;;NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;GLENNIE ET AL., J. IMMUNOL., vol. 139, 1987, pages 2367 - 2375;;""GENBANKO"", Database accession no. NM020219;;JESPERS ET AL., BIOTECHNOLOGY, vol. 12, 1994, pages 899;;CUNNINGHAMWELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;WEI ET AL., DRUG DISCOVERY TODAY, vol. 19, 2014, pages 95;;HAMBLEYGROSS, J. AMERICAN SOC. MASS SPECTROMETRY, vol. 16, 2005, pages 2057;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 31, 1992, pages 11335 - 11347;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 32, 1993, pages 6884 - 6891;;GIEGE ET AL., ACTA CRYSTALLOGR, vol. D50, 1994, pages 339 - 350;;MCPHERSON, EUR. J. BIOCHEM., vol. 189, 1990, pages 1 - 23;;CHAYEN, STRUCTURE, vol. 5, 1997, pages 1269 - 1274;;MCPHERSON, J. BIOL. CHEM., vol. 251, 1976, pages 6300 - 6303;;COX, J. P. L. ET AL.: ""A Directory of Human Germ-line V Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;TAMURA ET AL., SCIENCE, vol. 276A, 1997, pages 114,115 - 120;;BRICOGNE, ACTA CRYST, vol. D49, 1993, pages 37 - 60;;ROVERSI ET AL., ACTA CRYST, vol. D56, 2000, pages 1313 - 1323;;RIECHMANN, L ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;JONES, P ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;QUEEN, C ET AL., PROC. NATL. ACAD. SEE. U.S.A., vol. 86, 1989, pages 10029 - 10033;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NIH PUBLICATION;;TOMLINSON, I. M. ET AL.: ""The Repertoire of Human Germline V Sequences Reveals about Fifty Groups of V Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: doi:10.1016/0022-2836(92)90223-7;;MOLEC. IMMUNOL., vol. 29, no. 5, 1992, pages 633 - 9;;STROHL, CURRENT OPINION IN BIOTECHNOLOGY, vol. 20, 2009, pages 685 - 691;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;HINTON ET AL., J. BIOL. CHEM., vol. 279, no. 8, 2004, pages 6213 - 6216;;HINTON ET AL., JOURNAL OF IMMUNOLOGY, vol. 176, 2006, pages 346 - 356;;SHIELDS ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 9, 2001, pages 6591 - 6604;;DALL ACQUA ET AL., JOURNAL OF IMMUNOLOGY, vol. 169, 2002, pages 5171 - 5180;;DALL'ACQUA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, 2006, pages 23514 - 23524;;YEUNG ET AL., J IMMUNOL, vol. 182, 2010, pages 7663 - 7671;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;MARSHALL ET AL., ANNU REV BIOCHEM, vol. 41, 1972, pages 673 - 702;;GALAMORRISON, J. IMMUNOL, vol. 172, 2004, pages 5489 - 94;;WALLICK ET AL., J EXP MED, vol. 168, 1988, pages 1099 - 109;;SPIRO, GLYCOBIOLOGY, vol. 12, 2002, pages 43R - 56R;;PAREKH ET AL., NATURE, vol. 316, 1985, pages 452 - 7;;MIMURA ET AL., MOL IMMUNOL, vol. 37, 2000, pages 697 - 706;;KRISHNAMURTHY RMANNING M C, CURR PHARM BIOTECHNOL, vol. 3, 2002, pages 361 - 71;;CHEN ET AL., PHARM RES, vol. 20, 2003, pages 1952 - 60;;GHIRLANDO ET AL., IMMUNOL LETT, vol. 68, 1999, pages 47 - 52;;MURRAY ET AL., J. CHROMATOGR SCI, vol. 40, 2002, pages 343 - 9;;ALEXANDER A JHUGHES D E, ANAL CHEM, vol. 67, 1995, pages 3626 - 32;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;LONBERG, NHUSZAR, D, INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, FLONBERG, N, ANN. N.Y. ACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR, L ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J ET AL., EMBO J., vol. 12, 1993, pages 821 - 830;;TAYLOR, L ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;TOMIZUKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727;;KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 1202 - 83;;GOEDDEL: ""Gene Expression Technology. Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;TAKEBE, Y ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;BOSS, M. A.WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUBCHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMANP. A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;SENTER, P. D., CURR. OPIN. CHEM. BIOL., vol. 13, 2009, pages 235 - 244;;HACKENBERGER, C. P. R.SCHWARZER, D., ANGEW. CHEM. INT. ED. ENGL., vol. 47, 2008, pages 10030 - 10074;;SUNBUL, MYIN, J., ORG. BIOMOL. CHEM., vol. 7, 2009, pages 3361 - 3371;;FRESE, M. A.DIERKS, T., CHEMBIOCHEM, vol. 10, 2009, pages 425 - 427;;TAKI, M ET AL., PROT. ENG. DES. SEL., vol. 17, 2004, pages 119 - 126;;GAUTIER, A ET AL., CHEM. BIOL., vol. 15, 2008, pages 128 - 136;;BORDUSA, F., HIGHLIGHTS IN BIOORGANIC CHEMISTRY, 2004, pages 389 - 403;;REN, H ET AL., ANGEW. CHEM. INT. ED. ENGL., vol. 48, 2009, pages 9658 - 9662;;TAYLOR, E. VOGELIMPERIALI, B, NUCLEIC ACIDS AND MOLECULAR BIOLOGY, vol. 22, 2009, pages 65 - 96;;DE GRAAF, A. J. ET AL., BIOCONJUG. CHEM., vol. 20, 2009, pages 1281 - 1295;;KARPOVSKY ET AL., J. EXP. MED., vol. 160, 1984, pages 1686;;LIUMA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 8648;;PAULUS, BEHRING INS. MITT. NO., vol. 78, 1985, pages 118 - 132;;BERGE, S.M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;V.V. RANADE, J. CLIN. PHARMACOL., vol. 29, 1989, pages 685;;UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 153, 1988, pages 1038;;P.G. BLOEMAN ET AL., FEBS LETT, vol. 357, 1995, pages 140;;M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER, vol. 39, 1995, pages 180;;BRISCOE ET AL., AM. J. PHYSIOL., vol. 1233, 1995, pages 134;;SCHREIER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 9090;;K. KEINANENM.L. LAUKKANEN, FEBS LETT, vol. 346, 1994, pages 123;;J.J. KILLIONI.J. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;LOGOTHETIS, C., ASCO EDUCATIONAL BOOK SPRING, 2000, pages 414 - 428;;KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;RESTIFO, NSZNOL, M., CANCER VACCINES, CH., vol. 61, pages 3023 - 3043;;DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, S A, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOTSRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;MOKYR ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARD & O'GARRA, IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;WEINBERG ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF ET AL., NATURE, vol. 400, 1999, pages 173 - 177;;GREENBERGRIDDELL, SCIENCE, vol. 285, 1999, pages 546 - 51;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;VAN ELSAS ET AL., J. EXP. MED., vol. 194, 2001, pages 481 - 489;;OVERWIJK ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 96, 1999, pages 2982 - 2987;;ROSENBERGWHITE, J. IMMUNOTHER EMPHASIS TUMOR IMMUNOL, vol. 19, no. 1, 1996, pages 81 - 4;;HURWITZ ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071;;CAMACHO ET AL., J. CLIN. ONCOLOGY, vol. 22, 2004, pages 145;;MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304;;FULDA ET AL., NAT MED, vol. 8, 2002, pages 808 - 15;;HYER ET AL., CANCER RESEARCH, vol. 65, 2005, pages 4799 - 808;;""Physicians' Desk Reference (PDR"", 1996, MEDICAL ECONOMICS COMPANY;;LI ET AL., CELL CYCLE, vol. 11, 2012, pages 3343 - 3344",ACTIVE
228,EP,B1,EP 3610924 B1,151-787-760-137-577,2021-11-03,2021,EP 19184566 A,2015-06-03,US 201462008945 P;;US 201462082980 P;;EP 15742414 A;;US 2015/0033991 W,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/151-787-760-137-577,Granted Patent,yes,5,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,A61P35/00;;A61K39/00;;C07K16/28,,2,0,,,"BULLIARD YANNICK ET AL: ""Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies"", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 210, no. 9, 26 August 2013 (2013-08-26), pages 1685-1693, XP009176020, ISSN: 0022-1007;;ANN L. WHITE ET AL: ""Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies"", CANCER CELL, vol. 27, no. 1, 1 January 2015 (2015-01-01), pages 138-148, XP055193819, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2014.11.001",ACTIVE
229,US,B2,US 11802162 B2,078-143-310-632-635,2023-10-31,2023,US 201916663583 A,2019-10-25,US 201916663583 A;;US 201615369290 A;;US 2015/0033991 W;;US 201462082980 P;;US 201462008945 P,2014-06-06,Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2015-07-22),https://lens.org/078-143-310-632-635,Granted Patent,yes,116,0,63,65,394,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/00;;A61K39/395;;A61K47/68;;G01N33/574;;G01N33/68,,80,61,050-463-287-173-296;;051-374-571-260-065;;004-189-544-863-902;;043-054-515-242-505;;039-634-532-775-166;;045-706-253-475-176;;048-960-656-989-289;;037-103-075-806-573;;171-614-306-115-108;;086-268-955-647-163;;136-116-610-765-69X;;084-334-863-236-818;;019-741-156-878-521;;029-382-279-785-035;;009-483-512-107-343;;019-459-691-036-036;;087-404-567-384-381;;128-554-308-094-91X;;020-296-196-517-635;;055-706-543-681-974;;044-673-845-363-528;;056-584-393-786-220;;070-164-938-901-37X;;005-119-615-003-591;;013-323-148-570-367;;022-259-501-579-745;;055-329-732-668-508;;011-405-827-983-549;;141-244-428-002-001;;143-287-907-926-845;;124-353-299-096-166;;012-369-544-741-057;;055-677-065-531-946;;010-916-105-450-247;;019-791-912-221-046;;078-111-385-767-730;;017-588-579-721-840;;016-276-447-231-541;;045-714-831-915-963;;071-886-484-965-256;;145-500-434-317-873;;012-108-483-329-37X;;083-410-991-104-604;;013-888-189-100-394;;112-871-461-451-205;;082-582-794-395-339;;124-668-123-456-128;;039-943-095-184-294;;055-904-468-981-551;;008-019-042-176-997;;027-477-313-726-928;;030-950-631-666-077;;032-391-642-770-202;;097-339-730-628-695;;011-405-827-983-549;;008-117-373-727-019;;005-086-269-055-082;;120-141-881-915-542;;030-052-818-943-711;;008-727-266-329-179;;076-840-039-480-531,10.1084/jem.20041130;;15381730;;pmc2211964;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001;;9299585;;10.1006/scbi.1997.0058;;7490758;;10.1006/jmbi.1995.0626;;17360848;;10.1096/fj.06-7724com;;20734397;;10.1002/cncr.25371;;20012605;;10.1007/s00262-009-0803-7;;23856878;;10.1590/0037-8682-0029-2013;;21304271;;10.4161/mabs.3.2.14939;;pmc3092615;;20563707;;10.1007/82_2010_49;;pmc4060248;;12444126;;10.4049/jimmunol.169.11.6210;;7506686;;10.1016/0378-1119(93)90258-5;;15484187;;10.1002/eji.200324632;;10.1084/jem.20130573;;23897982;;pmc3754864;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;20480365;;10.1007/s00262-010-0866-5;;20454651;;pmc2862699;;10.1371/journal.pone.0010436;;10.1158/0008-5472.can-05-2813;;16651447;;pmc2242844;;9373310;;10.1016/s1380-2933(96)00045-0;;10.1016/s1074-7613(04)00054-8;;15030773;;15374887;;10.1182/blood-2004-06-2467;;10.3410/f.1001160.6701;;11520463;;10.1016/s1074-7613(01)00183-2;;10074428;;10.1016/s0960-9822(99)80093-1;;10.1016/0022-2836(92)90639-2;;1507232;;14573361;;10.1016/j.tibtech.2003.08.007;;10.1182/blood-2008-07-170274;;pmc2668854;;18941113;;10.4049/jimmunol.172.12.7306;;15187106;;23980122;;pmc3754862;;10.1084/jem.20131625;;17671218;;10.1158/0008-5472.can-06-4639;;10.1084/jem.20050940;;pmc2213162;;10.1084/jem.200509402092c;;16186187;;10.3410/f.1028385.337176;;10037686;;10.1074/jbc.274.10.6056;;10.1016/s0167-5699(00)01668-6;;10916138;;10.1186/1479-5876-12-36;;24502656;;pmc4104995;;10.1038/nbt0792-779;;1368267;;10.1016/s1074-7613(02)00280-7;;11869690;;pmc4397897;;23460535;;10.1158/1078-0432.ccr-13-0598;;10.1158/1078-0432.ccr-12-2065;;10.1158/1078-0432.ccr-12-2214;;23460531;;10.1158/1078-0432.ccr-09-3243;;20460483;;pmc21029;;9177197;;10.1073/pnas.94.12.6216;;10.1002/eji.200425818;;15770698;;10836847;;10.1038/sj.cdd.4400670;;10.1186/s40425-016-0132-2;;27822377;;pmc5096004;;27190629;;10.1186/s40425-016-0181-6;;pmc4869343;;10.1111/j.1365-2567.2009.03228.x;;20201988;;pmc2878467;;11533635;;10.1038/nbt0901-819;;10.1002/eji.200324804;;14991590;;21154120;;pmc3413251;;22245556;;10.1016/j.coi.2011.12.011;;10.1038/ni759;;11812990;;10.1002/jmr.679;;15227640;;15185369;;10.1002/cbic.200300806;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;26216629;;10.1016/s0065-230x(15)00083-4;;10.1016/bs.acr.2015.04.010;;10.1038/nrclinonc.2016.25;;26977780;;pmc5551685;;10.1155/2016/4683607;;26881264;;pmc4736366;;23980122;;pmc3754862;;10.1084/jem.20131625;;10.1016/j.ejca.2016.06.028;;27591414;;10.1016/j.pharmthera.2017.03.008;;pmc5600680;;28322974;;10.1016/j.bbcan.2017.10.007;;29126881;;28187290;;10.1016/j.cell.2017.01.017;;pmc5391692;;27511159;;10.1016/s1470-2045(16)30123-1;;26239999;;10.1002/ijc.29713,"Turk, et al., “Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma is Prevented by Regulatory T Cells,” Journal of Exp Medicine, vol. 200 (6) 771-782 (2004).;;U.S. Appl. No. 60/665,322, filed Mar. 25, 2005, 62 pages.;;U.S. Appl. No. 60/687,265, filed Jun. 3, 2005, 71 pages.;;Website Information for Monoclonal Anti-human GITR/TNFRSF 18 MAb (Clone 110416), Catalog No. MAB689, 1-2, Sep. 21, 2004.;;White, A. et al., “Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies,” Cancer Cell, vol. 27(1):138-148 (2015).;;Whiteside, S. et al., “IkB proteins: structure, function and regulation,” Seminars in Cancer Biology, vol. 8, 75-82 (1997).;;Yang, W. et al., “CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range,” J. Mol. Biol., vol. 254 (3): 392-403 (1995).;;Baltz, K. et al., “Cancer immunoediting by GITR (glucocorticoidinduced TNF-related protein) ligand in humans: NK cell/tumor cell interactions,” The FASEB Journal, Research Communication, vol. 21(8): 2442-2454 (2007).;;Chang, W. et al., “Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma,” Cancer, vol. 116(24): 5777-5788 (2010).;;Gasparoto, T. et al., “Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment,” Cancer Immunology, Immunotherapy, vol. 59: 819-828 (2010).;;Padovani, C. et al., “Glucocorticoid-induced tumor necrosis factor receptor expression in patients with cervical human papillomavirus infection,” Revista DA Sociedada Brasileira De Medicina Tropical, vol. 46(3):288-292 (2013).;;Arnett, S. et al., “IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society,” Dec. 5-9, 2010, San Diego, CA USA, mAbs, vol. 3 (2), Mar./Apr. 2011, 133-152.;;Avogadri, F. et al., “Modulation of CTLA-4 and GITR for Cancer Immunotherapy,” Curr Top Microbiol Immunol, vol. 344: 211-244 (2011).;;Baecher-Allan, B. et al., “Inhibition of Human CD4+CD25+ high Regulatory T Cell Function,” J. Immunol., vol. 169, 3210-6217 (2002).;;Balint, R. et al., “Antibody Engineering by Parsimonious Mutagenesis,” Gene, vol. 137: 109-118 (1993).;;Birebent, B. et al., “Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression,” Eur. J. Immunol., vol. 34:3485-3496 (2004).;;Bulliard, et al., “Activating Fc y receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies,” JEM, vol. 210 (9): 1685-1693 (2013).;;Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” PNAS, vol. 89, 4285-4289 (1992).;;Coe, D. et al., “Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy,” Cancer Immunol Immunother, vol. 59, 1367-1377 (2010).;;Cohen et al., “Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation,” PLoS, vol. 5, Iss. 5, 1-12 (2010).;;Cohen et al., “Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody,” Blood, ASH Annual Meeting Abstracts, Dec. 8-11, 2007, vol. 110 (11), 1788.;;Cohen, et al., “Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity,” Cancer Res., vol. 66: (9):4904-4912 (2006).;;Davies et al., “Affinity improvement of single antibody VH domains: residues in all three hypervanable regions affect antigen bnding,” Immunotechnology, vol. 2, 169-179 (1996).;;Dittmer et al., “Functional impairment of CD8+ T cellls by regulatory T cells during persistent retroviral infection,” Immunity, vol. 20, 293-303 (2004).;;Glaus et al., “In vivo SPECT/CT imaging of an anti-GITR antibody: A novel cancer immunotherapeutic,” J Nucl Med., vol. 54 (Supplement 2):327 (2013).;;Godrey et al., “Cord blood CD4+ CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function,” Blood, vol. 105 No 2, 750-758 (2005).;;Gross et al., “TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease: Impaired B Cell Maturation in Mice Lacking BLyS,” Immunity, vol. 15:289-302 (2001).;;Gurney et al., “Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR,” Current Biology, vol. 9 (4), 215-218 (1999).;;Hawkins, R.E. et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,” J. Mol. Biol., vol. 226(3): 889-896 (1992).;;Hiroyoshi Nishikawa, “Application of Modulators of Cancer Immunosuppression for Immunotherapy—GITR and CTLA-4,” The Medical Frontline, vol. 64 (11): 100-105 (2009).;;Holt, L. et al., “Domain antibodies: proteins for therapy,” Trends in Biotechnology, vol. 21 (11): 484-490 (2003).;;Houot et al., “T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need or chemotherapy,” Blood, vol. 113 (15):3546-3552 (2009).;;International Preliminary Report on Patentability, PCT/US2015/033991, dated Dec. 6, 2016, 11 pages.;;International Search Report and Written Opinion, PCT/US2015/033991, dated Dec. 8, 2015, 17 pages.;;Kanamaru et al., “Costimulation via Glucocorticoid-Induced TNF Receptor in Both Conventional and CD25+ Regulatory CD4+ T Cells,” The Journal of Immunology, 7306-7314 (2004).;;Kim et al., “Fcy receptors enable anticancer action of proapoptotic and immune-modulatory antibodies,” J Exp Med., vol. 210 (9) 1647-1651 (2013).;;Ko et al., “A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model,” Cancer Research, vol. 67 (15) 7477-7486 (2007).;;Ko et al., “Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+ CD4+ regulatory T cells,” JEM, vol. 202 (7), 885-891 (2005).;;Kwon et al., “Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand,” Journal of Biol Chem, vol. 274 (10) 6056-6061 (1999).;;Little et al., “Of Mice and Men: hybridoma and recombinant antibodies,” Immunology Today, vol. 21(8): 364-370 (2000).;;Lu et al. “Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs,” Journal of Translational Medicine, vol. 12 (36), 1-11 (2014).;;Marks, J. et al, “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,” Biotechnology, vol. 10(7): 779-783 (1992).;;McHugh et al., “CD4+CD25+ Immunoregulatory T Cells: Gene Expression Analysis Reveals a Functional Role for the Glucocorticoid-Induced TNF Receptor,” Immunity, vol. 16, 311-323 (2002).;;Melero et al., “Agonist Antibodies to TNFR Molecules That Costimulate Tand NK Cells,” Clinical Cancer Research, vol. 19 (5): 1044-1053, 1913 (2013).;;Melero et al., “Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination,” Clinical Cancer Research, vol. 19(5), 997-1008 (2013).;;Melero, I., “Immunological targets: Basic aspects,” IL29, Annals of Oncology, vol. 22 (Supplement 3), 1 page, (2011) doi:10.1093/annonc/mdr103.;;Mitsui et al, “Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals,” Clinical Cancer Res, vol. 16, 2781-2791(2010).;;National Cancer Institute, Immunotherapy Agent workshop Jul. 12, 2007, 1-77.;;Nocentini et al., “A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis,” PNAS, vol. 94, 6216-6221 (1997).;;Nocentini et al., “GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily,” Eur J of Immunol, vol. 35 Iss 4, 1016-1022 (2005).;;Nocentini et al., “Identification of three novel mRNA splice variants of GITR,” Cell Death and Differentiation, vol. 7, 408-410 (2000).;;Patel, M. et al., “Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma,” Journal for ImmunoTherapy of Cancer, vol. 4(28)13 pages (2016).;;Ponte et al., “Enhancement of humoral and cellular immunity with an antiglucocorticoid-induced tumour necrosis factor receptor monoclonal antibody,” Immunology, vol. 130, 231-242 (2010).;;Press Release, Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting, Cambridge, MA, Jun. 25, 2015, PR Newswire, 1-3.;;Printout from the R&D Systems website showing a list of available anti-GITR antibodies, Jul. 2, 2014, 1-2.;;Reichert, J., “Monoclonal antibodies in the clinic,” Nat. Biotech, vol. 19, 819-822 (2001).;;Ronchetti et al., “GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations,” Eur J Immunol, vol. 34, 613-622 (2004).;;Rosenzweig et al., “Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of nuGITR.,” ASCO Meeting Library 2010 Annual Meeting, 1-2.;;Schaer et al., “Anti-GITR antibodies—Potential Clinical applications for tumor immunotherapy,” Curr Opin in Investigational Drugs, vol. 11 (12), 1378-1386 (2010).;;Schaer, et al. “Modulation of GITR for cancer immunotherapy,” Curr Opin in Immunol, vol. 24, 217-224 (2012).;;Schimizu et al., “Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance,” Nature Immunol, vol. 3 (2), 135-142 (2002).;;Barrios, Y. et al., “Length of the antibody heavy chain complementarity determining region 3 as a specificity determining factor,” J Molecular Recognition, vol. 17: 332-338 (2004).;;Piatesi, A. et al., “Immunological Optimization of a Generic Hydrophobic Pocket for High Affinity Hapten Binding and Diets-Alder Activity,” ChemBio Chem., vol. 5: 460-466 (2004).;;Rudikoff, S. et al., “Single amino acid substitution altering antigen-binding specificity,” PNAS, vol. 79: 1979-1983 (1982).;;An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread, NIH U.S. National Library of Medicine ClinicalTrails.gov, Nov. 6, 2015 Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/NCT02598960 [retrieved on Aug. 10, 2018].;;International Preliminary Report on Patentability, PCT/US2018/032750, dated Nov. 19, 2019, 14 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, PCT/US2018/032750, dated Aug. 24, 2018, 21 pages.;;Khalil D. et al., “The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy,” Immunotherapy of Cancer in: Advances in Cancer Research, vol. 128, 1-68 (2015).;;Khalil, D. et al., “The future of cancer treatment: immunomodulation, CARs and combi-nation immunotherapy,” Nature Reviews Clinical Oncology, vol. 13(5):273-290(2016).;;Kim E. et al., “Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium,” Journal of Immunology Research, (2016).;;Kim et al., “Fcy receptors enable anticancer action of proapoptotic and immune-modulatory antibodies,” J Exp Med., vol. 210 (9) 1647-1657 (2013).;;Knee D. et al., “Rationale for anti-GITR cancer immunotherapy,” European Journal of Can-cer, vol. 67: 10 pages (2016).;;Lohmueller J. et al., “Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines,” Pharmacology and Therapeutics, vol. 178: 31-47 (2017).;;NIH U.S. National Library of Medicine: “Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastat-ic Malignancies,” ClinincalTrials.gov, (2017) Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/NCTO3126110 [retrieved on Aug. 9, 2018].;;Santoni, M. et al., “Triple negative breast cancer: Key role of Tumor-Associated Macro-phages in regulating the activity of anti-PD-1/PD-L1 agents,” BBA—Reviews on Cancer, vol. 1869(1):78-84 (2017).;;Sharma P. et al., “Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy,” Cell, Cell Press, vol. 168 (4):707-723 (2017).;;Tan, W-L., et al., “Novel therapeutic targets on the horizon for lung cancer,” The Lancet Oncology, vol. 17(8): e347:16 pages (2016).;;Yu, N. et al., “Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma,” International Journal of Cancer, vol. 138(2): 451-462 (2015).;;International Search Report and Written Opinion, PCT/US2018/032750, dated Oct. 31, 2018, 24 pages.;;Extended European Search Report, European Application No. 21199061.9, dated Mar. 18, 2022, 8 pages.",ACTIVE
230,US,B2,US 10501550 B2,174-265-020-726-41X,2019-12-10,2019,US 201615369290 A,2016-12-05,US 201615369290 A;;US 2015/0033991 W;;US 201462082980 P;;US 201462008945 P,2014-06-06,Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2015-07-22),https://lens.org/174-265-020-726-41X,Granted Patent,yes,79,6,63,65,394,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/00;;A61K39/395;;A61K47/68;;G01N33/574;;G01N33/68,,59,45,171-614-306-115-108;;086-268-955-647-163;;136-116-610-765-69X;;084-334-863-236-818;;019-741-156-878-521;;029-382-279-785-035;;009-483-512-107-343;;019-459-691-036-036;;087-404-567-384-381;;128-554-308-094-91X;;020-296-196-517-635;;055-706-543-681-974;;044-673-845-363-528;;056-584-393-786-220;;070-164-938-901-37X;;005-119-615-003-591;;013-323-148-570-367;;022-259-501-579-745;;124-668-123-456-128;;055-329-732-668-508;;011-405-827-983-549;;141-244-428-002-001;;143-287-907-926-845;;124-353-299-096-166;;012-369-544-741-057;;055-677-065-531-946;;010-916-105-450-247;;019-791-912-221-046;;078-111-385-767-730;;017-588-579-721-840;;016-276-447-231-541;;045-714-831-915-963;;071-886-484-965-256;;145-500-434-317-873;;012-108-483-329-37X;;083-410-991-104-604;;013-888-189-100-394;;112-871-461-451-205;;110-748-788-527-236;;082-582-794-395-339;;039-943-095-184-294;;050-463-287-173-296;;051-374-571-260-065;;004-189-544-863-902;;043-054-515-242-505,21304271;;10.4161/mabs.3.2.14939;;pmc3092615;;20563707;;10.1007/82_2010_49;;pmc4060248;;12444126;;10.4049/jimmunol.169.11.6210;;7506686;;10.1016/0378-1119(93)90258-5;;15484187;;10.1002/eji.200324632;;10.1084/jem.20130573;;23897982;;pmc3754864;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;20480365;;10.1007/s00262-010-0866-5;;20454651;;pmc2862699;;10.1371/journal.pone.0010436;;10.1158/0008-5472.can-05-2813;;16651447;;pmc2242844;;9373310;;10.1016/s1380-2933(96)00045-0;;10.1016/s1074-7613(04)00054-8;;15030773;;15374887;;10.1182/blood-2004-06-2467;;10.3410/f.1001160.6701;;11520463;;10.1016/s1074-7613(01)00183-2;;10074428;;10.1016/s0960-9822(99)80093-1;;10.1016/0022-2836(92)90639-2;;1507232;;14573361;;10.1016/j.tibtech.2003.08.007;;10.1182/blood-2008-07-170274;;pmc2668854;;18941113;;pmc3413251;;22245556;;10.1016/j.coi.2011.12.011;;10.4049/jimmunol.172.12.7306;;15187106;;23980122;;pmc3754862;;10.1084/jem.20131625;;17671218;;10.1158/0008-5472.can-06-4639;;10.1084/jem.20050940;;pmc2213162;;10.1084/jem.200509402092c;;16186187;;10.3410/f.1028385.337176;;10037686;;10.1074/jbc.274.10.6056;;10.1016/s0167-5699(00)01668-6;;10916138;;10.1186/1479-5876-12-36;;24502656;;pmc4104995;;10.1038/nbt0792-779;;1368267;;10.1016/s1074-7613(02)00280-7;;11869690;;pmc4397897;;23460535;;10.1158/1078-0432.ccr-13-0598;;10.1158/1078-0432.ccr-12-2065;;10.1158/1078-0432.ccr-12-2214;;23460531;;10.1158/1078-0432.ccr-09-3243;;20460483;;pmc21029;;9177197;;10.1073/pnas.94.12.6216;;10.1002/eji.200425818;;15770698;;10836847;;10.1038/sj.cdd.4400670;;10.1186/s40425-016-0132-2;;27822377;;pmc5096004;;27190629;;10.1186/s40425-016-0181-6;;pmc4869343;;10.1111/j.1365-2567.2009.03228.x;;20201988;;pmc2878467;;11533635;;10.1038/nbt0901-819;;10.1002/eji.200324804;;14991590;;10.1016/j.clim.2010.03.288;;21154120;;10.1038/ni759;;11812990;;10.1084/jem.20041130;;15381730;;pmc2211964;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001;;9299585;;10.1006/scbi.1997.0058;;7490758;;10.1006/jmbi.1995.0626,"Hiroyoshi Nishikawa, “Application of Modulators of Cancer Immunosuppression for Immunotherapy—GITR and CTLA-4,” The Medical Frontline, vol. 64 (11): 100-105 (2009).;;Arnett, S. et al., “IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society,” Dec. 5-9, 2010, San Diego, CA USA, mAbs, vol. 3 (2), Mar./Apr. 2011, 133-152.;;Avogadri, F. et al., “Modulation of CTLA-4 and GITR for Cancer Immunotherapy,” Curr Top Microbiol Immunol, vol. 344, 211-244 (2011).;;Baecher-Allan, B. et al., “Inhibition of Human CD4+CD25+ high Regulatory T Cell Function,” J. Immunol., vol. 169, 3210-6217 (2002).;;Balint, R. et al., “Antibody Engineering by Parsimonious Mutagenesis,” Gene, vol. 137: 109-118 (1993).;;Birebent, B. et al., “Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression,” Eur. J. Immunol., vol. 34, 3485-3496 (2004).;;Bulliard, et al., “Activating Fc y receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies,” JEM , vol. 210 (9): 1685-1693 (2013).;;Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” PNAS, vol. 89, 4285-4289 (1992).;;Coe, D. et al., “Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy,” Cancer Immunol Immunother, vol. 59, 1367-1377 (2010).;;Cohen et al., “Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation,” PLoS, vol. 5, Iss. 5, 1-12 (2010).;;Cohen et al., “Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody,” Blood, ASH Annual Meeting Abstracts, Dec. 8-11, 2007, vol. 110 (11), 1788.;;Cohen, et al., “Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity,” Cancer Res, vol. 66: (9):4904-4912 (2006).;;Davies et al., “ Affinity improvement of single antibody VH domains: residues in all three hypervanable regions affect antigen bnding,” Immunotechnology, vol. 2, 169-179 (1996).;;Dittmer et al., “Functional impairment of CD8+ T cellls by regulatory T cells during persistent retroviral infection,” Immunity, vol. 20, 293-303 (2004).;;Glaus et al., “In vivo SPECT/CT imaging of an anti-GITR antibody: A novel cancer immunotherapeutic,” J Nucl Med., vol. 54 (Supplement 2):327 (2013).;;Godrey et al., “Cord blood CD4+ CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function,” Blood, vol. 105 No. 2, 750-758 (2005).;;Gross et al., “TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease: Impaired B Cell Maturation in Mice Lacking BLyS,” Immunity, vol. 15:289-302 (2001).;;Gurney et al., “Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR,” Current Biology, vol. 9 (4), 215-218 (1999).;;Hawkins, R.E et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,” J. Mol. Biol., vol. 226(3): 889-896 (1992).;;Holt, L. et al., “Domain antibodies: proteins for therapy,” Trends in Biotechnology, vol. 21 (11): 484-490 (2003).;;Houot et al., “T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need or chemotherapy,” Blood, vol. 113 (15):3546-3552 (2009).;;Schaer, et al. “Modulation of GITR for cancer immunotherapy,” Curr Opin in Immunol, vol. 24, 217-224 (2012).;;International Preliminary Report on Patentability, PCT/US2015/033991, dated Dec. 6, 2016, 11 pages.;;International Search Report and Written Opinion, PCT/US2015/033991, dated Dec. 8, 2015, 17 pages.;;Kanamaru et al., “Costimulation via Glucocorticoid-Induced TNF Receptor in Both Conventional and CD25+ Regulatory CD4+ T Cells,” The Journal of Immunology, 7306-7314 (2004).;;Kim et al., “Fcy receptors enable anticancer action of proapoptotic and immune-modulatory antibodies,” J Exp Med., vol. 210 (9) 1647-1651 (2013).;;Ko et al., “A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model,” Cancer Research, vol. 67 (15) 7477-7486 (2007).;;Ko et al., “Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+ CD4+ regulatory T cells,” JEM, vol. 202 (7), 885-891 (2005).;;Kwon et al., “Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand,” Journal of Biol Chem, vol. 274 (10) 6056-6061 (1999).;;Little et al., “Of Mice and Men: hybridoma and recombinant antibodies,” Immunology Today, vol. 21(8): 364-370 (2000).;;Lu et al. “Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs,” Journal of Translational Medicine, vol. 12 (36), 1-11 (2014).;;Marks, J. et al, “ By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,” Biotechnology, vol. 10(7): 779-783 (1992).;;McHugh et al., “CD4+CD25+ Immunoregulatory T Cells: Gene Expression Analysis Reveals a Functional Role for the Glucocorticoid-Induced TNF Receptor,” Immunity, vol. 16, 311-323 (2002).;;Melero, I., “Immunological targets: Basic aspects,” IL29, Annals of Oncology, vol. 22 (Supplement 3), 1 page, (2011) doi:10.1093/annonc/mdr103.;;Melero et al., “Agonist Antibodies to TNFR Molecules That Costimulate Tand NK Cells,” Clinical Cancer Research, vol. 19 (5): 1044-1053, 1913 (2013).;;Melero et al., “Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination,” Clinical Cancer Research, vol. 19(5), 997-1008 (2013).;;Mitsui et al, “Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/ Inhibitory Signals,” Clinical Cancer Res, vol. 16, 2781-2791(2010).;;National Cancer Institute, Immunotherapy Agent Workshop, Jul. 12, 2007, 1-77.;;Nocentini et al., “A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis,” PNAS, vol. 94, 6216-6221 (1997).;;Nocentini et al., “GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily,” Eur J of Immunol, vol. 35 Iss 4, 1016-1022 (2005).;;Nocentini et al., “Identification of three novel mRNA splice variants of GITR,” Cell Death and Differentiation, vol. 7, 408-410 (2000).;;Patel, M. et al., “Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma,” Journal for ImmunoTherapy of Cancer, vol. 4(28)13 pages (2016).;;Ponte et al., “Enhancement of humoral and cellular immunity with an antiglucocorticoid-induced tumour necrosis factor receptor monoclonal antibody,” Immunology, vol. 130, 231-242 (2010).;;Press Release, Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting, Cambridge, MA, Jun. 25, 2015, PR Newswire, 1-3.;;Printout from the R&D Systems website showing a list of available anti-GITR antibodies, Jul. 2, 2014, 1-2.;;Reichert, J., “Monoclonal antibodies in the clinic,” Nat. Biotech, vol. 19, 819-822 (2001).;;Ronchetti et al., “GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations,” Eur J Immunol, vol. 34, 613-622 (2004).;;Rosenzweig et al., “Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR.,” ASCO Meeting Library 2010 Annual Meeting, 1-2.;;Schaer et al., “Anti-GITR antibodies—Potential Clinical applications for tumor immunotherapy,” Curr Opin in Investigational Drugs, vol. 11 (12), 1378-1386 (2010).;;Schimizu et al., “Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance,” Nature Immunol, vol. 3 (2), 135-142 (2002).;;Turk, et al., “Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells,” Journal of Exp Medicine, vol. 200 (6) 771-782 (2004).;;U.S. Appl. No. 60/665,322, filed Mar. 25, 2005, 62 pages.;;U.S. Appl. No. 60/687,265, filed Jun. 3, 2005, 71 pages.;;Website Information for Monoclonal Anti-human GITR/TNFRSF 18 MAb (Clone 110416), Catalog No. MAB689, 1-2, Sep. 21, 2004.;;White, A. et al., “Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies,” Cancer Cell, vol. 27(1):138-148 (2015).;;Whiteside, S. et al., “IkB proteins: structure, function and regulation,” Seminars in Cancer Biology, vol. 8, 75-82 (1997).;;Yang, W. et al., “CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range,” J. Mol. Biol., vol. 254 (3): 392-403 (1995).;;U.S. Appl. No. 16/133,418, filed Sep. 17, 2018, Suba Krishnan.;;U.S. Appl. No. 15/646,558, Sep. 26, 2018.",ACTIVE
231,US,A1,US 2017/0145104 A1,000-081-118-939-441,2017-05-25,2017,US 201615369290 A,2016-12-05,US 201615369290 A;;US 2015/0033991 W;;US 201462082980 P;;US 201462008945 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2015-07-22),https://lens.org/000-081-118-939-441,Patent Application,yes,0,15,63,65,381,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;G01N33/574,,0,0,,,,ACTIVE
232,US,A1,US 2020/0115463 A1,089-103-546-985-501,2020-04-16,2020,US 201916663583 A,2019-10-25,US 201916663583 A;;US 201615369290 A;;US 2015/0033991 W;;US 201462082980 P;;US 201462008945 P,2014-06-06,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2015-07-22),https://lens.org/089-103-546-985-501,Patent Application,yes,0,8,63,65,394,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/395;;G01N33/574;;G01N33/68,,0,0,,,,ACTIVE
233,TW,A,TW 201613972 A,032-179-537-535-659,2016-04-16,2016,TW 104118186 A,2015-06-04,US 201462008945 P;;US 201462082980 P,2014-06-06,Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/032-179-537-535-659,Patent of Addition,no,0,2,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,C07K16/28;;A61K39/395;;A61P35/00;;G01N33/574;;G01N33/68,,0,0,,,,ACTIVE
234,TW,B,TW I695843 B,173-073-398-453-158,2020-06-11,2020,TW 104118186 A,2015-06-04,US 201462008945 P;;US 201462082980 P,2014-06-06,Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING,,https://lens.org/173-073-398-453-158,Granted Patent,no,1,0,63,65,0,A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;G01N33/57492;;G01N33/6872;;A61K2039/505;;A61K2039/507;;C07K2317/56;;C07K2317/73;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N33/6863;;G01N2333/7151;;C07K16/2878;;A61P35/00;;C07K16/2878;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;C07K16/2863;;A61K39/3955;;C07K2317/92;;C07K2317/76;;C07K2317/75;;C07K2317/74;;C07K2317/732;;C07K2317/565;;C07K2317/53;;C07K2317/52;;C07K2317/34;;C07K2317/33;;C07K2317/21;;A61K2039/507;;A61K2039/505;;A61K39/3955;;C07K16/2818;;C07K16/2863;;C07K16/2878;;C12N5/0636;;G01N33/57492;;G01N33/6872;;A61K2039/505;;C07K2317/52;;C07K2317/565;;G01N2333/70578;;C07K16/2863;;A61K39/3955;;G01N33/6872;;G01N33/57492;;C07K2317/56;;C07K2317/73;;G01N2333/70578;;C07K16/2818;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/53;;C07K2317/565;;C07K2317/732;;C07K2317/74;;C07K2317/75;;C07K2317/76;;C07K2317/92;;A61K47/6851;;G01N2333/7151;;G01N33/6863;;C07K16/2878;;C07K2317/24,,,0,0,,,,ACTIVE
235,CN,A,CN 113056483 A,142-623-379-588-507,2021-06-29,2021,CN 201980057104 A,2019-07-08,US 201862695600 P;;US 201862744611 P;;US 2019/0040820 W,2018-07-09,Antibodies binding to ILT4,"The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.",FIVE PRIME THERAPEUTICS INC;;BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LIU;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;TRUONG HONG-AN;;SELBY MARK J;;KORMAN ALAN J;;LONBERG NILS;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G,,https://lens.org/142-623-379-588-507,Patent Application,no,0,1,21,23,0,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,C07K16/28;;A61K39/395,,0,0,,,,PENDING
236,SG,A,SG 11202100096X A,138-705-817-635-575,2021-02-25,2021,SG 11202100096X A,2019-07-08,US 201862695600 P;;US 201862744611 P;;US 2019/0040820 W,2018-07-09,ANTIBODIES BINDING TO ILT4,,FIVE PRIME THERAPEUTICS INC;;BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LINDA;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;TRUONG HONG-AN;;SELBY MARK J;;KORMAN ALAN J;;LONBERG NILS;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G,,https://lens.org/138-705-817-635-575,Unknown,no,0,0,21,23,0,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,C07K16/28;;A61K39/395,,0,0,,,,PENDING
237,IL,A,IL 279894 A,194-217-100-459-226,2021-03-01,2021,IL 27989420 A,2020-12-31,US 201862695600 P;;US 201862744611 P;;US 2019/0040820 W,2018-07-09,Antibodies binding to ilt4,,BRISTOL MYERS SQUIBB CO;;FIVE PRIME THERAPEUTICS INC;;LONBERG NILS;;HAN MICHELLE MINHUA;;SELBY MARK J;;CHEN GUODONG;;SCHEBYE XIAO MIN;;BEE CHRISTINE;;KORMAN ALAN J;;TRUONG HONG AN;;HUANG RICHARD Y;;CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LINDA;;DEYANOVA EKATERINA G,LONBERG NILS;;HAN MICHELLE MINHUA;;SELBY MARK J;;CHEN GUODONG;;SCHEBYE XIAO MIN;;BEE CHRISTINE;;KORMAN ALAN J;;TRUONG HONG-AN;;HUANG RICHARD Y;;CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LINDA;;DEYANOVA EKATERINA G,,https://lens.org/194-217-100-459-226,Patent Application,no,0,0,21,23,0,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,,,0,0,,,,PENDING
238,TW,B,TW I819024 B,046-993-883-016-629,2023-10-21,2023,TW 108123980 A,2019-07-08,US 201862695600 P;;US 201862744611 P,2018-07-09,Antibodies binding to ilt4,,FIVE PRIME THERAPEUTICS INC;;BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LINDA;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;TRUONG HONG-AN;;SELBY MARK J;;KORMAN ALAN J;;LONBERG NILS;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G,,https://lens.org/046-993-883-016-629,Granted Patent,no,1,0,21,23,0,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,,,0,0,,,,ACTIVE
239,BR,A2,BR 112020027095 A2,187-861-248-590-574,2021-03-30,2021,BR 112020027095 A,2019-07-08,US 2019/0040820 W;;US 201862695600 P;;US 201862744611 P,2018-07-09,anticorpos de ligação a ilt4,"anticorpos de ligação a ilt4. a presente invenção refere-se a anticorpos que se ligam especificamente a transcrito do tipo imunoglobulina 4 (ilt4), que é também conhecido como lilrb2, lir2, mir10 e cd85d, e ácidos nucleicos, células hospedeiras, composições e usos correspondentes. em algumas modalidades, os anticorpos se ligam especificamente a itl4 humano, mas não se ligam significantemente a ilt2, ilt3 ou ilt5 ou a outros membros das famílias lilra ou lilrb.",BRISTOL MYERS SQUIBB CO;;FIVE PRIME THERAPEUTICS INC,ALAN J KORMAN;;ANDREW RANKIN;;CHRISTINE BEE;;DIANA YUHUI CHEN;;EKATERINA G DEYANOVA;;GUODONG CHEN;;HONG-AN TRUONG;;JOSEPH TOTH;;LINDA LIANG;;MARK J SELBY;;MICHELLE MINHUA HAN;;NILS LONBERG;;RICHARD Y HUANG;;XIAO MIN SCHEBYE;;XIAODI DENG,,https://lens.org/187-861-248-590-574,Patent Application,no,0,0,21,23,0,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,A61K39/395;;C07K16/28,,0,0,,,,PENDING
240,US,A1,US 2020/0079848 A1,006-886-040-676-86X,2020-03-12,2020,US 201916506754 A,2019-07-09,US 201916506754 A;;US 2019/0040820 W;;US 201862695600 P;;US 201862744611 P,2018-07-09,Antibodies Binding to ILT4,"The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.",FIVE PRIME THERAPEUTICS INC;;BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LINDA;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;TRUONG HONG-AN;;SELBY MARK J;;LONBERG NILS;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G;;KORMAN ALAN J,BRISTOL-MYERS SQUIBB COMPANY (2019-11-07);;FIVE PRIME THERAPEUTICS INC (2020-02-05),https://lens.org/006-886-040-676-86X,Patent Application,yes,0,3,21,23,193,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,C07K16/28;;A61K39/395;;A61K45/06;;A61K47/68;;A61P35/00;;G01N33/563;;G01N33/577,,0,0,,,,ACTIVE
241,WO,A2,WO 2020/014132 A2,037-905-124-536-333,2020-01-16,2020,US 2019/0040820 W,2019-07-08,US 201862695600 P;;US 201862744611 P,2018-07-09,ANTIBODIES BINDING TO ILT4,"The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.",FIVE PRIME THERAPEUTICS INC;;BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LINDA;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;TRUONG HONG-AN;;SELBY MARK J;;KORMAN ALAN J;;LONBERG NILS;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G,,https://lens.org/037-905-124-536-333,Patent Application,yes,97,6,21,23,193,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,C07K16/28;;A61K39/395,,42,31,006-553-734-546-212;;068-238-957-669-243;;105-316-874-895-908;;021-215-766-622-525;;003-486-489-115-550;;027-354-519-809-462;;131-494-801-126-272;;020-126-213-879-311;;088-086-720-613-343;;070-318-112-524-781;;010-488-381-022-259;;082-210-673-349-152;;004-458-031-333-650;;041-909-244-299-232;;078-432-639-041-575;;042-740-484-382-110;;004-458-031-333-650;;003-752-183-823-430;;008-213-515-306-640;;053-703-232-770-99X;;020-986-423-793-233;;029-750-154-523-855;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;066-749-017-721-197;;001-467-559-709-949;;087-081-871-218-990;;116-852-773-281-868,8424945;;10.1021/bi00055a024;;10556249;;10.1093/protein/12.10.879;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;1710435;;10.1146/annurev.physiol.53.1.217;;10.1146/annurev.ph.53.030191.001245;;14528279;;10.1038/sj.onc.1206816;;10.1038/70928;;10581076;;12955574;;10.1007/s10147-003-0342-8;;17077181;;10.1093/intimm/dxl110;;19896358;;10.1016/j.copbio.2009.10.011;;10.1038/6179;;10052355;;14699147;;10.1074/jbc.c300470200;;10.4049/jimmunol.176.1.346;;16365427;;11096108;;10.1074/jbc.m009483200;;12391234;;10.4049/jimmunol.169.9.5171;;10.1074/jbc.m604292200;;16793771;;10.4049/jimmunol.0804182;;19494290;;11096108;;10.1074/jbc.m009483200;;11986321;;10.1074/jbc.m202069200;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;9850053;;15470033;;10.4049/jimmunol.173.8.4919;;10700237;;10.1038/73193;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;1545867;;10.1038/356152a0;;10.1007/s00216-014-7924-3;;24948090,"BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187;;KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999, pages 879 - 884;;BURKS, PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 412 - 417;;AGNEW, CHEM INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186;;KLAGSBRUND'AMORE, ANNU. REV. PHYSIOL., vol. 53, 1991, pages 217 - 39;;TONINI ET AL., ONCOGENE, vol. 22, 2003, pages 6549 - 6556;;FERRARAALITALO, NATURE MEDICINE, vol. 5, no. 12, 1999, pages 1359 - 1364;;SATO, INT. J. CLIN. ONCOL., vol. 8, 2003, pages 200 - 206;;MURAKAMI ET AL.: ""The Molecular Basis of Cancer"", 1995, W.B. SAUNDERS, article ""Cell cycle regulation, oncogenes, and antineoplastic drugs"";;WRIGHT ET AL., TIBTECH, vol. 15, 1997, pages 26 - 32;;PETKOVA ET AL., INTERNATIONAL IMMUNOLOGY, vol. 18, no. 12, 2006, pages 1759 - 1769;;STROHL, CURRENT OPINION IN BIOTECHNOLOGY, vol. 20, 2009, pages 685 - 691;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;HINTON ET AL., J. BIOL. CHEM., vol. 279, no. 8, 2004, pages 6213 - 6216;;HINTON, JOURNAL OF IMMUNOLOGY, vol. 176, 2006, pages 346 - 356;;SHIELDS ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 9, 2001, pages 6591 - 6604;;DALL ACQUA ET AL., JOURNAL OF IMMUNOLOGY, vol. 169, 2002, pages 5171 - 5180;;DALL'ACQUA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, 2006, pages 23514 - 23524;;YEUNG ET AL., J IMMUNOL, vol. 182, 2010, pages 7663 - 7671;;SHIELDS, R.L., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;HURWITZ ET AL., PRO. NATL. ACAD. SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071;;CAMACHO, J. CLIN. ONCOLOGY, vol. 22, no. 145, 2004;;MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;RESTIFO, N.SZNOL, M. ET AL.: ""Cancer Vaccines"", 1997, article ""Cancer: Principles and Practice of Oncology"", pages: 3023 - 3043;;DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, S A, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOTSRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;HOLLIGER, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;TANG ET AL., NATURE, vol. 356, 1992, pages 152 - 154;;GENNARO: ""Remington: The Science and Practice of Pharmacy with Facts and Comparisons: Drugfacts Plus"", 2003;;ANSEL ET AL.: ""Pharmaceutical Dosage Forms and Drug Delivery Systems"", 2004, LIPPENCOTT WILLIAMS AND WILKINS;;KIBBE ET AL.: ""Handbook of Pharmaceutical Excipients"", 2000, PHARMACEUTICAL PRESS;;HUANGCHEN, ANALYTICAL AND BIOANALYTICAL CHEM., vol. 406, 2014, pages 6541;;WEI ET AL., DRUG DISCOVERY TODAY, vol. 19, 2014, pages 95;;KARLSSON ET AL., ANALYTICAL BIOCHEM., vol. 349, 2005, pages 136",PENDING
242,CL,A1,CL 2021000011 A1,063-891-010-532-367,2021-05-24,2021,CL 2021000011 A,2021-01-05,US 201862695600 P;;US 201862744611 P,2018-07-09,Anticuerpos de unión a ilt4,"La presente solicitud se refiere a anticuerpos que se unen específicamente a la transcripción de tipo inmunoglobulina 4 (ILT4), que también se denomina LILRB2, LIR2, MIR10 y CD85d, y ácidos nucleicos, células hospedadoras, composiciones y usos correspondientes. En algunas realizaciones, los anticuerpos se unen específicamente a ILT4 humana, pero no se unen de manera significativa a ILT2, ILT3, o ILT5, o a otros miembros de las familias LILRA o LILRB.",BRISTOL MYERS SQUIBB CO;;FIVE PRIME THERAPEUTICS INC,XIAO MIN SCHEBYE;;DIANA YUHUI CHEN;;ANDREW RANKIN;;XIAODI DENG;;JOSEPH TOTH;;LINDA LIANG;;MICHELLE MINHUA HAN;;CHRISTINE BEE;;HONG-AN TRUONG;;MARK J SELBY;;ALAN J KORMAN;;NILS LONBERG;;GUODONG CHEN;;RICHARD Y HUANG;;EKATERINA G DEYANOVA,,https://lens.org/063-891-010-532-367,Patent Application,no,0,0,21,23,0,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,A61K39/395;;C07K16/28,,0,0,,,,PENDING
243,EP,A2,EP 3820904 A2,083-168-626-451-728,2021-05-19,2021,EP 19752302 A,2019-07-08,US 201862695600 P;;US 201862744611 P;;US 2019/0040820 W,2018-07-09,ANTIBODIES BINDING TO ILT4,,FIVE PRIME THERAPEUTICS INC;;BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LINDA;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;TRUONG HONG-AN;;SELBY MARK J;;KORMAN ALAN J;;LONBERG NILS;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G,,https://lens.org/083-168-626-451-728,Patent Application,yes,0,0,21,23,0,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,C07K16/28;;A61K39/395,,0,0,,,,PENDING
244,CO,A2,CO 2021000044 A2,187-879-061-192-467,2021-04-19,2021,CO 2021000044 A,2021-01-06,US 2019/0040820 W;;US 201862744611 P;;US 201862695600 P,2018-07-09,Anticuerpos de unión a ilt4,"La presente solicitud se refiere a anticuerpos que se unen específicamente a la transcripción de tipo inmunoglobulina 4 (ILT4), que también se denomina LILRB2, LIR2, MIR10 y CD85d, y ácidos nucleicos, células hospedadoras, composiciones y usos correspondientes. En algunas realizaciones, los anticuerpos se unen específicamente a ILT4 humana, pero no se unen de manera significativa a ILT2, ILT3, o ILT5, o a otros miembros de las familias LILRA o LILRB.",FIVE PRIME THERAPEUTICS INC;;BRISTOL MYERS SQUIBB CO,RANKIN ANDREW;;KORMAN ALAN J;;DENG XIAODI;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G;;SCHEBYE XIAO MIN;;CHEN DIANA YUHUI;;TOTH JOSEPH;;LIANG LINDA;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;TRUONG HONG-AN;;SELBY MARK J;;LONBERG NILS,,https://lens.org/187-879-061-192-467,Patent Application,no,0,0,21,23,0,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,C07K16/28;;A61K39/395,,0,0,,,,PENDING
245,US,A1,US 2023/0174647 A1,033-222-417-146-509,2023-06-08,2023,US 202217845742 A,2022-06-21,US 202217845742 A;;US 201916506754 A;;US 2019/0040820 W;;US 201862695600 P;;US 201862744611 P,2018-07-09,Antibodies Binding to ILT4,"The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.",FIVE PRIME THERAPEUTICS INC;;BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LINDA;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;TRUONG HONG-AN;;SELBY MARK J;;LONBERG NILS;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G;;KORMAN ALAN J,BRISTOL-MYERS SQUIBB COMPANY (2019-11-07);;FIVE PRIME THERAPEUTICS INC (2018-08-20),https://lens.org/033-222-417-146-509,Patent Application,yes,0,0,21,23,193,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,C07K16/28;;A61K39/395;;A61K45/06;;A61K47/68;;A61P35/00;;G01N33/563;;G01N33/577,,0,0,,,,PENDING
246,KR,A,KR 20210030405 A,120-957-943-274-43X,2021-03-17,2021,KR 20217003581 A,2019-07-08,US 201862695600 P;;US 201862744611 P;;US 2019/0040820 W,2018-07-09,ILT4에 결합하는 항체,"본 출원은 LILRB2, LIR2, MIR10, 및 CD85d로도 공지된 이뮤노글로불린-유사 전사체 4 (ILT4)에 특이적으로 결합하는 항체, 및 상응하는 핵산, 숙주 세포, 조성물 및 용도에 관한 것이다. 일부 실시양태에서, 항체는 인간 ILT4에 특이적으로 결합하지만, ILT2, ILT3, 또는 ILT5, 또는 LILRA 또는 LILRB 패밀리의 다른 구성원에는 유의하게 결합하지 않는다.",FIVE PRIME THERAPEUTICS INC;;BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LINDA;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;TRUONG HONG AN;;SELBY MARK J;;KORMAN ALAN J;;LONBERG NILS;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G,,https://lens.org/120-957-943-274-43X,Patent Application,no,0,0,21,23,386,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,C07K16/28;;A61K39/00;;A61K47/68;;A61P35/00,,0,0,,,,PENDING
247,CL,A1,CL 2022002868 A1,027-996-149-173-624,2023-05-26,2023,CL 2022002868 A,2022-10-18,CL 2022002868 A,2022-10-18,Anticuerpos de unión a ilt4,"La presente solicitud se refiere a anticuerpos que se unen específicamente a la transcripción de tipo inmunoglobulina 4 (ILT4), que también se denomina LILRB2, LIR2, MIR10 y CD85d, y ácidos nucleicos, células hospedadoras, composiciones y usos correspondientes. En algunas realizaciones, los anticuerpos se unen específicamente a ILT4 humana, pero no se unen de manera significativa a ILT2, ILT3, o ILT5, o a otros miembros de las familias LILRA o LILRB.",BRISTOL MYERS SQUIBB CO;;FIVE PRIME THERAPEUTICS INC,LINDA LIANG;;XIAO MIN SCHEBYE;;DIANA YUHUI CHEN;;ANDREW RANKIN;;XIAODI DENG;;JOSEPH TOTH;;MICHELLE MINHUA HAN;;CHRISTINE BEE;;HONG-AN TRUONG;;MARK J SELBY;;ALAN J KORMAN;;NILS LONBERG;;GUODONG CHEN;;RICHARD Y HUANG;;EKATERINA G DEYANOVA,,https://lens.org/027-996-149-173-624,Patent Application,no,0,0,1,1,0,,C07K16/28,,0,0,,,,PENDING
248,US,B2,US 11401328 B2,061-185-492-693-057,2022-08-02,2022,US 201916506754 A,2019-07-09,US 201916506754 A;;US 2019/0040820 W;;US 201862695600 P;;US 201862744611 P,2018-07-09,Antibodies binding to ILT4,"The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.",FIVE PRIME THERAPEUTICS INC;;BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LINDA;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;TRUONG HONG-AN;;SELBY MARK J;;LONBERG NILS;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G;;KORMAN ALAN J,BRISTOL-MYERS SQUIBB COMPANY (2019-11-07);;FIVE PRIME THERAPEUTICS INC (2020-02-05),https://lens.org/061-185-492-693-057,Granted Patent,yes,122,0,21,23,193,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,C07K16/28;;A61K39/00;;A61K39/395;;A61K45/06;;A61K47/68;;A61P35/00;;G01N33/563;;G01N33/577,,79,62,150-746-446-025-000;;114-823-911-733-960;;046-446-282-189-986;;138-356-007-290-218;;029-992-129-914-979;;023-624-618-317-537;;097-120-673-396-376;;136-507-001-496-998;;010-829-765-063-343;;065-500-481-266-394;;010-504-297-156-569;;044-315-739-871-334;;103-735-731-481-015;;110-079-038-245-98X;;006-287-718-869-696;;111-400-627-758-526;;077-056-595-044-99X;;030-299-175-766-161;;078-180-835-482-089;;039-932-170-148-880;;002-689-235-356-809;;083-473-057-988-39X;;032-277-525-328-563;;035-664-339-594-189;;114-384-212-948-872;;078-796-282-548-652;;103-172-693-854-178;;054-630-796-928-010;;027-748-683-255-715;;019-969-679-133-386;;085-276-403-804-208;;052-331-765-799-241;;104-121-312-250-669;;043-812-256-401-101;;096-064-940-485-622;;085-112-711-175-967;;082-971-915-533-822;;031-401-474-181-838;;046-437-851-287-531;;122-651-085-264-657;;014-785-568-174-419;;041-515-082-041-260;;005-226-489-522-350;;013-272-508-027-337;;037-004-510-644-49X;;107-161-692-726-969;;041-280-872-720-467;;066-845-548-052-447;;088-797-106-989-990;;034-718-986-388-52X;;115-187-284-674-712;;016-557-200-838-465;;019-346-654-388-357;;128-650-517-245-26X;;037-767-497-506-281;;102-691-866-030-707;;009-352-224-779-276;;018-742-775-434-952;;009-894-541-024-308;;021-172-935-281-50X;;093-092-340-797-250;;008-013-603-294-524,9548455;;10.4049/jimmunol.159.11.5192;;pmc2196312;;10.1084/jem.185.10.1743;;9151699;;10.1002/jlb.66.3.375;;10496306;;10764620;;10.1006/smim.2000.0214;;8962177;;10.4049/jimmunol.160.7.3096;;9531263;;11160312;;10.4049/jimmunol.166.4.2514;;8617928;;8662091;;10.1007/bf02602590;;10.1007/s002510050116;;10.1002/eji.200636498;;17163451;;10.1016/j.bbmt.2010.01.019;;pmc2854246;;20139023;;20231422;;pmc3373152;;10.1182/blood-2009-09-243071;;15094202;;10.1016/j.gene.2004.02.018;;10.1002/eji.200636031;;16897816;;21376641;;10.1016/j.immuni.2011.02.004;;pmc3064726;;9886363;;10.4049/jimmunol.162.1.5;;10.4049/jimmunol.171.12.6611;;14662864;;10.1155/2014/359748;;24800261;;pmc3995100;;9079806;;10.1002/eji.1830270313;;10.4049/jimmunol.165.7.3742;;11034379;;15589454;;10.1016/j.intimp.2004.09.003;;17161342;;10.1016/j.intimp.2006.07.017;;23018130;;10.1016/j.yexmp.2012.09.011;;9417473;;pmc2199159;;10.1084/jem.186.11.1803;;10.1038/nature11095;;pmc3367397;;22660330;;10.4049/jimmunol.1003151;;21543643;;10.4049/jimmunol.0900153;;19734236;;10.1158/1538-7445.am2016-586;;10.1038/nbt1137;;16151408;;pmc3503187;;23112154;;10.1073/pnas.1205785109;;10.1002/eji.200324550;;14971032;;19535644;;10.4049/jimmunol.0803277;;11875462;;10.1038/ni760;;23890059;;10.1016/j.immuni.2013.07.012;;10.1172/jci97570;;30352428;;pmc6264729;;10.1038/ni.2376;;10.3410/f.717953957.793459478;;22842346;;pmc3622453;;pmc1276010;;16221310;;10.1186/1471-2105-6-249;;7716543;;10.1126/science.7716543;;11462053;;pmc115016;;10.1128/jvi.75.16.7769-7773.2001;;020083673;;10.4049/jimmunol.0903059;;pmc3128800;;20083673;;24899623;;pmc4126332;;10.1182/blood-2014-01-549162;;22437938;;10.1038/nri3175;;pmc3587148;;10.1182/blood-2011-08-377416;;pmc3622243;;10.4049/jimmunol.1102711;;22593621;;10.1084/jem.20100687;;pmc2964580;;20937702;;16938543;;10.1016/s0065-2776(06)91007-4;;10.1073/pnas.0803341105;;18550825;;pmc2448841;;pmc2118510;;10.1084/jem.20061865;;18025130;;10.1093/intimm/10.6.775;;9678758;;26056041;;pmc4673246;;10.18632/oncotarget.4217;;pmc3050492;;21056730;;10.1016/b978-0-12-380995-7.00004-5;;10.1016/s0966-3274(03)00058-3;;12967778;;10.1084/jem.20060631;;pmc2118540;;17420263;;22009533;;10.1158/0008-5472.can-11-1487;;10.1146/annurev.immunol.25.022106.141609;;17134371;;pmc2895922;;17400062;;10.1016/j.humimm.2006.11.008;;10.1084/jem.20100799;;21300911;;pmc3039860;;10.1073/pnas.1431057100;;12853576;;pmc166403;;pmc1637596;;10.1073/pnas.0605228103;;17056715;;pmc2574986;;18706830;;10.1016/j.cyto.2008.06.013;;10.1378/chest.07-1100;;18625675;;15879080;;10.4049/jimmunol.174.10.5907,"Borges et al., “A Family of Human Lymphoid and Myeloid Ig-Like Receptors, Some of Which Bind to MHC Class I Molecules,” J. of Immunology, 1997, 159:5192-5196.;;Cella et al, “A Novel Inhibitory Receptor (ILT3) Expressed on Monocytes, Macrophages, and Dendritic Cells Involved in Antigen Processing,” J. Exp. Med., 1997, 185(10):1743-1751.;;Colonna et al., “A novel family of Ig-like receptors for HLA Class I molecules that modulate function of lymphoid and myeloid cells,” J. Leukoc. Biol, 1999, 66:375-381.;;Colonna et al., “A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells,” Immunology, 2000, 12:121-127.;;Colonna et al., Human Killer Inhibitory Receptors: Specificity for HLA-Class I Molecules and Mechanisms of Signal Transduction, Transplantation Proceedings, 1996, 28(6):3035.;;Colonna et al., “Human Myelomonocytic Cells Express an Inhibitory Receptor for Classical and Nonclassical MHC Class I Molecules,” Journal of Immunology, 1998, 160:3096-3100.;;Dietrich et al., “Ig-Like Transcript 2 (ILT2)/Leukocyte Ig-Like Receptor 1 (LIR1) Inhibits TCR Signaling and Actin Cytoskeleton Reorganization,” J. of Immunology, 2001, 166:2514-2521.;;Dohring et al., “A Human Killer Inhibitory Receptor Specific for HLA-A 1,2,” Journal of Immunology, 1996, 156:3098-3101.;;Dohring et al., “Alternatively spliced forms of human killer inhibitory receptors,” Immunogenetics, 1996, 44:227-230.;;GenBank H26010.1, yl52b10.s1 Soares breast 3NbHBst Homo sapiens cDNA clone image sequence, 1995.;;Gleissner et al., “IL-10 inhibits endothelium-dependent T cell costimulation by up-regulation of ILT¾ in human vascular endothelial cells,” Eur. J. Immunol., 2007, 37:177-192.;;Godal et al., “NK cell killing of AML and ALL blasts by Killer-Immunoglobulin Receptor (KIR) negative NK cells after NKG2A and LIR-1 blockade,” Biol Blood Marrow Transplant, 2010, 16(5):612-621.;;Isnardi et al., “Complement receptor 2/CD21-human naive B cells contain mostly autoreactive unresponsive clones,” Blood, 2010, 115(24):5026-5036.;;Ju et al., “Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation,” Gene, 2004, 331: 159-164.;;Liang et al., “Human ILT2 receptor associates with murine MHC class I molecules in vivo and impairs T cell function,” Eur. J. Immunol.,2006, 36:2457-2471.;;Ma et al., “Paired Immunoglobin Like Receptor-B regulates the suppressive function and fate of myeloid derived suppressor cells,” Immunity, 2011, 34(3): 385-395.;;Nakajima et al., “Human Myeloid Cells Express an Activating ILT Receptor (ILT1) That Associates with Fc Receptor y-Chain”, Journal of Immunology, 1999, 162:5-8.;;Nakajima et al., “Transcriptional Regulation of ILT Family Receptors,” J of Immunology, 2003, 171:661-6620.;;Rouas-Freiss et al., “The Dual Role of HLA-G in Cancer,” J Immunol. Research, 2014, Article 359748, 10 pages.;;Samaridis and Colonna, “Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: structural evidence for new stimulatory and inhibitory pathways,” Eur. J. Immunol., 1997, 27:660-665.;;Saverino et al., “The CD85/LIR-1/ILT2 Inhibitory Receptor is Expressed by All Human T Lymphocytes and Down-Regulates Their Functions,” J. of Immunology, 2000, 165:3742-3755.;;Suciu-Foca et al., “Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review,” 2005, International Immunopharmacology, 5:7-11.;;Vlad et al., “Immunosuppressive activity of recombinant ILT3,” International Immunopharmacology, 2006, 6:1889-1894.;;Vlad et al., “Induction of antigen-specific human T suppressor cells by membrane and soluble ILT3,” Experimental and Molecular Pathology, 2012, 93:294-301.;;Yokoyama, “What Goes Up Must Come Down: The Emerging Spectrum of Inhibitory Receptors,” J. Exp. Med., 1997, 186(11):1803-1808.;;Zheng et al., “Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development,” Nature, 2012, 485:656-660.;;Von Bubnoff, D. et al. “Identification of IDO-positive and IDO-negative human dendritic cells after activation by various proinflammatory stimuli.” J. Immunol. 186:6701-9 (2011).;;Wenink et al “The inhibitory Fc gamma Ilb receptor dampens TLR4-mediated immune responses and is selectively up-regulated on dendritic cells from rheumatoid arthritis patients with quiescent disease.” J. Immunol. 183:4509-20 (2009).;;Wong, J. “Discover of a novel TIM3 binding partner and a key role for TIM3 on macrophages: identification of specific antibodies capable of converting immune-suppressive macrophages to immune-enhancing” AACR Annual Meeting, Apr. 17, 2016, Abstract No. 586, poster1.;;Adams et al. “Monoclonal antibody therapy of cancer” Nature Biotechnology, 23(9):1147-1157, 2005.;;Anonymous, “Invitrogen Data Sheet: CD85d (ILT4) Monoclonal Antibody (42D1), Functional Grade, eBioscience Catalog No. 16-5149-85,” Jan. 1, 2015, XP002788854, https://www.thermofisher.com/order/genome-database/generatePdf?productname=CD85d%20(ILT4)&assayType=PRANT&detailed=true&productId=16-5149-85, 4 pages.;;Banchereau et al. “Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming” PNAS 109(46):18885-18890 (2012).;;Beinhauer, et al. “Interleukin 10 regulates cell surface and soluble LIR-2 (CD85d) expression on dendritic cells resulting in T cell hyporesponsiveness in vitro” Eur. J. Immunol. 34: 74-80 (2004).;;Brenk et al. “Tryptophan Deprivation Induces Inhibitory Receptors ILT3 and ILT4 on Dendritic Cells Favoring the Induction of Human CD4+ CD25+ Foxp3+ T Regulatory Cells” J Immunol 183:145-154 (2009).;;Chang et al. “Tolerization of dendritic cells by Ts cells: the crucial role in inhibitory receptors ILT3 and ILT4” Nature Immunology 3(3): 237-243 (2002).;;Chen and Mellman “Oncology Meets Immunology: The Cancer-Immunity Cycle” Immunity 39, 1-10 (2013).;;Chen et al., “Blocking Immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity,” J Clin Invest, 2018, 128(12):5647-5662.;;Chiba et al, “Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1” Nat Immunol 13:832-843 (2012).;;Choo et al., “SPdb—a signal peptide database” BMC Bioinformatics, 6: 249 (2005).;;Colonna and Samaridis “Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells” Science 268:405 (1995).;;Crill, W. D., et al “Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption in Vero Cells” Journal of Virology, 75(16):7769-7773 (2001).;;Dekruyff et al, “T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells” J Immunol, 184:1918-1930 (2010).;;Deng et al., “A motif in LILRB2 critical for Angpt12 binding and activation,” Blood, 2014, 124(6):924-935.;;File History of U.S. Appl. No. 14/921,096, filed Oct. 23, 2015.;;File History of U.S. Appl. No. 14/921,100, filed Oct. 23, 2015.;;File History of U.S. Appl. No. 16/159,586, filed Oct. 12, 2018.;;File History of U.S. Appl. No. 16/159,592, filed Oct. 12, 2018.;;File History of U.S. Appl. No. 16/857,810, filed Apr. 24, 2020.;;File History of U.S. Appl. No. 16/857,878, filed Apr. 24, 2020.;;Gabrilovich et al. “Coordinated regulation of myeloid cells by tumours” Nat. Rev. Immun. 12:253-268 (2012).;;Gregori, et al. “Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway” Blood 116(6): 935-944 (2010).;;Giles, J et al. “HLA-B27 homodimers and free H chains are stronger ligands for leukocyte Ig-like receptor B2 than classical HLA class I.” J. Immunol. 188:6184-93 (2012).;;Human ILT2, precursor, with signal peptide, UniProtKB Ref. Q8NHL6.1, Jul. 24, 2013.;;Human ILT3, precursor, with signal peptide, UniProtKB Ref. Q8NHJ6.3, Sep. 18, 2013.;;Human ILT4 precursor, with signal peptide, isoform 2, NCBI Ref. NP_001074447.1, Mar. 30, 2014.;;Human ILT4 precursor, with signal peptide, UniProtKB Ref. Q8N423.4, Jul. 24, 2013.;;Human ILT5, precursor, with signal peptide, UniProtKB Ref. O75022.3, Jul. 24, 2013.;;Human TIM3 precursor, with signal peptide, UniProtKB Ref. Q8TDQ0.3, Sep. 18, 2013.;;International Search Report and Written Opinion in PCT/US/2019/040820 dated Jan. 23, 2020, 28 pages.;;Jayaraman et al. “Tim3 binding to galectin-9 stimulates antimicrobial immunity” J. Exp. Med. 207(11): 2343-2354 (2010).;;Jounce Therapeutics, “Jounce Therapeutics to Present Program Updates at AACR Annual Meeting 2016” Press Release, Mar. 16, 2016.;;Katz “Inhibition of Inflammatory Responses by LeukocyteIg-Like Receptors” Advances in Immunology, 91:251-272 (2006).;;Liang, et al. “Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6—STAT3 signaling pathway” Proc Natl Acad Sci U S A. Jun. 17, 2008;105(24):8357-62.;;Lichterfeld et al. “A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells” JEM vol. 204 No. 12 2813, (2007).;;Liu et al. “Specific suppression of allo-MHC” International immunology 10:775 (1998).;;Liu et al., “ANGPTL2/LILRB2 Signaling Promotes the Propagation of Lung Cancer Cells,” Oncotarget, 6(25): 21004-21015.;;Maldonado and Von Andrian “How Tolerogenic Dendritic Cells Induce Regulatory T Cells” Advances in Immunology, vol. 108, Chapter 4, 111-165 (2010).;;Manavalan, et al. “High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells” Transplant Immunology 11: 245-258 (2003).;;Masuda, T. et al. “Cis binding between inhibitory receptors and MHC class I can regulate mast cell activation.” J. Exp. Med. 204:907-20 (2007).;;Mouse TIM3 precursor, with signal peptide, UniProtKB Ref. Q8VIM0.1, Sep. 18, 2013.;;Ngiow, et al. “Prospects for TIM3-Targeted Antitumor Immunotherapy” Cancer Res; 71(21): 6567-6571 (2011).;;Rabinovich, et al. “Immunosuppressive Strategies that are Mediated by Tumor Cells” Annu. Rev. Immunol. 25: 267-296 (2007).;;Ristich, V. et al. “Mechanisms of prolongation of allograft survival by HLA-G/ILT4-modified dendritic cells.” Hum. Immunol. 68 (4): 264-271, (2007).;;Saito et al. “Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells” J. Exp. Med, 208(2): 235-249 (2011).;;Shiroishi, M. et al. “Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G” Proc. Natl. Acad. Sci. U.S.A 100:(15):8856-61 (2003).;;Shiroishi, M. et al. “Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d).” Proc. Natl. Acad. Sci. U.S.A 103: 16412-16417, (2006).;;Su et al. “TIM-1 and TIM-3 Proteins in Immune Regulation” Cytokine, 44(1): 9-13 (2008).;;Sun et al. “Expression of Ig-Like Transcript 4 Inhibitory Receptor in Human Non-small Cell Lung Cancer” Chest, 134:783-788, 2008.;;Vlad et al. “License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC” J Immunol 174, 5907-14 (2005).",ACTIVE
249,MX,A,MX 2021000009 A,064-301-560-792-677,2021-03-09,2021,MX 2021000009 A,2019-07-08,US 201862695600 P;;US 201862744611 P;;US 2019/0040820 W,2018-07-09,ANTIBODIES BINDING TO ILT4.,"The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.",FIVE PRIME THERAPEUTICS INC,LONBERG NILS;;SELBY MARK J;;HAN MICHELLE MINHUA;;CHEN GUODONG;;LIANG LINDA;;HUANG RICHARD Y;;SCHEBYE XIAO MIN;;BEE CHRISTINE;;RANKIN ANDREW;;KORMAN ALAN J;;DENG XIAODI;;DEYANOVA EKATERINA G;;CHEN DIANA YUHUI;;TOTH JOSEPH;;TRUONG HONG-AN,,https://lens.org/064-301-560-792-677,Patent Application,no,0,0,21,23,0,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,A61K39/395;;C07K16/28,,0,0,,,,PENDING
250,WO,A3,WO 2020/014132 A3,189-179-684-334-068,2020-02-20,2020,US 2019/0040820 W,2019-07-08,US 201862695600 P;;US 201862744611 P,2018-07-09,ANTIBODIES BINDING TO ILT4,"The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.",FIVE PRIME THERAPEUTICS INC;;BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LINDA;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;TRUONG HONG-AN;;SELBY MARK J;;KORMAN ALAN J;;LONBERG NILS;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G,,https://lens.org/189-179-684-334-068,Search Report,yes,8,0,21,23,0,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,C07K16/28;;A61K39/395,,4,3,014-785-568-174-419;;034-718-986-388-52X;;096-064-940-485-622,24899623;;pmc4126332;;10.1182/blood-2014-01-549162;;26056041;;pmc4673246;;10.18632/oncotarget.4217;;10.1172/jci97570;;30352428;;pmc6264729,"ANONYMOUS: ""Invitrogen Data sheet: CD85d (ILT4) Monoclonal Antibody (42D1),Functional Grade, eBioscience Catalog Number 16-5149-85"", INTERNET CITATION, 1 January 2015 (2015-01-01), XP002788854, Retrieved from the Internet <URL:https://www.thermofisher.com/order/genome-database/generatePdf?productName=CD85d%20(ILT4)&assayType=PRANT&detailed=true&productId=16-5149-85> [retrieved on 1077];;M. DENG ET AL: ""A motif in LILRB2 critical for Angptl2 binding and activation"", BLOOD, vol. 124, no. 6, 7 August 2014 (2014-08-07), pages 924 - 935, XP055204710, ISSN: 0006-4971, DOI: 10.1182/blood-2014-01-549162;;XIAOYE LIU ET AL: ""ANGPTL2/LILRB2 signaling promotes the propagation of lung cancer cells"", ONCOTARGET, vol. 6, no. 25, 28 August 2015 (2015-08-28), XP055471907, DOI: 10.18632/oncotarget.4217;;HUI-MING CHEN ET AL: ""Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity"", JOURNAL OF CLINICAL INVESTIGATION, vol. 128, no. 12, 22 October 2018 (2018-10-22), GB, pages 5647 - 5662, XP055554809, ISSN: 0021-9738, DOI: 10.1172/JCI97570",PENDING
251,TW,A,TW 202012438 A,085-566-671-219-57X,2020-04-01,2020,TW 108123980 A,2019-07-08,US 201862695600 P;;US 201862744611 P,2018-07-09,Antibodies binding to ILT4,"The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.",FIVE PRIME THERAPEUTICS INC;;BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LINDA;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;TRUONG HONG-AN;;SELBY MARK J;;KORMAN ALAN J;;LONBERG NILS;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G,,https://lens.org/085-566-671-219-57X,Patent of Addition,no,0,0,21,23,0,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,C07K16/18;;A61K39/395;;C12N15/13,,0,0,,,,ACTIVE
252,CA,A1,CA 3104530 A1,094-191-063-719-341,2020-01-16,2020,CA 3104530 A,2019-07-08,US 201862695600 P;;US 201862744611 P;;US 2019/0040820 W,2018-07-09,ANTIBODIES BINDING TO ILT4,"The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.",FIVE PRIME THERAPEUTICS INC;;BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LINDA;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;TRUONG HONG-AN;;SELBY MARK J;;KORMAN ALAN J;;LONBERG NILS;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G,,https://lens.org/094-191-063-719-341,Patent Application,no,0,0,21,23,193,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,C07K16/28;;A61K39/395,,0,0,,,,PENDING
253,AU,A1,AU 2019/302454 A1,181-189-029-340-523,2021-02-25,2021,AU 2019/302454 A,2019-07-08,US 201862744611 P;;US 201862695600 P;;US 2019/0040820 W,2018-07-09,Antibodies binding to ILT4,"The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.",BRISTOL MYERS SQUIBB CO;;FIVE PRIME THERAPEUTICS INC,SCHEBYE XIAO MIN;;CHEN DIANA YUHUI;;RANKIN ANDREW;;DENG XIAODI;;TOTH JOSEPH;;LIANG LINDA;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;TRUONG HONG-AN;;SELBY MARK J;;KORMAN ALAN J;;LONBERG NILS;;CHEN GUODONG;;HUANG RICHARD Y;;DEYANOVA EKATERINA G,,https://lens.org/181-189-029-340-523,Patent Application,no,0,0,21,23,0,C07K16/2803;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61K47/6803;;A61K2039/505;;A61P35/00;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/563;;G01N33/577;;C07K16/2803;;A61K47/6803;;A61P35/00;;C07K2317/92;;C07K2317/565;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/74;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K47/6803;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/40;;C07K2317/55;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;G01N33/563;;G01N33/577,C07K16/28;;A61K39/395,,0,0,,,,PENDING
254,ES,T3,ES 2810856 T3,198-571-987-851-196,2021-03-09,2021,ES 16731700 T,2016-06-02,US 201562170579 P;;US 2016/0035514 W,2015-06-03,Anticuerpos ANTI-GITR para diagnóstico de cáncer,"Un método para determinar el nivel de expresión del receptor de TNF inducible por glucocorticoides (GITR) en linfocitos infiltrantes de tumores (TIL) y/o en células tumorales en una muestra de tejido, que comprende (a) poner en contacto una muestra de tejido de un paciente con un anticuerpo o una porción de unión a antígeno del mismo, que comprenden las CDR1, CDR2 y CDR3 de la región variable de cadena pesada que comprenden las secuencias de aminoácidos expuestas en las SEQ ID NO: 5-7, respectivamente, y las CDR1, CDR2 y CDR3 de la región variable de cadena ligera que comprenden las secuencias de aminoácidos expuestas en las SEQ ID NO: 8-10, respectivamente, en donde el anticuerpo o la porción de unión a antígeno del mismo se unen a GITR humano, (b) detectar la unión del anticuerpo a GITR en TIL y células tumorales de la muestra de tejido mediante inmunohistoquímica; y, opcionalmente, (c) teñir la muestra de tejido con marcadores de TIL y/o células tumorales y/o con hematoxilina y eosina, para identificar los TIL y/o las células tumorales que se identificaron como GITR positivos en la etapa (b).",BRISTOL MYERS SQUIBB CO,WANG XI-TAO;;ADELAKUN OLUFEMI;;LEWIN ANNE;;KORMAN ALAN;;SELBY MARK;;WANG CHANGYU;;HUANG HAICHUN;;HENNING KARLA;;LONBERG NILS;;SRINIVASAN MOHAN;;HAN MICHELLE;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;WONG SUSAN;;LI HUIMING,,https://lens.org/198-571-987-851-196,Granted Patent,no,0,0,16,16,0,C07K16/2878;;G01N33/566;;C07K2317/56;;C07K2317/24;;C07K2317/21;;C07K2317/92;;G01N2800/52;;G01N2800/7028;;G01N2333/70578;;C07K16/2878;;G01N33/566;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/92;;G01N2333/70578;;G01N2800/52;;G01N2800/7028;;A61P35/00;;A61P43/00;;C07K2317/21;;C07K2317/92;;G01N33/566;;C07K2317/24;;G01N2800/7028;;C07K2317/56;;C07K16/2878;;G01N2800/52;;G01N2333/70578;;C07K16/2866;;G01N33/57492;;G01N2333/4703;;G01N2333/7051;;G01N2333/7151,G01N33/566;;C07K16/28,,0,0,,,,ACTIVE
255,ES,T3,ES 2926969 T3,171-765-547-422-457,2022-10-31,2022,ES 16805668 T,2016-11-17,US 201562257599 P;;US 201662303990 P;;US 2016/0062540 W,2015-11-19,Anticuerpos contra el receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos,"En el presente documento se proporcionan anticuerpos, o porciones de unión a antígeno de los mismos, que se unen al receptor de TNF inducible por glucocorticoides (GITR). También se proporcionan usos de estas proteínas en aplicaciones terapéuticas, como en el tratamiento del cáncer. Además se proporcionan células que producen los anticuerpos, polinucleótidos que codifican la región variable de cadena pesada y/o ligera de los anticuerpos y vectores que comprenden los polinucleótidos que codifican la región variable de cadena pesada y/o ligera de los anticuerpos. (Traducción automática con Google Translate, sin valor legal)",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN;;SELBY MARK;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING;;BARNHART BRYAN;;YAMNIUK AARON;;LEI MING;;SCHWEIZER LIANG;;HATCHER SANDRA;;RAJPAL ARVIND,,https://lens.org/171-765-547-422-457,Granted Patent,no,0,0,20,20,0,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,C07K16/28;;A61K39/00,,0,0,,,,ACTIVE
256,SG,A,SG 11201803817P A,101-632-663-319-897,2018-06-28,2018,SG 11201803817P A,2016-11-17,US 201562257599 P;;US 201662303990 P;;US 2016/0062540 W,2015-11-19,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN;;SELBY MARK;;SRINIVASAN MOHAN;;HENNING KARLA;;HAN MICHELLE;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN;;LI HUIMING;;BARNHART BRYAN;;YAMNIUK AARON;;LEI MING;;SCHWEIZER LIANG;;HATCHER SANDRA;;RAJPAL ARVIND,,https://lens.org/101-632-663-319-897,Unknown,no,0,0,20,20,0,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,C07K16/28;;A61K39/00,,0,0,,,,PENDING
257,US,A1,US 2018/0298097 A1,125-844-920-950-600,2018-10-18,2018,US 201816017489 A,2018-06-25,US 201816017489 A;;US 201715649380 A;;US 201762459499 P;;US 201662362541 P,2016-07-14,ANTIBODIES AGAINST TIM3 AND USES THEREOF,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TROUNG HONG-AN,BRISTOL-MYERS SQUIBB COMPANY (2017-07-21),https://lens.org/125-844-920-950-600,Patent Application,yes,1,2,36,39,385,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28;;A61K39/00;;C07K16/30,,0,0,,,,ACTIVE
258,US,A1,US 2019/0248893 A1,152-852-332-582-353,2019-08-15,2019,US 201716316991 A,2017-07-13,US 201716316991 A;;US 201662362541 P;;US 201762459499 P;;US 2017/0041946 W,2016-07-14,ANTIBODIES AGAINST TIM3 AND USES THEREOF,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD Y;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/152-852-332-582-353,Patent Application,yes,2,0,36,39,385,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28;;A61K47/68;;A61P35/00;;G01N33/574,,9,9,000-139-141-530-387;;023-538-920-210-254;;058-417-996-127-86X;;014-113-432-888-031;;043-435-453-778-150;;051-707-000-800-833;;055-003-061-629-507;;015-526-281-580-102;;000-763-425-467-323,10.1242/dmm.024547;;26839397;;pmc4770152;;10.1016/j.sbi.2009.08.003;;19765975;;pmc7276102;;32641900;;10.1007/s00044-020-02582-9;;12218124;;10.4049/jimmunol.169.6.3076;;16162266;;10.1111/j.1365-2567.2005.02208.x;;pmc1817819;;12079396;;10.1016/s0022-2836(02)00264-4;;10.1073/pnas.0403255101;;pmc438954;;15197260;;16358815;;10.1111/j.1087-0024.2005.200409.x;;30374066;;10.1038/s41588-018-0251-4,"Justice et al. Using the mouse to model human disease: increasing validity and reproducibility, Disease, Models & Mechanisms 9:101-103, (2016). (Year: 2016);;Tokuriki et al., Stability effects of mutations and protein evolvability. Curr. Opin. Struc. Biol. 19:596-604; (2009). (Year: 2009);;Fenton et al. Rheostat positions: A new classification of protein positions relevant to pharmacogenomics Medicinal Chemistry Research 29:1133-1146; (2020). (Year: 2020);;De Pascalis et al. Grafting of ""abbreviated"" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. The Journal of Immunology, 169:3076- 3084, (2002). (Year: 2002);;Bose and Sinha. Problems in using statistical analysis of replacement and silent mutations in antibody genes for determining antigen-driven affinity selection. Immunology, Vol. 116:172-183, (2005). (Year: 2005);;Vajdos et al. Comprehensive functional maps of the antigen-binding site of an anti-ErobB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol. 320(2):415-428; (2002). (Year: 2002);;Guo et al. Protein tolerance to random amino acid change. PNAS USA 101(25):9205-10; (2004). (Year: 2004);;Ha et al. Animal Models of Melanoma. JID Symposium Proceedings pages 86-89) (November 2005). (Year: 2005);;Gayden et al. Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nature Genetics Vol 50:1650-1657 (December 2018). (Year: 2018)",PENDING
259,CL,A1,CL 2021000698 A1,199-270-768-248-183,2021-08-13,2021,CL 2021000698 A,2021-03-22,US 201662362541 P;;US 201762459499 P,2016-07-14,Anticuerpos contra tim3 y usos de los mismos (divisional solicitud n° 201900100),"La presente invención se refiere a anticuerpos, o porciones de unión al antígeno de los mismos, que se unen a la proteína 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos T (TIM3). También se proporcionan usos de estos anticuerpos, o porciones de unión al antígeno de los mismos, en aplicaciones terapéuticas, tales como el tratamiento del cáncer. También se proporcionan células que producen los anticuerpos, o porciones de unión al antígeno de los mismos, polinucleótidos que codifican las regiones de las cadenas pesada y1'o ligera de los anticuerpos, o porciones de unión al antígeno de los mismos, y vectores que comprenden los polinucleótidos que codifican las regiones de las cadenas pesada yio ligera de los anticuerpos, o porciones de unión al antígeno de los mismos.",BRISTOL MYERS SQUIBB CO,XIAO MIN SCHEBYE;;MARK J SELBY;;MICHELLE MINHUA HAN;;CHRISTINE BEE;;ANDY X DENG;;ANAN CHUNTHARAPAI;;BRIGITTE DEVAUX;;HUIMING LI;;PAUL O SHEPPARD;;ALAN J KORMAN;;DANIEL F ARDOUREL;;EKATERINA DEYANOVA;;RICHARD HUANG;;GUODONG CHEN;;MICHELLE KUHNE;;HONG-AN TRUONG,,https://lens.org/199-270-768-248-183,Patent Application,no,0,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28,,0,0,,,,PENDING
260,WO,A1,WO 2016/196792 A1,043-521-854-674-695,2016-12-08,2016,US 2016/0035514 W,2016-06-02,US 201562170579 P,2015-06-03,ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS,"Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.",BRISTOL MYERS SQUIBB CO,WANG XI-TAO;;ADELAKUN OLUFEMI A;;LEWIN ANNE C;;KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;HUANG HAICHUN;;HENNING KARLA A;;LONBERG NILS;;SRINIVASAN MOHAN;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;WONG SUSAN CHIEN-SZU;;LI HUIMING,,https://lens.org/043-521-854-674-695,Patent Application,yes,3,62,16,16,228,C07K16/2878;;G01N33/566;;C07K2317/56;;C07K2317/24;;C07K2317/21;;C07K2317/92;;G01N2800/52;;G01N2800/7028;;G01N2333/70578;;C07K16/2878;;G01N33/566;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/92;;G01N2333/70578;;G01N2800/52;;G01N2800/7028;;A61P35/00;;A61P43/00;;C07K2317/21;;C07K2317/92;;G01N33/566;;C07K2317/24;;G01N2800/7028;;C07K2317/56;;C07K16/2878;;G01N2800/52;;G01N2333/70578;;C07K16/2866;;G01N33/57492;;G01N2333/4703;;G01N2333/7051;;G01N2333/7151,G01N33/566;;C07K16/28,,4,4,037-103-075-806-573;;039-634-532-775-166;;045-706-253-475-176;;048-960-656-989-289,23856878;;10.1590/0037-8682-0029-2013;;17360848;;10.1096/fj.06-7724com;;20734397;;10.1002/cncr.25371;;20012605;;10.1007/s00262-009-0803-7,"CACILDA TEZELLI JUNQUEIRA PADOVANI ET AL: ""Glucocorticoid-induced tumor necrosis factor receptor expression in patients with cervical human papillomavirus infection"", REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL., vol. 46, no. 3, 1 June 2013 (2013-06-01), BR, pages 288 - 292, XP055301933, ISSN: 0037-8682, DOI: 10.1590/0037-8682-0029-2013;;K. M. BALTZ ET AL: ""Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions"", THE FASEB JOURNAL, vol. 21, no. 10, 1 August 2007 (2007-08-01), US, pages 2442 - 2454, XP055301914, ISSN: 0892-6638, DOI: 10.1096/fj.06-7724com;;WEN-CHUN CHANG ET AL: ""Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma"", CANCER., vol. 116, no. 24, 15 December 2010 (2010-12-15), US, pages 5777 - 5788, XP055301514, ISSN: 0008-543X, DOI: 10.1002/cncr.25371;;THA PRG A-S HELENA GASPAROTO ET AL: ""Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment"", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 59, no. 6, 12 December 2009 (2009-12-12), pages 819 - 828, XP019800202, ISSN: 1432-0851",PENDING
261,TW,A,TW 202244061 A,096-008-278-921-12X,2022-11-16,2022,TW 111102986 A,2017-07-13,US 201662362541 P;;US 201762459499 P,2016-07-14,Antibodies against TIM3 and uses thereof,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/096-008-278-921-12X,Patent of Addition,no,0,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28;;A61K39/395;;A61P35/00;;A61P37/04;;C07K16/42;;G01N33/566,,0,0,,,,PENDING
262,CN,A,CN 109757103 A,175-672-490-111-836,2019-05-14,2019,CN 201780056616 A,2017-07-13,US 201662362541 P;;US 201762459499 P;;US 2017/0041946 W,2016-07-14,ANTIBODIES AGAINST TIM3 AND USES THEREOF,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/175-672-490-111-836,Patent Application,no,5,7,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28,,2,0,,,"KIKUSHIGE Y等: ""TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia"", 《ANNALS OF THE NEW YORK ACADEMY OF SCIENCES》;;FERRIS R L等: ""Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion"", 《THE JOURNAL OF IMMUNOLOGY》",ACTIVE
263,TW,A,TW 201811829 A,058-090-983-208-319,2018-04-01,2018,TW 106123527 A,2017-07-13,US 201662362541 P;;US 201762459499 P,2016-07-14,Antibodies against TIM3 and uses thereof,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/058-090-983-208-319,Patent of Addition,no,0,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28;;A61K39/395;;A61P35/00;;A61P37/04;;C07K16/42;;G01N33/566,,0,0,,,,ACTIVE
264,US,B2,US 11591392 B2,108-557-249-250-289,2023-02-28,2023,US 201916697653 A,2019-11-27,US 201916697653 A;;US 201816017489 A;;US 201715649380 A;;US 201762459499 P;;US 201662362541 P,2016-07-14,Antibodies against TIM3 and uses thereof,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,BRISTOL-MYERS SQUIBB COMPANY (2017-07-21),https://lens.org/108-557-249-250-289,Granted Patent,yes,285,0,36,39,385,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,A61P35/00;;A61K39/00;;A61K47/68;;C07K16/28;;C07K16/30;;G01N33/574,,91,79,018-069-206-369-372;;017-150-654-990-340;;005-112-559-456-657;;006-553-734-546-212;;105-316-874-895-908;;022-179-293-052-569;;018-694-084-068-187;;041-909-244-299-232;;078-432-639-041-575;;087-879-787-031-413;;089-689-557-564-287;;035-135-729-507-737;;052-219-543-437-800;;073-130-138-292-805;;020-986-423-793-233;;082-210-673-349-152;;010-488-381-022-259;;066-749-017-721-197;;008-213-515-306-640;;002-264-966-090-625;;127-416-339-660-812;;030-249-121-435-10X;;020-123-860-433-320;;068-238-957-669-243;;104-212-297-137-759;;038-478-749-169-986;;084-388-182-984-099;;043-108-278-056-872;;032-820-729-763-323;;030-630-100-818-462;;005-022-447-377-963;;012-746-915-512-650;;053-703-232-770-99X;;023-676-781-371-861;;009-621-637-014-514;;003-763-873-758-289;;070-624-200-848-669;;024-348-828-966-680;;001-467-559-709-949;;030-323-674-660-051;;042-204-626-457-327;;068-450-506-389-89X;;027-326-505-837-755;;111-914-031-290-975;;012-300-595-074-789;;004-458-031-333-650;;003-752-183-823-430;;040-577-067-037-463;;062-029-719-290-327;;094-082-569-858-098;;088-086-720-613-343;;071-707-020-428-907;;047-951-914-695-080;;092-023-577-402-127;;060-375-551-951-388;;033-754-369-798-314;;070-318-112-524-781;;051-940-176-386-905;;094-685-907-794-422;;074-817-300-512-106;;056-422-417-058-69X;;042-740-484-382-110;;034-714-253-790-433;;122-651-085-264-657;;026-418-623-750-230;;057-102-333-317-731;;071-623-595-422-33X;;015-507-770-980-445;;077-737-756-070-317;;023-291-888-616-366;;000-139-141-530-387;;023-538-920-210-254;;058-417-996-127-86X;;014-113-432-888-031;;043-435-453-778-150;;051-707-000-800-833;;055-003-061-629-507;;015-526-281-580-102;;003-652-724-305-102,10.1158/2326-6066.cir-14-0039;;24795351;;3140379;;10.1126/science.3140379;;10.1126/science.3925553;;3925553;;8424945;;10.1021/bi00055a024;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.1002/eji.1830240409;;8149953;;10.1126/science.2471267;;2471267;;12391234;;10.4049/jimmunol.169.9.5171;;10.1074/jbc.m604292200;;16793771;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10.1084/jem.20100637;;20819923;;pmc2947081;;10.4049/jimmunol.172.9.5489;;15100290;;2958547;;10.4049/jimmunol.139.7.2367;;24339828;;10.3389/fimmu.2013.00449;;pmc3857553;;15470033;;10.4049/jimmunol.173.8.4919;;10.4049/jimmunol.176.1.346;;16365427;;14699147;;10.1074/jbc.c300470200;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;9930702;;10.1038/16717;;15930300;;10.1158/0008-5472.can-04-3319;;10.1016/0014-5793(94)00313-0;;8206150;;10556249;;10.1093/protein/12.10.879;;10.4049/jimmunol.148.5.1547;;1531669;;10.2174/1389201023378229;;12463418;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;7494109;;10.3109/08830189509061738;;8159246;;10.1038/368856a0;;10.1038/348552a0;;2247164;;9176498;;10.1038/nm0697-682;;11275255;;10.1016/s0161-5890(00)00105-x;;9850053;;10.1126/science.3929380;;3929380;;10.1093/chromsci/40.6.343;;12137207;;10.1182/blood-2008-10-185884;;19224762;;10.1038/316452a0;;3927174;;10.1182/blood-2010-10-310425;;21385853;;pmc3099570;;10.1016/s0969-2126(94)00113-8;;7704521;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;3127726;;10.1038/332323a0;;21810406;;pmc3175029;;10.1016/j.bbamem.2011.07.026;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1016/0161-5890(92)90200-h;;1533898;;10.1016/j.cbpa.2009.03.023;;19414278;;11096108;;10.1074/jbc.m009483200;;11986321;;10.1074/jbc.m202069200;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;12042244;;10.1093/glycob/12.4.43r;;17875730;;10.1158/0008-5472.can-07-0696;;19896358;;10.1016/j.copbio.2009.10.011;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;1404388;;10.1016/0022-2836(92)90223-7;;8144892;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;10.1038/6179;;10052355;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;2459288;;pmc2189025;;10.1084/jem.168.3.1099;;10.1038/341544a0;;2677748;;10657670;;10.4049/jimmunol.164.4.2160;;10.4049/jimmunol.0804182;;19494290;;10.1111/j.0105-2896.2010.00903.x;;pmc2914464;;20536563;;020083673;;10.4049/jimmunol.0903059;;pmc3128800;;20083673;;20073133;;pmc2726606;;10.4161/mabs.1.4.9122;;11725301;;10.1038/ni739;;10.1038/415536a;;11823861;;24046178;;10.1007/s12185-013-1433-6;;25086175;;pmc4120324;;10.4049/jimmunol.1400557;;16272294;;10.4049/jimmunol.175.10.6420;;10.1242/dmm.024547;;26839397;;pmc4770152;;10.1016/j.sbi.2009.08.003;;19765975;;pmc7276102;;32641900;;10.1007/s00044-020-02582-9;;12218124;;10.4049/jimmunol.169.6.3076;;16162266;;10.1111/j.1365-2567.2005.02208.x;;pmc1817819;;12079396;;10.1016/s0022-2836(02)00264-4;;10.1073/pnas.0403255101;;pmc438954;;15197260;;16358815;;10.1111/j.1087-0024.2005.200409.x;;10.5732/cjc.011.10007;;pmc4013311;;21352692,"Anderson, A.C., “Tim-3: an Emerging Target in the Cancer Immunotherapy Landscape ,” Cancer Immunology Research 2(5):393-398, American Association for Cancer Research, United States (2014).;;Bird, R.E., et al., “Single-chain Antigen-binding Proteins,” Science 242(4877):423-426, Association for the Advancement of Science, United States (Oct. 1988).;;Brennan, M., et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science 229(4708):81-83, American Association for the Advancement of Science, United States (Jul. 1985).;;Brummell, D.A., et al., “Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues,” Biochemistry 32(4):1180-1187, American Chemical Society, United States (1993).;;Burks, E.A., et al., “In vitro Scanning Saturation Mutagenesis of an Antibody Binding Pocket,” Proceedings of the National Academy of Sciences USA 94(2):412-417, Plenum Publishing Corporation, United States (1997).;;Cox, J.P., et al., “A Directory of Human Germ-line V kappa Segments Reveals a Strong Bias in their Usage,” European Journal of Immunology 24(4):827-836, Verlag Chemie GmbH, Germany (Apr. 1994).;;Cunningham, B.C. and Wells, J.A., “High-resolution Epitope Mapping of hGH-receptor Interactions by Alanine-scanning Mutagenesis,” Science 244(4908):1081-1085, American Association for the Advancement of Science, United States (Jun. 1989).;;Dall Acqua, W.F., et al., “Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences,” The Journal of Immunology 169(9):5171-5180, American Association of Immunologists, United States (Nov. 2002).;;Dall'Acqua, W.F., et al., “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn),” The Journal of Biological Chemistry 281 (33):23514-23524, American □ Society for Biochemistry and Molecular Biology, United States (2006).;;Dranoff, G., et al., “Vaccination With Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-macrophage Colony-stimulating Factor Stimulates Potent, Specific, and Long-lasting -Anti-tumor Immunity,” Proceedings of the National Academy of Sciences of the United States of America 90(8):3539-3543, National Academy of Sciences, United States (1993).;;Fourcade, J., et al., “Upregulation of Tim-3 and PDd-1 Expression Is Associated With Tumor Antigen-specific CD8+ T Cell Dysfunction in Melanoma Patients,” The Journal of Experimental □ Medicine 207(10):2175-2186, Rockefeller University Press, United States (2010).;;Gala, F.A. and Morrison, S.L., “V Region Carbohydrate and Antibody Expression,” The Journal of Immunology 172(9):5489-5494, Williams & Wilkins, United States (2004).;;Genbank, “HAVCR2 protein [Homo sapiens],” Accession No. AAH20843.1, accessed on https://www.ncbi.nlm.nih.gov/protein/AAH20843, Sep. 16, 2003.;;Genbank, “Hepatitis A Virus Cellular Receptor 2 Precursor [Homo sapiens],” Accession No. NP_116171.3, accessed on https://www.ncbi.nlm.nih.gov/protein/NP_116171, Jun. 15, 2017.;;Genbank, “Homo sapiens Hepatitis A Virus Cellular Receptor 2 (HAVCR2), mRNA,” Accession No. NM 032782.4, accessed on https://www.ncbi.nlm.nih.gov/nuccore/NM 032782.4, Jun. 15, □ 2017.;;Genbank, “Homo sapiens Hepatitis A Virus Cellular Receptor 2, mRNA (cDNA clone IMAGE:4701288), Complete Cds,” Accession No. BC020843.1, accessed on □ https://www.ncbi.nlm.nih.gov/nuccore/BC020843.1, Sep. 16, 2003.;;Glennie, M.J., et al., “Preparation and Performance of Bispecific F(Ab′ Gamma)2 Antibody Containing Thioether-linked Fab′ Gamma Fragments,” Journal of Immunology 139(7):2367-2375, □ American Association of Immunologists, United States (1987).;;Han, G., et al., “Tim-3: an Activation Marker and Activation Limiter of Innate Immune Cells,” Frontiers in Immunology 4:449, Frontiers Research, Switzerland (2013).;;He, Y-F., et al., “Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine,” The Journal of Immunology 173(8):4919-4928, The American Association of Immunologists, United States (Oct. 2004).;;Hinton, P.R., et al., “An Engineered Human IgG1 Antibody with Longer Serum Half-Life,” Journal of Immunology 176(1):346-356, American Association of Immunologists, United States (2006).;;Hinton, P.R., et al., “Engineered Human IgG Antibodies With Longer Serum Half-lives in Primates,” The Journal of Biological Chemistry 279(8):6213-6216, American Society for Biochemistry and □ Molecular Biology, United States (2004).;;Holliger, P., et al., “Diabodies: Small Bivalent and Bispecific Antibody Fragments,” Proceedings of the National Academy of Sciences USA 90(14):6444-6448, National Academy of Sciences, United States (Jul. 1993).;;Hurwitz, A.A., et al., “CTLA-4 Blockade Synergizes With Tumor-derived Granulocyte-macrophage Colony-stimulating Factor for Treatment of an Experimental Mammary Carcinoma,” Proceedings of the National Academy of Sciences of the United States of America 95(17):10067-10071, National Academy of Sciences, United States (1998).;;Huston, J.S., et al., “Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-digoxin Single-chain Fv Analogue Produced in Escherichia coli,” Proceedings of the National Academy of Sciences USA 85(16):5879-5883, National Academy of Sciences, United States (Aug. 1988).;;Hutloff, A., et al., “ICOS is an Inducible T-cell Co-stimulator Structurally and Functionally Related to CD28,” Nature 397(6716):263-266, Nature Publishing Group, England (Jan. 1999).;;Hyer, M.L., et al., “Synthetic Triterpenoids Cooperate With Tumor Necrosis Factor-related Apoptosis-inducing Ligand to Induce Apoptosis of Breast Cancer Cells,” Cancer Research 65(11):4799-4808, American Association for Cancer Research, United States (2005).;;Kabat, E.A., et al., “Sequences of Proteins of Immunological Interest,” 5th Edition, U.S. Department of Public Health and Human Services, Public Health Service, National Institutes of Health, Bethesda (1991).;;Keinanen, K. and Laukkanen, M.L., “Biosynthetic Lipid-tagging of Antibodies,” FEBS Letters 346(1):123-126, John Wiley & Sons Ltd, England (1994).;;Kobayashi, H., et al., “Tryptophan H33 Plays an Important Role in Pyrimidine (6-4) Pyrimidone Photoproduct Binding by a High-Affinity Antibody,” Protein Engineering Design and Selection 12(10):879-884, Oxford University Press, United States (1999).;;Kostelny, S.A., et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology 148(5):1547-1553, American Association of Immunologists, United States (Mar. 1992).;;Krishnamurthy, R. and Manning, M.C., “The Stability Factor: Importance in Formulation Development,” Current Pharmaceutical Biotechnology 3(4):361-371, Bentham Science Publishers, Netherlands (2002).;;Liu, M.A., et al., “Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America 82(24):8648-8652, National Academy of Sciences, United States (1985).;;Lonberg, N. and Huszar, D., “Human Antibodies from Transgenic Mice,” International Reviews of Immunology 13(1):65-93, Informa Healthcare, England (1995).;;Lonberg, N., et al., “Antigen-specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications,” Nature 368(6474):856-859, Nature Publishing Group, United States (Apr. 1994).;;McCafferty, J., et al., “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains,” Nature 348(6301):552-554, Nature Publishing Group, London (Dec. 1990).;;Melero, I., et al., “Monoclonal Antibodies Against the 4-1 BB T-cell Activation Molecule Eradicate Established Tumors,” Nature Medicine 3(6):682-685, Nature Publishing Company, United States (1997).;;Mimura, Y., et al., “The Influence of Glycosylation on the Thermal Stability and Effector Function Expression of Human IgG1-Fc: Properties of a Series of Truncated Glycoforms,” Molecular Immunology 37(12-13):697-706, Pergamon Press, England (2000).;;Mokyr, M.B., et al., “Realization of the Therapeutic Potential of CTLA-4 Blockade in Low-dose Chemotherapy-treated Tumor-bearing Mice,” Cancer Research 58(23):5301-5304, American Association for Cancer Research, United States (1998).;;Morrison, S.L., “Transfectomas Provide Novel Chimeric Antibodies,” Science 229(4719): 1202-1207, Association for the Advancement of Science, United States (Sep. 1985).;;Murray, A., et al., “Epitope Affinity Chromatography and Biophysical Studies of Monoclonal Antibodies and Recombinant Antibody Fragments,” Journal of Chromatographic Science 40(6):343-349, Oxford University Press, United States (2002).;;Nakayama, M., et al., “Tim-3 Mediates Phagocytosis of Apoptotic Cells and Cross-presentation,” Blood 113(16):3821-3830, American Society of Hematology, United States (2009).;;Ngiow, S.F., et al., “Anti-TIM3 Antibody Promotes T Cell IFN-γ-mediated Antitumor Immunity and Suppresses Established Tumors,” Cancer Research 71(10):3540-3451, American Association for Cancer Research, United States (2011).;;Parekh, R.B., et al., “Association of Rheumatoid Arthritis and Primary Osteoarthritis with Changes in the Glycosylation Pattern of Total Serum IgG,” Nature 316(6027):452-457, Nature Publishing Group, England (1985).;;Zhou, Q., et al., “Coexpression of Tim-3 and PD-1 Identifies a CD8+ T-Cell Exhaustion Phenotype in Mice With Disseminated Acute Myelogenous Leukemia,” Blood 117(17):4501-4510, American Society of Hematology, United States (Apr. 2011).;;Pei-Show Juo., The Concise Dictionary of Biomedicine and Molecular Biology, 2nd Edition, CRC Press, United States (2002).;;Poljak, R.J., “Production and Structure of Diabodies,” Structure 2(12):1121-1123, Cell Press, United States (1994).;;Queen, C., et al., “A Humanized Antibody that Binds to the Interleukin 2 Receptor,” Proceedings of the National Academy of Sciences USA 86(24):10029-10033, National Academy of Sciences, United States (Dec. 1989).;;Riechmann, L., et al., “Reshaping Human Antibodies for Therapy,” Nature 332(6162):323-327, Nature Publishing Group, United States (Mar. 1988).;;Riedl, S., et al., “In Search of a Novel Target—Phosphatidylserine Exposed by Non-apoptotic Tumor Cells and Metastases of Malignancies With Poor Treatment Efficacy,” Biochimica Et Biophysica Acta 1808(11):2638-2645, Elsevier Pub. Co., Netherlands (2011).;;Rosenberg, S.A., “A New Era for Cancer Immunotherapy Based on the Genes That Encode Cancer Antigens,” Immunity 10(3):281-287, Cell Press, United States (1999).;;Sarmay, G., et al., “Mapping and Comparison of the Interaction Sites on the Fc Region of IgG Responsible for Triggering Antibody Dependent Cellular Cytotoxicity (ADCC) Through Different Types of Human Fc Gamma Receptor,” Molecular Immunology 29(5):633-639, Pergamon Press, England (1992).;;Senter, P.D., “Potent Antibody Drug Conjugates for Cancer Therapy,” Current Opinion in Chemical Biology 13(3):235-244, Elsevier, England (2009).;;Shields, R.L., et al., “High Resolution Mapping of the Binding Site on Human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIH, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc gamma R,” The Journal of Biological Chemistry 276(9):6591-6604, American Society for Biochemistry and Molecular Biology, United States (Mar. 2001).;;Shields, R.L., et al., “Lack of Fucose on Human IgG1 N-linked Oligosaccharide Improves Binding to Human Fcgamma RIII and Antibody-Dependent Cellular Toxicity,” The Journal of Biological—Chemistry 277(30):26733-26740, American Society for Biochemistry and Molecular Biology, United States (2002).;;Songsivilai, S. and Lachmann, P.J., “Bispecific Antibody: A Tool for Diagnosis and Treatment of Disease,” Clinical and Experimental Immunology 79(3):315-321, Blackwell Scientific Publications, England (1990).;;Spiro, R.G., “Protein Glycosylation: Nature, Distribution, Enzymatic Formation, and Disease Implications of Glycopeptide Bonds,” Glycobiology 12(4):43R-56R, IRL Press at Oxford University Press, England (2002).;;Stavenhagen, J.B., et al., “Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells in Vitro and Controls Tumor Expansion in Vivo via Low-affinity Activating Fcgamma Receptors,” Cancer Research 67(18):8882-8890, American Association for Cancer Research, United States (2007).;;Strohl, W.R., “Optimization of Fc-mediated Effector Functions of Monoclonal Antibodies,” Current Opinion in Biotechnology 20(6):685-691, Elsevier, England (2009).;;Taylor, L.D., et al., “A Transgenic Mouse That Expresses a Diversity of Human Sequence Heavy and Light Chain Immunoglobulins,” Nucleic Acids Research 20(23):6287-6295, Oxford University Press, England (1992).;;Tomizuka, K., et al., “Double Trans-chromosomic Mice: Maintenance of Two Individual Human Chromosome Fragments Containing Ig Heavy and kappa loci and Expression of Fully Human Antibodies,” Proceedings of the National Academy of Sciences USA 97(2):722-727, National Academy of Sciences, United States (Jan. 2000).;;Tomlinson, I.M., et al., “The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops,” Journal of Molecular Biology 227(3):776-798, Elsevier, Netherlands (Oct. 1992).;;Tuaillon, N., et al., “Biased Utilization of DHQ52 and JH4 Gene Segments in a Human Ig Transgenic Minilocus Is Independent of Antigenic Selection,” The Journal of Immunology 152(6):2912-2920, Williams & Wilkins, United States (1994).;;Tuaillon, N., et al., “Human Immunoglobulin Heavy-chain Minilocus Recombination in Transgenic Mice: Gene-segment Use in Mu and Gamma Transcripts,” Proceedings of the National Academy of Sciences of the United States of America 90(8):3720-3724, National Academy of Sciences, United States (1993).;;Umana, P., et al., “Engineered Glycoforms of an Antineuroblastoma lgG1 with Optimized Antibody-Dependent Cellular Cytotoxic Activity,” Nature Biotechnology 17(2):176-180, Nature America Publishing, United States (1999).;;Urlaub, G. and Chasin, L.A., “Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity,” Proceedings of the National Academy of Sciences USA 77(7):4216-4220, National Academy of Sciences, United States (Jul. 1980).;;Wallick, S.C., et al., “Glycosylation of a Vh Residue of a Monoclonal Antibody Against Alpha (1—6) Dextran Increases Its Affinity for Antigen,” The Journal of Experimental Medicine 168(3):1099-1109, Rockefeller University Press, United States (1988).;;Ward, E.S., et al., “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia coli,” Nature 341 (6242):544-546, Nature Publishing Group, England (Oct. 1989).;;Weinberg, A.D., et al., “Engagement of the OX-40 Receptor in Vivo Enhances Antitumor Immunity,” Journal of Immunology 164(4):2160-2169, American Association of Immunologists, United States (2000).;;Yeung, Y.A., et al., “Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates,” Journal of Immunology 182(12):7663-7671, American Association of Immunologists, United States (2009).;;Freeman, G., et al., “TIM genes: a family of cell surface phosphatidlyserine receptors that regulate innate and adaptive immunity,” Immunol Rev. 235(1):172-189, Elsevier, Netherlands (2010).;;Dekruyff, R.H., et al., “T Cell/Transmembrne, Ig, and Mucin-3 Allelic variants Differentially Recognize Phosphatidylserine and mdiate Phagocytosis of Apoptotic cells,” Journal of Immunology 184:1918-1930, American Association of Immunologist, United States (2010).;;Jefferis,R., et al., “Human Immunoglobulin allotypes,” MAbs 1(4):332-338, Taylor & Francis, United Kingdom (2009).;;Protein Data Bank, “Human T-cell immunoglobulin and mucin domain protein 3 (hTIM-3),” 5F71, accessed at http://www.rcsb.org/pdb/explore/explore.do?pdbId=5F71, accessed on Jul. 27, 2017, 2 pages.;;Protein Data Bank, “Structure of Tim-3 in complex with phosphatidylserine,” 3KAA, accessed at http://www.rcsb.org/pdb/explore/explore.do?structureId=3kaa, accessed on Jul. 27, 2017, 2 pages.;;McIntire, J.J., et al., “Identification of Tapr (An Airway Hyperreactivity Regulatory Locus) and the Linked Tim Gene Family,” Nature Immunology 2(12):1109-1116, Nature America Inc, United States (Dec. 2001).;;Monney, L., et al., “Identification and Characterization of Novel Cell Surface Molecules Expressed on TH1 cells,” Scandinavian Journal of Immunology 54:35, (2001).;;Monney, L., et al., “Th1-Specific Cell Surface Protein Tim-3 Regulates Macrophage Activation and Severity of an Autoimmune Disease,” Nature 415(6871):536-541, Nature Publishing Group, England (Jan. 2002).;;Kikushige, Y., et al., “TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells,” International Journal of Hematology 98 (6):627-633, Springer Publishing Company, United States (2013).;;Ferris, R.L., et al., “Too Much of a Good thing? Tim-3 and TCR Signaling in T Cell Exhaustion,” The Journal of Immunology 193(4):1525-1530, The American Association of Immunologists, United States (2014).;;International Search Report and Written Opinion for International Application No. PCT/US2017/041946, European Patent Office, Iceland, dated Jan. 3, 2018, 22 pages.;;Kreig, C., et al., “Functional analysis of B and T lymphocyte attenuator engagement on CD4+ and CD8+ T cells,” J Immunol 175(10):6420-7 (Nov. 2005).;;Justice et al., “Using the mouse to model human disease: increasing validity and reproducibility,” Disease, Models & Mechanisms 9: 101-103 (Feb. 2016).;;Tokuriki et al., “Stability effects of mutations and protein evolvability,” Curr. Opin. Struc. Biol. 19:596-604 (Sep. 2009).;;Fenton et al., “Rheostat positions: A new classification of protein positions relevant to pharmacogenomics,” Medicinal Chemistry Research 29:1133-46 (Jun. 2020).;;De Pascalis et al., “Grafting of ‘abbreviated’ complementarity-determining regions containing specificity-determining residues essential for ligant contact to engineer a less immunogenic humanized monoclonal antibody,” J. Immunol. 169:3076-84 (Sep. 2002).;;Bose and Sinha, “Problems in using statistical analysis of replacement and silent mutations in antibody genes for determining antigen-driven affinity selection,” Immunology 116:172-83 (Oct. 2005).;;Vajdos et al., “Comprehensive functional maps of the antigen-binding site of an anti-ErobB2 antibody obtained with shotgun scanning mutagenesis,” J. Mol. Biol. 320(2):415-28 (Jul. 2002).;;Guo et al., “Protein tolerance to random amino acid change,” PNAS USA 101(25):9205-10 (Jun. 2004).;;Ha et al., “Animal models of melanoma,” JID Symposium Proceedings: 86-89 (Nov. 2005).;;Non-final Office Action dated Dec. 19, 2022, in U.S. Appl. No. 16/316,991, filed Jan. 10, 2019 (22 pages).;;McKinney and Holmen, “Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma,” Chinese J. Cancer 30(3):153-162 (Mar. 2011).",ACTIVE
265,US,A1,US 2020/0190186 A1,161-124-984-158-604,2020-06-18,2020,US 201916697653 A,2019-11-27,US 201916697653 A;;US 201816017489 A;;US 201715649380 A;;US 201762459499 P;;US 201662362541 P,2016-07-14,ANTIBODIES AGAINST TIM3 AND USES THEREOF,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,BRISTOL-MYERS SQUIBB COMPANY (2017-07-21),https://lens.org/161-124-984-158-604,Patent Application,yes,0,0,36,39,385,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28;;A61K47/68;;A61P35/00;;C07K16/30;;G01N33/574,,0,0,,,,ACTIVE
266,CL,A1,CL 2019000100 A1,194-881-165-159-529,2019-05-10,2019,CL 2019000100 A,2019-01-11,US 201662362541 P;;US 201762459499 P,2016-07-14,Anticuerpos contra tim3 y suso de los mismos.,"UN ANTICUERPO AISLADO (POR EJEMPLO, ANTICUERPO HUMANO), O UNA PORCIÓN DE UNIÓN AL ANTÍGENO DEL MISMO, CARACTERIZADO PORQUE SE UNE A LA PROTEÍNA 3 QUE CONTIENE EL DOMINIO DE MUCINA E INMUNOGLOBULINA DE LINFOCITOS T (TIM3) HUMANA Y PRESENTA LAS SIGUIENTES PROPIEDADES: 10 (A) SE UNE A TIM3 HUMANA SOLUBLE; SE UNE A TIN3 HUMANA UNIDA A LA MEMBRANA; INDUCE O MEJORA LA ACTIVACIÓN DE LINFOCITOS T; Y OPCIONALMENTE: SE UNE A TIM3 DE MONO CINOMÓLOGO SOLUBLE; Y (E) SE UNE A TIN3 DE MONO CINOMÓLOGO DE MEMBRANA.",BRISTOL MYERS SQUIBB CO,XIAO MIN SCHEBYE;;MARK J SELBY;;MICHELLE MINHUA HAN;;CHRISTINE BEE;;ANDY X DENG;;ANAN CHUNTHARAPAI;;BRIGITTE DEVAUX;;HUIMING LI;;PAUL O SHEPPARD;;ALAN J KORMAN;;DANIEL F ARDOUREL;;EKATERINA DEYANOVA;;RICHARD HUANG;;GUODONG CHEN;;MICHELLE KUHNE;;HONG-AN TRUONG,,https://lens.org/194-881-165-159-529,Patent Application,no,0,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28,,0,0,,,,PENDING
267,BR,A2,BR 112019000431 A2,013-264-659-497-336,2019-07-09,2019,BR 112019000431 A,2017-07-13,US 2017/0041946 W;;US 201662362541 P;;US 201762459499 P,2016-07-14,anticorpos contra tim3 e usos dos mesmos,"são fornecidos aqui anticorpos, ou porções de ligação a antígeno dos mesmos, que se ligam à imunoglobulina de célula t e proteína que contêm o domínio de mucina-3 (tim3). também são fornecidos usos destes anticorpos, ou porções de ligação a antígeno dos mesmos, em aplicações terapêuticas, tal como o tratamento de câncer. são fornecidas ainda células que produzem os anticorpos ou porções de ligação a antígeno dos mesmos, polinucleotídeos que codificam as regiões de cadeias pesada e/ou leve dos anticorpos ou porções de ligação a antígeno dos mesmos e vetores que compreendem os polinucleotídeos que codificam as regiões de cadeias pesada e/ou leve dos anticorpos ou porções de ligação a antígeno dos mesmos.",BRISTOL MYERS SQUIBB CO,ALAN J KORMAN;;ANAN CHUNTHARAPAI;;ANDY X DENG;;BRIGITTE DEVAUX;;CHRISTINE BEE;;DANIEL F ARDOUREL;;EKATERINA DEYANOVA;;GUODONG CHEN;;HONG-AN TRUONG;;HUIMING LI;;MARK J SELBY;;MICHELLE KUHNE;;MICHELLE MINHUA HAN;;PAUL O SHEPPARD;;RICHARD HUANG;;XIAO MIN SCHEBYE,,https://lens.org/013-264-659-497-336,Patent Application,no,0,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28,,0,0,,,,PENDING
268,EP,B1,EP 3304079 B1,016-637-917-150-684,2020-06-03,2020,EP 16731700 A,2016-06-02,US 201562170579 P;;US 2016/0035514 W,2015-06-03,ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS,,BRISTOL MYERS SQUIBB CO,WANG XI-TAO;;ADELAKUN OLUFEMI A;;LEWIN ANNE C;;KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;HUANG HAICHUN;;HENNING KARLA A;;LONBERG NILS;;SRINIVASAN MOHAN;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;WONG SUSAN CHIEN-SZU;;LI HUIMING,,https://lens.org/016-637-917-150-684,Granted Patent,yes,3,0,16,16,0,C07K16/2878;;G01N33/566;;C07K2317/56;;C07K2317/24;;C07K2317/21;;C07K2317/92;;G01N2800/52;;G01N2800/7028;;G01N2333/70578;;C07K16/2878;;G01N33/566;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/92;;G01N2333/70578;;G01N2800/52;;G01N2800/7028;;A61P35/00;;A61P43/00;;C07K2317/21;;C07K2317/92;;G01N33/566;;C07K2317/24;;G01N2800/7028;;C07K2317/56;;C07K16/2878;;G01N2800/52;;G01N2333/70578;;C07K16/2866;;G01N33/57492;;G01N2333/4703;;G01N2333/7051;;G01N2333/7151,G01N33/566;;C07K16/28,,4,0,,,"CACILDA TEZELLI JUNQUEIRA PADOVANI ET AL: ""Glucocorticoid-induced tumor necrosis factor receptor expression in patients with cervical human papillomavirus infection"", REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL., vol. 46, no. 3, 1 June 2013 (2013-06-01), pages 288-292, XP055301933, BR ISSN: 0037-8682, DOI: 10.1590/0037-8682-0029-2013;;K. M. BALTZ ET AL: ""Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions"", THE FASEB JOURNAL, vol. 21, no. 10, 1 August 2007 (2007-08-01), pages 2442-2454, XP055301914, US ISSN: 0892-6638, DOI: 10.1096/fj.06-7724com;;WEN-CHUN CHANG ET AL: ""Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma"", CANCER., vol. 116, no. 24, 15 December 2010 (2010-12-15), pages 5777-5788, XP055301514, US ISSN: 0008-543X, DOI: 10.1002/cncr.25371;;THA PRG A-S HELENA GASPAROTO ET AL: ""Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment"", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 59, no. 6, 12 December 2009 (2009-12-12), pages 819-828, XP019800202, ISSN: 1432-0851",ACTIVE
269,CN,A,CN 111886255 A,053-824-213-773-686,2020-11-03,2020,CN 201980018622 A,2019-01-11,US 201862616723 P;;US 2019/0013246 W,2018-01-12,ANTIBODIES AGAINST TIM3 AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/053-824-213-773-686,Patent Application,no,3,2,8,8,0,C07K16/2803;;A61K2039/505;;A61K2039/507;;C07K2317/33;;C07K2317/34;;C07K2317/74;;C07K2317/76;;C07K2317/92;;A61P35/00;;C07K16/2878;;G01N33/6857;;A61P35/00;;C07K2317/33;;C07K2317/34;;C07K2317/74;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K2039/507;;A61P35/00;;A61K2039/507;;C07K16/2803;;C07K2317/21;;C07K2317/31;;C07K2317/34;;C07K2317/74;;C07K2317/76;;C07K2317/92;;G01N33/6854;;G01N2333/70503,C07K16/28;;A61P35/00,,2,0,,,"陶景莲等: ""TIM3在肿瘤微环境中作用的研究进展"", 《中国免疫学杂志》, vol. 32, no. 07, pages 1070 - 1073;;KAREN O DIXON等: ""Tim3/galectin-9 alleviates the inflammation of TAO patients via suppressing Akt/NF-kB signaling pathway"", 《BIOCHEM BIOPHYS RES COMMUN》, vol. 491, no. 4, pages 966 - 972, XP085167420, DOI: 10.1016/j.bbrc.2017.07.144",PENDING
270,IL,A,IL 264011 A,003-974-197-139-000,2019-01-31,2019,IL 26401118 A,2018-12-28,US 201662362541 P;;US 201762459499 P;;US 2017/0041946 W,2016-07-14,Antibodies against tim3 and uses thereof,,BRISTOL MYERS SQUIBB CO;;CHEN GUODONG;;HUANG RICHARD;;LI HUIMING;;SHEPPARD PAUL O;;SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;KUHNE MICHELLE;;TRUONG HONG AN,CHEN GUODONG;;HUANG RICHARD;;LI HUIMING;;SHEPPARD PAUL O;;SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/003-974-197-139-000,Patent Application,no,0,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,,,0,0,,,,PENDING
271,EP,A2,EP 3484920 A2,071-693-479-779-482,2019-05-22,2019,EP 17742626 A,2017-07-13,US 201662362541 P;;US 201762459499 P;;US 2017/0041946 W,2016-07-14,ANTIBODIES AGAINST TIM3 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/071-693-479-779-482,Patent Application,yes,0,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28,,0,0,,,,PENDING
272,SG,A,SG 11201900026T A,072-667-134-275-307,2019-01-30,2019,SG 11201900026T A,2017-07-13,US 201662362541 P;;US 201762459499 P;;US 2017/0041946 W,2016-07-14,ANTIBODIES AGAINST TIM3 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/072-667-134-275-307,Unknown,no,0,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28,,0,0,,,,PENDING
273,US,A1,US 2023/0382992 A1,114-256-840-911-441,2023-11-30,2023,US 202318175420 A,2023-02-27,US 202318175420 A;;US 201916697653 A;;US 201816017489 A;;US 201715649380 A;;US 201762459499 P;;US 201662362541 P,2016-07-14,ANTIBODIES AGAINST TIM3 AND USES THEREOF,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,BRISTOL-MYERS SQUIBB COMPANY (2017-07-21),https://lens.org/114-256-840-911-441,Patent Application,yes,1,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28;;A61K47/68;;A61P35/00;;C07K16/30;;G01N33/574,,0,0,,,,PENDING
274,AU,A1,AU 2017/297506 A1,004-839-931-922-011,2019-02-21,2019,AU 2017/297506 A,2017-07-13,US 201762459499 P;;US 201662362541 P;;US 2017/0041946 W,2016-07-14,Antibodies against TIM3 and uses thereof,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/004-839-931-922-011,Patent Application,no,0,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28,,0,0,,,,PENDING
275,WO,A2,WO 2018/013818 A2,024-094-363-052-346,2018-01-18,2018,US 2017/0041946 W,2017-07-13,US 201662362541 P;;US 201762459499 P,2016-07-14,ANTIBODIES AGAINST TIM3 AND USES THEREOF,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/024-094-363-052-346,Patent Application,yes,202,49,36,39,385,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28,,180,125,018-069-206-369-372;;068-450-506-389-89X;;003-763-873-758-289;;089-689-557-564-287;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;040-577-067-037-463;;104-212-297-137-759;;010-953-281-569-514;;092-334-939-903-42X;;014-277-808-472-992;;061-754-151-573-898;;113-327-994-370-771;;006-553-734-546-212;;068-238-957-669-243;;105-316-874-895-908;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;040-701-579-915-050;;018-694-084-068-187;;104-557-841-648-936;;034-441-292-442-799;;038-895-768-831-047;;132-281-029-747-299;;087-667-912-261-011;;001-835-514-097-551;;002-377-881-851-166;;038-595-729-934-153;;065-102-359-566-736;;042-204-626-457-327;;006-574-964-805-278;;030-323-674-660-051;;092-023-577-402-127;;022-179-293-052-569;;088-086-720-613-343;;010-488-381-022-259;;082-210-673-349-152;;004-458-031-333-650;;041-909-244-299-232;;078-432-639-041-575;;042-740-484-382-110;;004-458-031-333-650;;003-752-183-823-430;;070-318-112-524-781;;071-163-081-597-04X;;035-135-729-507-737;;094-685-907-794-422;;062-029-719-290-327;;070-624-200-848-669;;012-746-915-512-650;;038-478-749-169-986;;035-554-935-107-802;;099-647-105-451-350;;009-621-637-014-514;;100-985-030-110-978;;030-630-100-818-462;;106-753-778-592-300;;032-820-729-763-323;;083-549-078-331-651;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;033-754-369-798-314;;077-525-954-203-403;;028-969-172-280-017;;060-375-551-951-388;;020-753-772-581-741;;038-613-711-274-229;;047-951-914-695-080;;062-485-301-455-912;;038-613-711-274-229;;023-676-781-371-861;;026-744-100-669-883;;117-663-803-983-152;;051-940-176-386-905;;012-300-595-074-789;;031-815-870-004-331;;040-841-912-862-912;;011-583-491-184-648;;126-659-091-098-052;;038-166-075-279-931;;083-079-509-375-354;;043-654-077-374-418;;084-388-182-984-099;;042-354-196-879-741;;005-112-559-456-657;;052-219-543-437-800;;007-364-858-655-289;;056-942-841-068-650;;107-302-749-967-437;;039-238-464-990-600;;036-564-551-324-053;;020-123-860-433-320;;011-516-147-270-264;;020-986-423-793-233;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;007-709-585-201-038;;056-422-417-058-69X;;005-022-447-377-963;;127-416-339-660-812;;098-407-145-404-736;;066-749-017-721-197;;001-467-559-709-949;;049-089-244-500-629;;078-061-292-153-737;;055-646-175-554-792;;129-390-507-012-794;;008-213-515-306-640;;053-703-232-770-99X;;033-109-855-318-388;;030-249-121-435-10X;;077-494-681-161-754;;120-423-033-110-106,10.1158/2326-6066.cir-14-0039;;24795351;;21810406;;pmc3175029;;10.1016/j.bbamem.2011.07.026;;10.1182/blood-2008-10-185884;;19224762;;10.1084/jem.20100637;;20819923;;pmc2947081;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1038/nbt1135;;16151405;;10.1385/0896033759;;10.4049/jimmunol.137.11.3614;;2431039;;10.1016/0042-6822(90)90025-m;;1693247;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;8424945;;10.1021/bi00055a024;;10556249;;10.1093/protein/12.10.879;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;7521646;;10.1038/nbt0994-899;;10.1126/science.2471267;;2471267;;16263307;;10.1016/j.jasms.2005.09.008;;10.1021/bi00161a011;;1332755;;10.1021/bi00078a011;;7687462;;15299382;;10.1107/s0907444994001344;;2185018;;10.1111/j.1432-1033.1990.tb15454.x;;9351804;;10.1016/s0969-2126(97)00279-7;;977570;;10.1016/s0021-9258(20)81858-4;;15299544;;10.1107/s0907444992010400;;27799107;;10.1016/s0076-6879(97)76070-1;;3127726;;10.1038/332323a0;;10.1038/321522a0;;3713831;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;19896358;;10.1016/j.copbio.2009.10.011;;14699147;;10.1074/jbc.c300470200;;10.4049/jimmunol.176.1.346;;16365427;;11096108;;10.1074/jbc.m009483200;;12391234;;10.4049/jimmunol.169.9.5171;;10.1074/jbc.m604292200;;16793771;;10.4049/jimmunol.0804182;;19494290;;11096108;;10.1074/jbc.m009483200;;11986321;;10.1074/jbc.m202069200;;10.1038/6179;;10052355;;10.1146/annurev.bi.41.070172.003325;;4563441;;10.4049/jimmunol.172.9.5489;;15100290;;2459288;;pmc2189025;;10.1084/jem.168.3.1099;;12042244;;10.1093/glycob/12.4.43r;;10.1038/316452a0;;3927174;;11275255;;10.1016/s0161-5890(00)00105-x;;10.2174/1389201023378229;;12463418;;10.1023/b:pham.0000008042.15988.c0;;14725359;;10397155;;10.1016/s0165-2478(99)00029-2;;10.1093/chromsci/40.6.343;;12137207;;8644915;;10.1021/ac00116a002;;10.1038/348552a0;;2247164;;1172191;;10.1038/256495a0;;8159246;;10.1038/368856a0;;10.1007/978-3-642-78432-3_3;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;8144892;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nbt727;;12172556;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1126/science.3929380;;3929380;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;10.1016/j.cbpa.2009.03.023;;19414278;;10.1002/anie.200801313;;19072788;;10.1039/b908687k;;19675886;;10.1002/cbic.200800801;;19130455;;10.1016/j.chembiol.2008.01.007;;18291317;;19924746;;pmc4878437;;10.1002/anie.200903627;;10.1021/bc800294a;;19191567;;6239899;;10.1084/jem.160.6.1686;;pmc2187539;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;3833240;;10.1126/science.3925553;;3925553;;2958547;;10.4049/jimmunol.139.7.2367;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;3390170;;10.1016/s0006-291x(88)81333-0;;10.1128/aac.39.1.180;;pmc162506;;7695303;;7907597;;10.1016/s0021-9258(17)37081-3;;10.1016/0014-5793(94)00313-0;;8206150;;7820457;;10.1006/immu.1994.1029;;15470033;;10.4049/jimmunol.173.8.4919;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;9624003;;10.1038/30989;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;9930702;;10.1038/16717;;10417377;;10.1126/science.285.5427.546;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;11514604;;10.3410/f.1000338.7202;;pmc2193490;;10.1084/jem.194.4.481;;pmc15881;;10.1073/pnas.96.6.2982;;10077623;;10.1097/00002371-199601000-00009;;8859727;;10.1038/22124;;10408445;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;9850053;;10.1038/nm735;;12118245;;10.3410/f.1008846.113460;;15930300;;10.1158/0008-5472.can-04-3319;;10.4324/9780203967621-49;;21430066;;10.1158/0008-5472.can-11-0096,"HAN G ET AL., FRONT LMMUNOL., vol. 4, 2013, pages 449;;ANDERSON AC, CANCER IMMUNOL RES., vol. 2, 2014, pages 393 - 8;;RIEDL S ET AL., BIOCHIM BIOPHYSACTA, vol. 1808, 2011, pages 2638 - 2645;;NAKAYAMA M ET AL., BLOOD, vol. 113, 2009, pages 3821 - 30;;FOURCADE ET AL., J EXP MED., vol. 207, 2010, pages 2175 - 2186;;JUO, PEI-SHOW: ""Concise Dictionary of Biomedicine and Molecular Biology, 2nd ed."", 2002, CRC PRESS;;""The Dictionary of Cell and Molecular Biology, 3rd ed."", 1999, ACADEMIC PRESS;;""Oxford Dictionary Of Biochemistry And Molecular Biology"", 2000, OXFORD UNIVERSITY PRESS;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;SONGSIVILAI; LACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY, J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;LONBERG, NATURE BIOTECH, vol. 23, no. 9, 2005, pages 1117 - 1125;;JEFFERIS ET AL., MABS, vol. 1, 2009, pages 1;;G. E. MORRIS: ""Epitope Mapping Protocols in Methods in Molecular Biology"", vol. 66, 1996;;ED HARLOW AND DAVID LANE: ""Using Antibodies"", 1999, COLD SPRING HARBOR LABORATORY PRESS, COLD SPRING HARBOR, article ""Chapter 11"";;STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 9, 1983, pages 242;;KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR PRESS;;MOREL ET AL., MOL. IMMUNOL., vol. 25, no. 1, 1988, pages 7;;CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546;;MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77;;BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187;;KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999, pages 879 - 884;;BURKS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 412 - 417;;E. MEYERS; W. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17;;NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;F. AUSUBEL, ET AL.: ""Current Protocols in Molecular Biology"", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest, 5th ed."", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, NIH PUBLICATION;;JESPERS ET AL., BIOTECHNOLOGY, vol. 12, 1994, pages 899;;CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;WEI ET AL., DRUG DISCOVERY TODAY, vol. 19, 2014, pages 95;;HAMBLEY; GROSS, J. AMERICAN SOC. MASS SPECTROMETRY, vol. 16, 2005, pages 2057;;ZINN- JUSTIN ET AL., BIOCHEMISTRY, vol. 31, 1992, pages 11335 - 11347;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 32, 1993, pages 6884 - 6891;;GIEGE ET AL., ACTA CRYSTALLOGR, vol. D50, 1994, pages 339 - 350;;MCPHERSON, EUR. J. BIOCHEM., vol. 189, 1990, pages 1 - 23;;CHAYEN, STRUCTURE, vol. 5, 1997, pages 1269 - 1274;;MCPHERSON, J. BIOL. CHEM., vol. 251, 1976, pages 6300 - 6303;;SCOPES: ""Protein Purification: Principles and Practice, 3rd ed."", 1994, SPRINGER- VERLAG;;BLUNDELL; JOHNSON: ""Meth. Enzymol."", 1985, ACADEMIC PRESS, pages: 114 - 115;;BRICOGNE, ACTA CRYST, vol. D49, 1993, pages 37 - 60;;BRICOGNE: ""Meth. Enzymol."", vol. 276A, 1997, pages: 361 - 423;;ROVERSI ET AL., ACTA CRYST., vol. D56, 2000, pages 1313 - 1323;;RIECHMANN, L. ET AL., NATURE, vol. 332, 1998, pages 323 - 327;;JONES, P. ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;QUEEN, C. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 86, 1989, pages 10029 - 10033;;TOMLINSON, I. M. ET AL.: ""The Repertoire of Human Germline V Sequences Reveals about Fifty Groups of V Segments with Different Hypervariable Loops"", MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: doi:10.1016/0022-2836(92)90223-7;;COX, J. P. L. ET AL.: ""A Directory of Human Germ-line V Segments Reveals a Strong Bias in their Usage'' Eur"", J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;JEFFERIES ET AL., MABS, vol. 1, 2009, pages 1;;MOLEC. IMMUNOL., vol. 29, no. 5, 1992, pages 633 - 9;;STROHL, CURRENT OPINION IN BIOTECHNOLOGY, vol. 20, 2009, pages 685 - 691;;PAUL, W. E.: ""Fundamental immunology, 4th ed."", 1999, LIPPINCOTT-RAVEN;;HINTON ET AL., J. BIOL. CHEM., vol. 279, no. 8, 2004, pages 6213 - 6216;;HINTON ET AL., JOURNAL OF IMMUNOLOGY, vol. 176, 2006, pages 346 - 356;;SHIELDS ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 9, 2001, pages 6591 - 6604;;DALL ACQUA ET AL., JOURNAL OF IMMUNOLOGY, vol. 169, 2002, pages 5171 - 5180;;DALL'ACQUA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, 2006, pages 23514 - 23524;;YEUNG ET AL., JLMMUNOL, vol. 182, 2010, pages 7663 - 7671;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;MARSHALL ET AL., REV BIOCHEM, vol. 41, 1972, pages 673 - 702;;GALA; MORRISON, J. IMMUNOL, vol. 172, 2004, pages 5489 - 94;;WALLICK ET AL., J EXP MED, vol. 168, 1988, pages 1099 - 109;;SPIRO, GLYCOBIOLOGY, vol. 12, 2002, pages 43R - 56R;;PAREKH ET AL., NATURE, vol. 316, 1985, pages 452 - 7;;MIMURA ET AL., MOL IMMUNOL, vol. 37, 2000, pages 697 - 706;;KRISHNAMURTHY R; MANNING M C, CURR PHARM BIOTECHNOL, vol. 3, 2002, pages 361 - 71;;CHEN ET AL., PHARM RES, vol. 20, 2003, pages 1952 - 60;;GHIRLANDO ET AL., IMMUNOL LETT, vol. 68, 1999, pages 47 - 52;;MURRAY ET AL., J. CHROMATOGR SCI, vol. 40, 2002, pages 343 - 9;;ALEXANDER A J; HUGHES D E, ANAL CHEM, vol. 67, 1995, pages 3626 - 32;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest, 5th ed."", 1991, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NIH PUBLICATION;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;LONBERG, N., HANDBOOK OF EXPERIMENTAL PHARMACOLOGY, vol. 113, 1994, pages 49 - 101;;LONBERG, N.; HUSZAR, D., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F.; LONBERG, N., ANN. N.Y. ACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 3720 - 3724;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J. ET AL., EMBO J., vol. 12, 1993, pages 821 - 830;;TUAILLON ET AL., IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;TOMIZUKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727;;KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894;;FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;MORRISON, S., SCIENCE, vol. 229, 1985, pages 1202;;GOEDDEL: ""Gene Expression Technology. Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;TAKEBE, Y. ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;BOSS, M. A.; WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMAN; P. A. SHARP, MOL. BIOL., vol. 759, 1982, pages 601 - 621;;SENTER, P. D., CURR. OPIN. CHEM. BIOL., vol. 13, 2009, pages 235 - 244;;HACKENBERGER, C. P. R.; SCHWARZER, D., ANGEW. CHEM. INT. ED. ENGL., vol. 47, 2008, pages 10030 - 10074;;SUNBUL, M.; YIN, J., ORG. BIOMOL. CHEM., vol. 7, 2009, pages 3361 - 3371;;FRESE, M. A.; DIERKS, T., CHEMBIOCHEM, vol. 10, 2009, pages 425 - 427;;TAKI, M. ET AL., PROT. ENG. DES. SEL., vol. 17, 2004, pages 119 - 126;;GAUTIER, A. ET AL., CHEM. BIOL., vol. 15, 2008, pages 128 - 136;;BORDUSA, F., HIGHLIGHTS IN BIOORGANIC CHEMISTRY, 2004, pages 389 - 403;;REN, H. ET AL., ANGEW. CHEM. INT. ED. ENGL., vol. 48, 2009, pages 9658 - 9662;;TAYLOR; E. VOGEL; IMPERIALI, B, NUCLEIC ACIDS AND MOLECULAR BIOLOGY, vol. 22, 2009, pages 65 - 96;;GRAAF, A. J. ET AL., BIOCONJUG. CHEM., vol. 20, 2009, pages 1281 - 1295;;KARPOVSKY ET AL., J. EXP. MED., vol. 160, 1984, pages 1686;;LIU, MA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 8648;;PAULUS, BEHRING INS. MITT., vol. 78, 1985, pages 118 - 132;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83;;GLENNIE ET AL., J. IMMUNOL., vol. 139, 1987, pages 2367 - 2375;;BERGE, S.M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;J.R. ROBINSON: ""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;V.V. RANADE, J. CLIN. PHARMACOL., vol. 29, 1989, pages 685;;UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 153, 1988, pages 1038;;P.G. BLOEMAN ET AL., FEBSLETT., vol. 357, 1995, pages 140;;M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 39, 1995, pages 180;;BRISCOE ET AL., AM. J. PHYSIOL., vol. 1233, 1995, pages 134;;SCHREIER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 9090;;K. KEINANEN; M.L. LAUKKANEN, FEBS LETT., vol. 346, 1994, pages 123;;J.J. KILLION; I.J. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273;;HE, J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;ROSENBERG, S.: ""Development of Cancer Vaccines"", ASCO EDUCATIONAL BOOK SPRING, 2000, pages 60 - 62;;LOGOTHETIS, C, ASCO EDUCATIONAL BOOK SPRING, 2000, pages 300 - 302;;KHAYAT, D., ASCO EDUCATIONAL BOOK SPRING, 2000, pages 414 - 428;;FOON, K.: ""ASCO Educational Book Spring"", 2000, pages: 730 - 738;;DEVITA ET AL.: ""Cancer: Principles and Practice of Oncology, Fifth Edition"", vol. 61, 1997, article RESTIFO, N. AND SZNOL, M.: ""Cancer Vaccines, Ch. 61"", pages: 3023 - 3043;;DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, S A, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT; SRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050;;O'GARRA, IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;RIDGE ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;WEINBERG ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;GREENBERG; RIDDELL, SCIENCE, vol. 285, 1999, pages 546 - 51;;HOLLIGER, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;VAN ELSAS ET AL., J. EXP. MED., vol. 194, 2001, pages 481 - 489;;OVERWIJK ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 96, 1999, pages 2982 - 2987;;ROSENBERG; WHITE, J. IMMUNOTHER EMPHASIS TUMOR IMMUNOL, vol. 19, no. 1, 1996, pages 81 - 4;;SCHENK ET AL., NATURE, vol. 400, 1999, pages 173 - 177;;TANSEY, DRUG DISCOVERY TODAY 00: 1, 2009, pages 1;;HURWITZ ET AL., PRO. NATL. ACAD. SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071;;CAMACHO ET AL., J. CLIN. ONCOLOGY, vol. 22, no. 145, 2004;;MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304;;FULDA ET AL., NAT MED, vol. 8, 2002, pages 808 - 15;;HYER ET AL., CANCER RESEARCH, vol. 65, 2005, pages 4799 - 808;;SAMBROOK ET AL.: ""Molecular Cloning A Laboratory Manual, 2nd ed."", 1989, COLD SPRING HARBOR LABORATORY PRESS;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 1992, COLD SPRINGS HARBOR LABORATORY;;D. N. GLOVER: ""DNA Cloning"", vol. I and II, 1985;;GAIT: ""Oligonucleotide Synthesis"", 1984;;HAMES AND HIGGINS: ""Nucleic Acid Hybridization"", 1984;;HAMES AND HIGGINS,: ""Transcription And Translation"", 1984;;FRESHNEY: ""Culture Of Animal Cells"", 1987, ALAN R. LISS, INC.;;""Immobilized Cells And Enzymes"", 1986, IRL PRESS;;PERBAL, A PRACTICAL GUIDE TO MOLECULAR CLONING, 1984;;""Methods In Enzymology"", ACADEMIC PRESS, INC.;;MILLER AND CALOS: ""Gene Transfer Vectors For Mammalian Cells"", 1987, COLD SPRING HARBOR LABORATORY;;WU ET AL.: ""Methods In Enzymology"", vol. 154, 155;;MAYER AND WALKER: ""Immunochemical Methods In Cell And Molecular Biology"", 1987, ACADEMIC PRESS;;WEIR AND BLACKWELL: ""Handbook Of Experimental Immunology"", vol. I-IV, 1986;;""Manipulating the Mouse Embryo"", 1986, COLD SPRING HARBOR LABORATORY PRESS, COLD SPRING HARBOR;;CROOKS: ""Antisense drug Technology: Principles, strategies and applications, 2nd ed."", 2007, CRC PRESS;;AUSUBEL ET AL.: ""Current Protocols in Molecular Biology"", 1989, JOHN WILEY AND SONS;;NGIOW ET AL., CANCER RES., vol. 71, 2011, pages 3540;;DEKRUYFF ET AL., J. IMMUNOLOGY, 2010;;ROSEMARIE ET AL., J IMMUNOL, vol. 184, 2010, pages 1918;;FREEMEN ET AL., IMMUNOL REV., vol. 235, 2010, pages 172",PENDING
276,US,A1,US 2018/0016336 A1,176-417-094-697-909,2018-01-18,2018,US 201715649380 A,2017-07-13,US 201715649380 A;;US 201762459499 P;;US 201662362541 P,2016-07-14,ANTIBODIES AGAINST TIM3 AND USES THEREOF,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TROUNG HONG-AN,BRISTOL-MYERS SQUIBB COMPANY (2017-07-21),https://lens.org/176-417-094-697-909,Patent Application,yes,0,4,36,39,385,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28;;A61K39/00;;C07K16/30,,0,0,,,,ACTIVE
277,MX,A,MX 2019000443 A,019-506-980-496-396,2019-06-20,2019,MX 2019000443 A,2017-07-13,US 201662362541 P;;US 201762459499 P;;US 2017/0041946 W,2016-07-14,ANTIBODIES AGAINST TIM3 AND USES THEREOF.,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,ALAN J KORMAN;;MARK J SELBY;;MICHELLE MINHUA HAN;;GUODONG CHEN;;RICHARD HUANG;;HUIMING LI;;BRIGITTE DEVAUX;;PAUL O SHEPPARD;;DANIEL F ARDOUREL;;XIAO MIN SCHEBYE;;CHRISTINE BEE;;ANDY X DENG;;ANAN CHUNTHARAPAI;;EKATERINA DEYANOVA;;MICHELLE KUHNE;;HONG- AN TRUONG,,https://lens.org/019-506-980-496-396,Patent Application,no,0,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28,,0,0,,,,PENDING
278,KR,A,KR 20200108870 A,047-605-011-083-954,2020-09-21,2020,KR 20207022936 A,2019-01-11,US 201862616723 P;;US 2019/0013246 W,2018-01-12,TIM3에 대한 항체 및 그의 용도,"T-세포 이뮤노글로불린 및 뮤신-도메인 함유-3 (TIM3) 단백질에 결합하는 항체 또는 그의 항원 결합 부분이 본원에 제공된다. 치료적 적용, 예컨대 암의 치료에서의 이들 항체 또는 그의 항원 결합 부분의 용도가 또한 제공된다. 항체 또는 그의 항원 결합 부분을 생산하는 세포, 항체 또는 그의 항원 결합 부분의 중쇄 및/또는 경쇄 영역을 코딩하는 폴리뉴클레오티드, 및 항체 또는 그의 항원 결합 부분의 중쇄 및/또는 경쇄 영역을 코딩하는 폴리뉴클레오티드를 포함하는 벡터가 추가로 제공된다.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG AN,,https://lens.org/047-605-011-083-954,Patent Application,no,0,0,8,8,894,C07K16/2803;;A61K2039/505;;A61K2039/507;;C07K2317/33;;C07K2317/34;;C07K2317/74;;C07K2317/76;;C07K2317/92;;A61P35/00;;C07K16/2878;;G01N33/6857;;A61P35/00;;C07K2317/33;;C07K2317/34;;C07K2317/74;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K2039/507;;A61P35/00;;A61K2039/507;;C07K16/2803;;C07K2317/21;;C07K2317/31;;C07K2317/34;;C07K2317/74;;C07K2317/76;;C07K2317/92;;G01N33/6854;;G01N2333/70503,C07K16/28;;A61K39/00;;A61P35/00;;G01N33/68,,0,0,,,,PENDING
279,WO,A1,WO 2019/140229 A1,087-898-625-090-342,2019-07-18,2019,US 2019/0013246 W,2019-01-11,US 201862616723 P,2018-01-12,ANTIBODIES AGAINST TIM3 AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/087-898-625-090-342,Patent Application,yes,207,4,8,8,448,C07K16/2803;;A61K2039/505;;A61K2039/507;;C07K2317/33;;C07K2317/34;;C07K2317/74;;C07K2317/76;;C07K2317/92;;A61P35/00;;C07K16/2878;;G01N33/6857;;A61P35/00;;C07K2317/33;;C07K2317/34;;C07K2317/74;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K2039/507;;A61P35/00;;A61K2039/507;;C07K16/2803;;C07K2317/21;;C07K2317/31;;C07K2317/34;;C07K2317/74;;C07K2317/76;;C07K2317/92;;G01N33/6854;;G01N2333/70503,C07K16/28;;A61P35/00,,181,125,014-766-704-525-495;;018-069-206-369-372;;068-450-506-389-89X;;003-763-873-758-289;;089-689-557-564-287;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;040-577-067-037-463;;104-212-297-137-759;;010-953-281-569-514;;014-277-808-472-992;;061-754-151-573-898;;113-327-994-370-771;;006-553-734-546-212;;068-238-957-669-243;;105-316-874-895-908;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;040-701-579-915-050;;018-694-084-068-187;;104-557-841-648-936;;034-441-292-442-799;;038-895-768-831-047;;132-281-029-747-299;;087-667-912-261-011;;001-835-514-097-551;;002-377-881-851-166;;038-595-729-934-153;;065-102-359-566-736;;042-204-626-457-327;;006-574-964-805-278;;030-323-674-660-051;;092-023-577-402-127;;022-179-293-052-569;;088-086-720-613-343;;010-488-381-022-259;;082-210-673-349-152;;004-458-031-333-650;;041-909-244-299-232;;078-432-639-041-575;;042-740-484-382-110;;004-458-031-333-650;;003-752-183-823-430;;070-318-112-524-781;;071-163-081-597-04X;;035-135-729-507-737;;094-685-907-794-422;;062-029-719-290-327;;070-624-200-848-669;;012-746-915-512-650;;038-478-749-169-986;;035-554-935-107-802;;099-647-105-451-350;;009-621-637-014-514;;100-985-030-110-978;;030-630-100-818-462;;106-753-778-592-300;;032-820-729-763-323;;083-549-078-331-651;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;033-754-369-798-314;;077-525-954-203-403;;028-969-172-280-017;;060-375-551-951-388;;020-753-772-581-741;;038-613-711-274-229;;047-951-914-695-080;;062-485-301-455-912;;038-613-711-274-229;;023-676-781-371-861;;026-744-100-669-883;;117-663-803-983-152;;051-940-176-386-905;;012-300-595-074-789;;031-815-870-004-331;;040-841-912-862-912;;011-583-491-184-648;;126-659-091-098-052;;038-166-075-279-931;;083-079-509-375-354;;043-654-077-374-418;;084-388-182-984-099;;042-354-196-879-741;;005-112-559-456-657;;052-219-543-437-800;;007-364-858-655-289;;056-942-841-068-650;;107-302-749-967-437;;039-238-464-990-600;;036-564-551-324-053;;020-123-860-433-320;;011-516-147-270-264;;020-986-423-793-233;;067-739-856-772-54X;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;007-709-585-201-038;;056-422-417-058-69X;;005-022-447-377-963;;127-416-339-660-812;;098-407-145-404-736;;066-749-017-721-197;;001-467-559-709-949;;049-089-244-500-629;;078-061-292-153-737;;055-646-175-554-792;;129-390-507-012-794;;008-213-515-306-640;;053-703-232-770-99X;;033-109-855-318-388;;030-249-121-435-10X;;120-423-033-110-106,10.2147/ott.s170385;;pmc6198883;;30410357;;10.1158/2326-6066.cir-14-0039;;24795351;;21810406;;pmc3175029;;10.1016/j.bbamem.2011.07.026;;10.1182/blood-2008-10-185884;;19224762;;10.1084/jem.20100637;;20819923;;pmc2947081;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1038/nbt1135;;16151405;;10.4049/jimmunol.137.11.3614;;2431039;;10.1016/0042-6822(90)90025-m;;1693247;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;8424945;;10.1021/bi00055a024;;10556249;;10.1093/protein/12.10.879;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;7521646;;10.1038/nbt0994-899;;10.1126/science.2471267;;2471267;;16263307;;10.1016/j.jasms.2005.09.008;;10.1021/bi00161a011;;1332755;;10.1021/bi00078a011;;7687462;;15299382;;10.1107/s0907444994001344;;2185018;;10.1111/j.1432-1033.1990.tb15454.x;;9351804;;10.1016/s0969-2126(97)00279-7;;977570;;10.1016/s0021-9258(20)81858-4;;15299544;;10.1107/s0907444992010400;;27799107;;10.1016/s0076-6879(97)76070-1;;3127726;;10.1038/332323a0;;10.1038/321522a0;;3713831;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;19896358;;10.1016/j.copbio.2009.10.011;;14699147;;10.1074/jbc.c300470200;;10.4049/jimmunol.176.1.346;;16365427;;11096108;;10.1074/jbc.m009483200;;12391234;;10.4049/jimmunol.169.9.5171;;10.1074/jbc.m604292200;;16793771;;10.4049/jimmunol.0804182;;19494290;;11096108;;10.1074/jbc.m009483200;;11986321;;10.1074/jbc.m202069200;;10.1038/6179;;10052355;;10.1146/annurev.bi.41.070172.003325;;4563441;;10.4049/jimmunol.172.9.5489;;15100290;;2459288;;pmc2189025;;10.1084/jem.168.3.1099;;12042244;;10.1093/glycob/12.4.43r;;10.1038/316452a0;;3927174;;11275255;;10.1016/s0161-5890(00)00105-x;;10.2174/1389201023378229;;12463418;;10.1023/b:pham.0000008042.15988.c0;;14725359;;10397155;;10.1016/s0165-2478(99)00029-2;;10.1093/chromsci/40.6.343;;12137207;;8644915;;10.1021/ac00116a002;;10.1038/348552a0;;2247164;;1172191;;10.1038/256495a0;;8159246;;10.1038/368856a0;;10.1007/978-3-642-78432-3_3;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;8144892;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nbt727;;12172556;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1126/science.3929380;;3929380;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;10.1016/j.cbpa.2009.03.023;;19414278;;10.1002/anie.200801313;;19072788;;10.1039/b908687k;;19675886;;10.1002/cbic.200800801;;19130455;;10.1016/j.chembiol.2008.01.007;;18291317;;19924746;;pmc4878437;;10.1002/anie.200903627;;10.1021/bc800294a;;19191567;;6239899;;10.1084/jem.160.6.1686;;pmc2187539;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;3833240;;10.1126/science.3925553;;3925553;;2958547;;10.4049/jimmunol.139.7.2367;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;3390170;;10.1016/s0006-291x(88)81333-0;;10.1128/aac.39.1.180;;pmc162506;;7695303;;7907597;;10.1016/s0021-9258(17)37081-3;;10.1016/0014-5793(94)00313-0;;8206150;;7820457;;10.1006/immu.1994.1029;;15470033;;10.4049/jimmunol.173.8.4919;;10.1016/s0960-7404(97)90012-8;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;9624003;;10.1038/30989;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;9930702;;10.1038/16717;;10417377;;10.1126/science.285.5427.546;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;11514604;;10.3410/f.1000338.7202;;pmc2193490;;10.1084/jem.194.4.481;;pmc15881;;10.1073/pnas.96.6.2982;;10077623;;10.1097/00002371-199601000-00009;;8859727;;10.1038/22124;;10408445;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;9850053;;10.1038/nm735;;12118245;;10.3410/f.1008846.113460;;15930300;;10.1158/0008-5472.can-04-3319;;21430066;;10.1158/0008-5472.can-11-0096,"HE YAYI ET AL: ""TIM-3, a promising target for cancer immunotherapy"", ONCOTARGETS AND THERAPY, DOVE MEDICAL PRESS LTD, GB, vol. 11, 1 January 2018 (2018-01-01), pages 7005 - 7009, XP002789761, ISSN: 1178-6930;;HAN G ET AL., FRONT LMMUNOL., vol. 4, 2013, pages 449;;ANDERSON AC, CANCER IMMUNOL RES., vol. 2, 2014, pages 393 - 8;;RIEDL S ET AL., BIOCHIM BIOPHYSACTA, vol. 1808, 2011, pages 2638 - 2645;;NAKAYAMA M ET AL., BLOOD, vol. 113, 2009, pages 3821 - 30;;FOURCADE J ET AL., J EXP MED., vol. 207, 2010, pages 2175 - 2186;;""Concise Dictionary of Biomedicine and Molecular Biology"", 2002, CRC PRESS;;""The Dictionary of Cell and Molecular Biology"", 1999, ACADEMIC PRESS;;""Oxford Dictionary Of Biochemistry And Molecular Biology, Revised"", 2000, OXFORD UNIVERSITY PRESS;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;SONGSIVILAI; LACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY, J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;LONBERG, NATURE BIOTECH., vol. 23, no. 9, 2005, pages 1117 - 1125;;JEFFERIS ET AL., MABS, vol. 1, 2009, pages 1;;""Epitope Mapping Protocols in Methods in Molecular Biology"", vol. 66, 1996;;""Using Antibodies"", 1999, COLD SPRING HARBOR LABORATORY PRESS, COLD SPRING HARBOR;;STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 9, 1983, pages 242;;KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614;;HARLOW; LANE; ANTIBODIES: ""A Laboratory Manual"", 1988, COLD SPRING HARBOR PRESS;;MOREL ET AL., MOL. IMMUNOL., vol. 25, no. 1, 1988, pages 7;;CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546;;MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77;;BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187;;KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999, pages 879 - 884;;BURKS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 412 - 417;;E. MEYERS; W. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17;;NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;""Current Protocols in Molecular Biology"", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, NIH;;JESPERS ET AL., BIOTECHNOLOGY, vol. 12, 1994, pages 899;;CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;WEI ET AL., DRUG DISCOVERY TODAY, vol. 19, 2014, pages 95;;HAMBLEY; GROSS, J. AMERICAN SOC. MASS SPECTROMETRY, vol. 16, 2005, pages 2057;;ZINN- JUSTIN ET AL., BIOCHEMISTRY, vol. 31, 1992, pages 11335 - 11347;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 32, 1993, pages 6884 - 6891;;GIEGE ET AL., ACTA CRYSTALLOGR., vol. D50, 1994, pages 339 - 350;;MCPHERSON, EUR. J. BIOCHEM., vol. 189, 1990, pages 1 - 23;;CHAYEN, STRUCTURE, vol. 5, 1997, pages 1269 - 1274;;MCPHERSON, J. BIOL. CHEM., vol. 251, 1976, pages 6300 - 6303;;SCOPES: ""Protein Purification: Principles and Practice"", 1994, SPRINGER-VERLAG;;BLUNDELL; JOHNSON ET AL.: ""Meth. Enzymol."", 1985, ACADEMIC PRESS, pages: 114,115;;BRICOGNE, ACTA CRYST., vol. D49, 1993, pages 37 - 60;;BRICOGNE, METH. ENZYMOL., vol. 276A, 1997, pages 361 - 423;;ROVERSI ET AL.: ""Acta Cryst."", vol. D56, 2000, pages: 1313 - 1323;;RIECHMANN, L. ET AL., NATURE, vol. 332, 1998, pages 323 - 327;;JONES, P. ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;QUEEN, C. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 86, 1989, pages 10029 - 10033;;TOMLINSON, I. M. ET AL.: ""The Repertoire of Human Germline V Sequences Reveals about Fifty Groups of V Segments with Different Hypervariable Loops"", MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: doi:10.1016/0022-2836(92)90223-7;;COX, J. P. L. ET AL.: ""A Directory of Human Germ-line V Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;JEFFERIES ET AL., MABS, vol. 1, 2009, pages 1;;MOLEC. IMMUNOL., vol. 29, no. 5, 1992, pages 633 - 9;;STROHL, CURRENT OPINION IN BIOTECHNOLOGY, vol. 20, 2009, pages 685 - 691;;""Fundamental immunology"", 1999, LIPPINCOTT-RAVEN;;HINTON ET AL., J. BIOL. CHEM., vol. 279, no. 8, 2004, pages 6213 - 6216;;HINTON ET AL., JOURNAL OF IMMUNOLOGY, vol. 176, 2006, pages 346 - 356;;SHIELDS ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 9, 2001, pages 6591 - 6604;;DALL ACQUA ET AL., JOURNAL OF IMMUNOLOGY, vol. 169, 2002, pages 5171 - 5180;;DALL'ACQUA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, 2006, pages 23514 - 23524;;YEUNG ET AL., JLMMUNOL, vol. 182, 2010, pages 7663 - 7671;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;MARSHALL ET AL., ANNU REV BIOCHEM, vol. 41, 1972, pages 673 - 702;;GALA; MORRISON, J. IMMUNOL, vol. 172, 2004, pages 5489 - 94;;WALLICK ET AL., J EXP MED, vol. 168, 1988, pages 1099 - 109;;SPIRO, GLYCOBIOLOGY, vol. 12, 2002, pages 43R - 56R;;PAREKH ET AL., NATURE, vol. 316, 1985, pages 452 - 7;;MIMURA ET AL., MOL IMMUNOL, vol. 37, 2000, pages 697 - 706;;KRISHNAMURTHY R; MANNING M C, CURR PHARM BIOTECHNOL, vol. 3, 2002, pages 361 - 71;;CHEN ET AL., PHARM RES, vol. 20, 2003, pages 1952 - 60;;GHIRLANDO ET AL., IMMUNOL LETT, vol. 68, 1999, pages 47 - 52;;MURRAY ET AL., J. CHROMATOGR SCI, vol. 40, 2002, pages 343 - 9;;ALEXANDER A J; HUGHES D E, ANAL CHEM, vol. 67, 1995, pages 3626 - 32;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;LONBERG, N.: ""Handbook of Experimental Pharmacology"", vol. 113, 1994, pages: 49 - 101;;LONBERG, N.; HUSZAR, D., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F.; LONBERG, N., ANN. N.Y. ACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 3720 - 3724;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J. ET AL., EMBO J., vol. 12, 1993, pages 821 - 830;;TUAILLON ET AL., IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;TOMIZUKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727;;KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894;;FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;MORRISON, S., SCIENCE, vol. 229, 1985, pages 1202;;GOEDDEL: ""Methods in Enzymology 185"", 1990, ACADEMIC PRESS, article ""Gene Expression Technology"";;TAKEBE, Y. ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;BOSS, M. A.; WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMAN; P. A. SHARP, MOL. BIOL., vol. 759, 1982, pages 601 - 621;;SENTER, P. D., CURR. OPIN. CHEM. BIOL., vol. 13, 2009, pages 235 - 244;;HACKENBERGER, C. P. R.; SCHWARZER, D., ANGEW. CHEM. INT. ED. ENGL., vol. 47, 2008, pages 10030 - 10074;;SUNBUL, M.; YIN, J., ORG. BIOMOL. CHEM., vol. 7, 2009, pages 3361 - 3371;;FRESE, M. A.; DIERKS, T., CHEMBIOCHEM., vol. 10, 2009, pages 425 - 427;;TAKI, M. ET AL., PROT. ENG. DES. SEL., vol. 17, 2004, pages 119 - 126;;GAUTIER, A. ET AL., CHEM. BIOL., vol. 15, 2008, pages 128 - 136;;BORDUSA, F., HIGHLIGHTS IN BIOORGANIC CHEMISTRY, 2004, pages 389 - 403;;REN, H. ET AL., ANGEW. CHEM. INT. ED. ENGL., vol. 48, 2009, pages 9658 - 9662;;TAYLOR, E. VOGEL; IMPERIALI, B: ""Nucleic Acids and Molecular Biology"", vol. 22, 2009, PROTEIN ENGINEERING, pages: 65 - 96;;DE GRAAF, A. J. ET AL., BIOCONJUG. CHEM., vol. 20, 2009, pages 1281 - 1295;;KARPOVSKY ET AL., J. EXP. MED., vol. 160, 1984, pages 1686;;LIU, MA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 8648;;PAULUS, BEHRING INS. MITT., vol. 78, 1985, pages 118 - 132;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83;;GLENNIE ET AL., J. IMMUNOL., vol. 139, 1987, pages 2367 - 2375;;BERGE, S.M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;V.V. RANADE, J. CLIN. PHARMACOL., vol. 29, 1989, pages 685;;UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 153, 1988, pages 1038;;P.G. BLOEMAN ET AL., FEBSLETT., vol. 357, 1995, pages 140;;M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 39, 1995, pages 180;;BRISCOE ET AL., AM. J. PHYSIOL., vol. 1233, 1995, pages 134;;SCHREIER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 9090;;K. KEINANEN; M.L. LAUKKANEN, FEBSLETT., vol. 346, 1994, pages 123;;J.J. KILLION; I.J. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;ROSENBERG, S.: ""ASCO Educational Book Spring"", 2000, ASCO EDUCATIONAL BOOK SPRING, article ""Development of Cancer Vaccines"", pages: 60 - 62;;LOGOTHETIS, C: ""ASCO Educational Book Spring"", 2000, pages: 300 - 302;;KHAYAT, D.: ""ASCO Educational Book Spring"", 2000, pages: 414 - 428;;FOON, K., ASCO EDUCATIONAL BOOK SPRING, 2000, pages 730 - 738;;RESTIFO, N.; SZNOL, M., CANCER VACCINES, vol. 61, pages 3023 - 3043;;""Cancer: Principles and Practice of Oncology"", 1997;;DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, S A, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT; SRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARD; O'GARRA, IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;RIDGE ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;WEINBERG ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;GREENBERG; RIDDELL, SCIENCE, vol. 285, 1999, pages 546 - 51;;HOLLIGER, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;VAN ELSAS ET AL., J. EXP. MED., vol. 194, 2001, pages 481 - 489;;OVERWIJK ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 96, 1999, pages 2982 - 2987;;ROSENBERG; WHITE, J. IMMUNOTHER EMPHASIS TUMOR IMMUNOL, vol. 19, no. 1, 1996, pages 81 - 4;;SCHENK ET AL., NATURE, vol. 400, 1999, pages 173 - 177;;TANSEY, DRUG DISCOVERY TODAY, vol. 00, 2009, pages 1;;HURWITZ ET AL., PRO. NATL. ACAD. SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071;;CAMACHO ET AL., J. CLIN. ONCOLOGY, vol. 22, 2004, pages 145;;MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304;;FULDA ET AL., NAT MED, vol. 8, 2002, pages 808 - 15;;HYER ET AL., CANCER RESEARCH, vol. 65, 2005, pages 4799 - 808;;""Molecular Cloning A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;""Molecular Cloning: A Laboratory Manual"", 1992, COLD SPRINGS HARBOR LABORATORY;;""DNA Cloning"", vol. I;II, 1985;;""Oligonucleotide Synthesis"", 1984;;""Nucleic Acid Hybridization"", 1984;;""Transcription And Translation"", 1984;;FRESHNEY: ""Culture Of Animal Cells"", 1987, ALAN R. LISS, INC.;;""Immobilized Cells And Enzymes"", 1986, IRL PRESS;;PERBAL, A PRACTICAL GUIDE TO MOLECULAR CLONING, 1984;;""Methods In Enzymology"", ACADEMIC PRESS, INC.;;""Gene Transfer Vectors For Mammalian Cells"", 1987, COLD SPRING HARBOR LABORATORY;;""Methods In Enzymology"", vol. 154;155;;""Immunochemical Methods In Cell And Molecular Biology"", 1987, ACADEMIC PRESS;;""Handbook Of Experimental Immunology"", vol. I-IV, 1986;;""Manipulating the Mouse Embryo"", 1986, COLD SPRING HARBOR LABORATORY PRESS, COLD SPRING HARBOR;;CROOKS: ""Antisense drug Technology: Principles, strategies and applications"", 2007, CRC PRESS;;AUSUBEL ET AL.: ""Current Protocols in Molecular Biology"", 1989, JOHN WILEY AND SONS;;NGIOW ET AL., CANCER RES., vol. 71, 2011, pages 3540;;DEKRUYFF ET AL., J. IMMUNOLOGY, 2010;;ROSEMARIE ET AL., JIMMUNOL, vol. 184, 2010, pages 1918;;FREEMEN ET AL., IMMUNOL REV., vol. 235, 2010, pages 172",PENDING
280,PE,A1,PE 20190418 A1,096-041-934-006-590,2019-03-19,2019,PE 2019000055 A,2017-07-13,US 201662362541 P;;US 201762459499 P,2016-07-14,ANTICUERPOS CONTRA PROTEINA 3 QUE CONTIENE EL DOMINIO DE MUCINA E INMUNOGLOBULINA DE LINFOCITOS T (TIM3) Y SUS USOS,"Referido a un anticuerpo aislado o una porcion de union al antigeno del mismo, se une a la proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos T (TIM3), con propiedades como: union a TIM3 humana soluble, union a TIM3 humana unida a la membrana, induce o mejora la activacion de linfocitos T; y opcionalmente se une a TIM3 de mono cinomologo soluble; y se une a TIM3 de mono cinomologo de membrana. Tambien se refiere a polinucleotidos que codifican las regiones de las cadenas pesada y/o ligera de los anticuerpos, o porciones de union al antigeno de los mismos, y vectores que comprenden los polinucleotidos que codifican las regiones de las cadenas pesada y/o ligera de los anticuerpos, o porciones de union al antigeno de los mismos. Estos se caracterizan porque el CDR3 de la cadena pesada comprende una secuencia de aminoacidos seleccionados de: SEQ ID NO: 53, 54, 55, entre otros; CDR1 de la cadena ligera comprende X1, X2, X3, X4, X5 y X6, y en donde X1 es S o ninguno; X2 es R o ninguno; X3 es S, R o D, X4 es Y o H; X5 es W o M, y X6 es G, N, S o H. Ademas, se caracteriza por estimular la respuesta inmunitaria antitumoral, y su uso aplicaciones terapeuticas, tales como el tratamiento del cancer.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHERPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/096-041-934-006-590,Patent Application,no,0,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28,,0,0,,,,PENDING
281,SG,A,SG 10201911972Q A,147-354-108-448-448,2020-02-27,2020,SG 10201911972Q A,2017-07-13,US 201662362541 P;;US 201762459499 P,2016-07-14,ANTIBODIES AGAINST TIM3 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/147-354-108-448-448,Unknown,no,0,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,,,0,0,,,,PENDING
282,BR,A2,BR 112017025297 A2,178-886-970-343-145,2018-08-14,2018,BR 112017025297 A,2016-06-02,US 2016/0035514 W;;US 201562170579 P,2015-06-03,anticorpos anti-gitr para diagnóstico do câncer,"a presente invenção refere-se a anticorpos diagnósticos que se ligam ao receptor do fator de necrose tumoral induzido por glicocorticoides (gitr). tais anticorpos são úteis para os métodos de detectar a expressão do gitr em amostras biológicas, por exemplo, o tecido de tumor, e identificar um paciente com câncer propenso a responder à imunoterapia anti-gitr ou predizer se um paciente com câncer responderá à imunoterapia anti-gitr.",BRISTOL MYERS SQUIBB CO,ALAN J KORMAN;;ANNE C LEWIN;;CHANGYU WANG;;GUODONG CHEN;;HAICHUN HUANG;;HUIMING LI;;INDRANI CHAKRABORTY;;KARLA A HENNING;;MARK J SELBY;;MICHELLE MINHUA HAN;;MOHAN SRINIVASAN;;NILS LONBERG;;OLUFEMI A ADELAKUN;;RICHARD HUANG;;SUSAN CHIEN-SZU WONG;;XI-TAO WANG,,https://lens.org/178-886-970-343-145,Patent Application,no,0,0,16,16,0,C07K16/2878;;G01N33/566;;C07K2317/56;;C07K2317/24;;C07K2317/21;;C07K2317/92;;G01N2800/52;;G01N2800/7028;;G01N2333/70578;;C07K16/2878;;G01N33/566;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/92;;G01N2333/70578;;G01N2800/52;;G01N2800/7028;;A61P35/00;;A61P43/00;;C07K2317/21;;C07K2317/92;;G01N33/566;;C07K2317/24;;G01N2800/7028;;C07K2317/56;;C07K16/2878;;G01N2800/52;;G01N2333/70578;;C07K16/2866;;G01N33/57492;;G01N2333/4703;;G01N2333/7051;;G01N2333/7151,C07K16/28;;G01N33/566,,0,0,,,,DISCONTINUED
283,CO,A2,CO 2019000372 A2,046-330-191-226-45X,2019-01-18,2019,CO 2019000372 A,2019-01-14,US 2017/0041946 W;;US 201762459499 P;;US 201662362541 P,2016-07-14,Anticuerpos contra proteína 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos,"La presente invención se refiere a anticuerpos, o porciones de unión al antígeno de los mismos, que se unen a la proteína 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos T (TIM3). También se proporcionan usos de estos anticuerpos, o porciones de unión al antígeno de los mismos, en aplicaciones terapéuticas, tales como el tratamiento del cáncer. También se proporcionan células que producen los anticuerpos, o porciones de unión al antígeno de los mismos, polinucleótidos que codifican las regiones de las cadenas pesada y/o ligera de los anticuerpos, o porciones de unión al antígeno de los mismos, y vectores que comprenden los polinucleótidos que codifican las regiones de las cadenas pesada y/o ligera de los anticuerpos, o porciones de unión al antígeno de los mismos.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/046-330-191-226-45X,Patent Application,no,0,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28,,0,0,,,,PENDING
284,MX,A,MX 2017015260 A,097-495-277-005-055,2018-02-19,2018,MX 2017015260 A,2016-06-02,US 201562170579 P;;US 2016/0035514 W,2015-06-03,ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS.,"Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.",BRISTOL MYERS SQUIBB CO,HAICHUN HUANG;;NILS LONBERG;;ALAN J KORMAN;;MARK J SELBY;;CHANGYU WANG;;MOHAN SRINIVASAN;;MICHELLE MINHUA HAN;;INDRANI CHAKRABORTY;;GUODONG CHEN;;RICHARD HUANG;;HUIMING LI;;KARLA A HENNING;;SUSAN CHIEN- SZU WONG;;XI- TAO WANG;;OLUFEMI A ADELAKUN;;ANNE C LEWIN,,https://lens.org/097-495-277-005-055,Patent Application,no,0,0,16,16,0,C07K16/2878;;G01N33/566;;C07K2317/56;;C07K2317/24;;C07K2317/21;;C07K2317/92;;G01N2800/52;;G01N2800/7028;;G01N2333/70578;;C07K16/2878;;G01N33/566;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/92;;G01N2333/70578;;G01N2800/52;;G01N2800/7028;;A61P35/00;;A61P43/00;;C07K2317/21;;C07K2317/92;;G01N33/566;;C07K2317/24;;G01N2800/7028;;C07K2317/56;;C07K16/2878;;G01N2800/52;;G01N2333/70578;;C07K16/2866;;G01N33/57492;;G01N2333/4703;;G01N2333/7051;;G01N2333/7151,G01N33/566;;C07K16/28,,0,0,,,,PENDING
285,TW,B,TW I780057 B,091-906-146-403-307,2022-10-11,2022,TW 106123527 A,2017-07-13,US 201662362541 P;;US 201762459499 P,2016-07-14,Antibodies against tim3 and uses thereof,,BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/091-906-146-403-307,Granted Patent,no,2,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,,,0,0,,,,ACTIVE
286,KR,A,KR 20190027384 A,120-446-326-933-263,2019-03-14,2019,KR 20197004275 A,2017-07-13,US 201662362541 P;;US 201762459499 P;;US 2017/0041946 W,2016-07-14,TIM3에 대한 항체 및 그의 용도,"T-세포 이뮤노글로불린 및 뮤신-도메인 함유-3 (TIM3) 단백질에 결합하는 항체 또는 그의 항원-결합 부분이 본원에 제공된다. 또한 치료 용도, 예컨대 암의 치료에서의 이들 항체 또는 그의 항원-결합 부분의 용도가 제공된다. 추가로 항체 또는 그의 항원-결합 부분을 생산하는 세포, 항체 또는 그의 항원-결합 부분의 중쇄 및/또는 경쇄 영역을 코딩하는 폴리뉴클레오티드, 및 항체 또는 그의 항원-결합 부분의 중쇄 및/또는 경쇄 영역을 코딩하는 폴리뉴클레오티드를 포함하는 벡터가 제공된다.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG AN,,https://lens.org/120-446-326-933-263,Patent Application,no,5,0,36,39,770,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28;;A61K39/00;;A61P35/00;;C07K16/30,,0,0,,,,ACTIVE
287,CA,A1,CA 2988115 A1,133-004-844-079-929,2016-12-08,2016,CA 2988115 A,2016-06-02,US 201562170579 P;;US 2016/0035514 W,2015-06-03,ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS,"Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.",BRISTOL MYERS SQUIBB CO,WANG XI-TAO;;ADELAKUN OLUFEMI A;;LEWIN ANNE C;;KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;HUANG HAICHUN;;HENNING KARLA A;;LONBERG NILS;;SRINIVASAN MOHAN;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;WONG SUSAN CHIEN-SZU;;LI HUIMING,,https://lens.org/133-004-844-079-929,Patent Application,no,0,0,16,16,228,C07K16/2878;;G01N33/566;;C07K2317/56;;C07K2317/24;;C07K2317/21;;C07K2317/92;;G01N2800/52;;G01N2800/7028;;G01N2333/70578;;C07K16/2878;;G01N33/566;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/92;;G01N2333/70578;;G01N2800/52;;G01N2800/7028;;A61P35/00;;A61P43/00;;C07K2317/21;;C07K2317/92;;G01N33/566;;C07K2317/24;;G01N2800/7028;;C07K2317/56;;C07K16/2878;;G01N2800/52;;G01N2333/70578;;C07K16/2866;;G01N33/57492;;G01N2333/4703;;G01N2333/7051;;G01N2333/7151,G01N33/566;;C07K16/28,,0,0,,,,DISCONTINUED
288,UY,A,UY 37325 A,155-330-817-936-94X,2018-01-31,2018,UY 37325 A,2017-07-13,US 201662362541 P;;US 201762459499 P,2016-07-14,ANTICUERPOS MONOCLONALES QUE SE ENLAZAN A TIM3 PARA ESTIMULAR RESPUESTAS INMUNITARIAS Y COMPOSICIONES QUE LOS CONTIENEN,"Se divulgan anticuerpos, o porciones de fijación al antígeno de estos, que se fijan a la proteína 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos T (TIM3). También se proporcionan usos de estos anticuerpos, o porciones de fijación al antígeno de estos, en aplicaciones terapéuticas, tales como el tratamiento del cáncer. También se proporcionan células que producen los anticuerpos, o porciones de fijación al antígeno de estos, polinucleótidos que codifican las regiones de las cadenas pesada y/o liviana de los anticuerpos, o porciones de fijación al antígeno de estos, y vectores que los comprenden.",BRISTOL MYERS SQUIBB COMPANY UNA CORPORACION DEL ESTADO DE DELAWARE,ALAN J KORMAN;;MARK J SELBY;;MICHELLE MINHUA HAN;;CHEN GUODONG;;HUANG RICHARD;;LI HUIMING;;XIAO MIN SCHEBYE;;BEE CHRISTINE;;ANDY X DENG;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;PAUL O SHEPPARD;;DANIEL F ARDOUREL;;DEYANOVA EKATERINA;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/155-330-817-936-94X,Patent Application,no,0,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,A61P35/00;;A61K39/395;;A61P37/04;;C07K16/28;;C07K16/30;;C07K16/46;;C07K19/00;;C12N5/10;;C12N15/13;;C12N15/85;;C12P21/08;;G01N33/577,,0,0,,,,DISCONTINUED
289,WO,A3,WO 2018/013818 A3,023-356-795-797-246,2018-02-22,2018,US 2017/0041946 W,2017-07-13,US 201662362541 P;;US 201762459499 P,2016-07-14,ANTIBODIES AGAINST TIM3 AND USES THEREOF,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG AN,,https://lens.org/023-356-795-797-246,Search Report,yes,5,0,36,39,0,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28,,2,2,015-507-770-980-445;;077-737-756-070-317,24046178;;10.1007/s12185-013-1433-6;;25086175;;pmc4120324;;10.4049/jimmunol.1400557,"YOSHIKANE KIKUSHIGE ET AL: ""TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells"", INTERNATIONAL JOURNAL OF HEMATOLOGY, vol. 98, no. 6, 18 September 2013 (2013-09-18), pages 627 - 633, XP055181432, ISSN: 0925-5710, DOI: 10.1007/s12185-013-1433-6;;ROBERT L. FERRIS ET AL: ""Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion"", THE JOURNAL OF IMMUNOLOGY, vol. 193, no. 4, 1 August 2014 (2014-08-01), US, pages 1525 - 1530, XP055327897, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1400557",PENDING
290,AR,A1,AR 109262 A1,117-138-629-432-703,2018-11-14,2018,AR P170101959 A,2017-07-13,US 201662362541 P,2016-07-14,ANTICUERPOS CONTRA TIM3 Y SUS USOS,"Anticuerpos, o porciones de fijación al antígeno de estos, que se fijan a la proteína 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos T (TIM3). Reivindicación 13: El anticuerpo, o la porción de fijación al antígeno de este, de acuerdo con cualquiera de las reivindicaciones anteriores, caracterizado porque el anticuerpo, o la porción de fijación al antígeno de este, comprende CDR1, CDR2 y CDR3 de la cadena pesada y CDR1, CDR2 y CDR3 de la cadena liviana, en donde CDR3 de la cadena pesada comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: SEQ ID Nº 53, SEQ ID Nº 54, SEQ ID Nº 55, SEQ ID Nº 56, SEQ ID Nº 57, SEQ ID Nº 58, SEQ ID Nº 59, SEQ ID Nº 126, SEQ ID Nº 127, SEQ ID Nº 128 o SEQ ID Nº 129.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;CHUNTHARAPAI ANAN;;DENG ANDY X;;BEE CHRISTINE;;HAN MICHELLE MINHUA;;SELBY MARK J;;TRUONG HONG;;AN - KUHNE MICHELLE;;CHEN GUODONG;;HUANG RICHARD;;DEYANOVA EKATERINA;;ARDOUREL DANIEL F;;KORMAN ALAN J;;SHEPPARD PAUL O;;LI HUIMING;;DEVAUX BRIGITTE,,https://lens.org/117-138-629-432-703,Patent Application,no,0,0,2,39,0,,C07K16/28;;A61K39/00;;A61P35/00;;C12N5/22;;C12N15/13;;C12N15/82,,0,0,,,,PENDING
291,MA,A,MA 45661 A,138-536-571-925-905,2019-05-22,2019,MA 45661 A,2017-07-13,US 201662362541 P,2016-07-14,ANTICORPS ANTI-TIM3 ET LEURS UTILISATIONS,,BRISTOL MYERS SQUIBB CO,ARDOUREL DANIEL F;;BEE CHRISTINE;;CHEN GUODONG;;CHUNTHARAPAI ANAN;;DENG ANDY X;;DEVAUX BRIGITTE;;DEYANOVA EKATERINA;;HAN MICHELLE MINHUA;;HUANG RICHARD;;KORMAN ALAN J;;KUHNE MICHELLE;;LI HUIMING;;SCHEBYE XIAO MIN;;SELBY MARK J;;SHEPPARD PAUL O;;TRUONG HONG-AN,,https://lens.org/138-536-571-925-905,Unknown,no,0,0,2,39,0,,C07K16/28,,0,0,,,,PENDING
292,CA,A1,CA 3030765 A1,158-550-039-396-660,2018-01-18,2018,CA 3030765 A,2017-07-13,US 201662362541 P;;US 201762459499 P;;US 2017/0041946 W,2016-07-14,ANTIBODIES AGAINST TIM3 AND USES THEREOF,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/158-550-039-396-660,Patent Application,no,0,0,36,39,385,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28,,0,0,,,,PENDING
293,US,B2,US 10533052 B2,135-457-657-307-070,2020-01-14,2020,US 201816017489 A,2018-06-25,US 201816017489 A;;US 201715649380 A;;US 201762459499 P;;US 201662362541 P,2016-07-14,Antibodies against TIM3 and uses thereof,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,BRISTOL-MYERS SQUIBB COMPANY (2017-07-21),https://lens.org/135-457-657-307-070,Granted Patent,yes,276,2,36,39,385,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/30;;A61K39/00;;A61K47/68;;A61P35/00;;C07K16/28;;G01N33/574,,80,69,018-069-206-369-372;;017-150-654-990-340;;005-112-559-456-657;;006-553-734-546-212;;105-316-874-895-908;;022-179-293-052-569;;018-694-084-068-187;;041-909-244-299-232;;078-432-639-041-575;;087-879-787-031-413;;089-689-557-564-287;;035-135-729-507-737;;052-219-543-437-800;;073-130-138-292-805;;020-986-423-793-233;;082-210-673-349-152;;010-488-381-022-259;;066-749-017-721-197;;008-213-515-306-640;;002-264-966-090-625;;127-416-339-660-812;;030-249-121-435-10X;;020-123-860-433-320;;068-238-957-669-243;;104-212-297-137-759;;038-478-749-169-986;;084-388-182-984-099;;043-108-278-056-872;;032-820-729-763-323;;030-630-100-818-462;;005-022-447-377-963;;012-746-915-512-650;;053-703-232-770-99X;;023-676-781-371-861;;009-621-637-014-514;;003-763-873-758-289;;070-624-200-848-669;;024-348-828-966-680;;001-467-559-709-949;;030-323-674-660-051;;042-204-626-457-327;;068-450-506-389-89X;;027-326-505-837-755;;111-914-031-290-975;;012-300-595-074-789;;004-458-031-333-650;;003-752-183-823-430;;040-577-067-037-463;;062-029-719-290-327;;094-082-569-858-098;;088-086-720-613-343;;071-707-020-428-907;;047-951-914-695-080;;092-023-577-402-127;;060-375-551-951-388;;033-754-369-798-314;;070-318-112-524-781;;051-940-176-386-905;;094-685-907-794-422;;074-817-300-512-106;;056-422-417-058-69X;;042-740-484-382-110;;034-714-253-790-433;;122-651-085-264-657;;026-418-623-750-230;;057-102-333-317-731;;071-623-595-422-33X;;015-507-770-980-445;;077-737-756-070-317,10.1158/2326-6066.cir-14-0039;;24795351;;3140379;;10.1126/science.3140379;;10.1126/science.3925553;;3925553;;8424945;;10.1021/bi00055a024;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.1002/eji.1830240409;;8149953;;10.1126/science.2471267;;2471267;;12391234;;10.4049/jimmunol.169.9.5171;;10.1074/jbc.m604292200;;16793771;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10.1084/jem.20100637;;20819923;;pmc2947081;;10.4049/jimmunol.172.9.5489;;15100290;;2958547;;10.4049/jimmunol.139.7.2367;;24339828;;10.3389/fimmu.2013.00449;;pmc3857553;;15470033;;10.4049/jimmunol.173.8.4919;;10.4049/jimmunol.176.1.346;;16365427;;14699147;;10.1074/jbc.c300470200;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;9930702;;10.1038/16717;;15930300;;10.1158/0008-5472.can-04-3319;;10.1016/0014-5793(94)00313-0;;8206150;;10556249;;10.1093/protein/12.10.879;;10.4049/jimmunol.148.5.1547;;1531669;;10.2174/1389201023378229;;12463418;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;7494109;;10.3109/08830189509061738;;8159246;;10.1038/368856a0;;10.1038/348552a0;;2247164;;9176498;;10.1038/nm0697-682;;11275255;;10.1016/s0161-5890(00)00105-x;;9850053;;10.1126/science.3929380;;3929380;;10.1093/chromsci/40.6.343;;12137207;;10.1182/blood-2008-10-185884;;19224762;;10.1038/316452a0;;3927174;;10.1182/blood-2010-10-310425;;21385853;;pmc3099570;;10.1016/s0969-2126(94)00113-8;;7704521;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;3127726;;10.1038/332323a0;;21810406;;pmc3175029;;10.1016/j.bbamem.2011.07.026;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1016/0161-5890(92)90200-h;;1533898;;10.1016/j.cbpa.2009.03.023;;19414278;;11096108;;10.1074/jbc.m009483200;;11986321;;10.1074/jbc.m202069200;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;12042244;;10.1093/glycob/12.4.43r;;17875730;;10.1158/0008-5472.can-07-0696;;19896358;;10.1016/j.copbio.2009.10.011;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;1404388;;10.1016/0022-2836(92)90223-7;;8144892;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;10.1038/6179;;10052355;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;2459288;;pmc2189025;;10.1084/jem.168.3.1099;;10.1038/341544a0;;2677748;;10657670;;10.4049/jimmunol.164.4.2160;;10.4049/jimmunol.0804182;;19494290;;10.1111/j.0105-2896.2010.00903.x;;pmc2914464;;20536563;;020083673;;10.4049/jimmunol.0903059;;pmc3128800;;20083673;;20073133;;pmc2726606;;10.4161/mabs.1.4.9122;;11725301;;10.1038/ni739;;10.1038/415536a;;11823861;;24046178;;10.1007/s12185-013-1433-6;;25086175;;pmc4120324;;10.4049/jimmunol.1400557,"Anderson, A.C., “Tim-3: an Emerging Target in the Cancer Immunotherapy Landscape ,” Cancer Immunology Research 2(5):393-398, American Association for Cancer Research, United States (2014).;;Bird, R.E., et al., “Single-chain Antigen-binding Proteins,” Science 242(4877):423-426, Association for the Advancement of Science, United States (Oct. 1988).;;Brennan, M., et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science 229(4708):81-83, American Association for the Advancement of Science, United States (Jul. 1985).;;Brummell, D.A., et al., “Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues,” Biochemistry 32(4):1180-1187, American Chemical Society, United States (1993).;;Burks, E.A., et al., “In vitro Scanning Saturation Mutagenesis of an Antibody Binding Pocket,” Proceedings of the National Academy of Sciences USA 94(2):412-417, Plenum Publishing Corporation , United States (1997).;;Cox, J.P., et al., “A Directory of Human Germ-line V kappa Segments Reveals a Strong Bias in their Usage,” European Journal of Immunology 24(4):827-836, Verlag Chemie GmbH, Germany (Apr. 1994).;;Cunningham, B.C. and Wells, J.A., “High-resolution Epitope Mapping of hGH-receptor Interactions by Alanine-scanning Mutagenesis,” Science 244(4908):1081-1085, American Association for the Advancement of Science, United States (Jun. 1989).;;Dall Acqua, W.F., et al., “Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences,” The Journal of Immunology 169(9):5171-5180, American Association of Immunologists, United States (Nov. 2002).;;Dall'Acqua, W.F., et al., “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn),” The Journal of Biological Chemistry 281(33):23514-23524, American Society for Biochemistry and Molecular Biology, United States (2006).;;Dranoff, G., et al., “Vaccination With Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-macrophage Colony-stimulating Factor Stimulates Potent, Specific, and Long-lasting Anti-tumor Immunity,” Proceedings of the National Academy of Sciences of the United States of America 90(8):3539-3543, National Academy of Sciences, United States (1993).;;Fourcade, J., et al., “Upregulation of Tim-3 and PDd-1 Expression Is Associated With Tumor Antigen-specific CD8+ T Cell Dysfunction in Melanoma Patients,” The Journal of Experimental Medicine 207(10):2175-2186, Rockefeller University Press, United States (2010).;;Gala, F.A. and Morrison, S.L., “V Region Carbohydrate and Antibody Expression,” The Journal of Immunology 172(9):5489-5494, Williams & Wilkins, United States (2004).;;GenBank, “HAVCR2 protein [Homo sapiens],” Accession No. AAH20843.1, accessed on https://www.ncbi.nlm.nih.gov/protein/AAH20843, Sep. 16, 2003.;;GenBank, “Hepatitis A Virus Cellular Receptor 2 Precursor [Homo sapiens],” Accession No. NP_116171.3, accessed on https://www.ncbi.nlm.nih.gov/protein/NP_116171, Jun. 15, 2017.;;GenBank, “Homo sapiens Hepatitis A Virus Cellular Receptor 2 (HAVCR2), mRNA,” Accession No. NM_032782.4, accessed on https://www.ncbi.nlm.nih.gov/nuccore/NM_032782.4, Jun. 15, 2017.;;GenBank, “Homo sapiens Hepatitis A Virus Cellular Receptor 2, mRNA (cDNA clone Image:4701288), Complete Cds,” Accession No. BC020843.1, accessed on https://www.ncbi.nlm.nih.gov/nuccore/BC020843.1, Sep. 16, 2003.;;Glennie, M.J., et al., “Preparation and Performance of Bispecific F(Ab' Gamma)2 Antibody Containing Thioether-linked Fab' Gamma Fragments,” Journal of Immunology 139(7):2367-2375, American Association of Immunologists, United States (1987).;;Han, G., et al., “Tim-3: an Activation Marker and Activation Limiter of Innate Immune Cells,” Frontiers in Immunology 4:449, Frontiers Research, Switzerland (2013).;;He, Y-F., et al., “Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine,” The Journal of Immunology 173(8):4919-4928, The American Association of Immunologists, United States (Oct. 2004).;;Hinton, P.R., et al., “An Engineered Human IgG1 Antibody with Longer Serum Half-Life,” Journal of Immunology 176(1):346-356, American Association of Immunologists, United States (2006).;;Hinton, P.R., et al., “Engineered Human IgG Antibodies With Longer Serum Half-lives in Primates,” The Journal of Biological Chemistry 279(8):6213-6216, American Society for Biochemistry and Molecular Biology, United States (2004).;;Holliger, P., et al., “Diabodies: Small Bivalent and Bispecific Antibody Fragments,” Proceedings of the National Academy of Sciences USA 90(14):6444-6448, National Academy of Sciences, United States (Jul. 1993).;;Hurwitz, A.A., et al., “CTLA-4 Blockade Synergizes With Tumor-derived Granulocyte-macrophage Colony-stimulating Factor for Treatment of an Experimental Mammary Carcinoma,” Proceedings of the National Academy of Sciences of the United States of America 95(17):10067-10071, National Academy of Sciences, United States (1998).;;Huston, J.S., et al., “Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-digoxin Single-chain Fv Analogue Produced in Escherichia coli,” Proceedings of the National Academy of Sciences USA 85(16):5879-5883, National Academy of Sciences, United States (Aug. 1988).;;Hutloff, A., et al., “ICOS is an Inducible T-cell Co-stimulator Structurally and Functionally Related to CD28,” Nature 397(6716):263-266, Nature Publishing Group, England (Jan. 1999).;;Hyer, M.L., et al., “Synthetic Triterpenoids Cooperate With Tumor Necrosis Factor-related Apoptosis-inducing Ligand to Induce Apoptosis of Breast Cancer Cells,” Cancer Research 65(11):4799-4808, American Association for Cancer Research, United States (2005).;;Kabat, E.A., et al., “Sequences of Proteins of Immunological Interest,” 5th Edition, U.S. Department of Public Health and Human Services, Public Health Service, National Institutes of Health, Bethesda (1991).;;Keinanen, K. and Laukkanen, M.L., “Biosynthetic Lipid-tagging of Antibodies,” FEBS Letters 346(1):123-126, John Wiley & Sons Ltd, England (1994).;;Kobayashi, H., et al., “Tryptophan H33 Plays an Important Role in Pyrimidine (6-4) Pyrimidone Photoproduct Binding by a High-Affinity Antibody,” Protein Engineering Design and Selection 12(10):879-884, Oxford University Press, United States (1999).;;Kostelny, S.A., et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology 148(5):1547-1553, American Association of Immunologists, United States (Mar. 1992).;;Krishnamurthy, R. and Manning, M.C., “The Stability Factor: Importance in Formulation Development,” Current Pharmaceutical Biotechnology 3(4):361-371, Bentham Science Publishers, Netherlands (2002).;;Liu, M.A., et al., “Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America 82(24):8648-8652, National Academy of Sciences, United States (1985).;;Lonberg, N. and Huszar, D., “Human Antibodies from Transgenic Mice,” International Reviews of Immunology 13(1):65-93, Informa Healthcare, England (1995).;;Lonberg, N., et al., “Antigen-specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications,” Nature 368(6474):856-859, Nature Publishing Group, United States (Apr. 1994).;;McCafferty, J., et al., “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains,” Nature 348(6301):552-554, Nature Publishing Group, London (Dec. 1990).;;Melero, I., et al., “Monoclonal Antibodies Against the 4-1BB T-cell Activation Molecule Eradicate Established Tumors,” Nature Medicine 3(6):682-685, Nature Publishing Company, United States (1997).;;Mimura, Y., et al., “The Influence of Glycosylation on the Thermal Stability and Effector Function Expression of Human IgG1-Fc: Properties of a Series of Truncated Glycoforms,” Molecular Immunology 37(12-13):697-706, Pergamon Press, England (2000).;;Mokyr, M.B., et al., “Realization of the Therapeutic Potential of CTLA-4 Blockade in Low-dose Chemotherapy-treated Tumor-bearing Mice,” Cancer Research 58(23):5301-5304, American Association for Cancer Research, United States (1998).;;Morrison, S.L., “Transfectomas Provide Novel Chimeric Antibodies,” Science 229(4719):1202-1207, Association for the Advancement of Science, United States (Sep. 1985).;;Murray, A., et al., “Epitope Affinity Chromatography and Biophysical Studies of Monoclonal Antibodies and Recombinant Antibody Fragments,” Journal of Chromatographic Science 40(6):343-349, Oxford University Press, United States (2002).;;Nakayama, M., et al., “Tim-3 Mediates Phagocytosis of Apoptotic Cells and Cross-presentation,” Blood 113(16):3821-3830, American Society of Hematology, United States (2009).;;Ngiow, S.F., et al., “Anti-TIM3 Antibody Promotes T Cell IFN-γ-mediated Antitumor Immunity and Suppresses Established Tumors,” Cancer Research 71(10):3540-3451, American Association for Cancer Research, United States (2011).;;Parekh, R.B., et al., “Association of Rheumatoid Arthritis and Primary Osteoarthritis with Changes in the Glycosylation Pattern of Total Serum IgG,” Nature 316(6027):452-457, Nature Publishing Group, England (1985).;;Zhou, Q., et al., “Coexpression of Tim-3 and PD-1 Identifies a CD8+ T-Cell Exhaustion Phenotype in Mice With Disseminated Acute Myelogenous Leukemia,” Blood 117(17):4501-4510, American Society of Hematology, United States (Apr. 2011).;;Pei-Show Juo., The Concise Dictionary of Biomedicine and Molecular Biology, 2nd Edition, CRC Press, United States (2002).;;Poljak, R.J., “Production and Structure of Diabodies,” Structure 2(12):1121-1123, Cell Press, United States (1994).;;Queen, C., et al., “A Humanized Antibody that Binds to the Interleukin 2 Receptor,” Proceedings of the National Academy of Sciences USA 86(24):10029-10033, National Academy of Sciences, United States (Dec. 1989).;;Riechmann, L., et al., “Reshaping Human Antibodies for Therapy,” Nature 332(6162):323-327, Nature Publishing Group, United States (Mar. 1988).;;Riedl, S., et al., “In Search of a Novel Target—Phosphatidylserine Exposed by Non-apoptotic Tumor Cells and Metastases of Malignancies With Poor Treatment Efficacy,” Biochimica Et Biophysica Acta 1808(11):2638-2645, Elsevier Pub. Co., Netherlands (2011).;;Rosenberg, S.A., “A New Era for Cancer Immunotherapy Based on the Genes That Encode Cancer Antigens,” Immunity 10(3):281-287, Cell Press, United States (1999).;;Sarmay, G., et al., “Mapping and Comparison of the Interaction Sites on the Fc Region of IgG Responsible for Triggering Antibody Dependent Cellular Cytotoxicity (ADCC) Through Different Types of Human Fc Gamma Receptor,” Molecular Immunology 29(5):633-639, Pergamon Press, England (1992).;;Senter, P.D., “Potent Antibody Drug Conjugates for Cancer Therapy,” Current Opinion in Chemical Biology 13(3):235-244, Elsevier, England (2009).;;Shields, R.L., et al., “High Resolution Mapping of the Binding Site on Human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc gamma R,” The Journal of Biological Chemistry 276(9):6591-6604, American Society for Biochemistry and Molecular Biology, United States (Mar. 2001).;;Shields, R.L., et al., “Lack of Fucose on Human IgG1 N-linked Oligosaccharide Improves Binding to Human Fcgamma RIII and Antibody-Dependent Cellular Toxicity,” The Journal of Biological Chemistry 277(30):26733-26740, American Society for Biochemistry and Molecular Biology, United States (2002).;;Songsivilai, S. and Lachmann, P.J., “Bispecific Antibody: A Tool for Diagnosis and Treatment of Disease,” Clinical and Experimental Immunology 79(3):315-321, Blackwell Scientific Publications, England (1990).;;Spiro, R.G., “Protein Glycosylation: Nature, Distribution, Enzymatic Formation, and Disease Implications of Glycopeptide Bonds,” Glycobiology 12(4):43R-56R, IRL Press at Oxford University Press, England (2002).;;Stavenhagen, J.B., et al., “Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells in Vitro and Controls Tumor Expansion in Vivo via Low-affinity Activating Fcgamma Receptors,” Cancer Research 67(18):8882-8890, American Association for Cancer Research, United States (2007).;;Strohl, W.R., “Optimization of Fc-mediated Effector Functions of Monoclonal Antibodies,” Current Opinion in Biotechnology 20(6):685-691, Elsevier, England (2009).;;Taylor, L.D., et al., “A Transgenic Mouse That Expresses a Diversity of Human Sequence Heavy and Light Chain Immunoglobulins,” Nucleic Acids Research 20(23):6287-6295, Oxford University Press, England (1992).;;Tomizuka, K., et al., “Double Trans-chromosomic Mice: Maintenance of Two Individual Human Chromosome Fragments Containing Ig Heavy and kappa loci and Expression of Fully Human Antibodies,” Proceedings of the National Academy of Sciences USA 97(2):722-727, National Academy of Sciences, United States (Jan. 2000).;;Tomlinson, I.M., et al., “The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops,” Journal of Molecular Biology 227(3):776-798, Elsevier, Netherlands (Oct. 1992).;;Tuaillon, N., et al., “Biased Utilization of DHQ52 and JH4 Gene Segments in a Human Ig Transgenic Minilocus Is Independent of Antigenic Selection,” The Journal of Immunology 152(6):2912-2920, Williams & Wilkins, United States (1994).;;Tuaillon, N., et al., “Human Immunoglobulin Heavy-chain Minilocus Recombination in Transgenic Mice: Gene-segment Use in Mu and Gamma Transcripts,” Proceedings of the National Academy of Sciences of the United States of America 90(8):3720-3724, National Academy of Sciences, United States (1993).;;Umana, P., et al., “Engineered Glycoforms of an Antineuroblastoma IgG1 with Optimized Antibody-Dependent Cellular Cytotoxic Activity,” Nature Biotechnology 17(2):176-180, Nature America Publishing, United States (1999).;;Urlaub, G. and Chasin, L.A., “Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity,” Proceedings of the National Academy of Sciences USA 77(7):4216-4220, National Academy of Sciences, United States (Jul. 1980).;;Wallick, S.C., et al., “Glycosylation of a Vh Residue of a Monoclonal Antibody Against Alpha (1----6) Dextran Increases Its Affinity for Antigen,” The Journal of Experimental Medicine 168(3):1099-1109, Rockefeller University Press, United States (1988).;;Ward, E.S., et al., “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia coli,” Nature 341(6242):544-546, Nature Publishing Group, England (Oct. 1989).;;Weinberg, A.D., et al., “Engagement of the OX-40 Receptor in Vivo Enhances Antitumor Immunity,” Journal of Immunology 164(4):2160-2169, American Association of Immunologists, United States (2000).;;Yeung, Y.A., et al., “Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates,” Journal of Immunology 182(12):7663-7671, American Association of Immunologists, United States (2009).;;Freeman, G., et al., “TIM genes: a family of cell surface phosphatidlyserine receptors that regulate innate and adaptive immunity,” Immunol Rev. 235(1):172-189, Elsevier, Netherlands (2010).;;Dekruyff, R.H., et al., “T Cell/Transmembrne, Ig, and Mucin-3 Allelic variants Differentially Recognize Phosphatidylserine and mdiate Phagocytosis of Apoptotic cells,” Journal of Immunology 184:1918-1930, American Association of Immunologist, United States (2010).;;Jefferis,R., et al., “Human Immunoglobulin allotypes,” MAbs 1(4):332-338, Taylor & Francis, United Kingdom (2009).;;Protein Data Bank, “Human T-cell immunoglobulin and mucin domain protein 3 (hTIM-3),” 5F71, accessed at http://www.rcsb.org/pdb/explore/explore.do?pdbld=5F71 , accessed on Jul. 27, 2017, 2 pages.;;Protein Data Bank, “Structure of Tim-3 in complex with phosphatidylserine,” 3KAA, accessed at http://www.rcsb.org/pdb/explore/explore.do?structureId=3kaa, accessed on Jul. 27, 2017, 2 pages.;;McIntire, J.J., et al., “Identification of Tapr (An Airway Hyperreactivity Regulatory Locus) and the Linked Tim Gene Family,” Nature Immunology 2(12):1109-1116, Nature America Inc, United States (Dec. 2001).;;Monney, L., et al., “Identification and Characterization of Novel Cell Surface Molecules Expressed on TH1 cells,” Scandinavian Journal of Immunology 54:35, (2001).;;Monney, L., et al., “Th1-Specific Cell Surface Protein Tim-3 Regulates Macrophage Activation and Severity of an Autoimmune Disease,” Nature 415(6871):536-541, Nature Publishing Group, England (Jan. 2002).;;Kikushige, Y., et al., “TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells,” International Journal of Hematology 98 (6):627-633, Springer Publishing Company, United States (2013).;;Ferris, R.L., et al., “Too Much of a Good thing? Tim-3 and TCR Signaling in T Cell Exhaustion,” The Journal of Immunology 193(4):1525-1530, The American Association of Immunologists, United States (2014).;;International Search Report and Written Opinion for International Application No. PCT/US2017/041946, European Patent Office, Iceland, dated Jan. 3, 2018, 22 pages.",ACTIVE
294,EP,A1,EP 3737700 A1,004-806-515-651-848,2020-11-18,2020,EP 19702762 A,2019-01-11,US 201862616723 P;;US 2019/0013246 W,2018-01-12,ANTIBODIES AGAINST TIM3 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,,https://lens.org/004-806-515-651-848,Patent Application,yes,0,0,8,8,0,C07K16/2803;;A61K2039/505;;A61K2039/507;;C07K2317/33;;C07K2317/34;;C07K2317/74;;C07K2317/76;;C07K2317/92;;A61P35/00;;C07K16/2878;;G01N33/6857;;A61P35/00;;C07K2317/33;;C07K2317/34;;C07K2317/74;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K2039/507;;A61P35/00;;A61K2039/507;;C07K16/2803;;C07K2317/21;;C07K2317/31;;C07K2317/34;;C07K2317/74;;C07K2317/76;;C07K2317/92;;G01N33/6854;;G01N2333/70503,C07K16/28;;A61P35/00,,0,0,,,,PENDING
295,US,B2,US 10023634 B2,001-986-423-347-023,2018-07-17,2018,US 15649380,2017-07-13,,,Antibodies against TIM3 and uses thereof,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",Bristol-Myers Squibb Company,Xiao Min Schebye;;Mark J. Selby;;Michelle Minhua Han;;Christine Bee;;Andy X. Deng;;Anan Chuntharapai;;Brigitte Devaux;;Huiming Li;;Paul O. Sheppard;;Alan J. Korman;;Daniel F. Ardourel;;Ekaterina Deyanova;;Richard Huang;;Guodong Chen;;Michelle Kuhne;;Hong-An Troung,,https://lens.org/001-986-423-347-023,Granted Patent,yes,264,0,1,1,385,C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;A61K2039/505;;A61K2039/507;;C07K2317/21;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/41;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/71;;C07K2317/74;;C07K2317/76;;C07K2317/92;;C07K2317/94,C07K16/00;;C07K16/28;;C07K16/30;;A61K39/00,,79,0,,,"Anderson, A.C., “Tim-3: an Emerging Target in the Cancer Immunotherapy Landscape ,” Cancer Immunology Research 2(5):393-398, American Association for Cancer Research, United States (2014).;;Bird, R.E., et al., “Single-chain Antigen-binding Proteins,” Science 242(4877):423-426, Association for the Advancement of Science, United States (Oct. 1988).;;Brennan, M., et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science 229(4708):81-83, American Association for the Advancement of Science, United States (Jul. 1985).;;Brummell, D.A., et al., “Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues,” Biochemistry 32(4):1180-1187, American Chemical Society, United States (1993).;;Burks, E.A., et al., “In vitro Scanning Saturation Mutagenesis of an Antibody Binding Pocket,” Proceedings of the National Academy of Sciences USA 94(2):412-417, Plenum Publishing Corporation , United States (1997).;;Cox, J.P., et al., “A Directory of Human Germ-line V kappa Segments Reveals a Strong Bias in their Usage,” European Journal of Immunology 24(4):827-836, Verlag Chemie GmbH, Germany (Apr. 1994).;;Cunningham, B.C. and Wells, J.A., “High-resolution Epitope Mapping of hGH-receptor Interactions by Alanine-scanning Mutagenesis,” Science 244(4908):1081-1085, American Association for the Advancement of Science, United States (Jun. 1989).;;Dall' Acqua, W.F., et al., “Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences,” The Journal of Immunology 169(9):5171-5180, American Association of Immunologists, United States (Nov. 2002).;;Dall'Acqua, W.F., et al., “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn),” The Journal of Biological Chemistry 281(33):23514-23524, American Society for Biochemistry and Molecular Biology, United States (2006).;;Dranoff, G., et al., “Vaccination With Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-macrophage Colony-stimulating Factor Stimulates Potent, Specific, and Long-lasting Anti-tumor Immunity,” Proceedings of the National Academy of Sciences of the United States of America 90(8):3539-3543, National Academy of Sciences, United States (1993).;;Fourcade, J., et al., “Upregulation of Tim-3 and PDd-1 Expression Is Associated With Tumor Antigen-specific CD8+ T Cell Dysfunction in Melanoma Patients,” The Journal of Experimental Medicine 207(10):2175-2186, Rockefeller University Press, United States (2010).;;Gala, F.A. and Morrison, S.L., “V Region Carbohydrate and Antibody Expression,” The Journal of Immunology 172(9):5489-5494, Williams & Wilkins, United States (2004).;;GenBank, “HAVCR2 protein [Homo sapiens],” Accession No. AAH20843.1, accessed on https://www.ncbi.nlm.nih.gov/protein/AAH20843, Sep. 16, 2003.;;GenBank, “Hepatitis A Virus Cellular Receptor 2 Precursor [Homo sapiens],” Accession No. NP_116171.3, accessed on https://www.ncbi.nlm.nih.gov/protein/NP_116171, Jun. 15, 2017.;;GenBank, “Homo sapiens Hepatitis A Virus Cellular Receptor 2 (HAVCR2), mRNA,” Accession No. NM_032782.4, accessed on https://www.ncbi.nlm.nih.gov/nuccore/NM_032782.4, Jun. 15, 2017.;;GenBank, “Homo sapiens Hepatitis A Virus Cellular Receptor 2, mRNA (cDNA clone Image:4701288), Complete Cds,” Accession No. BC020843.1, accessed on https://www.ncbi.nlm.nih.gov/nuccore/BC020843.1, Sep. 16, 2003.;;Glennie, M.J., et al., “Preparation and Performance of Bispecific F(Ab′ Gamma)2 Antibody Containing Thioether-linked Fab′ Gamma Fragments,” Journal of Immunology 139(7):2367-2375, American Association of Immunologists, United States (1987).;;Han, G., et al., “Tim-3: an Activation Marker and Activation Limiter of Innate Immune Cells,” Frontiers in Immunology 4:449, Frontiers Research, Switzerland (2013).;;He, Y-F., et al., “Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine,” The Journal of Immunology 173(8):4919-4928, The American Association of Immunologists, United States (Oct. 2004).;;Hinton, P.R., et al., “An Engineered Human IgG1 Antibody with Longer Serum Half-Life,” Journal of Immunology 176(1):346-356, American Association of Immunologists, United States (2006).;;Hinton, P.R., et al., “Engineered Human IgG Antibodies With Longer Serum Half-lives in Primates,” The Journal of Biological Chemistry 279(8):6213-6216, American Society for Biochemistry and Molecular Biology, United States (2004).;;Holliger, P., et al., “Diabodies: Small Bivalent and Bispecific Antibody Fragments,” Proceedings of the National Academy of Sciences USA 90(14):6444-6448, National Academy of Sciences, United States (Jul. 1993).;;Hurwitz, A.A., et al., “CTLA-4 Blockade Synergizes With Tumor-derived Granulocyte-macrophage Colony-stimulating Factor for Treatment of an Experimental Mammary Carcinoma,” Proceedings of the National Academy of Sciences of the United States of America 95(17):10067-10071, National Academy of Sciences, United States (1998).;;Huston, J.S., et al., “Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-digoxin Single-chain Fv Analogue Produced in Escherichia coli,” Proceedings of the National Academy of Sciences USA 85(16):5879-5883, National Academy of Sciences, United States (Aug. 1988).;;Hutloff, A., et al., “ICOS is an Inducible T-cell Co-stimulator Structurally and Functionally Related to CD28,” Nature 397(6716):263-266, Nature Publishing Group, England (Jan. 1999).;;Hyer, M.L., et al., “Synthetic Triterpenoids Cooperate With Tumor Necrosis Factor-related Apoptosis-inducing Ligand to Induce Apoptosis of Breast Cancer Cells,” Cancer Research 65(11):4799-4808, American Association for Cancer Research, United States (2005).;;Kabat, E.A., et al., “Sequences of Proteins of Immunological Interest,” 5th Edition, U.S. Department of Public Health and Human Services, Public Health Service, National Institutes of Health, Bethesda (1991).;;Keinanen, K. and Laukkanen, M.L., “Biosynthetic Lipid-tagging of Antibodies,” FEBS Letters 346(1):123-126, John Wiley & Sons Ltd, England (1994).;;Kobayashi, H., et al., “Tryptophan H33 Plays an Important Role in Pyrimidine (6-4) Pyrimidone Photoproduct Binding by a High-Affinity Antibody,” Protein Engineering Design and Selection 12(10):879-884, Oxford University Press, United States (1999).;;Kostelny, S.A., et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology 148(5):1547-1553, American Association of Immunologists, United States (Mar. 1992).;;Krishnamurthy, R. and Manning, M.C., “The Stability Factor: Importance in Formulation Development,” Current Pharmaceutical Biotechnology 3(4):361-371, Bentham Science Publishers, Netherlands (2002).;;Liu, M.A., et al., “Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America 82(24):8648-8652, National Academy of Sciences, United States (1985).;;Lonberg, N. and Huszar, D., “Human Antibodies from Transgenic Mice,” International Reviews of Immunology 13(1):65-93, Informa Healthcare, England (1995).;;Lonberg, N., et al., “Antigen-specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications,” Nature 368(6474):856-859, Nature Publishing Group, United States (Apr. 1994).;;McCafferty, J., et al., “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains,” Nature 348(6301):552-554, Nature Publishing Group, London (Dec. 1990).;;Melero, I., et al., “Monoclonal Antibodies Against the 4-1BB T-cell Activation Molecule Eradicate Established Tumors,” Nature Medicine 3(6):682-685, Nature Publishing Company, United States (1997).;;Mimura, Y., et al., “The Influence of Glycosylation on the Thermal Stability and Effector Function Expression of Human IgG1-Fc: Properties of a Series of Truncated Glycoforms,” Molecular Immunology 37(12-13):697-706, Pergamon Press, England (2000).;;Mokyr, M.B., et al., “Realization of the Therapeutic Potential of CTLA-4 Blockade in Low-dose Chemotherapy-treated Tumor-bearing Mice,” Cancer Research 58(23):5301-5304, American Association for Cancer Research, United States (1998).;;Morrison, S.L., “Transfectomas Provide Novel Chimeric Antibodies,” Science 229(4719):1202-1207, Association for the Advancement of Science, United States (Sep. 1985).;;Murray, A., et al., “Epitope Affinity Chromatography and Biophysical Studies of Monoclonal Antibodies and Recombinant Antibody Fragments,” Journal of Chromatographic Science 40(6):343-349, Oxford University Press, United States (2002).;;Nakayama, M., et al., “Tim-3 Mediates Phagocytosis of Apoptotic Cells and Cross-presentation,” Blood 113(16):3821-3830, American Society of Hematology, United States (2009).;;Ngiow, S.F., et al., “Anti-TIM3 Antibody Promotes T Cell IFN-γ-mediated Antitumor Immunity and Suppresses Established Tumors,” Cancer Research 71(10):3540-3451, American Association for Cancer Research, United States (2011).;;Parekh, R.B., et al., “Association of Rheumatoid Arthritis and Primary Osteoarthritis with Changes in the Glycosylation Pattern of Total Serum IgG,” Nature 316(6027):452-457, Nature Publishing Group, England (1985).;;Zhou, Q., et al., “Coexpression of Tim-3 and PD-1 Identifies a CD8+ T-Cell Exhaustion Phenotype in Mice With Disseminated Acute Myelogenous Leukemia,” Blood 117(17):4501-4510, American Society of Hematology, United States (Apr. 2011).;;Pei-Show Juo., The Concise Dictionary of Biomedicine and Molecular Biology, 2nd Edition, CRC Press, United States (2002).;;Poljak, R.J., “Production and Structure of Diabodies,” Structure 2(12):1121-1123, Cell Press, United States (1994).;;Riechmann, L., et al., “Reshaping Human Antibodies for Therapy,” Nature 332(6162):323-327, Nature Publishing Group, United States (Mar. 1988).;;Riedl, S., et al., “In Search of a Novel Target—Phosphatidylserine Exposed by Non-apoptotic Tumor Cells and Metastases of Malignancies With Poor Treatment Efficacy,” Biochimica Et Biophysics Acta 1808(11):2638-2645, Elsevier Pub. Co., Netherlands (2011).;;Rosenberg, S.A., “A New Era for Cancer Immunotherapy Based on the Genes That Encode Cancer Antigens,” Immunity 10(3):281-287, Cell Press, United States (1999).;;Sarmay, G., et al., “Mapping and Comparison of the Interaction Sites on the Fc Region of IgG Responsible for Triggering Antibody Dependent Cellular Cytotoxicity (ADCC) Through Different Types of Human Fc Gamma Receptor,” Molecular Immunology 29(5):633-639, Pergamon Press, England (1992).;;Senter, P.D., “Potent Antibody Drug Conjugates for Cancer Therapy,” Current Opinion in Chemical Biology 13(3):235-244, Elsevier, England (2009).;;Shields, R.L., et al., “High Resolution Mapping of the Binding Site on Human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc gamma R,” The Journal of Biological Chemistry 276(9):6591-6604, American Society for Biochemistry and Molecular Biology, United States (Mar. 2001).;;Shields, R.L., et al., “Lack of Fucose on Human IgG1 N-linked Oligosaccharide Improves Binding to Human Fcgamma RIII and Antibody-Dependent Cellular Toxicity,” The Journal of Biological Chemistry 277(30):26733-26740, American Society for Biochemistry and Molecular Biology, United States (2002).;;Songsivilai, S. and Lachmann, P.J., “Bispecific Antibody: A Tool for Diagnosis and Treatment of Disease,” Clinical and Experimental Immunology 79(3):315-321, Blackwell Scientific Publications, England (1990).;;Spiro, R.G., “Protein Glycosylation: Nature, Distribution, Enzymatic Formation, and Disease Implications of Glycopeptide Bonds,” Glycobiology 12(4):43R-56R, IRL Press at Oxford University Press, England (2002).;;Stavenhagen, J.B., et al., “Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells in Vitro and Controls Tumor Expansion in Vivo via Low-affinity Activating Fcgamma Receptors,” Cancer Research 67(18):8882-8890, American Association for Cancer Research, United States (2007).;;Strohl, W.R., “Optimization of Fc-mediated Effector Functions of Monoclonal Antibodies,” Current Opinion in Biotechnology 20(6):685-691, Elsevier, England (2009).;;Taylor, L.D., et al., “A Transgenic Mouse That Expresses a Diversity of Human Sequence Heavy and Light Chain Immunoglobulins,” Nucleic Acids Research 20(23):6287-6295, Oxford University Press, England (1992).;;Tomizuka, K., et al., “Double Trans-chromosomic Mice: Maintenance of Two Individual Human Chromosome Fragments Containing Ig Heavy and kappa loci and Expression of Fully Human Antibodies,” Proceedings of the National Academy of Sciences USA 97(2):722-727, National Academy of Sciences, United States (Jan. 2000).;;Tomlinson, I.M., et al., “The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops,” Journal of Molecular Biology 227(3):776-798, Elsevier, Netherlands (Oct. 1992).;;Tuaillon, N., et al., “Biased Utilization of DHQ52 and JH4 Gene Segments in a Human Ig Transgenic Minilocus Is Independent of Antigenic Selection,” The Journal of Immunology 152(6):2912-2920, Williams & Wilkins, United States (1994).;;Tuaillon, N., et al., “Human Immunoglobulin Heavy-chain Minilocus Recombination in Transgenic Mice: Gene-segment Use in Mu and Gamma Transcripts,” Proceedings of the National Academy of Sciences of the United States of America 90(8):3720-3724, National Academy of Sciences, United States (1993).;;Umana, P., et al., “Engineered Glycoforms of an Antineuroblastoma IgG1 with Optimized Antibody-Dependent Cellular Cytotoxic Activity,” Nature Biotechnology 17(2):176-180, Nature America Publishing, United States (1999).;;Urlaub, G. and Chasin, L.A., “Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity,” Proceedings of the National Academy of Sciences USA 77(7):4216-4220, National Academy of Sciences, United States (Jul. 1980).;;Wallick, S.C., et al., “Glycosylation of a Vh Residue of a Monoclonal Antibody Against Alpha (1----6) Dextran Increases Its Affinity for Antigen,” The Journal of Experimental Medicine 168(3):1099-1109, Rockefeller University Press, United States (1988).;;Ward, E.S., et al., “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia coli,” Nature 341(6242):544-546, Nature Publishing Group, England (Oct. 1989).;;Weinberg, A.D., et al., “Engagement of the OX-40 Receptor in Vivo Enhances Antitumor Immunity,” Journal of Immunology 164(4):2160-2169, American Association of Immunologists, United States (2000).;;Yeung, Y.A., et al., “Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates,” Journal of Immunology 182(12):7663-7671, American Association of Immunologists, United States (2009).;;Freeman, G., et al., “TIM genes: a family of cell surface phosphatidlyserine receptors that regulate innate and adaptive immunity,” Immunol Rev. 235(1):172-189, Elsevier, Netherlands (2010).;;Dekruyff, R.H., et al., “T Cell/Transmembrne, Ig, and Mucin-3 Allelic variants Differentially Recognize Phosphatidylserine and mdiate Phagocytosis of Apoptotic cells,” Journal of Immunology 184:1918-1930, American Association of Immunologist, United States (2010).;;Jefferis,R., et al., “Human Immunoglobulin allotypes,” MAbs 1(4):332-338, Taylor & Francis, United Kingdom (2009).;;Protein Data Bank, “Human T-cell immunoglobulin and mucin domain protein 3 (hTIM-3),” 5F71, accessed at http://www.rcsb.org/pdb/explore/explore.do?pdbld=5F71 , accessed on Jul. 27, 2017, 2 pages.;;Protein Data Bank, “Structure of Tim-3 in complex with phosphatidylserine,” 3KAA, accessed at http://www.rcsb.org/pdb/explore/explore.do?structureId=3kaa, accessed on Jul. 27, 2017, 2 pages.;;McIntire, J.J., et al., “Identification of Tapr (an Airway Hyperreactivity Regulatory Locus) and the Linked Tim Gene Family,” Nature Immunology 2(12):1109-1116, Nature America Inc, United States (Dec. 2001).;;Monney, L., et al., “Identification and Characterization of Novel Cell Surface Molecules Expressed on TH1 cells,” Scandinavian Journal of Immunology 54:35, (2001).;;Monney, L., et al., “Th1-Specific Cell Surface Protein Tim-3 Regulates Macrophage Activation and Severity of an Autoimmune Disease,” Nature 415(6871):536-541, Nature Publishing Group, England (Jan. 2002).;;Kikushige, Y., et al., “Tim-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells,” International Journal of Hematology 98 (6):627-633, Springer Publishing Company, United States (2013).;;Ferris, R.L., et al., “Too Much of a Good thing? Tim-3 and TCR Signaling in T Cell Exhaustion,” The Journal of Immunology 193(4):1525-1530, The American Association of Immunologists, United States (2014).;;International Search Report and Written Opinion for International Application No. PCT/US2017/041946, European Patent Office, Iceland, dated Jan. 3, 2018, 22 pages.",UNKNOWN
296,EP,A1,EP 3304079 A1,033-693-253-086-87X,2018-04-11,2018,EP 16731700 A,2016-06-02,US 201562170579 P;;US 2016/0035514 W,2015-06-03,ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS,,BRISTOL MYERS SQUIBB CO,WANG XI-TAO;;ADELAKUN OLUFEMI A;;LEWIN ANNE C;;KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;HUANG HAICHUN;;HENNING KARLA A;;LONBERG NILS;;SRINIVASAN MOHAN;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;WONG SUSAN CHIEN-SZU;;LI HUIMING,,https://lens.org/033-693-253-086-87X,Patent Application,yes,0,0,16,16,0,C07K16/2878;;G01N33/566;;C07K2317/56;;C07K2317/24;;C07K2317/21;;C07K2317/92;;G01N2800/52;;G01N2800/7028;;G01N2333/70578;;C07K16/2878;;G01N33/566;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/92;;G01N2333/70578;;G01N2800/52;;G01N2800/7028;;A61P35/00;;A61P43/00;;C07K2317/21;;C07K2317/92;;G01N33/566;;C07K2317/24;;G01N2800/7028;;C07K2317/56;;C07K16/2878;;G01N2800/52;;G01N2333/70578;;C07K16/2866;;G01N33/57492;;G01N2333/4703;;G01N2333/7051;;G01N2333/7151,G01N33/566;;C07K16/28,,0,0,,,,ACTIVE
297,KR,A,KR 20230020562 A,081-703-904-987-872,2023-02-10,2023,KR 20237002822 A,2017-07-13,US 201662362541 P;;US 201762459499 P;;KR 20197004275 A;;US 2017/0041946 W,2016-07-14,TIM3 ANTIBODIES AGAINST TIM3 AND USES THEREOF,"T-세포 이뮤노글로불린 및 뮤신-도메인 함유-3 (TIM3) 단백질에 결합하는 항체 또는 그의 항원-결합 부분이 본원에 제공된다. 또한 치료 용도, 예컨대 암의 치료에서의 이들 항체 또는 그의 항원-결합 부분의 용도가 제공된다. 추가로 항체 또는 그의 항원-결합 부분을 생산하는 세포, 항체 또는 그의 항원-결합 부분의 중쇄 및/또는 경쇄 영역을 코딩하는 폴리뉴클레오티드, 및 항체 또는 그의 항원-결합 부분의 중쇄 및/또는 경쇄 영역을 코딩하는 폴리뉴클레오티드를 포함하는 벡터가 제공된다.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG AN,,https://lens.org/081-703-904-987-872,Patent Application,no,0,0,36,39,464,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/28;;A61K39/00;;A61P35/00,,0,0,,,,DISCONTINUED
298,US,B2,US 10077306 B2,109-224-923-873-631,2018-09-18,2018,US 201715649380 A,2017-07-13,US 201715649380 A;;US 201762459499 P;;US 201662362541 P,2016-07-14,Antibodies against TIM3 and uses thereof,"Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TROUNG HONG-AN,BRISTOL-MYERS SQUIBB COMPANY (2017-07-21),https://lens.org/109-224-923-873-631,Granted Patent,yes,274,3,36,39,385,A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61P35/00;;A61P35/00;;C07K16/2803;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/74;;C07K2317/76;;C07K2317/71;;C07K2317/41;;C07K2317/34;;C07K2317/33;;C07K2317/31;;C07K2317/21;;A61K2039/507;;C07K2317/21;;C07K2317/41;;C07K2317/55;;C07K2317/71;;C07K2317/74;;A61K2039/505;;C07K16/2803;;C07K16/2827;;C07K16/30;;C07K16/3046;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/92;;C07K2317/94;;A61K47/6849;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/732;;C07K2317/734;;G01N33/57492,C07K16/00;;A61K39/00;;C07K16/28;;C07K16/30,,79,68,018-069-206-369-372;;017-150-654-990-340;;005-112-559-456-657;;006-553-734-546-212;;105-316-874-895-908;;022-179-293-052-569;;018-694-084-068-187;;041-909-244-299-232;;078-432-639-041-575;;087-879-787-031-413;;089-689-557-564-287;;035-135-729-507-737;;052-219-543-437-800;;073-130-138-292-805;;020-986-423-793-233;;082-210-673-349-152;;010-488-381-022-259;;066-749-017-721-197;;008-213-515-306-640;;002-264-966-090-625;;127-416-339-660-812;;030-249-121-435-10X;;020-123-860-433-320;;068-238-957-669-243;;104-212-297-137-759;;038-478-749-169-986;;084-388-182-984-099;;043-108-278-056-872;;032-820-729-763-323;;030-630-100-818-462;;005-022-447-377-963;;012-746-915-512-650;;053-703-232-770-99X;;023-676-781-371-861;;009-621-637-014-514;;003-763-873-758-289;;070-624-200-848-669;;024-348-828-966-680;;001-467-559-709-949;;042-204-626-457-327;;068-450-506-389-89X;;027-326-505-837-755;;111-914-031-290-975;;012-300-595-074-789;;004-458-031-333-650;;003-752-183-823-430;;040-577-067-037-463;;062-029-719-290-327;;094-082-569-858-098;;088-086-720-613-343;;071-707-020-428-907;;047-951-914-695-080;;092-023-577-402-127;;060-375-551-951-388;;033-754-369-798-314;;070-318-112-524-781;;051-940-176-386-905;;094-685-907-794-422;;074-817-300-512-106;;056-422-417-058-69X;;042-740-484-382-110;;034-714-253-790-433;;122-651-085-264-657;;026-418-623-750-230;;057-102-333-317-731;;071-623-595-422-33X;;015-507-770-980-445;;077-737-756-070-317,10.1158/2326-6066.cir-14-0039;;24795351;;3140379;;10.1126/science.3140379;;10.1126/science.3925553;;3925553;;8424945;;10.1021/bi00055a024;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.1002/eji.1830240409;;8149953;;10.1126/science.2471267;;2471267;;12391234;;10.4049/jimmunol.169.9.5171;;10.1074/jbc.m604292200;;16793771;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10.1084/jem.20100637;;20819923;;pmc2947081;;10.4049/jimmunol.172.9.5489;;15100290;;2958547;;10.4049/jimmunol.139.7.2367;;24339828;;10.3389/fimmu.2013.00449;;pmc3857553;;15470033;;10.4049/jimmunol.173.8.4919;;10.4049/jimmunol.176.1.346;;16365427;;14699147;;10.1074/jbc.c300470200;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;9930702;;10.1038/16717;;15930300;;10.1158/0008-5472.can-04-3319;;10.1016/0014-5793(94)00313-0;;8206150;;10556249;;10.1093/protein/12.10.879;;10.4049/jimmunol.148.5.1547;;1531669;;10.2174/1389201023378229;;12463418;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;7494109;;10.3109/08830189509061738;;8159246;;10.1038/368856a0;;10.1038/348552a0;;2247164;;9176498;;10.1038/nm0697-682;;11275255;;10.1016/s0161-5890(00)00105-x;;9850053;;10.1126/science.3929380;;3929380;;10.1093/chromsci/40.6.343;;12137207;;10.1182/blood-2008-10-185884;;19224762;;10.1038/316452a0;;3927174;;10.1182/blood-2010-10-310425;;21385853;;pmc3099570;;10.1016/s0969-2126(94)00113-8;;7704521;;3127726;;10.1038/332323a0;;21810406;;pmc3175029;;10.1016/j.bbamem.2011.07.026;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1016/0161-5890(92)90200-h;;1533898;;10.1016/j.cbpa.2009.03.023;;19414278;;11096108;;10.1074/jbc.m009483200;;11986321;;10.1074/jbc.m202069200;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;12042244;;10.1093/glycob/12.4.43r;;17875730;;10.1158/0008-5472.can-07-0696;;19896358;;10.1016/j.copbio.2009.10.011;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;1404388;;10.1016/0022-2836(92)90223-7;;8144892;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;10.1038/6179;;10052355;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;2459288;;pmc2189025;;10.1084/jem.168.3.1099;;10.1038/341544a0;;2677748;;10657670;;10.4049/jimmunol.164.4.2160;;10.4049/jimmunol.0804182;;19494290;;10.1111/j.0105-2896.2010.00903.x;;pmc2914464;;20536563;;020083673;;10.4049/jimmunol.0903059;;pmc3128800;;20083673;;20073133;;pmc2726606;;10.4161/mabs.1.4.9122;;11725301;;10.1038/ni739;;10.1038/415536a;;11823861;;24046178;;10.1007/s12185-013-1433-6;;25086175;;pmc4120324;;10.4049/jimmunol.1400557,"Anderson, A.C., “Tim-3: an Emerging Target in the Cancer Immunotherapy Landscape ,” Cancer Immunology Research 2(5):393-398, American Association for Cancer Research, United States (2014).;;Bird, R.E., et al., “Single-chain Antigen-binding Proteins,” Science 242(4877):423-426, Association for the Advancement of Science, United States (Oct. 1988).;;Brennan, M., et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science 229(4708):81-83, American Association for the Advancement of Science, United States (Jul. 1985).;;Brummell, D.A., et al., “Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues,” Biochemistry 32(4):1180-1187, American Chemical Society, United States (1993).;;Burks, E.A., et al., “In vitro Scanning Saturation Mutagenesis of an Antibody Binding Pocket,” Proceedings of the National Academy of Sciences USA 94(2):412-417, Plenum Publishing Corporation , United States (1997).;;Cox, J.P., et al., “A Directory of Human Germ-line V kappa Segments Reveals a Strong Bias in their Usage,” European Journal of Immunology 24(4):827-836, Verlag Chemie GmbH, Germany (Apr. 1994).;;Cunningham, B.C. and Wells, J.A., “High-resolution Epitope Mapping of hGH-receptor Interactions by Alanine-scanning Mutagenesis,” Science 244(4908):1081-1085, American Association for the Advancement of Science, United States (Jun. 1989).;;Dall' Acqua, W.F., et al., “Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences,” The Journal of Immunology 169(9):5171-5180, American Association of Immunologists, United States (Nov. 2002).;;Dall'Acqua, W.F., et al., “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn),” The Journal of Biological Chemistry 281(33):23514-23524, American Society for Biochemistry and Molecular Biology, United States (2006).;;Dranoff, G., et al., “Vaccination With Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-macrophage Colony-stimulating Factor Stimulates Potent, Specific, and Long-lasting Anti-tumor Immunity,” Proceedings of the National Academy of Sciences of the United States of America 90(8):3539-3543, National Academy of Sciences, United States (1993).;;Fourcade, J., et al., “Upregulation of Tim-3 and PDd-1 Expression Is Associated With Tumor Antigen-specific CD8+ T Cell Dysfunction in Melanoma Patients,” The Journal of Experimental Medicine 207(10):2175-2186, Rockefeller University Press, United States (2010).;;Gala, F.A. and Morrison, S.L., “V Region Carbohydrate and Antibody Expression,” The Journal of Immunology 172(9):5489-5494, Williams & Wilkins, United States (2004).;;GenBank, “HAVCR2 protein [Homo sapiens],” Accession No. AAH20843.1, accessed on https://www.ncbi.nlm.nih.gov/protein/AAH20843, Sep. 16, 2003.;;GenBank, “Hepatitis A Virus Cellular Receptor 2 Precursor [Homo sapiens],” Accession No. NP_116171.3, accessed on https://www.ncbi.nlm.nih.gov/protein/NP_116171, Jun. 15, 2017.;;GenBank, “Homo sapiens Hepatitis A Virus Cellular Receptor 2 (HAVCR2), mRNA,” Accession No. NM_032782.4, accessed on https://www.ncbi.nlm.nih.gov/nuccore/NM_032782.4, Jun. 15, 2017.;;GenBank, “Homo sapiens Hepatitis A Virus Cellular Receptor 2, mRNA (cDNA clone Image:4701288), Complete Cds,” Accession No. BC020843.1, accessed on https://www.ncbi.nlm.nih.gov/nuccore/BC020843.1, Sep. 16, 2003.;;Glennie, M.J., et al., “Preparation and Performance of Bispecific F(Ab′ Gamma)2 Antibody Containing Thioether-linked Fab′ Gamma Fragments,” Journal of Immunology 139(7):2367-2375, American Association of Immunologists, United States (1987).;;Han, G., et al., “Tim-3: an Activation Marker and Activation Limiter of Innate Immune Cells,” Frontiers in Immunology 4:449, Frontiers Research, Switzerland (2013).;;He, Y-F., et al., “Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine,” The Journal of Immunology 173(8):4919-4928, The American Association of Immunologists, United States (Oct. 2004).;;Hinton, P.R., et al., “An Engineered Human IgG1 Antibody with Longer Serum Half-Life,” Journal of Immunology 176(1):346-356, American Association of Immunologists, United States (2006).;;Hinton, P.R., et al., “Engineered Human IgG Antibodies With Longer Serum Half-lives in Primates,” The Journal of Biological Chemistry 279(8):6213-6216, American Society for Biochemistry and Molecular Biology, United States (2004).;;Holliger, P., et al., “Diabodies: Small Bivalent and Bispecific Antibody Fragments,” Proceedings of the National Academy of Sciences USA 90(14):6444-6448, National Academy of Sciences, United States (Jul. 1993).;;Hurwitz, A.A., et al., “CTLA-4 Blockade Synergizes With Tumor-derived Granulocyte-macrophage Colony-stimulating Factor for Treatment of an Experimental Mammary Carcinoma,” Proceedings of the National Academy of Sciences of the United States of America 95(17):10067-10071, National Academy of Sciences, United States (1998).;;Huston, J.S., et al., “Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-digoxin Single-chain Fv Analogue Produced in Escherichia coli,” Proceedings of the National Academy of Sciences USA 85(16):5879-5883, National Academy of Sciences, United States (Aug. 1988).;;Hutloff, A., et al., “ICOS is an Inducible T-cell Co-stimulator Structurally and Functionally Related to CD28,” Nature 397(6716):263-266, Nature Publishing Group, England (Jan. 1999).;;Hyer, M.L., et al., “Synthetic Triterpenoids Cooperate With Tumor Necrosis Factor-related Apoptosis-inducing Ligand to Induce Apoptosis of Breast Cancer Cells,” Cancer Research 65(11):4799-4808, American Association for Cancer Research, United States (2005).;;Kabat, E.A., et al., “Sequences of Proteins of Immunological Interest,” 5th Edition, U.S. Department of Public Health and Human Services, Public Health Service, National Institutes of Health, Bethesda (1991).;;Keinanen, K. and Laukkanen, M.L., “Biosynthetic Lipid-tagging of Antibodies,” FEBS Letters 346(1):123-126, John Wiley & Sons Ltd, England (1994).;;Kobayashi, H., et al., “Tryptophan H33 Plays an Important Role in Pyrimidine (6-4) Pyrimidone Photoproduct Binding by a High-Affinity Antibody,” Protein Engineering Design and Selection 12(10):879-884, Oxford University Press, United States (1999).;;Kostelny, S.A., et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology 148(5):1547-1553, American Association of Immunologists, United States (Mar. 1992).;;Krishnamurthy, R. and Manning, M.C., “The Stability Factor: Importance in Formulation Development,” Current Pharmaceutical Biotechnology 3(4):361-371, Bentham Science Publishers, Netherlands (2002).;;Liu, M.A., et al., “Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America 82(24):8648-8652, National Academy of Sciences, United States (1985).;;Lonberg, N. and Huszar, D., “Human Antibodies from Transgenic Mice,” International Reviews of Immunology 13(1):65-93, Informa Healthcare, England (1995).;;Lonberg, N., et al., “Antigen-specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications,” Nature 368(6474):856-859, Nature Publishing Group, United States (Apr. 1994).;;McCafferty, J., et al., “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains,” Nature 348(6301):552-554, Nature Publishing Group, London (Dec. 1990).;;Melero, I., et al., “Monoclonal Antibodies Against the 4-1BB T-cell Activation Molecule Eradicate Established Tumors,” Nature Medicine 3(6):682-685, Nature Publishing Company, United States (1997).;;Mimura, Y., et al., “The Influence of Glycosylation on the Thermal Stability and Effector Function Expression of Human IgG1-Fc: Properties of a Series of Truncated Glycoforms,” Molecular Immunology 37(12-13):697-706, Pergamon Press, England (2000).;;Mokyr, M.B., et al., “Realization of the Therapeutic Potential of CTLA-4 Blockade in Low-dose Chemotherapy-treated Tumor-bearing Mice,” Cancer Research 58(23):5301-5304, American Association for Cancer Research, United States (1998).;;Morrison, S.L., “Transfectomas Provide Novel Chimeric Antibodies,” Science 229(4719):1202-1207, Association for the Advancement of Science, United States (Sep. 1985).;;Murray, A., et al., “Epitope Affinity Chromatography and Biophysical Studies of Monoclonal Antibodies and Recombinant Antibody Fragments,” Journal of Chromatographic Science 40(6):343-349, Oxford University Press, United States (2002).;;Nakayama, M., et al., “Tim-3 Mediates Phagocytosis of Apoptotic Cells and Cross-presentation,” Blood 113(16):3821-3830, American Society of Hematology, United States (2009).;;Ngiow, S.F., et al., “Anti-TIM3 Antibody Promotes T Cell IFN-γ-mediated Antitumor Immunity and Suppresses Established Tumors,” Cancer Research 71(10):3540-3451, American Association for Cancer Research, United States (2011).;;Parekh, R.B., et al., “Association of Rheumatoid Arthritis and Primary Osteoarthritis with Changes in the Glycosylation Pattern of Total Serum IgG,” Nature 316(6027):452-457, Nature Publishing Group, England (1985).;;Zhou, Q., et al., “Coexpression of Tim-3 and PD-1 Identifies a CD8+ T-Cell Exhaustion Phenotype in Mice With Disseminated Acute Myelogenous Leukemia,” Blood 117(17):4501-4510, American Society of Hematology, United States (Apr. 2011).;;Pei-Show Juo., The Concise Dictionary of Biomedicine and Molecular Biology, 2nd Edition, CRC Press, United States (2002).;;Poljak, R.J., “Production and Structure of Diabodies,” Structure 2(12):1121-1123, Cell Press, United States (1994).;;Riechmann, L., et al., “Reshaping Human Antibodies for Therapy,” Nature 332(6162):323-327, Nature Publishing Group, United States (Mar. 1988).;;Riedl, S., et al., “In Search of a Novel Target—Phosphatidylserine Exposed by Non-apoptotic Tumor Cells and Metastases of Malignancies With Poor Treatment Efficacy,” Biochimica Et Biophysics Acta 1808(11):2638-2645, Elsevier Pub. Co., Netherlands (2011).;;Rosenberg, S.A., “A New Era for Cancer Immunotherapy Based on the Genes That Encode Cancer Antigens,” Immunity 10(3):281-287, Cell Press, United States (1999).;;Sarmay, G., et al., “Mapping and Comparison of the Interaction Sites on the Fc Region of IgG Responsible for Triggering Antibody Dependent Cellular Cytotoxicity (ADCC) Through Different Types of Human Fc Gamma Receptor,” Molecular Immunology 29(5):633-639, Pergamon Press, England (1992).;;Senter, P.D., “Potent Antibody Drug Conjugates for Cancer Therapy,” Current Opinion in Chemical Biology 13(3):235-244, Elsevier, England (2009).;;Shields, R.L., et al., “High Resolution Mapping of the Binding Site on Human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc gamma R,” The Journal of Biological Chemistry 276(9):6591-6604, American Society for Biochemistry and Molecular Biology, United States (Mar. 2001).;;Shields, R.L., et al., “Lack of Fucose on Human IgG1 N-linked Oligosaccharide Improves Binding to Human Fcgamma RIII and Antibody-Dependent Cellular Toxicity,” The Journal of Biological Chemistry 277(30):26733-26740, American Society for Biochemistry and Molecular Biology, United States (2002).;;Songsivilai, S. and Lachmann, P.J., “Bispecific Antibody: A Tool for Diagnosis and Treatment of Disease,” Clinical and Experimental Immunology 79(3):315-321, Blackwell Scientific Publications, England (1990).;;Spiro, R.G., “Protein Glycosylation: Nature, Distribution, Enzymatic Formation, and Disease Implications of Glycopeptide Bonds,” Glycobiology 12(4):43R-56R, IRL Press at Oxford University Press, England (2002).;;Stavenhagen, J.B., et al., “Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells in Vitro and Controls Tumor Expansion in Vivo via Low-affinity Activating Fcgamma Receptors,” Cancer Research 67(18):8882-8890, American Association for Cancer Research, United States (2007).;;Strohl, W.R., “Optimization of Fc-mediated Effector Functions of Monoclonal Antibodies,” Current Opinion in Biotechnology 20(6):685-691, Elsevier, England (2009).;;Taylor, L.D., et al., “A Transgenic Mouse That Expresses a Diversity of Human Sequence Heavy and Light Chain Immunoglobulins,” Nucleic Acids Research 20(23):6287-6295, Oxford University Press, England (1992).;;Tomizuka, K., et al., “Double Trans-chromosomic Mice: Maintenance of Two Individual Human Chromosome Fragments Containing Ig Heavy and kappa loci and Expression of Fully Human Antibodies,” Proceedings of the National Academy of Sciences USA 97(2):722-727, National Academy of Sciences, United States (Jan. 2000).;;Tomlinson, I.M., et al., “The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops,” Journal of Molecular Biology 227(3):776-798, Elsevier, Netherlands (Oct. 1992).;;Tuaillon, N., et al., “Biased Utilization of DHQ52 and JH4 Gene Segments in a Human Ig Transgenic Minilocus Is Independent of Antigenic Selection,” The Journal of Immunology 152(6):2912-2920, Williams & Wilkins, United States (1994).;;Tuaillon, N., et al., “Human Immunoglobulin Heavy-chain Minilocus Recombination in Transgenic Mice: Gene-segment Use in Mu and Gamma Transcripts,” Proceedings of the National Academy of Sciences of the United States of America 90(8):3720-3724, National Academy of Sciences, United States (1993).;;Umana, P., et al., “Engineered Glycoforms of an Antineuroblastoma IgG1 with Optimized Antibody-Dependent Cellular Cytotoxic Activity,” Nature Biotechnology 17(2):176-180, Nature America Publishing, United States (1999).;;Urlaub, G. and Chasin, L.A., “Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity,” Proceedings of the National Academy of Sciences USA 77(7):4216-4220, National Academy of Sciences, United States (Jul. 1980).;;Wallick, S.C., et al., “Glycosylation of a Vh Residue of a Monoclonal Antibody Against Alpha (1----6) Dextran Increases Its Affinity for Antigen,” The Journal of Experimental Medicine 168(3):1099-1109, Rockefeller University Press, United States (1988).;;Ward, E.S., et al., “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia coli,” Nature 341(6242):544-546, Nature Publishing Group, England (Oct. 1989).;;Weinberg, A.D., et al., “Engagement of the OX-40 Receptor in Vivo Enhances Antitumor Immunity,” Journal of Immunology 164(4):2160-2169, American Association of Immunologists, United States (2000).;;Yeung, Y.A., et al., “Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates,” Journal of Immunology 182(12):7663-7671, American Association of Immunologists, United States (2009).;;Freeman, G., et al., “TIM genes: a family of cell surface phosphatidlyserine receptors that regulate innate and adaptive immunity,” Immunol Rev. 235(1):172-189, Elsevier, Netherlands (2010).;;Dekruyff, R.H., et al., “T Cell/Transmembrne, Ig, and Mucin-3 Allelic variants Differentially Recognize Phosphatidylserine and mdiate Phagocytosis of Apoptotic cells,” Journal of Immunology 184:1918-1930, American Association of Immunologist, United States (2010).;;Jefferis,R., et al., “Human Immunoglobulin allotypes,” MAbs 1(4):332-338, Taylor & Francis, United Kingdom (2009).;;Protein Data Bank, “Human T-cell immunoglobulin and mucin domain protein 3 (hTIM-3),” 5F71, accessed at http://www.rcsb.org/pdb/explore/explore.do?pdbld=5F71 , accessed on Jul. 27, 2017, 2 pages.;;Protein Data Bank, “Structure of Tim-3 in complex with phosphatidylserine,” 3KAA, accessed at http://www.rcsb.org/pdb/explore/explore.do?structureId=3kaa, accessed on Jul. 27, 2017, 2 pages.;;McIntire, J.J., et al., “Identification of Tapr (an Airway Hyperreactivity Regulatory Locus) and the Linked Tim Gene Family,” Nature Immunology 2(12):1109-1116, Nature America Inc, United States (Dec. 2001).;;Monney, L., et al., “Identification and Characterization of Novel Cell Surface Molecules Expressed on TH1 cells,” Scandinavian Journal of Immunology 54:35, (2001).;;Monney, L., et al., “Th1-Specific Cell Surface Protein Tim-3 Regulates Macrophage Activation and Severity of an Autoimmune Disease,” Nature 415(6871):536-541, Nature Publishing Group, England (Jan. 2002).;;Kikushige, Y., et al., “Tim-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells,” International Journal of Hematology 98 (6):627-633, Springer Publishing Company, United States (2013).;;Ferris, R.L., et al., “Too Much of a Good thing? Tim-3 and TCR Signaling in T Cell Exhaustion,” The Journal of Immunology 193(4):1525-1530, The American Association of Immunologists, United States (2014).;;International Search Report and Written Opinion for International Application No. PCT/US2017/041946, European Patent Office, Iceland, dated Jan. 3, 2018, 22 pages.",ACTIVE
299,CN,A,CN 107743586 A,147-033-908-966-406,2018-02-27,2018,CN 201680032362 A,2016-06-02,US 201562170579 P;;US 2016/0035514 W,2015-06-03,Anti-GITR antibodies for cancer diagnostics,"Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.",BRISTOL MYERS SQUIBB CO,WANG XI-TAO;;ADELAKUN OLUFEMI A;;LEWIN ANNE C;;KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;HUANG HAICHUN;;HENNING KARLA A;;LONBERG NILS;;SRINIVASAN MOHAN;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;WONG SUSAN CHIEN-SZU;;LI HUIMING,,https://lens.org/147-033-908-966-406,Patent Application,no,2,0,16,16,0,C07K16/2878;;G01N33/566;;C07K2317/56;;C07K2317/24;;C07K2317/21;;C07K2317/92;;G01N2800/52;;G01N2800/7028;;G01N2333/70578;;C07K16/2878;;G01N33/566;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/92;;G01N2333/70578;;G01N2800/52;;G01N2800/7028;;A61P35/00;;A61P43/00;;C07K2317/21;;C07K2317/92;;G01N33/566;;C07K2317/24;;G01N2800/7028;;C07K2317/56;;C07K16/2878;;G01N2800/52;;G01N2333/70578;;C07K16/2866;;G01N33/57492;;G01N2333/4703;;G01N2333/7051;;G01N2333/7151,G01N33/566;;C07K16/28,,3,3,048-960-656-989-289;;045-706-253-475-176;;037-103-075-806-573,20012605;;10.1007/s00262-009-0803-7;;20734397;;10.1002/cncr.25371;;23856878;;10.1590/0037-8682-0029-2013,"THAIS HELENA GASPAROTO, ET AL: ""Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment"", 《CANCER IMMUNOL IMMUNOTHER》;;WEN-CHUN CHANG, ET AL: ""Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma"", 《CANCER》;;CACILDA TEZELLI JUNQUEIRA PADOVANI, ET AL: ""Glucocorticoid-induced tumor necrosis factor receptor expression in patients with cervical human papillomavirus infection"", 《REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL》",ACTIVE
300,US,A1,US 2018/0164321 A1,046-391-236-512-492,2018-06-14,2018,US 201615578874 A,2016-06-02,US 201615578874 A;;US 201562170579 P;;US 2016/0035514 W,2015-06-03,ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS,"Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.",BRISTOL MYERS SQUIBB CO,WANG XI-TAO;;ADELAKUN OLUFEMI A;;LEWIN ANNE C;;KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;HUANG HAICHUN;;HENNING KARLA A;;LONBERG NILS;;SRINIVASAN MOHAN;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD Y;;CHAKRABORTY INDRANI;;WONG SUSAN CHIEN-SZU;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2018-04-05),https://lens.org/046-391-236-512-492,Patent Application,yes,0,5,16,16,228,C07K16/2878;;G01N33/566;;C07K2317/56;;C07K2317/24;;C07K2317/21;;C07K2317/92;;G01N2800/52;;G01N2800/7028;;G01N2333/70578;;C07K16/2878;;G01N33/566;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/92;;G01N2333/70578;;G01N2800/52;;G01N2800/7028;;A61P35/00;;A61P43/00;;C07K2317/21;;C07K2317/92;;G01N33/566;;C07K2317/24;;G01N2800/7028;;C07K2317/56;;C07K16/2878;;G01N2800/52;;G01N2333/70578;;C07K16/2866;;G01N33/57492;;G01N2333/4703;;G01N2333/7051;;G01N2333/7151,G01N33/574;;C07K16/28,,0,0,,,,ACTIVE
301,US,A1,US 2021/0011022 A1,167-446-135-006-286,2021-01-14,2021,US 202016870006 A,2020-05-08,US 202016870006 A;;US 201715578874 A;;US 2016/0035514 W;;US 201562170579 P,2015-06-03,ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS,"Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.",BRISTOL MYERS SQUIBB CO,WANG XI-TAO;;ADELAKUN OLUFEMI A;;LEWIN ANNE C;;KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;HUANG HAICHUN;;HENNING KARLA A;;LONBERG NILS;;SRINIVASAN MOHAN;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD Y;;CHAKRABORTY INDRANI;;WONG SUSAN CHIEN-SZU;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2018-04-05),https://lens.org/167-446-135-006-286,Patent Application,yes,0,3,16,16,228,C07K16/2878;;G01N33/566;;C07K2317/56;;C07K2317/24;;C07K2317/21;;C07K2317/92;;G01N2800/52;;G01N2800/7028;;G01N2333/70578;;C07K16/2878;;G01N33/566;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/92;;G01N2333/70578;;G01N2800/52;;G01N2800/7028;;A61P35/00;;A61P43/00;;C07K2317/21;;C07K2317/92;;G01N33/566;;C07K2317/24;;G01N2800/7028;;C07K2317/56;;C07K16/2878;;G01N2800/52;;G01N2333/70578;;C07K16/2866;;G01N33/57492;;G01N2333/4703;;G01N2333/7051;;G01N2333/7151,G01N33/574;;C07K16/28;;G01N33/566,,0,0,,,,ACTIVE
302,US,B2,US 10690674 B2,082-647-191-076-245,2020-06-23,2020,US 201615578874 A,2016-06-02,US 201615578874 A;;US 201562170579 P;;US 2016/0035514 W,2015-06-03,Anti-GITR antibodies for cancer diagnostics,"Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.",BRISTOL MYERS SQUIBB CO,WANG XI-TAO;;ADELAKUN OLUFEMI A;;LEWIN ANNE C;;KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;HUANG HAICHUN;;HENNING KARLA A;;LONBERG NILS;;SRINIVASAN MOHAN;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD Y;;CHAKRABORTY INDRANI;;WONG SUSAN CHIEN-SZU;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2018-04-05),https://lens.org/082-647-191-076-245,Granted Patent,yes,3,5,16,16,228,C07K16/2878;;G01N33/566;;C07K2317/56;;C07K2317/24;;C07K2317/21;;C07K2317/92;;G01N2800/52;;G01N2800/7028;;G01N2333/70578;;C07K16/2878;;G01N33/566;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/92;;G01N2333/70578;;G01N2800/52;;G01N2800/7028;;A61P35/00;;A61P43/00;;C07K2317/21;;C07K2317/92;;G01N33/566;;C07K2317/24;;G01N2800/7028;;C07K2317/56;;C07K16/2878;;G01N2800/52;;G01N2333/70578;;C07K16/2866;;G01N33/57492;;G01N2333/4703;;G01N2333/7051;;G01N2333/7151,G01N33/566;;C07K16/28;;G01N33/574,,7,4,039-634-532-775-166;;045-706-253-475-176;;048-960-656-989-289;;037-103-075-806-573,17360848;;10.1096/fj.06-7724com;;20734397;;10.1002/cncr.25371;;20012605;;10.1007/s00262-009-0803-7;;23856878;;10.1590/0037-8682-0029-2013,"Cohen et al (PLoS ONE; 2010, 5(5): 1-12).;;Baltz, K.M., et al., “Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions,” The FASEB Journal, vol. 21(10):2442-2454 (2007).;;Chang, W-C., et al., “Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma,” Cancer, vol. 116(24):5777-5788 (2010).;;Gasparoto, T. et al., “Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment,” Cancer Immunology, Immunotherapy, vol. 59(6):819-828 (2009).;;International Preliminary Report on Patentability, PCT/US2016/035514, dated Dec. 5, 2017, 10 pages.;;International Search Report and Written Opinion, PCT/US2016/035514, dated Sep. 29, 2016, 15 pages.;;Padovani, C., et al., “Glucocorticoid-induced tumor necrosis factor receptor expression in patients with cervical human papillomavirus infection,” Revista da Sociedade Brasileira de Medicina Tropical, vol. 46(3):288-292 (2013).",ACTIVE
303,US,A1,US 2022/0089720 A1,012-165-478-561-853,2022-03-24,2022,US 201916961545 A,2019-01-11,US 201916961545 A;;US 201862616723 P;;US 2019/0013246 W,2018-01-12,ANTIBODIES AGAINST TIM3 AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD YU-CHENG;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN,BRISTOL-MYERS SQUIBB COMPANY (2023-03-14),https://lens.org/012-165-478-561-853,Patent Application,yes,2,0,8,8,448,C07K16/2803;;A61K2039/505;;A61K2039/507;;C07K2317/33;;C07K2317/34;;C07K2317/74;;C07K2317/76;;C07K2317/92;;A61P35/00;;C07K16/2878;;G01N33/6857;;A61P35/00;;C07K2317/33;;C07K2317/34;;C07K2317/74;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K2039/507;;A61P35/00;;A61K2039/507;;C07K16/2803;;C07K2317/21;;C07K2317/31;;C07K2317/34;;C07K2317/74;;C07K2317/76;;C07K2317/92;;G01N33/6854;;G01N2333/70503,C07K16/28;;A61P35/00;;G01N33/68,,8,5,027-477-313-726-928;;033-546-490-406-937;;028-957-881-551-731;;015-239-659-590-870;;027-960-937-319-909,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1002/9783527619740;;7764191;;10.1038/nbt1193-1293;;10.4049/jimmunol.150.3.880;;8423344;;10.1006/jmbi.2000.3512;;10677285,"Rudikoff et al. (Proceedings of the National Academy of Sciences USA, Vol., 79, Pg. 1979-1983, 1982) (Year: 1982);;Dubel (Handbook of Therapeutic Antibodies, 2007, Pg. 100-101) (Year: 2007);;Johnson and Wu (Methods in Molecular Biology, Antibody Engineering: Methods and Protocols, Vol. 248, Pg. 11-25, 2004) (Year: 2004);;Harris (Biotechnology, Vol. 11, Pg. 1293-1297, 1993) (Year: 1993);;Paul (Fundamental Immunology, 3rd Edition, 1993, pp. 292-295) (Year: 1993);;Bendig M. M. (Methods: A Companion to Methods in Enzymology, 1995; 8:83-93) (Year: 1995);;Portolano (The Journal of Immunology, Vol. 150, No. 3, Pg. 880-887, 1993) (Year: 1993);;Beiboer (J. Mol. Biol. (2000) 296:833-849) (Year: 2000)",PENDING
304,US,B2,US 11408889 B2,195-830-878-803-827,2022-08-09,2022,US 202016870006 A,2020-05-08,US 202016870006 A;;US 201715578874 A;;US 2016/0035514 W;;US 201562170579 P,2015-06-03,Anti-GITR antibodies for cancer diagnostics,"Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.",BRISTOL MYERS SQUIBB CO,WANG XI-TAO;;ADELAKUN OLUFEMI A;;LEWIN ANNE C;;KORMAN ALAN J;;SELBY MARK J;;WANG CHANGYU;;HUANG HAICHUN;;HENNING KARLA A;;LONBERG NILS;;SRINIVASAN MOHAN;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD Y;;CHAKRABORTY INDRANI;;WONG SUSAN CHIEN-SZU;;LI HUIMING,BRISTOL-MYERS SQUIBB COMPANY (2018-04-05),https://lens.org/195-830-878-803-827,Granted Patent,yes,95,1,16,16,228,C07K16/2878;;G01N33/566;;C07K2317/56;;C07K2317/24;;C07K2317/21;;C07K2317/92;;G01N2800/52;;G01N2800/7028;;G01N2333/70578;;C07K16/2878;;G01N33/566;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/92;;G01N2333/70578;;G01N2800/52;;G01N2800/7028;;A61P35/00;;A61P43/00;;C07K2317/21;;C07K2317/92;;G01N33/566;;C07K2317/24;;G01N2800/7028;;C07K2317/56;;C07K16/2878;;G01N2800/52;;G01N2333/70578;;C07K16/2866;;G01N33/57492;;G01N2333/4703;;G01N2333/7051;;G01N2333/7151,G01N33/566;;C07K16/28;;G01N33/574,,108,56,171-614-306-115-108;;086-268-955-647-163;;136-116-610-765-69X;;084-334-863-236-818;;055-904-468-981-551;;019-741-156-878-521;;029-382-279-785-035;;029-382-279-785-035;;009-483-512-107-343;;019-459-691-036-036;;128-554-308-094-91X;;020-296-196-517-635;;055-706-543-681-974;;044-673-845-363-528;;056-584-393-786-220;;070-164-938-901-37X;;005-119-615-003-591;;013-323-148-570-367;;022-259-501-579-745;;055-329-732-668-508;;011-405-827-983-549;;141-244-428-002-001;;143-287-907-926-845;;035-924-762-030-733;;124-353-299-096-166;;012-369-544-741-057;;055-677-065-531-946;;010-916-105-450-247;;019-791-912-221-046;;078-111-385-767-730;;017-588-579-721-840;;016-276-447-231-541;;045-714-831-915-963;;071-886-484-965-256;;145-500-434-317-873;;012-108-483-329-37X;;008-019-042-176-997;;083-410-991-104-604;;039-634-532-775-166;;045-706-253-475-176;;087-404-567-384-381;;048-960-656-989-289;;037-103-075-806-573;;013-888-189-100-394;;112-871-461-451-205;;110-748-788-527-236;;027-477-313-726-928;;082-582-794-395-339;;124-668-123-456-128;;039-943-095-184-294;;013-904-324-770-460;;013-904-324-770-460;;050-463-287-173-296;;051-374-571-260-065;;004-189-544-863-902;;043-054-515-242-505,21304271;;10.4161/mabs.3.2.14939;;pmc3092615;;20563707;;10.1007/82_2010_49;;pmc4060248;;12444126;;10.4049/jimmunol.169.11.6210;;7506686;;10.1016/0378-1119(93)90258-5;;10.1002/jmr.679;;15227640;;15484187;;10.1002/eji.200324632;;10.1084/jem.20130573;;23897982;;pmc3754864;;10.1084/jem.20130573;;23897982;;pmc3754864;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;20480365;;10.1007/s00262-010-0866-5;;10.1158/0008-5472.can-05-2813;;16651447;;pmc2242844;;9373310;;10.1016/s1380-2933(96)00045-0;;10.1016/s1074-7613(04)00054-8;;15030773;;15374887;;10.1182/blood-2004-06-2467;;10.3410/f.1001160.6701;;11520463;;10.1016/s1074-7613(01)00183-2;;10074428;;10.1016/s0960-9822(99)80093-1;;10.1016/0022-2836(92)90639-2;;1507232;;14573361;;10.1016/j.tibtech.2003.08.007;;10.1182/blood-2008-07-170274;;pmc2668854;;18941113;;10.4049/jimmunol.172.12.7306;;15187106;;23980122;;pmc3754862;;10.1084/jem.20131625;;17671218;;10.1158/0008-5472.can-06-4639;;10.1084/jem.20050940;;pmc2213162;;10.1084/jem.200509402092c;;16186187;;10.3410/f.1028385.337176;;20197484;;10.1158/1078-0432.ccr-09-2425;;10037686;;10.1074/jbc.274.10.6056;;10.1016/s0167-5699(00)01668-6;;10916138;;10.1186/1479-5876-12-36;;24502656;;pmc4104995;;10.1038/nbt0792-779;;1368267;;10.1016/s1074-7613(02)00280-7;;11869690;;pmc4397897;;23460535;;10.1158/1078-0432.ccr-13-0598;;10.1158/1078-0432.ccr-12-2065;;10.1158/1078-0432.ccr-12-2214;;23460531;;10.1158/1078-0432.ccr-09-3243;;20460483;;pmc21029;;9177197;;10.1073/pnas.94.12.6216;;10.1002/eji.200425818;;15770698;;10836847;;10.1038/sj.cdd.4400670;;10.1186/s40425-016-0132-2;;27822377;;pmc5096004;;27190629;;10.1186/s40425-016-0181-6;;pmc4869343;;15185369;;10.1002/cbic.200300806;;10.1111/j.1365-2567.2009.03228.x;;20201988;;pmc2878467;;17360848;;10.1096/fj.06-7724com;;20734397;;10.1002/cncr.25371;;20454651;;pmc2862699;;10.1371/journal.pone.0010436;;20012605;;10.1007/s00262-009-0803-7;;23856878;;10.1590/0037-8682-0029-2013;;11533635;;10.1038/nbt0901-819;;10.1002/eji.200324804;;14991590;;10.1016/j.clim.2010.03.288;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;21154120;;pmc3413251;;22245556;;10.1016/j.coi.2011.12.011;;10.1038/ni759;;11812990;;10.1200/jco.2017.35.15_suppl.104;;10.1200/jco.2017.35.15_suppl.104;;10.1084/jem.20041130;;15381730;;pmc2211964;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001;;9299585;;10.1006/scbi.1997.0058;;7490758;;10.1006/jmbi.1995.0626,"An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread, ClinicalTrials.gov Identifier: NCT02598960, date first posted: Nov. 6, 2015, dated last updated: Feb. 1, 2018, 7 pages, date retrieved: Feb. 14, 2018 <https://clinicaltrials.gov/ct2/show/NCT02598960?term=BMS-986156&rank=1>.;;Arnett, S. et al., “IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society,” Dec. 5-9, 2010, San Diego, CA USA, mAbs, vol. 3(2), Mar./Apr. 2011, 133-152.;;Avogadri, F. et al., “Modulation of CTLA-4 and GITR for Cancer Immunotherapy,” Curr Top Microbiol Immunol, vol. 344: 211-244 (2011).;;Baecher-Allan, B. et al., “Inhibition of Human CD4+CD25+ high Regulatory T Cell Function,” J. Immunol., vol. 169, 3210-6217 (2002).;;Balint, R. et al., “Antibody Engineering by Parsimonious Mutagenesis,” Gene, vol. 137: 109-118 (1993).;;Barrios, Y. et al., “Length of the antibody heavy chain complementarity determining region 3 as a specificity determining factor,” J Molecular Recognition, vol. 17: 332-338 (2004).;;Birebent, B. et al., “Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression,” Eur. J. Immunol., vol. 34:3485-3496 (2004).;;Bulliard, et al., “Activating Fc y receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies,” JEM, vol. 210 (9): 1685-1693 (2013).;;Bulliard, et al., “Activating Fc y receptors contribute to the antitumor activities of immunoregulatory receptortargeting antibodies,” Novartis Institutes for Biomedical Research and Dana Farber Cancer Institutes USA, No date, 1-3.;;Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” PNAS, vol. 89, 4285-4289 (1992).;;Coe, D. et al., “Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy,” Cancer Immunol Immunother, vol. 59, 1367-1377 (2010).;;Cohen et al., “Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody,” Blood, ASH Annual Meeting Abstracts, Dec. 8-11, 2007, vol. 110 (11), 1788.;;Cohen, et al., “Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity,” Cancer Res., vol. 66: (9):4904-4912 (2006).;;Davies et al., “Affinity improvement of single antibody VH domains: residues in all three hypervanable regions affect antigen bnding,” Immunotechnology, vol. 2, 169-179 (1996).;;Dittmer et al., “Functional impairment of CD8+ T cellls by regulatory T cells during persistent retroviral infection,” Immunity, vol. 20, 293-303 (2004).;;Glaus et al., “In vivo SPECT/CT imaging of an anti-GITR antibody: A novel cancer immunotherapeutic,” J Nucl Med., vol. 54 (Supplement 2):327 (2013).;;Godrey et al., “Cord blood CD4+ CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function,” Blood, vol. 105 No. 2, 750-758 (2005).;;Gross et al., “TACI-lg Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease: Impaired B Cell Maturation in Mice Lacking BLyS,” Immunity, vol. 15:289-302 (2001).;;Gurney et al., “Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR,” Current Biology, vol. 9 (4), 215-218 (1999).;;Hawkins, R.E. et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,” J. Mol. Biol., vol. 226(3): 889-896 (1992).;;Hiroyoshi Nishikawa, “Application of Modulators of Cancer Immunosuppression for Immunotherapy—GITR and CTLA-4,” The Medical Frontline, vol. 64 (11): 100-105 (2009).;;Holt, L. et al., “Domain antibodies: proteins for therapy,” Trends in Biotechnology, vol. 21 (11): 484-490 (2003).;;Houot et al., “T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need or chemotherapy,” Blood, vol. 113 (15):3546-3552 (2009).;;International Preliminary Reporton Patentability, PCT/US2015/033991, dated Dec. 6, 2016, 11 pages.;;International Preliminary Report on Patentability, PCT/US2016/062540, dated May 22, 2018, 17 pages.;;International Search Report and Written Opinion, PCT/US2015/033991, dated Dec. 8, 2015,17 pages.;;International Search Report and Written Opinion, PCT/US2016/062540, dated Jun. 26, 2017, 26 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fees, PCT/US2016/062540, dated May 3, 2017, 25 pages.;;Kanamaru et al., “Costimulation via Glucocorticoid-Induced TNF Receptor in Both Conventional and CD25+ Regulatory CD4+ T Cells,” The Journal of Immunology, 7306-7314 (2004).;;Kim et al., “Fcy receptors enable anticancer action of proapoptotic and immune-modulatory antibodies,” J Exp Med., vol. 210 (9) 1647-1651 (2013).;;Ko et al., “A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model,” Cancer Research, vol. 67 (15) 7477-7486 (2007).;;Ko et al., “Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+ CD4+ regulatory T cells,” JEM, vol. 202 (7), 885-891 (2005).;;Kuenen, B. et al., “A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies,” Clin Cancer Res., vol. 16(6): 1915-1923 (2010).;;Kwon et al., “Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand,” Journal of Biol Chem, vol. 274 (10) 6056-6061 (1999).;;Little et al., “Of Mice and Men: hybridoma and recombinant antibodies,” Immunology Today, vol. 21(8): 364-370 (2000).;;Lu et al. “Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs,” Journal of Translational Medicine, vol. 12 (36), 1-11 (2014).;;Marks, J. et al, “By-Passing Immunization: Building High Affinity Human Antibodies By Chain Shuffling,” Biotechnology, vol. 10(7): 779-783 (1992).;;McHugh et al., “CD4+CD25+ Immunoregulatory T Cells: Gene Expression Analysis Reveals a Functional Role for the Glucocorticoid-Induced TNF Receptor,” Immunity, vol. 16, 311-323 (2002).;;Melero et al., “Agonist Antibodies to TNFR Molecules That Costimulate Tand NK Cells,” Clinical Cancer Research, vol. 19 (5): 1044-1053, 1913 (2013).;;Melero et al., “Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination,” Clinical Cancer Research, vol. 19(5), 997-1008 (2013).;;Melero, I., “Immunological targets: Basic aspects,” IL29, Annals of Oncology, vol. 22 (Supplement 3), 1 page, (2011) doi:10.1093/annonc/mdr103.;;Mitsui et al, “Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals,” Clinical Cancer Res, vol. 16, 2781-2791(2010).;;National Cancer Institute, Immunotherapy Agent workshop Jul. 12, 2007, 1-77.;;Nocentini et al., “A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis,” PNAS, vol. 94, 6216-6221 (1997).;;Nocentini et al., “GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily,” Eur J of Immunol, vol. 35 Iss 4, 1016-1022 (2005).;;Nocentini et al., “Identification of three novel mRNA splice variants of GITR,” Cell Death and Differentiation, vol. 7, 408-410 (2000).;;Patel, M. et al., “Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma,” Journal for ImmunoTherapy of Cancer, vol. 4(28)13 pages (2016).;;Piatesi, A. et al., “Immunological Optimization of a Generic Hydrophobic Pocket for High Affinity Hapten Binding and Diets-Alder Activity,” ChemBio Chem., vol. 5: 460-466 (2004).;;Ponte et al., “Enhancement of humoral and cellular immunity with an antiglucocorticoid-induced tumour necrosis factor receptor monoclonal antibody,” Immunology, vol. 130, 231-242 (2010).;;Press Release, Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting, Cambridge, MA, Jun. 25, 2015, PR Newswire, 1-3.;;Baltz, K. et al., “Cancer immunoediting by GITR (glucocorticoidinduced TNF-related protein) ligand in humans: NK cell/tumor cell interactions,” The FASEB Journal, Research Communication, vol. 21(8): 2442-2454 (2007).;;Chang, W. et al., “Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma,” Cancer, vol. 116 (24): 5777-5788 (2010).;;Cohen et al., “Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation,” PLoS One, vol. 5, Iss. 5, 1-12 (2010).;;Gasparoto, T. et al., “Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment,” Cancer Immunology, Immunotherapy, vol. 59: 819-828 (2010).;;Padovani, C. et al., “Glucocorticoid-induced tumor necrosis factor receptor expression in patients with cervical human papillomavirus infection,” Revista DA Sociedada Brasileira De Medicina Tropical, vol. 46(3):288-292 :(2013).;;U.S. Appl. No. 15/578,874, filed Dec. 1, 2017, Xi-Tao Wang.;;U.S. Appl. No. 15/369,290, filed Dec. 5, 2016, Changyu Wang.;;U.S. Appl. No. 16/663,583, filed Oct. 25, 2019, Changyu Wang.;;U.S. Appl. No. 16/578,987, filed Sep. 23, 2019, Changyu Wang.;;U.S. Appl. No. 15/646,558, filed Jul. 11, 2017, Changyu Wang.;;U.S. Appl. No. 14/949,424, filed Nov. 23, 2015, Changyu Wang.;;U.S. Appl. No. 14/732,082, filed Jun. 5, 2015, Changyu Wang.;;U.S. Appl. No. 15/776,591, filed May 16, 2018, Changyu Wang.;;U.S. Appl. No. 15/578,874, Feb. 10, 2020, S. Aeder.;;U.S. Appl. No. 15/578,874, Oct. 10, 2019, J. Roark.;;U.S. Appl. No. 15/369,290, Oct. 24, 2019, J. Roark.;;U.S. Appl. No. 15/369,290, Jul. 25, 2019, J. Roark.;;U.S. Appl. No. 15/369,290, Nov. 8, 2018, J. Roark.;;U.S. Appl. No. 15/369,290, Jul. 16, 2018, J. Roark.;;U.S. Appl. No. 15/369,290, Feb. 8, 2018, J. Roark.;;U.S. Appl. No. 15/776,591, Sep. 29, 2020, M. Pak.;;U.S. Appl. No. 15/776,591, Jan. 29, 2020, S. Shafer.;;U.S. Appl. No. 15/776,591, Nov. 4, 2019, S. Shafer.;;U.S. Appl. No. 16/578,987, Apr. 27, 2020, S. Shafer.;;U.S. Appl. No. 15/646,558, Jun. 21, 2019, S. Shafer.;;U.S. Appl. No. 15/646,558, Feb. 4, 2019, S. Shafer.;;U.S. Appl. No. 15/646,558, Sep. 26, 2018, S. Shafer.;;U.S. Appl. No. 15/646,558, May 30, 2018, S. Shafer.;;U.S. Appl. No. 14/949,424, Apr. 20, 2017, S. Shafer.;;U.S. Appl. No. 14/949,424, Apr. 13, 2017, S. Shafer.;;U.S. Appl. No. 14/949,424, Jan. 25, 2017, S. Shafer.;;U.S. Appl. No. 14/949,424, Nov. 4, 2016, S. Shafer.;;U.S. Appl. No. 14/732,082, Aug. 24, 2015, S. Shafer.;;U.S. Appl. No. 14/732,082, Jul. 13, 2015, S. Shafer.;;U.S. Appl. No. 16/578,987, Oct. 16, 2020, M. Pak.;;U.S. Appl. No. 15/776,591, Jan. 1, 2021, M. Pak.;;Printout from the R&D Systems website showing a list of available anti-GITR antibodies, Jul. 2, 2014, 1-2.;;Reichert, J., “Monoclonal antibodies in the clinic,” Nat. Biotech, vol. 19, 819-822 (2001).;;Ronchetti et al., “GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations,” Eur J Immunol, vol. 34, 613-622 (2004).;;Rosenzweig et al., “Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR.,” ASCO Meeting Library 2010 Annual Meeting, 1-2.;;Rudikoff, S. et al., “Single amino acid substitution altering antigen-binding specificity,” PNAS, vol. 79: 1979-1983 (1982).;;Safety Study of AMG 228 to Treat Solid Tumors, ClinicalTrials.gov Identifier: NCT02437916, date first posted: May 8, 2015, date last updated: Feb. 6, 2017,date retrieved: Feb. 14, 2018, 7 pages, <https://clinicaltrials.gov/show/NCT02437916>.;;Schaer et al., “Anti-GITR antibodies—Potential Clinical applications for tumor immunotherapy,” Curr Opin in Investigational Drugs, vol. 11 (12), 1378-1386 (2010).;;Schaer, et al. “Modulation of GITR for cancer immunotherapy,” Curr Opin in Immunol, vol. 24, 217-224 (2012).;;Schimizu et al., “Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance,” Mature Immunol, vol. 3 (2), 135-142 (2002).;;Siu, L. et al., “Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor-related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors,” Journal of Clinical Oncology, vol. 35 (15):Supp. 104: (May 2017) 4 page, retrieved date: Feb. 14, 2018, <http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.104>.;;Siu, L. et al., Preliminary Results of a Phase 1/2a Study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor-related gene [GITR] agonist) Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors, slides presented at the ASCO Annual Meeting 2017, Jun. 2, 2017, 18 pages.;;Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001), ClinicalTrials.gov Identifier: NCT02553499, date first posted: Sep. 17, 2015 date last updated: Feb. 2, 2018, date retrieved: Feb. 14, 2018, 6 pages <https://clinicaltrials.gov/show/NCT02553499>.;;Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001), ClinicalTrials.gov Identifier: NCT02132754, date first posted: May 7, 2014, date last updated: Jan. 25, 2018, date retrieved: Feb. 14, 2018, 7 pages <https://clinicaltrials.gov/ct2/show/NCT02132754?term=mk4166&rank=1>.;;Turk, et al., “Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells,” Journal of Exp Medicine, vol. 200 (6) 771-782 (2004).;;U.S. Appl. No. 60/665,322, filed Mar. 25, 2005, 62 pages.;;U.S. Appl. No. 60/687,265, filed Jun. 3, 2005, 71 pages.;;Wang, H. et al., “Integration of Nonclinical PK/PD Data for First-in-Human Starting Dose Selection of Cancer Immune therapeutics,” presented on Oct. 18, 2017 at 2017 (ISoP) International Society of Pharmacometrics—8th American Conference on Pharmacometrics (ACoP 8), 17 pages.;;Website Information for Monoclonal Anti-human GITR/TNFRSF 18 MAb (Clone 110416), Catalog No. MAB689, 1-2, Sep. 21, 2004.;;White, A. et al., “Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies,” Cancer Cell, vol. 27(1):138-148 (2015).;;Whiteside, S. et al., “IkB proteins: structure, function and regulation,” Seminars in Cancer Biology, vol. 8, 75-82 (1997).;;Yang, W. et al., “CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range,” J. Mol. Biol., vol. 254 (3): 392-403 (1995).;;Page 39 of the 1988 Stratagene Catalog, 2 pages.",ACTIVE
305,CA,A1,CA 3005855 A1,049-454-627-946-92X,2017-05-26,2017,CA 3005855 A,2016-11-17,US 201562257599 P;;US 201662303990 P;;US 2016/0062540 W,2015-11-19,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN CHIEN-SZU;;LI HUIMING;;BARNHART BRYAN C;;YAMNIUK AARON P;;LEI MING;;SCHWEIZER LIANG;;HATCHER SANDRA V;;RAJPAL ARVIND,,https://lens.org/049-454-627-946-92X,Patent Application,no,0,0,20,20,432,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,C07K16/28;;A61K39/00,,0,0,,,,DISCONTINUED
306,EP,A2,EP 3377532 A2,072-236-138-670-449,2018-09-26,2018,EP 16805668 A,2016-11-17,US 201562257599 P;;US 201662303990 P;;US 2016/0062540 W,2015-11-19,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN CHIEN-SZU;;LI HUIMING;;BARNHART BRYAN C;;YAMNIUK AARON P;;LEI MING;;SCHWEIZER LIANG;;HATCHER SANDRA V;;RAJPAL ARVIND,,https://lens.org/072-236-138-670-449,Patent Application,yes,0,0,20,20,0,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,C07K16/28;;A61K39/00,,0,0,,,,ACTIVE
307,MX,A,MX 2018006072 A,058-499-214-275-457,2018-08-01,2018,MX 2018006072 A,2016-11-17,US 201562257599 P;;US 201662303990 P;;US 2016/0062540 W,2015-11-19,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF.,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,HAICHUN HUANG;;NILS LONBERG;;AARON P YAMNIUK;;ALAN J KORMAN;;MARK J SELBY;;CHANGYU WANG;;MOHAN SRINIVASAN;;MICHELLE MINHUA HAN;;INDRANI CHAKRABORTY;;GUODONG CHEN;;RICHARD HUANG;;HUIMING LI;;BRYAN C BARNHART;;KARLA A HENNING;;MING LEI;;SANDRA V HATCHER;;ARVIND RAJPAL;;SUSAN CHIEN- SZU WONG;;LIANG SCHWEIZER,,https://lens.org/058-499-214-275-457,Patent Application,no,0,0,20,20,0,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,C07K16/28;;A61K39/00,,0,0,,,,PENDING
308,WO,A2,WO 2017/087678 A2,196-604-955-050-912,2017-05-26,2017,US 2016/0062540 W,2016-11-17,US 201562257599 P;;US 201662303990 P,2015-11-19,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN CHIEN-SZU;;LI HUIMING;;BARNHART BRYAN C;;YAMNIUK AARON P;;LEI MING;;SCHWEIZER LIANG;;HATCHER SANDRA V;;RAJPAL ARVIND,,https://lens.org/196-604-955-050-912,Patent Application,yes,211,63,20,20,542,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,C07K16/28,,157,125,045-714-831-915-963;;075-363-665-052-387;;079-191-303-518-861;;039-943-095-184-294;;073-108-237-457-07X;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;040-577-067-037-463;;104-212-297-137-759;;010-953-281-569-514;;013-795-151-218-458;;092-334-939-903-42X;;014-277-808-472-992;;061-754-151-573-898;;113-327-994-370-771;;006-553-734-546-212;;068-238-957-669-243;;105-316-874-895-908;;056-201-471-905-934;;028-862-168-091-90X;;040-701-579-915-050;;018-694-084-068-187;;034-441-292-442-799;;038-895-768-831-047;;132-281-029-747-299;;087-667-912-261-011;;001-835-514-097-551;;002-377-881-851-166;;038-595-729-934-153;;065-102-359-566-736;;042-204-626-457-327;;006-574-964-805-278;;030-323-674-660-051;;092-023-577-402-127;;022-179-293-052-569;;088-086-720-613-343;;010-488-381-022-259;;082-210-673-349-152;;004-458-031-333-650;;041-909-244-299-232;;078-432-639-041-575;;042-740-484-382-110;;004-458-031-333-650;;003-752-183-823-430;;070-318-112-524-781;;071-163-081-597-04X;;035-135-729-507-737;;094-685-907-794-422;;062-029-719-290-327;;070-624-200-848-669;;012-746-915-512-650;;038-478-749-169-986;;035-554-935-107-802;;099-647-105-451-350;;009-621-637-014-514;;100-985-030-110-978;;030-630-100-818-462;;106-753-778-592-300;;032-820-729-763-323;;083-549-078-331-651;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;033-754-369-798-314;;077-525-954-203-403;;028-969-172-280-017;;060-375-551-951-388;;020-753-772-581-741;;038-613-711-274-229;;047-951-914-695-080;;062-485-301-455-912;;038-613-711-274-229;;023-676-781-371-861;;026-744-100-669-883;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;012-300-595-074-789;;031-815-870-004-331;;040-841-912-862-912;;011-583-491-184-648;;126-659-091-098-052;;038-166-075-279-931;;083-079-509-375-354;;043-654-077-374-418;;084-388-182-984-099;;042-354-196-879-741;;005-112-559-456-657;;052-219-543-437-800;;007-364-858-655-289;;056-942-841-068-650;;107-302-749-967-437;;039-238-464-990-600;;036-564-551-324-053;;020-123-860-433-320;;011-516-147-270-264;;020-986-423-793-233;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;007-709-585-201-038;;056-422-417-058-69X;;005-022-447-377-963;;127-416-339-660-812;;098-407-145-404-736;;066-749-017-721-197;;001-467-559-709-949;;049-089-244-500-629;;078-061-292-153-737;;055-646-175-554-792;;129-390-507-012-794;;008-213-515-306-640;;053-703-232-770-99X;;033-109-855-318-388;;030-249-121-435-10X;;001-091-081-800-619,pmc21029;;9177197;;10.1073/pnas.94.12.6216;;pmc299905;;14608036;;10.1073/pnas.2334901100;;15771565;;10.1146/annurev.immunol.23.021704.115839;;10.1038/ni759;;11812990;;16140769;;pmc1212625;;10.1128/jvi.79.18.11935-11942.2005;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1038/nbt1135;;16151405;;9780179;;10.4049/jimmunol.161.8.4083;;10.1385/0896033759;;10.4049/jimmunol.137.11.3614;;2431039;;10.1016/0042-6822(90)90025-m;;1693247;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;8424945;;10.1021/bi00055a024;;10556249;;10.1093/protein/12.10.879;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;7521646;;10.1038/nbt0994-899;;10.1126/science.2471267;;2471267;;10.1021/bi00161a011;;1332755;;10.1021/bi00078a011;;7687462;;15299382;;10.1107/s0907444994001344;;2185018;;10.1111/j.1432-1033.1990.tb15454.x;;9351804;;10.1016/s0969-2126(97)00279-7;;977570;;10.1016/s0021-9258(20)81858-4;;15299544;;10.1107/s0907444992010400;;27799107;;10.1016/s0076-6879(97)76070-1;;3127726;;10.1038/332323a0;;10.1038/321522a0;;3713831;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;19896358;;10.1016/j.copbio.2009.10.011;;14699147;;10.1074/jbc.c300470200;;10.4049/jimmunol.176.1.346;;16365427;;11096108;;10.1074/jbc.m009483200;;12391234;;10.4049/jimmunol.169.9.5171;;10.1074/jbc.m604292200;;16793771;;10.4049/jimmunol.0804182;;19494290;;11096108;;10.1074/jbc.m009483200;;11986321;;10.1074/jbc.m202069200;;10.1038/6179;;10052355;;10.1146/annurev.bi.41.070172.003325;;4563441;;10.4049/jimmunol.172.9.5489;;15100290;;2459288;;pmc2189025;;10.1084/jem.168.3.1099;;12042244;;10.1093/glycob/12.4.43r;;10.1038/316452a0;;3927174;;11275255;;10.1016/s0161-5890(00)00105-x;;10.2174/1389201023378229;;12463418;;10.1023/b:pham.0000008042.15988.c0;;14725359;;10397155;;10.1016/s0165-2478(99)00029-2;;10.1093/chromsci/40.6.343;;12137207;;8644915;;10.1021/ac00116a002;;10.1038/348552a0;;2247164;;1172191;;10.1038/256495a0;;8159246;;10.1038/368856a0;;10.1007/978-3-642-78432-3_3;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;8144892;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nbt727;;12172556;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1126/science.3929380;;3929380;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;10.1016/j.cbpa.2009.03.023;;19414278;;10.1002/anie.200801313;;19072788;;10.1039/b908687k;;19675886;;10.1002/cbic.200800801;;19130455;;10.1016/j.chembiol.2008.01.007;;18291317;;19924746;;pmc4878437;;10.1002/anie.200903627;;10.1021/bc800294a;;19191567;;6239899;;10.1084/jem.160.6.1686;;pmc2187539;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;3833240;;10.1126/science.3925553;;3925553;;2958547;;10.4049/jimmunol.139.7.2367;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;3390170;;10.1016/s0006-291x(88)81333-0;;10.1128/aac.39.1.180;;pmc162506;;7695303;;7907597;;10.1016/s0021-9258(17)37081-3;;10.1016/0014-5793(94)00313-0;;8206150;;7820457;;10.1006/immu.1994.1029;;15470033;;10.4049/jimmunol.173.8.4919;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;9624003;;10.1038/30989;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;9930702;;10.1038/16717;;10417377;;10.1126/science.285.5427.546;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;11514604;;10.3410/f.1000338.7202;;pmc2193490;;10.1084/jem.194.4.481;;pmc15881;;10.1073/pnas.96.6.2982;;10077623;;10.1097/00002371-199601000-00009;;8859727;;10.1038/22124;;10408445;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;9850053;;10.1038/nm735;;12118245;;10.3410/f.1008846.113460;;15930300;;10.1158/0008-5472.can-04-3319;;22918247;;10.4161/cc.21842;;pmc3466534,"NOCENTINI ET AL., PNAS, vol. 94, 1997, pages 6216 - 21;;TONE ET AL., PNAS, vol. 100, 2003, pages 15059 - 64;;WATTS, ANNUAL REVIEWS IN IMMUNOLOGY, vol. 23, 2005, pages 23 - 68;;SHIMIZU ET AL., NATURE IMMUNOLOGY, vol. 3, 2002, pages 135 - 42;;STEPHANS ET AL., JI, vol. 173, no. 8, 15 December 2003 (2003-12-15), pages 5008 - 20;;SUVAS ET AL., J VIROL., vol. 79, 2005, pages 11935 - 42;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;SONGSIVILAI; LACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;LONBERG, NATURE BIOTECH., vol. 23, no. 9, 2005, pages 1117 - 1125;;JEFFERIS ET AL., MABS, vol. 1, 2009, pages 1;;ROUX ET AL., J. IMMUNOL., vol. 161, 1998, pages 4083;;ROUX ET AL., J IMMUNOL, vol. 161, 1998, pages 4083;;G. E. MORRIS: ""Epitope Mapping Protocols in Methods in Molecular Biology"", vol. 66, 1996;;ED HARLOW; DAVID LANE, COLD SPRING HARB PROTOC, 2006;;ED HARLOW; DAVID LANE: ""Using Antibodies"", 1999, COLD SPRING HARBOR LABORATORY PRESS;;STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 9, 1983, pages 242;;KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR PRESS;;MOREL ET AL., MOL. IMMUNOL., vol. 25, no. 1, 1988, pages 7;;CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546;;MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77;;BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187;;KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999, pages 879 - 884;;BURKS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 412 - 417;;E. MEYERS; W. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17;;NEEDLEMAN; WUNSCH, J. MOL. BIOL., 1970, pages 444 - 453;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;F. AUSUBEL, ET AL.: ""Current Protocols in Molecular Biology"", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;;ALLEN ET AL., BIOCHEMISTRY, vol. 48, 2009, pages 3755;;JESPERS ET AL., BIOTECHNOLOGY, vol. 12, 1994, pages 899;;CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 31, 1992, pages 11335 - 11347;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 32, 1993, pages 6884 - 6891;;GIEGE ET AL., ACTA CRYSTALLOGR, vol. D50, 1994, pages 339 - 350;;MCPHERSON, EUR. J. BIOCHEM., vol. 189, 1990, pages 1 - 23;;CHAYEN, STRUCTURE, vol. 5, 1997, pages 1269 - 1274;;MCPHERSON, J. BIOL. CHEM., vol. 251, 1976, pages 6300 - 6303;;SCOPES: ""Protein Purification: Principles and Practice, 3rd ed."", 1994, SPRINGER-VERLAG;;BLUNDELL; JOHNSON ET AL.: ""Meth. Enzymol."", 1985, ACADEMIC PRESS, pages: 114,115;;BRICOGNE, ACTA CRYST., vol. D49, 1993, pages 37 - 60;;BRICOGNE: ""Meth. Enzymol."", vol. 276A, 1997, pages: 361 - 423;;ROVERSI ET AL., ACTA CRYST., vol. D56, 2000, pages 1313 - 1323;;RIECHMANN, L ET AL., NATURE, vol. 332, 1998, pages 323 - 327;;JONES, P. ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;QUEEN, C. ET AL., PROC. NATL. ACAD. SEE. U.S.A., vol. 86, 1989, pages 10029 - 10033;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest, 5th ed."", 1991, NIH PUBLICATION NO. 91-3242;;TOMLINSON, I. M. ET AL.: ""The Repertoire of Human Germline V Sequences Reveals about Fifty Groups of V Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: doi:10.1016/0022-2836(92)90223-7;;COX, J. P. L. ET AL.: ""A Directory of Human Germ-line V Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;MOLEC. IMMUNOL., vol. 29, no. 5, 1992, pages 633 - 9;;STROHL, CURRENT OPINION IN BIOTECHNOLOGY, vol. 20, 2009, pages 685 - 691;;HINTON ET AL., J. BIOL. CHEM., vol. 279, no. 8, 2004, pages 6213 - 6216;;HINTON ET AL., JOURNAL OF IMMUNOLOGY, vol. 176, 2006, pages 346 - 356;;SHIELDS ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 9, 2001, pages 6591 - 6604;;DALL ACQUA ET AL., JOURNAL OF IMMUNOLOGY, vol. 169, 2002, pages 5171 - 5180;;DALL'ACQUA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, 2006, pages 23514 - 23524;;YEUNG ET AL., J IMMUNOL, vol. 182, 2010, pages 7663 - 7671;;SHIELDS, R.L ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;MARSHALL ET AL., ANNU REV BIOCHEM, vol. 41, 1972, pages 673 - 702;;GALA; MORRISON, J. IMMUNOL, vol. 172, 2004, pages 5489 - 94;;WALLICK ET AL., J EXP MED, vol. 168, 1988, pages 1099 - 109;;SPIRO, GLYCOBIOLOGY, vol. 12, 2002, pages 43R - 56R;;PAREKH ET AL., NATURE, vol. 316, 1985, pages 452 - 7;;MIMURA ET AL., MOL IMMUNOL, vol. 37, 2000, pages 697 - 706;;KRISHNAMURTHY R; MANNING M C, CURR PHARM BIOTECHNOL, vol. 3, 2002, pages 361 - 71;;CHEN ET AL., PHARM RES, vol. 20, 2003, pages 1952 - 60;;GHIRLANDO ET AL., IMMUNOL LETT, vol. 68, 1999, pages 47 - 52;;MURRAY ET AL., J. CHROMATOGR SCI, vol. 40, 2002, pages 343 - 9;;ALEXANDER A J; HUGHES D E, ANAL CHEM, vol. 67, 1995, pages 3626 - 32;;KABAT, E. A.: ""Sequences of Proteins of Immunological Interest"", 1991, NIH PUBLICATION NO. 91-3242;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;LONBERG, N.: ""Handbook of Experimental Pharmacology"", vol. 113, 1994, pages: 49 - 101;;LONBERG, N.; HUSZAR, D., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F.; LONBERG, N., ANN. N.Y. ACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 3720 - 3724;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J. ET AL., EMBO J., vol. 12, 1993, pages 821 - 830;;TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;TAYLOR, L ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;TOMIZUKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727;;KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894;;FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;MORRISON, S., SCIENCE, vol. 229, 1985, pages 1202;;GOEDDEL: ""Gene Expression Technology. Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;TAKEBE, Y. ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;BOSS, M. A.; WOOD, C. R, IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMAN; P. A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;SENTER, P. D., CURR. OPIN. CHEM. BIOL., vol. 13, 2009, pages 235 - 244;;HACKENBERGER, C. P. R.; SCHWARZER, D., ANGEW. CHEM. INT. ED. ENGL., vol. 47, 2008, pages 10030 - 10074;;SUNBUL, M.; YIN, J., ORG. BIOMOL. CHEM., vol. 7, 2009, pages 3361 - 3371;;FRESE, M. A.; DIERKS, T., CHEMBIOCHEM., vol. 10, 2009, pages 425 - 427;;TAKI, M. ET AL., PROT. ENG. DES. SEL., vol. 17, 2004, pages 119 - 126;;GAUTIER, A. ET AL., CHEM. BIOL., vol. 15, 2008, pages 128 - 136;;BORDUSA, F., HIGHLIGHTS IN BIOORGANIC CHEMISTRY, 2004, pages 389 - 403;;REN, H. ET AL., ANGEW. CHEM. INT. ED. ENGL., vol. 48, 2009, pages 9658 - 9662;;TAYLOR, E. VOGEL; IMPERIALI, B: ""Nucleic Acids and Molecular Biology"", PROTEIN ENGINEERING, vol. 22, 2009, pages 65 - 96;;DE GRAAF, A. J. ET AL., BIOCONJUG. CHEM., vol. 20, 2009, pages 1281 - 1295;;KARPOVSKY ET AL., J. EXP. MED., vol. 160, 1984, pages 1686;;LIU, MA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 8648;;PAULUS, BEHRING INS. MITT. NO., vol. 78, 1985, pages 118 - 132;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83;;GLENNIE ET AL., J. IMMUNOL., vol. 139, 1987, pages 2367 - 2375;;BERGE, S.M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;J.R. ROBINSON: ""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;V.V. RANADE, J. CLIN. PHARMACOL., vol. 29, 1989, pages 685;;UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN, vol. 153, 1988, pages 1038;;P.G. BLOEMA ET AL., FEBS LETT., vol. 357, 1995, pages 140;;M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 39, 1995, pages 180;;BRISCOE ET AL., AM. J. PHYSIOL., vol. 1233, 1995, pages 134;;SCHREIER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 9090;;K. KEINANEN; M.L. LAUKKANEN, FEBS LETT., vol. 346, 1994, pages 123;;J.J. KILLION; I.J. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;ROSENBERG, S: ""Development of Cancer Vaccines"", 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 60 - 62;;LOGOTHETIS, C.: ""DEVELOPMENT OF CANCER VACCINES"", 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 300 - 302;;KHAYAT, D.: ""DEVELOPMENT OF CANCER VACCINES"", 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 414 - 428;;FOON, K.: ""Cancer: Principles and Practice of Oncology"", 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 730 - 738;;RESTIFO, N.; SZNOL, M. ET AL.: ""Cancer: Principles and Practice of Oncology, 5th ed."", 1997, article ""Cancer Vaccines (Ch. 61)"", pages: 3023 - 3043;;DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, S A, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT; SRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARD; O'GARRA, IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;RIDGE ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;WEINBERG ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;GREENBERG; RIDDELL, SCIENCE, vol. 285, 1999, pages 546 - 51;;HOLLIGER, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;VAN ELSAS ET AL., J. EXP. MED., vol. 194, 2001, pages 481 - 489;;OVERWIJK ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 96, 1999, pages 2982 - 2987;;ROSENBERG; WHITE, J. IMMUNOTHER EMPHASIS TUMOR IMMUNOL, vol. 19, no. 1, 1996, pages 81 - 4;;SCHENK ET AL., NATURE, vol. 400, 1999, pages 173 - 177;;HURWITZ ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071;;CAMACHO ET AL., J. CLIN. ONCOLOGY, vol. 22, no. 145, 2004;;MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304;;FULDA ET AL., NAT MED, vol. 8, 2002, pages 808 - 15;;HYER ET AL., CANCER RESEARCH, vol. 65, 2005, pages 4799 - 808;;LI ET AL., CELL CYCLE, vol. 11, 2012, pages 3343 - 3344",PENDING
309,IL,A,IL 259399 A,174-427-757-450-816,2018-07-31,2018,IL 25939918 A,2018-05-16,US 201562257599 P;;US 201662303990 P;;US 2016/0062540 W,2015-11-19,Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof,,BRISTOL MYERS SQUIBB CO;;CHAKRABORTY INDRANI;;KORMAN ALAN J;;SRINIVASAN MOHAN;;WONG SUSAN CHIEN SZU;;LONBERG NILS;;LEI MING;;SCHWEIZER LIANG;;RAJPAL ARVIND;;BARNHART BRYAN C;;YAMNIUK AARON P;;WANG CHANGYU;;SELBY MARK J;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;HUANG HAICHUN;;LI HUIMING;;HATCHER SANDRA V,CHAKRABORTY INDRANI;;KORMAN ALAN J;;SRINIVASAN MOHAN;;WONG SUSAN CHIEN-SZU;;LONBERG NILS;;LEI MING;;SCHWEIZER LIANG;;RAJPAL ARVIND;;BARNHART BRYAN C;;YAMNIUK AARON P;;WANG CHANGYU;;SELBY MARK J;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;HUANG HAICHUN;;LI HUIMING;;HATCHER SANDRA V,,https://lens.org/174-427-757-450-816,Patent Application,no,0,0,20,20,0,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,,,0,0,,,,PENDING
310,US,A1,US 2018/0339042 A1,066-361-413-050-320,2018-11-29,2018,US 201615776591 A,2016-11-17,US 201615776591 A;;US 201662303990 P;;US 201562257599 P;;US 2016/0062540 W,2015-11-19,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN CHIEN-SZU;;LI HUIMING;;BARNHART BRYAN C;;YAMNIUK AARON P;;LEI MING;;SCHWEIZER LIANG;;HATCHER SANDRA V;;RAJPAL ARVIND,BRISTOL-MYERS SQUIBB COMPANY (2018-07-27),https://lens.org/066-361-413-050-320,Patent Application,yes,0,9,20,20,542,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,A61K39/395;;A61P35/04;;C07K16/28;;G01N33/574;;G01N33/68,,0,0,,,,ACTIVE
311,KR,A,KR 20180082563 A,185-150-298-987-20X,2018-07-18,2018,KR 20187016781 A,2016-11-17,US 201562257599 P;;US 201662303990 P;;US 2016/0062540 W,2015-11-19,글루코코르티코이드-유도된 종양 괴사 인자 수용체 (GITR)에 대한 항체 및 그의 용도,"글루코코르티코이드-유도성 TNF 수용체 (GITR)에 결합하는 항체 또는 그의 항원 결합 부분이 본원에 제공된다. 또한, 암의 치료와 같은 치료 용도에서의 이들 단백질의 용도가 제공된다. 추가로, 항체를 생산하는 세포, 항체의 중쇄 및/또는 경쇄 가변 영역을 코딩하는 폴리뉴클레오티드, 및 항체의 중쇄 및/또는 경쇄 가변 영역을 코딩하는 폴리뉴클레오티드를 포함하는 벡터가 제공된다.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN CHIEN SZU;;LI HUIMING;;BARNHART BRYAN C;;YAMNIUK AARON P;;LEI MING;;SCHWEIZER LIANG;;HATCHER SANDRA V;;RAJPAL ARVIND,,https://lens.org/185-150-298-987-20X,Patent Application,no,0,0,20,20,1084,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,C07K16/28,,0,0,,,,PENDING
312,CN,A,CN 108738324 A,059-126-970-265-275,2018-11-02,2018,CN 201680079209 A,2016-11-17,US 201562257599 P;;US 201662303990 P;;US 2016/0062540 W,2015-11-19,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN CHIEN-SZU;;LI HUIMING;;BARNHART BRYAN C;;YAMNIUK AARON P;;LEI MING;;SCHWEIZER LIANG;;HATCHER SANDRA V;;RAJPAL ARVIND,,https://lens.org/059-126-970-265-275,Patent Application,no,3,0,20,20,0,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,C07K16/28;;A61K39/00,,1,1,051-374-571-260-065,10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001,"ANN L WHITE: ""Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies"", 《CANCER CELL》",ACTIVE
313,BR,A2,BR 112018010172 A2,169-175-549-847-641,2018-11-21,2018,BR 112018010172 A,2016-11-17,US 2016/0062540 W;;US 201562257599 P;;US 201662303990 P,2015-11-19,anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos,"a presente invenção refere-se a anticorpos, ou porções de ligação a antígeno dos mesmos, que se ligam ao receptor de tnf induzível por glicocorticoide (gitr). são também fornecisos usos dessas proteínas em aplicações terapêuticas, tal como no tratamento de câncer. são tambem fornecidas células que produzem os anticorpos, polinucleotídeos codificando a região variável de cadeia pesada e/ou leve dos anticorpos, e vetores compreendendo os polinucleotídeos codificando a região variável de cadeia pesada e/ou leve dos anticorpos.",BRISTOL MYERS SQUIBB CO,AARON P YAMNIUK;;ALAN J KORMAN;;ARVIND RAJPAL;;BRYAN C BARNHART;;CHANGYU WANG;;GUODONG CHEN;;HAICHUN HUANG;;HUIMING LI;;INDRANI CHAKRABORTY;;KARLA A HENNING;;LIANG SCHWEIZER;;MARK J SELBY;;MICHELLE MINHUA HAN;;MING LEI;;MOHAN SRINIVASAN;;NILS LONBERG;;RICHARD HUANG;;SANDRA V HATCHER;;SUSAN CHIEN-SZU WONG,,https://lens.org/169-175-549-847-641,Patent Application,no,0,0,20,20,0,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,C07K16/28;;A61K39/00,,0,0,,,,DISCONTINUED
314,WO,A3,WO 2017/087678 A3,129-892-378-495-274,2017-08-03,2017,US 2016/0062540 W,2016-11-17,US 201562257599 P;;US 201662303990 P,2015-11-19,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN CHIEN-SZU;;LI HUIMING;;BARNHART BRYAN C;;YAMNIUK AARON P;;LEI MING;;SCHWEIZER LIANG;;HATCHER SANDRA V;;RAJPAL ARVIND,,https://lens.org/129-892-378-495-274,Search Report,yes,5,0,20,20,0,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,C07K16/28;;A61K39/00,,1,1,051-374-571-260-065,10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001,"ANN L. WHITE ET AL: ""Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies"", CANCER CELL, vol. 27, no. 1, 1 January 2015 (2015-01-01), pages 138 - 148, XP055193819, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2014.11.001",PENDING
315,AU,A1,AU 2016/356780 A1,035-548-880-252-031,2018-06-28,2018,AU 2016/356780 A,2016-11-17,US 201562257599 P;;US 201662303990 P;;US 2016/0062540 W,2015-11-19,Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN CHIEN-SZU;;LI HUIMING;;BARNHART BRYAN C;;YAMNIUK AARON P;;LEI MING;;SCHWEIZER LIANG;;HATCHER SANDRA V;;RAJPAL ARVIND,,https://lens.org/035-548-880-252-031,Patent Application,no,0,0,20,20,0,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,C07K16/28;;A61K39/00,,0,0,,,,DISCONTINUED
316,EP,B1,EP 3377532 B1,168-830-627-141-33X,2022-07-27,2022,EP 16805668 A,2016-11-17,US 201562257599 P;;US 201662303990 P;;US 2016/0062540 W,2015-11-19,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN CHIEN-SZU;;LI HUIMING;;BARNHART BRYAN C;;YAMNIUK AARON P;;LEI MING;;SCHWEIZER LIANG;;HATCHER SANDRA V;;RAJPAL ARVIND,,https://lens.org/168-830-627-141-33X,Granted Patent,yes,5,0,20,20,0,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,C07K16/28;;A61K39/00,,2,2,051-374-571-260-065;;051-374-571-260-065,10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001,"ANN L. WHITE ET AL: ""Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies"", CANCER CELL, vol. 27, no. 1, 1 January 2015 (2015-01-01), pages 138 - 148, XP055193819, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2014.11.001;;ANN L. WHITE ET AL: ""Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies"", CANCER CELL, vol. 27, no. 1, 1 January 2015 (2015-01-01), pages 138 - 148, XP055193819, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2014.11.001",ACTIVE
317,WO,A1,WO 2019/143607 A1,188-517-304-076-46X,2019-07-25,2019,US 2019/0013638 W,2019-01-15,US 201862617828 P;;US 201862618561 P;;US 201862633477 P,2018-01-16,METHODS OF TREATING CANCER WITH ANTIBODIES AGAINST TIM3,"This disclosure provides a method for treating a subject afflicted with a tumor or a cancer, wherein the method comprises administering to the subject therapeutically effective amounts of an anti- TIM3 antibody, alone or in combination with an inhibitor of the PD-1 signaling pathway ( e.g. , anti-PD-1 antibody). In some embodiments, the antibody is administered as a flat dose or a weight-based dose.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN;;PATAH POLIANA;;JACKSON JEFFREY R;;FLEMING RONALD A,,https://lens.org/188-517-304-076-46X,Patent Application,yes,83,4,6,6,448,C07K16/2803;;C07K16/2818;;A61K2039/507;;A61P35/00;;C07K16/2803;;C07K16/2818;;C07K16/2878;;C07K16/2827;;A61P35/00;;A61K2039/507;;A61P35/00;;A61K39/3955;;A61K2039/505;;A61K2039/507;;A61K2039/545;;C07K16/2803;;C07K16/2818;;C07K2317/21;;C07K2317/52;;C07K2317/565,C07K16/28;;A61K39/395;;A61P35/00,,58,21,014-766-704-525-495;;077-322-394-487-953;;019-709-193-272-051;;013-097-935-371-671;;095-501-820-764-762;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;010-953-281-569-514;;014-277-808-472-992;;061-754-151-573-898;;113-327-994-370-771;;006-553-734-546-212;;068-238-957-669-243;;105-316-874-895-908;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;052-660-996-132-29X;;051-218-620-433-15X;;142-369-222-567-694,10.2147/ott.s170385;;pmc6198883;;30410357;;10.1158/1538-7445.am2017-2628;;10.1158/1535-7163.mct-16-0665;;28265006;;28520840;;10.1093/annonc/mdx235;;pmc5834087;;10.1158/1538-7445.am2017-ct101;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1038/nbt1135;;16151405;;10.4049/jimmunol.137.11.3614;;2431039;;10.1016/0042-6822(90)90025-m;;1693247;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;8424945;;10.1021/bi00055a024;;10556249;;10.1093/protein/12.10.879;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;28679395;;pmc5499002;;10.1186/s13045-017-0506-z;;24872026;;10.1158/2326-6066.cir-14-0040;;10.1158/1078-0432.ccr-13-0855;;23674495;;pmc4102335,"HE YAYI ET AL: ""TIM-3, a promising target for cancer immunotherapy."", ONCOTARGETS AND THERAPY 2018, vol. 11, 2018, pages 7005 - 7009, XP002789761, ISSN: 1178-6930;;LEI ZHENG ET AL.: ""Abstract A203: Generation of human TIM3 knock-in mice for preclinical efficacy assessment of therapeutic antibodies"", 30 October 2017 (2017-10-30), XP002789762, Retrieved from the Internet <URL:http://mct.aacrjournals.org/content/17/1_Supplement/A203> [retrieved on 20190315];;WEISS G J: ""A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors"", JOURNAL FOR IMMUNOTHERAPY OF CANCER 20171101 BIOMED CENTRAL LTD. NLD, vol. 5, no. Supplement 2, 1 November 2017 (2017-11-01), XP002789763, ISSN: 2051-1426;;DEANGELIS N ET AL: ""Development of JNJ-64158120, an anti-TIM-3 antibody to overcome innate and acquired mechanisms of resistance to PD-1 therapy"", JOURNAL FOR IMMUNOTHERAPY OF CANCER 20171101 BIOMED CENTRAL LTD. NLD, vol. 5, no. Supplement 2, 1 November 2017 (2017-11-01), XP002789764, ISSN: 2051-1426;;TONG ZHANG ET AL.: ""Abstract 2628: BGB-A425: a humanized anti-human Tim-3 antibody that exhibits strong immune cell activation"", 5 April 2017 (2017-04-05), XP002789765, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/77/13_Supplement/2628> [retrieved on 20190315];;BUROVA E ET AL: ""Characterization of the Anti PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice"", MOL CANCER THER. 2017 MAY,, vol. 16, no. 5, 6 March 2017 (2017-03-06), pages 861 - 870, XP002788765;;NOVARTIS PHARMACEUTICALS: ""Study NCT02608268 on Date: December 14, 2017 (v15)"", 14 December 2017 (2017-12-14), XP002789766, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT02608268?V_15> [retrieved on 20190315];;ZHAO X ET AL: ""Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors."", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY 01 AUG 2017, vol. 28, no. 8, 1 August 2017 (2017-08-01), pages 2002 - 2008, XP002789767, ISSN: 1569-8041;;ZHAO ET AL: ""Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types"", July 2017 (2017-07-01), XP002789768, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/77/13_Supplement/CT101> [retrieved on 20190315];;JUO, PEI-SHOW: ""Concise Dictionary of Biomedicine and Molecular Biology"", CRC PRESS;;""The Dictionary of Cell and Molecular Biology"", 1999, ACADEMIC PRESS;;""Oxford Dictionary Of Biochemistry And Molecular Biology"", 2000, OXFORD UNIVERSITY PRESS;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;LONBERG, NATURE BIOTECH., vol. 23, no. 9, 2005, pages 1117 - 1125;;JEFFERIS ET AL., MABS, vol. 1, 2009, pages 1;;""Epitope Mapping Protocols in Methods in Molecular Biology"", vol. 66, 1996;;ED HARLOW; DAVID LANE, COLD SPRING HARB PROTOC, 2006;;ED HARLOW; DAVID LANE: ""Using Antibodies"", 1999, COLD SPRING HARBOR LABORATORY PRESS;;STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 9, 1983, pages 242;;KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR PRESS;;MOREL ET AL., MOL. IMMUNOL., vol. 25, no. 1, 1988, pages 7;;CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546;;MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77;;BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187;;KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999, pages 879 - 884;;BURKS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 412 - 417;;E. MEYERS; W. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17;;NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;""Current Protocols in Molecular Biology"", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;;SI-YANG LIU ET AL., J. HEMATOL. ONCOL., vol. 10, 2017, pages 136;;WANG ET AL., CANCER IMMUNOL RES., vol. 2, no. 9, 2014, pages 846 - 56;;HERBST ET AL., J CLIN ONCOL, vol. 31, 2013, pages 3000;;ZHANG ET AL., CELL DISCOV., vol. 7, March 2017 (2017-03-01), pages 3;;GORELIK ET AL., AACR, vol. 4606, April 2016 (2016-04-01);;NCCN GUIDELINES, 2014, Retrieved from the Internet <URL:worldwideweb.nccn.org/professionals/physician_gls/f_guidelines.asp>;;CHEN ET AL., CLIN CANCER RES, vol. 19, no. 13, 2013, pages 3462 - 3473;;""Molecular Cloning A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;""Molecular Cloning: A Laboratory Manual"", 1992, COLD SPRINGS HARBOR LABORATORY;;""DNA Cloning"", vol. I;II, 1985;;""Oligonucleotide Synthesis"", 1984;;""Nucleic Acid Hybridization"", 1984;;""Transcription And Translation"", 1984;;FRESHNEY: ""Culture Of Animal Cells"", 1987, ALAN R. LISS, INC.;;""Immobilized Cells And Enzymes"", 1986, IRL PRESS;;PERBAL: ""A Practical Guide To Molecular Cloning"", 1984;;""Methods In Enzymology"", ACADEMIC PRESS, INC.;;""Gene Transfer Vectors For Mammalian Cells"", 1987, COLD SPRING HARBOR LABORATORY;;""Methods In Enzymology"", vol. 154;155;;""Immunochemical Methods In Cell And Molecular Biology"", 1987, ACADEMIC PRESS;;""Handbook Of Experimental Immunology"", vol. I-IV, 1986;;""Manipulating the Mouse Embryo"", 1986, COLD SPRING HARBOR LABORATORY PRESS;;CROOKS: ""Antisense drug Technology: Principles, strategies and applications"", 2007, CRC PRESS;;AUSUBEL ET AL.: ""Current Protocols in Molecular Biology"", 1989, JOHN WILEY AND SONS",PENDING
318,KR,A,KR 20200109339 A,163-155-615-858-271,2020-09-22,2020,KR 20207023142 A,2019-01-15,US 201862617828 P;;US 201862618561 P;;US 201862633477 P;;US 2019/0013638 W,2018-01-16,TIM3에 대한 항체를 사용하여 암을 치료하는 방법,"본 개시내용은 종양 또는 암을 앓고 있는 대상체에게 치료 유효량의 항-TIM3 항체를 단독으로 또는 PD-1 신호전달 경로의 억제제 (예를 들어, 항-PD-1 항체)와 조합하여 투여하는 것을 포함하는, 종양 또는 암을 앓고 있는 대상체를 치료하는 방법을 제공한다. 일부 실시양태에서, 항체는 균일 용량 또는 체중-기준 용량으로 투여된다.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG AN;;PATAH POLIANA;;JACKSON JEFFREY R;;FLEMING RONALD A,,https://lens.org/163-155-615-858-271,Patent Application,no,0,0,6,6,894,C07K16/2803;;C07K16/2818;;A61K2039/507;;A61P35/00;;C07K16/2803;;C07K16/2818;;C07K16/2878;;C07K16/2827;;A61P35/00;;A61K2039/507;;A61P35/00;;A61K39/3955;;A61K2039/505;;A61K2039/507;;A61K2039/545;;C07K16/2803;;C07K16/2818;;C07K2317/21;;C07K2317/52;;C07K2317/565,C07K16/28;;A61K39/00;;A61P35/00,,0,0,,,,PENDING
319,EP,A1,EP 3740506 A1,126-344-326-310-235,2020-11-25,2020,EP 19706784 A,2019-01-15,US 201862617828 P;;US 201862618561 P;;US 201862633477 P;;US 2019/0013638 W,2018-01-16,METHODS OF TREATING CANCER WITH ANTIBODIES AGAINST TIM3,,BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN;;PATAH POLIANA;;JACKSON JEFFREY R;;FLEMING RONALD A,,https://lens.org/126-344-326-310-235,Patent Application,yes,0,0,6,6,0,C07K16/2803;;C07K16/2818;;A61K2039/507;;A61P35/00;;C07K16/2803;;C07K16/2818;;C07K16/2878;;C07K16/2827;;A61P35/00;;A61K2039/507;;A61P35/00;;A61K39/3955;;A61K2039/505;;A61K2039/507;;A61K2039/545;;C07K16/2803;;C07K16/2818;;C07K2317/21;;C07K2317/52;;C07K2317/565,C07K16/28;;A61K39/395;;A61P35/00,,0,0,,,,PENDING
320,CN,A,CN 111868091 A,173-815-437-906-376,2020-10-30,2020,CN 201980019319 A,2019-01-15,US 201862617828 P;;US 201862618561 P;;US 201862633477 P;;US 2019/0013638 W,2018-01-16,METHODS OF TREATING CANCER WITH ANTIBODIES AGAINST TIM3,"This disclosure provides a method for treating a subject afflicted with a tumor or a cancer, wherein the method comprises administering to the subject therapeutically effective amounts of an anti- TIM3 antibody, alone or in combination with an inhibitor of the PD-1 signaling pathway (e.g., anti-PD-1 antibody). In some embodiments, the antibody is administered as a flat dose or a weight-based dose.",SQUIBB BRISTOL MYERS COMPANY,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD;;CHEN GUODONG;;KUHNE MICHELLE;;TRUONG HONG-AN;;PATAH POLIANA;;JACKSON JEFFREY R;;FLEMING RONALD A,,https://lens.org/173-815-437-906-376,Patent Application,no,2,2,6,6,0,C07K16/2803;;C07K16/2818;;A61K2039/507;;A61P35/00;;C07K16/2803;;C07K16/2818;;C07K16/2878;;C07K16/2827;;A61P35/00;;A61K2039/507;;A61P35/00;;A61K39/3955;;A61K2039/505;;A61K2039/507;;A61K2039/545;;C07K16/2803;;C07K16/2818;;C07K2317/21;;C07K2317/52;;C07K2317/565,C07K16/28;;A61K39/395;;A61P35/00,,0,0,,,,PENDING
321,US,A1,US 2022/0175921 A1,044-190-206-708-917,2022-06-09,2022,US 202117531061 A,2021-11-19,US 202117531061 A;;US 201815776591 A;;US 2016/0062540 W;;US 201662303990 P;;US 201562257599 P,2015-11-19,ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF,"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD Y;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN CHIEN-SZU;;LI HUIMING;;BARNHART BRYAN C;;YAMNIUK AARON P;;LEI MING;;SCHWEIZER LIANG;;HATCHER SANDRA V;;RAJPAL ARVIND,BRISTOL-MYERS SQUIBB COMPANY (2018-07-27),https://lens.org/044-190-206-708-917,Patent Application,yes,0,2,20,20,542,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,A61K39/395;;C07K16/28;;G01N33/574;;G01N33/68,,0,0,,,,PENDING
322,US,B2,US 11213586 B2,063-739-086-758-622,2022-01-04,2022,US 201615776591 A,2016-11-17,US 201615776591 A;;US 201662303990 P;;US 201562257599 P;;US 2016/0062540 W,2015-11-19,Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR),"Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.",BRISTOL MYERS SQUIBB CO,WANG CHANGYU;;LONBERG NILS;;KORMAN ALAN J;;SELBY MARK J;;SRINIVASAN MOHAN;;HENNING KARLA A;;HAN MICHELLE MINHUA;;CHEN GUODONG;;HUANG RICHARD Y;;CHAKRABORTY INDRANI;;HUANG HAICHUN;;WONG SUSAN CHIEN-SZU;;LI HUIMING;;BARNHART BRYAN C;;YAMNIUK AARON P;;LEI MING;;SCHWEIZER LIANG;;HATCHER SANDRA V;;RAJPAL ARVIND,BRISTOL-MYERS SQUIBB COMPANY (2018-07-27),https://lens.org/063-739-086-758-622,Granted Patent,yes,88,5,20,20,0,C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/21;;C07K2317/34;;C07K2317/732;;C07K2317/75;;C07K2317/77;;C07K2317/92;;A61P35/04;;C07K16/2818;;C07K16/2878;;C07K2317/75;;C07K2317/732;;C07K2317/34;;C07K2317/21;;C07K2317/92;;C07K2317/77;;C07K16/2818;;C07K16/2878;;A61K2039/507;;C07K2317/732;;C07K2317/77;;C07K2317/92;;C07K2317/75;;C07K2317/21;;C07K2317/34;;A61K39/39558;;A61K2039/572;;G01N33/574;;G01N33/6863,C07K16/28;;A61K39/00;;A61K39/395;;G01N33/574;;G01N33/68,,97,49,027-477-313-726-928;;055-904-468-981-551;;008-019-042-176-997;;013-888-189-100-394;;112-871-461-451-205;;082-582-794-395-339;;124-668-123-456-128;;039-943-095-184-294;;013-904-324-770-460;;013-904-324-770-460;;050-463-287-173-296;;051-374-571-260-065;;004-189-544-863-902;;043-054-515-242-505;;171-614-306-115-108;;086-268-955-647-163;;136-116-610-765-69X;;084-334-863-236-818;;019-741-156-878-521;;009-483-512-107-343;;019-459-691-036-036;;087-404-567-384-381;;128-554-308-094-91X;;020-296-196-517-635;;055-706-543-681-974;;044-673-845-363-528;;056-584-393-786-220;;070-164-938-901-37X;;005-119-615-003-591;;013-323-148-570-367;;022-259-501-579-745;;055-329-732-668-508;;011-405-827-983-549;;141-244-428-002-001;;143-287-907-926-845;;035-924-762-030-733;;124-353-299-096-166;;012-369-544-741-057;;055-677-065-531-946;;010-916-105-450-247;;019-791-912-221-046;;078-111-385-767-730;;017-588-579-721-840;;016-276-447-231-541;;045-714-831-915-963;;071-886-484-965-256;;145-500-434-317-873;;012-108-483-329-37X;;083-410-991-104-604,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1002/jmr.679;;15227640;;15185369;;10.1002/cbic.200300806;;11533635;;10.1038/nbt0901-819;;10.1002/eji.200324804;;14991590;;21154120;;pmc3413251;;22245556;;10.1016/j.coi.2011.12.011;;10.1038/ni759;;11812990;;10.1200/jco.2017.35.15_suppl.104;;10.1200/jco.2017.35.15_suppl.104;;10.1084/jem.20041130;;15381730;;pmc2211964;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001;;9299585;;10.1006/scbi.1997.0058;;7490758;;10.1006/jmbi.1995.0626;;21304271;;10.4161/mabs.3.2.14939;;pmc3092615;;20563707;;10.1007/82_2010_49;;pmc4060248;;12444126;;10.4049/jimmunol.169.11.6210;;7506686;;10.1016/0378-1119(93)90258-5;;15484187;;10.1002/eji.200324632;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;20480365;;10.1007/s00262-010-0866-5;;20454651;;pmc2862699;;10.1371/journal.pone.0010436;;10.1158/0008-5472.can-05-2813;;16651447;;pmc2242844;;9373310;;10.1016/s1380-2933(96)00045-0;;10.1016/s1074-7613(04)00054-8;;15030773;;15374887;;10.1182/blood-2004-06-2467;;10.3410/f.1001160.6701;;11520463;;10.1016/s1074-7613(01)00183-2;;10074428;;10.1016/s0960-9822(99)80093-1;;10.1016/0022-2836(92)90639-2;;1507232;;14573361;;10.1016/j.tibtech.2003.08.007;;10.1182/blood-2008-07-170274;;pmc2668854;;18941113;;10.4049/jimmunol.172.12.7306;;15187106;;23980122;;pmc3754862;;10.1084/jem.20131625;;17671218;;10.1158/0008-5472.can-06-4639;;10.1084/jem.20050940;;pmc2213162;;10.1084/jem.200509402092c;;16186187;;10.3410/f.1028385.337176;;20197484;;10.1158/1078-0432.ccr-09-2425;;10037686;;10.1074/jbc.274.10.6056;;10.1016/s0167-5699(00)01668-6;;10916138;;10.1186/1479-5876-12-36;;24502656;;pmc4104995;;10.1038/nbt0792-779;;1368267;;10.1016/s1074-7613(02)00280-7;;11869690;;pmc4397897;;23460535;;10.1158/1078-0432.ccr-13-0598;;10.1158/1078-0432.ccr-12-2065;;10.1158/1078-0432.ccr-12-2214;;23460531;;10.1158/1078-0432.ccr-09-3243;;20460483;;pmc21029;;9177197;;10.1073/pnas.94.12.6216;;10.1002/eji.200425818;;15770698;;10836847;;10.1038/sj.cdd.4400670;;10.1186/s40425-016-0132-2;;27822377;;pmc5096004;;27190629;;10.1186/s40425-016-0181-6;;pmc4869343;;10.1111/j.1365-2567.2009.03228.x;;20201988;;pmc2878467,"Rudikoff et al Proc NatlAcad Sci USA 79: 1979, 1982 (Year: 1982).;;Barrios et al J Molecular Recognition 17: 332-338, 2004 (Year: 2004).;;Piatesi et al. ChemBio Chem 5: 460-466, 2004 (Year: 2004).;;U.S. Appl. No. 16/578,987, filed Sep. 23, 2019, Changyu Wang.;;U.S. Appl. No. 16/663,583, filed Oct. 25, 2019, Changyu Wang.;;U.S. Appl. No. 15/646,558, filed Jun. 21, 2019, S. Shafer.;;U.S. Appl. No. 15/646,558, filed Feb. 4, 2019, S. Shafer.;;U.S. Appl. No. 15/369,290, filed Oct. 24, 2019, J. Roark.;;U.S. Appl. No. 15/369,290, filed Jul. 25, 2019, J. Roark.;;U.S. Appl. No. 15/369,290, filed Nov. 8, 2018, J. Roark.;;Reichert, J. et al., “Monoclonal antibodies in the clinic,” Nat. Biotech, vol. 19, 819-822 (2001).;;Ronchetti et al., “GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations,” Eur J Immunol, vol. 34, 613-622 (2004).;;Rosenzweig et al., “Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of nuGITR.,” ASCO Meeting Library 2010 Annual Meeting, 1-2.;;Safety Study of AMG 228 to Treat Solid Tumors, ClinicalTrials.gov Identifier: NCT02437916, date first posted: May 8, 2015, date last updated: Feb. 6, 2017,date retrieved: Feb. 14, 2018, 7 pages, <https://clinicaltrials.gov/show/NCT02437916>.;;Schaer et al., “Anti-GITR antibodies—Potential Clinical applications for tumor immunotherapy,” Curr Opin in Investigational Drugs, vol. 11 (12), 1378-1386 (2010).;;Schaer, et al. “Modulation of GITR for cancer immunotherapy,” Curr Opin in Immunol, vol. 24, 217-224 (2012).;;Shimizu et al., “Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance,” Nature Immunol, vol. 3 (2), 135-142 (2002).;;Siu, L. et al., “Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor-related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors,” Journal of Clinical Oncology, vol. 35 (15):Supp. 104: (May 2017) 4 page, retrieved date: Feb. 14, 2018, <http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.104>.;;Siu, L. et al., Preliminary Results of a Phase 1/2a Study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor-related gene [GITR] agonist) Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors, slides presented at the ASCO Annual Meeting 2017, Jun. 2, 2017, 18 pages.;;Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001), ClinicalTrials.gov Identifier: NCT02553499, date first posted: Sep. 17, 2015 date last updated: Feb. 2, 2018, date retrieved: Feb. 14, 2018, 6 pages <https://clinicaltrials.gov/show/NCT02553499>.;;Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001), ClinicalTrials.gov Identifier: NCT02132754, date first posted: May 7, 2014, date last updated Jan. 25, 2018, date retrieved: Feb. 14, 2018, 7 pages <https://clinicaltrials.gov/ct2/show/NCT02132754?term=mk41668rank=1 >.;;Turk, et al., “Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells,” Journal of Exp Medicine, vol. 200 (6) 771-782 (2004).;;U.S. Appl. No. 60/665,322, filed Mar. 25, 2005, 62 pages.;;U.S. Appl. No. 60/687,265, filed Jun. 3, 2005, 71 pages.;;Wang, H. et al., “Integration of Nonclinical PK/PD Data for First-in-Human Starting Dose Selection of Cancer Immune therapeutics,” presented on Oct. 18, 2017 at 2017 (ISoP) International Society of Pharmacometrics—8th American Conference on Pharmacometrics (ACoP 8), 17 pages.;;Website Information for human GITR/TNFRSF 18 MAb (Clone 110416), Catalog No. MAB589, 1-2.;;White, A. et al., “Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies,” Cancer Cell, vol. 27(1):138-148 (2015).;;Whiteside, S. et al., “IkB proteins: structure, function and regulation,” Seminars in Cancer Biology, vol. 8, 75-82 (1997).;;Yang, W. et al., “CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range,” J. Mol. Biol., vol. 254 (3): 392-403 (1995).;;U.S. Appl. No. 16/133,418, filed Sep. 17, 2018, Suba Krishnan.;;U.S. Appl. No. 15/264,266, filed Sep. 13, 2016, Suba Krishnan.;;U.S. Appl. No. 15/369,290, filed Dec. 5, 2016, Changyu Wang.;;U.S. Appl. No. 15/646,558, filed Jul. 11, 2017, Changyu Wang.;;U.S. Appl. No. 14/949,424, filed Nov. 23, 2015, Changyu Wang.;;U.S. Appl. No. 14/732,082, filed Jun. 5, 2015, Changyu Wang.;;U.S. Appl. No. 15/369,290, filed Jul. 16, 2018, J. Roark.;;U.S. Appl. No. 15/369,290, filed Feb. 8, 2018, J. Roark.;;U.S. Appl. No. 15/646,558, filed Sep. 26, 2018, S. Shafer.;;U.S. Appl. No. 15/646,558, filed May 30, 2018, S. Shafer.;;U.S. Appl. No. 14/949,424, filed Apr. 20, 2017, S. Shafer.;;U.S. Appl. No. 14/949,424, filed Apr. 13, 2017, S. Shafer.;;U.S. Appl. No. 14/949,424, filed Jan. 25, 2017, S. Shafer.;;U.S. Appl. No. 14/949,424, filed Nov. 4, 2016, S. Shafer.;;U.S. Appl. No. 14/732,082, filed Aug. 24, 2015, S. Shafer.;;U.S. Appl. No. 14/732,082, filed Jul. 13, 2015, S. Shafer.;;An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread, ClinicalTrials.gov Identifier NCT02598960, date first posted: Nov. 6, 2015, dated last updated: Feb. 1, 2018, 7 pages, date retrieved: Feb. 14, 2018 <https://clinicaltrials.gov/ct2/show/NCT02598960?term=BMS-986156&rank=1>.;;Arnett, S. et al., “IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of The Antibody Society,” Dec. 5-9, 2010, San Diego, CA USA, mAbs, vol. 3 (2), Mar./Apr. 2011, 133-152.;;Avogadri, F. et al., “Modulation of CTLA- 4 and GITR for Cancer Immunotherapy,” Curr Top Microbiol Immunol, vol. 344:211-244(2011).;;Baecher-Allan, B. et al., “Inhibition of Human CD4+CD25+ high Regulatory T Cell Function,” J. Immunol., vol. 169: 6210-6217 (2002).;;Balint, R. et al., “Antibody Engineering by Parsimonious Mutagenesis,” Gene, vol. 137:109-118 (1993).;;Birebent, B. et al., “Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression,” Eur. J. Immunol., vol. 34:3485-3496 (2004).;;Bulliard, et al., “Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies,” JEM, vol. 210 (9): 1685-1693 (2013).;;Bulliard, et al., “Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies,” Novartis Institutes for Biomedical Research and Dana Farber Cancer Institutes USA, No date, 1-3.;;Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” PNAS, vol. 89, 4285-4289 (1992).;;Coe, D. et al., “Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy,” Cancer Immunol Immunother, vol. 59, 1367-1377 (2010).;;Cohen et al., “Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation,” PLoS, vol. 5, Iss. 5, 1-12 (2010).;;Cohen et al., “Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody,” Blood, ASH Annual Meeting Abstracts, Dec. 8-11, 2007, vol. 110 (11), 1788.;;Cohen, et al., “Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity,” Cancer Res., vol. 66: (9):4904-4912 (2006).;;Davies et al., “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen bnding,” Immunotechnology, vol. 2, 169-179 (1996).;;Dittmer et al., “Functional impairment of CD8+ T cellls by regulatory T cells during persistent retroviral infection,” Immunirty, vol. 20, 293-303 (2004).;;Glaus et al., “In vivo SPECT/CT imaging of an anti-GITR antibody: A novel cancer immunotherapeutic,” J Nucl Med., vol. 54 (Supplement 2):327 (2013).;;Godrey et al., “Cord blood CD4+ CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function,” Blood, vol. 105 No. 2, 750-758 (2005).;;Gross et al., “TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease: Impaired B Cell Maturation in Mice Lacking BLyS,” Immunity, vol. 15:289-302 (2001).;;Gurney et al., “Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR,” Current Biology, vol. 9 (4), 215-218 (1999).;;Hawkins, R.E. et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,” J. Mol. Biol., vol. 226(3): 889-896 (1992).;;Hiroyoshi Nishikawa, “Application of Modulators of Cancer Immunosuppression for Immunotherapy—GITR and CTLA-4,” The Medical Frontline, vol. 64 (11): 100-105 (2009).;;Holt, L. et al., “Domain antibodies: proteins for therapy,”Trends in Biotechnology, vol. 21 (11): 484-490 (2003).;;Houot et al., “T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need or chemotherapy,” Blood, vol. 113 (15):3546-3552 (2009).;;International Preliminary Reporton Patentability, PCT/US2015/033991, dated Dec. 6, 2016, 11 pages.;;International Preliminary Report on Patentability, PCT/US2016/062540, dated May 22, 2018, 17 pages.;;International Search Report and Written Opinion, PCT/US2015/033991, dated Dec. 8, 2015, pp. 17.;;International Search Report and Written Opinion, PCT/US2016/062540, dated Jun. 26, 2017, 26 pages.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fees, PCT/US2016/062540, dated May 3, 2017, 25 pages.;;Kanamaru et al., “Costimulation via Glucocorticoid-Induced TNF Receptor in Both Conventional and CD25+ Regulatory CD4+ T Cells,” The Journal of Immunology, 7306-7314 (2004).;;Kim et al., “Fcy receptors enable anticancer action of proapoptotic and immune-modulatory antibodies,” J Exp Med., vol. 210 (9) 1647-1657 (2013).;;Ko et al., “A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor mmunity in a Tolerogenic Murine Tumor Model,” Cancer Research, vol. 67 (15) 7477-7486 (2007).;;Ko et al., “Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+ CD4+ regulatory T cells,” JEM, vol. 202 (7), 885-891 (2005).;;Kuenen, B. et al., “A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies,” Clin Cancer Res., vol. 16(6) 1915-1923 (2010).;;Kwon et al., “Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand,” Journal of Biol Chem, vol. 274 (10) 6056-6061 (1999).;;Little et al., “Of Mice and Men: hybridoma and recombinant antibodies,” Immunology Today, vol. 21(8): 364-370 (2000).;;Lu et al. “Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs,” Journal of Translational Medicine, vol. 12 (36), 1-11 (2014).;;Marks, J. et al., “By-Passing Immunization: Building High Affinity Human Antibodies By Chain Shuffling,” Biotechnology, vol. 10(7): 779-783 (1992).;;McHugh et al., “CD4+CD25+ Immunoregulatory T Cells: Gene Expression Analysis Reveals a Functional Role for the Glucocorticoid-Induced TNF Receptor,” Immunity, vol. 16, 311-323 (2002).;;Melero et al., “Agonist Antibodies to TNFR Molecules That Costimulate Tand NK Cells,” Clinical Cancer Research, vol. 19 (5): 1044-1053, 1913 (2013).;;Melero et al., “Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination,” Clinical Cancer Research, vol. 19(5), 997-1008 (2013).;;Melero, I., “Immunological targets: Basic aspects,” IL29, Annals of Oncology, vol. 22 (Supplement 3), 8 pages, (2011) doi:10.1093/annonc/mdr103.;;Mitsui et al., “Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals,” Clinical Cancer Res, vol. 16, 2781-2791(2010).;;National Cancer Institute, Immunotherapy Agent workshop Jul. 12, 2007, 1-77.;;Nocentini et al., “A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis,” PNAS, vol. 94, 6216-6221 (1997).;;Nocentini et al., “GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily,” Eur J of Immunol, vol. 35 Iss 4, 1016-1022 (2005).;;Nocentini et al., “Identification of three novel mRNA splice variants of GITR,”Cell Death and Differentiation, vol. 7, 408-410 (2000).;;Patel, M. et al., “Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma,” Journal for ImmunoTherapy of Cancer, vol. 4(28):13 pages (2007).;;Ponte et al., “Enhancement of humoral and cellular immunity with an antiglucocorticoid- induced tumour necrosis factor receptor monoclonal antibody,” Immunology, vol. 130, 231-242 (2010).;;Press Release, Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting, Cambridge, MA, Jun. 25, 2015, PR Newswire, 1-3.;;Printout from the R&D Systems website showing a list of available anti-GITR antibodies, Jul. 2, 2014, 1-2.;;U.S. Appl. No. 16/793,737, filed Feb. 18, 2020, Suba Krishnan.;;U.S. Appl. No. 16/578,987, filed Apr. 27, 2020, S. Shafer.",ACTIVE
323,US,A1,US 2021/0363242 A1,037-820-876-460-316,2021-11-25,2021,US 201916962805 A,2019-01-15,US 201916962805 A;;US 201862617828 P;;US 201862618561 P;;US 201862633477 P;;US 2019/0013638 W,2018-01-16,METHODS OF TREATING CANCER WITH ANTIBODIES AGAINST TIM3,"This disclosure provides a method for treating a subject afflicted with a tumor or a cancer, wherein the method comprises administering to the subject therapeutically effective amounts of an anti-TIM3 antibody, alone or in combination with an inhibitor of the PD-1 signaling pathway (e.g., anti-PD-1 antibody). In some embodiments, the antibody is administered as a flat dose or a weight-based dose.",BRISTOL MYERS SQUIBB CO,SCHEBYE XIAO MIN;;SELBY MARK J;;HAN MICHELLE MINHUA;;BEE CHRISTINE;;DENG ANDY X;;CHUNTHARAPAI ANAN;;DEVAUX BRIGITTE;;LI HUIMING;;SHEPPARD PAUL O;;KORMAN ALAN J;;ARDOUREL DANIEL F;;DEYANOVA EKATERINA;;HUANG RICHARD YU-CHENG;;CHEN GUODONG;;KUHNE MICHELLE RENNE;;TRUONG HONG-AN;;PATAH POLIANA;;JACKSON JEFFREY R;;FLEMING RONALD A,BRISTOL-MYERS SQUIBB COMPANY (2018-04-24),https://lens.org/037-820-876-460-316,Patent Application,yes,2,1,6,6,448,C07K16/2803;;C07K16/2818;;A61K2039/507;;A61P35/00;;C07K16/2803;;C07K16/2818;;C07K16/2878;;C07K16/2827;;A61P35/00;;A61K2039/507;;A61P35/00;;A61K39/3955;;A61K2039/505;;A61K2039/507;;A61K2039/545;;C07K16/2803;;C07K16/2818;;C07K2317/21;;C07K2317/52;;C07K2317/565,C07K16/28;;A61K39/395;;A61P35/00,,7,6,018-069-206-369-372;;091-637-220-567-447;;034-863-257-615-287;;077-322-394-487-953;;030-454-062-264-322;;004-040-568-027-145,10.1158/2326-6066.cir-14-0039;;24795351;;24115948;;pmc3792396;;10.3389/fimmu.2013.00302;;pmc8726659;;10.1080/19420862.2021.1999195;;34780320;;10.1158/1538-7445.am2017-2628;;10.3389/fimmu.2021.625667;;pmc7994325;;33777008;;10.3390/antib8040055;;pmc6963682;;31816964,"Anderson, A., Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape, Cancer Immunol Res (2014) 2 (5): 393–398. (Year: 2014);;Sela-Culang, I. et al, The Structural basis of Antibody-Antigen Recognition, Frontiers in Immunology, Vol 4, Article 302, October 2013 (Year: 2013);;Cunningham, O. et al, Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns, MABS, Vol 13, NO. 1 2021 (Year: 2021);;Zhang, T. et al. ""BGB-A425: a humanized anti-human Tim-3 antibody that exhibits strong immune cell activation."" Cancer Research 77.13_Supplement (2017): 2628-2628. (Year: 2017);;Jorgovanovic D. et al, ROles of IFN-γ in tumor progression and regression: a review. Biomarker Research 8, 49, 2020 (Year: 2020);;Lee, J. et al, The Multifaceted Tole of TH1, Th9, and Th17 cells in Immune Checkpoint Inhibition Therapy. Frontiers in Immunology, 12:625667, 2021 (Year: 2021);;Chiu M. et al, Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies 8(4), 55, 2019 (Year: 2019)",DISCONTINUED
